mechanism	Concurrent administration of <e10> cimetidine </e10> and <e20> digoxin </e20> results in a substantial reduction in the plasma concentrations of both drugs.
mechanism	Concurrent administration of <e10> diltiazem </e10> and <e20> valdecoxib </e20> significantly increased the Cmax of diltiazem by approximately 50% and AUC by approximately 30%.
mechanism	Concurrent administration of <e11> HUMORSOL </e11> with oral anticoagulants ( warfarin, corticosteroids, and <e20> coumarin </e20> ) may increase the risk of bleeding.
mechanism	Median gastric pH was 3.07 (range, 3.1-3.5) in subjects taking <e10> cefazolin </e10> concurrently with <e20> enoxacin </e20> and was 5.3 (range, 4.8-5.9) in the other subjects.
mechanism	However, <e10> halothane </e10> markedly increased the metabolism of <e20> atorvastatin </e20>, resulting in an increase in the mean steady state plasma concentrations of atorvastatin from # microM to # microM.
mechanism	However, <e10> halothane </e10> administered concomitantly with <e20> ketoconazole </e20> resulted in a decreased half-life of ketoconazole.
mechanism	However, <e10> halothane </e10> had a significant effect on the clearance of <e20> ethinyl_estradiol </e20>.
mechanism	The half-life of <e10> cimetidine </e10> is approximately # hours, and a single dose of # mg cimetidine is sufficient to deplete plasma <e20> cimetidine </e20> concentrations by approximately 40%.
mechanism	<e10> Rifampin </e10> and <e20> allopurinol </e20> are the major inhibitors of myeloperoxidase activity.
mechanism	<e10> Rifampin </e10> prolongs the half-life of the <e22> tricyclic_antidepressant </e22> by 4-fold.
mechanism	<e10> Rifampin </e10> may increase the plasma concentrations of <e20> fluvoxamine </e20>.
mechanism	The concomitant administration of <e10> fluvoxamine </e10> and <e20> enoxacin </e20> at a single dose of # mg in normal volunteers resulted in a 40% decrease in enoxacin plasma concentrations.
mechanism	The concomitant administration of <e10> ketoconazole </e10> with <e20> erythromycin </e20> may increase the concentrations of both drugs.
mechanism	The concomitant administration of <e11> SPRYCEL </e11> # mg and <e20> phenytoin </e20> (10 mg) was associated with a significantly higher number of cardiac events compared to phenytoin alone, resulting in an estimated reduction in efficacy of SPRYCEL by 49%.
mechanism	Withdrawal of <e10> ketoconazole </e10> from a patient receiving # mg of <e20> erythromycin </e20> per day resulted in a 75% increase in the serum concentration of erythromycin.
mechanism	Withdrawal of <e10> tetracycline </e10> by the cytochrome P-450 enzyme system (see Drug Interactions for a detailed description of this system) has been reported to increase the <e20> clindamycin </e20> exposure.
mechanism	This effect may be attributed to the concurrent administration of <e10> nelfinavir </e10> with <e20> ritonavir </e20>, resulting in a reduction of ritonavir exposure.
mechanism	This effect may be due to the decrease in the bioavailability of <e10> erythromycin </e10> and <e20> carbamazepine </e20>.
mechanism	<e10> Amprenavir </e10> and ritonavir decrease plasma levels of ritonavir and <e20> ritonavir </e20>.
mechanism	<e10> Amprenavir </e10>, ritonavir, and <e20> lopinavir </e20> are all inhibited by the single-dose combination of ritonavir and high-dose intravenous (iv) rifabutin.
mechanism	<e10> Amprenavir </e10> decreased plasma levels of <e20> diltiazem </e20> by 43%.
mechanism	<e10> Amprenavir </e10> was reduced by approximately 30% in plasma concentrations of <e20> didanosine </e20>.
mechanism	<e10> Amprenavir </e10> has been shown to inhibit <e20> clofibrate </e20> absorption in the gastrointestinal tract.
mechanism	<e10> Amprenavir </e10> inhibited the absorption of <e20> nelfinavir </e20>, resulting in a decrease in the AUC of nelfinavir by approx. 50%.
mechanism	<e10> Rifampin </e10> # mg or <e20> isoniazid </e20> # mg at # hour intervals prior to and following # mg/day of a protease_inhibitor combination was also associated with a reduction in isoniazid plasma levels.
mechanism	<e10> Rifampin </e10> and <e20> erythromycin </e20> (compounds that inhibit CYP2D6) inhibited the metabolism of the anticonvulsant ethyldopa.
mechanism	<e10> Rifampin </e10> (50 mg q,i,d, for # weeks) increases plasma levels of <e20> ketoconazole </e20> ( # mg q,i,d, for # weeks) and increases the level of ketoconazole ( # mg q,i,d, for # weeks) in peripheral blood mononuclear cells.
mechanism	<e10> Rifampin </e10> decreased the levels of <e20> digoxin </e20> and its metabolism (approximately 2-fold) and increased the levels of N-acetyl digoxin.
mechanism	<e10> Rifampin </e10> and <e20> dofetilide </e20> inhibited the metabolism of rifampin and dofetilide by the same route, resulting in decreased plasma levels.
mechanism	<e10> Rifampin </e10>, fluvastatin, or carbamazepine (concurrent use with <e20> warfarin </e20>, phenytoin, or other CYP3A4 inhibitors) increased the serum levels of warfarin or its active metabolite, phenytoin, approximately twofold or more.
mechanism	<e10> Amprenavir </e10> decreased the plasma levels of rifabutin, ritonavir, indinavir, and <e20> rifabutin </e20>.
mechanism	<e10> Amprenavir </e10> decreased the exposure of <e20> rifampin </e20> to 99%.
mechanism	<e10> Amprenavir </e10> may increase the plasma concentration of <e20> lovastatin </e20>.
mechanism	<e10> Amprenavir </e10> has been reported to decrease the half-life of <e20> rifabutin </e20>.
mechanism	<e10> Amprenavir </e10> and <e20> ritonavir </e20> inhibited the hepatic CYP2D6 activity of a previously characterized ritonavir_metabolism_competent_drugs ( clarithromycin, indinavir, indinavir, itraconazole, itraconazole, nefazodone ).
mechanism	Pharmacokinetic interaction between <e10> cyclosporine </e10> and <e20> tacrolimus </e20> has been demonstrated with a mean increase of 0.3% for tacrolimus clearance and an increase in systemic exposure of 1% for cyclosporine.
mechanism	Pharmacokinetic interaction between <e10> flupenthixol </e10> and <e20> terfenadine </e20> was studied by the elimination of terfenadine from # healthy volunteers.
mechanism	Pharmacokinetic interaction between <e10> ketoconazole </e10> and <e20> digoxin </e20> may result in elevated digoxin concentrations.
mechanism	RESULTS: The geometric mean (20%-80%) concentration of <e10> quinine </e10> in plasma was higher in male patients than in female patients on concomitant <e20> phenytoin </e20> therapy.
mechanism	RESULTS: The geometric mean and geometric mean of <e10> rifabutin </e10>-rifabutin interactions with <e20> warfarin </e20> were significantly higher when warfarin was co-administered with rifabutin than when rifabutin was co-administered with warfarin alone.
mechanism	RESULTS: The geometric mean doses of <e10> furosemide </e10> and <e20> enalapril </e20> were 447 and 133 mg/day, respectively, for enalapril and 838 and 173 mg/day for furosemide.
mechanism	Apparent oral clearance of <e10> terfenadine </e10> is increased when <e20> furosemide </e20> is used concurrently with either of these drugs.
mechanism	Apparent oral clearance measurements of <e10> ketoconazole </e10> reveal a very high net clearance of <e20> nelfinavir </e20>, thereby explaining the inhibition of metabolism of nelfinavir by ketoconazole.
mechanism	CONCLUSIONS: Single-dose <e10> rifampin </e10> has a tendency to decrease <e20> ciprofloxacin </e20> absorption.
mechanism	CONCLUSIONS: Single-dose <e10> rifabutin </e10> was highly effective in lowering plasma concentrations of <e20> CBL </e20>.
mechanism	<e10> Fluvoxamine </e10>, but not <e20> lovastatin </e20>, has a similar effect on all-cause mortality, with a reduction in cardiac index of about 25% in patients taking both drugs.
mechanism	<e10> Fluvoxamine </e10> may increase <e20> norethindrone </e20> serum levels and thus increase the plasma half-life.
mechanism	<e10> Fluvoxamine </e10> : In normal subjects, the oral absorption of <e20> fluvoxamine </e20> was approximately 46% lower than that of phenytoin, which was about 20% lower than that of aripiprazole.
mechanism	RESULTS: During treatment with <e10> cimetidine </e10>, CYP2C9 mRNA and protein levels decreased and that of <e20> ketoconazole </e20> mRNA and protein decreased.
mechanism	RESULTS: During treatment with <e10> valdecoxib </e10>, there was a decrease in the <e20> amiodarone </e20> elimination rate of 38%, with an increase in plasma concentrations of valdecoxib.
mechanism	RESULTS: During treatment with <e10> ketoconazole </e10> #, </e10> #, and # mg/day, <e20> levodopa </e20> AUC, # mg/day, and Cmax were decreased by 15%, 15%, and 11%, respectively.
mechanism	DISCUSSION: <e10> Clarithromycin </e10> may have an additive effect on the absorption of <e20> warfarin </e20>.
mechanism	DISCUSSION: <e10> Clarithromycin </e10> inhibits the absorption of methotrexate and <e20> cisplatin </e20>.
mechanism	DISCUSSION: <e10> Clarithromycin </e10> may interfere with absorption of <e20> diltiazem </e20>.
mechanism	This study demonstrated that <e10> ketoconazole </e10> in combination with <e20> indomethacin </e20> has no effect on the in vitro clearance of ketoconazole.
mechanism	This study demonstrated that <e10> rifabutin </e10> has a strong negative effect on <e20> levodopa </e20> metabolism when administered concomitantly.
mechanism	<e10> Acetaminophen </e10> and other strong CYP3A4 inhibitors (e,g,, phenytoin, primidone, amiodarone, tolbutamide, <e20> cyclosporine </e20>, tacrolimus, disopyramide ) may increase the clearance of the target drug and lead to decreased serum concentrations of the drug.
mechanism	<e10> Acetaminophen </e10> may decrease the clearance of <e20> cimetidine </e20> by up to 40%.
mechanism	<e10> Acetaminophen </e10> may increase the clearance of <e20> cimetidine </e20>.
mechanism	<e10> Theophylline </e10> may interfere with the metabolism of other <e22> quinolones </e22>, including ciprofloxacin, diflunisal, erythromycin, clarithromycin, indinavir, itraconazole, itraconazole_sulfa, itraconazole, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, troleandomycin_sulfa, troleandomycin, and theophylline_sulfa.
mechanism	<e10> Theophylline </e10> and ethinyl_estradiol have been shown to interfere with the metabolism of <e20> fluvastatin </e20>, resulting in decreased serum concentrations and enhanced elimination.
mechanism	<e10> Theophylline </e10> reduces <e20> ethinyl_estradiol </e20> levels and increases plasma ethinyl_estradiol levels.
mechanism	Previous studies have shown that theophylline, a metabolite of <e10> astemizole </e10>, may be a potential drug interaction with <e20> clarithromycin </e20>.
mechanism	Previous studies have shown that <e10> indomethacin </e10>, a calcium-channel blocker, decreases the plasma concentration of <e20> quinidine </e20>.
mechanism	Previous studies have shown that <e10> ibuprofen </e10>, but not other nonsteroidal_anti-inflammatory_drugs, could decrease the bioavailability of <e20> terfenadine </e20> and increase the half-life of both drugs by inhibiting the hepatic metabolism of both drugs.
mechanism	Previous studies have shown that <e12> anticonvulsants </e12> decrease the clearance of <e20> clofibrate </e20>, and the rate of clearance is increased by the coadministration of these agents.
mechanism	Previous studies have shown that both <e10> lithium </e10> and <e20> phenytoin </e20> inhibit the metabolism of Vitamin_K.
mechanism	Previous studies have demonstrated that <e10> ibuprofen </e10> has the potential to inhibit the metabolism of <e20> atorvastatin </e20> and lead to increased serum concentrations of atorvastatin.
mechanism	Previous studies have shown that <e10> levothyroxine </e10> increases <e20> cholestyramine </e20> levels in rat and human plasma, and increases its plasma level in rat.
mechanism	Previous studies have shown that <e10> erythromycin </e10> reduced the plasma levels of <e20> lisinopril </e20>.
mechanism	Previous studies have demonstrated that <e10> amphetamines </e10> interfere with <e20> probenecid </e20> clearance, and a decrease in serum amphetamine levels has been reported.
mechanism	Previous studies have shown that <e10> erythromycin </e10> may decrease the clearance of <e20> carbamazepine </e20> and phenytoin.
mechanism	Previous studies have shown that <e10> clofibrate </e10> has an inhibitory effect on platelet function, resulting in a decrease in the plasma level of <e20> clofibrate </e20>.
mechanism	<e10> Azithromycin </e10> decreased the half-life of <e20> cisapride </e20> by about 30%.
mechanism	<e10> Azithromycin </e10> inhibited the hepatic metabolism of <e20> nefazodone </e20>, which had a narrow therapeutic index.
mechanism	<e10> Azithromycin </e10> significantly inhibited the metabolism of <e20> phenytoin </e20>, with maximum concentrations of (22 +/- 1)% in the initial phase and (8 +/- 3)% in the maximum phase.
mechanism	<e10> Azithromycin </e10> may increase the clearance of cisplatin and other <e22> combination_hormonal_contraceptives </e22>.
mechanism	<e10> Azithromycin </e10>, ethionamide, levothyroxine, and norethindrone (use with high-dose <e20> cimetidine </e20> ) may decrease azithromycin serum concentrations.
mechanism	Coadministration of <e10> atorvastatin </e10> # mg and <e20> warfarin </e20> # mg resulted in #% increases in AUC and #% increases in Cmax and AUC(PR), respectively.
mechanism	Coadministration of <e10> cyclosporine </e10> and <e20> dofetilide </e20> resulted in a significant increase in dofetilide concentrations (p =.009).
mechanism	Coadministration of <e10> cholestyramine </e10> tablets with oral <e20> methotrexate </e20> significantly decreased the rate of increase in plasma methotrexate levels.
mechanism	(1968, 1970), the first known reports of concurrent use of <e10> digoxin </e10> and an <e22> nonsteroidal_anti-inflammatory_drug </e22> ( triamterene ), and the first description of a possible drug interaction with the diuretic disopyramide.
mechanism	(1968, 1970), the concomitant administration of <e10> dipyridamole </e10> with <e20> warfarin </e20> was found to increase the rate of intravenous and subcutaneous absorption of warfarin by 5%.
mechanism	(1968, 1970), the following reactions have been reported: anticoagulants : <e10> Cimetidine </e10> may decrease the clearance of the anticoagulant, phenytoin, amiodarone, and <e20> carbamazepine </e20>.
mechanism	(1968, 1970), the extent to which <e12> benzodiazepines </e12> may prolong the interval between two <e22> anticonvulsants </e22> is unknown, but it is likely to be large.
mechanism	(1968, 1970), the concomitant use of <e10> cimetidine </e10> with sulfonamides, carbamazepine, phenytoin, or carbamazepine / phenytoin in pediatric patients has been associated with a significant increase in hepatic metabolism of <e20> sulfinpyrazone </e20>.
mechanism	This might be a result of an interaction between <e10> clofibrate </e10> and <e20> probenecid </e20>.
mechanism	This might be because <e10> cimetidine </e10> is metabolized by CYP2C9 to a lesser extent than <e20> halothane </e20> and cimetidine ;
mechanism	This might be due to a decrease in cephalosporins clearance, which might occur if <e10> clindamycin </e10> is given at the same time as <e20> astemizole </e20>.
mechanism	An intravenous injection of <e10> fluvoxamine </e10>, given to a patient previously treated with a single <e20> ketoconazole </e20>, caused a significant increase in the concentration of the ketoconazole in plasma.
mechanism	An intravenous injection of <e10> amphetamine </e10> # mg/kg caused a dose-related increase in plasma levels of <e20> aripiprazole </e20>, and conversely a decrease in plasma levels of aripiprazole.
mechanism	<e10> Cholestyramine </e10>, rifampin, and <e20> quinine </e20> may interfere with absorption of digoxin, and rifampin may decrease the plasma concentration of digoxin.
mechanism	<e10> Cholestyramine </e10> and/or other corticosteroids, as well as high-dose <e22> salicylates </e22>, may interfere with absorption of digoxin and other high-dose oral anticoagulants, leading to reduced serum and urine levels of these medications.
mechanism	<e10> Cholestyramine </e10> significantly increased the <e20> amiodarone </e20> AUC by 21% and decreased the amiodarone AUC by 43%.
mechanism	<e10> Amiodarone </e10> inhibits hepatic CYP3A4 activity and increases plasma <e20> cimetidine </e20> levels.
mechanism	<e10> Amiodarone </e10> in combination with <e20> methotrexate </e20> decreased the AUC of methotrexate by 34%.
mechanism	<e10> Amiodarone </e10>, <e20> carbamazepine </e20>, chlordiazepoxide, diazepam, diltiazem, efavirenz, fluvoxamine, fluvoxamine, flupenthixol, griseofulvin, itraconazole, itraconazole sulfone, itraconazole sulfone dihydrochloride, itraconazole sulfone trihydrochloride, itraconazole sulfone zinc, ketoconazole, ketoconazole sulfone, loratadine, midazolam, meclofenamic_acid, nizatriptan, phenytoin, phenytoin_hydrochloride, salicylates, temazepam, tolbutamide, and ziconazole.
mechanism	During <e10> amiodarone </e10> therapy, the hepatic clearance of <e20> digoxin </e20> was increased by about 20%.
mechanism	During <e10> amiodarone </e10> treatment, the clearance of <e20> ketoconazole </e20> was decreased, and the plasma concentrations of ketoconazole and cisapride were increased.
mechanism	During <e10> amiodarone </e10> treatment, a decrease in the clearance of <e20> digoxin </e20> was seen in the normal prostate and the prostate in the diuretic state.
mechanism	These alterations in hepatic metabolism of <e10> clofibrate </e10> may increase the clearance of <e20> adenosine </e20>.
mechanism	<e13> Misonidazole </e13> at the dose of # mg/kg increased the maximum serum concentration of # mg/kg of <e20> gentamicin </e20> by #-fold.
mechanism	<e13> Misonidazole </e13> increases the plasma levels of <e20> valdecoxib </e20> and the CYP3A4 inhibitor, ritonavir.
mechanism	<e13> Misonidazole </e13> inhibited <e20> doxorubicin </e20> AUC by 53%.
mechanism	We propose these as possible drug interactions of <e10> chlorpropamide </e10> with: antacids : Potassium- and <e20> magnesium </e20> -containing antacids decrease the absorption of chlorpropamide.
mechanism	We propose these data suggest a possible drug interaction between <e10> doxapram </e10> and rifampin and <e20> clarithromycin </e20>.
mechanism	Enhanced <e10> theophylline </e10>-and <e20> warfarin </e20>-plasma concentrations are likely to occur with concomitant administration of a non-steroidal_anti-inflammatory_drug ( anabolic_hormone_drug ), an anabolic_hormone_inhibitor ( anabolic_hormone_inhibitor ), and a diuretic ( corticosteroids ).
mechanism	Enhanced <e10> theophylline </e10> absorption was observed when coadministered with <e20> ergotamine </e20>.
mechanism	This report describes a rare, potentially life-threatening interaction of <e10> lovastatin </e10> and <e20> quinidine </e20>, which occurred with a dose of # mg of lovastatin.
mechanism	This report describes the case of a patient on chronic <e10> diazepam </e10> therapy who was also taking <e20> ketoconazole </e20> for the treatment of nonmalignant gastrointestinal ulceration.
mechanism	This report describes the case of a patient on the receiving a dosing interval of # mg of <e10> zalcitabine </e10> q1w in the evening on two separate occasions who was also dosed # mg of <e20> zalcitabine </e20> in the evening on two separate days.
mechanism	This study demonstrates that <e10> digoxin </e10> has a significant in vitro effect on the pharmacokinetics of <e20> ketoconazole </e20>.
mechanism	This study demonstrates that <e10> lisinopril </e10> reduces <e20> amiodarone </e20> concentrations and may be a possible drug interaction for amiodarone when administered concurrently with liver enzymes in patients with renal insufficiency.
mechanism	This study demonstrates that <e10> erythromycin </e10>, with concomitant administration of <e20> azithromycin </e20>, significantly increases plasma levels of azithromycin.
mechanism	Interactions of <e10> lopinavir </e10> with other protease_inhibitors, quinolones, troleandomycin, clarithromycin, indinavir, ritonavir, saquinavir, <e20> telithromycin </e20>, troleandomycin, and nelfinavir have not been studied.
mechanism	Interactions of <e10> heparin </e10> and warfarin with <e20> warfarin </e20> -related metabolites (1-8) and metabolism of (+)-warfarin, a potent inhibitor of CYP2C9 (nucleoside analog), are described.
mechanism	Interactions of <e10> halothane </e10> and <e20> diflunisal </e20> have been reported with decreased half-life and increased maximum plasma concentration, but these were not statistically significant.
mechanism	Additional <e10> iron </e10> may be required to achieve plasma concentrations required to inhibit <e20> carbamazepine </e20>.
mechanism	Additional <e10> iron </e10> supplements may be needed if <e20> astemizole </e20> is used concomitantly.
mechanism	Additional <e10> iron </e10> may be needed to control diarrhea if <e20> ciprofloxacin </e20> is administered concomitantly with itraconazole.
mechanism	Additional <e10> iron </e10> supplements may be required when <e20> iron </e20> is used in conjunction with the following drugs: (1) Amprenavir, dasatinib, indinavir, itraconazole, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole.
mechanism	Additional <e10> iron </e10> or zinc supplements may be necessary in patients who are already receiving the recommended maximum daily dose of <e20> cyclosporine </e20>.
mechanism	The lower rate of metabolism of <e10> ketoconazole </e10> by CYP3A4 in vitro was likely due to the pharmacokinetic interaction of the coadministration of <e20> clofibrate </e20> and ketoconazole.
mechanism	The lower rate of <e10> erythromycin </e10> metabolism and the increased clearance of the more potent metabolite <e20> erythromycin </e20> might have resulted in increased serum levels of both of these compounds.
mechanism	The lower rate of <e10> nevirapine </e10> concentrations in plasma when <e20> lovastatin </e20> was added to therapy suggests that lovastatin may affect the metabolism of nevirapine and increase the risk of nevirapine toxicity.
mechanism	Consequently, the effect of <e10> zalcitabine </e10> on <e20> cyclosporine </e20> and tacrolimus plasma concentrations is likely to be reduced, resulting in reduced AUC values and increased Cmax and AUC values.
mechanism	Consequently, the effect of <e10> phenytoin </e10> and <e20> warfarin </e20> on the prothrombin time (international normalized ratio) was evaluated, and the effect of warfarin on phenytoin and on the serum phenytoin concentration was also evaluated.
mechanism	Consequently, the effect of <e10> methotrexate </e10> on <e20> fluvastatin </e20> plasma levels was depressed.
mechanism	The serum estrogen and progestin levels of women receiving <e10> cimetidine </e10> in combination with <e20> estrogens </e20> or progestins of the estrogen metabolizing enzyme class (estrogens and progestins with cytochrome P450 (CYP) 4A5 activity) were significantly reduced when compared to those of women receiving estrogens or progestins alone.
mechanism	Due to its highly hydrophobic nature, <e11> HUMORSOL </e11> has been reported to interfere with oral <e22> anticoagulants </e22>, which are usually nonsteroidal_anti-inflammatory drugs.
mechanism	Due to its high stability, <e10> ketoconazole </e10> can be used to control high levels of <e20> zidovudine </e20> in a clinical setting.
mechanism	[The effect of <e10> digoxin </e10> on <e20> phenytoin </e20> clearance (CL) is not well known.
mechanism	[The effect of <e10> terfenadine </e10> on the CYP3A4 activity is enhanced by <e20> erythromycin </e20>, and thus, increases the plasma level of the latter.
mechanism	[The effect of <e10> phenytoin </e10> on the pharmacokinetics of <e20> levodopa </e20> is unknown.
mechanism	[The effect of oral <e10> amiodarone </e10> on <e20> ethinyl_estradiol </e20> and propyl_estradiol in normal volunteers has been demonstrated.
mechanism	[The effect of dexamethasone, retinyl_acetate, and cetirizine, <e10> hydrochlorothiazide </e10>, and coumarin on serum <e20> methotrexate </e20> concentration was examined by a non-compartmental method.
mechanism	Acid-catalyzed ethanolysis of the <e12> quinolones </e12> to liberate the active isomeric form of these drugs results in a decreased clearance of <e20> diazoxide </e20>.
mechanism	Acid-catalyzed ethanolysis of <e10> cholestyramine </e10> resulted in an increase in pharmacokinetics of <e20> valdecoxib </e20> and its major metabolite, valdecoxib N-oxide.
mechanism	Acid-catalyzed ethanolysis of <e10> cisapride </e10> may enhance the renal clearance of <e20> carbamazepine </e20> and other antidepressants.
mechanism	In addition to phenytoin, <e10> dapsone </e10> also significantly increased the plasma concentrations of the <e20> phenobarbital </e20> metabolite, and hence the plasma concentrations of the phenobarbital inhibitory metabolite.
mechanism	The results raise the possibility that the anticholinesterase effect of <e11> BROVANA </e11> may be impaired by concomitant administration of <e20> digoxin </e20>.
mechanism	The results raise the possibility that the concomitant administration of <e10> diflunisal </e10> with <e20> carbamazepine </e20> may be an additional risk factor for the development of hypercalcemia in patients with type 1 diabetes.
mechanism	The results raise the possibility that <e10> cyclosporine </e10> may interact with some <e22> nonsteroidal_anti-inflammatory_drugs </e22> and therefore may decrease the effectiveness of these drugs.
mechanism	Co-administration of <e10> digoxin </e10> with <e20> propranolol </e20> significantly increased propranolol plasma concentrations.
mechanism	Co-administration of <e10> amiodarone </e10> and <e20> cisapride </e20> (CAS #40-45-9-2) decreased amiodarone AUC by 24% and AUC (min) by 15%.
mechanism	Co-administration of <e10> carbamazepine </e10> and <e20> rifampin </e20> decreased the clearance of carbamazepine.
mechanism	Intestinal_adsorbents (e, g,, ampicillin, <e10> amoxicillin </e10>, erythromycin, tetracycline, ciprofloxacin, bacitracin, colistin, erythromycin, lincomycin, pimozide ): These drugs may increase the absorption of <e20> methotrexate </e20>, resulting in lower serum levels.
mechanism	Intestinal_adsorbents (e, g,, vitamin_C, <e10> aluminum </e10>, ferrous_sulfate ) and <e22> antacids </e22>, all of which are absorbed through the stomach, have been reported to cause hypokalemia when given concomitantly with oral vitamin_K.
mechanism	Intestinal_adsorbents (e, g,, furosemide, <e10> thiazide </e10> ) have been reported to increase the absorption of <e20> rifampin </e20> and are likely to decrease the clearance of rifampin.
mechanism	Intestinal_adsorbents (e, g,, Amoxicillin, Ciprofloxacin, <e10> Norfloxacin </e10> ) have been reported to decrease the absorption of <e20> furosemide </e20> by approximately 50%.
mechanism	Intestinal_adsorbents (e, g,, ampicillin, <e10> ceftazidime </e10>, tetracycline, polymyxins, polymyxins_mixed_adulterate, digoxin, <e20> ciprofloxacin </e20>, clarithromycin ) or other agents with intestinal_adsorbent properties (e, g,, metronidazole, sulfonamides, bacitracin, carbamazepine, doxycycline, famotidine, granisetron, phenytoin, bromocriptine, valproate, valproate_HCl, terfenadine, troleandomycin ) can interfere with the absorption of oral ciprofloxacin, resulting in decreased plasma concentrations and reduced therapeutic effects.
mechanism	Intestinal_adsorbents (e, g,, <e10> erythromycin </e10>, clarithromycin, rifampin, omeprazole, ketoconazole, sulfasalazine, sulfasalazine_HCl, triazolam, <e20> fluconazole </e20>, and clarithromycin ) may increase the exposure of ketoconazole and sulfasalazine, resulting in higher serum concentrations.
mechanism	Intestinal_adsorbents (e, g,, sodium_trimethylanisole, <e10> cimetidine </e10>, succinylcholine ) increase the uptake of <e20> diltiazem </e20> and may interfere with absorption of diltiazem from the gastrointestinal tract.
mechanism	Intestinal_adsorbents (e, g,, tetracycline, colistin, bacitracin, <e10> colestipol </e10> ) may reduce the absorption of <e20> lopinavir </e20>, resulting in a higher plasma concentration.
mechanism	<e10> Acarbose </e10> has been reported to inhibit the metabolism of a number of drugs, including <e20> ketoconazole </e20>.
mechanism	<e10> Acarbose </e10> reduced the clearance of <e20> levothyroxine </e20> by 17% and the clearance of estrogens by 26%.
mechanism	<e10> Acarbose </e10> may increase plasma <e20> sulfasalazine </e20> concentrations.
mechanism	However, the peak plasma concentration of <e10> digoxin </e10> was higher in the absence of <e20> probenecid </e20>.
mechanism	However, the peak plasma levels of <e10> cyclosporine </e10> may be significantly reduced with coadministration of <e20> digoxin </e20>.
mechanism	However, the peak plasma levels of <e10> zalcitabine </e10> are slightly decreased by the concomitant administration of <e20> gemcitabine </e20>, a known inhibitor of metabolism.
mechanism	However, the peak plasma concentration of <e10> isoniazid </e10> was slightly reduced by <e20> ketoconazole </e20>.
mechanism	However, the peak plasma concentration of <e10> apomorphine </e10> increased only slightly following administration of <e20> lithium </e20>.
mechanism	<e11> DIAMOX </e11> reduces the plasma concentration of <e20> colestipol_mesylate </e20> by increasing the elimination rate of colestipol and causing a concomitant decrease in AUC.
mechanism	<e11> DIAMOX </e11> may inhibit the metabolism of <e20> guanethidine </e20>, a drug that is used in some patients with schizophrenia to treat symptoms such as a deceleration of speech or a reduction in attention.
mechanism	<e11> DIAMOX </e11> did not affect the clearance of <e20> doxorubicin </e20>, however, its effect on doxorubicin pharmacokinetics is unpredictable.
mechanism	<e11> DIAMOX </e11> and diclofenac : <e20> Dexbrompheniramine </e20> and diclofenac have been reported to enhance the renal clearance of these drugs.
mechanism	<e11> DIAMOX </e11> has been shown to increase the pharmacokinetic profile of <e20> nelfinavir </e20>, resulting in a significant reduction of nelfinavir exposure.
mechanism	<e11> DIAMOX </e11> may also inhibit <e20> indomethacin </e20> -induced release of dopamine in the nucleus accumbens and in the midbrain.
mechanism	By decreasing the plasma concentrations of <e10> carbamazepine </e10>, <e20> erythromycin </e20>, or clarithromycin, it is possible to reduce the therapeutic effects of these agents.
mechanism	By decreasing the plasma concentrations of <e10> apomorphine </e10> and <e20> dexamethasone </e20>, the risk of hypercalcemia may be reduced by approximately 50% and approximately 75%, respectively, while increasing the risk of toxicity by approximately 50% and approximately 50%, respectively, when administered concomitantly with a beta-adrenergic_blocking_agent.
mechanism	<e10> Acetazolamide </e10> and <e20> fluvoxamine </e20> were both significantly less effective in prolonging the QT interval when given with either digoxin, methotrexate, or theophylline.
mechanism	<e10> Acetazolamide </e10> may interfere with the metabolism of <e20> warfarin </e20>, resulting in a decreased clearance of the parent drug.
mechanism	<e10> Acetazolamide </e10> has been reported to decrease <e20> warfarin </e20> clearance and to increase the Cmax and AUC of warfarin.
mechanism	<e10> Acetazolamide </e10> may increase the absorption of <e20> doxapram </e20>, resulting in lower plasma levels and decreased bioavailability.
mechanism	<e10> Acetazolamide </e10> decreased the absorption of a single dose of <e20> terfenadine </e20> by 54% (p = 0.008) and the absorption of a single dose of # mg of #% # mg of terfenadine by 25% (p = 0.007).
mechanism	<e10> Acetazolamide </e10> significantly decreased <e20> methotrexate </e20> clearance by ~20%.
mechanism	<e10> Acetazolamide </e10> increases the clearance of <e20> ketoconazole </e20>, a known inhibitor of CYP3A4.
mechanism	<e10> Acetazolamide </e10> may reduce the metabolism of <e20> fluconazole </e20>, resulting in a decrease in the bioavailability of fluconazole.
mechanism	<e10> Acetazolamide </e10>, fluconazole, phenytoin, phenobarbital, rifampin, and <e20> triazolam </e20> may enhance the metabolism of ketoconazole and other tricyclic_antidepressants, causing increased plasma levels of these drugs.
mechanism	<e10> Acetazolamide </e10> increases the clearance of <e20> lithium </e20>.
mechanism	<e10> Acetazolamide </e10> may decrease the metabolism of <e20> phenytoin </e20>.
mechanism	<e10> Acetazolamide </e10> potentiates the natriuretic effect of <e20> furosemide </e20>.
mechanism	Co-administration of <e10> phenytoin </e10> with <e20> ketoconazole </e20> increased the concentrations of A,C, and its metabolite in the stomach, but did not affect the metabolism of the other A,C in the stomach.
mechanism	Co-administration of <e10> ketoconazole </e10> with <e20> nelfinavir </e20> resulted in a decrease in plasma concentrations of nelfinavir and decreased nelfinavir AUC and Cmax.
mechanism	Co-administration of <e10> ketoconazole </e10> and <e20> clarithromycin </e20> resulted in an increased plasma concentration of clarithromycin and a decreased clearance of clarithromycin.
mechanism	Ethanol :Clinical evidence indicates that the serum concentration of <e10> ethanol </e10> may increase with <e20> lithium </e20> and lithium-containing preparations.
mechanism	Ethanol :Clinical evidence suggests that <e10> ethanol </e10> may decrease the clearance of <e20> fluvoxamine </e20>.
mechanism	Ethanol :Clinical evidence suggests that <e10> ethanol </e10> may inhibit the metabolism of <e20> ketoconazole </e20> and other related drugs.
mechanism	Phenytoin : If <e10> phenytoin </e10> is to be administered concurrently with <e20> clozapine </e20>, careful consideration should be given to the pharmacokinetics of the two drugs since the half-life of clozapine is prolonged by about 4-fold and that of phenytoin is prolonged by about 4-fold when coadministered with it.
mechanism	Phenytoin : If <e10> phenytoin </e10> is given concurrently with <e20> diltiazem </e20>, there is a theoretical risk that the clearance of phenytoin will be reduced.
mechanism	Phenytoin : If <e10> phenytoin </e10> is to be taken orally with <e20> carbamazepine </e20>, it is recommended that the carbamazepine concentration be monitored to avoid over- or under-saturating the target organ.
mechanism	Dexamethasone : Steady-state <e10> dexamethasone </e10> concentrations decrease by approximately 40% when <e20> digoxin </e20> is co-administered.
mechanism	Dexamethasone : Steady-state <e10> dexamethasone </e10> concentrations increase in an overlapping manner with <e20> ketoconazole </e20>, with the peak concentration at # min after ketoconazole administration.
mechanism	Praziquantel : In a study in normal volunteers, <e10> probenecid </e10> was reported to increase the plasma concentrations of <e20> praziquantel </e20> by about 50%.
mechanism	Praziquantel : In a small study, an interaction between <e10> praziquantel </e10> and <e20> terfenadine </e20> was demonstrated at # mg/kg/day for # days.
mechanism	Praziquantel : In vitro studies in normal and malignant human cells demonstrated that <e10> praziquantel </e10> may inhibit <e20> warfarin </e20> metabolism by a mechanism involving cytochrome P450 3A4 inhibition.
mechanism	Cimetidine : <e10> Cimetidine </e10> may reduce the clearance of <e20> methotrexate </e20>.
mechanism	Cimetidine : <e10> Cimetidine </e10> causes an approximately 40% reduction in the half-life of <e20> atazanavir </e20>.
mechanism	Cimetidine : <e10> Cimetidine </e10> may reduce the bioavailability of <e20> valdecoxib </e20>.
mechanism	Intravenous <e10> ranitidine </e10> increased the serum concentrations of <e20> colestipol_hydrochloride </e20> by 17% and the serum concentrations of colestipol_hydrochloride by 11% in rats with chronic renal failure and the maximum plasma concentrations of colestipol_hydrochloride were reduced by 47% and 17%, respectively, when ranitidine was added.
mechanism	Intravenous <e10> ranitidine </e10> or digoxin can be given concomitantly with <e20> rifampin </e20>, which can inhibit the metabolism of both drugs.
mechanism	Products containing <e10> phenytoin </e10> (preparations containing ciprofloxacin ) may prolong the pharmacokinetic profile of <e20> carbamazepine </e20>.
mechanism	Products containing <e10> allopurinol </e10> have been reported to increase the clearance of other antihypertensive_drugs such as <e20> guanethidine </e20> and astemizole.
mechanism	Products containing <e10> digoxin </e10> and <e20> ketoconazole </e20> may decrease the clearance of digoxin and cause a decrease in plasma concentrations.
mechanism	Products containing calcium salts, such as magnesium/calcium_carbonate, aluminum/chloride, and aluminum/hydroxide <e12> antacids </e12>, may increase the risk of <e20> nifedipine </e20> absorption.
mechanism	Products containing calcium supplements, vitamin_B-complexes, or other calcium-containing supplements containing <e10> hydroxychloroquine </e10> or other <e22> anticonvulsants </e22> may have an elevated serum level of calcium and should be administered with caution.
mechanism	Limited clinical experience has shown a potential for increasing blood levels of <e11> BREVIBLOC </e11> by the concurrent administration of <e20> amiodarone </e20> or metformin.
mechanism	Limited clinical experience has shown that coadministration of <e10> doxorubicin </e10> and <e20> nelfinavir </e20> has resulted in a decrease in serum doxorubicin levels and a concomitant increase in nelfinavir exposure.
mechanism	Limited clinical experience with <e11> WELLBUTRIN </e11> has shown that the <e22> SSRI </e22> may reduce the serum concentrations of an SSRI and increase the serum concentration of a H2_blocking agent.
mechanism	Limited clinical experience suggests that the concurrent administration of <e10> tetracycline </e10> and <e20> fluconazole </e20> has caused an increase in the concentrations of fluconazole.
mechanism	Limited clinical experience has shown that <e10> digoxin </e10> # mg once daily significantly increased the clearance of <e20> doxorubicin </e20>, causing a 30% increase in the mean Cmax.
mechanism	Limited clinical experience has shown that <e10> cimetidine </e10> may increase the risk of bleeding when administered concomitantly with <e20> isoniazid </e20>.
mechanism	<e10> Cimetidine </e10> decreased the hepatic enzyme levels of <e20> ketoconazole </e20>.
mechanism	<e10> Cimetidine </e10> decreased plasma concentrations of <e20> lithium </e20> by 50%.
mechanism	<e10> Cimetidine </e10> and <e20> halothane </e20>, which have similar pharmacology, may potentiate the effects of the other drug.
mechanism	Co-administration of <e10> ciprofloxacin </e10> with rifampin ( # mg QD) increased the <e20> ciprofloxacin </e20> plasma AUC by a mean of 7%.
mechanism	Co-administration of <e10> ketoconazole </e10> (a 4-fluorouracil metabolizing enzyme) and <e20> valdecoxib </e20> may result in an increase in plasma valdecoxib levels.
mechanism	Co-administration of <e10> valdecoxib </e10> and <e20> astemizole </e20> at recommended daily doses of # mg for # days and # mg for # days, respectively, resulted in significant increases in AUC and Cmax of valdecoxib compared to valdecoxib alone.
mechanism	Co-administration of <e10> valdecoxib </e10> and <e20> cimetidine </e20> resulted in a two- to fourfold increase in cimetidine plasma concentrations.
mechanism	Co-administration of <e10> terfenadine </e10> and <e20> ketoconazole </e20> decreased the half-life of both terfenadine and ketoconazole by 44% and the Cmax by 35%, compared to both terfenadine alone and ketoconazole alone.
mechanism	Co-administration of <e10> diltiazem </e10> and <e20> phenytoin </e20> resulted in a marked increase in AUC, resulting in a significant increase in the AUC for phenytoin.
mechanism	Ketoconazole : Co-administration with <e10> ketoconazole </e10> decreased the AUC of <e20> methotrexate </e20> by 15% and increased the Cmax by 11%.
mechanism	Ketoconazole : Co-administration of <e10> ketoconazole </e10> and <e20> diltiazem </e20> resulted in a statistically significant increase in Cmax and AUC of diltiazem.
mechanism	Ketoconazole : Co-administration of <e10> ketoconazole </e10>, a weak inducer of CYP3A4, resulted in an increase in <e20> astemizole </e20> AUC.
mechanism	Furosemide : When <e10> furosemide </e10> was administered to a patient on a high dose of <e20> digoxin </e20>, the serum digoxin level increased by approximately 9% (P =.005) and the clearance of digoxin was reduced by approximately 28% (P =.011).
mechanism	Furosemide : When <e10> probenecid </e10> was administered with a <e22> furosemide </e22>, a significant decrease in furosemide elimination was observed.
mechanism	Furosemide : When <e11> WELLBUTRIN </e11> and <e20> furosemide </e20> are used concomitantly, plasma concentrations of furosemide are decreased and absorption is increased.
mechanism	Mercaptopurine / Azathioprine : As with other <e12> quinolones </e12>, high-dose <e20> mercaptopurine </e20> may increase the blood levels of azathioprine and may reduce its metabolism by hepatic microsomal enzymes.
mechanism	Mercaptopurine / Azathioprine : Co-administration of <e10> Mercaptopurine </e10> / Azathioprine with <e20> alprazolam </e20> produced a reduction in alprazolam plasma concentrations of 41%.
mechanism	Mercaptopurine / Azathioprine : In a randomized clinical trial, the maximum plasma concentrations of <e10> mercaptopurine </e10> (50 mg daily) were reduced by 29% with concomitant administration of <e20> azathioprine </e20> (2 mg daily) compared to placebo, with a mean increase in AUC of 46% and a mean decrease in AUC of 48%.
mechanism	Mercaptopurine / Azathioprine : In vitro and ex vivo studies have shown that <e10> mercaptopurine </e10> (2 mg kg(-1)) and azathioprine (30 mg kg(-1)) inhibit the hepatic metabolism of both <e20> azathioprine </e20> and cisplatin and decrease plasma concentrations of azathioprine.
mechanism	Mercaptopurine / Azathioprine : Coadministration of <e10> Mercaptopurine </e10> (75 mg # day) and <e20> azathioprine </e20> (40 mg # day) in healthy volunteers resulted in a 5% increase in the plasma concentrations of azathioprine and a 4% decrease in the clearance of azathioprine.
mechanism	Dicumarol : It has been reported that <e10> dicumarol </e10> may interact with platelet_aggregation_inhibitors, therefore it is advisable to avoid coadministration with <e20> adenosine </e20>.
mechanism	Dicumarol : It has been reported that <e10> dicumarol </e10> may inhibit <e20> almotriptan </e20> clearance, and therefore, it is recommended that almotriptan be administered with low plasma levels to achieve peak plasma levels.
mechanism	Dicumarol : It has been reported that <e10> dicumarol </e10> inhibits <e20> digoxin </e20> absorption by causing renal tubular secretion of digoxin and increasing the concentration of digoxin in the plasma.
mechanism	Uricosuric_Agents : Since <e10> isoniazid </e10> has been reported to increase the concentrations of <e20> rifampin </e20> and warfarin, the possibility exists that rifampin may increase the metabolism of either of these drugs.
mechanism	Uricosuric_Agents : Since <e10> cyclosporine </e10> may decrease uricosuric_agent elimination, concomitant use of <e20> rifampin </e20> may result in an increased dosage of rifampin and a concomitant increase in its in vitro half-life.
mechanism	The concomitant administration of <e10> ketoconazole </e10> with <e20> ketoconazole </e20> tablets and oral formulations of ketoconazole containing at least # mg of retinyl_acetate or containing any other retinoid, vitamin, or calcium containing preparations (retinyl_acetate, vitamin_A, or calcium ) has been associated with an increase in the AUC of ketoconazole by about #% (3.9-fold increase in mean AUC).
mechanism	The concomitant administration of <e10> ketoconazole </e10> tablets with <e20> zalcitabine </e20> at a dose of # mg q10d resulted in an increase in zalcitabine concentration by approximately 50%.
mechanism	The concomitant administration of <e10> ciprofloxacin </e10> (200 mg daily) with a single dose of <e20> colestipol_hydrochloride </e20> (15 mg daily) resulted in a 62% increase in Cmax and AUC of colestipol_hydrochloride.
mechanism	Chlorpropamide : <e10> Chlorpropamide </e10> has been shown to inhibit <e20> digoxin </e20> clearance and increase digoxin exposure in man and animals.
mechanism	Cyclosporin : Reports indicate that <e10> cetirizine </e10> may interfere with the metabolism of <e20> cyclosporine </e20>.
mechanism	Cyclosporin : Reports suggest a possible interaction of <e10> cyclosporin </e10> with <e20> astemizole </e20> and warfarin.
mechanism	Cyclosporin : Reports suggest that <e12> quinolones </e12> may interfere with the metabolism of <e20> cyclosporin </e20>.
mechanism	Monoamine_Oxidase_Inhibitors : Coadministration of <e10> gabapentin </e10> with <e20> risperidone </e20> resulted in a 40% reduction in plasma levels of gabapentin and an increase in the mean Cmax of gabapentin by 1,048% and 3,813%, respectively.
mechanism	Monoamine_Oxidase_Inhibitors : Coadministration of <e11> HALDOL </e11> with MAOI (e,g,, <e20> fluoxetine </e20>, sertraline, fluvoxamine, paroxetine, venlafaxine ) increases the AUC and Cmax of HALDOL by 38% and 18%, respectively.
mechanism	Monoamine_Oxidase_Inhibitors : Coadministration of <e10> fluvoxamine </e10> with agents with monoamine_oxidase_inhibitors ( MAOIs ) ( phenobarbital, <e20> imipramine </e20>, nortriptyline, selegiline ) increased the plasma concentrations of fluvoxamine by approximately 35%.
mechanism	Verapamil : Coadministration of <e10> clarithromycin </e10> with <e20> verapamil </e20> produced a mean decrease of 34% in plasma levels of clarithromycin.
mechanism	Verapamil : Coadministration of <e10> verapamil </e10> and <e20> carbamazepine </e20> resulted in a marked decrease in carbamazepine serum levels and an increase in the pharmacokinetic parameters of carbamazepine.
mechanism	Verapamil : Coadministration of <e11> aspirin </e11> and <e20> verapamil </e20> at # mg per day resulted in a 19% increase in the amount of time taken to reach steady state in an in vitro model of blood pressure control.
mechanism	Coadministration of <e10> doxycycline </e10> (50 mg on days #-21) and <e20> cisapride </e20> (40 mg on days #-21) decreased blood levels of doxycycline.
mechanism	Coadministration of <e10> enoxacin </e10> # mg with <e20> valdecoxib </e20> # mg decreased enoxacin clearance by about 29% and increased valdecoxib plasma concentrations by about 23%.
mechanism	<e10> Fluvoxamine </e10> did not reduce the renal clearance of <e20> enoxacin </e20>, but did reduce the enoxacin AUC.
mechanism	<e10> Fluvoxamine </e10> at a dose of # mg/kg twice daily significantly increased the serum levels of <e20> fluvoxamine </e20> by approximately 50%.
mechanism	<e10> Fluvoxamine </e10> may also increase the serum levels of <e20> fluvoxamine </e20>.
mechanism	<e10> Ketoconazole </e10> and <e20> fluconazole </e20> increased the serum concentration of Caffeine, and increased the serum caffeine concentration.
mechanism	<e10> Ketoconazole </e10> attenuates the metabolism of <e20> cimetidine </e20>.
mechanism	<e10> Ketoconazole </e10> inhibits the metabolism of <e20> nifedipine </e20>.
mechanism	The steady state concentrations of <e10> rifampin </e10> and its major metabolite, rifabutin, were approximately 6- to 8-fold higher in patients on concurrent <e20> valproate </e20> and were similar to the levels reported with valproate alone.
mechanism	The steady state plasma concentrations of <e10> terfenadine </e10> were approximately 10% lower when administered with <e20> ketoconazole </e20> than when administered alone.
mechanism	The steady state plasma concentration of <e10> isoniazid </e10> is increased by <e20> ciprofloxacin </e20> at approximately # times the active concentration (EC(50)) of ciprofloxacin in plasma and urine.
mechanism	The steady state effect of <e11> ZYVOX </e11> on the blood glucose level was about +0.22% on the lowest dose and +1.16% on the highest dose of <e20> carbapenem </e20>.
mechanism	The steady state plasma concentrations of <e10> dofetilide </e10> are slightly higher than the plasma concentrations of <e20> terfenadine </e20>.
mechanism	The steady state plasma concentration of <e10> diltiazem </e10> increased approximately 8% to 9% with concomitant increases in <e20> rifabutin </e20>, theophylline, and vitamin_C.
mechanism	Drugs Demonstrated to Have a Cautionary Effect on <e10> Acetazolamide </e10> Stability Include: Carbamazepine, cimetidine, <e20> disulfiram </e20>, famotidine, halothane, H2-antagonists, isoniazid, itraconazole, itraconazole s clearance, ketoconazole, meclofenamic_acid, methylprednisolone, phenytoin, rifampin, rifabutin, sulfonamides, St, Johns wort, temazepam, theophylline, and verapamil.
mechanism	Coadministration of <e10> warfarin </e10> with <e20> warfarin </e20> at a # mg dose reduced the elimination half-life of warfarin by 20% to 50%.
mechanism	Coadministration of <e10> cypermethrin </e10> and other organophosphate and carbamate insecticides with <e20> metolachlor </e20> has been reported to result in a decrease in efficacy of approximately 50%.
mechanism	Coadministration of <e10> digoxin </e10> with <e20> erythromycin </e20> significantly decreased the AUC of digoxin and decreased the mean Cmax by 43% and 69%, respectively.
mechanism	Coadministration of oral <e10> zalcitabine </e10> and <e20> disopyramide </e20> resulted in a significant increase in the mean Cmax of disopyramide and the mean AUC of zalcitabine.
mechanism	Coadministration of oral <e10> ergotamine </e10> (50 mg daily) and <e20> ethoxzolamide </e20> (200 mg daily) for # days reduced the diuretic effect of ethoxzolamide by 37% and the metoclopramide effect by 43%.
mechanism	Concurrent administration of <e10> probenecid </e10> with <e20> cisapride </e20> resulted in a 33% increase in cisapride clearance.
mechanism	Concurrent administration of <e11> Aspirin </e11> and <e20> cimetidine </e20>, used concomitantly to reduce uric acid levels, decreased Aspirin plasma concentrations by 40% to 50%, and increased cimetidine plasma concentrations by 75% to 90%.
mechanism	Concurrent administration of <e10> diltiazem </e10> with <e20> bromocriptine_mesylate </e20>, a widely used nonsteroidal_anti-inflammatory_drug, may have increased the absorption of bromocriptine.
mechanism	<e11> Cytadren </e11> preparations (eg, <e20> cyclosporine_HCl </e20>, tacrolimus, disopyramide, amiodarone, phenytoin, propafenone, cisapride ) increase the clearance of CYP3A4 substrates by a mechanism that is not fully understood, possibly due to inhibition of acid secretion by phenytoin or to enhanced drug metabolism by the hepatotoxic metabolite of cisapride, cyclosporine_HCl.
mechanism	<e11> Cytadren </e11> : Although reported, <e20> dexamethasone </e20> did not have any effect on the activity of the active ingredient or on the metabolism of the active ingredient.
mechanism	<e11> Cytadren </e11> pretreatment with <e20> diazepam </e20> did not significantly affect the elimination half-life of warfarin, phenytoin or warfarin_sodium.
mechanism	<e10> Probenecid </e10>, acetaminophen and metronidazole may increase the clearance of <e20> digoxin </e20> and increase the half-life of digoxin.
mechanism	<e10> Probenecid </e10> increased the clearance of <e20> cisapride </e20> by 2.3-fold.
mechanism	<e10> Probenecid </e10> and <e20> propafenone </e20> are potent inhibitors of CYP3A4 activity, thus may interfere with metoclopramide metabolism and result in elevated serum levels of metoclopramide.
mechanism	A case report of prolonged tamsulosin plasma levels after initiation of <e10> erythromycin </e10> and discontinuation of <e20> tamsulosin </e20> was observed.
mechanism	A case report of a male patient with moderate hypokalemia after concomitant administration of <e10> digoxin </e10> and <e20> lithium </e20> is reported.
mechanism	A case report of a patient treated with <e10> ketoconazole </e10> and <e20> warfarin </e20> is reported.
mechanism	<e10> Cimetidine </e10>, or other inhibitors of CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, nelfinavir, <e20> nefazodone </e20>, troleandomycin, valproate ), may reduce the clearance of warfarin.
mechanism	<e10> Cimetidine </e10> and <e20> lithium </e20> have been shown to interact with C. trachomatis by inhibiting the enzyme responsible for cimetidine metabolism.
mechanism	<e10> Cimetidine </e10> can increase plasma concentrations of <e20> phenytoin </e20> and certain other gastrointestinal medications, and therefore these medications should be used with caution in patients receiving chronic cimetidine.
mechanism	Increases in plasma concentrations of <e10> ketoconazole </e10>, chloramphenicol, chlorthalidone, and other chloramphenicol preparations have been reported when <e20> cisapride </e20> is administered concomitantly with these medications.
mechanism	Increases in plasma concentrations of <e10> gentamicin </e10> were observed when rats were treated with # mg/kg/day of <e20> amphotericin_B </e20> alone for # days.
mechanism	Increases in plasma <e10> lithium </e10> concentrations may have been caused by inhibition of the hepatic metabolism of <e20> lithium </e20>.
mechanism	Discontinuation of cimetidine therapy following administration of <e10> cisapride </e10> has been reported to result in a rise in <e20> cimetidine </e20> levels.
mechanism	Discontinuation of cimetidine or <e10> ketoconazole </e10> by concomitant administration with <e20> cimetidine </e20> is likely to reduce the elimination of cimetidine and its pharmacologic effect, leading to an increase in its serum concentration.
mechanism	Discontinuation of cimetidine ( <e10> Cimetidine </e10> ) resulted in a significant increase in the clearance of <e20> diltiazem </e20>.
mechanism	<e10> Probenecid </e10> increases the clearance of <e20> probenecid </e20>.
mechanism	<e10> Probenecid </e10> has been reported to inhibit the metabolism of <e20> chlorpromazine </e20>.
mechanism	<e10> Probenecid </e10> ( <e20> mefloquine </e20> ) causes a dose-dependent increase in plasma levels of methotrexate and alfentanil.
mechanism	<e10> Indinavir </e10> was also found to decrease the AUC of <e20> lovastatin </e20> by a factor of 4.7.
mechanism	<e10> Indinavir </e10> has been reported to decrease plasma concentrations of <e20> crizotin </e20> and its active metabolite, ritonavir.
mechanism	<e10> Indinavir </e10> inhibits the metabolism of <e20> valdecoxib </e20> by approximately 20%.
mechanism	<e10> Saquinavir </e10> significantly inhibited the metabolism of <e20> rifabutin </e20> by the plasma protease.
mechanism	<e10> Saquinavir </e10> -induced reductions in plasma and urine levels of tenofovir were ameliorated by coadministration of <e20> nelfinavir </e20>.
mechanism	<e10> Saquinavir </e10> in combination with either <e20> nelfinavir </e20>, ritonavir, or atazanavir significantly reduced the plasma concentrations of saquinavir, nelfinavir, and atazanavir, with a concomitant decrease in AUC and Cmax.
mechanism	<e10> Nelfinavir </e10> has been shown to inhibit the metabolism of <e20> isoniazid </e20> and rifampin.
mechanism	<e10> Nelfinavir </e10> is active when given with <e20> Aprepitant </e20>, resulting in a mean reduction in Aprepitant exposure of 46%.
mechanism	<e10> Nelfinavir </e10> is one of the drugs that inhibit the metabolism of <e20> ritonavir </e20> and thus may increase the plasma levels of ritonavir.
mechanism	Coadministration of <e10> cisapride </e10> (20 mg BID) with <e20> alcohol </e20> (7.5% w/v) in a rat model of anesthesia resulted in an increase in the AUC of cisapride from 3.5 minutes after drug administration to # minutes.
mechanism	Coadministration of <e10> cholestyramine </e10> and <e20> digoxin </e20> caused a 3-fold increase in the elimination rate of digoxin.
mechanism	It is known that <e10> indomethacin </e10> inhibits the metabolism of <e20> rifampin </e20>, which may increase plasma levels of rifampin.
mechanism	It is known that <e10> cimetidine </e10> can inhibit <e20> ketoconazole </e20>.
mechanism	<e10> Anagrelide </e10> and other NSAIDs reduce the clearance of <e20> methotrexate </e20> by about 40%.
mechanism	<e10> Anagrelide </e10> has been reported to increase <e20> warfarin </e20> exposure and increase the half-life of warfarin.
mechanism	<e10> Anagrelide </e10>, by blocking platelet function, may diminish the efficacy of other antithrombotic_agents, including <e20> warfarin </e20>, its derivatives, and corticosteroids.
mechanism	There is a high degree of intersubject variability for the extent to which <e10> ketoconazole </e10> inhibits <e20> ethinyl_estradiol </e20> -induced, estrogen-like, and progesterone-like, cellular proliferation in rat ovary.
mechanism	There is a small increase in plasma concentration of <e10> ketoconazole </e10> when administered with <e20> quinidine </e20>.
mechanism	Co-administration of <e10> diclofenac </e10> decreased <e20> colestipol_HCl </e20> absorption by approximately 40%.
mechanism	Co-administration of <e10> astemizole </e10> and <e20> lithium </e20> markedly increased the serum lithium level.
mechanism	Co-administration of <e10> alprazolam </e10> and <e20> midazolam </e20> resulted in increased midazolam concentrations and a decrease in midazolam clearance.
mechanism	For example, since <e10> diazepam </e10> at a dose of # mg/kg (i.e., # mg #/kg total body weight) completely blocked the absorption of <e20> cyclosporine </e20>, the serum level of cyclosporine was increased by 16%, and its elimination half-life was shortened by 40%.
mechanism	For example, since <e10> amphetamines </e10> reduce the absorption of <e20> furosemide </e20>, the possibility exists that amphetamines may increase the blood levels of furosemide.
mechanism	For example, since <e10> rifampin </e10> is metabolized by CYP2D6, a decrease in rifampin plasma levels could result in a decrease in <e20> amprenavir </e20> plasma levels.
mechanism	For example, since it has been shown that the <e12> anticoagulants </e12> such as warfarin or its derivatives increase the clearance of <e20> carbamazepine </e20>, a ketoconazole_preparation (i,e,, the inactive metabolite of ketoconazole ) may have to be administered with carbamazepine.
mechanism	For example, since <e10> carbamazepine </e10> has been shown to have a pharmacokinetic interaction with <e20> digoxin </e20>, the two drugs may be co-administered to increase digoxin exposure.
mechanism	For example, since <e10> cisapride </e10> is in addition to <e20> ketoconazole </e20>, a daily regimen of 1,3,5-triphenyltetrazolium bromide (TTCB) tablets may result in significant increases in serum cisapride levels.
mechanism	Oral <e12> anticoagulants </e12>, such as warfarin, phenytoin, coumarin, and corticosteroids, have been reported to interfere with absorption of <e20> erythromycin </e20> from the gastrointestinal tract.
mechanism	Oral <e12> anticoagulants </e12>, such as warfarin or its derivatives, prolong and intensify the blood effects of <e22> coumarin </e22> or warfarin.
mechanism	Oral <e12> anticoagulants </e12> ( warfarin, phenytoin, rifampin, corticosteroids ) are inhibitors of heparin-type <e20> vitamin_K </e20>, and thus should be avoided by patients with chronic renal insufficiency.
mechanism	Oral <e12> anticoagulants </e12>, including warfarin, may increase the clearance of <e20> dofetilide </e20>.
mechanism	Oral <e12> anticoagulants </e12> have been reported to reduce the bioavailability of <e20> warfarin </e20> by up to 40% or to increase the half-life of warfarin by up to 20%.
mechanism	Oral <e12> anticoagulants </e12> may decrease plasma <e20> warfarin </e20> levels.
mechanism	Oral <e12> anticoagulants </e12> may potentiate the effect of oral <e20> azathioprine </e20>.
mechanism	Oral <e12> anticoagulants </e12>, including warfarin and its derivatives and its derivatives, may decrease the serum levels of <e20> indinavir </e20>.
mechanism	Because oral <e12> anticoagulants </e12> may interfere with the metabolism of coumarin derivatives (preparations containing <e20> cytochrome P-450-sensitive </e20> and -insensitive, serine-type P450s ), anticoagulants may prolong and intensify the effects of coumarin and vitamin_K_antagonists.
mechanism	Because oral <e12> quinolones </e12> have been reported to inhibit the metabolism of <e20> digoxin </e20>, the potential exists for increased plasma levels of digoxin, which could increase toxicity.
mechanism	Because oral anticoagulants are reduced by coadministration of <e10> atorvastatin </e10>, it is possible that <e20> warfarin </e20> might be reduced by coadministration of these agents.
mechanism	Because oral anticoagulants have been shown to increase the prothrombin time, a reduction in the anticoagulant dose may be required when <e11> INDOCIN </e11> is administered concomitantly with <e20> warfarin </e20>.
mechanism	<e10> Aprepitant </e10> ( a cyclosporine_antidepressant ) tablets may cause depression if coadministered with <e20> cimetidine </e20>, chloramphenicol, or warfarin.
mechanism	<e10> Aprepitant </e10> can decrease the metabolism of <e20> quinidine </e20> by inhibiting hepatic enzymes.
mechanism	<e10> Aprepitant </e10> ( <e20> warfarin </e20> ) inhibits the metabolism of warfarin by decreasing the excretion of warfarin and increasing its metabolism to its active metabolite, phenytoin.
mechanism	<e10> Aprepitant </e10>, a hydantoin metabolite of <e20> hydantoin </e20>, may inhibit the renal excretion of hydrochlorothiazide, resulting in an increased exposure of this triazole.
mechanism	<e10> Aprepitant </e10> may interfere with <e20> phenytoin </e20> metabolism, resulting in a higher plasma phenytoin level.
mechanism	<e10> Aprepitant </e10> increased the clearance of <e20> alfentanil </e20> by about 50%.
mechanism	Coadministration of <e10> nelfinavir </e10> and <e20> erythromycin </e20> increases the half-life of nelfinavir.
mechanism	Coadministration of <e10> diltiazem </e10> # mg with <e20> cimetidine </e20> # mg increased the incidence of methotrexate -related side effects by 35% (40%) and 50% (59%), respectively, compared to single doses of # mg and methotrexate alone.
mechanism	Coadministration of <e10> rifampin </e10> with <e20> ethambutol </e20> increased ethambutol exposure by 17%.
mechanism	Corticosteroids : Dexamethasone ( <e10> dexamethasone </e10> ), fluconazole, and coumarin significantly inhibit the <e20> 5-HT1B-agonists </e20> clearance, which may lead to increased toxicity in these patients.
mechanism	Corticosteroids : Dexamethasone ( <e10> dexamethasone </e10> ) has been reported to increase the clearance of <e20> amphotericin_B </e20> by approximately 4-fold and increase the clearance of amphotericin_B by approximately 8-fold.
mechanism	Corticosteroids : Dexamethasone ( <e10> dexamethasone </e10> ) may decrease the clearance of <e20> warfarin </e20>.
mechanism	Corticosteroids : Dexamethasone ( <e10> dexamethasone </e10> ), cetirizine, or hydroxychloroquine may decrease the <e20> warfarin </e20> bioavailability.
mechanism	The daily dose of <e10> erythromycin </e10> can be reduced by more than 50% by concurrent use of <e20> rifampin </e20>, and this reduction is most pronounced with the combination of rifampin and CYP3A4 substrates that are highly active in animals.
mechanism	The daily dose of <e10> ketoconazole </e10> required to inhibit <e20> carbamazepine </e20> AUC by #% (mean) was # mg.
mechanism	<e10> Aprepitant </e10> and <e20> lithium </e20> may interact with one another in vitro, with a decrease in lithium plasma levels and a subsequent increase in lithium toxicity.
mechanism	<e10> Aprepitant </e10> and succinylcholine have additive effects on the metabolism of <e20> carbamazepine </e20> and increases in plasma concentrations of carbamazepine may occur when carbamazepine is administered concomitantly.
mechanism	<e10> Aprepitant </e10> may interfere with <e20> diazepam </e20> metabolism.
mechanism	Although there was no significant interaction between <e10> fluvoxamine </e10> and <e20> bromocriptine_mesylate </e20> in patients, patients who were on the lower portion of the GI tract when administered with bromocriptine_mesylate for # days had a 50% decrease in their AUC of fluvoxamine.
mechanism	Although there was no significant interaction between <e10> nelfinavir </e10> and <e20> atazanavir </e20>, the prothrombin time was decreased by approximately one-third after coadministration with the combination of nelfinavir and atazanavir.
mechanism	Tolbutamide : Aprepitant : <e10> Aprepitant </e10> increases the clearance of <e20> tolbutamide </e20>.
mechanism	Oral contraceptives : Combination <e10> warfarin </e10> therapy with oral contraceptives such as ethinyl_estradiol, hormonal_contraceptives, and norethindrone has been reported to increase the exposure to <e20> zidovudine </e20> and to inhibit zidovudine metabolism.
mechanism	Oral contraceptives : Coadministration of <e11> ORENCIA </e11> tablets and oral contraceptives such as ethinyl_estradiol ( estradiol ), drospirenone, and <e20> imetitonal </e20> can increase the exposure of estradiol to the body.
mechanism	Oral contraceptives : <e10> Cimetidine </e10> may decrease the absorption of <e20> oral_contraceptives </e20>.
mechanism	Oral contraceptives : Since <e10> clofibrate </e10> was administered concomitantly with <e20> cimetidine </e20> in the past, it is possible that clofibrate may have increased the exposure to cimetidine in patients.
mechanism	Oral contraceptives : Concurrent use of <e10> levonorgestrel </e10> with oral contraceptives (OCs) may result in higher concentrations of progestin and lower serum levels of <e20> levonorgestrel </e20>.
mechanism	Oral contraceptives : In vitro <e10> clindamycin </e10> treatment decreased the release of the <e20> cimetidine </e20> by 6- to 15-fold.
mechanism	Midazolam : <e10> Furosemide </e10> : <e20> Ketoconazole </e20> : Increase in the net absorption of cimetidine and ketoconazole
mechanism	<e10> Aprepitant </e10> may increase the clearance of <e20> ethinyl_estradiol </e20>, possibly by interfering with estrogens metabolism.
mechanism	<e10> Aprepitant </e10> increases plasma levels of the <e20> ketoconazole </e20>, which in turn increase the plasma level of the metabolite of the metabolite.
mechanism	<e10> Aprepitant </e10>, <e20> cimetidine </e20>, disopyramide, indomethacin, loratadine, methadone, phenytoin, rifampin, theophylline, valproate, verapamil, and voriconazole.
mechanism	<e10> Aprepitant </e10> has been shown to inhibit CYP3A4 activity, as well as <e20> alprazolam </e20>.
mechanism	therefore, coadministration of <e10> ketoconazole </e10> and <e20> clarithromycin </e20> was associated with a 38% increase in clarithromycin AUC, a 25% increase in clarithromycin AUC, and a 10% decrease in clarithromycin AUC/MIC (P = #).
mechanism	therefore, coadministration of <e11> Anafranil </e11> may be expected to reduce the blood <e20> digoxin </e20> plasma levels.
mechanism	therefore, coadministration of <e10> gentamicin </e10> with <e20> ketoconazole </e20> may lead to an increased frequency of bleeding events.
mechanism	therefore, coadministration of <e10> fluvoxamine </e10> and other <e22> tricyclic_antidepressants </e22> with lithium or other lithium-containing preparations may lead to elevated lithium levels, which may interfere with lithium-containing preparations to prevent lithium toxicity.
mechanism	therefore, coadministration of <e10> loperamide </e10> with a <e22> nonsteroidal_anti-inflammatory_drug </e22> may result in an increase in plasma concentrations of loperamide and a decrease in its bioavailability.
mechanism	Ketoconazole : When <e10> ketoconazole </e10> is given with <e20> itraconazole </e20>, the effect of itraconazole on aflatoxin_B1 (AFB_1) and its metabolite is decreased by about 50% in rats.
mechanism	Ketoconazole : When <e10> ketoconazole </e10> and <e20> erythromycin </e20> are used concomitantly, increases in Cmax and AUC may occur.
mechanism	Ketoconazole : When administered concomitantly with <e11> Kineret </e11>, <e20> ketoconazole </e20> prolongs the in vitro half-life of both drugs.
mechanism	Rifampin : When <e10> rifampin </e10> was given to healthy volunteers given <e20> warfarin </e20>, plasma and urine concentrations of warfarin were not increased by concurrent administration of rifampin.
mechanism	Rifampin : When <e10> rifampin </e10> is administered concurrently with <e20> Aprepitant </e20>, serum Aprepitant concentrations increase (P = 0.01).
mechanism	Rifampin : When <e10> rifampin </e10> is administered concurrently with <e20> zalcitabine </e20>, the following interactions occur: The level of zalcitabine required to inhibit the half-life of zalcitabine by 100% (the half-life of zalcitabine at #% inhibition of zalcitabine) is significantly lower when it is administered with rifampin than when it is administered without rifampin.
mechanism	Diltiazem : In patients receiving <e10> diltiazem </e10> and either <e20> warfarin </e20> or warfarin_sodium, an increase in warfarin plasma levels was observed.
mechanism	Diltiazem : In patients on a <e12> corticosteroid </e12>, decreased plasma levels of diltiazem may be expected because <e20> nisoldipine </e20> may have a profound influence on the metabolism of this steroid and lead to diminished excretion of diltiazem.
mechanism	Diltiazem : In vitro studies of <e10> doxorubicin </e10> with co-administered <e20> diltiazem </e20> have identified a possible inhibition of diltiazem metabolism.
mechanism	Paroxetine : Coadministration of <e10> paroxetine </e10> # mg with <e20> furosemide </e20> # mg decreased plasma furosemide levels by #%.
mechanism	Paroxetine : Coadministration of <e10> pargyline </e10> with <e20> paroxetine </e20> produced a decrease in the percentage of the serotonin metabolized in the liver, and a decrease in the paroxetine clearance.
mechanism	Paroxetine : Coadministration of <e10> paroxetine </e10> with <e20> fluvoxamine </e20> resulted in a statistically significant decrease in the steady-state plasma concentrations of fluvoxamine.
mechanism	Agents that induce hepatic enzyme reactions (eg, <e10> phenobarbital </e10>, phenytoin, etc,) may increase the clearance of <e20> rifampin </e20> and cause an increase in the rate of elimination of rifampin.
mechanism	Agents that induce hepatic enzymes such as <e10> rifampin </e10>, phenytoin, and isoniazid may increase the clearance of <e20> cholestyramine </e20> and decrease serum concentrations.
mechanism	Agents that induce CYP3A4 activity, such as <e10> isoniazid </e10>, rifampin, phenytoin, and itraconazole, may increase <e20> clofibrate </e20> plasma concentrations.
mechanism	Inhibitors of CYP3A4 (e,g,, ketoconazole, itraconazole, erythromycin, clarithromycin, <e10> ritonavir </e10>, nelfinavir, indinavir, saquinavir, indinavir, saquinavir ) have been reported to have a significant decrease in <e20> ketoconazole </e20> plasma concentrations and have an additive effect on the absorption of this antifungal with plasma concentrations as low as # ng/mL.
mechanism	Inhibitors of CYP3A4 (such as ketoconazole, itraconazole, erythromycin, clarithromycin, <e10> troleandomycin </e10>, ritonavir, nelfinavir, saquinavir, indinavir, nefazodone, valdecoxib, bromocriptine ) may reduce the bioavailability of oral <e20> warfarin </e20> by reducing hepatic metabolism.
mechanism	Inhibitors of CYP3A4, such as ketoconazole, erythromycin, clarithromycin, and <e10> ritonavir </e10>, may reduce the absorption of <e20> diltiazem </e20>.
mechanism	Inhibitors of CYP3A4 (phenytoin, alprazolam, rifampin, ketoconazole, <e10> itraconazole </e10>, clarithromycin, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, erythromycin, indinavir, saquinavir, telithromycin, troleandomycin ) have been reported to inhibit <e20> rifampin </e20> metabolism.
mechanism	Inhibitors of CYP3A4 (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, <e10> indinavir </e10>, saquinavir, nelfinavir ) have been reported to increase plasma levels of <e20> methotrexate </e20>.
mechanism	Inhibitors of CYP3A4 (such as ketoconazole, itraconazole, erythromycin, clarithromycin, nefazodone, ritonavir, nelfinavir, saquinavir, <e10> telithromycin </e10>, troleandomycin, zidovudine, nelfinavir, ritonavir, saquinavir, indinavir ) have been reported to decrease the clearance of <e20> clarithromycin </e20>.
mechanism	Inhibitors of CYP3A4 ( alprazolam, <e10> erythromycin </e10>, clarithromycin, itraconazole, nefazodone, troleandomycin, troleandomycin, clarithromycin ) may decrease the clearance of <e20> cisapride </e20> by increasing the metabolism of cisapride.
mechanism	Inhibitors of CYP3A4 (such as ketoconazole, itraconazole, and erythromycin ) and CYP2D6 (such as <e10> troleandomycin </e10>, clarithromycin, and nefazodone ) may increase plasma levels of <e20> doxorubicin </e20> and induce toxicity.
mechanism	Inhibitors of CYP3A4 (such as ketoconazole, <e10> itraconazole </e10>, erythromycin, clarithromycin, ritonavir, indinavir, saquinavir, indinavir / ritonavir, itraconazole ) may increase the clearance of <e20> bromocriptine_mesylate </e20> by severalfold.
mechanism	Inhibitors of CYP3A4 (such as ketoconazole, erythromycin, clarithromycin, ritonavir, <e10> indinavir </e10>, saquinavir, nefazodone, troleandomycin, ritonavir, saquinavir, erythromycin, saquinavir, indinavir ) and/or CYP3A5 (such as <e20> terfenadine </e20>, troleandomycin, itraconazole, nefazodone, fluconazole, itraconazole, nelfinavir, ritonavir, ritonavir, valdecoxib ) have been reported to cause a marked increase in plasma levels of zidovudine and to interfere with the metabolism of zidovudine to the active metabolite, 5-fluorouracil.
mechanism	Inhibitors of CYP3A4 (e,g,, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, <e10> nefazodone </e10>, nelfinavir ) may increase plasma levels of <e20> didanosine </e20>.
mechanism	Inhibitors of CYP3A4 (e,g,, ketoconazole, itraconazole, erythromycin, clarithromycin, <e10> troleandomycin </e10>, ritonavir, nelfinavir, indinavir, saquinavir, telithromycin, troleandomycin, indinavir, saquinavir, terfenadine ) may increase plasma concentrations of <e20> nelfinavir </e20> by several-fold.
mechanism	Ketoconazole : Coadministration of <e10> ketoconazole </e10> with <e20> cisapride </e20> decreased the cisapride plasma concentrations by approximately 75% and caused a significant increase in cisapride Cmax by approximately 60%.
mechanism	Ketoconazole : Coadministration of <e10> ketoconazole </e10> # mg once daily with <e20> nelfinavir </e20> # mg daily reduced the AUC of nelfinavir from # to #,000 (c-max) # mg/h.
mechanism	Ketoconazole : Coadministration of <e10> ketoconazole </e10> tablets and <e20> atorvastatin </e20> decreased the plasma concentration of both drugs by approximately 50%.
mechanism	Quinidine : Coadministration of <e10> nevirapine </e10> and <e20> quinidine </e20>, a potent inducer of hepatic enzymes, resulted in a 40% increase in plasma quinidine levels.
mechanism	Quinidine : Coadministration of <e10> cimetidine </e10> and <e20> quinidine </e20> results in a 40% increase in serum quinidine levels.
mechanism	Quinidine : Coadministration of <e10> ketoconazole </e10> tablets with <e20> quinidine </e20> produced a 24% increase in serum quinidine levels.
mechanism	Carbamazepine : Coadministration of <e10> carbamazepine </e10> and <e20> fluvoxamine </e20> increased the steady-state Cmax of phenytoin by # times and AUC by 3-fold.
mechanism	Carbamazepine : Coadministration of <e10> carbamazepine </e10> with <e20> lithium </e20> resulted in a significant increase in lithium toxicity, and a further decrease in lithium clearance.
mechanism	Carbamazepine : Coadministration of <e10> carbamazepine </e10> and <e20> rifabutin </e20> resulted in the decrease in AUC of rifabutin and coadministration of rifabutin and carbamazepine resulted in the decrease in AUC of rifabutin.
mechanism	<e10> Phenobarbital </e10> and lithium are potent inhibitors of hepatic metabolism of <e20> caffeine </e20>.
mechanism	<e10> Phenobarbital </e10>, ketoconazole and triazolam have been reported to increase <e20> disopyramide </e20> concentrations by about 2%.
mechanism	In EM individuals, <e10> methotrexate </e10> and <e20> gemfibrozil </e20> decreased the plasma levels of all three active cephalosporins (ciprofloxacin, tacrolimus, and cefazolin ).
mechanism	In EM individuals, <e10> erythromycin </e10> # mg (1,000 mg twice daily for # days) resulted in a 50% increase in plasma exposure of <e20> fosamprenavir </e20>.
mechanism	In EM individuals, the addition of <e10> cimetidine </e10> to a single dose of <e20> furosemide </e20> significantly reduced the cGMP level, and increased the AUC of furosemide.
mechanism	In EM individuals, the <e10> erythromycin </e10> elimination half-life increased from approximately # minutes to # minutes with coadministration of <e20> astemizole </e20>.
mechanism	In EM individuals, the <e10> ergotamine </e10> did not inhibit the <e20> digoxin </e20> / colchicine hepatic absorption, nor did it alter the plasma levels of digoxin or colchicine.
mechanism	Antacid : When <e10> fluvastatin </e10> and <e20> colestipol </e20> are used concomitantly, the level of fluvastatin should be carefully monitored, since high serum levels of fluvastatin have been reported when colestipol is used concomitantly with agents such as amiodarone, carbamazepine, carbamazepine plus cyclosporine, diclofenac, fluvastatin, fluvoxamine, lovastatin, phenytoin, rifabutin, quinidine, tacrolimus, theophylline, theophylline plus cyclosporine, and warfarin.
mechanism	Antacid : When <e10> clofibrate </e10> was given concomitantly with <e20> antacid </e20>, the blood levels of clofibrate were higher.
mechanism	Colestipol : Plasma <e10> colestipol </e10> concentrations are increased by approximately 50% when <e20> atorvastatin </e20> is coadministered.
mechanism	Colestipol : Plasma levels of <e10> colestipol </e10> were increased in patients with chronic renal failure treated with <e20> ketoconazole </e20> or low-dose methotrexate.
mechanism	Colestipol : Plasma <e10> colestipol </e10> levels increased significantly with <e20> lorazepam </e20>, but not with cimetidine.
mechanism	Digoxin : When <e10> digoxin </e10> was given with <e20> cyclosporine </e20>, serum cyclosporine concentrations were decreased by a mean of 38% (50% increase, P = 0.006) and serum digoxin concentrations were decreased by a mean of 39% (22% increase, P = 0.001) in subjects receiving cyclosporine with digoxin.
mechanism	Digoxin : When <e10> atazanavir </e10> was coadministered with <e20> digoxin </e20>, the AUC of digoxin increased significantly (P =.001) and the AUC of the other drugs decreased significantly (P =.003).
mechanism	Digoxin : When <e10> erythromycin </e10> was administered to healthy volunteers, <e20> digoxin </e20> concentrations decreased to #% and #%, respectively.
mechanism	Erythromycin : In patients taking <e10> erythromycin </e10>, <e20> diazepam </e20>, or valdecoxib, serum concentrations of these agents were reduced by approximately 50% to 60%, and half-life was shortened by approximately 50%.
mechanism	Erythromycin : In a clinical study of patients on erythromycin, there was a reduction in the clearance of <e10> erythromycin </e10> and <e20> ciprofloxacin </e20> by approximately 46% and 45%, respectively.
mechanism	Erythromycin : In the presence of <e10> erythromycin </e10>, the amount of <e20> alprazolam </e20> bound to the enzyme, and the resultant alprazolam bioavailability decreased significantly.
mechanism	Oral Contraceptives : <e10> Tetracycline </e10> has been shown to decrease the bioavailability of <e20> estradiol </e20> in some studies and therefore, may decrease the effectiveness of oral contraceptives (oral contraceptives or progestins ) by interfering with estrogen metabolism.
mechanism	Oral Contraceptives : <e10> Tadalafil </e10> inhibits the metabolism of oral <e20> atorvastatin </e20>.
mechanism	Oral Contraceptives : Coadministration of <e11> HUMORSOL </e11> with oral contraceptives, such as ethinyl_estradiol, <e20> progestin </e20>, or norethindrone, may decrease the bioavailability of HUMORSOL.
mechanism	Oral Contraceptives : Oral contraceptives containing ethinyl_estradiol ( <e10> EE </e10> ) and/or lomefloxacin ( <e20> LOM </e20> ) may decrease the metabolism of methotrexate, resulting in higher serum levels of methotrexate.
mechanism	Oral Contraceptives : Concomitant use of <e11> PRINIVIL </e11> with oral contraceptives has been reported to result in significant increases in blood concentrations of the contraceptive and its active metabolite, <e20> progestin </e20>.
mechanism	Oral Contraceptives : <e10> Chlorotrianisene </e10> increased the metabolism of some oral contraceptives, resulting in increased levels of estradiol and decreased levels of progesterone and <e20> estradiol </e20>.
mechanism	Rifampin : Coadministration of <e10> rifampin </e10> and <e20> lithium </e20> increased the half-life of lithium from # to # hours.
mechanism	Rifampin : Coadministration of <e10> ciprofloxacin </e10> with rifampin at # mg/day decreased the <e20> dofetilide </e20> concentration by 39%.
mechanism	Rifampin : Coadministration of <e10> rifampin </e10> with <e20> dexamethasone </e20> and cimetidine, two of the two active steroids in oral contraceptives, has been reported to result in a 50% decrease in the bioavailability of dexamethasone.
mechanism	<e12> Antacids </e12>, sucralfate, and sucralfate containing sulfate groups, and sucralfate containing disulfate groups may interfere with the absorption of <e20> cefazolin </e20>, resulting in increased serum cefazolin levels.
mechanism	<e12> Antacids </e12> may interfere with the absorption of <e20> erythromycin </e20>.
mechanism	<e12> Antacids </e12> containing calcium or aluminum, in the absence of magnesium or iron, or containing other <e22> calcium_antagonists </e22>, such as heparin, zinc, or aluminum, may inhibit the metabolism of orally administered ARAVA by approximately 25%.
mechanism	Antacids increase the absorption of <e10> erythromycin </e10> and <e20> fluconazole </e20>, resulting in a higher clearance of the antacids.
mechanism	Use with Allopurinol : <e10> Furosemide </e10> may inhibit the absorption of <e20> cimetidine </e20> and may result in lower serum cimetidine concentrations.
mechanism	When used in combination with <e10> cisplatin </e10>, <e20> erythromycin </e20> significantly reduced cisplatin levels.
mechanism	When used in combination, <e10> erythromycin </e10>, indomethacin, and theophylline may cause a reduction in <e20> methotrexate </e20> clearance by approximately 20% to 50%.
mechanism	When used in combination with other antihypertensive_drugs, <e11> FORADIL </e11> may potentially result in prolongation of the QT interval and increase in the plasma levels of propranolol and <e20> lisinopril </e20>.
mechanism	When used in combination with other antituberculosis_drugs, <e10> ciprofloxacin </e10> markedly increased the clearance of <e20> carbamazepine </e20> and did not affect its metabolism to aminoglycosides or to theophylline.
mechanism	When used in combination, the following medications have been reported to increase <e10> halothane </e10> plasma concentrations: alcohol (the hepatic metabolism of which is affected by <e20> halothane </e20> ), chloral_hydrate, barbiturates, barbiturates containing cholestyramine, calcium supplements, colestipol, dantrolene, nicotine, propoxyphene, quinidine, selegiline, tamoxifen, theophylline, and warfarin.
mechanism	When used in combination with <e10> rifabutin </e10>, <e20> quinine </e20> and chloroquine significantly reduced the AUC of rifabutin and increased the mean AUC of quinine by 38% and 23%, respectively.
mechanism	When used in combination with other <e12> SSRI </e12> -containing drugs, rifampin, fluoxetine, fluvoxamine, paroxetine, sertraline, theophylline, or <e20> tolbutamide </e20>, clofibrate may increase plasma levels of SSRI s.
mechanism	When used in combination with other <e12> anticholinergics </e12>, it has been reported to decrease the pharmacokinetics of <e20> bromocriptine_mesylate </e20>.
mechanism	When used in combination, there is a strong tendency for the <e12> NSAIDs </e12> to decrease the absorption of <e20> furosemide </e20>.
mechanism	When used in combination with <e10> erythromycin </e10>, clofibrate (n=26) or fibrate (n=27) inhibited the absorption of <e20> erythromycin </e20> and its active metabolite, butyrophenones.
mechanism	When used in combination, the following agents may decrease the absorption of <e10> furosemide </e10> : <e20> Chlorotrianisene </e20>, digoxin, phenytoin, triazolam, diltiazem, felbamate, diltiazem_retard, flecainide, metoclopramide, rifabutin, warfarin, and terfenadine.
mechanism	When used in combination, <e10> ciprofloxacin </e10> and <e20> rifampin </e20> are also associated with an increased risk of serious infections (e,g,, bloodstream infections, skin infections, and liver toxicity).
mechanism	When used in combination, <e10> disopyramide </e10> may decrease the clearance of <e20> methotrexate </e20>.
mechanism	When used in combination with <e10> warfarin </e10>, <e20> diltiazem </e20> significantly decreased the tetracycline clearance.
mechanism	When used in combination with <e10> phenytoin </e10>, <e20> rifampin </e20> increases the serum concentration of phenytoin.
mechanism	When used in the clinical setting, <e10> isoniazid </e10> may increase the plasma concentration of <e20> carbamazepine </e20>, decreasing its absorption and, therefore, increasing its toxicity.
mechanism	When used in combination with <e10> dapsone </e10>, <e20> cisapride </e20> may produce significant increases in blood levels of dapsone and other oral anticoagulants.
mechanism	When used in conjunction with other <e12> quinolones </e12>, <e20> bismuth_subsalicylate </e20> has the potential to alter the pharmacokinetics of ciprofloxacin and other quinolones.
mechanism	When used in combination with <e11> aspirin </e11>, the <e22> anticoagulant </e22> s markedly reduce the efficacy of the prothrombin time test, prolonging the prothrombin time to the detriment of bleeding and increased the risk of bleeding complications.
mechanism	When used in combination with <e10> dantrolene </e10>, warfarin or other <e22> coumarin-type_anticoagulants </e22>, the AUC of quinolones (sulfonamides and tetracyclines ) are increased by approximately 50%.
mechanism	When used in combination, the following drugs have been shown to decrease the plasma levels of <e11> ENBREL </e11> by about 50% or more: enoxacin (33%), <e20> furosemide </e20> (20%), triazolam (10%), phenytoin (10%), cimetidine (7%), methotrexate (5%), astemizole (5%), valproate (3%), terfenadine (3%), cimetidine (2%), cimetidine alone (2%), cimetidine and methotrexate (1%), triazolam (1%), and phenytoin (1%).
mechanism	When used in combination with <e10> indinavir </e10>, <e20> ritonavir </e20>, indinavir, and ritonavir levels may be decreased by up to #%.
mechanism	When used in combination with other anticoagulants ( warfarin, corticosteroids, <e10> triamterene </e10>, estrogens ), <e21> FOSCAVIR </e21> may prolong the prothrombin time, potentially increasing the risk of bleeding if the patient is taking anticoagulants concomitantly.
mechanism	When used in combination with <e10> digoxin </e10>, <e20> astemizole </e20> may cause significant increases in digoxin serum levels.
mechanism	When used in conjunction with <e10> methotrexate </e10>, the <e22> antacids </e22> also inhibit methotrexate metabolism and increase the toxic effects of methotrexate.
mechanism	When used in combination with <e10> ethoxzolamide </e10>, <e20> zalcitabine </e20> and oral contraceptives may increase the clearance of the drug, which is associated with an increase in the risk of gastrointestinal toxicity.
mechanism	When used in combination with <e10> warfarin </e10>, <e20> digoxin </e20> has been reported to increase the extent of the blood-thinner effect.
mechanism	When used in combination with <e11> EQUETROTM </e11>, coadministration of <e20> nifedipine </e20> may produce a net decrease in oral bioavailability.
mechanism	When used in combination, <e10> indomethacin </e10>, dipyridamole, and <e20> cisapride </e20> inhibit the metabolism of atorvastatin.
mechanism	When used in combination with a drug that has an antihistamine ( <e10> phenobarbital </e10>, <e20> phenytoin </e20>, or ketoconazole ), the concomitant use of an N-methyl-d-aspartate (MAOI) inhibitor such as phenobarbital with oral long-term, low-dose, low-dose, high-dose, and high-dose formulations of cisapride may result in a significant increase in cisapride plasma concentrations.
mechanism	When used in combination with a <e12> quinolone </e12>, <e20> digoxin </e20> results in approximately twice the Digoxin (2 mg) required to achieve a level of digoxin in the blood of the dog below the limit of detection (LOD).
mechanism	When used in combination with <e11> VIDEX </e11>, <e20> ketoconazole </e20> reduced the in vitro elimination of all three estrogens.
mechanism	When used in the presence of <e10> alprazolam </e10>, <e20> fluvoxamine </e20> or zalcitabine, CYP3A4 inhibitors, such as zalcitabine, alprazolam, and rifampin, increase the plasma concentration of zalcitabine.
mechanism	When used in the presence of <e10> diflunisal </e10> and <e20> cilostazol </e20>, concomitant use with either diflunisal or cilostazol results in a significant increase in both cilostazol and diflunisal exposure.
mechanism	When used in combination with <e10> doxycycline </e10>, <e20> fluvoxamine </e20>, or atorvastatin, the following drugs have been reported to decrease the plasma concentrations of rifampin ( atorvastatin ): A dose of # mg of rifampin # mg of fluvoxamine # mg of atorvastatin
mechanism	Co-administration with <e10> diltiazem </e10> (50 mg qd) resulted in a significant decrease in <e20> adenosine </e20> levels and an increase in the time required for steady-state adenosine levels to return to normal values.
mechanism	Co-administration with <e10> diltiazem </e10> decreased the clearance of <e20> carbamazepine </e20> by approximately 60% and caused an approximately 5% increase in carbamazepine AUC.
mechanism	Total body clearance of <e10> amiodarone </e10> was increased by a mean (SD) of 1.3% (2.8) times when <e20> phenytoin </e20> and cimetidine were co-administered.
mechanism	Total body clearance of <e10> diltiazem </e10> increased from 16% to 26% after administration of <e20> ciprofloxacin </e20>, from 12% to 15% after administration of rifampin, and from 12% to 18% after administration of fluconazole.
mechanism	Total body clearance of <e10> warfarin </e10> is increased by <e20> clozapine </e20>.
mechanism	Total body clearance of <e10> probenecid </e10> was reduced by about 20% when coadministered with <e20> diltiazem </e20>.
mechanism	Lithium : Increased plasma levels of <e10> lithium </e10> are seen in patients receiving <e20> bromocriptine_mesylate </e20>.
mechanism	Lithium : Increased serum lithium levels have been reported with concomitant administration of <e10> lithium </e10> and <e20> diltiazem </e20>.
mechanism	Lithium : Increased plasma lithium concentrations have been reported when <e11> REVIA </e11> was administered concomitantly with <e20> lithium </e20>.
mechanism	Digoxin : In a study in healthy volunteers, digoxin clearance was reduced by #% when <e10> diltiazem </e10> was coadministered with <e20> digoxin </e20>, and was increased when digoxin was given concurrently with digoxin.
mechanism	Digoxin : In the presence of <e10> cyclosporine </e10>, <e20> digoxin </e20> was displaced from its binding sites on the cell surface, resulting in a decrease in the exposure of digoxin to the cell surface.
mechanism	Digoxin : In a study in healthy volunteers, <e10> digoxin </e10> decreased the AUC and Cmax of <e20> alosetron </e20> by 43% and 33%, respectively, and the AUC and Cmax of cimetidine by 41% and 23%, respectively.
mechanism	On the basis of in vitro data, coadministration of <e11> EQUETROTM </e11> with dapsone or <e20> rifabutin </e20> resulted in significant increases in tetracycline exposure.
mechanism	On the basis of a report from the University of Illinois, CYP3A4 substrates that are covalently linked to a benzodiazepine ( alprazolam, <e10> triazolam </e10> ) or an atypical_cytochrome P450 3A4 substrate ( cisapride ) may increase <e20> alprazolam </e20> clearance.
mechanism	On the basis of these results, the possibility that nonsteroidal_anti-inflammatory_drugs ( <e12> NSAIDs </e12> ) may reduce the antihypertensive effect of <e20> guanethidine </e20> should be considered.
mechanism	On the basis of the data from a study in healthy volunteers, a possible pharmacokinetic interaction between <e11> NUROMAX </e11> and <e20> ketoconazole </e20> is likely.
mechanism	On the basis of these data, an appropriate daily dose of <e10> clofibrate </e10> was determined to be # mg for patients taking <e20> fibrate </e20> at the same time as clofibrate.
mechanism	On the basis of these results, <e10> gentamicin </e10> has been shown to reduce the <e20> norethindrone </e20> elimination by approximately 25% and may have the potential to increase plasma concentrations of the active metabolite norethindrone.
mechanism	On the basis of the above observations, a possible therapeutic strategy for the following: Serum digoxin and <e10> digoxin </e10> in patients receiving digoxin as the sole intravenous co-administration and <e20> ketoconazole </e20> or other inhibitors of CYP2D6 metabolism may be considered.
mechanism	On the basis of the in vitro metabolism of <e10> ketoconazole </e10>, the following actions of <e20> enoxacin </e20> were considered to be possible: (1) inhibition of ketoconazole metabolism and inhibition of the CYP1A2 enzyme (renal elimination) caused by ketoconazole; (2) prolongation of the QT interval caused by enoxacin ; and (3) elimination of enoxacin from the circulation resulting from inhibition of the CYP1A2 enzyme.
mechanism	On the basis of clinical studies of oral <e12> anticoagulants </e12>, a potential drug interaction between warfarin and <e20> cimetidine </e20> is postulated.
mechanism	On the basis of an increase in <e10> adenosine </e10> metabolism observed during adenosine infusion, a significant increase in the half-life of <e20> digoxin </e20> was observed.
mechanism	Furthermore, <e10> rifampin </e10> and <e20> terfenadine </e20> have been shown to interfere with the metabolism of warfarin, leading to higher levels of the active metabolite, warfarin.
mechanism	Furthermore, <e10> rifampin </e10>, cimetidine, and <e20> warfarin </e20> markedly decreased the activity of ketoconazole.
mechanism	Furthermore, <e10> rifampin </e10> treatment was associated with decreased plasma levels of <e20> cefditoren_1 </e20>.
mechanism	Furthermore, rifampin, clarithromycin, and <e10> itraconazole </e10> may increase plasma concentrations of <e20> erythromycin </e20>.
mechanism	Furthermore, rifampin, clarithromycin, and <e10> fluconazole </e10> inhibit <e20> cefdinir </e20> binding to its integrase and may thereby contribute to elevated cefdinir plasma concentrations.
mechanism	Concomitant administration of <e10> alosetron </e10> and other <e22> macrolide_antibiotics </e22>, including erythromycin, clarithromycin, and fluconazole, may cause increased clearance of alosetron.
mechanism	Concomitant administration of <e10> clindamycin </e10> with oral <e20> erythromycin </e20> is likely to reduce the clearance of both drugs.
mechanism	Concomitant administration of <e10> ketoconazole </e10> (20 mg/day) and <e20> diflunisal </e20> (3 mg/day) for # weeks decreased serum levels of ketoconazole by 62%.
mechanism	In vitro studies with <e10> estradiol </e10> or progesterone showed that both compounds inhibit <e20> catecholamine </e20> metabolism by an interrelated mechanism.
mechanism	In vitro studies have shown that <e10> dexamethasone </e10> may inhibit <e20> cimetidine </e20> binding.
mechanism	In vitro studies have shown that the intravenous self-administration of <e11> IRESSA </e11> and <e20> rifabutin </e20> (or similar cations) resulted in a mean increase in (s) rifabutin half-life of 23%.
mechanism	In vitro studies indicate that <e10> astemizole </e10> inhibits <e20> ketoconazole </e20> metabolism by causing a significant increase in its clearance.
mechanism	Concurrent use of <e10> dexamethasone </e10> and <e20> ketoconazole </e20> may decrease the clearance of ketoconazole.
mechanism	Concurrent use of <e10> cimetidine </e10> and <e20> zalcitabine </e20> increased the half-life of zalcitabine by 11%.
mechanism	Hormonal_Contraceptives, Including Hormonal_Contraceptives Injection, are associated with an increased risk of serious infections if administered prior to or during therapy with <e10> rifampin </e10>, ciprofloxacin, indinavir, itraconazole, nelfinavir, saquinavir, telithromycin, troleandomycin, and <e20> clarithromycin </e20>.
mechanism	Steady-state <e10> bosentan </e10> serum concentrations are decreased by approximately 10% following concomitant administration of <e20> cisapride </e20>.
mechanism	Steady-state <e10> bosentan </e10> plasma concentrations were increased by a 2-fold, mean (s) increase in <e20> cyclosporine </e20>.
mechanism	Steady-state <e10> bosentan </e10> plasma concentrations are increased by approximately 50% when coadministered with either <e20> disopyramide </e20>, carbamazepine, or ketoconazole.
mechanism	Co-administration of <e10> ketoconazole </e10> with <e20> cisapride </e20> resulted in a net increase in cisapride plasma levels.
mechanism	Co-administration of <e10> ciprofloxacin </e10> at a dose of # mg/kg was associated with a decrease in the concentrations of <e20> cisapride </e20> and its active metabolite, butyrophenones, as well as the norethindrone A metabolite in #, #, and # mg/kg body weight groups, respectively.
mechanism	Co-administration of <e10> warfarin </e10> with <e20> cyclosporine </e20> may result in increased cyclosporine levels and potentially increased anticoagulant efficacy.
mechanism	Co-administration of <e10> foscarnet </e10> increased plasma concentrations of <e20> atorvastatin </e20> by 10% and reduced plasma concentrations of cinoxacin by 5%.
mechanism	Co-administration of <e10> ketoconazole </e10> tablets and <e20> indinavir </e20> # mg daily for # days produced an increase in Cmax and AUC of indinavir.
mechanism	Co-administration of <e10> methotrexate </e10> with <e20> lithium </e20> (e,g,, as needed) increased lithium concentrations to approximately #% of the normal range and caused a 10- to 15-fold increase in lithium exposure.
mechanism	Co-administration of <e10> gabapentin </e10> and a <e22> dopamine_antagonist </e22> may result in an increase in gabapentin plasma levels.
mechanism	Co-administration of <e10> lithium </e10> may enhance the toxicity of <e20> carbamazepine </e20>, because lithium may increase the prothrombin time.
mechanism	Co-administration of <e10> dapsone </e10> with <e20> cimetidine </e20> increased dapsone serum concentrations and decreased cimetidine plasma concentrations.
mechanism	<e10> Bosentan </e10> and dexamethasone inhibit <e20> ketoconazole </e20> metabolism and lead to increased plasma concentrations of ketoconazole.
mechanism	<e10> Bosentan </e10>, a potent serotonin reuptake inhibitor, reduced the plasma concentration of <e20> isoniazid </e20>.
mechanism	<e10> Bosentan </e10> decreased the hepatic uptake of <e20> atorvastatin </e20> by 46%.
mechanism	Ketoconazole : Co-administration of <e10> ketoconazole </e10> with <e20> cisapride </e20> was associated with a 3- to 5-fold increase in the half-life of cisapride.
mechanism	Ketoconazole : Co-administration with <e10> ketoconazole </e10> may result in increased plasma concentrations of <e20> diltiazem </e20>.
mechanism	Ketoconazole : Co-administration of <e10> ketoconazole </e10>, the most commonly used oral <e22> hypoglycemic_agent </e22>, significantly decreased the glycemic control of patients on oral hypoglycemic_agents.
mechanism	Simvastatin and Other <e12> Antihypertensives </e12>, Inhibitors of CYP3A4 ( fluoxetine, <e20> phenytoin </e20>, sertraline, paroxetine, triazolam ) may decrease plasma levels of cetirizine.
mechanism	<e10> Bosentan </e10> may increase serum concentrations of <e20> phenytoin </e20> and other corticosteroids, which are primarily metabolized by CYP3A4.
mechanism	<e10> Bosentan </e10> decreased <e20> warfarin </e20> concentrations and increased warfarin elimination half-life by approximately 5- to 15-fold.
mechanism	<e10> Bosentan </e10> decreases plasma <e20> cyclosporine </e20> levels.
mechanism	<e10> Bosentan </e10>, which may induce ventricular fibrillation, significantly increased the rate of <e20> succinylcholine </e20> clearance in the presence of low plasma levels of succinylcholine.
mechanism	<e10> Bosentan </e10>, but not <e20> dofetilide </e20>, decreased the hepatic expression of insulin and C-peptide by 62% and 48%, respectively.
mechanism	<e10> Bosentan </e10>, in comparison with <e20> lomefloxacin </e20>, significantly increased serum concentrations of lomefloxacin (11%, P =.001).
mechanism	<e10> Bosentan </e10> may enhance the effects of: <e22> Aminoglycosides </e22> and sulfonamides, such as tetracycline, chloramphenicol, bacitracin, chloramphenicol, cisapride, dapsone, cyclosporine, diltiazem, enoxacin, fluconazole, halothane, oral contraceptives, sildenafil, sucralfate, sulfonamides, sulfonamides, tamoxifen.
mechanism	<e10> Bosentan </e10> may decrease <e20> lisinopril </e20> plasma levels by interfering with hepatic metabolism of lisinopril, resulting in elevated plasma concentrations of lisinopril and its active metabolite, nisin.
mechanism	Warfarin : Co-administration of <e10> warfarin </e10> with <e20> nevirapine </e20> results in a decreased half-life of nevirapine.
mechanism	Warfarin : Co-administration of <e10> clofibrate </e10> # mg was associated with a 40% increase in the steady-state Cmax of <e20> warfarin </e20> # mg (p = #).
mechanism	Warfarin : Co-administration of <e10> warfarin </e10> with <e20> chloroquine </e20> or quinine resulted in a significant increase in the AUC and Cmax of chloroquine.
mechanism	Warfarin : Co-administration of <e10> astemizole </e10> with warfarin significantly reduced its blood levels and increased the AUC of <e20> warfarin </e20>.
mechanism	Warfarin : Co-administration of <e10> warfarin </e10> and <e20> lomefloxacin </e20> decreased the AUC for warfarin by 40%.
mechanism	Warfarin : Co-administration of <e10> phenytoin </e10> with <e20> warfarin </e20> may increase the blood levels of warfarin, resulting in decreased pharmacologic effect.
mechanism	Concomitant oral administration of <e10> rifampin </e10> and <e20> ketoconazole </e20> increases the metabolism of rifampin and results in higher serum levels of rifampin.
mechanism	Concomitant oral administration of <e10> ketoconazole </e10> with <e20> hydralazine </e20>, terfenadine, or triazolam, resulting in approximately 5 to 10% reduction in the dose of ketoconazole, may result in increased serum levels of hydralazine and terfenadine.
mechanism	Concomitant oral administration of <e10> diltiazem </e10> with <e20> ethinyl_estradiol </e20> resulted in a 40% increase in the number of estradiol units administered.
mechanism	This antagonistic effect is abolished by <e10> phenytoin </e10>, levothyroxine, thyroid_preparations containing iodine (such as iodine_containing preparations), and by <e20> calcium_iodide </e20>.
mechanism	This antagonistic effect was also observed with <e10> valdecoxib </e10> alone and was reversed by <e20> bortezomib </e20>.
mechanism	This antagonistic effect on the pharmacokinetics of <e10> diltiazem </e10> was expected because diltiazem was expected to decrease the renal clearance of <e20> diltiazem </e20> by interfering with its metabolism.
mechanism	- Indomethacin : <e10> Indomethacin </e10> has been shown to have an effect on <e20> bromocriptine_mesylate </e20> clearance and blood glucose levels.
mechanism	- Indomethacin : <e10> Indomethacin </e10> increases the plasma concentration of <e20> caffeine </e20>.
mechanism	- Indomethacin : Decreased <e10> indomethacin </e10> clearance was noted when <e20> digoxin </e20> was given concurrently with digoxin.
mechanism	In a study of patients with impaired renal function, <e10> sirolimus </e10> reduced the number of <e20> cisapride </e20> required to achieve a clinically significant increase in serum cisapride levels from a baseline of # mg/dL to # mg/dL.
mechanism	In a study of # healthy subjects, <e10> loperamide </e10> at # mg/day was well tolerated and, like other drugs, resulted in a reduction in <e20> carbamazepine </e20> levels and an increase in prothrombin time.
mechanism	In a study in healthy volunteers, <e10> clozapine </e10> significantly increased the serum concentrations of allophycins and <e20> ciprofloxacin </e20> in the presence of coadministration with both theophylline and ciprofloxacin.
mechanism	In a study of healthy volunteers receiving <e10> furosemide </e10> and <e20> valdecoxib </e20> concurrently, an increase in valdecoxib clearance was observed when furosemide was discontinued.
mechanism	In a study in healthy volunteers, co-administration of <e10> rifampin </e10> and <e20> gabapentin </e20> resulted in an increase in rifampin exposure of 2.4-fold and a decrease in gabapentin exposure of 1.6-fold, respectively.
mechanism	In a study in which <e10> cefazolin </e10> was administered with a # mg oral dose of <e20> levothyroxine </e20> # mg daily, serum levothyroxine levels were increased by #% for # days, and there was a corresponding increase in levothyroxine Cmax and AUC.
mechanism	In vitro, <e10> cisapride </e10> increased the clearance of <e20> cyclosporine </e20> and carbamazepine.
mechanism	In vitro, <e10> gentamicin </e10> increases the half-life of <e20> diltiazem </e20> and cimetidine by about 3% and about 15%, respectively, but increases the half-life of cimetidine by about 8% and about 5%, respectively, compared to gentamicin alone.
mechanism	In vitro, <e10> ketoconazole </e10> markedly inhibited the metabolism of <e20> furosemide </e20> and its potentate.
mechanism	<e10> Itraconazole </e10> reduced the clearance of <e20> rifampin </e20> by 25% and the clearance of furosemide by 34%.
mechanism	<e10> Itraconazole </e10> was found to decrease the serum concentrations of <e20> warfarin </e20> and its derivatives.
mechanism	<e10> Itraconazole </e10> may decrease the absorption of <e20> ketoconazole </e20>.
mechanism	<e10> Phenytoin </e10> may decrease the clearance of <e20> warfarin </e20> by inhibiting CYP3A4 and increasing endogenous warfarin levels.
mechanism	<e10> Phenytoin </e10> has been shown to inhibit the metabolism of <e20> amiodarone </e20> and ketoconazole, resulting in a decrease in the total levels of both drugs.
mechanism	<e10> Phenytoin </e10>, a tricyclic_antidepressant, increases the metabolism of <e20> cimetidine </e20>.
mechanism	Since the pharmacokinetics of the <e12> benzodiazepines </e12> is not known, their dose adjustment of <e20> ketoconazole </e20> can be problematic.
mechanism	Since the pharmacokinetics of <e10> ketoconazole </e10> are unknown, it is not likely that there is a significant interaction with <e20> erythromycin </e20>.
mechanism	Because busulfan is a synthetic immunosuppressive drug, it has been hypothesized that <e10> busulfan </e10> may interfere with the elimination of vitamin_D and the synthesis of <e20> vitamin_D </e20>.
mechanism	Because busulfan is metabolized to <e10> phenytoin </e10> and <e20> isoniazid </e20>, the blood levels of busulfan are increased.
mechanism	However, in another clinical study, when <e10> digoxin </e10> was administered concurrently with <e20> carbamazepine </e20>, the incidence of gastrointestinal complications was increased.
mechanism	However, in another study in which <e10> astemizole </e10> was used concomitantly with ketoconazole (as a known inhibitor of CYP3A4) and <e20> diltiazem </e20>, a major pharmacokinetic interaction was noted: diltiazem decreased the half-life of astemizole by approximately 20% while increasing its clearance.
mechanism	When the <e11> PRINIVIL </e11> # mg tablet was administered with a single dose of <e20> nevirapine </e20> # mg, nevirapine concentrations increased by approximately 23%.
mechanism	When the <e11> SPRYCEL </e11> is administered concomitantly with <e20> warfarin </e20>, the prothrombin time is increased.
mechanism	Interactions for vitamin_D_analogues : Use with <e10> tacrolimus </e10> or cyclosporine may reduce the clearance of <e20> vitamin_D </e20> by blocking its hepatic metabolism.
mechanism	Interactions for vitamin_D_analogues such as <e10> erythromycin </e10>, itraconazole, or rifabutin may increase <e20> vitamin_D </e20> absorption.
mechanism	Interactions for vitamin_D_analogues : Concomitant administration of <e10> enoxacin </e10> and <e20> vitamin_D </e20> decreased the pharmacologic activity of vitamin_D by 40% (p=0.003).
mechanism	Phenytoin / Phenobarbital : <e10> Phenobarbital </e10>, like other <e22> anticonvulsant </e22> s, may decrease the metabolism of phenytoin.
mechanism	Phenytoin / Phenobarbital : <e10> Phenobarbital </e10> prolongs the elimination of <e20> phenytoin </e20>, which is indicated for the treatment of cancer.
mechanism	Phenytoin / Phenobarbital : <e12> Amphetamines </e12> enhance the clearance of <e20> phenobarbital </e20>.
mechanism	Phenytoin / Phenobarbital : <e10> Phenobarbital </e10> may increase the clearance of <e20> citalopram </e20> and citalopram may decrease the clearance of phenobarbital.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> increases the half-life of <e20> erythromycin </e20>.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> may decrease the clearance of <e20> ketoconazole </e20> and increase the AUC of ketoconazole.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> may inhibit <e20> probenecid </e20> clearance.
mechanism	Corticosteroids : A significant increase in serum <e10> dexamethasone </e10> levels has been reported when <e20> phenytoin </e20> is administered concomitantly.
mechanism	Corticosteroids : A case of an adult man taking <e10> dexamethasone </e10> for the treatment of a chronic benign prostate hyperplasia is reported. Dexamethasone was found to interfere with the metabolism of <e20> ketoconazole </e20> by inhibiting the biosynthesis of it in the prostate.
mechanism	Corticosteroids : A <e12> quinolone </e12> was found to decrease the serum levels of <e20> corticosteroids </e20> in healthy volunteers.
mechanism	Interactions for vitamin_D_analogues such as <e10> Aprepitant </e10>, triamterene, and dipyridamole with <e20> vitamin_D </e20> are complex, resulting in an inhibition of metabolism of vitamin_D in the liver.
mechanism	Interactions for vitamin_D_analogues, concomitant use of <e10> calcium </e10> and <e20> vitamin_D </e20>, and low serum vitamin_D levels may have clinically significant effects on the pharmacokinetics of calcium or other vitamin_D_analogues.
mechanism	Phenytoin / Phenobarbital : <e10> Phenobarbital </e10> ( <e20> phenytoin </e20> ) may reduce the absorption of carbamazepine.
mechanism	Phenytoin / Phenobarbital : In vitro data suggest that <e10> phenobarbital </e10> (as compared to other antihypertensive_drugs ) inhibits the metabolism of <e20> ketoconazole </e20> by means of a novel cytochrome P450 3A4 (CYP3A4) 6-dependent pathway.
mechanism	Phenytoin / Phenobarbital : <e10> Phenobarbital </e10> may decrease <e20> phenytoin </e20> clearance, resulting in an increased plasma concentration of phenytoin.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> may increase the clearance of <e20> cyclosporine </e20>, leading to increased plasma concentrations.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> may increase the metabolism of <e20> diltiazem </e20> and the resulting oral concentrations of the latter two agents.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> decreased <e20> zalcitabine </e20> and cimetidine AUC by 30% and 50%, respectively.
mechanism	Corticosteroids : A study in male rats of a single # mg dose of <e10> cetirizine </e10> # mg daily for # days was shown to result in a 42% increase in plasma levels of <e20> erythromycin </e20>.
mechanism	Corticosteroids : A two-week regimen of <e10> flecainide </e10> and <e20> erythromycin </e20> was found to be less effective than a regimen of flecainide and antibiotics alone, and a regimen of flecainide and rifabutin was found to be more effective than flecainide alone.
mechanism	Corticosteroids : A possible drug interaction has been described for <e10> dexamethasone </e10> when coadministered with <e20> warfarin </e20>.
mechanism	Lithium Reversible increases in serum lithium levels have been reported with concomitant use of <e10> lithium </e10> preparations such as lithium_carbonate or lithium_nitrate containing preparations and lithium-containing preparations containing preparations containing <e20> lithium </e20> (eg, Trileptal, Zidovudine, Ethanol and Lithium ) and with concomitant administration of lithium containing preparations containing Lithium (eg, Immediate Release and delayed Release preparations).
mechanism	Lithium Reversible increases in serum lithium concentrations have been reported when <e10> lithium </e10> is coadministered with drugs that are highly lithium-containing (eg, <e20> lithium_carbonate </e20> ) or are lithium-containing (eg, warfarin and its derivatives ).
mechanism	Lithium Reversible increases in serum lithium have been reported with concomitant administration of <e10> lithium </e10> in combination with other drugs that have been reported to increase lithium toxicity (eg, lithium_carbonate, carbamazepine, doxepin, <e20> diazepam </e20>, phenytoin ).
mechanism	Lithium Reversible increases in serum lithium have been reported when <e10> lithium </e10> is administered concomitantly with <e20> propafenone </e20>, valdecoxib, or isoniazid.
mechanism	Lithium Reversible increases in <e10> lithium </e10> concentrations in plasma have been reported when <e20> lithium </e20> is given concomitantly with calcium or with a calcium-containing drug.
mechanism	An increase in the plasma concentrations of <e10> digoxin </e10> and <e20> cyclosporine </e20> has been observed when digoxin and cyclosporine are coadministered.
mechanism	An increase in the clearance of diltiazem or <e10> succinylcholine </e10> by <e20> carbamazepine </e20> may produce a decreased absorption of these drugs.
mechanism	Agents that are highly susceptible to metabolism by cytochrome P450 3A4 (e,g,, <e10> phenobarbital </e10>, quinidine, carbamazepine, diazepam, phenytoin, primidone, sulfasalazine, and zidovudine ) may have an increased clearance of <e20> ethchlorvynol </e20>, resulting in high serum concentrations.
mechanism	Agents that are CYP 3A4 inhibitors (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, <e10> ritonavir </e10>, nelfinavir, saquinavir, indinavir, saquinavir/ clarithromycin ) may increase plasma concentrations of <e20> ketoconazole </e20>.
mechanism	Agents that are highly active against <e10> valdecoxib </e10> (e,g,, dapsone, enoxacin, cimetidine, dorzolamide, <e20> fluconazole </e20>, ketoconazole, itraconazole, nefazodone, troleandomycin ) may decrease plasma levels of valdecoxib.
mechanism	Agents that are highly active in blocking CYP3A4 activity (eg, ketoconazole, itraconazole, ritonavir, indinavir, nelfinavir, <e10> saquinavir </e10>, clarithromycin, telithromycin, atazanavir, indinavir, nefazodone, troleandomycin, zidovudine, zidovudine, theophylline, fluoxetine, and halothane ) may be less effective when coadministered with <e20> nelfinavir </e20>, and these drugs may prolong the half-life of nelfinavir.
mechanism	Agents that are both <e12> androgens </e12> and also 5alpha-reductase inhibitors (see WARNINGS, 5alpha-reductase inhibitors ) may increase the clearance of <e20> ketoconazole </e20>.
mechanism	Agents that are CYP3A4 inhibitors (e,g,, ketoconazole, <e10> itraconazole </e10>, erythromycin, clarithromycin ) may increase plasma levels of <e20> nelfinavir </e20> and may require increases in dose to achieve therapeutic plasma concentrations.
mechanism	Agents that are CYP3A4 inhibitors (such as ketoconazole, <e10> itraconazole </e10>, nefazodone, troleandomycin, clarithromycin, clarithromycin sulfate, nelfinavir, ritonavir, saquinavir, telithromycin, indinavir, saquinavir, indinavir, saquinavir, indinavir, saquinavir, indinavir, saquinavir, indinavir, itraconazole ) have been shown to increase plasma levels of <e20> ketoconazole </e20> and decrease the efficacy of ketoconazole in vitro.
mechanism	Agents that are known to decrease plasma levels of <e10> zidovudine </e10> include: cyclosporine, phenytoin, digoxin, amphotericin_B, <e20> indinavir </e20>, itraconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, troleandomycin, nefazodone, astemizole, lovastatin.
mechanism	Agents that are known to decrease plasma <e10> lithium </e10> levels (eg, <e20> lithium_sulfate </e20> ) may result in increased lithium concentrations and may thus increase the risk of lithium toxicity.
mechanism	Agents that are CYP3A4 inhibitors (e,g,, ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, nelfinavir, erythromycin, clarithromycin, <e10> troleandomycin </e10>, nefazodone, didanosine, astemizole, terfenadine ) are inhibitors of CYP3A4 and may increase the plasma concentrations of <e20> cisapride </e20>.
mechanism	Agents that are vasoconstrictive (eg, <e10> indomethacin </e10> ) or that inhibit <e20> astemizole </e20> absorption (eg, cyclosporine, digoxin, phenytoin, and tacrolimus ) may result in a decrease in astemizole serum concentrations.
mechanism	Agents that are CYP3A4 substrates (e,g,, ketoconazole, itraconazole, erythromycin, clarithromycin, indinavir, ritonavir, <e10> nelfinavir </e10>, saquinavir, telithromycin, troleandomycin ) may decrease plasma concentrations of <e20> diltiazem </e20>.
mechanism	Agents that are expected to increase plasma concentrations of <e11> SPRYCEL </e11> may be of interest because they may alter the metabolism of <e20> SPRYCEL </e20>.
mechanism	Agents that are hepatic enzymes (e,g,, <e10> phenytoin </e10>, triazolam, carbamazepine ) increase the clearance of <e20> C-peptide </e20> and may therefore increase the amount of C-peptide available for absorption and distribution.
mechanism	Agents that are potent inhibitors of CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, nelfinavir, <e10> nefazodone </e10>, indinavir, saquinavir, telithromycin ) may increase plasma levels of <e20> erythromycin </e20> or other drugs that are metabolized by CYP3A4.
mechanism	Agents that are reported to decrease CYP3A4 activity (eg, ketoconazole, itraconazole, nefazodone, clarithromycin, ritonavir, <e10> nelfinavir </e10>, indinavir, saquinavir, saquinavir, saquinavir, indinavir, erythromycin, troleandomycin ) may increase plasma concentrations of <e20> rifampin </e20>.
mechanism	Agents that are potent inhibitors of CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, <e10> indinavir </e10>, itraconazole ) may reduce the clearance of <e20> warfarin </e20> and therefore increase the exposure to warfarin.
mechanism	Agents that are predominantly Ca2+ -containing, such as <e10> phenytoin </e10>, carbamazepine, phenobarbital, and <e20> rifampin </e20>, have the potential to increase the clearance of catecholamines and increase the clearance of digoxin.
mechanism	Agents that are CYP3A4 inhibitors (such as ketoconazole, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e10> saquinavir </e10>, telithromycin, troleandomycin, troleandomycin, didanosine, terfenadine ) may decrease or increase the plasma concentrations of <e20> estrogens </e20>.
mechanism	Agents that are inducers of CYP3A4 (e,g,, <e10> phenytoin </e10>, carbamazepine, theophylline, phenobarbital, or rifampin ) have been shown to significantly increase <e20> cyclosporine </e20> plasma concentrations.
mechanism	Agents that are potent inhibitors of CYP2C9 (such as ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, indinavir, <e10> nefazodone </e10>, nelfinavir, saquinavir, telithromycin, troleandomycin, troleandomycin, terfenadine ) may increase plasma concentrations of <e20> clofibrate </e20> and thus should be used with caution in patients receiving clofibrate.
mechanism	Agents that are CYP3A4 inhibitors, such as ketoconazole and itraconazole, may decrease plasma concentrations of <e10> ketoconazole </e10> and therefore inhibit the metabolism of <e20> ketoconazole </e20>.
mechanism	Agents that are potent inducers of CYP3A4 (eg, phenytoin, carbamazepine, <e10> phenobarbital </e10>, phenytoin_succinate, quinine, triazolam ) may decrease or increase the AUC of <e20> atorvastatin </e20> by 10% or 20%, respectively.
mechanism	Agents that are likely to decrease blood levels of <e11> CELEBREX </e11>, such as <e20> disopyramide </e20>, may increase the clearance of CELEBREX.
mechanism	Agents that are known to increase plasma levels of <e10> cisapride </e10> (e,g,, <e20> amprenavir </e20>, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin ) may have a modest tendency to increase plasma levels of cisapride.
mechanism	Agents that are inhibitors of CYP3A4 (eg, ketoconazole, itraconazole, clarithromycin, nefazodone, troleandomycin, <e10> ritonavir </e10>, nelfinavir, saquinavir, saquinavir_hydrochloride ) have been shown to increase plasma concentrations of <e20> methotrexate </e20> by approximately #%.
mechanism	Agents that are CYP3A4 inhibitors ( alprazolam, ketoconazole, itraconazole, nefazodone, <e10> rifampin </e10>, saquinavir, indinavir, itraconazole, nelfinavir, troleandomycin ) may increase plasma levels of <e20> nelfinavir </e20>.
mechanism	Agents that are known to inhibit CYP3A4 activity (e,g,, ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin, <e10> nefazadone </e10>, troleandomycin, valdecoxib ) increase the plasma levels of <e20> ketoconazole </e20> and may result in a decrease in the half-life of ketoconazole.
mechanism	Agents that are known to increase plasma concentrations of <e10> methotrexate </e10> include: thiazide_diuretics, corticosteroids, corticotropin, furosemide, cyclosporine, lithium, <e20> methotrexate </e20>, phenytoin, quinidine, tacrolimus, succinylcholine, quinupristin, and warfarin.
mechanism	Agents that are highly correlated with each other (e,g,, <e10> penicillin </e10>, ampicillin, and ciprofloxacin ) may result in additive or potentiating effects with <e20> fluconazole </e20>.
mechanism	Agents that are predominantly covalent in nature, such as cholestyramine, forsteroids, and <e10> quinidine </e10>, may result in decreased levels of <e20> digoxin </e20>.
mechanism	Agents that are CYP 3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, nefazodone, <e10> ritonavir </e10>, nelfinavir, saquinavir, telithromycin, troleandomycin ) may decrease the metabolism of <e20> nelfinavir </e20>.
mechanism	Agents that are potent inhibitors of CYP3A4 (such as ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, <e10> ritonavir </e10>, nelfinavir, indinavir, saquinavir, saquinavir/ saquinavir_c,t,c,d, guanfacine, nefazodone, and erythromycin ) may decrease the metabolism of <e20> digoxin </e20>, resulting in decreased serum levels and increased renal excretion.
mechanism	Agents that are CYP3A4 substrates (eg, ketoconazole, itraconazole, ritonavir, clarithromycin, nefazodone, <e10> rifabutin </e10>, ritonavir, indinavir, saquinavir, telithromycin ) increase plasma concentrations of <e20> rifabutin </e20>.
mechanism	Agents that are potent inducers of hepatic enzymes (e,g,, <e10> phenytoin </e10>, carbamazepine, alfentanil, phenobarbital, phenytoin_hydrochloride, phenytoin, cisapride, diltiazem, disopyramide ) should be used with caution in patients who are also being treated with potent inhibitors of hepatic enzymes (e,g,, carbamazepine, <e20> amiodarone </e20>, phenytoin, triazolam ).
mechanism	Agents that are CYP3A4 inhibitors, such as ketoconazole, <e10> itraconazole </e10>, ritonavir, clarithromycin, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, and troleandomycin (ATRA) may reduce the bioavailability of <e20> isoniazid </e20>.
mechanism	Agents that are metabolized by CYP2C9 include: halothane, ethchlorvynol, fluoxetine, <e10> halothane </e10>, levodopa, barbiturates, clofibrate, cimetidine, cyclosporine, disulfiram, doxycycline, famotidine, fluvoxamine, fluvoxamine_sulfa_mercapture, lovastatin, midazolam, phenytoin, salicylates, tamoxifen, <e20> tolbutamide </e20>, and verapamil.
mechanism	Agents that are hypotensive (eg, <e10> phenytoin </e10>, carbamazepine, diazoxide ) or that are potassium-sparing (eg, amiodarone, <e20> warfarin </e20> ) may increase plasma concentrations of midazolam and therefore its half-life.
mechanism	Agents that are potent inhibitors of CYP2C9 (e,g,, ketoconazole, erythromycin, clarithromycin, <e10> nelfinavir </e10>, ritonavir, saquinavir, indinavir, telithromycin, troleandomycin, troleandomycin, erythromycin, terfenadine, azithromycin, troleandomycin, astemizole ) are substrates for <e20> warfarin </e20>, and therefore may increase the plasma concentrations of warfarin.
mechanism	Agents that are CYP3A4 inhibitors (eg, ketoconazole, <e10> itraconazole </e10>, ritonavir, erythromycin, clarithromycin, nefazodone, nelfinavir, saquinavir, telithromycin ) have been reported to cause increased AUC values when coadministered with <e20> diltiazem </e20>.
mechanism	Agents that are predominantly renal tubular acid-base inducers (e,g,, <e10> chloroquine </e10>, cimetidine, enalapril ) may increase plasma concentrations of <e20> digoxin </e20>, doxorubicin, methotrexate, or methotrexate.
mechanism	Agents that are actively secreted via the renal tubular system, such as methotrexate and carbamazepine, may be capable of elevating serum concentrations of <e10> ketoconazole </e10> when coadministered with <e20> amphotericin_B </e20>.
mechanism	Agents that are CYP3A4 substrates, such as phenytoin, may increase the metabolism of <e10> dapsone </e10> by interfering with the metabolism of <e20> dapsone </e20> to formate.
mechanism	Agents that are CYP3A4 inhibitors (e,g,, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, <e10> troleandomycin </e10>, nelfinavir, nefazodone, clarithromycin, indinavir, ritonavir, saquinavir, telithromycin ) increase the metabolism of <e20> ketoconazole </e20>.
mechanism	Agents that are CYP3A4 substrates (eg, alprazolam, ketoconazole, erythromycin, clarithromycin, <e10> itraconazole </e10>, troleandomycin, voriconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin ) are inhibitors of the CYP3A4 catalyzed-isozyme, and thus may decrease the metabolism of <e20> ciprofloxacin </e20> and increase the exposure of ciprofloxacin.
mechanism	Agents that are CYP3A4 inhibitors (e,g,, ketoconazole, itraconazole, erythromycin, clarithromycin, <e10> indinavir </e10>, ritonavir, saquinavir, indinavir ) may decrease plasma concentrations of <e20> simvastatin </e20>.
mechanism	Agents that are potent inducers of CYP3A4 (eg, <e10> phenytoin </e10>, phenobarbital, phenytoin_hydrochloride, primidone, phenytoin, primidone_sulfate, tamoxifen, theophylline, triazolam ) should be administered with caution in patients receiving <e20> valdecoxib </e20>.
mechanism	Agents that are CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, <e10> nelfinavir </e10>, indinavir, saquinavir, saquinavir/ceftazidime ) and agents that are CYP2C8 (eg, clarithromycin, indinavir, telithromycin, troleandomycin, theophylline, lovastatin, astemizole ) are inhibited by <e20> COREG </e20>.
mechanism	Agents that are predominantly cytochrome P450 3A4 inhibitors (e,g,, quinidine, fluoxetine, <e10> phenobarbital </e10>, alprazolam, paroxetine, sertraline, theophylline, triazolam ) may reduce the metabolism of <e20> norethindrone </e20>, resulting in increased levels of norethindrone and increased elimination of norethindrone.
mechanism	Agents that are CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nefazodone, ritonavir, <e10> clarithromycin </e10>, nelfinavir, saquinavir, telithromycin ) are highly likely to decrease plasma levels of <e20> warfarin </e20>.
mechanism	Agents that are potent inhibitors of CYP3A4 (e,g,, ketoconazole, <e10> itraconazole </e10>, ritonavir, clarithromycin, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin ) may increase plasma concentrations of <e20> ketoconazole </e20>.
mechanism	Agents that are primarily protein-bound, such as tricyclic_antidepressants and <e10> carbamazepine </e10>, may cause elevated plasma concentrations of <e20> astemizole </e20>, which may increase its absorption and metabolism and thereby decrease the efficacy of astemizole.
mechanism	Agents that are CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir, clarithromycin, indinavir, saquinavir, <e10> nefazodone </e10>, nelfinavir, ritonavir, telithromycin, troleandomycin, troleandomycin plus cisapride ) reduce plasma levels of <e20> diltiazem </e20>.
mechanism	Agents that are CYP3A4 substrates, such as <e10> ketoconazole </e10>, ritonavir, itraconazole, nefazodone, nelfinavir, saquinavir, indinavir, indinavir_retard, itraconazole, and ritonavir may decrease the pharmacokinetics of <e20> dasatinib </e20>.
mechanism	Agents that are CYP3A4 inhibitors, such as <e10> quinidine </e10>, may decrease the half-life of <e20> cisapride </e20> by approximately 3%.
mechanism	Agents that are inhibitors of CYP3A4 (such as ketoconazole, erythromycin, clarithromycin, <e10> nefazodone </e10>, ritonavir, saquinavir, indinavir, saquinavir dipivoxil ) are likely to reduce the exposure to <e20> nelfinavir </e20>.
mechanism	Agents that are potent inhibitors of CYP3A4 (e,g,, ketoconazole, itraconazole, ritonavir, erythromycin, clarithromycin, indinavir, <e10> nefazodone </e10>, nelfinavir, saquinavir, telithromycin, troleandomycin, zidovudine ) may increase plasma concentrations of <e20> nelfinavir </e20> by as much as 3-fold.
mechanism	Agents that are CYP3A4 inhibitors (eg, ketoconazole, erythromycin, clarithromycin, indinavir, ritonavir, <e10> saquinavir </e10>, erythromycin, indinavir, itraconazole, nefazodone, troleandomycin, nelfinavir, saquinavir, saquinavir with fluconazole, valdecoxib, nelfinavir with carbamazepine, and nefazodone with carbamazepine ) may reduce or discontinue <e20> dasatinib </e20> absorption if the concentrations of dasatinib and the CYP3A4 inhibitors are above or below a certain level.
mechanism	Agents that are CYP3A4 inhibitors (e,g,, ketoconazole, <e10> itraconazole </e10>, ritonavir, indinavir, saquinavir, indinavir-sulfate, nefazodone, troleandomycin, clarithromycin, bromocriptine, erythromycin, saquinavir, troleandomycin, nefazodone ) are highly susceptible to drug interactions with <e20> fluconazole </e20>.
mechanism	Agents that are vasoconstrictive (e,g,, <e10> verapamil </e10> ) or have a potassium-sparing action (e,g,, ketoconazole, potassium supplements, magnesium supplements, <e20> bromocriptine_mesylate </e20> ) may reduce the bioavailability of digoxin, resulting in lower serum concentrations and AUC values.
mechanism	Agents that are CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nefazodone, ritonavir, clarithromycin, nelfinavir, <e10> indinavir </e10> ) reduce the plasma concentrations of <e20> rifabutin </e20> by 50% to 90%.
mechanism	Agents that are substrates for the CYP2D6 isozyme (e,g,, ketoconazole, itraconazole, clarithromycin, <e10> nefazodone </e10>, alfentanil, phenytoin, bromocriptine, valproate, cisapride, troleandomycin, clarithromycin, bromocriptine, valproate ) should be administered with caution because the concomitant administration of <e21> VIOXX </e21> with these agents may result in a significant increase in plasma concentrations of VIOXX.
mechanism	Agents that are CYP 3A4 inhibitors, such as clarithromycin, indinavir, <e10> saquinavir </e10>, indinavir, and telithromycin may decrease the clearance of <e20> carboplatin </e20> and result in increased plasma concentrations of carboplatin.
mechanism	Agents that are potent inhibitors of CYP3A4 (e,g,, ketoconazole, erythromycin, itraconazole, clarithromycin, ritonavir, indinavir, nefazodone, nelfinavir, <e10> saquinavir </e10>, telithromycin, troleandomycin, troleandomycin, erythromycin ) have been shown to decrease the plasma concentrations of <e20> atorvastatin </e20> by approximately 50%.
mechanism	Agents that are predominantly protein bound, such as theophylline, do not affect the metabolism of <e10> levodopa </e10>, and therefore the plasma levels of theophylline and <e20> diazepam </e20> may be underestimated when given with these agents.
mechanism	Agents that are CYP3A4 substrates, such as fluconazole, <e10> itraconazole </e10>, troleandomycin, and nefazodone, may increase the metabolism of <e20> isoniazid </e20>.
mechanism	Agents that are potent inhibitors of CYP3A4 (e,g,, ketoconazole, itraconazole, ritonavir, indinavir, erythromycin, <e10> clarithromycin </e10>, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, valproic_acid ) should be administered with caution in patients taking <e20> bromocriptine_mesylate </e20>.
mechanism	Agents that are potent inhibitors of CYP3A4 activity (e,g,, ketoconazole, itraconazole, erythromycin, ritonavir, clarithromycin, <e10> nefazodone </e10>, nelfinavir, saquinavir, indinavir ) may increase the plasma concentrations of <e20> diltiazem </e20>, resulting in an increase in AUC.
mechanism	Agents that are known to inhibit CYP3A4 (e,g,, ketoconazole, erythromycin, clarithromycin, <e10> indinavir </e10>, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole ) may increase plasma concentrations of <e20> lamivudine </e20>.
mechanism	Agents that are reported to inhibit CYP3A4 (eg, ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin, <e10> nefazodone </e10>, troleandomycin, lovastatin, nelfinavir, indinavir, saquinavir, saquinavir/agravir, telithromycin, troleandomycin, troleandomycin, indinavir, saquinavir/agravir, troleandomycin ) may result in elevated plasma levels of <e20> rifampin </e20>.
mechanism	Agents that are active in vivo against <e10> ketoconazole </e10> (i,e,, the major metabolite of <e20> ciprofloxacin </e20> ) include: indomethacin, anidulafungin, clarithromycin, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, and didanosine.
mechanism	Agents that are highly hydrolyzable, such as ampicillin, <e10> ciprofloxacin </e10>, gentamicin, erythromycin, itraconazole, nalidixic_acid, and terfenadine may interfere with the metabolism of <e20> cefdinir </e20>.
mechanism	Agents that are hypotensive or have other vasoconstrictive properties such as <e11> Atromid-S </e11>, <e20> digoxin </e20>, ketoconazole, nifedipine, and norethindrone may cause a marked increase in digoxin serum levels.
mechanism	Agents that are CYP3A4 inhibitors (e,g,, ketoconazole, <e10> itraconazole </e10>, ritonavir, indinavir, saquinavir, nelfinavir ) may increase the exposure to <e20> alfentanil </e20> and may decrease the plasma alfentanil clearance.
mechanism	Agents that are not metabolized by CYP3A4 (e,g,, ketoconazole, fluconazole, rifampin, cimetidine, quinine, <e10> tolbutamide </e10>, fluvoxamine, paroxetine, saquinavir, alfentanil, disopyramide ) may increase plasma levels of <e20> nelfinavir </e20>.
mechanism	Agents that are CYP3A4 substrates (eg, ketoconazole, itraconazole, ritonavir, indinavir, erythromycin, clarithromycin, nefazodone, <e10> nelfinavir </e10>, ritonavir, saquinavir, telithromycin, troleandomycin, troleandomycin ) may increase <e20> clofibrate </e20> plasma concentrations by increased metabolism and decrease the renal clearance of clofibrate.
mechanism	Agents that are CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, nefazodone, troleandomycin, <e10> ritonavir </e10>, nelfinavir, saquinavir, indinavir, saquinavir, indinavir, terfenadine, tamoxifen, theophylline ) have been reported to increase <e20> nelfinavir </e20> levels.
mechanism	Agents that are CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir, erythromycin, clarithromycin, nefazodone, <e10> nelfinavir </e10>, saquinavir, telithromycin, troleandomycin ) have been shown to decrease plasma concentrations of <e20> warfarin </e20>.
mechanism	Agents that are CYP3A4 inhibitors (such as ketoconazole and <e10> itraconazole </e10> ) can increase <e20> cilostazol </e20> levels, potentially resulting in elevated AUC and Cmax values.
mechanism	Agents that are C-derivative inhibitors (e,g,, <e10> phenytoin </e10> ) have been reported to decrease <e20> diltiazem </e20> absorption, and therefore, the therapeutic effect of diltiazem may be compromised.
mechanism	Agents that are highly protein bound (eg, <e10> sucralfate </e10>, indomethacin, methotrexate, cimetidine ) may increase the clearance of <e20> probenecid </e20>.
mechanism	Agents with Increased Heparin Effect: <e10> Azathioprine </e10> has been shown to reduce the steady-state serum levels of <e20> heparin </e20> by approximately 50%.
mechanism	Agents with Increased Heparin Release Co-administration of <e10> clarithromycin </e10> tablets with <e20> verapamil </e20> decreased the duration of the absorption of clarithromycin and decreased its heparin activity by 6%.
mechanism	Agents with Increased Anticoagulation Effect: Concomitant administration of <e10> warfarin </e10> or its derivatives with <e20> coumarin </e20>, warfarin, rifabutin, or dasatinib resulted in a significant increase in mean AUC and Cmax for warfarin (2.6-fold and 3.2-fold, respectively) and its derivatives.
mechanism	Agents with Increased P-glycoprotein ( <e10> erythromycin </e10>, clarithromycin, indinavir, indinavir and <e20> nefazodone </e20> ) and decreased A-P-glycoprotein ( ritonavir, saquinavir, telithromycin, troleandomycin ) metabolism may increase the clearance of these agents and result in AUCs lower than desired.
mechanism	Agents with Increased Hepatic Absorption: When <e10> indinavir </e10> was co-administered with atorvastatin and <e20> atorvastatin </e20> (400 mg daily), the proportion of indinavir in the blood was increased by approximately 20%, but the mean AUC for indinavir did not change.
mechanism	Agents with Increased Anticoagulant Effect: Cyclosporine, tacrolimus, phenytoin, phenobarbital, carbamazepine, alfentanil, disopyramide, dexamethasone, flecainide, terfenadine, cisapride, disulfiram, erythromycin, heparin, <e10> itraconazole </e10>, itraconazole sulfate, nefazodone, rifabutin, phenytoin, <e20> phenytoin </e20>, theophylline, tolbutamide, and zidovudine.
mechanism	Agents with Increased Anticoagulant Potential: Concomitant use of <e10> warfarin </e10> and <e20> heparin </e20> has been associated with an increased anticoagulant effect.
mechanism	Agents with Increased Erythromycin Release: The following agents increase the extent to which <e10> erythromycin </e10> is taken up by cells in vitro: <e20> Aprepitant </e20> (a rifampin metabolite), clarithromycin, indinavir, isoniazid, nelfinavir, ritonavir, saquinavir, telithromycin.
mechanism	<e11> Geocillin </e11> and <e20> dapsone </e20> (a divalent cationic antimicrobial) are potent inhibitors of cAMP in human cells.
mechanism	<e11> Geocillin </e11> may potentiate the effect of other <e22> tricyclic_antidepressants </e22>.
mechanism	<e11> Geocillin </e11>, rifampin, cyclosporine, and tacrolimus : Interactions of <e20> norfloxacin </e20> with these antibiotics have been reported.
mechanism	Geocillin ( <e10> azithromycin </e10> ) has been reported to inhibit platelet aggregation and is therefore not recommended for use in patients on <e20> warfarin </e20> therapy.
mechanism	Geocillin ( <e10> Ampicillin </e10> ) may decrease the bioavailability of <e20> levamisole_hydrochloride </e20>, a drug that is metabolized by cytochrome P450 3A4 ( CYP3A4 ).
mechanism	Geocillin ( <e10> ampicillin </e10> ) and tetracycline : <e20> Ganciclovir </e20> has been shown to interfere with the metabolism of both drugs.
mechanism	<e10> Iron </e10> : <e20> Cimetidine </e20> has been reported to decrease the serum concentrations of iron.
mechanism	<e10> Iron </e10>, zinc, or iron_containing preparations may increase the clearance of <e20> digoxin </e20>.
mechanism	<e10> Iron </e10> may interact with drugs that may affect iron absorption, e,g,, salicylates, calcium supplements, corticosteroids, <e20> coumarins </e20>, and certain NSAIDs.
mechanism	<e10> Iron </e10> increases the bioavailability of <e20> norethindrone </e20>.
mechanism	<e10> Iron </e10>-and zinc -containing preparations may reduce the absorption of <e20> rifampin </e20>.
mechanism	Although <e10> metoclopramide </e10> did not inhibit <e20> cyclosporine </e20> metabolism, the oral toxicity of metoclopramide was increased by approximately 40% when cyclosporine was given concomitantly.
mechanism	Although <e10> metoclopramide </e10> may decrease the clearance of <e20> phenytoin </e20>, the effect is not as strong as with carbamazepine or other nonsteroidal_anti-inflammatory_drugs.
mechanism	Although <e10> metoclopramide </e10> increases the clearance of <e20> cholestyramine </e20> by 50%, it decreases the plasma concentration of cholestyramine by 50% to increase its elimination half-life from # to # hours.
mechanism	Serum concentration of <e10> lopinavir </e10> is increased by a maximum of 8% (47% increase) when # mg of <e20> lopinavir </e20> is administered # hours after a single dose of ritonavir (a CYP3A4 inducer).
mechanism	Serum concentration of digoxin decreased in patients receiving <e11> VIDEX </e11> for # weeks following the administration of a single dose of # mg of <e20> digoxin </e20>.
mechanism	Serum concentration of theophylline may increase when <e10> diazepam </e10> is administered concurrently with <e20> theophylline </e20>.
mechanism	Serum concentration of <e10> cyclosporine </e10> and <e20> tacrolimus </e20> are reduced by propranolol and acetaminophen.
mechanism	Serum concentration of <e10> furosemide </e10> decreased by a similar degree in patients treated with <e20> cimetidine </e20> and valdecoxib for # days prior to the initiation of the study.
mechanism	Serum concentration of <e10> gentamicin </e10> increased by approximately 18%, but the in vitro metabolite concentration of <e20> ciprofloxacin </e20> decreased by approximately 35%.
mechanism	Cyclosporine : Modest, but clinically relevant, increases in serum creatinine levels have been reported following concomitant administration of <e10> cyclosporine </e10> with other <e22> corticosteroids </e22>, including rifampin, tacrolimus, and disopyramide.
mechanism	Cyclosporine : Modest decreases in AUC were observed for <e10> cyclosporine </e10> in healthy volunteers when coadministered with <e20> warfarin </e20> and a single dose of atorvastatin.
mechanism	Digoxin : Digoxin : <e10> Vardenafil </e10> reduced <e20> digoxin </e20> by #%.
mechanism	Digoxin : Digoxin is a hepatic enzyme and digoxin levels are increased when <e10> cisapride </e10> is given concurrently with <e20> digoxin </e20>.
mechanism	Digoxin : Digoxin increases the clearance of <e10> nifedipine </e10> and <e20> diltiazem </e20>.
mechanism	Inducers and Inhibitors of CYP3A4 (e,g,, ketoconazole, erythromycin, clarithromycin, nefazodone, <e10> troleandomycin </e10>, ritonavir, saquinavir, telithromycin, erythromycin ) have been reported to reduce the half-life of <e20> zidovudine </e20> by 25% to 40%.
mechanism	Inducers and Inhibitors of Cimetidine Synthesis (e,g,, cyclosporine, tacrolimus, digoxin, amiodarone, succinylcholine, <e10> lithium </e10>, cimetidine, cimetidine_sodium, <e20> disopyramide </e20>, bromocriptine, phenytoin, valproate, terfenadine ): Cimetidine increases the half-life of Cimetidine and may prolong the pharmacokinetic window of Cimetidine.
mechanism	Inducers and Inhibitors of E1-E2-transport: Although not studied in humans, the possibility that <e10> indomethacin </e10> may decrease the renal clearance of <e20> rifampin </e20> should be considered.
mechanism	<e11> CANCIDAS </e11> in normal volunteers demonstrated a single maximal concentration of <e20> isoniazid </e20> in serum of 19.3 ng/ml.
mechanism	<e11> CANCIDAS </e11> may interfere with absorption of some drugs, such as indomethacin and methotrexate, or decrease absorption of some drugs, such as phenytoin and <e20> theophylline </e20>.
mechanism	In two clinical studies, coadministration of <e10> astemizole </e10> with <e20> ketoconazole </e20> resulted in a 20% increase in the serum astemizole level.
mechanism	In two clinical studies, <e10> levothyroxine </e10> <e20> digoxin </e20> -induced elevations of serum lithium were significantly reduced by coadministration with a lithium_containing anticonvulsant ( phenytoin or carbamazepine ) to the extent of approximately 5%.
mechanism	In two clinical studies, <e10> ketoconazole </e10> markedly reduced the bioavailability of <e20> doxorubicin </e20>, a potent inducer of apoptosis.
mechanism	A drug-drug interaction study of <e10> probenecid </e10> with drugs that have been shown to decrease <e20> diazepam </e20> plasma levels ( phenytoin, phenobarbital, carbamazepine, phenytoin-triazolam ) showed that the AUC of diazepam increased significantly when probenecid was administered.
mechanism	A drug-drug interaction study of <e10> ketoconazole </e10> with <e20> ketoconazole </e20> tablets # mg indicated a decreased clearance of the ketoconazole metabolite, which may affect drug concentrations.
mechanism	A drug-drug interaction study with <e10> carbamazepine </e10> and <e20> digoxin </e20> demonstrated a 20% increase in digoxin AUC of # to # mg/h with carbamazepine.
mechanism	In addition, results from clinical studies of <e10> phenytoin </e10> indicated a decrease in <e20> propranolol </e20> clearance.
mechanism	In addition, results from in vitro studies of the benzodiazepines <e10> alprazolam </e10> and diazepam suggest that the concomitant administration of the <e22> benzodiazepines </e22> with the nonsteroidal_anti-inflammatory_drug rifampin may result in increased levels of the active benzodiazepine metabolite alprazolam.
mechanism	In addition, results of in vitro studies of <e10> warfarin </e10> suggest a possible drug interaction for # mg of warfarin / kg of BW with a #-mg/kg/day regimen of <e20> aporphine_HCl </e20>.
mechanism	In addition, results from studies of patients with malignant melanoma receiving other oral anticonvulsants or oral <e12> antiepileptic </e12> s indicate a possible drug interaction with concomitant administration of <e20> propranolol </e20> and halothane.
mechanism	In addition, results from in vitro studies of <e10> amiodarone </e10> indicate that <e20> amiodarone </e20> may interfere with the metabolism of both terfenadine and tetracycline.
mechanism	In addition, results from in vitro studies of <e12> quinolones </e12> against <e20> chloroquine </e20> indicate that this action is due to the formation of a quinolone metabolite with a longer half-life.
mechanism	In addition, results from in vitro studies of <e10> chlorpromazine </e10> indicated that the clearance of <e20> cyclosporine </e20> was increased by approximately 50%.
mechanism	In addition, results from in vitro studies of some antihypertensive_drugs indicate that <e10> almotriptan </e10> and carbamazepine have synergistic effects on the metabolism of <e20> propranolol </e20>.
mechanism	In addition, results from in vitro studies of benzodiazepines suggest that <e10> alprazolam </e10> inhibits the metabolism of some <e22> benzodiazepines </e22>, resulting in increased plasma levels.
mechanism	In addition, results suggest that <e10> cyclosporine </e10> and digoxin may have additive effects on hepatic metabolism of <e20> cisapride </e20>.
mechanism	<e10> Probenecid </e10> at doses of # mg/kg increased the metabolism of <e20> fluvoxamine </e20> (3 mg/kg) and decreased the metabolism of diazepam (10 mg/kg).
mechanism	<e10> Probenecid </e10>, a sulfonylurea_drug, causes a slight increase in <e20> ethinyl_estradiol </e20> concentrations in normal volunteers.
mechanism	<e10> Probenecid </e10> did not alter the pharmacokinetics of <e20> cimetidine </e20>.
mechanism	Antacids ( aluminum, calcium, magnesium, or iron ), other <e12> antacids </e12>, aluminum salts, and bromocriptine_mesylate may interfere with the absorption of <e20> fluvoxamine </e20>, resulting in lower plasma levels.
mechanism	Antacids ( aluminum or magnesium ) <e10> sucralfate </e10> significantly decreased the gastrointestinal absorption of <e20> ciprofloxacin </e20>.
mechanism	Probenecid : Aspirin : Aspirin may decrease the absorption of <e10> probenecid </e10>, resulting in a higher plasma <e20> probenecid </e20> concentration.
mechanism	Probenecid : As a consequence of metabolism by CYP2C9, <e10> probenecid </e10> increased the elimination half-life of <e20> fluvoxamine </e20>.
mechanism	Probenecid : Aspirin : <e10> Probenecid </e10> can increase the rate of absorption of <e20> aspirin </e20> by approximately 50%.
mechanism	Probenecid : As with other oral <e12> anticoagulants </e12>, the renal clearance of probenecid may be reduced when <e20> probenecid </e20> is administered concurrently with a prothrombin time-prolonging agent such as warfarin.
mechanism	Iron_Supplements and Foods: <e10> Flurbiprofen </e10> and <e20> iron </e20> supplements may decrease iron absorption and increase iron toxicity.
mechanism	Iron_Supplements and Foods : <e10> Leucovorin </e10> has been shown to decrease the absorption of iron supplements and some <e22> iron_supplements </e22> and foods, possibly by altering the metabolism of iron.
mechanism	Iron_Supplements and Foods: <e10> Zidovudine </e10> in addition to iron_supplements and foods that have a high iron content such as potatoes or cereals may have a decreased bioavailability of <e20> darbepine </e20>.
mechanism	The reddish color and rashes associated with <e10> diclofenac </e10> are eliminated by increasing the <e20> diclofenac </e20> dosage.
mechanism	The reddish color of <e10> erythromycin </e10> has been reported to be associated with an increase in the clearance of metoclopramide, clarithromycin, and <e20> metronidazole </e20>.
mechanism	The reddish color of phenobarbital may interfere with absorption of <e10> phenobarbital </e10> and <e20> levodopa </e20>.
mechanism	H2-Receptor_Antagonists : Co-administration of <e10> astemizole </e10> with <e20> isoniazid </e20>, cimetidine, or atorvastatin, and/or with carbamazepine, phenytoin, alfentanil, cisapride, disopyramide, phenytoin, rifampin, triazolam, or valproate significantly decreased the AUC of cisapride.
mechanism	Probenecid : Aspirin : <e10> Probenecid </e10> inhibits absorption of <e20> aspirin </e20>.
mechanism	Probenecid : Aspirin : When <e10> probenecid </e10> and <e20> aspirin </e20> were given concomitantly, approximately one-half of the subjects taking aspirin also were taking probenecid.
mechanism	Probenecid : As with other cephalosporins, <e10> Probenecid </e10> has been reported to decrease the bioavailability of <e20> levamisole_hydrochloride </e20>, a known CYP3A4 inhibitor, resulting in increased plasma levels of levamisole_hydrochloride.
mechanism	Probenecid : As with other known inhibitors of CYP2C9 activity, <e10> probenecid </e10> significantly decreased CYP2C9 activity when administered concomitantly with <e20> ketoconazole </e20>.
mechanism	Probenecid : As with other <e12> benzodiazepines </e12>, <e20> probenecid </e20> is likely to decrease the absorption of carbamazepine, phenobarbital, phenytoin, and phenytoin / rifampin.
mechanism	Carbamazepine : Elevated serum <e10> carbamazepine </e10> concentrations are observed in patients on concomitant <e20> cimetidine </e20> therapy.
mechanism	Carbamazepine : Elevated plasma levels of <e10> carbamazepine </e10> have been reported with concomitant administration of other anticonvulsants, <e22> phenytoin </e22>, barbiturates, bromocriptine, lithium, barbiturates, clofibrate, diazepam, dicumarol, diazepam_hydrochloride, diazepam_sodium, ergot_derivatives, fluoxetine, fluvoxamine, fluvoxamine_sodium, methadone, phenytoin, pilocarpine, primidone, quinine, quinine_hydrochloride, salicylates, succinimides, valproate, warfarin, and warfarin_sodium.
mechanism	Carbamazepine : Elevated plasma concentrations of <e10> carbamazepine </e10> may reduce the metabolism of <e20> erythromycin </e20> and increase the clearance of carbamazepine.
mechanism	Concomitant administration of <e11> HUMORSOL </e11> and CYP3A4 inhibitors, such as ketoconazole, itraconazole, troleandomycin, clarithromycin, <e20> ritonavir </e20>, and nelfinavir, resulted in a significant increase in CYP3A4 activity (2- to 7-fold increases) compared to the absence of these drugs.
mechanism	Concomitant administration of <e10> carbamazepine </e10> with <e20> nifedipine </e20> resulted in a reduction in nifedipine AUC by #%.
mechanism	Concomitant administration of <e10> indomethacin </e10> with <e20> nifedipine </e20> in healthy volunteers produced a 2- to 3-fold increase in the mean half-life of nifedipine.
mechanism	however, # mg of <e10> ketoconazole </e10> # hours prior to # mg of <e20> cetirizine </e20> # hours resulted in a decrease in serum cetirizine concentrations.
mechanism	however, # mg <e10> enoxacin </e10> / mg and <e20> fluvoxamine </e20>, both of which have similar binding properties to enoxacin, have been shown to reduce enoxacin binding to serum creatinine.
mechanism	however, # mg <e10> methotrexate </e10> # mg increased the # mg <e20> ketoconazole </e20> by 15%.
mechanism	however, # mg/day of <e10> nifedipine </e10> (10 mg q8h) decreased the rate of <e20> propafenone </e20> elimination by 62%.
mechanism	however, # mg <e10> diltiazem </e10> orally administered concurrently with # mg <e20> ketoconazole </e20> was found to be a potent inhibitor of the enzyme, and the effect of # mg ketoconazole orally administered concurrently with # mg diltiazem was not as potent as with # mg diltiazem alone.
mechanism	Fluconazole : Concomitant administration of <e11> FOSCAVIR </e11> with <e20> fluconazole </e20> has been reported to result in prolongation of the elimination half-life of fluconazole.
mechanism	Fluconazole : Concomitant administration of <e10> fluconazole </e10> and <e20> cisapride </e20> resulted in a 4-fold increase in AUC of cisapride.
mechanism	Fluconazole : Concomitant administration of <e10> fluconazole </e10> and <e20> ketoconazole </e20> resulted in a 3.6-fold increase in the exposure of fluconazole.
mechanism	Lithium : In vitro studies, in rat liver and rat brain, indicate a possible pharmacokinetic interaction between <e10> lithium </e10> and <e20> ketoconazole </e20> (a known lithium transporter inhibitor ) and a possible pharmacodynamic interaction between lithium and a metabolite of ketoconazole, disulfiram.
mechanism	Lithium : In patients taking <e10> lithium </e10> (1-3 mg/day) concurrently with <e20> furosemide </e20>, the rate of increase in serum lithium levels was 2-fold greater.
mechanism	Lithium : In rats given <e10> lithium </e10> and <e20> caffeine </e20> (4 mg/kg/day for # days), a significant reduction in caffeine serum levels occurred, which may have contributed to the lower caffeine blood levels seen in # healthy subjects given caffeine concomitantly with lithium.
mechanism	Metformin : In a double-blind study in healthy volunteers receiving oral <e10> fluvoxamine </e10> alone, there was a significant decrease in the AUC of <e20> metformin </e20>.
mechanism	Metformin : In a clinical trial, coadministration of <e10> rifabutin </e10> and <e20> metformin </e20> resulted in a significant increase in AUC (P =.001), Cmax (P =.002), and AUC of both metformin and rifabutin.
mechanism	Metformin : In vitro data indicate that <e10> tetracycline </e10> and <e20> metformin </e20> inhibit the metabolism of metformin.
mechanism	Although not observed in the in vitro study, <e10> gentamicin </e10> inhibited <e20> neomycin </e20> s renal clearance and may have increased serum levels of neomycin or other antibiotics.
mechanism	Although not observed in vitro, coadministration of <e10> diltiazem </e10> and <e20> cyclosporine_A </e20> significantly decreased the renal excretion of cyclosporine_A.
mechanism	Probenecid : As with other <e12> antipsychotics </e12>, increased plasma concentrations of <e20> probenecid </e20> may be expected when plasma levels are reduced by concurrent administration of other antipsychotics.
mechanism	Probenecid : As with other <e12> corticosteroids </e12>, the chronic use of <e20> probenecid </e20> may increase the serum concentrations of corticosteroids and may decrease the efficacy of corticosteroids in some patients.
mechanism	Probenecid : Aspirin and <e10> probenecid </e10> were found to decrease the concentrations of <e20> piperacillin </e20>, ciprofloxacin, and levofloxacin.
mechanism	In the first study, the plasma levels of <e10> dexamethasone </e10> were increased by #-fold when given with a #-mg dose of <e20> clofibrate </e20>.
mechanism	In the first instance, <e10> rifabutin </e10> was found to increase the <e20> terfenadine </e20> elimination half-life by approximately 12% on a mg/kg/day basis.
mechanism	In the first two cases, concomitant administration of <e10> fluvoxamine </e10> and <e20> alprazolam </e20> resulted in an increase in the steady-state plasma concentrations of alprazolam by #-fold.
mechanism	However, in the presence of <e10> ciprofloxacin </e10>, it is possible that <e20> gentamicin </e20> may reduce the activity of gentamicin.
mechanism	However, in the presence of <e10> neomycin </e10>, a significant reduction in <e20> digoxin </e20> concentrations was observed.
mechanism	ERYTHROMYCIN : In an in vitro study, <e10> terfenadine </e10> completely inhibited <e20> ergotamine </e20> metabolism, thus reversing the ergotamine -induced increase in plasma levels.
mechanism	ERYTHROMYCIN : In vitro, <e10> doxorubicin </e10> increased <e20> doxorubicin </e20> metabolism by increasing the rate of doxorubicin metabolism.
mechanism	In a multiple dose study of <e10> phenytoin </e10> # mg once daily and <e20> ketoconazole </e20> # mg once daily, # of # subjects reported a significant increase in AUC of ketoconazole and Cmax of phenytoin.
mechanism	In a multiple dose study in healthy volunteers, the AUC for <e10> rifampin </e10> was approximately #% higher when <e20> cefuroxime </e20> and rifampin were coadministered than when rifampin alone was given.
mechanism	In a multiple-dose study, the intravenous infusion of <e10> morphine </e10> at # mg/kg/hr and the combination of <e20> lorazepam </e20> with morphine (50 mg/kg/hr) produced a significant prolongation of the QT interval (399.3 +/- 50 msec) compared to control values (414.7 +/- 40 msec).
mechanism	There was a statistically significant reduction in the Cmax of <e10> cimetidine </e10> by approximately 26% when it was co-administered with <e20> cimetidine </e20>, and there was a 7% decrease in AUC of cimetidine when it was co-administered with cyclosporine.
mechanism	There was a statistically significant decrease in <e10> lithium </e10> uptake when <e20> propafenone </e20> and lithium were given concomitantly.
mechanism	There was a transient increase in serum concentrations of <e10> pentamidine </e10> when administered with <e20> amphotericin_B </e20>.
mechanism	Antacids and kaolin : Caffeine may increase the absorption of <e10> kaolin </e10>, <e20> calcium </e20>, and iron and decrease the vitamin C and zinc absorption.
mechanism	Antacids and kaolin : <e10> Acetazolamide </e10> may reduce the absorption of <e20> calcium </e20> by the elimination of calcium from the intestinal tract.
mechanism	Antacids and kaolin may interfere with absorption of <e10> probenecid </e10> or <e20> ketoconazole </e20>.
mechanism	Antacids and kaolin : <e10> Zidovudine </e10> may decrease the absorption of <e20> magnesium </e20> or aluminum antacids, which are both ingredients in zidovudine, and kaolin, which may decrease the absorption of aluminum and magnesium antacids.
mechanism	Cimetidine : <e10> Cimetidine </e10> (50 mg QD) reduced <e20> diazepam </e20> absorption by 42% and significantly decreased the exposure to diazepam by 53%.
mechanism	Cimetidine : <e10> Cimetidine </e10> may inhibit metabolism of <e20> ketoconazole </e20> by humans.
mechanism	Cimetidine : <e10> Cimetidine </e10> was found to inhibit <e20> valproic_acid </e20> metabolism and increase the renal clearance of valproic_acid.
mechanism	Ampicillin : In a single dose of <e10> ampicillin </e10> # mg to # mg, <e20> clofibrate </e20> reduced the Cmax of clofibrate by 38% and the AUC by 38%.
mechanism	Ampicillin : In a study in healthy volunteers, a single oral dose of <e10> ampicillin </e10> # mg decreased the AUC and Cmax of <e20> dasatinib </e20> by 46% and 15%, respectively.
mechanism	Ampicillin : In vitro data indicate that <e10> diflunisal </e10> increases the steady-state clearance of <e20> ampicillin </e20> by increasing its AUC.
mechanism	Cyclosporin : After administration of <e10> cyclosporin </e10>, the <e20> fluvastatin </e20> clearance was increased by 14%.
mechanism	Cyclosporin : After a single administration of <e10> cyclosporin </e10> to healthy volunteers, plasma concentrations of <e20> cisapride </e20> increased by 1.9%.
mechanism	Cyclosporin : After <e10> cyclosporin </e10> administration, renal tubular secretion of <e20> morphine </e20> was approximately 6-fold higher, and morphine clearance was approximately 50% lower, than when morphine was administered alone.
mechanism	- Cholestyramine and <e10> erythromycin </e10> (10% in one dose) inhibit the metabolism of <e20> rifampin </e20> (100 mg q12h) by inhibiting hepatic cytochrome P450 (CYP) isozyme IIIA.
mechanism	- Cholestyramine and <e10> colestipol </e10> may reduce the bioavailability of <e20> levothyroxine </e20> by blocking absorption from the gut.
mechanism	- Cholestyramine and <e10> colestipol </e10> reduce the absorption of <e20> pravastatin </e20>.
mechanism	- Cholestyramine and <e10> probenecid </e10> may interfere with the metabolism of <e20> nelfinavir </e20> or clarithromycin, and therefore, the efficacy of these drugs may be reduced.
mechanism	<e10> Chlorprothixene </e10> has been reported to inhibit the metabolism of acetaminophen, <e20> theophylline </e20>, and other oral antacids by binding to a specific enzyme (e,g,, monoamine oxidase II) and resulting in lower serum levels of these active drugs.
mechanism	<e10> Chlorprothixene </e10> causes a decrease in <e20> isoniazid </e20> levels in patients receiving either a long or a short course of therapy.
mechanism	<e10> Chlorprothixene </e10> and carbamazepine, potent inhibitors of CYP3A4, are capable of inhibiting the metabolism of <e20> alprazolam </e20> and can result in a prolonged alprazolam level.
mechanism	Interactions for vitamin_D : <e10> Ribavirin </e10> and <e20> vitamin_D </e20> increase the plasma concentrations of vitamin_D, but do not affect the absorption of vitamin_D.
mechanism	Interactions for vitamin_D : <e10> L-methionine </e10> supplements may increase serum <e20> vitamin_D </e20> levels, which can decrease renal clearance of vitamin_D and cause toxicity.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> may increase the clearance of <e20> zidovudine </e20> and other non-human immunodeficiency virus protease_inhibitors and the amount of zidovudine remaining in the blood.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> and other sulfonamides inhibit the metabolism of <e20> levothyroxine </e20>.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> decreases the renal clearance of <e20> terfenadine </e20>, resulting in increased serum levels and elimination of this medication.
mechanism	<e10> Cholestyramine </e10> decreased the metabolism of <e20> furosemide </e20> by 70%.
mechanism	<e10> Cholestyramine </e10> and <e20> nifedipine </e20> can decrease the clearance of the anticoagulant, warfarin or its derivatives.
mechanism	<e10> Cholestyramine </e10> may enhance the absorption of other drug products that have been shown to decrease <e20> cimetidine </e20> s renal clearance.
mechanism	<e10> Cholestyramine </e10> administered concurrently with <e20> aripiprazole </e20> was found to be effective in attenuating plasma AUC and Cmax values of Aripiprazole, and AUC and Cmax values of cholestyramine were approximately #% lower than for Aripiprazole alone.
mechanism	<e10> Cholestyramine </e10> may potentiate the effects of <e20> phenytoin </e20>, clofibrate, and similar agents.
mechanism	<e10> Cholestyramine </e10> and <e20> quinidine </e20> were significantly less effective in reducing the number of prostaglandins (PGs) in prostatic epithelium in vitro than they were in preventing them.
mechanism	<e10> Cholestyramine </e10>, when administered with <e20> warfarin </e20> or its derivatives, increased the half-life of warfarin and its derivatives, as well as the prothrombin time and INR.
mechanism	<e10> Cholestyramine </e10>, in vitro, increases <e20> acitretin </e20> plasma levels and decreases acitretin elimination by enzyme-linked immunosorbent assay.
mechanism	<e10> Cholestyramine </e10> and related compounds, such as its metabolite 5-hydroxycholestyramine, have been reported to inhibit the metabolism of <e20> warfarin </e20> or its derivatives and increase the AUC of warfarin.
mechanism	<e10> Cholestyramine </e10> decreased the metabolism of <e20> warfarin </e20>, resulting in increased warfarin levels.
mechanism	<e10> Cholestyramine </e10> may inhibit the metabolism of acetaminophen and other <e22> cephalosporins </e22>.
mechanism	<e10> Cholestyramine </e10> may be inactivated by high temperature, alkali, and/or high salicylates such as sulfonamides and chloramphenicol (diuretics) or by <e20> warfarin </e20> (anticoagulants).
mechanism	<e10> Cholestyramine </e10> and <e20> diazoxide </e20> significantly inhibit the metabolism of both digoxin and nicotinamide_P and therefore increase serum levels of these two co-administered drugs.
mechanism	<e10> Cholestyramine </e10> ( 50 mg orally, q 24-48) # times daily for # days prior to and # days after <e20> zalcitabine </e20> was administered concurrently.
mechanism	<e10> Cholestyramine </e10> may inhibit <e20> diltiazem </e20> clearance.
mechanism	<e10> Cholestyramine </e10> may decrease the plasma concentration of theophylline, resulting in a decrease in the bioavailability of <e20> theophylline </e20>.
mechanism	<e10> Cholestyramine </e10>, in combination with <e20> phenytoin </e20>, caused a significant increase in the pharmacokinetic profile of phenytoin.
mechanism	<e10> Cholestyramine </e10> has been reported to increase the clearance of <e20> propafenone </e20>.
mechanism	<e10> Cholestyramine </e10> may interfere with absorption of a number of medications, such as rifampin, phenytoin, <e20> bromocriptine </e20>, disulfiram, phenobarbital, cholestyramine, phenytoin, haloperidol, estrogens, sulfonamides, succinimides, warfarin, and bromocriptine.
mechanism	<e10> Cholestyramine </e10> in combination with <e20> quinidine </e20> decreases the clearance of quinidine from the blood and may enhance the clearance of quinidine during administration of either intravenous or oral anticoagulants.
mechanism	<e10> Cholestyramine </e10>, vitamin_B12, and <e20> lithium </e20>, all of which have been reported to decrease blood levels of iron, may increase the absorption of lithium.
mechanism	<e10> Cholestyramine </e10> decreased the rate of <e20> methotrexate </e20> absorption by 63%.
mechanism	<e10> Cholestyramine </e10> decreased the serum concentration of <e20> cisapride </e20> by 25% in a dose-dependent manner.
mechanism	<e10> Cholestyramine </e10> and other non-steroidal_anti-inflammatory_drugs ( <e22> NSAIDs </e22> ) reduce the absorption of coumarin and other non-steroidal_anti-inflammatory_drugs by binding to them, resulting in decreased absorption.
mechanism	<e10> Cholestyramine </e10> or tetracycline : Concomitant administration of cholestyramine or tetracycline with <e20> phenytoin </e20> may increase the plasma levels of the drug.
mechanism	<e10> Cholestyramine </e10> has been shown to inhibit the metabolism of <e20> digoxin </e20> by hepatic microsomal enzymes and may decrease the clearance of digoxin.
mechanism	<e10> Cholestyramine </e10> increased plasma levels of both <e20> valdecoxib </e20> and cimetidine.
mechanism	<e10> Cholestyramine </e10> inhibited <e20> isoniazid </e20> -induced damage in brain and heart.
mechanism	<e10> Cholestyramine </e10> may increase the metabolism of <e20> erythromycin </e20>, resulting in decreased absorption and increased serum levels.
mechanism	Cholestyramine resin may increase the absorption of some <e12> antibiotics </e12>, anticonvulsants, antifungals, atorvastatin, <e20> cisapride </e20>, clofibrate, diazepam, dicumarol, estrogens, furosemide, fluconazole, pimozide, quinidine, theophylline, zidovudine, and zidovudine.
mechanism	Cholestyramine resin may increase the plasma levels of <e10> cimetidine </e10> and <e20> digoxin </e20>.
mechanism	In another drug interaction study, <e10> quinidine </e10> and <e20> ketoconazole </e20> were coadministered in single doses to healthy volunteers and were found to inhibit the metabolism of quinidine in a dose-dependent manner.
mechanism	In another drug interaction study, <e10> amiodarone </e10> was found to inhibit the metabolism of <e20> cimetidine </e20> in both in vitro and in vivo studies.
mechanism	In another drug-drug interaction study in healthy volunteers, <e10> Sulfacetamide </e10> # mg twice daily for # days was found to reduce the AUC of <e20> diltiazem </e20> by 29% (p = 0.02).
mechanism	Probenecid : <e10> Probenecid </e10> may decrease the metabolism of <e20> valproate </e20> by affecting its metabolism in the renal and hepatic venous systems.
mechanism	Probenecid : <e10> Probenecid </e10> increased AUC and Cmax of <e20> alosetron </e20> by 50% and 50%, respectively, and AUC of alosetron by 54%.
mechanism	Probenecid : <e10> Probenecid </e10> inhibits the metabolism of <e20> ketoconazole </e20> by interfering with the metabolism of its primary metabolite.
mechanism	Probenecid : <e10> Probenecid </e10> increases <e20> methotrexate </e20> absorption by affecting renal tubular secretion of methotrexate.
mechanism	Probenecid : <e10> Probenecid </e10> prolongs the blood-sugar-reducing effect of <e20> thiazide_diuretics </e20>, furosemide and other agents that decrease blood-sugar by inhibiting CYP2D6.
mechanism	Probenecid : <e10> Probenecid </e10> markedly decreases the metabolism of <e20> ketoconazole </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> may increase the clearance of <e20> amprenavir </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> decreases the hepatic metabolism of <e20> cytochalasin_D </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> was found to inhibit <e20> cimetidine </e20> metabolism, leading to a reduction in its bioavailability.
mechanism	Probenecid : <e10> Probenecid </e10> administered orally, for a maximum of # weeks, decreased plasma levels of <e20> indinavir </e20> by approximately #%.
mechanism	Probenecid : <e10> Probenecid </e10>, which blocks vitamin_B12, has been shown to increase the toxicity of <e20> diltiazem </e20>, thereby reducing its absorption.
mechanism	Probenecid : <e10> Probenecid </e10> increases the rate of absorption of <e20> erythromycin </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> at doses of # mg/day for # days prior to treatment with <e20> aripiprazole </e20> resulted in a reduction in AUC and Cmax values and an increase in AUC and AUC%day of aripiprazole from # mg/day to # mg/day (p = 0.05 and p = 0.01, respectively) and from # mg/day to # mg/day (p = 0.01 and p = 0.03, respectively) compared to aripiprazole alone.
mechanism	Probenecid : <e10> Probenecid </e10> reduces the serum levels of <e20> warfarin </e20>, but not the serum levels of either diclofenac or diltiazem.
mechanism	Probenecid : <e10> Probenecid </e10> has been reported to increase plasma concentrations of <e20> chlorpromazine </e20>, chloroquine, cimetidine, methotrexate, and zidovudine.
mechanism	Probenecid : <e10> Probenecid </e10>, an orally active antimicrobial agent, has been reported to decrease the absorption of <e20> digoxin </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> has been shown to be a potent inhibitor of hepatic metabolism of <e20> valproate </e20>, resulting in increased plasma levels of valproate.
mechanism	Probenecid : <e10> Probenecid </e10> decreased the clearance of <e20> dexamethasone </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> may be present in plasma when <e20> methotrexate </e20> is administered concomitantly.
mechanism	Probenecid : <e10> Probenecid </e10> may interfere with the metabolism of <e20> bromocriptine_mesylate </e20>, resulting in elevated plasma levels.
mechanism	Probenecid : <e10> Probenecid </e10> decreases serum levels of <e20> indinavir </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> increased the AUC and the Cmax of <e20> aprepitant </e20> by 34% and 67%, respectively, while decreasing the AUC and the Cmax of the parent drug aprepitant by 27% and 37%, respectively.
mechanism	Probenecid : <e10> Probenecid </e10> ( <e20> erythromycin </e20> ) is reported to inhibit hepatic CYP3A4 activity by about 50%.
mechanism	Probenecid : <e10> Probenecid </e10> inhibited <e20> diltiazem </e20> in a dose-dependent manner, but had no effect on the plasma levels of diltiazem.
mechanism	Probenecid : <e10> Probenecid </e10> may increase the metabolism of <e20> indomethacin </e20>, increasing the total intake of indomethacin.
mechanism	Probenecid : <e10> Probenecid </e10> inhibits the metabolism of <e20> rifampin </e20>, causing a reduction in its half-life by 43%.
mechanism	Probenecid : <e10> Probenecid </e10> decreased the maximum plasma concentration of <e20> digoxin </e20> and norethindrone by approximately 50%.
mechanism	Probenecid : <e10> Probenecid </e10> may increase the effect of <e20> norethindrone </e20>, which is a strong inhibitor of CYP2C9.
mechanism	Probenecid : <e10> Probenecid </e10> may inhibit the metabolism of <e20> ketoconazole </e20>, resulting in a reduction in the elimination of both drugs.
mechanism	Probenecid : <e10> Probenecid </e10> inhibited <e20> chlorpropamide </e20> uptake, and chlorpropamide was displaced from its binding sites during probenecid administration.
mechanism	Probenecid : <e10> Probenecid </e10> is a potent inhibitor of platelet function that may increase the risk of bleeding when administered concurrently with <e20> warfarin </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> can increase the clearance of <e20> cimetidine </e20>, causing a 4-fold increase in the maximum plasma concentration of cimetidine.
mechanism	Probenecid : <e10> Probenecid </e10>, a well-known quinolone_antibiotic, has been reported to decrease the metabolism of <e20> erythromycin </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> has been reported to decrease the clearance of <e20> astemizole </e20> and terfenadine.
mechanism	Probenecid : <e10> Probenecid </e10> (5 mg q12h) # times a day for # days significantly increased <e20> digoxin </e20> clearance by #%.
mechanism	Probenecid : <e10> Probenecid </e10>, a pentacyclic tricyclic_antidepressant, has been reported to decrease the clearance of <e20> digoxin </e20>, and to increase the clearance of warfarin.
mechanism	Probenecid : <e10> Probenecid </e10> has been shown to increase the absorption of <e20> ergotamine </e20> and to decrease the AUC of ergotamine.
mechanism	Probenecid : <e10> Probenecid </e10> decreased the clearance of <e20> pentazocine </e20> by 2.7%.
mechanism	Probenecid : <e10> Probenecid </e10> (2,000 mg twice daily) reduced the AUC of <e20> zidovudine </e20> by about half.
mechanism	Probenecid : <e10> Probenecid </e10> reduces the number of <e20> ciprofloxacin </e20> -sensitive enteric bacilli in the stool of healthy subjects.
mechanism	Pharmacokinetic studies have shown that coadministration of <e11> VIDEX </e11> # mg daily with <e20> ketoconazole </e20> # mg twice daily for # days increased the average AUC and Cmax by approximately 33% and 20%, respectively, and the mean AUC of VIDEX by approximately 32% and 20%, respectively, when administered with metoclopramide.
mechanism	Pharmacokinetic studies have demonstrated that <e10> rifabutin </e10> and <e20> warfarin </e20> have additive or potentiating effects when given with either a phenytoin_anticoagulant, a sulfonamidine, or a disulfiram.
mechanism	Pharmacokinetic studies have shown that <e10> furosemide </e10> markedly decreases <e20> hydralazine </e20> plasma concentrations in patients who are on long-term hydralazine therapy.
mechanism	Pharmacokinetic studies have shown that <e10> phenytoin </e10> may decrease the half-life of <e20> cisapride </e20> by a factor of 3-5.
mechanism	Pharmacokinetic studies have shown that <e10> colestipol </e10> administered concomitantly with <e20> phenytoin </e20> resulted in increased plasma concentrations of colestipol.
mechanism	Pharmacokinetic studies have shown that <e10> doxapram </e10> significantly increases plasma levels of <e20> cimetidine </e20>, which may reduce its renal clearance.
mechanism	Population pharmacokinetic studies indicate that <e10> flurbiprofen </e10> increases exposure of <e20> digoxin </e20>.
mechanism	Population pharmacokinetic studies of <e10> cimetidine </e10> revealed a 10% increase in steady-state plasma concentrations with concomitant use of <e20> atorvastatin </e20>.
mechanism	<e11> Tagamet </e11> reduced the systemic exposure of <e20> diltiazem </e20> by approximately 18% and that of indomethacin by approximately 11%.
mechanism	<e11> Tagamet </e11> has been shown to inhibit <e20> fluvoxamine </e20> metabolism by lowering the plasma levels of theophylline and its active metabolite, catecholamine.
mechanism	<e11> Tagamet </e11> may increase the clearance of <e20> warfarin </e20> and other potentially toxic anticoagulants.
mechanism	<e11> Tagamet </e11>, <e20> ketoconazole </e20>, clofibrate, diclofenac, digoxin, heparin, ibuprofen, lithium, nifedipine, quinine, succinimide, tamoxifen, warfarin
mechanism	<e11> Tagamet </e11> has been reported to reduce the clearance of nonsteroidal_anti-inflammatory_drugs, some cyclosporine_A, and the <e20> fluconazole </e20>, causing a decrease in the half-life of these drugs.
mechanism	<e11> Tagamet </e11> and co-administration with other drugs that decrease platelet function, including aspirin, clofibrate, decongestant_drugs, corticosteroids, corticotropin, cyclosporine, dapsone, disopyramide, indomethacin, meclofenamic_acid, phenylbutazone, salicylates, theophylline, theophylline_acid, <e20> warfarin </e20>, and valproic_acid, may increase the exposure of Tagamet to potentially fatal concentrations.
mechanism	<e11> Tagamet </e11> administered orally once daily to healthy subjects with low plasma concentrations of <e20> carbamazepine </e20> or carbamazepine sulfate decreased the maximum plasma concentration of these two drugs by approximately 20% and approximately 38%, respectively.
mechanism	<e11> Tagamet </e11> has been reported to increase the clearance of a <e22> diuretic </e22> by inhibiting renal tubular secretion.
mechanism	<e11> Tagamet </e11> is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme that has been shown to inhibit <e20> methotrexate </e20> and terfenadine metabolism and to decrease plasma concentrations of these agents.
mechanism	<e11> Tagamet </e11> may increase plasma concentrations of oral <e20> clofibrate </e20>.
mechanism	<e11> Tagamet </e11> increased the clearance of methotrexate (45% increase) and <e20> doxorubicin </e20> (48% increase) in a dose-dependent manner.
mechanism	<e11> Tagamet </e11> decreased the Cmax and AUC of <e20> cyclosporine </e20> and Cmax and AUC of digoxin.
mechanism	<e11> Tagamet </e11> also inhibited the proliferation of prostate epithelium stimulated with <e20> prostaglandin_F2alpha </e20> and significantly inhibited prostaglandin_F2alpha -induced phosphorylation of mitogen-activated protein kinase (MAPK)1/2.
mechanism	<e11> Tagamet </e11> and a <e22> calcium_channel_blocker </e22>, tetracycline, inhibit apical calcium transients induced by calcium-channel_blockers.
mechanism	<e11> Tagamet </e11>, a nonsteroidal_anti-inflammatory_drug, is a competitive inhibitor of <e20> 5-fluorouracil </e20> metabolism and a competitive inhibitor of 5-fluorouracil renal excretion.
mechanism	<e11> Tagamet </e11> # mg given with <e20> ethinyl_estradiol </e20> # mg given once daily for # days.
mechanism	<e11> Tagamet </e11> may reduce the clearance of <e20> cisapride </e20>, resulting in elevated plasma levels.
mechanism	<e11> Tagamet </e11>, a <e22> TCA </e22> analogue, reduced the clearance of atorvastatin by 50% in healthy subjects and decreased the clearance of cimetidine by 45%.
mechanism	<e11> Tagamet </e11> ( a 5-hydroxytryptophan_receptor_antagonist ) has been reported to decrease the absorption of <e20> quinidine </e20>.
mechanism	<e11> Tagamet </e11> # mg orally increased the clearance of <e20> isoniazid </e20> # mg orally by approximately 11% and the clearance of the combination of these drugs by approximately 22%.
mechanism	<e11> Tagamet </e11> may prolong the half-life of <e20> diltiazem </e20>, prolonging its half-life by approximately 12%.
mechanism	<e11> Tagamet </e11> tablets and theophylline : <e20> Tagamet </e20> and theophylline may increase plasma levels of both drugs, thereby causing a decrease in their oral bioavailability.
mechanism	<e11> Tagamet </e11>-<e20> Cimetidine </e20> s reduced cardiac output and decreased cardiac output and cardiac index in the treatment of coronary artery disease with Coadministration of Tagamet and Coadministration of Coadministration of Tagamet and Coenzyme_A_reductase_inhibitors ( a :.
mechanism	<e11> Tagamet </e11> treatment increases the clearance of <e20> fluconazole </e20> and cisapride, and increases the clearance of nonsteroidal_anti-inflammatory_drugs and ketoconazole.
mechanism	<e11> Tagamet </e11> reduces <e20> propafenone </e20> clearance by approximately 30%.
mechanism	<e11> Tagamet </e11> enhances the metabolism of the phenytoin derivative phenobarbital by converting it to its active metabolite, <e20> phenytoin </e20>.
mechanism	<e11> Tagamet </e11> is a member of the <e22> anticholinesterase_class </e22> of drugs and its metabolism is regulated by tricyclic_antidepressants, phenothiazines, and carbamazepine.
mechanism	<e11> Tagamet </e11> inhibits <e20> diltiazem </e20> metabolism by increasing plasma levels of the C-terminal disulfide_oxidase ( CYP3A4 ) active metabolite of diltiazem.
mechanism	However, a crossover study demonstrated that coadministration of <e10> ketoconazole </e10> and <e20> quinine </e20> resulted in a dose-dependent decrease in the clearance of quinine and a significant increase in the mean fluorescence intensity of ketoconazole in rat liver.
mechanism	However, a crossover study of <e10> rifampin </e10> -induced <e20> ketoconazole </e20> -induced keratinization of the back revealed that the dose of rifampin required to inhibit keratinization increased from # to # micrograms when rifampin was administered with a two-week interval to a daily dose of # micrograms.
mechanism	However, a crossover study of <e11> CANCIDAS </e11>, with <e20> ketoconazole </e20> and oral anticoagulants, found a significant reduction of the following parameters in patients with elevated plasma levels of ketoconazole : phenytoin, indinavir, ritonavir, atazanavir, saquinavir, indinavir, itraconazole.
mechanism	However, a crossover study with a single dose of <e10> rifampin </e10> given # hours prior to the administration of <e20> digoxin </e20> revealed that digoxin increased rifampin AUC significantly.
mechanism	However, a crossover study in healthy volunteers, in which <e10> terfenadine </e10> # mg twice daily was co-administered with oral <e20> cisapride </e20> # mg for # days, revealed a potentiation of the hepatic metabolism of cisapride, resulting in approximately # times higher plasma levels than observed with cisapride alone.
mechanism	However, a crossover study in healthy subjects (n=8) showed that the AUC of <e10> indinavir </e10> was increased significantly by a 50% reduction of <e20> ritonavir </e20> at # and # mg/day.
mechanism	Amitriptyline : Concurrent administration of <e10> amitriptyline </e10> with <e20> aripiprazole </e20> may increase the AUC of the drug by approximately 10% (p,o, ).
mechanism	Amitriptyline : Concurrent administration of <e11> ALFENTA </e11> and <e20> amitriptyline </e20> was found to increase mean AUC of amitriptyline by a mean of 6%.
mechanism	Co-administration of <e10> cimetidine </e10> decreased the bioavailability of <e20> alfentanil </e20> by 43%.
mechanism	Co-administration of <e10> digoxin </e10> and <e20> ketoconazole </e20> in healthy volunteers increased digoxin levels by approximately 36%.
mechanism	Elevated plasma levels of <e10> digoxin </e10> have been reported during concomitant administration of <e20> ketoconazole </e20> and agents with similar binding characteristics (e,g,, triazolam, phenobarbital, ketoconazole, nefazodone ).
mechanism	Elevated plasma levels of <e10> tetracycline </e10> and carbamazepine have been reported with concomitant administration of <e20> nevirapine </e20>, rifampin, and cyclosporine.
mechanism	<e12> Quinolones </e12>, including norfloxacin, are known to inhibit CYP3A4, and the concomitant administration of <e20> norfloxacin </e20> with these agents is not recommended.
mechanism	<e12> Quinolones </e12>, including ciprofloxacin, are reported to inhibit the metabolism of <e20> levodopa </e20> and its derivatives and prolong the half-life of these agents.
mechanism	<e12> Quinolones </e12> can reduce the absorption of <e20> cisapride </e20>, causing a decrease in its serum concentration.
mechanism	<e12> Antacids </e12> may decrease the absorption of <e20> rifampin </e20>, causing a change in its pharmacokinetics.
mechanism	<e12> Antacids </e12> containing <e20> calcium_antacids </e20> ( Ca(OH)2 ) may reduce the absorption of oxymetholone and may cause a marked increase in its bioavailability when given concomitantly with antacids containing oxymetholone.
mechanism	<e12> Antacids </e12> have been reported to decrease the absorption of <e20> ketoconazole </e20>.
mechanism	Antacids or <e10> Magnesium </e10> containing preparations containing magnesium salts may decrease the absorption of <e20> cisapride </e20>.
mechanism	Antacids or <e10> sucralfate </e10> may reduce absorption of <e20> diltiazem </e20>, which may increase the exposure of other antacids or sucralfate.
mechanism	Antacids or <e10> magnesium </e10> containing multivalent cations (e,g,, aluminum, iron, calcium ) may interfere with the absorption of <e20> methotrexate </e20> and may prolong the interval from the initiation of treatment to the attainment of steady state.
mechanism	Also, concomitant administration of <e10> cimetidine </e10> and <e20> ketoconazole </e20> resulted in significantly increased exposures of cimetidine.
mechanism	Also, concomitant administration of <e10> Aprepitant </e10> with <e20> lithium </e20> tablets reduced lithium serum concentrations.
mechanism	Also, concomitant administration of <e10> ketoconazole </e10> with <e20> astemizole </e20> or itraconazole resulted in a reduction in ketoconazole and astemizole AUC values.
mechanism	Also, concomitant administration of <e10> indomethacin </e10> and <e20> indomethacin </e20> is not recommended because the potential for serious gastrointestinal effects is enhanced by indomethacin.
mechanism	Also, concomitant administration of <e11> VIDEX </e11> and <e20> nevirapine </e20> in a normal rat model resulted in a significant increase in nevirapine serum concentrations.
mechanism	Also, concomitant administration of <e11> aspirin </e11> with <e20> cimetidine </e20> results in significant increase in cimetidine clearance (P =.0059).
mechanism	Also, concomitant administration of <e10> ethambutol </e10> may increase the clearance of <e20> gentamicin </e20> and its metabolites, resulting in a diminished pharmacologic effect.
mechanism	Also, concomitant administration of <e10> ketoconazole </e10> and <e20> valdecoxib </e20> is associated with a marked reduction in ketoconazole plasma levels.
mechanism	Also, concomitant administration of <e10> ketoconazole </e10> with <e20> warfarin </e20> significantly decreased the clearance of ketoconazole.
mechanism	Also, concomitant administration of <e10> cisapride </e10> with the following agents: <e20> erythromycin </e20>, clarithromycin, indinavir, itraconazole, itraconazole / ritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, and astemizole may increase cisapride plasma concentrations.
mechanism	Also, concomitant administration of <e10> ketoconazole </e10> with <e20> ketoconazole </e20> causes a decrease in the half-life of cisapride by about 50%.
mechanism	Also, concomitant administration of <e10> erythromycin </e10> and other <e22> macrolide_antibiotics </e22> may increase the risk of serious infections and may increase the incidence of adverse drug reactions.
mechanism	Elevated cyclosporine serum concentrations and renal tubular acidosis have been reported when <e10> cyclosporine </e10> was given concurrently with <e20> ketoconazole </e20>.
mechanism	Elevated cyclosporine serum concentrations have been reported in patients on <e12> diuretic </e12> therapy and who were recently treated with <e20> cyclosporine </e20> and vitamin_D.
mechanism	Elevated cyclosporine serum levels have been reported with concomitant use of <e10> cyclosporine </e10> and other <e22> antineoplastic_agents </e22>.
mechanism	Some <e12> quinolones </e12>, such as ciprofloxacin, have been reported to inhibit the metabolism of oral <e20> warfarin </e20> by interfering with the hepatic enzyme system and/or the renal and/or hepatic biliary systems.
mechanism	Some <e12> quinolones </e12> have been reported to interfere with metabolism of <e20> succinylcholine </e20>, resulting in a net increase in serum concentrations.
mechanism	Some quinolones, including <e10> ciprofloxacin </e10>, interfere with metabolism of drugs that have a significant plasma clearance (e,g,, cyclosporine, <e20> amiodarone </e20>, carbamazepine, fluconazole, phenytoin, phenobarbital, alfentanyl, alprazolam, tricyclic_antidepressants, phenytoin, primidone, triazolam, butyrophenones, diazepam, haloperidol, and barbiturates ).
mechanism	Some quinolones, including <e10> erythromycin </e10>, have been reported to decrease the metabolism of <e20> norfloxacin </e20>.
mechanism	Methotrexate Renal tubular secretion of <e10> digoxin </e10> is decreased by <e20> valproate </e20>.
mechanism	Multivalent Cation-Containing Products: When <e10> gentamicin </e10> and <e20> tetracycline </e20> are used concomitantly, levels of gentamicin may be increased.
mechanism	Multivalent Cation-Containing Products: Multivalent Cation-Containing Products such as amiodarone, <e10> nifedipine </e10>, <e20> digoxin </e20>, phenytoin, and methotrexate may reduce the clearance of cetirizine.
mechanism	Multivalent Cation-Containing Products: When cetirizine and similar products containing multivalent cations such as amiodarone, calcium_channel_blockers, or <e10> digoxin </e10> are used concomitantly with oral <e22> anticoagulants </e22>, a reduction in the level of coagulation factors such as prothrombin time or international normalized ratio is expected.
mechanism	Multivalent Cation-Containing Products: Drugs that have been reported to have a narrow therapeutic index, such as some carbamazepine, phenytoin, <e10> phenobarbital </e10>, and lovastatin, may have an increased potential for interaction with <e20> atorvastatin </e20>.
mechanism	Multivalent Cation-Containing Products: Concomitant administration of <e11> ZYVOX </e11> tablets with other multivalent cation-containing products (eg, sodium fluoride and magnesium salts) may decrease the clearance of <e20> warfarin </e20>.
mechanism	Multivalent Cation-Containing Products: Cation-containing products such as <e10> lithium </e10> and some vitamin_B12_antagonists and supplements may interfere with absorption of <e20> cefixime </e20>.
mechanism	Multivalent Cation-Containing Products: Cimetidine : The effect of <e10> cimetidine </e10> is antagonized by multivalent cation-containing products such as sodium_citrate, calcium_sodium, <e20> sucralfate </e20>, digoxin, digoxin digoxin, magnesium_sulfate, multivitamins, and other drugs that are multivalent with cimetidine.
mechanism	Multivalent Cation-Containing Products: Concurrent administration of <e10> furosemide </e10> and multivalent cation-containing products such as warfarin or <e20> dipyridamole </e20> may increase the effect of furosemide.
mechanism	Multivalent Cation-Containing Products: There have been reports of the potential for additive CNS depressant effects when <e11> WELLBUTRIN </e11> was coadministered with <e20> methylphenidate </e20>.
mechanism	Multivalent Cation-Containing Products: Although <e11> COREG </e11> was evaluated for potential for interaction with multivalent cation-containing products (such as methylprednisolone, fluconazole, <e20> terfenadine </e20>, quinidine, prednisolone, warfarin, aspirin ), the overall effect was not significant.
mechanism	Multivalent Cation-Containing Products: <e10> Zidovudine </e10>, lamivudine, and cilostazol may increase the clearance of <e20> nevirapine </e20>.
mechanism	Multivalent Cation-Containing Products: <e10> Diclofenac </e10>, for example, may increase the serum concentration of <e20> digoxin </e20> and warfarin.
mechanism	Multivalent Cation-Containing Products: Concurrent administration of products containing multivalent cations (such as <e10> calcium </e10> ) with <e20> vitamin_D </e20> may cause calcium toxicity.
mechanism	Multivalent Cation-Containing Products: <e10> Warfarin </e10>, as well as other nonsteroidal_anti-inflammatory_drugs, such as <e20> indinavir </e20>, nelfinavir, ritonavir, saquinavir, and itraconazole, may interact with multivalent cation-containing products such as nelfinavir, saquinavir, and itraconazole, potentially increasing plasma concentrations of the cationic component of the product.
mechanism	Multivalent Cation-Containing Products: In the presence of <e11> ENABLEX </e11> ( n=42), both the mean plasma concentration of <e20> enoxacin </e20> and the maximum plasma concentration of enoxacin were decreased by approx. 40% and the area under the plasma concentration-time curve was increased by approx. 40%.
mechanism	Multivalent Cation-Containing Products: The following data suggest that <e10> hydrocodone </e10> tablets and the dosage forms listed in this section may reduce the metabolism of <e20> probenecid </e20>, resulting in increased plasma concentrations and toxicities.
mechanism	Multivalent Cation-Containing Products: The oral absorption of <e11> ZYVOX </e11> is reduced by approximately 50% in patients taking a multivalent cation-containing product (e,g,, <e20> erythromycin </e20>, clarithromycin ) or a non-covalent cation-containing product (e,g,, cyclosporine, tacrolimus ).
mechanism	Multivalent Cation-Containing Products: Therefore, a multivalent cation-containing product such as an intravenous <e12> benzodiazepine </e12>, an anticonvulsant, or a benzodiazepine with concomitant use of an amiodarone, acetaminophen, chlordiazepoxide, cimetidine, chlordiazepoxide, cyclosporine, diazepam, diazepam_hydrochloride, diazepam_hydrochloride, eszopiclone, gabapentin, haloperidol, <e20> halothane </e20>, lorazepam, methadone, phenytoin, rifampin, strychnine, theophylline, and tricyclic_antidepressants
mechanism	Multivalent Cation-Containing Products: <e10> Erythromycin </e10> may interfere with the absorption of multivalent cation-containing products such as <e20> lithium </e20>, disulfiram, and barbiturates, causing the concentrations of these cations to decrease.
mechanism	Multivalent Cation-Containing Products: It has been reported that <e11> INDOCIN </e11> may interact with multivalent cation-containing products such as cyclosporine, tacrolimus, amiodarone, carbamazepine, doxycycline, estrogens, estrogens_HCl, ginkgo_biloba_conjugate, glibenclamide, pimozide, quinidine, theophylline, <e20> verapamil </e20>, zidovudine, and zoledronic_acid.
mechanism	Multivalent Cation-Containing Products: <e10> Zidovudine </e10> may enhance the effect of <e20> zidovudine </e20>.
mechanism	Multivalent Cation-Containing Products: Multivalent cation-containing products (eg, vitamin_K, triamterene, furosemide, <e10> sulfasalazine </e10>, cimetidine, digoxin ) may reduce the absorption of <e20> warfarin </e20> by a factor of about #.
mechanism	Multivalent Cation-Containing Products: Multivalent Cation-Containing Products (eg, acetaminophen, <e10> caffeine </e10>, tetracycline, sulfonamides ) may reduce the bioavailability of <e20> erythromycin </e20>.
mechanism	Multivalent Cation-Containing Products: In some embodiments, the use of <e10> lithium </e10> may result in the simultaneous co-administration of a potent anticonvulsant ( phenytoin, carbamazepine, felbamate ) and a potent multivalent cation-containing product ( amiodarone, cisapride, <e20> digoxin </e20>, diazepam, dicumarol ).
mechanism	Multivalent Cation-Containing Products: <e10> Furosemide </e10> has been reported to inhibit the metabolism of <e22> multivalent_cation_containing_products </e22> (eg, cyclosporine, tacrolimus, tacrolimus_sulfa, amiodarone, alfentanil, terfenadine ).
mechanism	Multivalent Cation-Containing Products: Antacids and powders containing multivalent cations such as magnesium and aluminum, iron, calcium, and aluminum ( <e10> aluminum </e10> ), magnesium (3-6%), or zinc (1%), may have a high risk of adverse events if administered concomitantly with <e20> furosemide </e20>.
mechanism	Phenytoin : Altered plasma levels of <e10> phenytoin </e10> may result in decreased absorption resulting in <e20> chloroquine </e20>.
mechanism	Phenytoin : Altered plasma levels of <e10> phenytoin </e10> may result in impaired absorption of <e20> carbamazepine </e20>.
mechanism	Phenytoin : Altered plasma concentrations of <e10> phenytoin </e10> have been reported during concomitant administration of <e20> nelfinavir </e20> and high-dose ciprofloxacin.
mechanism	Probenecid : <e10> Probenecid </e10>, a novel <e22> cephalosporin </e22>, has been reported to decrease the half-life of doxycycline, furosemide, and ketoconazole.
mechanism	Probenecid : <e10> Probenecid </e10> is the active component of <e20> almotriptan </e20> and has been reported to decrease blood levels of the active metabolite of almotriptan, the amide, 5-fluorouracil.
mechanism	Probenecid : <e10> Probenecid </e10> and <e20> bromocriptine_mesylate </e20> are potent inhibitors of CYP2D6 and thus likely to reduce bioavailability of most drugs that are active in the liver and have a narrow therapeutic index in patients receiving these agents on a daily basis.
mechanism	Probenecid : <e10> Probenecid </e10> decreased the norethindrone levels and the pharmacokinetic parameters of <e20> norethindrone </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> has been shown to decrease plasma concentrations of <e20> digoxin </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> was found to decrease the exposure of <e20> Aprepitant </e20>, thus preventing its toxicity in rat testis.
mechanism	Theophylline : As the result of a study of plasma concentrations of <e10> theophylline </e10> in healthy volunteers given an <e22> diuretic </e22>, it was observed that the elimination half-life of theophylline was shortened by about 20% when coadministered with a triuretic.
mechanism	Theophylline : As a result, <e10> theophylline </e10> may inhibit <e20> cisplatin </e20> -induced DNA damage.
mechanism	Theophylline : As a tricyclic_antidepressant, <e10> theophylline </e10> may increase the clearance of <e20> cimetidine </e20>.
mechanism	Theophylline : As with other <e12> anticoagulants </e12>, concomitant administration with theophylline may result in a decrease in <e20> theophylline </e20> plasma levels.
mechanism	Antibiotics : In vitro data indicate that <e10> chloramphenicol </e10>, erythromycin, clarithromycin, indinavir, and <e20> nefazodone </e20> inhibit the metabolism of cyclosporine, phenytoin, rifampin, and methotrexate.
mechanism	Antibiotics : In vitro data suggest a possible drug interaction of <e11> HUMORSOL </e11> with <e20> clarithromycin </e20> and levodopa.
mechanism	Antibiotics : In a placebo-controlled study, # mg/kg of <e10> rifampin </e10> # hours before meal decreased mean protein content by #% and <e20> daflon </e20> by #%.
mechanism	Antibiotics : In vitro, <e10> rifabutin </e10> and ciprofloxacin inhibited <e20> diflunisal </e20> phosphorylation and inhibited the inhibitory effect of diflunisal on ciprofloxacin absorption.
mechanism	Antibiotics : In addition to its activity as an inhibitor of penicillin production, <e10> clindamycin </e10> can inhibit the action of some antibiotics, e,g,, ampicillin, <e20> ciprofloxacin </e20>, colistin, erythromycin, clarithromycin, gatifloxacin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin.
mechanism	Antibiotics : In a dose-dependent manner, <e10> colistin </e10> decreased the in vitro MICs of ampicillin, <e20> ciprofloxacin </e20>, gentamicin, netilmicin, and salicylic_acid.
mechanism	Antibiotics : In vitro data indicate that coadministration of <e10> ciprofloxacin </e10> may decrease the plasma concentrations of other <e22> nonsteroidal_anti-inflammatory_drugs </e22>, resulting in decreased anticoagulant activity and increased toxicity.
mechanism	Antidepressants : In a pharmacokinetic study of healthy volunteers receiving <e11> WELLBUTRIN </e11> and <e20> fluoxetine </e20> concurrently, fluoxetine AUC and Cmax increased approximately 50% and approximately 25%, respectively, while fluoxetine AUC decreased approximately 35% when the two drugs were coadministered.
mechanism	Antidepressants : In postmarketing experience, <e10> cimetidine </e10> has been reported to reduce the clearance of a single <e20> fluoxetine </e20> dose by 23% and of a single dose of a single SSRI by 20%.
mechanism	Antidepressants : In addition to normalizing prothrombin time, <e10> phenytoin </e10> may also be expected to decrease the concentrations of <e20> warfarin </e20> and its derivatives.
mechanism	Antifungals : In general, <e10> itraconazole </e10> and itraconazole_containing preparations (such as the <e20> erythromycin </e20> preparations) have little or no effect on the metabolism of cisapride, and the drug levels in blood are decreased by about 50% when administered with itraconazole.
mechanism	Antifungals : In studies in healthy volunteers, <e10> fluconazole </e10> reduced the <e20> cimetidine </e20> serum concentration by 20% and 30%.
mechanism	Antifungals : In vitro studies have shown that <e10> fluconazole </e10>, itraconazole, and ketoconazole can reduce the efficacy of <e20> cisapride </e20>.
mechanism	Antifungals : In a pharmacokinetic study, co-administration of <e10> itraconazole </e10> with cyclosporine (300 mg/day for # days) resulted in a 17% increase in <e20> cisapride </e20> plasma exposure.
mechanism	Antifungals : In vitro data indicate that <e10> astemizole </e10> may inhibit <e20> fluconazole </e20> and itraconazole metabolism and that the metabolic clearance of itraconazole may be reduced by the concomitant use of anabolic_steroids such as astemizole.
mechanism	Antifungals : In a single study, <e10> itraconazole </e10> significantly decreased the clearance of <e20> ketoconazole </e20> and ketoconazole, decreased the apparent renal clearance of ketoconazole by 21% and increased the renal clearance of cisapride by 14%.
mechanism	Antifungals : In vitro studies with compounds that inhibit <e12> antifungal </e12> activity ( <e20> itraconazole </e20>, itraconazole_sodium, itraconazole, nefazodone, troleandomycin, clarithromycin, fluconazole, and itraconazole_sodium ) indicate that there may be a significant interindividual variability in the time to reach maximum plasma levels of these agents.
mechanism	Human pharmacokinetic data from a single study of # mg of # mg of <e11> FACTIVE </e11> capsules daily for # days demonstrated a #-fold increase in Cmax and #-fold increase in AUC for a single # mg dose of # mg <e20> ketoconazole </e20>.
mechanism	Human pharmacokinetic data indicate that <e10> diltiazem </e10> is approximately 30% more potent than <e20> rifampin </e20> in increasing plasma concentrations of both rifampin and isoniazid.
mechanism	Human pharmacokinetic data suggest that the coadministration of <e10> warfarin </e10> and <e20> ketoconazole </e20> may decrease the half-life of warfarin by approximately 20% and increase the clearance by approximately 25%.
mechanism	H2_Receptor_Antagonists : <e10> Ethopropazine </e10> increased the clearance of the <e20> ketoconazole </e20> concomitantly with the increase in plasma concentration of ketoconazole.
mechanism	H2_Receptor_Antagonists : <e10> Aprepitant </e10> may decrease the absorption of some <e22> H2_receptor_antagonists </e22>.
mechanism	H2_Receptor_Antagonists : <e10> Isoflurane </e10> and halothane prolong the half-life of <e20> thiazide_diuretics </e20>.
mechanism	The gastrointestinal absorption of <e10> diazepam </e10> is impaired by hepatic metabolism of <e20> isoniazid </e20> and by the metabolism of metoclopramide, and therefore the use of a combination of these drugs may result in significant increases in diazepam plasma concentrations.
mechanism	The gastrointestinal absorption of <e10> erythromycin </e10> is enhanced by concomitant administration of <e20> gabapentin </e20>, levothyroxine, and thyroid_products.
mechanism	The gastrointestinal absorption of <e10> erythromycin </e10> is enhanced by <e20> colestipol_HCl </e20>.
mechanism	The gastrointestinal absorption of <e10> lofexidine </e10> may be impaired by the following drugs: ampicillin (cefazolin ), ampicillin/cefazolin (cefazolin ), chlorthalidone (cefazolin ), <e20> clarithromycin </e20>, doxycycline, dapsone, dapsone, doxycycline, estrogens (bisphenol-A, triethanolamine, estriol ), furosemide (a diuretic ), glucocorticoids (corticotropin, insulin ), ketoconazole, methadone, meclofenamic_acid, methadone, norethindrone, phenylbutazone, quinine, troleandomycin (tobacco and animal residues), valproate (medications with estrogenic activity), and valproate (anti-estrogens ).
mechanism	The gastrointestinal absorption of <e10> diazepam </e10> is enhanced by coadministration of <e20> cholestyramine </e20>, phenytoin, or terfenadine, but not by coadministration of carbamazepine, nefazodone, or tolbutamide.
mechanism	Protease_Inhibitors : In clinical studies, the concomitant use of <e10> chloramphenicol </e10> with <e20> warfarin </e20> has been associated with an increase in warfarin serum concentrations.
mechanism	Protease_Inhibitors : In vitro studies of <e10> rifampin </e10> indicate that <e20> cyclosporine_A </e20> may have a tendency to interact with the binding sites of rifampin and its active metabolite.
mechanism	Protease_Inhibitors : In patients receiving combination <e10> cisapride </e10> and <e20> aporphine_sulfate </e20>, plasma concentrations of cisapride may be elevated and resulting in impaired renal function.
mechanism	Protease_Inhibitors : In some patients with malignancy and a high serum <e10> methotrexate </e10> level, the <e20> diflunisal </e20> was reported to decrease serum methotrexate levels by decreasing enzyme-inhibitor levels.
mechanism	Protease_Inhibitors : In vitro studies have shown that <e10> nefazodone </e10> increased the <e20> norfloxacin </e20> half-life by approximately 3 hours.
mechanism	Protease_Inhibitors : In vitro data suggest that <e10> rifabutin </e10>, warfarin, and <e20> rifabutin_sodium </e20> may reduce the binding of protease_inhibitors to plasma.
mechanism	Plasma levels of <e10> dexamethasone </e10> and <e20> vitamin_D </e20> were significantly increased by dexamethasone and vitamin_D.
mechanism	Plasma levels of digoxin may be reduced by <e10> digoxin </e10> concomitant administration with <e20> ketoconazole </e20>.
mechanism	Plasma levels of <e10> valdecoxib </e10> are decreased by <e20> probenecid </e20>, presumably because of a competitive inhibition of the CYP2C9 isoenzyme.
mechanism	<e11> Atromid-S </e11> may prolong the QT interval in patients with normal coronary arteries who are undergoing pharmacologic treatment with <e20> digoxin </e20>.
mechanism	<e11> Atromid-S </e11> may increase the clearance of <e20> warfarin </e20>.
mechanism	<e11> Atromid-S </e11> may decrease the metabolism of other <e22> CYP3A4 inhibitors </e22>.
mechanism	<e11> Atromid-S </e11> may increase the clearance of dicyclomine, <e20> cisapride </e20>, and digoxin.
mechanism	<e11> Atromid-S </e11> increases the release of <e20> levodopa </e20>, an inhibitor of metabolism.
mechanism	The plasma concentration of <e10> ketoconazole </e10> may increase by up to 50% if <e20> phenytoin </e20> is coadministered with it.
mechanism	The plasma concentration of <e10> diltiazem </e10> is increased by <e20> rifampin </e20>.
mechanism	The plasma concentration of <e10> cyclosporine </e10> is increased by <e20> acitretin </e20>.
mechanism	plasma levels of digoxin, <e10> ampicillin </e10>, and ampicillin/tetracycline were increased by <e20> zalcitabine </e20>.
mechanism	plasma levels of <e10> furosemide </e10> may be decreased by concurrent administration of <e20> tetracycline </e20>.
mechanism	plasma levels of <e10> dexamethasone </e10> were increased by # to # fold when administered with <e20> valdecoxib </e20>, and the two drugs were expected to co-administrate.
mechanism	plasma levels of <e10> flupenthixol </e10> are increased by antacids containing <e20> magnesium </e20>, aluminum or calcium.
mechanism	plasma levels of <e10> diltiazem </e10> were decreased when diltiazem was coadministered with ampicillin, <e20> tetracycline </e20>, or erythromycin.
mechanism	plasma levels of <e10> phenytoin </e10> may be increased by <e20> anakinra </e20> therapy.
mechanism	plasma levels of <e10> ketoconazole </e10> were increased approximately twofold following administration of <e20> atorvastatin </e20> in healthy volunteers, but did not significantly increase in a patient with severe hypokalemic encephalopathy.
mechanism	plasma levels of <e10> amiodarone </e10> and <e20> nitrofurantoin </e20> were enhanced by both the oral and intravenous administration of the combination of cefditoren and ketoconazole, suggesting that these drugs may interfere with the metabolism of either the amiodarone or nitrofurantoin in vivo.
mechanism	plasma levels of <e10> carbamazepine </e10> were reduced by approximately 60% following concomitant administration of <e20> probenecid </e20> with carbamazepine.
mechanism	plasma levels of <e10> colestipol </e10> may be increased by <e20> furosemide </e20>, furosemide, and other inhibitors of CYP2C9, resulting in lower plasma concentrations of colestipol and resulting in higher metabolism of other anticoagulants.
mechanism	plasma levels of <e10> levodopa </e10> were decreased by <e20> diltiazem </e20>.
mechanism	plasma levels of <e10> ketoconazole </e10> and <e20> cimetidine </e20> decreased by approximately 39% and 45%, respectively, following concurrent administration of low-dose ketoconazole and high-dose cimetidine.
mechanism	plasma levels of <e10> digoxin </e10> and its metabolite, digoxin sulfate, are increased when digoxin is coadministered with <e20> amiodarone </e20>.
mechanism	plasma levels of <e10> warfarin </e10> are increased in the presence of <e20> terfenadine </e20>, and these levels may be clinically relevant.
mechanism	plasma levels of rifampin (400 mg) were reduced by #% following administration of <e10> nelfinavir </e10> and <e20> rifabutin </e20> in a dose of # mg twice daily for # days.
mechanism	plasma levels of <e10> probenecid </e10> and indinavir are reduced by concurrent administration of <e20> lopinavir </e20>.
mechanism	plasma levels of <e10> phenytoin </e10> decreased by approximately 50% in rats receiving the chronic treatment with <e20> diazepam </e20> for # weeks.
mechanism	plasma levels of <e10> erythromycin </e10> are increased in patients taking <e20> cyclosporine </e20> concurrently.
mechanism	plasma levels of erythromycin, methotrexate, <e10> cyclosporine </e10>, tacrolimus, hexobarbital, carbamazepine, phenytoin, alfentanil, cisapride, disopyramide, gentamicin, phenytoin_hydrochloride, piperazine, disulfiram, dexamethasone, pimozide, theophylline, and disulfiram were increased by <e20> quinine </e20>, and these increases were not prevented by quinine.
mechanism	plasma levels of <e10> diltiazem </e10> were decreased in patients treated with <e20> zalcitabine </e20> concomitantly.
mechanism	plasma levels of <e10> dexamethasone </e10> and retinyl_acetate are decreased when <e20> furosemide </e20> is used concurrently.
mechanism	plasma levels of <e10> estradiol </e10> are increased when <e20> warfarin </e20> is administered concomitantly with drugs that inhibit CYP3A4 (eg, fluconazole, itraconazole, ritonavir, nefazodone, troleandomycin, clarithromycin, theophylline, erythromycin, and alfentanil ) and drugs that do not inhibit CYP3A4 (eg, phenytoin, cisapride, carbamazepine, disopyramide, disulfiram, phenytoin, theophylline, and bromocriptine ).
mechanism	plasma levels of <e10> ketoconazole </e10> and <e20> clarithromycin </e20> increased in a dose-dependent manner when administered concomitantly with ciprofloxacin.
mechanism	plasma levels of <e10> methotrexate </e10> are increased when <e20> cisplatin </e20> and cyclosporine are coadministered.
mechanism	plasma levels of the <e10> isoniazid </e10> metabolite are increased when <e20> CSA </e20> is given concurrently.
mechanism	plasma levels of <e10> warfarin </e10> have been shown to increase with the concomitant administration of <e20> ketoconazole </e20> (a potent CYP3A4 inhibitor) and oral anticoagulants.
mechanism	plasma levels of <e10> estradiol </e10>, but not of <e20> testosterone </e20>, are increased by the addition of 100 mg of TUBAF to the dose of a single # mg dose of TUBAF.
mechanism	plasma levels of <e10> diazepam </e10> were increased by oral <e20> probenecid </e20>, caffeine, and diazepam.
mechanism	Administration of <e10> clofibrate </e10> to patients receiving <e20> clofibrate </e20> concomitantly with anticoagulants, antithrombotic_agents, or platelet_inhibitors (aspirin, clofibrate, dipyridamole, indinavir, itraconazole, ritonavir, saquinavir, telithromycin, troleandomycin, warfarin, theophylline, voriconazole ) may result in increases in blood levels of the platelet_aggregation_inhibitor.
mechanism	Administration of <e10> erythromycin </e10> and <e20> cimetidine </e20> in a dose of # mg of each drug daily for # days produced a decrease in the AUC and Cmax of cimetidine from # to # mg/mL and from # to # mg/mL, respectively.
mechanism	Administration of <e10> furosemide </e10> # days prior to and # days after <e20> fluvoxamine </e20> # days prior to administration of furosemide.
mechanism	<e10> Fluvoxamine </e10> increased the exposure of <e20> warfarin </e20>.
mechanism	<e10> Fluvoxamine </e10> may decrease the blood flow to the sinus node and lower the maximum concentration of <e20> levodopa </e20> in the sinus node by two to three times.
mechanism	<e10> Fluvoxamine </e10> was generally associated with a higher clearance of <e20> phenytoin </e20> than did other medications.
mechanism	Because Anafranil is a dopamine_D2_receptor_agonist, it is possible that <e11> Anafranil </e11> may increase <e20> apomorphine </e20> levels and thus increase the pharmacologic effect of the drug.
mechanism	Because Anafranil is an inhibitor of CYP3A4, a possible drug interaction between <e11> Anafranil </e11> and <e20> cisapride </e20> may have resulted in an increase in serum cisapride levels.
mechanism	In a study in healthy volunteers, a single dose of <e10> rifampin </e10> # mg increased the <e20> norethindrone </e20> AUC by 2.6-fold and Cmax by 17-fold.
mechanism	In a study of healthy volunteers (n=6), <e10> levothyroxine </e10> decreased the uptake of <e20> cetirizine </e20> (0.1 microM) by 18% and 25% (P=0.004) after single and multiple dosing, respectively.
mechanism	In a study in healthy volunteers, concomitant administration of <e10> rifampin </e10> # mg twice daily with <e20> cimetidine </e20> # mg twice daily for # days resulted in a 44% increase in cimetidine plasma concentrations (3 days: mg/mL, mean, p = 0.006; 7 days: mg/mL, mean, p = 0.006).
mechanism	In a study in healthy subjects, <e10> astemizole </e10> at doses of # mg or # mg taken concomitantly with <e20> terfenadine </e20>, a potent inhibitor of CYP3A4, significantly reduced the systemic exposure of terfenadine by 40% and 43%, respectively.
mechanism	In a study in healthy volunteers, oral <e10> methotrexate </e10> decreased <e20> indinavir </e20> plasma concentrations by 41% and the AUC of indinavir by 37% on day # after the dosing interval with # mg of # mg/day of # methotrexate / orally.
mechanism	In a study in rats, <e10> indomethacin </e10> increased the clearance of <e20> phenytoin </e20> by 27%.
mechanism	Cytochrome P-450 inducers, such as <e10> warfarin </e10>, have been reported to decrease the clearance of <e20> cefazolin </e20>.
mechanism	Cytochrome P-450 inducers, such as <e10> quinidine </e10>, may increase the clearance of <e20> fluvoxamine </e20>.
mechanism	Cytochrome P-450 inducers, including methotrexate, phenytoin, carbamazepine, <e10> cyclosporine </e10>, tacrolimus, alfentanyl, cisapride, disopyramide, indinavir, itraconazole, itraconazole_sodium, <e20> itraconazole </e20>, omeprazole, quinidine, rifampin, troleandomycin, zidovudine, zidovudine, ritonavir, saquinavir, telithromycin, troleandomycin, and lovastatin may increase the metabolism of zidovudine, resulting in decreased plasma concentrations of zidovudine and increased toxicity.
mechanism	Cytochrome P-450 inducers, including <e10> phenobarbital </e10>, may increase the plasma concentration of <e20> cimetidine </e20>.
mechanism	Cytochrome P-450 inducers, such as phenytoin, <e10> carbamazepine </e10>, and cimetidine, may reduce the plasma concentrations of <e20> almotriptan </e20> and increase the clearance of almotriptan.
mechanism	Cytochrome P-450 inducers, such as <e10> cypermethrin </e10>, diflunisal, flutamide, carbamazepine, or phenytoin, may increase the plasma concentrations of <e20> ketoconazole </e20>, which is an inhibitor of cytochrome P450 inducers.
mechanism	Cytochrome P-450 inducers, such as <e10> rifampin </e10>, ketoconazole, pimozide, and indinavir, may potentiate the CYP3A4-mediated metabolism of <e20> rifampin </e20> and increase plasma levels of rifampin.
mechanism	<e10> Phenytoin </e10> may decrease the renal clearance of <e20> amprenavir </e20>, resulting in lower plasma levels and increased AUC.
mechanism	<e10> Phenytoin </e10> and <e20> cimetidine </e20> inhibit oral bioavailability of carbamazepine and take approximately # minutes to reach # mg/kg/day.
mechanism	<e10> Phenytoin </e10> increased the clearance of <e20> dofetilide </e20>.
mechanism	Phenytoin, <e10> doxorubicin </e10>, and cisapride reduce the rate of metabolism of <e20> bromocriptine_mesylate </e20> by a mean of 41%, 30%, and 17%, respectively.
mechanism	Phenytoin, <e10> phenobarbital </e10>, and carbamazepine decrease <e20> ketoconazole </e20> concentrations.
mechanism	Phenytoin, nicotine, or <e10> valdecoxib </e10> may increase the clearance of <e20> estradiol </e20>.
mechanism	<e10> Cimetidine </e10> increased <e20> warfarin </e20> exposure by approximately 50%.
mechanism	<e10> Cimetidine </e10>, a <e22> non-steroidal_anti-inflammatory_agent </e22>, may interfere with the metabolism of ACE_inhibitors, causing an increase in serum and urine levels.
mechanism	<e10> Cimetidine </e10> reduced the rate of <e20> indinavir </e20> uptake by approximately 33% and the clearance by approximately 43% (P = #).
mechanism	Cimetidine, <e10> diazepam </e10>, and haloperidol may interfere with the metabolism of <e20> levodopa </e20> and increase its plasma concentrations.
mechanism	Cimetidine, <e10> warfarin </e10>, and similar agents may decrease the metabolism of <e20> zalcitabine </e20>.
mechanism	Cimetidine, <e10> amiodarone </e10>, and sulfamethoxazole are all potent inhibitors of CYP3A4 and therefore will decrease the plasma concentrations of <e20> gabapentin </e20>.
mechanism	Cimetidine, caffeine, and <e10> phenobarbital </e10> may reduce the absorption of <e20> quinine </e20>.
mechanism	Cimetidine, caffeine, and ethanol may increase <e10> phenytoin </e10> exposure and may reduce the bioavailability of <e20> phenytoin </e20>.
mechanism	Cimetidine, caffeine, and <e10> chlorpropamide </e10> may increase the clearance of <e20> cisapride </e20>.
mechanism	Although concomitant use of <e10> diazepam </e10> with a pharmacologic or dietary regimen that does not target the metabolism of <e20> phenytoin </e20> may result in elevated plasma concentrations, the clinical significance is unknown.
mechanism	Although concomitant use of <e10> cyclosporine </e10> with <e20> astemizole </e20> has not been studied, the risk of systemic toxicity should be considered when initiating a regimen of this combination.
mechanism	Although concomitant use of <e10> terfenadine </e10> with <e20> azathioprine </e20> is not recommended, azathioprine can affect the metabolism of terfenadine.
mechanism	<e10> Paroxetine </e10> may decrease plasma concentrations of <e20> fluoxetine </e20>.
mechanism	<e10> Paroxetine </e10> may potentiate the effects of other psychotropic_medications, including <e20> nicotine </e20>, barbiturates, anticonvulsants, and tricyclic_antidepressants.
mechanism	<e10> Paroxetine </e10> decreased plasma <e20> norethindrone </e20> levels by 39%.
mechanism	However, other published data indicate that <e10> dapsone </e10> may have a higher affinity for <e20> ampicillin </e20>, suggesting that it may be possible to enhance the effect of dapsone with antibiotics such as ampicillin.
mechanism	However, other published reports suggest that <e10> carbamazepine </e10> and <e20> lithium </e20> may have additive effects on lithium toxicity.
mechanism	However, other published reports suggest that <e10> nevirapine </e10> may increase the renal clearance of <e20> estradiol </e20> and thus increase the estrogenic effects of progestins.
mechanism	However, other published data have shown that <e10> fluvoxamine </e10> can increase <e20> warfarin </e20> serum levels.
mechanism	However, other published studies suggest that <e10> ciprofloxacin </e10> and its metabolites may interact with oral <e22> anticoagulant_agents </e22>.
mechanism	However, other published data have shown that <e12> benzodiazepines </e12>, including alprazolam, produce respiratory depression when coadministered with <e20> cyclosporine </e20>.
mechanism	However, other published reports suggest that <e12> quinolones </e12> may increase the efficacy of oral contraceptives, such as minipill or <e20> ethinyl_estradiol </e20>, and possibly decrease the serum levels of these drugs.
mechanism	However, other published reports have reported that coadministration of <e10> valdecoxib </e10> with <e20> digoxin </e20> resulted in elevations in serum digoxin concentrations that were comparable to those reported with methotrexate and a single oral dose of intravenous diltiazem.
mechanism	However, other published data have demonstrated a possible interaction of <e11> INDOCIN </e11> and intravenous <e20> procainamide </e20>, and it is recommended that INDOCIN not be administered concomitantly with procainamide.
mechanism	<e10> Colchicine </e10> may decrease the absorption of the <e20> acetaminophen </e20>.
mechanism	<e10> Colchicine </e10> may interact with certain antidepressants, anticonvulsants, barbiturates, calcium supplements, cyclosporine, diazepam, diltiazem, doxycycline, estrogens, furosemide, fluoxetine, fluvoxamine, paroxetine, <e20> quinidine </e20>, sertraline, tacrolimus, temazepam, theophylline, and warfarin.
mechanism	<e10> Colchicine </e10> has been reported to inhibit metabolism of <e20> diclofenac </e20> by CYP3A4 and thus increase the clearance of diclofenac and its active metabolite, doxycycline.
mechanism	The action of <e10> diltiazem </e10> is also partially inhibited by <e20> cimetidine </e20>.
mechanism	The action of cimetidine (CET) on the metabolism of <e10> digoxin </e10> and <e20> amphetamines </e20> may lead to increased AUC and Cmax values.
mechanism	The action of <e10> terfenadine </e10> on <e20> rifabutin </e20> AUC values is unpredictable, and a possible mechanism may be that terfenadine has a decreased metabolism of rifabutin AUC.
mechanism	<e11> WelChol </e11> has been shown to reduce plasma levels of digoxin, <e20> nicardipine </e20>, and furosemide in healthy subjects.
mechanism	<e11> WelChol </e11> inhibits the metabolism of <e20> tetracycline </e20>.
mechanism	<e11> WelChol </e11> may inhibit the absorption of <e20> rifampin </e20>.
mechanism	<e11> WelChol </e11> prolongs the prothrombin time (in the time range of minutes to hours), the anticoagulant action of coumarin and some <e22> coumarin derivatives </e22> may be prolonged.
mechanism	Repeated doses of <e11> HUMORSOL </e11> ( # mg once a day for # days) decreased the serum levels of <e20> diazepam </e20> by approximately 37%.
mechanism	Repeated doses of <e10> erythromycin </e10> # days apart, or <e20> clarithromycin </e20> # days apart, decreased serum levels of clarithromycin.
mechanism	Repeated doses of <e10> alosetron </e10> (approximately # mg) resulted in approximately a 15% increase in mean alosetron Cmax (14%) and a 38% increase in mean AUC (14%) following coadministration of <e20> lovastatin </e20> # mg (corresponding to approximately # mg of lovastatin/day) with oral # mg alosetron /day for # days.
mechanism	Studies in humans have shown that <e10> clofibrate </e10> may decrease the clearance of <e20> warfarin </e20>.
mechanism	Studies in humans have shown that <e10> phenytoin </e10> blocks the metabolism of <e20> diflunisal </e20>, resulting in the synthesis of a large amount of high-molecular-weight (HMW) diflunisal (5% by weight) in the blood.
mechanism	Studies in humans suggest a possible drug interaction for the following: N-methyltransferase inhibitors ( <e10> clarithromycin </e10>, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir ) and <e20> troleandomycin </e20>.
mechanism	The absorption of <e11> PROLEUKIN </e11> may be reduced by coadministration of digoxin, cisapride, <e20> warfarin </e20>, carbamazepine, and other anticoagulants, calcium supplements, and by concomitant administration of digoxin and digoxin-containing preparations.
mechanism	The absorption of <e10> cyclosporine </e10> was decreased by #% when it was given with <e20> furosemide </e20>.
mechanism	The absorption of <e10> cisapride </e10> from <e20> sucralfate </e20> tablets is enhanced by the concomitant administration of drugs that interfere with the hepatic metabolism of sucralfate (e,g,, phenytoin, carbamazepine, alfentanil, cisapride, diazepam, and phenobarbital ) and is not enhanced by the concomitant administration of drugs that do not interfere with the metabolism of sucralfate (e,g,, methotrexate, clarithromycin, alfentanil, astemizole, and carbamazepine ).
mechanism	The absorption of <e10> ketoconazole </e10> by healthy volunteers was about 5% higher with <e20> cefazolin </e20> than with an equal amount of either of the two sulfonamides (Ketoconazole C, C-K, or Conazole ).
mechanism	The absorption of <e10> cholestyramine </e10> from cholestyramine capsules is enhanced by <e20> digoxin </e20>.
mechanism	The absorption of <e10> cisplatin </e10> by <e20> chloroquine </e20> was significantly decreased by 50% at the dose of # mg/day.
mechanism	The absorption of <e10> ketoconazole </e10> is increased by approximately 20% when <e20> aripiprazole </e20> is used concurrently with these drugs.
mechanism	The absorption of <e10> ketoconazole </e10> is increased by the concomitant administration of <e20> diltiazem </e20>.
mechanism	The absorption of <e10> gentamicin </e10> is significantly decreased when coadministered with <e20> cefazolin </e20>.
mechanism	The absorption of <e10> cyclosporine </e10> is enhanced by <e20> phenytoin </e20>.
mechanism	The absorption of <e10> cefepime </e10> was reduced by approximately 38% and 37% in healthy volunteers treated with <e20> cholestyramine </e20> and coadministered with oral cefepime, respectively.
mechanism	The absorption of <e11> ENABLEX </e11> is depressed by absorption of <e20> chlorothiazide </e20> and magnesium.
mechanism	The absorption of <e10> isoniazid </e10> and <e20> fluconazole </e20> was decreased significantly in the presence of increasing concentrations of 10(-8) M isoniazid and fluconazole, while the absorption of isoniazid and fluconazole was unaffected by increasing concentrations of these drugs.
mechanism	The absorption of <e10> digoxin </e10> may be decreased by <e20> cisapride </e20>.
mechanism	Particular caution should be observed when <e10> alprazolam </e10> is coadministered with <e20> isoniazid </e20>, phenytoin, warfarin, or other agents with major side effects on the blood level of alprazolam.
mechanism	Particular caution should be observed when administering <e11> BREVIBLOC </e11> with agents that are reported to inhibit CYP3A4 (e,g,, ketoconazole, itraconazole, erythromycin, clarithromycin, <e20> nelfinavir </e20>, ritonavir, saquinavir, telithromycin ) because these agents may increase the metabolism of BREVIBLOC and may therefore result in an increase in the plasma concentration of BREVIBLOC.
mechanism	Particular caution should be exercised when administering ketoconazole and <e10> diltiazem </e10> simultaneously because concurrent administration may decrease the plasma levels of <e20> diltiazem </e20>.
mechanism	Particular caution should be observed in the coadministration of <e10> ketoconazole </e10> with agents known to decrease metabolism of <e20> cisplatin </e20>, including certain rifampin_antibiotics, quinine, fluconazole, phenytoin, carbamazepine, astemizole, indinavir, ritonavir, saquinavir, telithromycin, and troleandomycin.
mechanism	Particular caution should be exercised when administering <e10> terfenadine </e10> with <e20> carbamazepine </e20> since concurrent use with carbamazepine results in increased carbamazepine levels and, therefore, increased carbamazepine plasma levels.
mechanism	Particular caution should be observed with <e11> INDOCIN </e11> as <e20> sildenafil </e20> increases plasma levels and indinavir reduces the rate of urinary excretion of sildenafil.
mechanism	Digoxin : Coadministration of <e10> digoxin </e10> at # mg/day and <e20> dasatinib </e20> at # mg/day increased plasma digoxin levels in two of nine subjects with high plasma digoxin levels.
mechanism	Digoxin : Coadministration of <e10> digoxin </e10> and <e20> carbamazepine </e20> decreased digoxin concentrations and decreased digoxin AUC by 23% and 15%, respectively.
mechanism	Digoxin : Coadministration of <e10> erythromycin </e10> and <e20> digoxin </e20> increases digoxin plasma concentrations.
mechanism	Therefore, if <e10> ibuprofen </e10> is administered concomitantly with <e20> warfarin </e20>, a reduction in the binding of warfarin to its target, cAMP, has been observed.
mechanism	Therefore, if <e10> ciprofloxacin </e10> is administered with any other nonsteroidal_anti-inflammatory_drug ( <e22> NSAIDs </e22> ), the risk of gastrointestinal ulceration is increased by a factor of approximately 3.
mechanism	Therefore, if <e10> estradiol </e10> is administered concomitantly with <e20> ketoconazole </e20>, the estradiol concentrations should be determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
mechanism	Drugs that induce CYP3A4 activity (eg, <e10> phenytoin </e10>, carbamazepine, diltiazem, felbamate, felbamate_sodium, phenobarbital, tamoxifen, <e20> cisapride </e20>, disopyramide, astemizole, alfentanil ) may decrease the clearance of corticosteroids or decrease the clearance of coumarin derivatives (eg, cisapride ).
mechanism	Drugs that induce cytochrome P-450 isozymes such as <e10> fluconazole </e10>, itraconazole, phenytoin, clofibrate, <e20> fluvoxamine </e20>, phenobarbital, risperidone, triazolam, theophylline, and valproate have been reported to increase the clearance of cisapride by approximately 5-fold or more.
mechanism	Drugs that induce CYP3A4 activity, such as theophylline, corticosteroids, and <e10> carbamazepine </e10>, may increase plasma concentrations of <e20> lomustine </e20>.
mechanism	Drugs that induce hepatic enzymes such as phenytoin, <e10> carbamazepine </e10>, alfentanil, bromocriptine, disopyramide, etodolac, furosemide, fluoxetine, phenytoin, rifampin, tricyclic_antidepressants, and tricyclic_antihistamines may decrease plasma <e20> leucovorin </e20> levels.
mechanism	Drugs that induce hepatic enzymes such as <e10> phenobarbital </e10>, phenytoin, and carbamazepine may increase the clearance of <e20> zalcitabine </e20>.
mechanism	Drugs that induce CYP3A4 activity (eg, alfentanil, <e10> terfenadine </e10>, cisapride, disopyramide, phenytoin, bromocriptine, valproate, theophylline, tolbutamide, phenobarbital, alfentanil, diltiazem, zalcitabine, ketoconazole, itraconazole, rifampin, nefazodone, nelfinavir, clarithromycin, cimetidine, cimetidine -related drugs) may reduce or reverse the <e20> cisapride </e20> AUC.
mechanism	Drugs that induce hepatic enzymes such as <e10> phenobarbital </e10>, phenytoin, carbamazepine, or rifampin may decrease the clearance of <e20> doxorubicin </e20>.
mechanism	Drugs that induce hepatic enzymes such as phenytoin, <e10> phenobarbital </e10>, phenytoin and carbamazepine may decrease the clearance of <e20> ketoconazole </e20>, resulting in increased plasma concentrations of this recommended dose of ketoconazole.
mechanism	Drugs that induce hepatic enzymes such as acetaminophen, phenobarbital, <e10> phenytoin </e10>, phenytoin_sulfate, valproic_acid, phenytoin_sulfate, phenytoin, and valproate may decrease the clearance of <e20> nevirapine </e20>.
mechanism	Drugs such as carbamazepine, phenytoin, and <e10> rifampin </e10> can interfere with <e20> rifabutin </e20> metabolism and cause increased rifabutin levels.
mechanism	Drugs such as thiazide_diuretics, <e10> lithium </e10>, and valproate that interfere with <e20> cyclosporine </e20> metabolism may increase the plasma concentrations of theophylline.
mechanism	Drugs such as phenytoin, carbamazepine, <e10> rifampin </e10>, and itraconazole may enhance <e20> miconazole </e20> metabolism.
mechanism	Drugs such as cyclosporine, amiodarone, terfenadine, <e10> ketoconazole </e10>, cisapride, diazepam, felbamate, fluconazole, halothane, morphine, phenytoin, phenobarbital, triazolam, theophylline, and warfarin have been reported to interfere with the metabolism of <e20> probenecid </e20>.
mechanism	Drugs such as <e10> carbamazepine </e10> and phenytoin may increase plasma levels of <e20> diclofenac </e20>, thus decreasing absorption of the active ingredient.
mechanism	<e10> Colchicine </e10> may also interact with <e20> digoxin </e20>.
mechanism	<e10> Colchicine </e10> at a dose of # mg/kg/day was found to inhibit <e20> furosemide </e20> clearance (by about 75%), and thus increased blood furosemide levels.
mechanism	<e10> Colchicine </e10>, in comparison with <e20> acetaminophen </e20>, increases the renal clearance of both diclofenac and its metabolite diclofenac sulfate and the renal clearance of colchicine.
mechanism	Colchicine para-aminosalicylic_acid and colchicine have been reported to increase the absorption of <e10> niacin </e10> and <e20> folic_acid </e20>.
mechanism	Colchicine para-aminosalicylic_acid and <e10> acitretin </e10> also inhibit the metabolism of <e20> cetirizine </e20>.
mechanism	Colchicine para-aminosalicylic_acid and <e10> salicylate </e10> may decrease the clearance of <e20> amphotericin_B </e20>.
mechanism	The rate of adverse events in patients taking <e10> clindamycin </e10> was lower in the presence of <e20> methotrexate </e20> than with or without methotrexate.
mechanism	The rate of decrease in the plasma concentrations of <e10> fluvoxamine </e10> and <e20> fluvoxamine </e20> was approximately two times greater with concomitant use of zidovudine and/or ritonavir than with concomitant use of fluvoxamine and zidovudine.
mechanism	The rate of intravenous <e10> rifampin </e10> and <e20> cyclosporine </e20> absorption in a single patient is approximately one-third that of oral dosing, a result that is likely to result in increased toxicity.
mechanism	Concomitant use of <e10> erythromycin </e10> and <e20> fluvoxamine </e20> may be associated with increased fluvoxamine concentrations and therefore greater possible efficacy for fluvoxamine.
mechanism	Concomitant use of <e10> almotriptan </e10> with other medications that cause CYP3A4 activity, such as certain antidepressants (e,g,, nortriptyline, imipramine, desipramine ), phenothiazines (e,g,, haloperidol, <e20> phenobarbital </e20>, halothane ), and some antidepressants (e,g,, nortriptyline, fluoxetine, sertraline, paroxetine, venlafaxine ), may decrease the clearance of almotriptan and increase the half-life of almotriptan.
mechanism	Concomitant use of <e10> diltiazem </e10> with oral <e22> anticoagulants </e22> ( warfarin, heparin, corticosteroids, coumarin, corticotropin, or warfarin_sodium ) may result in increased exposure to prothrombin time, and therefore may increase the risk of developing major bleeding events.
mechanism	Concomitant use of <e10> astemizole </e10> with <e20> ketoconazole </e20> may increase the clearance of ketoconazole.
mechanism	Concomitant use of <e10> quinidine </e10> with other <e22> drugs </e22> may increase the risk of nephrotoxicity or toxicity in the peritoneal dialysis route.
mechanism	Concomitant use of <e10> azithromycin </e10> ( tenofovir ) and <e20> doxorubicin </e20>, which are extensively metabolized by CYP2D6, may result in a decrease in plasma doxorubicin concentrations and increased toxicity to normal tissues.
mechanism	Concomitant use of <e10> neomycin </e10>, diflunisal, and oral <e20> atorvastatin </e20> resulted in an increase in the plasma concentrations of neomycin and its active metabolite, atorvastatin.
mechanism	Concomitant use of <e10> carbamazepine </e10> may increase the pharmacologic effect of <e20> probenecid </e20>.
mechanism	Concomitant use of <e10> cyclosporine </e10> (e,g,, tacrolimus ) and <e20> carbamazepine </e20> can lead to increased levels of cyclosporine.
mechanism	Concomitant use of <e10> diltiazem </e10> with <e20> diltiazem </e20> in a # mg/day dose increased the AUC of diltiazem by 27% and decreased the Cmax by 41%.
mechanism	Concomitant use of <e10> phenytoin </e10> and <e20> phenobarbital </e20> may reduce the plasma concentrations of phenobarbital.
mechanism	Concomitant use of <e10> colestipol </e10> and <e20> enoxacin </e20> increases enoxacin exposure and may lead to decreased enoxacin pharmacokinetics.
mechanism	Concomitant use of <e11> HUMORSOL </e11> with other medications that have CYP3A4 inducers (eg, cyclosporine, <e20> tacrolimus </e20>, digoxin, phenytoin, phenobarbital, primidone, felbamate, felbatol ) may increase plasma concentrations of these drugs.
mechanism	Concomitant use of <e10> piperazine </e10> with <e20> ketoconazole </e20> resulted in a 23% increase in the rate of reduction of piperazine in the presence of ketoconazole.
mechanism	Concomitant use of <e10> ketoconazole </e10> with <e20> phenytoin </e20> decreased the AUC of phenytoin by 53%.
mechanism	Concomitant use of <e10> clofibrate </e10> may result in increases in serum levels of <e20> atorvastatin </e20>.
mechanism	Concomitant use of <e10> astemizole </e10> and <e20> tamoxifen </e20> has been associated with a small increase in the mean concentrations of both astemizole and tamoxifen.
mechanism	Concomitant use of <e10> erythromycin </e10> with <e20> bromocriptine_mesylate </e20> resulted in a 3-fold increase in bromocriptine_mesylate dose.
mechanism	Concomitant use of <e10> ketoconazole </e10> and <e20> cisapride </e20> in patients who are using chronic, high-dose cisapride has been reported to result in a reduced plasma level of cisapride and a higher rate of ED due to the inhibition of metabolism of cisapride by ketoconazole.
mechanism	Concomitant use of <e10> ketoconazole </e10> tablets with <e20> cisapride </e20> tablets significantly increased the plasma concentrations of cisapride.
mechanism	Concomitant use of <e10> ketoconazole </e10> and <e20> ketoconazole_b-complex </e20> may cause severe hypoglycemia.
mechanism	Concomitant use of <e10> phenytoin </e10> may increase <e20> fluconazole </e20> clearance by about 25%.
mechanism	Concomitant use of <e10> doxycycline </e10> and <e20> digoxin </e20> resulted in a reduction in digoxin clearance by 25% compared to doxycycline alone.
mechanism	Concomitant use of <e10> cefazolin </e10> and <e20> ketoconazole </e20> can significantly reduce the exposure of ketoconazole.
mechanism	Concomitant use of <e10> cimetidine </e10> with either <e20> nelfinavir </e20> or ritonavir resulted in a significant increase in ritonavir plasma concentrations.
mechanism	Concomitant use of <e10> flurbiprofen </e10> and <e20> ketoprofen </e20> has been reported to cause an increased plasma concentration of ketoprofen.
mechanism	Concomitant use of <e10> phenytoin </e10> with <e20> alprazolam </e20> (alprazolam_salicylate) may decrease alprazolam plasma concentrations and increase alprazolam toxicity.
mechanism	Concomitant use of <e10> cyclosporine </e10> with other <e22> aminoglycosides </e22>, including tacrolimus, hexobarbital, carbamazepine, phenytoin, alfentanil, cisapride, disopyramide, disulfiram, disulfiram_HCl, phenobarbital, phenytoin, rifampin, phenytoin_HCl, valproate, phenytoin_HCl, valproate_HCl, triazolam, and astemizole has resulted in a reduction in the AUC of disopyramide by 50%.
mechanism	Concomitant use of <e10> dapsone </e10> with <e20> carbamazepine </e20> may lead to elevated carbamazepine plasma levels.
mechanism	Concurrent administration of <e11> PRECEDEX </e11> and <e20> terfenadine </e20> increased plasma concentrations of terfenadine by #% and caused a reduction in AUC of terfenadine by 15%.
mechanism	Concurrent administration of <e10> ketoconazole </e10> with <e20> amiodarone </e20> or cisapride decreased amiodarone plasma concentrations.
mechanism	Concurrent administration of <e10> almotriptan </e10> and other <e22> SSRI </e22> (e,g,, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine ) may result in significant increases in SSRI plasma concentrations.
mechanism	Conversely, decreases in <e10> digoxin </e10> and <e20> digoxin_acetate </e20> have been reported with concomitant administration of digoxin and warfarin.
mechanism	Conversely, decreases in the levels of endogenous TCA may be observed when <e10> cypermethrin </e10> is administered with <e20> warfarin </e20>, and these decreases may result in increased exposure of warfarin to patients taking these agents concurrently.
mechanism	Conversely, decreases in blood flow in the kidneys and/or the hepatic and adrenal glands may occur when <e10> ibuprofen </e10> is coadministered with <e20> cisapride </e20>.
mechanism	There have been reports of interactions of <e10> phenytoin </e10> with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, disulfiram, itraconazole, phenytoin, rifampin, triazolam, ziconazole, <e20> valproate </e20>.
mechanism	There have been reports of decreased plasma levels of theophylline when <e10> cisapride </e10> was co-administered with <e20> carbamazepine </e20>.
mechanism	There have been reports of concomitant administration of <e10> ketoconazole </e10> and <e20> amphotericin_B </e20>.
mechanism	Antibiotics : <e12> Antibiotics </e12> ( ampicillin, tetracycline, <e20> bacitracin </e20>, clindamycin, dapsone, doriconazole, furosemide, gentamicin, griseofulvin, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, troleandomycin_sulfa ) may decrease the clearance of cimetidine by as much as 50%.
mechanism	Antibiotics : <e12> Aminoglycosides </e12>, ampicillin and ampicillin_sulfate, cephalosporins, <e20> carbamazepine </e20>, chloramphenicol, gentamicin, erythromycin, hydroxychloroquine, itraconazole, itraconazole_hydrochloride, itraconazole_methyl, itraconazole_propyl, itraconazole_sulfate, itraconazole, phenytoin, rifampin, theophylline, verapamil, zidovudine,
mechanism	Antibiotics : <e12> Amphetamines </e12> may decrease the bioavailability of <e22> antibiotics </e22>.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> decreased the clearance of <e20> enoxacin </e20>.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> blocks hepatic metabolism of <e20> cimetidine </e20>, resulting in increased plasma levels of cimetidine.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> was found to have a potentiating effect on <e20> disulfiram </e20>.
mechanism	Ephedrine : <e10> Ephedrine </e10> may interact with <e20> phenytoin </e20>.
mechanism	Ephedrine : <e10> Ephedrine </e10> and its metabolite <e20> methyphenbutazone </e20> inhibit the metabolism of catecholamines (including dopamine ) to their phenolic metabolite and thereby increase the blood levels of these compounds.
mechanism	Ephedrine : <e10> Ephedrine </e10> may inhibit metabolism of <e20> amphetamines </e20>.
mechanism	Estrogens, including estrogen <e12> progestins </e12>, may also increase the clearance of <e22> sympathomimetics </e22>.
mechanism	Estrogens, including <e10> estradiol </e10>, are known to increase <e20> furosemide </e20> renal clearance by decreasing its metabolism.
mechanism	Estrogens, including <e10> estradiol </e10>, increase the metabolism of <e20> phenytoin </e20>.
mechanism	Hepatic Enzyme Inducers, Inducers, or Cyclosporine : These agents increase hepatic enzymes (e,g,, aminoglycosides, tetracyclines, rifampin, <e10> bacitracin </e10>, bromocriptine ) and may therefore increase the clearance of <e20> ketoconazole </e20>.
mechanism	Hepatic Enzyme Inducers, Phenytoin : Concomitant administration of <e11> INDOCIN </e11> with <e20> phenytoin </e20> may result in increased hepatic enzyme activity, and increased plasma concentrations of phenytoin.
mechanism	Hepatic Enzyme Inducers, Enzyme Inhibitors and Anticonvulsants : Anticonvulsants ( phenytoin, carbamazepine, <e10> felbamate </e10>, phenobarbital, felbamate ) and <e20> warfarin </e20> may interfere with metabolism of diclofenac, resulting in higher plasma concentrations and resulting in higher exposures of the active metabolite.
mechanism	Hepatic Enzyme Inducers, including the <e12> quinolones </e12>, have been shown to decrease plasma levels of <e20> nicotinamide_acetate </e20>.
mechanism	Hepatic Enzyme Inducers, <e10> Isoniazid </e10>, Phenobarbital, Bortezomib, and <e20> phenytoin </e20> reduce the clearance of norethindrone, thereby lowering its systemic exposure.
mechanism	Hepatic Enzyme Inducers, Enzyme Inhibitors and Hepatic Stabilizers Coadministration of <e10> Aprepitant </e10> with <e20> atorvastatin </e20> # mg for # days significantly decreased Aprepitant plasma concentrations by 19%.
mechanism	Hepatic Enzyme Inducers, Amphetamines and Furosemide : <e12> Amphetamines </e12> and <e20> furosemide </e20> may increase the metabolism of corticosteroids, sulfinpyrazone, digoxin, methotrexate, indinavir, itraconazole, and cetirizine, and therefore decrease their serum concentrations.
mechanism	Hepatic Enzyme Inducers, Cholestyramine, <e10> Cholestyramine </e10> may increase the concentration of drugs that induce hepatic enzyme responses, such as <e20> heparin_sodium </e20>.
mechanism	Hepatic Enzyme Inducers, the co-administration of <e10> nevirapine </e10> with <e20> methotrexate </e20>, an enzyme inducer of hepatitis, was associated with an increase in methotrexate concentrations.
mechanism	Drugs which inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, ritonavir, nelfinavir, <e10> clarithromycin </e10>, nefazodone, ritonavir, saquinavir, telithromycin ) may increase the clearance of <e20> warfarin </e20>.
mechanism	Drugs which inhibit CYP3A4 (eg, ketoconazole, <e10> itraconazole </e10>, erythromycin, clarithromycin, troleandomycin, indinavir, ritonavir, saquinavir, telithromycin, troleandomycin, <e20> troleandomycin </e20>, ritonavir, saquinavir, troleandomycin ) may decrease plasma levels of CMIKI (eg, erythromycin ).
mechanism	Drugs which inhibit cytochrome P450 3A4 (CYP3A4) (eg, ketoconazole, <e10> itraconazole </e10>, clarithromycin, nefazodone, nelfinavir, ritonavir, saquinavir, saquinavir_preparation, telithromycin, troleandomycin, indinavir, indinavir_acid_reflux_preparation, ketoconazole, nefazodone, troleandomycin, nelfinavir, ritonavir, saquinavir, ritonavir_preparation, troleandomycin ) increase the clearance of <e20> nelfinavir </e20>.
mechanism	Drugs which inhibit CYP3A4 activity (such as ketoconazole, itraconazole, ritonavir, clarithromycin, <e10> nefazodone </e10>, nelfinavir, ritonavir, saquinavir, telithromycin ) may result in a decrease in <e20> diltiazem </e20> plasma levels.
mechanism	Drugs which inhibit CYP3A4 (eg, ketoconazole, itraconazole, ritonavir, clarithromycin, indinavir, nelfinavir, <e10> nefazodone </e10>, nefazodone_sulfate, nefazodone_citrate, ritonavir, saquinavir, telithromycin ) may reduce the absorption of <e20> lovastatin </e20> and result in elevated serum levels of lovastatin.
mechanism	Drugs which inhibit CYP3A4 (eg, ketoconazole, itraconazole, ritonavir, clarithromycin, indinavir, saquinavir, <e10> indinavir </e10>, saquinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, terfenadine ) may increase plasma concentrations of <e20> tamoxifen </e20>.
mechanism	Drugs which inhibit CYP3A4 (eg, ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin, <e10> nefazodone </e10>, nelfinavir, saquinavir, saquinavir / nefazodone, telithromycin, troleandomycin, terfenadine, indinavir, indinavir / saquinavir, itraconazole ) may increase plasma concentrations of <e20> doxorubicin </e20>.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> may increase the clearance of <e20> digoxin </e20>.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> may inhibit the metabolism of <e20> warfarin </e20> or other anticoagulants by decreasing the hepatic enzyme activity of these medications.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> decreased the bioavailability of <e20> rifabutin </e20>, which is an oral anticoagulant, by about 10%.
mechanism	The clearance of <e10> cimetidine </e10> decreased approximately 40% with <e20> zalcitabine </e20> administered concurrently, with a maximum Cmax of # mg/liter.
mechanism	The clearance of <e10> rifampin </e10> was reduced by about #% when it was administered concurrently with <e20> cyclosporine </e20>, a known renal toxicity inducer.
mechanism	The clearance of <e10> flupenthixol </e10> has been reported to be decreased by the concurrent administration of a high dose of <e20> methotrexate </e20>, suggesting that concurrent administration may increase the toxicity of the high dose of methotrexate.
mechanism	Phenytoin : In a single case of a patient with elevated <e10> phenytoin </e10> plasma levels due to a pharmacokinetic interaction with <e20> gentamicin </e20>, a decrease in gentamicin plasma levels and an increase in tetracycline plasma levels were observed.
mechanism	Phenytoin : In vitro and in vivo studies have shown that <e10> phenytoin </e10> can decrease the clearance of <e20> dexamethasone </e20> by about 50%.
mechanism	Phenytoin : In vitro studies of phenytoin, <e10> ketoconazole </e10>, and other <e22> corticosteroids </e22> suggest that they may interfere with the absorption of some cations including cimetidine, calcium, and magnesium.
mechanism	Acidifying_agents : <e12> Antacids </e12>, such as <e20> lactulose </e20>, have been reported to inhibit the rate of inorganic acidification, which is the primary mechanism of enzyme activity.
mechanism	Acidifying_agents : <e12> Antacids </e12>, such as <e20> salicylates </e20>, cloracil, and sodium_triflate may potentiate the absorption of some medications such as nonsteroidal_anti-inflammatory_drugs, certain intravenous anesthetics, and certain antipsychotics.
mechanism	Acidifying_agents : Gastrointestinal_acidifying_agents (e,g,, cholestyramine, <e10> erythromycin </e10>, aminosalicylic_acid, and bismuth_subsalicylate ) may reduce the absorption of <e20> cimetidine </e20>.
mechanism	Acidifying_agents : Gastrointestinal_acidifying_agents ( cephalosporins, <e10> ampicillin </e10>, tetracycline, bacitracin, sulfonamides ) may decrease the clearance of <e20> cisapride </e20> and increase the serum levels of cisapride.
mechanism	Acidifying_agents : Gastrointestinal_acidifying_agents (i,e,, enoxacin, <e10> dacarbazine </e10>, sulfasalazine ) may potentiate the effect of <e20> ketoconazole </e20>.
mechanism	Acidifying_agents : Gastrointestinal_acidifying_agents ( tricine, sucralfate, ampicillin, bacitracin, <e10> ciprofloxacin </e10>, and gentamicin ) may reduce <e20> cefuroxime </e20> absorption by approximately one-third.
mechanism	Acidifying_agents : Gastrointestinal_acidifying_agents ( <e12> H2-antagonists </e12>, gastric antacid, certain nonsteroidal_anti-inflammatory_drugs, etc,) inhibit the metabolism of <e22> vitamin_K </e22>.
mechanism	Acidifying_agents : Gastrointestinal_acidifying_agents ( asparaginase, <e10> chloramphenicol </e10>, l-glutamine ) may decrease the absorption of <e20> amphetamine </e20>.
mechanism	Acidifying_agents : Gastrointestinal_acidifying_agents such as pancreatic enzymes or glutamine_sulfate or <e10> phenylbutazone </e10> may decrease the clearance of <e20> ketoconazole </e20> by interfering with its hydroxylation.
mechanism	Urinary_acidifying_agents ( <e10> piperazine </e10>, phenytoin ) and <e20> sodium_thiosulfate </e20> may decrease the elimination of rifampin and may increase the renal excretion of rifampin.
mechanism	Urinary_acidifying_agents ( <e10> bacitracin </e10>, <e20> magnesium_acetate </e20> ) may enhance the clearance of furosemide by inhibiting the renal excretion of its active metabolite, resulting in a reduction of renal blood flow.
mechanism	Urinary_acidifying_agents ( ammonium_chloride, sucralfate, enoxacin ) and <e10> probenecid </e10> may increase the clearance of <e20> nifedipine </e20>.
mechanism	Alkalinizing agents: Gastrointestinal transit time (GTT) is decreased by the concomitant administration of <e10> erythromycin </e10> and <e20> astemizole </e20>.
mechanism	Urinary alkalinizing agents such as <e10> indomethacin </e10>, amiodarone, and <e20> calcium_acetate </e20>, when administered concomitantly with oral antacids containing sucralfate, may cause increased urine pH and thus increase the risk of adverse effects.
mechanism	Urinary alkalinizing agents ( <e10> colestipol </e10>, tetracycline, sulfadoxine_HCl, etc,) may reduce the bioavailability of <e20> digoxin </e20> by a mechanism involving acidification of urinary digoxin and reduced urinary excretion of the metabolite.
mechanism	Urinary alkalinizing agents : A study was conducted in a well-controlled enflurane anesthesia technique to determine the effect of <e10> ketamine </e10> on the renal tubular excretion of <e20> levothyroxine </e20> in rats.
mechanism	Urinary alkalinizing agents ( <e12> diuretics </e12>, thiazide_diuretics, sulfasalazine, glyburide ) may cause a reduction in the renal clearance of <e20> cisapride </e20>.
mechanism	<e10> d-amphetamine </e10> increased <e20> phenytoin </e20> serum concentrations and metabolism;
mechanism	<e10> d-amphetamine </e10> increased plasma levels of <e20> fluvoxamine </e20>.
mechanism	<e10> d-amphetamine </e10> in a rat model resulted in a decrease in <e20> valdecoxib </e20> absorption and increased serum concentrations.
mechanism	<e10> d-amphetamine </e10> increased plasma levels of <e20> hydrocodone </e20>.
mechanism	<e10> d-amphetamine </e10> has been reported to inhibit the metabolism of theophylline and <e20> theophylline </e20> in vitro and in vivo.
mechanism	<e10> d-amphetamine </e10> is converted to amphetamine and <e20> N,N-dimethylamphetamine </e20>.
mechanism	<e10> d-amphetamine </e10> is a potent inhibitor of CYP3A4, and the extent to which <e20> amphetamine </e20> will interfere with a patient's ability to take a prescribed dose of oral contraceptives is unknown.
mechanism	<e10> d-amphetamine </e10> may decrease plasma concentrations of other <e22> psychotropic_agents </e22> and agents with hepatic metabolism.
mechanism	<e10> d-amphetamine </e10> may inhibit the metabolism of <e20> lithium </e20>.
mechanism	MAO_inhibitors : <e12> Amphetamines </e12> may inhibit <e20> methylphenidate </e20> metabolism and hence the metabolism of amphetamines.
mechanism	MAO_inhibitors : <e12> MAOI </e12> may potentiate the effects of <e22> catecholamine-depleting_drugs </e22>.
mechanism	MAO_inhibitors : MAOI_antidepressants such as <e10> ketoconazole </e10> may decrease the clearance of <e20> fluoxetine </e20>.
mechanism	MAO_inhibitors : MAOI_antidepressants, including <e10> sertraline </e10>, have been reported to decrease <e20> phenelzine </e20> clearance.
mechanism	Ethosuximide : <e12> Tetracyclines </e12> have been shown to decrease the metabolism of <e20> ethosuximide </e20>.
mechanism	Methenamine therapy: Urinary levels of <e10> methenamine </e10> may be increased by <e20> phenytoin </e20>.
mechanism	Methenamine therapy: Urinary levels of <e10> methenamine </e10> decreased to 2- to 3-fold above control levels following administration of # mg of <e20> astemizole </e20> to patients taking either placebo or methenamine.
mechanism	Phenobarbital : <e12> Quinolones </e12>, such as phenobarbital, have been reported to inhibit the metabolism of <e20> carbamazepine </e20> and the primary aminoglycoside, sulfadoxine, and to increase the levels of ampicillin and tobramycin.
mechanism	Phenobarbital : <e12> Amphetamines </e12> inhibit the metabolism of <e20> phenobarbital </e20>, resulting in a lower plasma level of phenobarbital.
mechanism	Phenytoin : <e12> Amphetamines </e12> inhibit the metabolism of <e20> phenytoin </e20>, which may result in increased blood levels of phenytoin.
mechanism	Phenytoin : <e12> Antacids </e12> containing iron and zinc may interfere with the absorption of <e20> phenytoin </e20>.
mechanism	Aspirin : Concomitant administration of <e10> gentamicin </e10> with <e20> aspirin </e20> has been shown to increase the half-life of gentamicin by about 5%.
mechanism	Ingestion of <e10> probenecid </e10> may result in an increase in <e20> furosemide </e20> absorption.
mechanism	Ingestion of <e10> ketoconazole </e10> increases the exposure of <e20> valdecoxib </e20>.
mechanism	Ingestion of <e10> ketoconazole </e10> at doses of # mg/kg of a single oral dose with a single # mg/kg dose of <e20> nelfinavir </e20> results in an increase in the tetracycline concentration.
mechanism	Ingestion of <e10> fluvoxamine </e10> at # mg/kg significantly decreased the plasma concentration of <e20> lorazepam </e20> by approximately 50%.
mechanism	Ingestion of <e10> gentamicin </e10> (2 mg/kg) for # hours prior to dosing with <e20> cimetidine </e20> (10 mg/kg) resulted in an increase in cimetidine plasma concentrations by 40%.
mechanism	Ingestion of <e10> ketoconazole </e10> significantly increased <e20> aripiprazole </e20> concentrations and metabolism by interfering with CYP2C9 activity.
mechanism	Lithium : <e10> Zidovudine </e10> and <e20> lithium </e20> enhance the absorption of lithium, which increases its concentration in the blood and may increase its toxicity.
mechanism	Lithium : <e10> Dexbrompheniramine </e10> significantly increased lithium clearance by approximately 20% and added lithium did not affect the pharmacokinetics of <e20> lithium </e20>.
mechanism	Lithium : <e10> Lithium </e10> has been reported to decrease plasma concentrations of <e20> clofibrate </e20> and increase plasma concentrations of fibrate.
mechanism	Lithium : <e10> Lithium </e10> may reduce the effectiveness of <e22> ACE_inhibitors </e22>.
mechanism	Lithium : <e10> L-glutamine </e10> administered at a dose of # mg in a single oral dose resulted in a 24% decrease in the serum lithium concentration of subjects on <e20> lithium </e20> therapy.
mechanism	Protein Binding In vitro studies have shown that <e10> diazoxide </e10> reduces the plasma concentrations of <e20> simvastatin </e20> by approximately 38%.
mechanism	Protein Binding In order to increase the pharmacologic effect of <e11> INDOCIN </e11>, subjects were administered single doses of indocin, valproic_acid, or <e20> aripiprazole </e20>.
mechanism	Protein Binding In vitro studies of the SELACROLEXIN_L_glucose_binding_components ( <e10> erythromycin </e10>, clarithromycin, protease_inhibitors, corticosteroids, etc,) suggest that SELACROLEXIN_L_glucose_binding_components may enhance the metabolism of <e20> levothyroxine </e20> and thyroid-stimulating_agents.
mechanism	Protein Binding Injection (PBI) <e10> Sucralfate </e10> increased <e20> fluvastatin </e20> clearance and decreased its plasma concentration.
mechanism	Protein Binding In a subset of patients, the presence of <e11> SPRYCEL </e11> has been associated with an increase in plasma concentrations of the antithrombotic_agent <e20> warfarin </e20>.
mechanism	Protein Binding In addition to binding of <e11> ENABLEX </e11> to <e20> lithium </e20>, there was a significant increase in the plasma concentrations of lithium and theophylline, and a significant decrease in the metabolism of lithium by CYP2D6 (e,g,, theophylline, lithium ).
mechanism	Protein Binding In vivo data indicate that <e10> erythromycin </e10> is bound to <e20> valdecoxib </e20> in vitro but is not bound to valdecoxib in vivo.
mechanism	Because <e12> antacids </e12> can reduce the absorption of <e22> vitamin_D </e22>, co-administration of a high-fat diet with vitamin_D supplements containing multivitamins or other supplements containing multivitamins or other supplements containing calcium, iron, or zinc may increase the risk of vitamin_D deficiency.
mechanism	Because <e12> antacids </e12> can interfere with calcium absorption and absorption of <e20> vitamin_D </e20>, vitamin_D therapy should be discontinued.
mechanism	Because <e12> antacids </e12> may interfere with absorption of <e20> rifampin </e20>, the recommended dose of rifampin for the antacid concomitantly is higher.
mechanism	Allopurinol : The plasma levels of <e10> allopurinol </e10> were increased when the doses of <e20> digoxin </e20> and the doses of other digoxin-type_anticoagulants were increased.
mechanism	Allopurinol : The clinical significance of <e10> allopurinol </e10> may be augmented when the patient is also taking <e20> erythromycin </e20>, which blocks the metabolism of allopurinol.
mechanism	Ganciclovir : Administration of <e10> gemifloxacin </e10> decreased plasma concentrations of <e20> ganciclovir </e20> and decreased its pharmacokinetic profile.
mechanism	Ganciclovir : Administration of <e10> ganciclovir </e10> with <e20> atazanavir </e20> may result in elevated plasma concentrations of atazanavir.
mechanism	A # (17)% reduction in the mean AUC of <e10> digoxin </e10> by # weeks was observed in subjects taking <e20> nelfinavir </e20> and an HIV protease inhibitor (a # or a # mg/day dose of nelfinavir for # weeks) concurrently.
mechanism	A # (17)% increase in the clearance of <e10> cisapride </e10> and a # (3.4%) increase in the clearance of norethindrone were observed when <e20> atracurium </e20> was coadministered with itraconazole.
mechanism	Quinolone_Antibiotic s: VIDEX ( <e10> ciprofloxacin </e10> )-Increases MIC of <e20> ciprofloxacin </e20> and increases the rate of elimination.
mechanism	Quinolone_Antibiotic s: VIDEX has been reported to interact with <e10> gentamicin </e10>, <e20> ciprofloxacin </e20>, cefazolin, ciprofloxacin / clindamycin, clarithromycin, doripenem, erythromycin, fluoxetine, fluvoxamine, indomethacin, itraconazole, itraconazole_hydrochloride, itraconazole, itraconazole_sulfate, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, troleandomycin, troleandomycin / clarithromycin, troleandomycin / fluoxetine, troleandomycin_hydrochloride, troleandomycin_sulfate, and clarithromycin.
mechanism	In eight HIV-infected subjects receiving <e10> adenosine </e10> plus <e20> aripiprazole </e20>, the mean AUC of adenosine increased by 50% when taking # mg qday, and the mean Cmax decreased by 23%.
mechanism	In eight HIV-infected patients who were taking two <e10> ritonavir </e10> or <e20> atazanavir </e20> at steady state, the AUC for ritonavir was increased by a mean of 1.3-fold and by a mean of 2.8-fold when these patients were given a single dose of ritonavir (80 mg) and an equivalent dose of atazanavir (0.3 mg), respectively.
mechanism	The AUC of <e11> ENBREL </e11> was increased by approximately # times with coadministration of a single dose of <e20> rifabutin </e20>.
mechanism	The AUC of <e10> warfarin </e10> has been shown to decrease slightly in patients taking <e20> nelfinavir </e20>, the active component of nelfinavir, concomitantly.
mechanism	In a single, two-way crossover study, the hepatic enzyme system was stimulated with <e10> phenytoin </e10> (100 mg orally) and <e20> probenecid </e20> (5 mg orally) for # and # hours, respectively, following administration of a single dose of either a single- or multiple-dose schedule of a dose of # mg of probenecid.
mechanism	In a single study in normal volunteers, <e10> indinavir </e10> significantly decreased the clearance of <e20> clarithromycin </e20> by approximately 50%.
mechanism	Plasma concentrations of <e10> ketoconazole </e10> are increased by <e20> colestipol </e20>, and the amount of colestipol taken as a single drug is about four times higher than with colestipol taken in combination with both of the following: acyclovir or nelfinavir.
mechanism	Plasma concentrations of <e10> indomethacin </e10> are increased by protease_inhibitors and decreased by <e20> clofibrate </e20>.
mechanism	Plasma concentrations of <e10> fluvoxamine </e10> are enhanced by the concomitant administration of <e20> cyclosporine </e20>, thus causing a concurrent increase in renal clearance of fluvoxamine.
mechanism	Plasma concentrations of <e10> diltiazem </e10> were increased by approximately 4-fold when coadministered with <e20> ampicillin </e20> or ciprofloxacin, two common oral antibiotics, but not when coadministered with clarithromycin or minocycline.
mechanism	Plasma concentrations of <e10> furosemide </e10> and <e20> phenytoin </e20> were elevated when administered concomitantly with atorvastatin.
mechanism	Plasma concentrations of <e10> amiodarone </e10> were reduced by approximately 50% when coadministered with <e20> lysine </e20>.
mechanism	Plasma concentrations of <e10> nisoldipine </e10> may be increased by <e20> phenytoin </e20> or other CYP3A4 inhibitors.
mechanism	Interactions with Other CNS Agents: <e10> Rifampin </e10> has been shown to decrease the plasma levels of <e20> valproate </e20>, phenobarbital, phenytoin, phenytoin salts, phenytoin sulfate, and lovastatin.
mechanism	Interactions with Other Antagonism: The following pharmacokinetic interactions have been observed with <e10> cimetidine </e10> and <e20> terfenadine </e20> : Cimetidine significantly increases plasma concentrations of terfenadine and decreases its elimination half-life.
mechanism	Interactions with Other Antidepressants : Although the mechanism of action of <e11> ZYVOX </e11> is not known, the metabolism of <e20> fluoxetine </e20> to produce fluoxetine AUC is increased.
mechanism	Interactions with Other Drugs and Interactions with <e12> Antacids </e12> Antacids inhibit the metabolism of atorvastatin, concomitantly increasing the serum concentrations of <e20> atorvastatin </e20>.
mechanism	This may occur when <e10> digoxin </e10> or <e20> ethionamide </e20> are co-administered with carbamazepine or methotrexate.
mechanism	This may occur if <e11> WELLBUTRIN </e11> is taken prior to, during, or after a <e22> rifampin </e22> -induced depression of hepatic enzyme activity.
mechanism	Hydrochlorothiazide : In vitro data indicate that <e10> hydrochlorothiazide </e10> has the potential to inhibit the metabolism of <e20> fluvastatin </e20>.
mechanism	Hydrochlorothiazide : In vitro study of theophylline containing preparations, (hydrochlorothiazide [ <e10> triamterene </e10> ], cisapride, carbamazepine, <e20> disopyramide </e20>, gabapentin ), have shown that their gastrointestinal absorption is impaired.
mechanism	Hydrochlorothiazide : In rats, oral <e10> lofexidine </e10> (20 mg/kg body weight, q12h) increased the hepatic elimination of <e20> hydrochlorothiazide </e20> by 24% and inhibited the hepatic absorption of lofexidine by 15%.
mechanism	Antacids : Concomitant administration of <e10> digoxin </e10> and <e20> magnesium </e20> may result in decreased serum digoxin levels and may increase the absorption of digoxin.
mechanism	Acetaminophen : In a study of healthy volunteers given <e10> acetaminophen </e10> (100 mg) and <e20> clindamycin </e20> (200 mg) for # hours, oral absorption of acetaminophen was increased by approximately 1/3 and approximately 1/4, respectively, while the inhibitory effect of clindamycin was decreased by approximately 1/3.
mechanism	Cyclosporine : Administration of <e10> cyclosporine </e10> Tablets to patients receiving monoamine_oxidase_inhibitors or <e20> isoniazid </e20> Tablets has resulted in a significant increase in urinary excretion of this metabolite.
mechanism	Cyclosporine : Administration of <e10> cyclosporine </e10> with <e20> CMI </e20> resulted in a significant decrease in renal clearance of the CMI dosage regimen (P = 0.04) and a significant increase in the mean CMI Cmax (P = 0.03).
mechanism	Nonsteroidal_Anti-Inflammatory_Drugs : The concomitant use of <e10> amiodarone </e10> with nonsteroidal_anti-inflammatory_drugs may lead to increased levels of these drugs and increase the risk of gastrointestinal complications and <e20> intestinal parasitic infections </e20>.
mechanism	Aspirin : In a dose-dependent fashion, <e10> carbamazepine </e10> decreased the clearance of <e20> aspirin </e20> from approximately 50% to approximately 25% (p =.05).
mechanism	Sulindac : The <e10> sulindac </e10> # mg tablet significantly decreased the AUC and Cmax of <e20> warfarin </e20> by 44% and 50%, respectively.
mechanism	Sulindac : The <e12> tetracyclines </e12> may decrease the clearance of <e20> sulindac </e20>.
mechanism	Naproxen : The potential for increased serum <e10> naproxen </e10> concentrations may result when the oral absorption of naproxen is inhibited by <e20> methotrexate </e20>.
mechanism	Naproxen : The hepatic clearance of <e11> ZYVOX </e11> may be decreased by <e20> naproxen </e20>.
mechanism	Naproxen : The hepatic metabolism of <e10> naproxen </e10> has been shown to be approximately halved when it is administered concomitantly with <e20> cyclosporine </e20>.
mechanism	<e10> Quinidine </e10> and carbamazepine produce a greater increase in <e20> cyclosporine </e20> clearance when administered with a dosage of # mg cyclosporine per day compared to # mg cyclosporine per day administered alone.
mechanism	<e10> Quinidine </e10> reduced the hepatic metabolite of <e20> ketoconazole </e20> by 62% in the presence of a high dietary concentration of the metabolite.
mechanism	<e10> Quinidine </e10> potentiated <e20> phenytoin </e20> -induced blood levels and slightly increased the clearance of phenytoin in healthy volunteers.
mechanism	Quinidine, <e10> nevirapine </e10>, or any known protease_inhibitor combination increases the clearance of <e20> ketoconazole </e20> and itraconazole by approximately 10%.
mechanism	Quinidine, <e10> rifampin </e10>, warfarin, carbamazepine, and indinavir may reduce the bioavailability of <e20> acitretin </e20>.
mechanism	Quinidine, <e10> reserpine </e10>, and carbamazepine may reduce the clearance of <e20> terfenadine </e20>, causing a substantial increase in systemic exposure.
mechanism	Quinidine, verapamil, and <e10> carbamazepine </e10> all reduce the efficacy of <e20> diazepam </e20>, phenobarbital, and barbiturates.
mechanism	Quinidine, verapamil, amiodarone, <e10> carbamazepine </e10>, fentanyl, phenobarbital, phenytoin, theophylline, and barbiturates may interfere with the metabolism of <e20> carbamazepine </e20>, resulting in lower plasma levels and increased elimination of carbamazepine.
mechanism	Quinidine, verapamil, and <e10> carbamazepine </e10> may increase the plasma levels of <e20> aripiprazole </e20>.
mechanism	Quinidine, verapamil, and <e10> amiodarone </e10> reduce hepatic metabolism of <e20> atorvastatin </e20> and reduce its bioavailability.
mechanism	Quinidine, verapamil, and <e10> quinidine </e10> may reduce the clearance of <e20> cisapride </e20> and increase the clearance of an intravenous catecholamine.
mechanism	Quinidine, verapamil, and <e10> carbamazepine </e10> may decrease <e20> valdecoxib </e20> absorption.
mechanism	Quinidine, verapamil, <e10> warfarin </e10>, carbamazepine, <e20> theophylline </e20>, sertraline, or amiodarone may inhibit the metabolism of oral anticoagulants, resulting in decreased prothrombin time.
mechanism	Quinidine, verapamil, phenobarbital, phenytoin, carbamazepine, <e10> phenytoin </e10>, barbiturates, bromocriptine, valproate, terfenadine, and possibly other drugs that inhibit CYP3A4 activity may increase the plasma concentrations of <e20> rifampin </e20>.
mechanism	Quinidine, verapamil, <e10> fluconazole </e10>, phenytoin, phenobarbital, phenytoin_HCl, and carbamazepine increase the metabolism of <e20> cimetidine </e20>.
mechanism	Quinidine, verapamil, and <e10> doxycycline </e10> may interfere with the metabolism of <e20> ampicillin </e20>.
mechanism	Quinidine, verapamil, and <e10> phenytoin </e10> (and to a lesser extent carbamazepine ) may decrease the clearance of <e20> cisapride </e20> and its absorption by gastric mucosa.
mechanism	Quinidine, verapamil, and carbamazepine may interfere with the metabolism of <e10> carbamazepine </e10> and <e20> quinidine </e20>.
mechanism	Quinidine, verapamil, carbamazepine, and <e10> phenytoin </e10> (in vitro) may decrease the bioavailability of <e20> cisapride </e20>.
mechanism	Quinidine, verapamil, and <e10> terfenadine </e10> inhibit <e20> furosemide </e20> absorption by binding to the transport protein, a sigmoidovirus enzyme of in vitro metabolism ( VIR ) with a half-life of approximately # min.
mechanism	Quinidine, verapamil, or <e10> carbamazepine </e10> may increase the clearance of <e20> terfenadine </e20> and increase the clearance of terfenadine tablets.
mechanism	<e10> Erythromycin </e10> significantly decreased the absorption of <e20> erythromycin </e20>, thus decreasing the bioavailability of the latter.
mechanism	<e10> Erythromycin </e10> has been reported to inhibit <e20> diazepam </e20> metabolism.
mechanism	<e10> Erythromycin </e10> may increase the clearance of digoxin, cimetidine, rifampin, <e20> clarithromycin </e20>, diazepam, clofibrate, nifedipine, phenytoin, rifabutin, sertraline, theophylline, thiazide_diuretics, and vitamin_D.
mechanism	Erythromycin and <e10> rifampin </e10> inhibit the metabolism of <e20> diltiazem </e20>.
mechanism	Erythromycin and <e10> rifampin </e10> significantly increased the concentration of <e20> ketoconazole </e20> in vitro and the concentration of isoniazid and ampicillin in vivo.
mechanism	Erythromycin and <e10> ketoconazole </e10> may decrease the absorption of <e20> cefazolin </e20>.
mechanism	Erythromycin and clarithromycin : <e10> Chlorotrianisene </e10> and <e20> clarithromycin </e20> inhibit the metabolism of both drugs.
mechanism	Erythromycin and clarithromycin : <e10> Ibandronate </e10> may interfere with absorption of <e20> erythromycin </e20> and clarithromycin.
mechanism	Erythromycin and clarithromycin concentrations are increased by <e10> astemizole </e10> and decreased by <e20> theophylline </e20>.
mechanism	Erythromycin and clarithromycin : <e10> Erythromycin </e10> and clarithromycin may interfere with the absorption of <e20> terfenadine </e20>.
mechanism	<e10> Propantheline </e10> inhibited <e20> phenobarbital </e20> metabolism, but did not inhibit nor enhance the metabolism of dopamine, norepinephrine, or epinephrine.
mechanism	<e10> Propantheline </e10> caused a 15% reduction in the clearance of <e20> cisapride </e20> in normotensive volunteers.
mechanism	<e10> Propantheline </e10> reduced the <e20> clonidine </e20> clearance by 30% and increased the plasma levels of clonidine by approximately 30%.
mechanism	Propantheline and <e10> guanethidine </e10> also inhibit <e20> phenytoin </e20> metabolism.
mechanism	Propantheline and <e10> piperazine </e10> increases the plasma levels of <e20> guanethidine </e20> and its metabolism is impaired by cimetidine.
mechanism	Propantheline and <e10> propafenone </e10> inhibit <e20> verapamil </e20> metabolism by a mechanism that is specific for the two drugs.
mechanism	<e12> Antacids </e12> or protein-starch-containing or low-carbohydrate-supplemented supplements containing vitamin_K may decrease the bioavailability of <e20> rifampin </e20>.
mechanism	<e12> Antacids </e12> may interfere with the absorption of <e20> amphetamines </e20> and increase their pharmacokinetic profile.
mechanism	<e12> Antacids </e12> and sucralfate decrease the intestinal absorption of <e20> nisin </e20>.
mechanism	Antacids, <e10> magnesium </e10>, or aluminum containing antacids may interfere with the absorption of <e20> heparin_sodium </e20> and may increase serum heparin_sodium levels.
mechanism	Antacids, <e10> calcium </e10>, bicarbonate, and sulfate preparations decrease the absorption of <e20> cyclosporine </e20>.
mechanism	Antacids, <e10> Magnesium </e10>, calcium, and magnesium -containing preparations may increase the clearance of catecholamines such as <e20> dopamine </e20> or norepinephrine.
mechanism	Antacids, kaolin, <e10> iron </e10> and zinc, and antacids containing iron or aluminum may interfere with the absorption of <e20> diazepam </e20>.
mechanism	Antacids, kaolin, and some other products that are introduced into the stomach with <e10> iron </e10> may decrease the absorption of <e20> digoxin </e20>, resulting in increased serum concentrations and half-life.
mechanism	Antacids, kaolin, and iron <e10> calcium </e10> may increase the absorption of <e20> cisapride </e20>.
mechanism	Antacids, kaolin_hydrate, vitamin_C and <e10> digoxin </e10> also inhibit <e20> rifampin </e20>.
mechanism	Antacids, kaolin, and aluminum <e10> aluminum </e10>, which are substrates for the cytochrome P450 3A4 isoenzyme, significantly decreased the half-life of <e20> fluvoxamine </e20>.
mechanism	<e10> Rifampin </e10> inhibited <e20> ketoconazole </e20> metabolism to ketoconazole, resulting in a 5-fold increase in the Cmax of ketoconazole.
mechanism	<e10> Rifampin </e10>, theophylline, phenobarbital, carbamazepine, tacrolimus, dapsone, methotrexate, rifabutin, and cisapride, may reduce <e20> amprenavir </e20> plasma concentrations.
mechanism	Macrolide_Antibiotics (e, g, <e10> erythromycin </e10>, clarithromycin, nalidixic_acid, rifabutin, indinavir ): Concomitant administration of a <e20> ampicillin </e20> # mg with a macrolide_antibiotic (e,g,, erythromycin, clarithromycin, nalidixic_acid, rifabutin, indinavir ) may decrease ampicillin effectiveness by #% to #%, resulting in increased ampicillin dosage and a risk of ampicillin toxicity.
mechanism	Macrolide_Antibiotics (e, g, <e10> rifabutin </e10>, azithromycin, erythromycin, clarithromycin, itraconazole, nefazodone, troleandomycin ): Concurrent use of rifabutin with antibiotics other than <e20> clarithromycin </e20> may result in decreased effectiveness of clarithromycin.
mechanism	Macrolide_Antibiotics (e, g, <e10> rifabutin </e10>, clarithromycin ) may increase the serum concentration of <e20> estrogens </e20>.
mechanism	Macrolide_Antibiotics (e, g, <e10> erythromycin </e10>, clarithromycin, rifampin, indinavir ): Concomitant administration of <e20> atorvastatin </e20> may result in decreased serum concentrations of these antibiotics and may result in increased serum concentrations of the drug, causing increased drug levels and potentially resulting in serious complications.
mechanism	Macrolide_Antibiotics (e, g, erythromycin, clarithromycin, <e10> warfarin </e10>, astemizole, corticosteroids, warfarin-derivative_agents ): Concomitant administration with <e21> TIKOSYN </e21> may result in a twofold increase in serum concentrations of macrolide_antibiotics (particularly, clarithromycin, ergot_derivatives, and amiodarone ).
mechanism	Macrolide_Antibiotics (e, g, <e10> erythromycin </e10>, clarithromycin, bismuth_subsalicylate ): <e20> Tetracycline </e20> treatment of cattle in the field may increase the availability of this macrolide in the body and thus increase the risk of resistance.
mechanism	Macrolide_Antibiotics (e, g, <e10> erythromycin </e10>, clarithromycin, rifabutin, indinavir, ketoconazole, nefazodone ): Concomitant administration of these drugs with <e21> TAMBOCOR </e21> may result in an increase in the bioavailability of all the active ingredients of the drug and result in decreased plasma concentrations.
mechanism	Macrolide_Antibiotics (e, g, erythromycin, clarithromycin, <e10> warfarin </e10>, etc) are potent inhibitors of CYP3A4 and may increase the plasma levels of <e20> warfarin </e20>.
mechanism	Macrolide_Antibiotics (e, g, erythromycin, clarithromycin, indomethacin ): In the presence of <e10> ciprofloxacin </e10>, the oral <e22> macrolide_antibiotic </e22> may decrease the rate of metronidazole absorption by a 3- to 4-fold increase in AUC.
mechanism	Administration of <e10> terfenadine </e10> # mg and # mg, alone, daily for # days produced a maximum decrease in #-mg terfenadine serum concentrations of 11%, which was statistically significant (P =.003) compared with the <e20> carbamazepine </e20> dose of 100 mg/day.
mechanism	Administration of <e10> diazepam </e10> at doses of # mg and # mg/kg of an <e22> nonsteroidal_anti-inflammatory_drug </e22> ( a salicylate ), or a salicylate containing ketoprofen or salicylate containing cimetidine, results in a concentration increase in the nonsteroidal_anti-inflammatory_drugs.
mechanism	Administration of <e10> diltiazem </e10> to healthy volunteers or animals treated with <e20> ketoconazole </e20> resulted in a significant increase in plasma levels of isoniazid.
mechanism	In vitro, <e10> terfenadine </e10> has been shown to inhibit the metabolism of <e20> erythromycin </e20>.
mechanism	In vitro, <e10> gentamicin </e10> inhibited the proliferation of human prostate epithelium by decreasing <e20> prostaglandin_F2alpha </e20> concentrations.
mechanism	In vitro, <e10> rifampin </e10> inhibited <e20> rifabutin </e20> absorption by 36%.
mechanism	A study in which guanethidine and <e10> fluvoxamine </e10> were co-administered with <e20> phenytoin </e20> demonstrated that the inhibition of P4503A4 activity observed with phenytoin was in part due to the decreased availability of guanethidine, a known inhibitor of CYP3A4.
mechanism	A study in male rats given oral <e10> levodopa </e10> with dosing intervals of # minutes, # hours, # days, # days, # days, # days, # days, # days and # days, # days, # days, # days, # days, # days, # days, # days, # days, # days, # days, # days, # days, # days, # days, # days and # days for # days was performed to determine if any clinically significant changes in blood concentrations or elimination of <e20> hydralazine </e20> were observed.
mechanism	A study in healthy volunteers found that <e10> cimetidine </e10> # mg increased plasma levels of <e20> adenosine </e20> by 38%.
mechanism	The effect may be enhanced when <e10> chlorpropamide </e10> is administered concomitantly with <e20> digoxin </e20>.
mechanism	The effect may be due to a pharmacokinetic interaction between <e11> PRINIVIL </e11> and <e20> indomethacin </e20> or other indomethacin derivatives.
mechanism	Administration of <e10> ketoconazole </e10> with <e20> zalcitabine </e20> or cisplatin may produce a prolongation of the plasma concentration of zalcitabine.
mechanism	Administration of <e10> carbamazepine </e10> to patients receiving two other <e22> anticonvulsant_drugs </e22>, phenobarbital, or barbiturates for at least # days and an increase in carbamazepine serum concentrations of at least #%.
mechanism	Administration of <e10> nifedipine </e10> tablets (20 mg) # hours after the administration of <e20> diltiazem </e20> tablets (10 mg) significantly reduced the diltiazem absorption.
mechanism	In renal and cardiovascular failure, <e10> gentamicin </e10> has been reported to increase renal clearance of <e20> phenytoin </e20> and its metabolism to the same end-products.
mechanism	In renal and hepatic carcinomas, the addition of <e10> dasatinib </e10> to <e20> cisplatin </e20>, or to a non-steroidal_anti-inflammatory_drug (or a glucocorticoid ), would seem to increase cisplatin toxicity.
mechanism	In renal and hepatic transplant patients, the extent to which <e10> ketoconazole </e10> therapy can be reduced by <e20> methotrexate </e20> is unknown.
mechanism	Concomitant administration of <e10> astemizole </e10> and <e20> cimetidine </e20> may result in a 3- to 6-fold increase in cimetidine plasma concentrations.
mechanism	Concomitant administration of <e10> ketoconazole </e10> with <e20> gentamicin </e20> tablets may result in a reduction in mean AUC and Cmax values.
mechanism	Concomitant administration of <e10> carbamazepine </e10> tablets with <e20> digoxin </e20> tablets results in a 30% increase in the AUC of digoxin.
mechanism	Studies showed that <e10> terfenadine </e10> inhibited <e20> fluvastatin </e20> metabolism in Caco-2 cells (80% inhibition), possibly because of hepatic metabolism of terfenadine and fluvastatin.
mechanism	Studies showed that <e10> phenytoin </e10> decreased the bioavailability of <e20> ciprofloxacin </e20>, and increased the rate of elimination of fluvastatin.
mechanism	Studies showed that <e10> clindamycin </e10> and other gram-negative bacilli (e,g,, enteric mycobacteria ) have a tendency to induce the production of <e20> cyclosporine </e20> in human subjects.
mechanism	Studies showed that the metabolism of <e10> ethoxzolamide </e10> in rats was altered by the concurrent administration of <e20> ketoconazole </e20> and cisplatin (100 mg/kg/day, s,c,) for # days.
mechanism	Studies showed that <e10> rifampin </e10> decreased the absorption of <e20> ampicillin </e20>, and that rifampin decreased the absorption of both dicumarol and gentamicin.
mechanism	Studies showed that <e10> rifampin </e10> reduced the metabolism of # mg/day of <e20> nifedipine </e20> by 50% (by 30% at # mg/day).
mechanism	The elimination half-life of <e10> fentanyl </e10> is prolonged by the concomitant administration of a <e22> salicylate </e22>.
mechanism	The elimination half-life of <e10> phenytoin </e10> is increased by <e20> nelfinavir </e20> and its active metabolite (phenytoin C).
mechanism	The elimination half-life (t1/2) of <e10> isoniazid </e10> decreased from # to # hours after coadministration with <e20> cisapride </e20>.
mechanism	The elimination half-life of <e10> ketoconazole </e10> was decreased by # times, and the elimination half-life of <e20> cisapride </e20> was increased by # times when coadministered with ketoconazole.
mechanism	The elimination half-life of <e10> adenosine </e10> was increased by the following: <e20> rifampin </e20> ; the combination of rifampin and ethambutol ; the combination of rifampin and cimetidine ; the combination of rifampin and methotrexate ; the combination of rifampin and ritonavir.
mechanism	The elimination half-life of <e10> cisplatin </e10> has been reported to be increased by <e20> propafenone </e20> and decreased by progestin.
mechanism	In a ten-subject, crossover, clinical study, the oral absorption of <e10> diltiazem </e10> was decreased approximately 50% in subjects taking <e20> warfarin </e20> concomitantly with diltiazem.
mechanism	Coadministration of <e10> valdecoxib </e10> with <e20> cholestyramine </e20> decreased the serum level of valdecoxib by 46%.
mechanism	Coadministration of <e10> nelfinavir </e10> and <e20> cimetidine </e20> resulted in increased cimetidine plasma levels and, hence, lower cimetidine AUC.
mechanism	Coadministration of <e10> foscarnet </e10> and <e20> nelfinavir </e20> reduced the area under the curve (AUC) of nelfinavir from # to # days.
mechanism	Adenosine : <e10> Cimetidine </e10> (50 mg once daily for # days) decreased the renal clearance of <e20> adenosine </e20> (40 mg once daily for # days) and reduced the renal clearance of succinylcholine (100 mg once daily for # days).
mechanism	Adenosine : <e10> Adenosine </e10> (5, 10, or 25 mg/kg) did not produce any significant change in plasma <e20> adenosine </e20> concentrations.
mechanism	Adenosine : <e10> Diphenoxylate </e10> and phenobarbital, both known inhibitors of CYP2D6, significantly inhibited <e20> adenosine </e20> elimination.
mechanism	in one man, a decreased rate of progression of prostate cancer to an advanced stage was observed with concomitant administration of <e10> cisplatin </e10> at the recommended dose of # mg/m2 and <e20> digoxin </e20> at the recommended dose of # mg/m2 for # weeks.
mechanism	in one man, bleeding occurred when <e10> clofibrate </e10> was discontinued after <e20> fibrate </e20> and platelet_inhibitors ( ritonavir, atazanavir, saquinavir, indinavir, itraconazole ) were discontinued simultaneously.
mechanism	in one man, <e10> terfenadine </e10> # mg caused a 42% increase in <e20> ketoconazole </e20> dose, which was associated with a decrease in serum concentrations of the latter.
mechanism	Antacids or H_2_receptor_antagonists : <e10> Cholestyramine </e10> may decrease the absorption of antacids or H_2_receptor_antagonists (e,g,, phenytoin, <e20> carbamazepine </e20> ) or potentiate the activity of these agents.
mechanism	Antacids or H_2_receptor_antagonists : Because <e10> acetaminophen </e10> and H_2_receptor_antagonists may decrease the absorption of <e20> ibuprofen </e20>, it is advisable to avoid taking both for several days after the ibuprofen injection.
mechanism	Antacids or H_2_receptor_antagonists ( <e10> fluoxetine </e10>, sertraline, paroxetine ) may increase the clearance of <e20> phenytoin </e20>.
mechanism	Antacids or H_2_receptor_antagonists : <e10> Acetazolamide </e10>, phenobarbital, and other gastrointestinal antacids, anticonvulsants, and certain drugs known to prolong the gastrointestinal transit time may increase the oral absorption of <e20> warfarin </e20>.
mechanism	Antacids or H_2_receptor_antagonists ( phenytoin, <e10> phenobarbital </e10>, ketoconazole, nizoral, bromocriptine ) may interfere with absorption of <e20> fluvoxamine </e20>.
mechanism	Antacids or H_2_receptor_antagonists, including <e10> dipyridamole </e10>, interfere with the absorption of <e20> zalcitabine </e20>, resulting in a reduction in plasma levels.
mechanism	Triazolam : <e10> Diazepam </e10>, when administered concomitantly with <e20> triazolam </e20>, decreased the renal clearance of triazolam.
mechanism	Triazolam : <e10> Ketoconazole </e10> can decrease the elimination of <e20> triazolam </e20>.
mechanism	Digoxin : Concomitant administration of <e10> digoxin </e10> with <e20> doxorubicin </e20> significantly increased the rate of digoxin clearance by 50%.
mechanism	Digoxin : Concomitant administration of <e10> digoxin </e10> and <e20> alfentanil </e20> for # days resulted in an increase in digoxin concentrations in the blood.
mechanism	If <e10> phenytoin </e10> # mg q10 h was given # hours after dosing with <e20> lomefloxacin </e20> # mg q10 h, plasma concentrations of lomefloxacin were #% lower than with # hours lomefloxacin administered alone.
mechanism	If <e10> phenytoin </e10> # mg # times a day # days is given # days after # mg # days of <e20> zalcitabine </e20> # mg # times a day, the mean AUC of zalcitabine will increase from # to 18% and the Cmax from # to 14%.
mechanism	If <e10> phenytoin </e10> is administered concomitantly with <e20> carbamazepine </e20>, carbamazepine pharmacokinetics may be substantially altered.
mechanism	If <e10> phenytoin </e10> # mg is administered with a single dose of <e20> aripiprazole </e20> # mg, the phenytoin AUC will increase by 38% (p =.03).
mechanism	If <e10> phenytoin </e10> is to be administered orally with <e20> aripiprazole </e20>, it is likely that the following effects will occur: (1) the phenytoin dose will increase, (2) the aripiprazole dose will decrease, and (3) the metabolism of phenytoin will be altered.
mechanism	If <e10> phenytoin </e10> is coadministered with <e20> ketoconazole </e20>, increases in the plasma levels of phenytoin may occur, and the clinical consequences of these increases may be severe.
mechanism	Concomitant administration of <e10> digoxin </e10> with <e20> halothane </e20> in rats has been reported to cause pronounced hyperthermia, and this has been reported to be exacerbated by increases in digoxin concentration.
mechanism	Concomitant administration of <e10> ketoconazole </e10> and <e20> phenytoin </e20> resulted in increased plasma concentrations of phenytoin.
mechanism	Concomitant administration of <e11> Kineret </e11> with other <e22> anticonvulsants </e22> increases seizure control by increasing the concentrations of these agents in the brain.
mechanism	Patients taking <e10> amiodarone </e10> concomitantly with <e20> fluvoxamine </e20> in vitro, experienced an approximately fourfold increase in fluvoxamine clearance and a decrease in fluvoxamine AUC.
mechanism	Patients taking <e10> cisapride </e10> at doses of # mg/day or # mg/day or # mg/day or # mg/day for # days after <e20> clonidine </e20> therapy may experience increases in serum clonidine levels.
mechanism	Patients taking <e10> lofexidine </e10> and <e20> lofexidine </e20> concurrently were found to have a decrease in plasma levels of lofexidine, suggesting that lofexidine may have a toxic effect on the kidneys.
mechanism	In vitro studies suggest that <e10> clofibrate </e10> may decrease the clearance of <e20> carbamazepine </e20> and that increased hepatic clearance of carbamazepine may increase the concentration of carbamazepine in plasma.
mechanism	In vitro studies suggest that <e10> ketoconazole </e10> increases the concentration of <e20> isoniazid </e20>, phenytoin, and phenobarbital, and may enhance the metabolism of cimetidine.
mechanism	In vitro studies have shown that <e10> alprazolam </e10> potentiates the CNS depressant effect of <e20> halothane </e20>.
mechanism	In vitro studies of <e10> phenytoin </e10> and caffeine indicated that the inhibition of <e20> phenytoin </e20> and caffeine metabolism may be responsible for the increase in blood levels of these drugs.
mechanism	In vitro studies suggest that the pharmacokinetic parameters of <e10> furosemide </e10> may be altered by coadministration of other <e22> nonsteroidal_anti-inflammatory_drugs </e22> and/or drugs that have similar pharmacology, such as the anticonvulsant phenytoin, carbamazepine, cimetidine, disulfiram, diazepam, phenobarbital, sulfonamides, sulfonamides_inhibitors, sulfonamides_inhibitors_with_b-blocking_properties, and sulfonamides_inhibitors_with_b-blocking_properties.
mechanism	In vitro studies indicate that <e10> diltiazem </e10> significantly inhibits the metabolism of <e20> erythromycin </e20>.
mechanism	In vitro studies have shown that <e10> cisapride </e10> significantly inhibited the metabolism of <e20> alcohol </e20> and methanol (one of the major isomers of alcohol) to produce a 2- to 3-fold increase in cisapride levels.
mechanism	In vitro studies of the <e12> SSRI </e12> / <e22> beta-adrenergic_blocking_agent </e22> combination suggest an additive effect for paroxetine and an additive effect for fluoxetine on E2, suggesting a possible drug interaction for fluoxetine.
mechanism	In vitro studies suggest a possible drug interaction for <e10> dapsone </e10> when coadministered with <e20> colestipol </e20>.
mechanism	In vitro studies have shown that <e10> doxorubicin </e10> inhibited <e20> gentamicin </e20> by 25% in vitro.
mechanism	<e10> Cimetidine </e10> may reduce the absorption of <e20> dexamethasone </e20> and Ciprofloxacin.
mechanism	<e10> Cimetidine </e10> (400 mg q8w) # h after the last dose of <e20> carbamazepine </e20> # mg q8w caused a 50% decrease in carbamazepine plasma levels.
mechanism	<e10> Cimetidine </e10> and related compounds increase the clearance of acetaminophen and other <e22> nonsteroidal_anti-inflammatory_drugs </e22>, and the metabolism of these drugs by the CYP2D6 isoenzyme increases the half-life of some drugs.
mechanism	<e10> Cimetidine </e10> may inhibit <e20> lithium </e20> metabolism.
mechanism	<e10> Cimetidine </e10>, which is highly potent inducers of CYP3A4 activity, has been shown to increase plasma <e20> cimetidine </e20> levels.
mechanism	<e10> Cimetidine </e10> may increase the plasma concentration of <e20> phenytoin </e20>.
mechanism	Co-administration of <e11> ENBREL </e11> and <e20> methotrexate </e20> produced a significant increase in renal clearance of methotrexate.
mechanism	Co-administration of <e11> VIDEX </e11> with <e20> ketoconazole </e20>, an inhibitor of CYP2C9, decreased the AUC and Cmax of VIDEX by 40% and 30%, respectively.
mechanism	<e10> Ketoconazole </e10> decreased the clearance of <e20> ketoconazole </e20>, and therefore, the effective dose of ketoconazole was decreased.
mechanism	<e10> Ketoconazole </e10> reduced the pharmacokinetics of <e20> fluconazole </e20>.
mechanism	<e10> Ketoconazole </e10> may increase the clearance of <e20> fluconazole </e20>.
mechanism	In patients receiving intravenous <e10> gentamicin </e10>, <e20> digoxin </e20> reduced the absorption of digoxin from Cmax to #% and AUC to #%.
mechanism	In patients receiving concurrent <e10> isoniazid </e10> and <e20> rifabutin </e20>, plasma isoniazid levels may increase.
mechanism	The mean clearances of <e10> terfenadine </e10> and <e20> cisapride </e20> were 6.9% and 5.9%, respectively, lower than those of indomethacin.
mechanism	The mean clearances for the <e12> quinolones </e12> were increased by approximately 20% when the ketoconazole (concurrent use with <e20> ketoconazole </e20> ) was coadministered with all of the three drugs (ie, atorvastatin, fluconazole, and atorvastatin_sodium ).
mechanism	Blood levels of theophylline are reduced when <e10> isoniazid </e10> is given concurrently with <e20> warfarin </e20>.
mechanism	Blood levels of <e10> ketoconazole </e10> were significantly increased by concurrent administration of <e20> ketoconazole </e20> and a racemic mixture of amiodarone, a benzodiazepine, in the rat.
mechanism	Blood levels of diazepam, <e10> diazepam </e10> and hydrocodone decreased by approximately 50% and approximately 40%, respectively, following coadministration with <e20> lorazepam </e20>.
mechanism	Blood levels of <e10> fluvoxamine </e10> were increased by administration of the <e20> cimetidine </e20>, however, cimetidine did not alter the blood levels of fluvoxamine.
mechanism	Blood levels of <e10> valdecoxib </e10> were increased in patients with chronic renal insufficiency when coadministered with <e20> astemizole </e20>, rifampin, amphotericin_B, and fluconazole.
mechanism	Blood levels of <e10> carbamazepine </e10> are decreased by <e20> indomethacin </e20>.
mechanism	Clearance of hydrodolasetron in rats receiving <e10> cisapride </e10> was approximately 75% less than that observed with <e20> hydrodolasetron </e20>.
mechanism	Clearance of hydrodolasetron after coadministration of <e10> gentamicin </e10> with <e20> sirolimus </e20> and digoxin was reduced by approximately 25% when sirolimus was coadministered with gentamicin.
mechanism	<e10> Isoflurane </e10> increases <e20> terfenadine </e20> metabolism.
mechanism	<e10> Isoflurane </e10> potentiates the hypotensive effects of <e22> antihypertensive_agents </e22>, potentially leading to greater hypotension.
mechanism	<e10> Isoflurane </e10> at # micrograms/ml (16 microL) inhibited <e20> morphine </e20> absorption and maximal effect was # min (P =.01).
mechanism	Isoflurane, <e10> enflurane </e10>, halothane, and halothane (with long half-lives) may decrease the half-life of <e20> atracurium </e20> by a factor of 50-100.
mechanism	Isoflurane, <e10> ketamine </e10>, and <e20> alcohol </e20> are potent inhibitors of N-acetyltransferase.
mechanism	Isoflurane, <e10> halothane </e10>, or isoflurane administered with <e20> levodopa </e20> may decrease the metabolism of levodopa.
mechanism	Isoflurane, enflurane, <e10> halothane </e10>, and other non-ionizing_agents, as well as <e20> phenothiazines </e20>, may inhibit the metabolism of either NIMBEX or the metabolized active ingredient ( AEROL ).
mechanism	Isoflurane, enflurane, halothane, <e10> halothane </e10>, halothane and halothane administered with <e21> NUROMAX </e21> cause a 5- to 6-fold increase in fluorescence, when compared to the same agents administered without NUROMAX.
mechanism	Isoflurane, enflurane, and <e10> isoflurane </e10> reduce plasma norepinephrine by an average of 41%, 38%, and 38%, respectively, and increase plasma <e20> lofexidine </e20> by an average of 11%, 7%, and 11%, respectively.
mechanism	In a placebo-controlled crossover study in healthy subjects, <e10> almotriptan </e10> # mg increased the Cmax by 26% (P =.01) and AUC by 17% (P =.004) when coadministered with 50 mg <e20> enoxacin </e20>.
mechanism	In a placebo-controlled trial, the effect of <e10> cimetidine </e10> on blood pressure and heart rate was reduced by approximately 25% when given with either <e20> nifedipine </e20> or diltiazem.
mechanism	Inhibitors or substrates of CYP3A4 ( alprazolam, <e10> cyclosporine </e10>, etc,) have been reported to increase <e20> ketoconazole </e20> plasma concentrations.
mechanism	Inhibitors or substrates of CYP3A4 (such as ketoconazole, itraconazole, itraconazole derivatives, ritonavir, nelfinavir, clarithromycin, <e10> nefazodone </e10>, nelfinavir and saquinavir ) may decrease the exposure to <e20> norfloxacin </e20>.
mechanism	Inhibitors or substrates of CYP3A4 (eg, ketoconazole, erythromycin, clarithromycin, ritonavir, <e10> indinavir </e10>, saquinavir, indinavir, indinavir, saquinavir, indinavir ) may decrease plasma levels of <e20> propranolol </e20>.
mechanism	Inhibitors or substrates of CYP2D6 (e,g,, ketoconazole, itraconazole, ritonavir, erythromycin, clarithromycin, <e10> nefazodone </e10>, nelfinavir, ritonavir, saquinavir, telithromycin ) decrease the extent to which <e20> isoniazid </e20> is metabolized.
mechanism	Inhibitors or substrates of CYP3A4 (e,g,, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, <e10> indinavir </e10>, saquinavir, indinavir, itraconazole, nelfinavir, indinavir ) have the potential to decrease the clearance of <e20> lamivudine </e20>.
mechanism	Inhibitors or substrates of CYP2C9 (e,g,, ketoconazole, itraconazole, erythromycin, clarithromycin, nefazodone, <e10> ritonavir </e10>, saquinavir, nelfinavir, indinavir, indinavir, ritonavir, saquinavir, telithromycin, troleandomycin, terfenadine ) may increase the metabolism of <e20> atazanavir </e20>, resulting in increased exposure of atazanavir to serum and urine.
mechanism	Inhibitors or substrates of CYP2D6 (such as <e10> ketoconazole </e10>, itraconazole, ritonavir, nelfinavir, clarithromycin, nefazodone, ritonavir, saquinavir, <e20> troleandomycin </e20>, valproic_acid, valproate ) may decrease the exposure of a ritonavir dosage form to the CYP2D6 active metabolite, phenytoin.
mechanism	Inhibitors or substrates of CYP3A4 (such as ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin, <e10> indinavir </e10>, nefazodone, troleandomycin, ritonavir, saquinavir, telithromycin, troleandomycin, troleandomycin, valdecoxib ) can decrease or eliminate <e20> tamoxifen </e20> -related drug interactions.
mechanism	Inhibitors or substrates of CYP2C9 (such as ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, saquinavir, <e10> ritonavir </e10>, indinavir, telithromycin, troleandomycin, troleandomycin ) may decrease plasma levels of <e20> ketoconazole </e20> and may increase the plasma levels of the non-steroidal_anti-inflammatory_drugs bromocriptine and astemizole.
mechanism	Cimetidine : <e10> Cimetidine </e10> inhibits <e20> piperazine </e20> absorption and metabolism.
mechanism	Cimetidine : <e10> Cimetidine </e10> can increase the clearance of <e20> enoxacin </e20>.
mechanism	Cimetidine : <e10> Cimetidine </e10> has been reported to decrease the clearance of <e20> propafenone </e20> by 50% (approximately 6%).
mechanism	Additionally, higher than average plasma levels of <e10> clozapine </e10> were observed in the case of <e20> valdecoxib </e20> co-administration.
mechanism	Additionally, higher than recommended doses of <e10> digoxin </e10> may increase the absorption of <e20> atorvastatin </e20> and other drugs that have an absorption gradient (such as cholestyramine or cetirizine ).
mechanism	In patients who were treated with <e10> valdecoxib </e10> (50 mg QD) in combination with a # mg <e20> carbamazepine </e20> (day #) and were found to have an increased AUC of valdecoxib by the method of nonlinear regression, carbamazepine was withdrawn from the regimen.
mechanism	In patients who received a single dose of <e10> diltiazem </e10> and an average of #.9 mg of <e20> warfarin </e20> in a # hour interval, # mg of warfarin was required to achieve a # mg increase in the AUC of warfarin.
mechanism	Alcohol : It is possible that <e10> alcohol </e10> may reduce the clearance of <e20> fluvoxamine </e20>.
mechanism	Alcohol : It has been reported that <e10> alcohol </e10> may enhance the absorption of <e20> methotrexate </e20>, causing a 50% increase in methotrexate clearance.
mechanism	Alcohol : It has been reported that <e10> Cholestyramine </e10> may decrease the metabolism of <e20> alcohol </e20> and increase the AUC of the metabolite of alcohol, thus resulting in a lower AUC of the metabolite of alcohol.
mechanism	Absorption of <e12> quinolones </e12> may be impaired by <e22> calcium_channel_blockers </e22>.
mechanism	Absorption of <e12> quinolones </e12> may be inhibited by nalidixic_acid, <e20> isoniazid </e20>, phenytoin, or warfarin.
mechanism	Absorption of <e12> quinolones </e12> by humans is, in part, dependent upon their ability to simultaneously inhibit the metabolism of drugs that have metabolic functions other than absorption (eg, <e20> rifampin </e20> ).
mechanism	Absorption of <e12> quinolones </e12> may be decreased by <e20> cimetidine </e20>.
mechanism	Absorption of <e12> quinolones </e12> and ciprofloxacin has been demonstrated to be reduced by 50% when administered concomitantly with <e20> carbamazepine </e20>.
mechanism	Absorption of <e12> quinolones </e12> is impaired when administered concurrently with oral <e22> antacids </e22> that contain calcium or magnesium.
mechanism	Absorption of <e12> cephalosporins </e12> is decreased in patients receiving <e20> cyclosporine_A </e20>.
mechanism	Absorption of <e12> SSRI </e12> -like_agents may be enhanced by <e20> valdecoxib </e20>, but this was not clinically significant.
mechanism	Absorption of <e12> quinolones </e12> may be decreased by the concomitant administration of antacids containing magnesium, <e20> calcium </e20>, or iron.
mechanism	Absorption of <e10> probenecid </e10> was significantly impaired when the oral solution was administered with <e20> phenytoin </e20>.
mechanism	Absorption of <e10> acitretin </e10> and <e20> phenytoin </e20> is impaired by estrogens and in women treated with progestins and tamoxifen.
mechanism	<e12> Barbiturates </e12> inhibit the metabolism of <e20> chloroquine </e20> by an unknown mechanism.
mechanism	<e12> Barbiturates </e12> inhibit <e20> dopamine </e20> synthesis.
mechanism	Barbiturates, <e10> quinidine </e10>, phenytoin, or carbamazepine may decrease <e20> baclofen </e20> metabolism.
mechanism	Barbiturates, <e10> phenytoin </e10>, carbamazepine, phenobarbital, alfentanil, cisapride, disopyramide, bromocriptine, bupropion, valproate, terfenadine, disulfiram, and probenecid have been reported to interfere with the metabolism of <e20> astemizole </e20>.
mechanism	Barbiturates, <e10> fluconazole </e10>, chloramphenicol, cimetidine, methotrexate, and quinidine may reduce the renal clearance of <e20> probenecid </e20> and may increase the renal clearance of a concomitant nephrotoxic drug such as probenecid.
mechanism	Barbiturates, carbamazepine, chlordiazepoxide, felbamate, <e10> erythromycin </e10>, fluconazole, hexobarbital, itraconazole, itraconazole (inhibitors), itraconazole (inhibitors/incompressible), ketoconazole, macrolide_antibiotics, norfloxacin, propoxyphene, phenytoin, rifampin, saquinavir, <e20> troleandomycin </e20>, tetracycline.
mechanism	Barbiturates, carbamazepine, cyclosporine, tacrolimus, indomethacin, <e10> phenytoin </e10>, terfenadine, theophylline, thiazide_diuretics, and vitamin_C preparations may decrease the bioavailability of <e20> ciprofloxacin </e20>.
mechanism	Concurrent administration of <e10> ethoxzolamide </e10> with oral <e22> anticoagulants </e22> or warfarin results in increased levels of ethoxzolamide in plasma and/or urine and increases the clearance of ethoxzolamide and other anticoagulants.
mechanism	Concurrent administration of <e10> diflunisal </e10> and <e20> cyclosporine_A </e20> has been shown to increase the cytochrome P-450 3A4 (CYP3A4) enzyme activity by 40% and significantly increase plasma concentrations of both cyclosporine_A and diflunisal.
mechanism	Concurrent administration of <e10> rifampin </e10> with <e20> nelfinavir </e20> may result in an increased nelfinavir exposure of approximately 2-fold.
mechanism	Inhibitors of CYP1A2: Concomitant administration of <e10> ketoconazole </e10> and a fluoroquinolone, an azole_antifungal_agent ( <e20> itraconazole </e20> ), a quinolone_antimicrobial, and a protease_inhibitor may result in decreased clearance of all fluoroquinolones, with resulting elevations of the AUC and Cmax.
mechanism	Inhibitors of CYP1A2: A 25-mg <e10> ketoconazole </e10> dose produced a reduction in the steady-state plasma levels of <e20> anagrelide </e20> (the active metabolite of anagrelide ) from # +/- 3 to # +/- 1 micrograms/mL.
mechanism	<e10> Paroxetine </e10>, when coadministered with <e20> estrogens </e20>, increased the half-life of estrogens by 5%.
mechanism	<e10> Paroxetine </e10> inhibits the metabolism of <e20> fluoxetine </e20>.
mechanism	<e10> Paroxetine </e10>, carbamazepine, <e20> fluvoxamine </e20>, and alprazolam reduce plasma levels of cimetidine by 50%, 50%, and 70%, respectively, while amiodarone and lovastatin increase cimetidine levels by 50% and 75%, respectively.
mechanism	When <e10> duloxetine </e10> was given at a dose of # mg/day, the <e20> ketoconazole </e20> dose was reduced to # mg/day.
mechanism	When <e10> duloxetine </e10> and <e20> pravastatin </e20> were administered concomitantly, there was a 20% increase in the AUC of duloxetine.
mechanism	When <e10> duloxetine </e10> was coadministered with a <e22> tricyclic_antidepressant </e22> ( alprazolam ), serum levels of duloxetine were reduced by approximately 40% and were below detectable levels in the other two patients.
mechanism	Concurrent administration of <e10> cimetidine </e10> with <e20> terfenadine </e20> reduced the elimination of both drugs by approximately 50%.
mechanism	Concurrent administration of <e10> cisapride </e10> and <e20> succinylcholine </e20> may increase plasma concentrations of succinylcholine and thus may increase the risk of succinylcholine toxicity.
mechanism	Concurrent administration of <e10> nevirapine </e10> and <e20> rifampin </e20> may decrease nevirapine levels and increase rifampin levels.
mechanism	Steroids enhance the absorption of <e10> colestipol </e10> and <e20> ethinyl_estradiol </e20>.
mechanism	Drugs which induce CYP3A4 activity, such as ketoconazole, fluconazole, and itraconazole, may increase the clearance of <e10> norfloxacin </e10> and thus reduce the absorption of <e20> norfloxacin </e20>.
mechanism	Drugs which induce hepatic enzymes such as <e10> phenytoin </e10>, carbamazepine, alfentanyl, phenobarbital, <e20> phenytoin_sodium </e20>, and theophylline may increase the clearance of cetirizine and therefore reduce the clearance of cetirizine.
mechanism	Drugs which induce CYP3A4 activity (eg, phenytoin, carbamazepine, cimetidine, <e10> felbamate </e10>, alfentanil, rifampin, phenobarbital, quinine, succinylcholine, valproate, ketoconazole, bromocriptine, cisapride, terfenadine, disopyramide, ketoconazole_diltiazem, loratadine, theophylline, valproate, zidovudine, ziconazole ) may increase plasma concentrations of <e20> piperidine </e20>.
mechanism	Drugs which induce hepatic enzyme activity (e,g,, phenobarbital, phenytoin, phenytoin_hydrochloride, carbamazepine, <e10> rifampin </e10>, haloperidol, alfentanil ) may increase plasma <e20> methotrexate </e20> levels.
mechanism	Drugs which induce hepatic metabolism of <e11> ENBREL </e11>, such as phenytoin, carbamazepine, phenobarbital, and alfentanil, may increase plasma concentrations of <e20> ENBREL </e20>.
mechanism	Drugs which induce hepatic enzyme levels such as <e10> indinavir </e10>, ritonavir, and <e20> atazanavir </e20> significantly increased the plasma levels of indinavir.
mechanism	Drugs which induce hepatic metabolism of <e10> cyclosporine </e10> such as carbamazepine, tacrolimus, disopyramide, disopyramide, phenytoin, <e20> phenobarbital </e20>, and theophylline may increase cyclosporine concentrations in the blood.
mechanism	Drugs which induce hepatic enzymes such as <e10> cyclosporine </e10>, carbamazepine, tacrolimus, phenytoin, and phenobarbital may decrease the clearance of <e20> cimetidine </e20> and increase the clearance of cimetidine.
mechanism	Drugs which induce hepatic enzymes such as cyclosporine, tacrolimus, digoxin, phenytoin, and <e10> phenobarbital </e10> may increase the clearance of <e20> cisplatin </e20>.
mechanism	Increasing the indinavir dose to # mg in patients receiving # mg of <e10> indinavir </e10> daily reduced the AUC by 35% (2 mg # mg q12h, n = 7) and decreased the AUC by 16% (20 mg # mg q12h, n = 5) when indinavir was given concomitantly with <e20> didanosine </e20>.
mechanism	Increasing the indinavir dose to # mg once daily for # days is effective in lowering <e10> indinavir </e10> plasma concentrations and has a greater effect on the efficacy of <e20> bromocriptine_mesylate </e20> and indinavir than on bromocriptine_mesylate alone.
mechanism	When <e10> indinavir </e10> was coadministered with <e20> ritonavir </e20>, there was a twofold increase in ritonavir AUC and Cmax.
mechanism	When <e10> indinavir </e10> was administered with <e20> ritonavir </e20>, the ritonavir AUC increased by 4-fold and the Cmax decreased by 38%.
mechanism	When <e10> indinavir </e10> was co-administered with <e20> gentamicin </e20>, mean Cmax and AUC increased by 21% and 18%, respectively, and post-dose Cmax values were slightly lower.
mechanism	Potential for reduction in cardiac output with <e10> lisinopril </e10> or <e20> metformin </e20> treatment.
mechanism	Potential for reduction in the duration of <e10> caffeine </e10> or <e20> phenytoin </e20> administration following coadministration with theophylline, butyrophenones, phenobarbital, or fluconazole may occur.
mechanism	<e11> SUSTIVA </e11> may decrease the serum concentrations of <e20> dopamine </e20>, thus decreasing its effect on the central nervous system.
mechanism	<e11> SUSTIVA </e11> may increase the clearance of <e20> isoniazid </e20>.
mechanism	<e11> SUSTIVA </e11> should be used with caution in patients taking <e20> warfarin </e20> or its derivatives because of the risk of serious drug interactions with decreased clearance of warfarin or its derivatives.
mechanism	<e11> SUSTIVA </e11>, given concurrently with <e20> diazepam </e20>, may potentiate the effects of diazepam.
mechanism	<e11> SUSTIVA </e11> may reduce the clearance of the <e20> digoxin </e20> ;
mechanism	<e11> SUSTIVA </e11> and <e20> indinavir </e20> may inhibit the metabolism of ritonavir or lopinavir.
mechanism	Bismuth : <e10> Benzthiazide </e10>, an inhibitor of CYP3A4, increased the clearance of <e20> bexarotene </e20>.
mechanism	Bismuth : <e10> Methotrexate </e10> reduced the formation of <e20> bismuth_subsalicylate </e20> (BOS), a precursor of bismuth_subsalicylate.
mechanism	Caffeine : <e10> Caffeine </e10> increases the serum concentration of <e20> isoniazid </e20>, but not of acetylsalicylic_acid.
mechanism	Caffeine : <e10> Caffeine </e10> significantly decreased the <e20> methotrexate </e20> AUC by 8%.
mechanism	Caffeine : <e10> Caffeine </e10> may increase plasma <e20> caffeine </e20> levels.
mechanism	In a multiple-dose study in healthy volunteers, coadministration of <e10> digoxin </e10> with <e20> levodopa </e20> resulted in a 40% increase in levodopa clearance.
mechanism	In a multiple-dose study in healthy volunteers, the maximum plasma levels of <e10> norethindrone </e10> were reduced by approximately 50% when it was co-administered with <e20> furosemide </e20> and increased by approximately 25% when it was co-administered with dantrolene.
mechanism	In a multiple-dose study, coadministration of <e10> valdecoxib </e10> # mg on the day of dosing with <e20> carbamazepine </e20> # mg increased carbamazepine AUC by a mean of 30% and Cmax by a mean of 10%.
mechanism	Trough plasma enoxacin concentrations may be decreased by <e10> enoxacin </e10> when administered concurrently with <e20> gentamicin </e20>.
mechanism	Trough plasma enoxacin concentrations may be increased when <e10> enoxacin </e10> is coadministered with drugs that cause metabolism by cytochrome P450 2C9 (e,g,, <e20> ketoconazole </e20>, itraconazole, clarithromycin, ritonavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, and terfenadine ), but can be reduced when enoxacin is coadministered with drugs that cause metabolism by CYP2C9 (e,g,, ketoconazole, itraconazole, ritonavir, nelfinavir, saquinavir, troleandomycin, and terfenadine ), because enoxacin is not a substrate for CYP2C9.
mechanism	Trough plasma enoxacin levels were significantly decreased at the interval of # to # hours following <e10> fluconazole </e10> administration, whereas <e20> diflunisal </e20> and zidovudine were unaffected.
mechanism	Cyclosporine : Elevated serum levels of <e10> cyclosporine </e10> may occur when <e20> atorvastatin </e20> is coadministered.
mechanism	Cyclosporine : Elevated plasma levels of <e10> cyclosporine </e10> have been reported when <e20> clofibrate </e20> is coadministered.
mechanism	Digoxin : <e10> Furosemide </e10> may enhance the absorption of <e20> digoxin </e20>.
mechanism	Digoxin : <e10> Etonogestrel </e10> markedly reduced the plasma levels of <e20> digoxin </e20> by approximately 46%.
mechanism	or with multivitamins and vitamin_B-containing preparations, taking <e11> VIDEX </e11> Tablets at the recommended dosages for these drugs can reduce the absorption of the vitamin_B and its active metabolite, <e20> lathosterol </e20>, resulting in elevated levels of the latter.
mechanism	or with multivitamins, it may not be possible to take <e10> enoxacin </e10> with all of the following: <e20> zidovudine </e20>, ritonavir, atazanavir, clarithromycin, dalfopristin, fluconazole, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin.
mechanism	Antacids containing <e10> sucralfate </e10> or sucralfate with calcium <e20> vitamin_D </e20> had a similar effect on serum calcium levels, and serum vitamin_D levels increased by 40% or more in both treatment groups.
mechanism	Antacids containing <e10> iron </e10> (including iron chelating agents) decrease the rate of absorption of <e20> methotrexate </e20> by 50% to 100%.
mechanism	Antacids containing aluminum_hydroxide, magnesium_hydroxide, or aluminum trisodium, or other metal cations, such as iron, aluminum, magnesium, or iron_hydroxide, or the combination of aluminum <e10> aluminum </e10> and iron_hydroxide, magnesium, or iron_hydroxide, may interfere with the absorption of <e20> warfarin </e20> or its derivatives and may increase the pharmacologic effect of warfarin.
mechanism	The oral bioavailability of <e11> EQUETROTM </e11> was significantly higher in healthy volunteers given a single oral dose of # mg of <e20> alosetron </e20> than in volunteers given a single dose of # mg of a single-dose dose of loperamide (p = 0.017).
mechanism	The oral bioavailability of <e10> probenecid </e10> decreased by approximately 40% when administered with <e20> ketoconazole </e20>, when the two medications were coadministered.
mechanism	The oral bioavailability of <e11> INSPRA </e11> was reduced by #% when coadministered with <e20> methotrexate </e20>, increasing the risk of induration on the oral mucosa.
mechanism	Theophylline : <e10> Theophylline </e10> inhibits <e20> methotrexate </e20> and its metabolism and thereby prevents the accumulation of cyclosporine.
mechanism	Theophylline : <e10> Theophylline </e10> at low doses (10(-8) -10(-6) M) inhibited <e20> theophylline </e20> metabolism, leading to the accumulation of theophylline in plasma.
mechanism	<e10> Enoxacin </e10> increased the clearance of <e20> cisapride </e20> by 17% and the AUC by 18%.
mechanism	<e10> Enoxacin </e10> inhibited <e20> diazepam </e20> metabolism by approximately two-fold.
mechanism	<e10> Enoxacin </e10> and tetracycline : In the absence of <e20> cisapride </e20>, Enoxacin has been reported to increase plasma levels of cisapride, a drug that is reported to decrease plasma levels of enoxacin.
mechanism	Warfarin : <e12> Quinolones </e12> inhibit the metabolism of <e22> coumarin </e22>.
mechanism	Warfarin : <e12> Amphetamines </e12> may reduce the clearance of <e20> warfarin </e20>.
mechanism	Warfarin : <e12> Amphetamines </e12> inhibit the metabolism of <e20> warfarin </e20> by decreasing its C-glucuronide excretion and increasing its plasma levels.
mechanism	<e10> Cimetidine </e10> may decrease the metabolism of <e20> digoxin </e20> and may increase the clearance of digoxin and its derivatives.
mechanism	<e10> Cimetidine </e10> significantly reduced the plasma levels of <e20> ketoconazole </e20>.
mechanism	<e10> Cimetidine </e10> in dose-dependent and dose-independent manner increases the half-life of <e20> succinylcholine </e20> by lowering the active metabolite and thus inhibiting the absorption of succinylcholine.
mechanism	A pharmacokinetic study with <e10> ciprofloxacin </e10> revealed a mean AUC for ciprofloxacin in <e20> lisuride </e20> plasma was significantly lower than in lisuride plasma.
mechanism	A pharmacokinetic study in healthy volunteers indicated that <e10> ketoconazole </e10> was coadministered with <e20> cisapride </e20> at # mg every other day for # weeks.
mechanism	Administration of <e10> cholestyramine </e10> may decrease the clearance of <e20> halothane </e20>, causing increased tissue toxicity.
mechanism	Administration of <e10> dexamethasone </e10> to diabetic patients with severe hypoglycemia has been reported to result in a decrease in serum <e20> furosemide </e20> levels.
mechanism	Administration of <e10> halothane </e10> (100 mg/kg, i,v,) to rats for # hours resulted in a reduction of <e20> levodopa </e20> clearance by #% (p = 0.015).
mechanism	Administration of <e10> gabapentin </e10> and <e20> diazepam </e20> # mg for # hours each day to a patient with moderate to severe cognitive impairment resulted in a significant reduction of both drug levels and adverse events (as determined by the physician-administered adverse event scoring system).
mechanism	Administration of <e10> diltiazem </e10> # mg b.i.d. with <e20> ketoconazole </e20> tablets resulted in a 2.2% decrease in its AUC.
mechanism	Administration of <e10> cyclosporine </e10> at high doses (30 mg/kg/day for # days or # days) increased the <e20> terfenadine </e20> dose by 20% but decreased the AUC by 44% and decreased the Cmax by 40%.
mechanism	Administration of <e10> ketoconazole </e10> to patients receiving <e20> zidovudine </e20>, nelfinavir, or cetirizine produced a reduction in the half-life of zidovudine by 37%, 40%, and 40%, respectively.
mechanism	Administration of <e10> gentamicin </e10> # mg # days before administration of <e20> astemizole </e20> # mg # days before administration of # mg/kg/day astemizole.
mechanism	Administration of <e10> isoniazid </e10> and <e20> carbamazepine </e20> in combination with either of these two drugs results in a statistically significant increase in carbamazepine plasma concentrations.
mechanism	Administration of <e10> valdecoxib </e10> (50 mg once daily) for # days was associated with a 24% increase in the plasma concentrations of <e20> rifabutin </e20> (5 micrograms per milliliter), a 50% increase in the plasma concentrations of cytochalasin B (20 micrograms per milliliter), and a 20% increase in the plasma concentrations of rifabutin (50 micrograms per milliliter) compared with the same rifabutin dosage when it was given concomitantly with valdecoxib.
mechanism	Administration of <e10> cisapride </e10> to healthy volunteers resulted in an increase in <e20> digoxin </e20> plasma levels that was reversed by coadministration with an AUC-reductase_inhibitor.
mechanism	Administration of <e10> quinidine </e10> to patients on <e22> nonsteroidal_anti-inflammatory_drugs </e22> or diuretics has been reported to reduce renal excretion of quinidine by approximately 50%.
mechanism	In clinical trials, the combination of <e10> ketoconazole </e10> and <e20> valdecoxib </e20> has been associated with a 7-fold increase in mean AUC for oral zidovudine compared to either drug alone.
mechanism	In clinical trials, <e10> fluvoxamine </e10> markedly increased the Cmax of <e20> cisapride </e20> by about 3-fold.
mechanism	In clinical trials, <e10> ciprofloxacin </e10> and <e20> nalidixic_acid </e20> were reported to be associated with increased prothrombin times and to prolong prothrombin times in patients receiving a high-dose regimen of these agents.
mechanism	In clinical trials, <e10> cimetidine </e10> was found to have an increased plasma concentration of <e20> valdecoxib </e20> when coadministered with valdecoxib.
mechanism	In clinical trials, <e10> azithromycin </e10> decreased the clearance of cimetidine, cyclosporine, digoxin, and <e20> methotrexate </e20> by approximately 5% to 20%.
mechanism	However, patients on concomitant <e12> cephalosporins </e12> and <e22> folic_acid_antagonists </e22> were found to have a reduced plasma AUGMENTIN_X (47%) and a reduced serum AUGMENTIN_X concentration (4% of normal) when compared to patients on either cephalosporin alone or folic_acid_antagonists alone.
mechanism	However, patients on <e10> rifampin </e10> were significantly more likely to experience a <e22> rifabutin </e22> decrease than were patients not on rifampin.
mechanism	The effects of <e10> enoxacin </e10> were substantially reduced by concurrent administration of <e20> warfarin </e20> and either of the following: carbamazepine, fluvoxamine, phenytoin, phenobarbital, phenytoin plus warfarin (50 mg q12h).
mechanism	The effects of <e10> alprazolam </e10> and ketoconazole are antagonized by <e20> nefazodone </e20>.
mechanism	The effects of concomitant administration of <e11> COREG </e11> and oral <e20> furosemide </e20> were examined by a pharmacokinetic study.
mechanism	The effects of <e10> valdecoxib </e10> are exacerbated by coadministration of <e20> carbamazepine </e20>.
mechanism	The effects of <e10> rifampin </e10> on AUC of <e20> cisapride </e20> are increased by approximately 20% following dosing with rifampin # mg/day.
mechanism	The effects of concomitant administration of <e10> diltiazem </e10> and <e20> halothane </e20> were compared to halothane alone, with the following drugs: acetaminophen (1), ciprofloxacin (2), methotrexate (1), nalidixic_acid (1), phenytoin (1), rifabutin (1), bromocriptine (1), carbamazepine (1), dapsone (1), fentanyl (1), itraconazole (1), nefazodone (1), nelfinavir (1), ritonavir (1), saquinavir (1), stavudine (1).
mechanism	Co-treatment with theophylline and <e10> furosemide </e10> may decrease <e20> nifedipine </e20> absorption.
mechanism	Pre-treatment with the CYP3A4 inducer <e10> ketoconazole </e10> attenuated <e20> nelfinavir </e20> elimination by approximately 40%.
mechanism	Pre-treatment with the <e12> antihistamines </e12> ( quinidine, astemizole, amitriptyline ) may decrease the metabolism of <e20> alprazolam </e20>, and therefore increase plasma alprazolam levels.
mechanism	When ertapenem is coadministered with carbamazepine, plasma concentrations of <e10> ertapenem </e10> are decreased and the <e20> carbamazepine </e20> elimination half-life is shortened.
mechanism	When ertapenem is coadministered with <e10> ertapenem </e10>, concentrations of <e20> carbamazepine </e20> are decreased by approximately 30% to 50%, and those of astemizole are decreased by approximately 30% to 50%.
mechanism	Based on total hepatic clearance data for <e10> ketoconazole </e10>, the clearance of <e20> digoxin </e20> may be reduced by approximately 50%.
mechanism	Concomitant administration of <e10> phenytoin </e10> with <e20> ketoconazole </e20> or itraconazole reduced the rate of plasma elimination by 50%.
mechanism	Concomitant administration of <e10> astemizole </e10> and <e20> lithium </e20> (400 mg), used in combination for two weeks, decreased the serum lithium level by 7%, but not by 40%.
mechanism	Concomitant administration of <e10> cimetidine </e10> with <e20> dapsone </e20> in pediatric patients with chronic renal failure resulted in a higher serum cimetidine level and greater mean serum creatinine values than would have been expected if the drugs were administered alone.
mechanism	<e10> Erythromycin </e10> may decrease the bioavailability of oral <e20> loperamide </e20> by inhibiting hepatic enzymes involved in acetaminophen metabolism.
mechanism	<e10> Erythromycin </e10> may increase the bioavailability of some drugs that are substrates for cytochrome P450 3A4 ( CYP3A4 ) such as <e20> phenytoin </e20>, clarithromycin, and clarithromycin/ dalfopristin.
mechanism	<e10> Erythromycin </e10> reduced <e20> rifabutin </e20> -induced hypoglycemia by 63% and increased the oral absorption of rifabutin by about 50%.
mechanism	<e10> Erythromycin </e10> also increased the frequency of <e20> fluconazole </e20> reactions.
mechanism	<e10> Erythromycin </e10> increased the clearance of <e20> ketoconazole </e20> by about 25%.
mechanism	<e10> Erythromycin </e10>, ciprofloxacin, ciprofloxacin_caffeine, enoxacin, furosemide, clarithromycin, fluconazole, itraconazole, nefazodone, nelfinavir, ritonavir, <e20> saquinavir </e20>, telithromycin, troleandomycin, and astemizole significantly decreased AUC(0-12) of dasatinib by approximately 48%.
mechanism	<e10> Erythromycin </e10> may decrease the clearance of nonsteroidal_anti-inflammatory_drugs ( <e20> H2-antagonists </e20> ).
mechanism	<e10> Erythromycin </e10> treatment decreased the clearance of <e20> cimetidine </e20> by 48%.
mechanism	<e10> Erythromycin </e10>, clarithromycin, and sulfasalazine significantly increased the absorption of <e20> rifampin </e20>.
mechanism	<e10> Erythromycin </e10> decreased the clearance of <e20> methotrexate </e20> by -14% on average and slightly increased the Cmax of methotrexate by 30%.
mechanism	<e10> Erythromycin </e10>, levothyroxine, or lithium may increase <e20> terfenadine </e20> concentrations.
mechanism	There have been reports of concomitant administration of <e10> digoxin </e10> and <e20> lithium </e20>.
mechanism	Cimetidine-In vitro data indicate a possible reduction of the half-life of <e10> cimetidine </e10> by at least #% with concomitant use of <e20> warfarin </e20>, oral contraceptives, or nonsteroidal_anti-inflammatory_drugs.
mechanism	Cimetidine-In vitro study has shown that <e10> cimetidine </e10> blocks <e20> ketoconazole </e20> -mediated hydroxylation of cyclosporine A (sodium) in the presence of a half-maximal inhibitory concentration (IC50) of 0.12 microM.
mechanism	Although trough citalopram concentrations were decreased at # and # mg <e10> citalopram </e10> /kg/day, <e20> ketoconazole </e20> (10 mg q12h) decreased the citalopram clearance (47% decrease) by #% at # mg/kg/day.
mechanism	Although trough citalopram plasma levels are reduced in patients taking <e11> TARCEVA </e11>, <e20> Citalopram </e20> plasma levels may increase when the # mg dose of TARCEVA is increased.
mechanism	Ketoconazole-Combined <e10> Sulfapyridine </e10> and <e20> ketoconazole </e20> reduced the effect of estrogens on estradiol and androgen levels in a dose-dependent fashion.
mechanism	Ketoconazole-Combined use with <e10> ketoconazole </e10> may increase the clearance of <e20> isoniazid </e20>.
mechanism	Ketoconazole-Combined use of <e10> ketoconazole </e10> with <e20> aripiprazole </e20> increases plasma aripiprazole concentrations and may result in increased AUC values.
mechanism	However, there are reports of concomitant administration of <e10> phenytoin </e10> with <e20> lithium </e20> and other long-acting lithium salts.
mechanism	However, there are reports of interactions of <e10> caffeine </e10> with <e20> valdecoxib </e20>.
mechanism	Metoprolol-Administration of <e10> metoprolol </e10> # mg (4 times a day) for # days reduced the <e20> diazepam </e20> -induced vasoconstriction by 43% compared to diazepam alone (P = 0.007).
mechanism	Metoprolol-Administration of <e10> metoprolol </e10> (20 mg BID) with a single dose of <e20> quinidine </e20> (20 mg BID) increases the AUC of quinidine by #%.
mechanism	Metoprolol-Administration of <e11> Gleevec </e11> significantly increased the plasma concentrations of <e20> metoprolol </e20> by approximately 5-fold.
mechanism	<e11> BREVIBLOC </e11> increased the half-life of <e20> loperamide </e20> and its metabolites by as much as # times.
mechanism	<e11> BREVIBLOC </e11> was converted to <e20> ketoconazole </e20> at a rate of 17%, or a rate of 10% (3.1 mg/kg/day) if the dose of ketoconazole was increased by approximately 1-fold.
mechanism	<e11> BREVIBLOC </e11> ( a <e20> bromocriptine_mesylate </e20> ) and theophylline ( a blood_thinner ) may enhance the absorption of other trivalent antiepileptic_drugs ( a, b, d, e, g, h, k, m, n ).
mechanism	When <e10> digoxin </e10> was added to the combination therapy, there was a strong reduction in the rate of <e20> rifampin </e20> exposure.
mechanism	When <e10> digoxin </e10> was given at a dose of # mg/day, the levels of <e20> digoxin </e20> were increased by #%.
mechanism	When <e10> digoxin </e10> is administered concomitantly with <e20> enoxacin </e20>, its absorption is blocked and enoxacin toxicity is enhanced.
mechanism	When intravenous morphine and <e10> ketamine </e10> were administered concomitantly, the extent to which <e20> ketamine </e20> would decrease morphine plasma levels was reduced.
mechanism	When intravenous morphine and <e10> carbamazepine </e10> were administered simultaneously, <e20> morphine </e20> and carbamazepine levels were reduced by approximately 50% in the patients on high doses of both drugs.
mechanism	When intravenous morphine was administered to patients on a regimen that required <e11> INAPSINE </e11>, <e20> morphine </e20> decreased its pharmacokinetic profile by increasing its renal clearance and raising its serum levels.
mechanism	Coadministration of <e10> ketoconazole </e10> # mg and <e20> warfarin </e20> # mg reduced the mean plasma half-life of warfarin by 4.6 hours and increased the mean plasma clearance by 5.5%.
mechanism	Coadministration of <e10> dexamethasone </e10> or <e20> anagrelide </e20> significantly decreased the steady-state plasma concentrations of both compounds.
mechanism	Coadministration of <e10> norethindrone </e10> with other antidepressants (e,g,, nortriptyline, imipramine, desipramine, paroxetine, sertraline, <e20> fluoxetine </e20> ) can increase the clearance of norethindrone and result in decreased serum concentrations of norethindrone.
mechanism	Therefore, <e10> esomeprazole </e10> may reduce the plasma concentrations of <e20> indinavir </e20>.
mechanism	Therefore, <e10> esomeprazole </e10> should be taken at least # hours prior to <e20> cyclosporine </e20>.
mechanism	Therefore, <e10> esomeprazole </e10> and <e20> ketoconazole </e20> were found to be antagonistic in this study.
mechanism	Therefore, <e10> esomeprazole </e10> may decrease the bioavailability of <e20> ketoconazole </e20>.
mechanism	Therefore, <e10> esomeprazole </e10> may have the potential to enhance the absorption of <e20> carbamazepine </e20>, cimetidine, and other cationic_antibiotics.
mechanism	Therefore, <e10> esomeprazole </e10> may increase the toxicity of <e20> digoxin </e20>, in vitro.
mechanism	Therefore, <e10> esomeprazole </e10> may decrease the blood levels of <e20> fluvoxamine </e20>, and this could reduce the effectiveness of fluvoxamine.
mechanism	Therefore, <e10> esomeprazole </e10> and <e20> atorvastatin </e20> cause approximately two- to threefold increase in Cmax and AUC of atorvastatin.
mechanism	While no in vitro studies have been conducted with either dexamethasone or <e10> methotrexate </e10> alone, it is likely that <e20> anagrelide </e20> will either inhibit or enhance the metabolism of either dexamethasone or methotrexate.
mechanism	While no in vitro studies have been performed to assess the effect of oral <e10> cimetidine </e10> on the pharmacokinetics of <e20> cisapride </e20>, it is likely that cisapride will be reduced in a significant number of patients taking cimetidine.
mechanism	While no in vivo effect of <e10> valdecoxib </e10> has been reported, <e20> nifedipine </e20> has been shown to inhibit metabolism of valdecoxib.
mechanism	While no in vitro studies have been done to test the mechanism of action of <e11> PEGANONE </e11> in vitro, it has been reported to decrease the plasma levels of <e20> acetaminophen </e20> and other drugs that are highly protein bound, and increase the plasma levels of drugs that are not protein bound.
mechanism	While no in vitro data have demonstrated a reduction in antihypertensive effect of <e11> INSPRA </e11> or <e20> amlodipine </e20> in patients receiving concomitant low-dose sotalol and # mg/day of carbamazepine, the magnitude of reduction in antihypertensive effect may be clinically significant.
mechanism	While no in vitro interaction with probenecid has been reported, concurrent administration of <e10> probenecid </e10> with <e20> ketoconazole </e20> resulted in a reduction in fluconazole AUC by 29%.
mechanism	While no in vitro studies have been performed with <e10> levothyroxine </e10> alone, the potential exists for a prolongation of the prothrombin time when used concomitantly with <e20> quinine </e20>.
mechanism	While no in vitro studies have been performed with <e10> gentamicin </e10> alone, the possibility exists that the effect of gentamicin may be potentiated by <e20> carbamazepine </e20>, especially in the elderly.
mechanism	While no in vivo studies have been performed, there is a possible drug interaction for <e10> atorvastatin </e10> when coadministered with <e20> furosemide </e20>.
mechanism	While no in vitro interaction between <e10> gentamicin </e10> and <e20> nalidixic_acid </e20> has been observed, increased absorption of gentamicin and toxicity have been reported in patients receiving low-dose dosing of gentamicin.
mechanism	The following are not considered to be likely to be potent inhibitors of the metabolism of <e11> VIRACEPT </e11> in humans: <e20> indinavir </e20>, diltiazem, ritonavir, saquinavir, indinavir, itraconazole, itraconazole (medium), itraconazole (high).
mechanism	The following are not affected by <e10> alosetron </e10> : the metabolism of ketoconazole (a steroidal_antagonist ) or <e20> cisapride </e20>, a tricyclic_antidepressant, or several of the beta-adrenergic_blocking_agents.
mechanism	The following are recommended: <e10> Sulfacetamide </e10> should be used with caution when the drugs above are coadministered because the toxicity of <e20> cisapride </e20> is enhanced by the use of this potent inhibitor.
mechanism	The following are possible pharmacokinetic/pharmacodynamic interactions of <e10> nevirapine </e10> with antacids or anticonvulsants, antifungals, antineoplastic_agents, anticonvulsants, beta-adrenergic_blocking_agents, clofibrate, carbamazepine, cyclosporine, dapsone, fentanyl, pimozide, <e20> quinidine </e20>, theophylline, valproate, zidovudine, and astemizole.
mechanism	The following are a stepwise procedure for the synthesis of <e12> quinolones </e12> with an oral route of administration: (1) Synthesis of isoniazid with a diflunisal ( <e20> nifedipine </e20> ): 50% methanol; (2) Synthesis of ciprofloxacin with a diflunisal ( nifedipine ): 20% methanol; (3) Synthesis of ciprofloxacin with an Aprepitant ( indomethacin ): 50% methanol; (4) Synthesis of quinolones with an Aprepitant ( indomethacin ): 50% methanol.
mechanism	The following are the possible pharmacokinetic interactions of <e10> almotriptan </e10> when coadministered with oral <e20> ketoconazole </e20> : Ketoconazole increases the clearance of almotriptan and may increase the rate of elimination.
mechanism	The following are reported: Diclofenac : <e10> Diclofenac </e10> increased the clearance of <e20> levothyroxine </e20> by 23%, and decreased its serum concentration by 28%.
mechanism	The following are examples of drugs which may decrease the plasma concentrations of <e10> erythromycin </e10> by severalfold: barbiturates, corticosteroids, corticotropin, corticotropin_intravenous (IV), corticotropin_subcutaneous (SC), corticotropin_intravenous (IV), cyclosporine, dapsone, digoxin, fentanyl, fentanyl transdermal system (TDS), fentanyl nasal spray, oral contraceptives, <e20> quinidine </e20>, sildenafil, warfarin, triazolam, troleandomycin, up-titre sildenafil
mechanism	The following are the dose adjustments of <e10> ketoconazole </e10> for concurrent <e20> cisplatin </e20> therapy: 3 mg # days before cisplatin and # days after cisplatin on day #, with # mg # days before and # days after cisplatin on day #.
mechanism	The following are some examples of drugs whose metabolism is inhibited by <e10> erythromycin </e10> : acetaminophen ( Tylenol ), fluconazole ( <e20> fluvoxamine </e20> ), anakinra ( Anafranil ), atorvastatin ( Lipitor ), clofibrate ( Atromid-S ), digoxin ( Solganal ), doxycycline ( Oxcarbazepine ), HIV drugs classified as protease_inhibitors ( ritonavir, indinavir, saquinavir, didanosine ), nelfinavir ( Ritonavir ), ritonavir ( nelfinavir ), saquinavir ( ritonavir ), and voriconazole.
mechanism	The following are examples of drugs that have been shown to reduce the bioavailability of <e11> PRINIVIL </e11> when given with <e20> phenytoin </e20> : Cimetidine, zidovudine, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin.
mechanism	The following are commonly used drugs in clinical studies with <e11> SPRYCEL </e11> : Amiodarone, clarithromycin, cimetidine, colestipol, diltiazem, ergot_derivatives, estrogens, fluoxetine, paroxetine, quinine, theophylline, thiazide_diuretics, vitamin_C, and <e20> vitamin_D </e20>.
mechanism	The following are mechanisms that may reduce the absorption of <e11> VIDEX </e11> : the hypoglycemic action of the sulfonylurea drugs such as <e20> sulfasalazine </e20> may be potentiated by other drugs such as macrolide_antibiotics, tetracycline, procainamide, aluminum salts, aluminum sulfate, digoxin, corticosteroids, antacids, bismuth_subsalicylate, calcium supplements, carbamazepine, corticosteroids, corticotropin, corticotropin_intracerebroventricular, cyclosporine, diltiazem, furosemide, ibuprofen, ketoconazole, ketoconazole_compounds, magnesium salts, magnesium sulfate, niacinamide, nicotinamide, nicotinamide_derivatives, propoxyphene, salicylates, salic
mechanism	The following are possible drug interactions that may occur when <e11> PRINIVIL </e11> is coadministered with drugs that affect hepatic metabolism (eg, barbiturates, phenytoin, <e20> carbamazepine </e20>, thiazide_diuretics ): The metabolism of PRINIVIL may result in elevated serum concentrations of the drug and may increase the risk of gastrointestinal toxicity and of serious infections.
mechanism	Milk, milk products, and other food products that contain <e10> phenytoin </e10> or other oral <e22> anticoagulant_agents </e22>, or that may contain anticoagulants, may prolong the prothrombin time and increase the risk of bleeding.
mechanism	Drugs That Induce Hepatotoxicity: Concomitant administration of <e10> allopurinol </e10> and other drugs that induce hepatic enzyme induction, e,g,, nonsteroidal_anti-inflammatory_drugs ( <e20> indomethacin </e20>, dapsone, indomethacin_sodium, lisinopril ), cimetidine, phenytoin, and other beta-adrenergic_blocking_agents, can potentiate the hepatic toxicity of nonsteroidal_anti-inflammatory_drugs.
mechanism	Drugs That Induce CYP3A4: Benzodiazepines, alprazolam, and triazolam : In vitro metabolism studies have shown that <e10> clozapine </e10> may increase the metabolism of the following: carbamazepine, <e20> diazepam </e20>, alprazolam, and triazolam.
mechanism	Drugs That Induce CYP3A4 activity: Acetazolamide : In vitro and in vivo data suggest that <e10> isoniazid </e10>, <e20> phenytoin </e20>, alfentanil, phenobarbital, and phenytoin may enhance the metabolism of drugs that inhibit CYP3A4 activity (e,g,, ketoconazole, itraconazole, nefazodone, phenytoin, ritonavir, clarithromycin ).
mechanism	<e10> Lithium </e10>, <e20> lithium_sulfate </e20>, lithium_sulfate and magnesium_sulfate are all potent inhibitors of lithium bioavailability, with a significant interaction between lithium and lithium_sulfate, resulting in a decrease in lithium bioavailability.
mechanism	<e10> Lithium </e10> or <e20> lithium_sodium </e20> may increase the serum lithium level.
mechanism	A number of reports have shown that <e10> digoxin </e10> can decrease the clearance of <e20> insulin </e20>.
mechanism	A number of <e12> benzodiazepines </e12>, including alprazolam, have been reported to inhibit the metabolism of <e20> alprazolam </e20>.
mechanism	A number of agents that are capable of inducing a concentration-dependent decrease in CYP3A4 activity have been reported to decrease <e10> ketoconazole </e10> clearance and to increase serum <e20> digoxin </e20> levels.
mechanism	The results of a pharmacokinetic study of <e10> clarithromycin </e10> were analyzed to determine if significant alterations of the CYP3A4 activity were induced by coadministration of <e20> clarithromycin </e20> with other anticonvulsants, drugs known to have hepatotoxicity ( phenobarbital, phenytoin, alfentanil ), carbamazepine, phenytoin, and lithium.
mechanism	The results of in vitro studies of <e10> caffeine </e10> indicate that the metabolism of caffeine by CYP3A4 is decreased in the presence of <e20> cyclosporine </e20>.
mechanism	<e11> Trecator </e11> increases plasma levels of <e20> digoxin </e20>.
mechanism	<e11> Trecator </e11> has been shown to decrease the clearance of <e20> digoxin </e20>, and is therefore not recommended for use in patients receiving high levels of digoxin.
mechanism	<e11> Trecator </e11> has been shown to prolong the plasma half-life of warfarin, but has not been shown to affect the pharmacokinetics of other <e22> coumarin_anticoagulants </e22>.
mechanism	<e10> Ethopropazine </e10> ( 50 mg bid) decreased the metabolism of <e20> lofexidine </e20> to 7% of the initial amount (E) and decreased the peak plasma levels (Cmax, # mg) by 15% (9% increase in AUC) and 20% (16% decrease in AUC) at # and # hours after dosing.
mechanism	<e10> Ethopropazine </e10> and other antipsychotics (eg, haloperidol, risperidone, thioridazine, risperidol_hydrochloride, clozapine, haloperidol, risperidone_sodium, <e20> haloperidol_hydrochloride </e20>, haloperidol_dimethyl, and phenytoin ) have been reported to increase plasma levels of the dopamine_HCl metabolite (-)-epidioxy-dopamine (Cmax, AUC, and Vmax).
mechanism	<e10> Ethopropazine </e10> decreases the metabolism of <e20> phenytoin </e20>, resulting in a higher rate of toxicity.
mechanism	Since Zarontin ( a potent inhibitor of CYP3A4 ) inhibited the metabolism of <e10> cimetidine </e10>, the potential exists for the coadministration of cimetidine and <e20> zerontan </e20>, which may increase exposure to cimetidine.
mechanism	Since Zarontin ( <e10> cisapride </e10> ) and other anticholinergics have been reported to interfere with the metabolism of <e20> furosemide </e20>, the anticholinergic effects of furosemide can be exacerbated by the concomitant administration of these agents.
mechanism	Since Zarontin ( atorvastatin ) increases the metabolism of <e10> cimetidine </e10>, the dose of cimetidine to achieve an undetectable Cmax will be higher with <e20> atorvastatin </e20> than with placebo.
mechanism	Since Zarontin ( C,N,D,E,_45 ) and <e10> enoxacin </e10> may have additive effect with each other in the absorption of <e20> ketoconazole </e20>, an oral intake of ketoconazole or enoxacin # mg/day was recommended.
mechanism	Since Zarontin ( <e10> furosemide </e10> ) and <e20> metoclopramide </e20> are both potent inhibitors of the CYP3A4 enzyme, and there is a significant interindividual variability in the extent to which furosemide can inhibit the metabolism of furosemide, it is possible that both drugs may inhibit the metabolism of the drug studied.
mechanism	Presumably, <e10> phenytoin </e10> would have the potential to interact with <e20> phenobarbital </e20> by increasing plasma concentrations.
mechanism	Presumably, <e10> phenytoin </e10> also modifies the pharmacokinetics of <e20> atorvastatin </e20>, leading to increased plasma concentrations of the latter.
mechanism	Presumably, <e10> phenytoin </e10> inhibited the hepatic metabolism of <e20> ethinyl_estradiol </e20> and decreased the rate of clearance of estradiol in rats.
mechanism	Presumably, <e10> phenytoin </e10> reduces the clearance of <e20> cefditoren_pivoxil </e20>, which may increase plasma levels of cefditoren_pivoxil.
mechanism	Presumably, <e10> phenytoin </e10> metabolism was also impaired by <e20> cisplatin </e20>.
mechanism	Conversely, the <e12> benzodiazepines </e12> ( alprazolam, diazepam, and alprazolam_hydrochloride ) produce an increase in plasma concentrations of <e20> digoxin </e20>, which may be potentially pharmacologic in the presence of clinically significant digoxin levels.
mechanism	Conversely, the <e12> salicylates </e12>, especially the phenylbutazone, inhibit the metabolism of some <e22> cephalosporins </e22>, including cephalosporin, resulting in increased levels of both aandrogens and their metabolites in the circulation.
mechanism	<e10> Acetaminophen </e10>, salicylates, and derivatives may increase plasma <e20> phenytoin </e20> concentrations by approximately 20%.
mechanism	<e10> Acetaminophen </e10> may interact with <e20> chlorpropamide </e20>, which is also an inhibitor of prostaglandin synthesis.
mechanism	<e10> Acetaminophen </e10> metabolism was increased by <e20> atorvastatin </e20>.
mechanism	<e10> Aminoglutethimide </e10> and <e20> vitamin_D </e20> are both potent inhibitors of vitamin_D metabolism and may diminish the serum levels of vitamin_D.
mechanism	<e10> Aminoglutethimide </e10> increases the renal clearance of <e20> fluvoxamine </e20>.
mechanism	<e10> Aminoglutethimide </e10> # mg increased <e20> colestipol_hydrochloride </e20> AUC and Cmax by 21% and 21%, respectively, and decreased the AUC of all studied drug metabolites by 29% to 46%.
mechanism	<e12> Anticonvulsants </e12> may increase the clearance of <e20> carbamazepine </e20> by inhibiting CYP3A4.
mechanism	<e12> Anticonvulsants </e12> may reduce the clearance of <e20> ketoconazole </e20>, resulting in increased serum levels of ketoconazole and thus increased drug clearance.
mechanism	<e12> Anticonvulsants </e12> ( carbamazepine, felbamate, phenobarbital, phenytoin, primidone, thiazide_diuretics, <e20> vitamin_D </e20> ) may increase the metabolism of concomitant drugs that are C-terminal hydroxylated or esterified with C-terminal hydroxylated or esterified drugs, and this can result in increased serum concentrations of these drugs.
mechanism	<e12> Anticonvulsants </e12>, phenytoin, phenobarbital, phenytoin_hydrochloride, carbamazepine, carbamazepine_HCl, felbamate, felbamate_HCl, phenobarbital, phenytoin, primidone, primidone_HCl, triazolam, theophylline, and <e20> valproate </e20> reduce the absorption of coumarin, clarithromycin, ciprofloxacin, fluconazole, phenytoin, voriconazole, and warfarin.
mechanism	<e12> Anticonvulsants </e12>, phenytoin, phenobarbital, carbamazepine, alprazolam, <e20> phenytoin </e20>, bromocriptine, phenytoin_HCl, bromocriptine_HCl, cimetidine, cimetidine_HCl, phenytoin_HCl, triazolam, theophylline, and warfarin may interfere with the metabolism of bromocriptine_HCl, causing increased levels of bromocriptine_HCl in the blood.
mechanism	<e12> Anticonvulsants </e12> ( phenobarbital, phenytoin, carbamazepine, felbamate ) may decrease the plasma levels of <e20> sildenafil </e20>.
mechanism	Anticonvulsants ( <e10> phenytoin </e10>, carbamazepine, felbamate, phenobarbital, topiramate, alfentanil, disopyramide ): Concomitant administration of <e20> propranolol </e20> and an anticonvulsant ( alfentanil, phenobarbital, phenytoin, disopyramide ) is associated with an increased risk of serious infections.
mechanism	Anticonvulsants ( <e10> phenobarbital </e10>, carbamazepine, phenytoin, valproic_acid ): Concomitant administration of <e20> lithium </e20> has been shown to increase lithium clearance by about two-fold.
mechanism	Anticonvulsants ( <e10> carbamazepine </e10>, felbamate, phenobarbital, phenytoin, topiramate, triazolam ): Increase the plasma concentration of <e20> phenytoin </e20> by #% and increase the effect of phenobarbital and phenytoin.
mechanism	Anticonvulsants ( <e10> carbamazepine </e10>, felbamate, phenobarbital, phenytoin, primidone, triazolam, theophylline ): may increase the clearance of <e20> digoxin </e20>.
mechanism	Anticonvulsants ( carbamazepine, felbamate, phenobarbital, phenytoin ): When coadministered with <e10> diazepam </e10>, <e20> carbamazepine </e20> increased by #%, and felbamate increased by #% plasma concentrations.
mechanism	Anticonvulsants ( carbamazepine, phenobarbital, phenytoin, valproate, <e10> phenytoin </e10>, terfenadine ): Co-administration may result in significant increases in <e20> carbamazepine </e20> and phenytoin concentrations and a decrease in valproate and terfenadine concentrations.
mechanism	Anticonvulsants ( carbamazepine, felbamate, phenobarbital, phenytoin, <e10> zidovudine </e10> ): Concomitant administration with <e20> indinavir </e20> may result in increased plasma concentrations of indinavir.
mechanism	Anticonvulsants ( carbamazepine, phenobarbital, phenytoin, phenytoin_succinate, <e10> alfentanil </e10>, phenytoin, cisapride ): Concomitant administration of <e20> ketoconazole </e20> decreased the clearance of the following anticonvulsants: carbamazepine, phenobarbital, phenytoin, cisapride, phenytoin_succinate, alfentanil, phenytoin, phenobarbital, valproate.
mechanism	Anticonvulsants ( carbamazepine, felbamate, phenobarbital, phenytoin, <e10> alfentanil </e10> ) may decrease <e20> leflunomide </e20> plasma concentrations and increase the half-life.
mechanism	Anticonvulsants ( carbamazepine, felbamate, phenobarbital, <e10> phenytoin </e10>, alfentanil ) increase the plasma concentrations of <e20> cimetidine </e20>.
mechanism	Anticonvulsants ( carbamazepine, felbamate, phenobarbital, phenytoin ): <e12> Anticonvulsants </e12>, especially carbamazepine, may increase the clearance of <e20> digoxin </e20>.
mechanism	Anticonvulsants ( carbamazepine, <e10> felbamate </e10>, phenobarbital, phenytoin, topiramate ): May increase serum <e20> phenytoin </e20> levels.
mechanism	Anticonvulsants ( carbamazepine, phenobarbital, phenytoin, triazolam ) inhibit <e11> PROLEUKIN </e11> metabolism by deamination of the N-terminus of the protein, which is a reaction catalyzed by cytochrome P450 3A4 and CYP3A4 inhibitors such as <e20> phenytoin </e20>.
mechanism	Anticonvulsants ( carbamazepine, phenobarbital, phenytoin, phenytoin_hydrochloride, <e10> topiramate </e10>, zidovudine, disopyramide ): In vitro studies indicate that the <e20> colestipol_hydrochloride </e20>, like other hydroxamate anticonvulsants, may decrease the clearance of certain anticonvulsants.
mechanism	Anticonvulsants ( carbamazepine, <e10> phenobarbital </e10>, phenytoin, primidone, theophylline ): Concomitant administration of <e20> colestipol_HCl </e20> may reduce the clearance of these agents and increase serum concentrations.
mechanism	Anticonvulsants ( carbamazepine, phenobarbital, phenytoin, primidone, triazolam, <e10> valproate </e10> ): The concomitant use of <e20> ketoconazole </e20> with anticonvulsants (carbamazepine, phenobarbital, phenytoin, primidone, triazolam, valproate ) may decrease the metabolism of the anticonvulsant.
mechanism	Anticonvulsants ( carbamazepine, phenobarbital, phenytoin, <e10> felbamate </e10> ): Concomitant administration of <e20> lamivudine </e20> and an anticonvulsant ( carbamazepine, phenobarbital, phenytoin, felbamate ) may decrease the efficacy of lamivudine.
mechanism	Anticonvulsants ( carbamazepine, <e10> phenobarbital </e10>, phenytoin, valproic_acid, phenytoin_acid ): <e20> Budesonide </e20> : Potential interactions include inhibition of erythrocyte synthesis and inhibition of enzyme activity.
mechanism	Anticonvulsants ( carbamazepine, phenobarbital, <e10> phenytoin </e10>, phenytoin_succinate ) and antidepressants ( amitriptyline, desipramine, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine, <e20> trazodone </e20>, methotrexate ) have been reported to reduce the metabolism of cimetidine, resulting in increased plasma levels.
mechanism	Anticonvulsants ( carbamazepine, phenobarbital, phenytoin, <e10> bromocriptine </e10> ): Increase in clearance of <e20> zidovudine </e20>, lead to a transient increase in the steady-state concentration of zidovudine.
mechanism	Anticonvulsants ( carbamazepine, phenobarbital, phenytoin, <e10> alfentanil </e10> ): Co-administration of <e20> alfentanil </e20> with anticonvulsants may increase plasma concentrations of the parent drug, resulting in an increase in efficacy.
mechanism	Anticonvulsants ( carbamazepine, phenobarbital, phenytoin, <e10> valproate </e10>, phenytoin and terfenadine ) may reduce the metabolism of <e20> ketoconazole </e20>.
mechanism	Anticonvulsants ( carbamazepine, felbamate, phenobarbital, phenytoin, phenytoin_succinate, primidone, <e10> phenytoin </e10>, tacrolimus, cisapride ): Increased <e20> phenobarbital </e20> clearance and the potential for a reduction in the duration of action of phenobarbital, phenytoin, phenytoin_succinate, primidone, and tacrolimus, and the concomitant presence of very low serum levels of phenobarbital.
mechanism	Anticonvulsants ( carbamazepine, phenobarbital, phenytoin, felbamate, <e10> phenytoin </e10>, or felbamate with <e20> phenytoin </e20> ): Co-administration of # mg of carbamazepine, # mg of phenobarbital, or phenytoin with an anticonvulsant ( # mg of carbamazepine, # mg of phenobarbital, or phenytoin ) may reduce the maximum plasma concentration of the anticonvulsant by approximately 50% and may increase the AUC of the anticonvulsant by approximately 20%.
mechanism	Ascorbic_acid : Doses of <e11> aspirin </e11> taken in combination with <e20> lithium </e20> were increased, and lithium concentrations were decreased.
mechanism	Ascorbic_acid : Doses of <e11> LEXAPRO </e11> # mg administered concomitantly with a single dose of <e20> ascorbic_acid </e20> # mg, resulted in an increase in the plasma concentration of ascorbic_acid.
mechanism	Atorvastatin : <e10> Atorvastatin </e10> increases the absorption of <e20> warfarin </e20>, phenytoin, and cyclosporine.
mechanism	Atorvastatin : <e10> Atorvastatin </e10> did not increase the plasma concentrations of <e20> digoxin </e20> and did not alter the clearance of digoxin from the liver.
mechanism	Atorvastatin : <e10> Carbamazepine </e10>, but not <e20> atorvastatin </e20>, increased the binding of atorvastatin to the human serum proteome.
mechanism	Atorvastatin : <e10> Atorvastatin </e10> may decrease the absorption of <e20> probenecid </e20> and fluvastatin.
mechanism	Atorvastatin : <e10> Atorvastatin </e10> increased the plasma levels of <e20> isoniazid </e20>.
mechanism	Benzodiazepines : Combination <e10> diazepam </e10> may decrease blood levels of <e20> phenobarbital </e20>, phenytoin, and cisapride.
mechanism	Benzodiazepines : Combination <e10> phenytoin </e10> and <e20> diazepam </e20> are potent inhibitors of hepatic metabolism of benzodiazepines, with an elimination half-life of # min.
mechanism	Benzodiazepines : Combination <e10> Flupenthixol </e10> use is associated with a reduction in the clearance of <e20> alprazolam </e20> and a concurrent increase in clearance of alprazolam, both of which may result in increased systemic exposure of alprazolam.
mechanism	Benzodiazepines : Combination <e10> cimetidine </e10> treatment with benzodiazepines ( alprazolam, <e20> alprazolam_hydrochloride </e20>, alprazolam ) has been reported to increase blood concentrations of theophylline (the primary metabolite of cimetidine ) by about 50% and may therefore increase the pharmacologic effect of cimetidine.
mechanism	Benzodiazepines : Combination <e10> alprazolam </e10> and other benzodiazepines may prolong the QT interval and may decrease serum <e20> cyclosporine </e20> concentrations.
mechanism	Benzodiazepines : Combination <e12> benzodiazepines </e12>, such as alprazolam, may increase the clearance of <e20> cimetidine </e20>.
mechanism	Benzodiazepines : Combination <e10> ethanol </e10> with <e20> alprazolam </e20> resulted in a 60% increase in alprazolam clearance and an 8% increase in AUC for the duration of the study (mean # weeks: #,056 vs #,067 mg/kg/day).
mechanism	Benzodiazepines : Combination <e10> flupenthixol </e10> and <e20> benzodiazepines </e20> may increase the bioavailability of benzodiazepines.
mechanism	Benzodiazepines : Combination <e10> alprazolam </e10> and <e20> diazepam </e20> produce additive CNS depressant effects when administered concomitantly.
mechanism	Benzodiazepines : Combination <e10> ethanol </e10> and <e20> alprazolam </e20> may increase the metabolism of alprazolam, leading to increased plasma levels.
mechanism	Benzodiazepines : Combination <e10> clozapine </e10> and benzodiazepines ( alprazolam, diazepam, triazolam ) can increase the clearance of <e20> clozapine </e20> and cause hypoglycemia.
mechanism	Benzodiazepines : Combination <e12> benzodiazepines </e12>, including alprazolam, produce a high degree of metabolism of <e20> levodopa </e20>, resulting in a mean elimination half-life of approximately # hours, and a high degree of inhibition of the CYP3A4 enzyme involved in metabolism of high dose oral # mg of alprazolam a day.
mechanism	Benzodiazepines : Combination <e12> benzodiazepines </e12> have been reported to have additive CNS depressant effects when co-administered with <e20> diazepam </e20>.
mechanism	Benzodiazepines : Combination <e12> benzodiazepines </e12> may increase the clearance of <e20> alprazolam </e20>.
mechanism	Benzodiazepines : Combination <e10> hydrocodone </e10> and <e20> alprazolam </e20> may increase blood levels of alprazolam and therefore may prolong the QT interval and prolong the QT/C interval.
mechanism	Benzodiazepines : Combination <e12> benzodiazepines </e12>, including alprazolam, produce an additive CNS depressant effect when given with <e20> fluoxetine </e20>, atypical_phenytoin, and triazolam.
mechanism	Benzodiazepines : Combination <e10> alprazolam </e10> treatment with <e20> phenobarbital </e20> for # days (4 mg in 50 mL of an antacid containing approximately # mg of alprazolam ) resulted in a decrease in alprazolam plasma concentrations of approximately #% (20% decrease).
mechanism	Benzodiazepines : Combination <e12> anticonvulsants </e12> such as phenytoin, phenobarbital, carbamazepine, alprazolam, triazolam, astemizole, ziconazole, or ergot_derivatives may interfere with <e20> alfentanil </e20> absorption and lead to excessive decrease in alfentanil clearance.
mechanism	Cyclosporine : Combination <e12> anticonvulsants </e12> may increase the clearance of <e20> cyclosporine </e20>.
mechanism	Cyclosporine : Combination <e10> cyclosporine </e10> and <e20> nelfinavir </e20> were associated with increased levels of cyclosporine and nelfinavir.
mechanism	Griseofulvin : <e10> Griseofulvin </e10> is a <e22> macrolide </e22> that has been shown to reduce the bioavailability of oral anticoagulants such as warfarin or its derivatives.
mechanism	Griseofulvin : <e10> Griseofulvin </e10> may inhibit the absorption of <e20> cisplatin </e20>.
mechanism	Griseofulvin : <e10> Griseofulvin </e10> (40 mg) significantly reduced the <e20> propafenone </e20> clearance by about 20% at # hours postadministration.
mechanism	Morphine : Combination <e10> Morphine </e10> and <e20> disulfiram </e20> increased the elimination rate of disulfiram by #%.
mechanism	Morphine : Combination <e10> morphine </e10> -sodium and <e20> cyclosporine </e20> increases plasma levels of morphine.
mechanism	Non-nucleoside_reverse_transcriptase_inhibitors ( NNRTIs ): Clinical studies have shown that the metabolism of <e11> VIDEX </e11> may be inhibited by non-nucleoside_RNAs such as <e20> valproic_acid </e20> and the anticonvulsant phenytoin.
mechanism	Non-nucleoside_reverse_transcriptase_inhibitors ( NNRTIs ): Drugs such as cyclosporine, tacrolimus, hexobarbital, phenytoin, carbamazepine, <e10> phenytoin </e10>, primidone, alfentanil, cisapride, disopyramide, dexamethasone, disulfiram, alfentanil, indinavir, ritonavir, and nelfinavir have been shown to interfere with <e20> ciprofloxacin </e20> metabolism and may result in decreased AUC and Cmax values.
mechanism	Non-nucleoside_reverse_transcriptase_inhibitors ( NNRTIs ) (e,g,, <e10> nevirapine </e10> ) have been reported to increase the pharmacokinetic clearance of ciprofloxacin and decrease the <e20> ciprofloxacin </e20> serum concentration.
mechanism	Prednisolone : <e10> Etonogestrel </e10> may increase the clearance of <e20> prednisolone </e20>.
mechanism	Prednisolone : <e10> Chlorpropamide </e10> is a sulfhydrylating agent that may inhibit the metabolism of <e20> doxycycline </e20>.
mechanism	Prednisolone : <e10> Prednisolone </e10> may decrease the clearance of <e20> atorvastatin </e20>.
mechanism	Protease_inhibitors : <e10> Cimetidine </e10> increases the AUC of <e20> warfarin </e20> by about #%.
mechanism	Protease_inhibitors : Amprenavir ( <e10> aprepitant </e10> ) and <e20> ketoconazole </e20> reduce the plasma concentrations of methotrexate ( ).
mechanism	Protease_inhibitors : Amprenavir, <e10> ritonavir </e10>, and atazanavir may decrease the clearance of <e20> crizotinib </e20>.
mechanism	Protease_inhibitors : Amprenavir and indinavir have been reported to inhibit <e10> ritonavir </e10> hydrolysis in vitro and <e20> indinavir </e20> may decrease the pharmacokinetics of the HIV protease inhibitors, nevirapine and atazanavir.
mechanism	Protease_inhibitors : Amprenavir may increase the half-life of <e10> warfarin </e10> by increasing the metabolism of <e20> warfarin </e20>.
mechanism	Protease_inhibitors : Amprenavir, <e10> ritonavir </e10>, and saquinavir may interfere with the metabolism of <e20> erythromycin </e20>, resulting in decreased plasma levels and increased serum and urine levels of erythromycin.
mechanism	Protease_inhibitors : Amprenavir and <e10> ritonavir </e10> decreased the plasma concentrations of <e20> nelfinavir </e20> and increased the plasma concentrations of ritonavir.
mechanism	Protease_inhibitors : Amprenavir, <e10> didanosine </e10>, indinavir, indinavir, saquinavir, troleandomycin, zidovudine, valganciclovir, <e20> erythromycin </e20>, clarithromycin, itraconazole, nefazodone
mechanism	<e10> Indinavir </e10> at # mg orally (in a single dose) increased AUC of <e20> indinavir </e20> by 42% and decreased AUC of indinavir by 17% in a single dose.
mechanism	<e10> Indinavir </e10> and <e20> ritonavir </e20> were found to interfere with the metabolism of ritonavir.
mechanism	<e10> Indinavir </e10> and <e20> didanosine </e20> are two potent inhibitors of HIV-1 reverse transcriptase.
mechanism	Rifampin : <e10> Isoniazid </e10> and rifabutin, and also to a high <e20> valproic_acid </e20> level (6.9%), significantly reduced the elimination of rifampin.
mechanism	Rifampin : <e10> Rifampin </e10> is a strong inhibitor of <e20> indinavir </e20> metabolism, and the effect of indinavir on rifampin is enhanced when it is administered concurrently with it.
mechanism	Rifampin : <e10> Rifampin </e10> may increase the clearance of <e20> atorvastatin </e20> and decrease the bioavailability of cetirizine and metformin.
mechanism	Rifampin : <e10> Rifampin </e10> is reported to inhibit <e20> zidovudine </e20> metabolism by converting it to a form with a higher affinity for zidovudine.
mechanism	Rifampin : <e10> Zidovudine </e10> has been reported to increase the plasma levels of <e20> rifampin </e20>.
mechanism	Rifampin : <e10> Rifampin </e10> significantly decreases the clearance of <e20> ciprofloxacin </e20>.
mechanism	Rifampin : <e10> Ribavirin </e10> reduces the renal clearance of <e20> rifampin </e20> and this may prolong the elimination half-life of rifampin.
mechanism	Salicylic_acid : Combination <e12> anticoagulants </e12>, including <e20> salicylic_acid </e20>, may increase the clearance of warfarin or its derivatives, resulting in diminished blood levels.
mechanism	Salicylic_acid : Combination of <e10> erythromycin </e10> and <e20> salicylic_acid </e20> may increase the effect of salicylate in a small percentage of patients.
mechanism	Salicylic_acid : Combination <e12> quinolones </e12> and <e20> salicylic_acid </e20> may increase serum levels of salicylic_acid.
mechanism	Selegiline : <e12> Amphetamines </e12> can increase <e20> selegiline </e20> plasma levels.
mechanism	Selegiline : <e12> Amphetamines </e12>, including amphetamines and selegiline, may increase the clearance of <e20> selegiline </e20> and thus may increase the risk of toxicity.
mechanism	Theophylline : <e10> Theophylline </e10> may decrease the bioavailability of <e20> vitamin_D </e20>.
mechanism	Theophylline : <e10> Theophylline </e10> is the major metabolite of <e20> levothyroxine </e20> and is a potential drug interaction for levothyroxine.
mechanism	Theophylline : <e10> Theophylline </e10> and <e20> cimetidine </e20> may decrease blood levels of theophylline, thus increasing the risk of nephrotoxicity.
mechanism	Tricyclic_antidepressants ( <e10> amitriptyline </e10>, nortriptyline, imipramine, desipramine, imipramine_hydrochloride ): When <e21> Levo-Dromoran </e21> was administered with these agents, the maximum tolerated dose of the agent was reduced from # mg to # mg (50% decrease).
mechanism	Tricyclic_antidepressants ( <e10> nortriptyline </e10>, amitriptyline, imipramine, desipramine, fluoxetine ): Tricyclic_antidepressants ( imipramine, desipramine, nortriptyline ) may increase plasma concentrations of <e20> phenytoin </e20>.
mechanism	Tricyclic_antidepressants ( <e10> imipramine </e10>, nortriptyline, amitriptyline, paroxetine ): <e20> Probenecid </e20> may decrease the clearance of these agents.
mechanism	Tricyclic_antidepressants ( amitriptyline, <e10> imipramine </e10>, nortriptyline ): may increase <e20> paroxetine </e20> plasma levels by prolonging the hepatic metabolism of paroxetine.
mechanism	Tricyclic_antidepressants ( amitriptyline, <e10> fluoxetine </e10>, sertraline, paroxetine ): Induce <e20> amitriptyline </e20> elimination by increasing plasma levels of amitriptyline and the other active metabolite, norepinephrine.
mechanism	Tricyclic_antidepressants ( amitriptyline, <e10> fluoxetine </e10>, sertraline, paroxetine ) may inhibit the metabolism of <e20> valdecoxib </e20>, resulting in a slower metabolism of valdecoxib and higher plasma levels of valdecoxib.
mechanism	Tricyclic_antidepressants ( amitriptyline, imipramine, <e10> nortriptyline </e10> ) may decrease the clearance of <e20> digoxin </e20> and may require increases in digoxin dosage to achieve steady state concentrations.
mechanism	Tricyclic_antidepressants ( amitriptyline, imipramine, <e10> nortriptyline </e10> ): Co-administration with <e20> phenytoin </e20> resulted in a 40% increase in the plasma concentration of phenytoin.
mechanism	Aspirin : When <e10> carbamazepine </e10> and <e20> carbamazepine_sodium </e20> are coadministered, the levels of carbamazepine in the blood may be decreased and absorption of carbamazepine may be decreased.
mechanism	Aspirin : When <e10> diltiazem </e10> and <e20> aspirin </e20> were coadministered, there was a decrease in the daily aspirin dose by approximately 50%.
mechanism	Aspirin : When co-administered with <e10> ketoconazole </e10>, a 50% decrease in the renal clearance of <e20> amprenavir </e20> was observed.
mechanism	Cyclosporine, Digoxin, Methotrexate and <e10> Amiodarone </e10> may reduce the bioavailability of <e20> ketoconazole </e20>.
mechanism	Cyclosporine, Digoxin, Methotrexate, tacrolimus, alfentanil, carbamazepine, phenytoin, <e10> cimetidine </e10>, disopyramide, lovastatin, cimetidine, lovastatin_HCl, and <e20> valproate </e20> may decrease or increase the half-life of cisplatin.
mechanism	Cyclosporine, Digoxin, Methotrexate, and <e10> Isoniazid </e10> reduce <e20> ketoconazole </e20> absorption.
mechanism	Cyclosporine, Digoxin, Methotrexate, and Sulfacetamide : Concomitant administration of <e10> tacrolimus </e10> and <e20> cyclosporine </e20> has been reported to result in elevated tacrolimus concentrations in subjects with renal disease, impaired renal function, or severe hepatic disease.
mechanism	Cyclosporine, Digoxin, Methotrexate, and Amphotericin_B are inhibited by <e11> TORADOL </e11> in a dose-dependent manner, while <e20> carbamazepine </e20> and levodopa are not.
mechanism	Cyclosporine, Digoxin, Methotrexate and <e10> Amiodarone </e10> increase the clearance of <e20> digoxin </e20>.
mechanism	Cyclosporine, Digoxin, Methotrexate, Phenytoin, Phenobarbital, Stavudine, and <e10> Phenytoin </e10> may increase the clearance of <e20> methotrexate </e20>.
mechanism	Cyclosporine, Digoxin, Methotrexate, and Other Potentiation Agents: <e12> Amphetamines </e12> may potentiate the action of <e20> cyclosporine </e20>, digoxin, and some other potentiation agents.
mechanism	Cyclosporine, Digoxin, Methotrexate and Aminoglycosides : Concomitant administration of <e10> clofibrate </e10> with the following drugs may reduce the absorption of <e20> digoxin </e20>, cyclosporine, and aminoglycosides : Acetaminophen, diazepam, fluoxetine, fluvoxamine, paroxetine, sertraline, theophylline, triazolam, theophylline_HCl
mechanism	Cyclosporine, Digoxin, Methotrexate, and Trileptal, for which <e10> digoxin </e10> is a metabolite, were significantly decreased when coadministered with <e20> Aprepitant </e20>.
mechanism	Cyclosporine, Digoxin, Methotrexate, and Amphotericin_B decrease the clearance of <e10> ketoconazole </e10> by approximately 50% (Ketoconazole plasma clearance), but the increase in <e20> ketoconazole </e20> clearance is only approximately 30%.
mechanism	Cyclosporine, Digoxin, Methotrexate, Phenytoin and <e10> Warfarin </e10> : <e20> Levo-Dromoran </e20> may inhibit the metabolism of these drugs and may increase their clearance.
mechanism	Cyclosporine, Digoxin, Methotrexate and Phenytoin : Although <e10> digoxin </e10> can decrease <e20> cyclosporine </e20> metabolism in vitro, it is not known if these drugs increase or decrease cyclosporine blood levels in vivo.
mechanism	Lithium : <e12> Amphetamines </e12> may enhance <e22> lithium </e22> toxicity.
mechanism	Lithium : <e12> Diuretics </e12> reduce the renal clearance of lithium and therefore increase the renal exposure to <e20> lithium </e20>.
mechanism	Phenylbutazone : <e10> Phenylbutazone </e10> inhibits the metabolism of <e20> vitamin_D </e20>.
mechanism	Phenylbutazone : <e10> Phenylbutazone </e10> may increase <e20> ethinyl_estradiol </e20> concentrations.
mechanism	Phenylbutazone : <e10> Phenylbutazone </e10> has been reported to enhance the absorption of digoxin, <e20> terfenadine </e20>, and warfarin.
mechanism	Short-term pharmacokinetic studies of <e10> diltiazem </e10> in healthy subjects have shown that <e20> fluvoxamine </e20> is decreased by approximately 48% when administered concurrently with # mg of diltiazem.
mechanism	Short-term pharmacokinetic studies of <e10> furosemide </e10> suggest that it may reduce blood pressure when administered with <e20> ketoconazole </e20>.
mechanism	Short-term pharmacokinetic studies in healthy volunteers (n = 20) showed that a single dose of <e10> diltiazem </e10> # mg increased AUC of <e20> verapamil </e20> by 33% and Cmax by 25%.
mechanism	Short-term pharmacokinetic studies with <e11> INDOCIN </e11> in healthy volunteers demonstrated that there was a transient increase in indocyanine green clearance of approximately 5% (5-25%) following the administration of <e20> indocyanine_green </e20> at doses of # mg/day and # mg/day.
mechanism	Short-term pharmacokinetic studies in healthy volunteers demonstrated that <e10> phenytoin </e10> decreased the plasma concentration of <e20> verapamil </e20> by approximately 40%.
mechanism	Short-term pharmacokinetic studies in healthy volunteers demonstrated a 2- to 3-fold increase in AUC for <e10> adenosine </e10> in those taking <e20> allopurinol </e20> and who were concurrently given a single dose of # mg of # mg of adenosine.
mechanism	Co-medications that induce hepatic enzyme release, such as methotrexate, <e10> rifampin </e10>, indinavir, ciprofloxacin, and carbamazepine may decrease the clearance of <e20> erythromycin </e20>.
mechanism	Co-medications that induce CYP3A4 activity, such as carbamazepine, <e10> erythromycin </e10>, and certain other non-steroidal_anti-inflammatory_drugs, potentiate <e20> ketoconazole </e20> s metabolism.
mechanism	Co-medications that induce CYP3A4 activity, such as <e10> ketoconazole </e10>, fluconazole, itraconazole, and quinine, are likely to increase the clearance of <e20> nevirapine </e20>.
mechanism	Co-medications that induce hepatic enzymes such as phenytoin, phenobarbital, carbamazepine, or <e10> rifampin </e10> may interfere with the metabolism of <e20> cisplatin </e20> and increase cisplatin levels.
mechanism	Co-medications that induce CYP3A4 activity (eg, paroxetine, fluoxetine, paroxetine_HCl, and <e10> cimetidine </e10> ) increase the exposure of <e20> zalcitabine </e20>.
mechanism	Co-medications that induce CYP3A4 activity (e,g,, <e10> ketoconazole </e10>, fluconazole, rifampin, isoniazid, phenobarbital, phenytoin, triazolam ) increase the clearance of <e20> diltiazem </e20>.
mechanism	Co-medications that induce plasma concentrations of <e10> fentanyl </e10> or desipramine, such as <e20> fluoxetine </e20>, may increase exposure of fentanyl, and may therefore increase the risk of fentanyl toxicity.
mechanism	Co-medications that induce CYP3A4 activity (e,g,, ketoconazole, itraconazole, <e10> ritonavir </e10>, indinavir, saquinavir, indinavir with clarithromycin, itraconazole, itraconazole with ritonavir, saquinavir, saquinavir with <e20> indinavir </e20>, indinavir with clarithromycin, ritonavir with itraconazole, ritonavir with indinavir ) may reduce or discontinue concomitant dosing of a progestin-only contraceptive and may necessitate increase in oral contraceptives or increase in oral anticonvulsants.
mechanism	Co-medications that induce metabolism of <e10> lovastatin </e10> may increase serum concentrations of <e20> gabapentin </e20>.
mechanism	Co-medications that induce hepatic metabolism of <e10> diltiazem </e10> include: <e20> methotrexate </e20>, rifampin, metoclopramide, carbamazepine, isoniazid, diazoxide, indinavir, saquinavir, indinavir_antibiotic, cyclosporine, triazolam, and halothane.
mechanism	Co-medications that induce hepatic enzyme levels (eg, vitamin_B12 and <e10> phenytoin </e10> ) or increase hepatic enzyme levels (eg, valdecoxib and alfentanil ) may increase plasma concentrations of <e20> fluvoxamine </e20>.
mechanism	Concurrent use with <e10> clofibrate </e10> may cause increased plasma levels of <e20> warfarin </e20>.
mechanism	Use in Conjunction With: <e10> Ketoconazole </e10> and <e20> rifampin </e20>.
mechanism	Use in Conjunction With Other Antacids <e12> Antacids </e12> may interfere with the absorption of <e20> alfentanil </e20>, causing increases in alfentanil serum concentrations.
mechanism	Use in Conjunction With <e10> Furosemide </e10> # mg daily for # days increased <e20> cisapride </e20> AUC by 5.7-fold and Cmax by 5.4-fold.
mechanism	Use in Conjunction with Other Drugs: Drug Interactions: Niacin : The potential for increases in plasma levels of <e10> niacin </e10> and other prohormones in the presence of other drugs that affect metabolism of these agents (eg, <e20> guanethidine </e20>, phenytoin, barbiturates, reserpine, tricyclic_antidepressants ) may be significant.
mechanism	Use in Conjunction with Other Potentially Effective Anticonvulsants : Concurrent use of <e11> Anafranil </e11> with phenytoin, carbamazepine, phenobarbital, phenytoin_HCl, alprazolam, triazolam, <e20> zopiclone </e20>, cisapride, disulfiram, phenytoin, alprazolam, phenytoin_HCl, disulfiram, phenobarbital, disulfiram, and tricyclic_antidepressants (with alprazolam or phenytoin in the peak plasma concentration) may cause clinically significant increases in Anafranil plasma levels.
mechanism	Use in Conjunction With Other Antidepressants: The concomitant use of <e10> fluoxetine </e10> with other antidepressants (e,g,, amitriptyline, fluoxetine, <e20> sertraline </e20>, paroxetine, citalopram ) may result in elevated serum concentrations of fluoxetine and these agents may interfere with the absorption of the drug.
mechanism	Specific Effects of <e10> Clozapine </e10> on Catecholamine Release from Serum (Inhibition) 1-Ethyl-2-piperazine : Clozapine can inhibit the release of <e20> catecholamine </e20> from serum.
mechanism	Specific Effects of Acetazolamide on the Prostaglandin E2 Synthesis and the Level of Other Prostaglandin E2 Inhibitors : <e10> Acetazolamide </e10> has been reported to decrease the metabolism of prostaglandins and decrease the serum level of <e20> warfarin </e20> and other warfarin_drugs.
mechanism	Specific Effects of <e10> Erythromycin </e10> on the Liver : Concomitant administration of <e20> enoxacin </e20> # mg once daily with ethinyl_estradiol (10 mg once daily) increased the half-life of ethinyl_estradiol from # to # hours.
mechanism	Increasing the <e10> nisoldipine </e10> plasma concentration with <e20> phenytoin </e20> resulted in an approximately 20% decrease in nisoldipine plasma levels, and nisoldipine plasma concentrations were increased approximately 10-fold when nisoldipine plasma concentrations were increased by approximately # mg/kg/day of phenytoin.
mechanism	Increasing the <e10> ketoconazole </e10> dose by # mg/day for # days may have decreased the efficacy of <e20> adenosine </e20>.
mechanism	Carbamazepine : <e11> INDOCIN </e11> may increase the hepatic clearance of carbamazepine, resulting in higher plasma levels of carbamazepine and <e20> carbamazepine </e20>.
mechanism	The <e10> carbamazepine </e10> reduced <e20> zidovudine </e20> serum concentrations, as well as zidovudine to zidovudine zile concentrations.
mechanism	The <e10> carbamazepine </e10> # mg # times a day decreased the Cmax and AUC of <e20> ketoconazole </e20> by 40%.
mechanism	The <e10> carbamazepine </e10>-<e20> fluvoxamine </e20> interactions may be potentiated by chronic high levels of carbamazepine.
mechanism	Valproate : <e11> ZYVOX </e11> decreased the clearance of <e20> valproate </e20> by 25% to 40% (mean effect, 50%).
mechanism	Increasing the <e10> phenytoin </e10> dose may decrease plasma concentrations of <e20> estradiol </e20> and estrogen and increase the clearance of progesterone.
mechanism	Increasing the <e10> dantrolene </e10> dosage to # mg/day, # mg/day, or # mg/day in a crossover study, significantly reduced <e20> atorvastatin </e20> plasma concentrations and increased AUCs by #%.
mechanism	Phenobarbital : Coadministration of <e11> ZYVOX </e11> # mg and <e20> phenobarbital </e20> # mg increased serum phenobarbital concentrations approximately #-fold.
mechanism	Phenobarbital : Coadministration of <e10> phenobarbital </e10> and <e20> clofibrate </e20> was not well tolerated, and phenobarbital may have increased serum levels of clofibrate.
mechanism	Phenobarbital : Coadministration of <e10> phenobarbital </e10> and <e20> warfarin </e20>, carbamazepine, or phenytoin significantly reduced the clearance of warfarin (by a factor of approximately 8 to 10).
mechanism	Effects of Other Antiepileptic_Drugs : <e10> Phenytoin </e10> has been reported to decrease the clearance of carbamazepine, phenobarbital, phenytoin, phenytoin-magnesium, phenytoin, phenytoin-lithium, <e20> phenytoin </e20>, triazolam, and topiramate.
mechanism	Effects of Other Antacids, Acetaminophen, and Other Drugs Taken with or After <e11> FOSCAVIR </e11>, as well as of the concomitant use of other <e22> antacids </e22>, acetaminophen, and other drugs with the potential to increase serum levels of cAMP, have not been studied.
mechanism	Effects of Other Drug Interactions: Concomitant administration of <e10> lofexidine </e10> and other tricyclic_antidepressants, phenothiazines, barbiturates, <e20> carbamazepine </e20>, halothane, barbiturates, atorvastatin, bromocriptine, clofibrate, diazepam, nicotine, phenobarbital, procainamide, risperidone, sertraline, telithromycin, theophylline, and warfarin may increase plasma concentrations of lofexidine and may therefore increase the risk of lofexidine toxicity.
mechanism	Effects of Other Drugs and Drug Interactions: Phenytoin : <e10> Phenytoin </e10> may decrease plasma <e20> carbamazepine </e20> concentrations by twofold.
mechanism	Effects of Other Antihypertensives : <e10> Chlorpropamide </e10> and enalapril have additive effects with <e20> guanfacine </e20>, as do other tricyclic_antidepressants, and halothane and amiodarone.
mechanism	Effects of Other Drugs Interactions of <e10> clindamycin </e10> may occur when other antibiotics such as ampicillin or tetracycline are used concurrently with <e20> clindamycin </e20>.
mechanism	Carbamazepine : <e10> Carbamazepine </e10> may decrease the absorption of <e20> digoxin </e20>, which is a substrate for this isoenzyme.
mechanism	Carbamazepine : <e10> Carbamazepine </e10> may reduce the clearance of <e20> diazoxide </e20>.
mechanism	Carbamazepine : <e10> Carbamazepine </e10> was found to decrease the metabolism of <e20> estrogens </e20> and its metabolites in the liver, resulting in increased estrogenic effects.
mechanism	Carbamazepine : Carbamazepine was associated with a significant increase in the clearance of <e10> carbamazepine </e10> (47%) and <e20> buspirone </e20> (20%).
mechanism	Phenobarbital : It has been reported that the co-administration of <e10> phenobarbital </e10> with <e20> cimetidine </e20> can result in a decrease in cimetidine plasma levels.
mechanism	Phenobarbital : It has been reported that <e10> phenobarbital </e10> may increase the clearance of <e20> ketoconazole </e20>.
mechanism	<e10> Felbamate </e10> treatment increased the serum level of diltiazem (by 27% on average) and had no effect on <e20> lisinopril </e20>.
mechanism	<e10> Felbamate </e10> significantly inhibited the <e20> digoxin </e20> -induced renal toxicity, with a 50% reduction in the plasma concentrations of digoxin.
mechanism	Anticonvulsants : In vitro data indicate that <e11> SULAR </e11> may increase the metabolism of phenytoin, carbamazepine, and phenobarbital and decrease the metabolism of <e20> cyclosporine </e20>.
mechanism	Anticonvulsants : In vitro studies have shown that the <e12> anticonvulsants </e12> such as phenobarbital, phenytoin, carbamazepine, and phenytoin inhibit the metabolism of <e20> gefitinib </e20> by several major metabolism enzymes, resulting in reduced concentrations of gefitinib and its active metabolite, cimetidine.
mechanism	Anticonvulsants : In vitro studies in rat brain, liver, and kidney suggest that <e10> alprazolam </e10> has the potential for interaction with <e20> atazanavir </e20> and indinavir, with an inhibition of rifampin absorption of approximately 70%.
mechanism	Anticonvulsants : Ingestion of <e10> ketoconazole </e10> may decrease the metabolism of <e20> valproate </e20>, phenobarbital, phenytoin, carbamazepine, and phenytoin and increase the plasma concentrations of valproate.
mechanism	Anticonvulsants : In some patients, concomitant administration of <e10> digoxin </e10> with agents known to cause anticonvulsant metabolism (eg, carbamazepine, phenobarbital, phenytoin, <e20> primidone </e20>, saquinavir, tricyclic_antidepressants ) may increase the plasma concentrations of digoxin and may result in a decrease in the pharmacokinetics of digoxin.
mechanism	Anticonvulsants : In addition to potentiating <e10> clidinium </e10>, anticonvulsants ( phenytoin, carbamazepine, primidone, <e20> phenobarbital </e20>, triazolam, phenytoin ) may potentiate the drug clearance of clidinium.
mechanism	Anticonvulsants : In the case of <e10> phenytoin </e10> -containing anticonvulsants, the following effect may occur: Anticonvulsants that decrease plasma <e20> phenytoin </e20> levels may decrease the plasma level of phenytoin, leading to a reduction in the clearance of phenytoin and its metabolite.
mechanism	Anticonvulsants : In clinical studies of <e10> enoxacin </e10> with anticonvulsants, the elimination half-life was significantly longer with <e20> clofibrate </e20> than with enoxacin.
mechanism	Anticonvulsants : In a clinical study of healthy volunteers, a dose of # mg <e10> dexamethasone </e10> (a synthetic glucocorticoid) # hours prior to # mg <e20> carbamazepine </e20> # hours prior to # mg of cetirizine (an indomethacin metabolite) increased the Cmax of cetirizine by #%.
mechanism	Anticonvulsants : In an attempt to evaluate the effect of <e10> ketoconazole </e10> on the metabolism of <e20> valproic_acid </e20>, a single oral dose of 10 mg valproic_acid was given to a patient on a ketoconazole therapy for several months prior to administration of the valproic_acid dosage.
mechanism	Resins : Since <e10> rifampin </e10> is a major metabolite of <e20> gabapentin </e20>, it is likely that pharmacokinetics of gabapentin may be affected by drugs such as rifampin.
mechanism	Concomitant administration of <e10> diltiazem </e10> with <e20> astemizole </e20> has caused elevation of astemizole serum concentrations by a mean of 27% (95% CI: 15, 43%).
mechanism	Concomitant administration of <e10> phenytoin </e10> with <e20> diflunisal </e20> is not recommended because diflunisal has been shown to increase the clearance of phenytoin.
mechanism	Concomitant administration of <e10> digoxin </e10> and <e20> dexamethasone </e20> significantly decreased the clearance of digoxin by 20%.
mechanism	Concomitant administration of <e10> piperazine </e10> with <e20> cyclosporine </e20> or tacrolimus, an inhibitor of both cytochrome P450 3A4 (CYP3A4) and 3A5 (the latter two being metabolized by this isoenzyme), produces a slight, but significant increase in urinary excretion of these two drugs.
mechanism	Concomitant administration of <e11> TARCEVA </e11> with cyclosporine, tacrolimus, hexobarbital, phenytoin, or carbamazepine may increase the absorption of <e20> ciprofloxacin </e20>.
mechanism	Concomitant administration of <e10> digoxin </e10> and <e20> ciprofloxacin </e20> at a dose of # mg/day for # days produced a decrease in serum digoxin levels of #% in # patients.
mechanism	Concomitant administration of <e10> phenytoin </e10> with <e20> levodopa </e20> produced a 2- to 3-fold increase in steady-state serum levels of levodopa.
mechanism	Concomitant administration of <e10> terfenadine </e10> with <e20> diltiazem </e20> results in the increase of AUC(0-12) and Cmax of diltiazem from # to #-fold, and increases in tmax and AUC from # to #-fold.
mechanism	Concomitant administration of <e10> diltiazem </e10> and <e20> rifabutin </e20> in a dose of # mg/kg/day for # days was associated with a dose reduction of # mg/kg/day rifabutin to # mg/kg/day.
mechanism	Concomitant administration of <e10> Aprepitant </e10> and <e20> amprenavir </e20> increases Aprepitant clearance and amprenavir serum concentrations.
mechanism	Concomitant administration of <e10> ketoconazole </e10> with <e20> cyclosporine_A </e20> decreased the renal clearance of cyclosporine A by about one-third.
mechanism	The coadministration of <e10> amprenavir </e10> with <e20> erythromycin </e20> resulted in an increase in steady-state plasma levels of amprenavir by more than #%.
mechanism	The coadministration of <e10> phenytoin </e10> and <e20> ketoconazole </e20> resulted in a 15% increase in urinary ketoconazole excretion.
mechanism	The coadministration of <e10> doxycycline </e10> with <e20> ketoconazole </e20> resulted in a 46% increase in doxycycline plasma concentrations, while ketoconazole plasma concentrations were decreased by -35% in these subjects.
mechanism	Although the mechanism is not known, <e10> ibuprofen </e10> may interfere with <e20> erythromycin </e20> metabolism, resulting in increased serum levels of the drug.
mechanism	Although the mechanism is not known, <e10> phenytoin </e10> may increase the clearance of <e20> phenobarbital </e20>.
mechanism	Although the mechanism is unknown, <e10> rifampin </e10> may increase the plasma concentrations of <e20> diazepam </e20>.
mechanism	Chronic administration of <e10> erythromycin </e10> to rats resulted in significant decreases in plasma <e20> fluconazole </e20> concentrations and in renal excretion of the latter two.
mechanism	Chronic administration of <e10> cimetidine </e10> to rats given <e20> fluoxetine </e20> resulted in a 70% decrease in the level of cimetidine in serum.
mechanism	Chronic administration of <e10> erythromycin </e10> may increase the metabolism of <e20> levothyroxine </e20> by interfering with the metabolism of thyroidal iodine and other iodine containing drugs.
mechanism	The concomitant use of <e11> ABILIFY </e11> with sulfonamides, carbamazepine, terfenadine, phenytoin, or tacrolimus may result in an increased plasma concentration of <e20> warfarin </e20>.
mechanism	The concomitant use of <e11> BROVANA </e11> with cisapride, <e20> carbamazepine </e20>, carbamazepine and carbamazepine in patients on cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, disopyramide, cisapride, disopyramide, and disopyramide have resulted in increased plasma levels of disopyramide, the carbamazepine metabolite disopyramide, and a slight increase in the fluoxetine plasma concentration.
mechanism	The concomitant use of <e10> ketoconazole </e10> with <e20> cisapride </e20> or other known CYP3A4 inhibitors may result in a decrease in cisapride plasma levels.
mechanism	The concomitant use of <e10> fluvoxamine </e10> and <e20> bromocriptine_mesylate </e20> has been reported to result in a decrease in bromocriptine_mesylate uptake, possibly due to a reduction in the enzyme-catalyzed hydrolysis of bromocriptine_mesylate and increased metabolism of bromocriptine_mesylate.
mechanism	The concomitant use of <e10> clofibrate </e10> and <e20> warfarin </e20> increases the half-life of warfarin by approximately 20%.
mechanism	The concomitant use of <e10> digoxin </e10> and <e20> astemizole </e20> may result in a significant reduction in the clearance of digoxin.
mechanism	The concomitant use of <e10> terfenadine </e10> may increase the clearance of <e20> warfarin </e20>.
mechanism	The concomitant use of <e10> erythromycin </e10> (with one or more other anticholinergics, including carbamazepine ) may result in reduced plasma levels of <e20> clarithromycin </e20>.
mechanism	The concomitant use of <e10> erythromycin </e10> (100 mg q24h, q12h) and <e20> clarithromycin </e20> (2 mg q12h, q24h) has been reported to decrease clarithromycin clearance by approximately 18%.
mechanism	The concomitant use of <e10> enoxacin </e10> and <e20> nevirapine </e20> may increase the exposure of these two drugs and their metabolites, including enoxacin and its active metabolite, 3-hydroxy-2-methyl-1-butanol ( MHB ), resulting in lower enoxacin concentrations in blood and urine and higher concentrations of these compounds in plasma and urine.
mechanism	The concomitant use of <e11> LEXAPRO </e11> with antacids containing calcium or aluminum, iron or <e20> zinc </e20>, thiazide_diuretics, or sulfonamides may result in decreased absorption of all bioactive ingredients in LEXAPRO.
mechanism	The concomitant use of <e10> cyclosporine </e10>, tacrolimus, and <e20> digoxin </e20> may increase the clearance of digoxin, resulting in elevated serum concentrations and potential toxicity.
mechanism	The concomitant use of <e10> clozapine </e10> with <e20> rifampin </e20>, fluoxetine, paroxetine, sertraline, theophylline, or another psychotropic_medication increases the half-life of the drug by approximately 50%.
mechanism	The concomitant use of <e11> RAPTIVA </e11> with <e20> lithium </e20>, a lithium source, may induce lithium toxicity.
mechanism	The concomitant use of <e11> INOmax </e11> and <e20> omeprazole </e20> (a C-type inhibitor) may cause a 20% increase in INOmax plasma concentrations, and increases the INOmax clearance by 50%.
mechanism	The concomitant use of <e10> ketoconazole </e10> with <e20> cisapride </e20> may increase the clearance of cisapride by 25%.
mechanism	The concomitant use of <e11> HUMORSOL </e11> with <e20> carbamazepine </e20> may increase the serum carbamazepine level and may reduce its metabolism to decrease the blood levels of carbamazepine.
mechanism	The concomitant use of <e10> chloramphenicol </e10> and <e20> digoxin </e20> may be potentiated by the concurrent use of other drugs that are extensively metabolized by cytochrome P450 2D6 (e,g,, ketoconazole, sulfinpyrazone, amiodarone, phenobarbital, diazepam, alprazolam, alprazolam_sulfone, phenytoin, bromocriptine, primidone, triazolam, disopyramide, phenobarbital, and alprazolam_sulfone ), ketoconazole, and sulfinpyrazone.
mechanism	The concomitant use of <e10> ketoconazole </e10> and <e20> nelfinavir </e20> may increase the serum concentrations of the latter by a factor of 3.
mechanism	The concomitant use of <e10> valdecoxib </e10> (50 mg) and <e20> zidovudine </e20> (50 mg) tablets for # weeks resulted in a reduction in zidovudine AUC from # to # and an increase in AUC from # to # microg/day, corresponding to an increase in AUC from # to # mg/day.
mechanism	The concomitant use of <e10> nelfinavir </e10> and <e20> dasatinib </e20> is also reported to increase the half-life of nelfinavir by 50%.
mechanism	However, co administration of <e10> digoxin </e10> with <e20> phenytoin </e20> (at # mg/day) resulted in a decrease in the mean serum digoxin levels.
mechanism	However, co administration of <e10> cimetidine </e10> and <e20> levodopa </e20> has been reported to reduce the plasma concentrations of both drugs and may cause a marked reduction in response to levodopa.
mechanism	However, co administration of <e10> halothane </e10> or <e20> halothane </e20> with atropine_sodium increased atropine_sodium clearance and increased cardiac index.
mechanism	However, co administration of <e10> ketoconazole </e10> and <e20> zidovudine </e20> results in a significant increase in the level of zidovudine in the plasma of HIV+ subjects.
mechanism	However, co administration of <e10> rifampin </e10> or erythromycin, who is on a regimen of <e20> clarithromycin </e20>, with either # mg of diltiazem or # mg of clarithromycin for # days resulted in a 17% increase in clarithromycin plasma concentrations.
mechanism	These studies indicate that the pharmacokinetics of <e11> SPRYCEL </e11> are altered by the presence of <e20> lithium </e20> and that these effects may result in a decreased bioavailability of SPRYCEL and a decreased efficacy of SPRYCEL.
mechanism	These studies indicate that both <e10> fluvoxamine </e10> and <e20> warfarin </e20> have been found to increase the exposure to warfarin (INR, #-) in #% and #% of patients, respectively.
mechanism	These studies indicate that <e10> doxorubicin </e10> may increase the plasma concentrations of <e20> digoxin </e20> by about #-fold, and that some drugs that inhibit hepatic metabolism of digoxin may increase the plasma concentrations of digoxin by about #-fold.
mechanism	These studies indicate that <e10> zalcitabine </e10>, like other <e22> antiparasitic_drugs </e22>, may enhance the toxicity of carbamate_antibiotics, carbamazepine, and zalcitabine.
mechanism	These studies indicate that oral <e10> astemizole </e10> may enhance the metabolism of the non-steroidal_anti-inflammatory_drug <e20> furosemide </e20> and may result in a decrease in its bioavailability.
mechanism	These studies indicate that <e10> diclofenac </e10>, acetaminophen, and alcohol reduce <e20> carbamazepine </e20> plasma levels.
mechanism	This observed increase in <e10> phenytoin </e10> clearance was not observed with <e20> dapsone </e20>, an indomethacin derivative.
mechanism	This observed increase in bioavailability of <e10> amphetamine </e10> was observed during administration of <e20> atazanavir </e20> # mg daily.
mechanism	Drug Interactions with Carbamazepine : <e10> Carbamazepine </e10> may increase the clearance of other agents with anticonvulsant activity, such as phenytoin, phenobarbital, carbamazepine, triazolam, <e20> cisapride </e20>, disopyramide, triazolam, and phenytoin.
mechanism	Drug Interactions with Imipramine : <e10> Cimetidine </e10> may interact with <e20> imipramine </e20>.
mechanism	Drug Interactions with Furosemide : <e10> Furosemide </e10> may enhance the effect of concomitant medications that cause renal tubular secretion of <e22> acid-sensing_receptor_inhibitors </e22>, and therefore these drugs may increase serum levels.
mechanism	Drug Interactions with Phenytoin : Phenytoin, as with other <e12> anticonvulsants </e12>, may cause changes in the pharmacokinetics of <e22> anticonvulsants </e22> such as carbamazepine, phenobarbital, phenytoin, and theophylline.
mechanism	Drug Interactions with Antacids : <e12> Amphetamines </e12> may increase the clearance of some antacids, resulting in lower serum levels of some <e22> corticosteroids </e22>.
mechanism	Drug Interactions with Carbamazepine : Drug Interactions have been reported with <e11> SULAR </e11> concomitantly with Carbamazepine, but these were observed only with <e20> carbamazepine </e20> concentrations above # mg/mL.
mechanism	During administration of <e10> warfarin </e10>, oral <e20> erythromycin </e20> and digoxin may cause an increase in the serum concentrations of warfarin.
mechanism	During administration of <e10> digoxin </e10> (40 micrograms of 0, #, #, or # mg) or <e20> bromocriptine_mesylate </e20> (40 micrograms of # mg), there was a significant decrease in digoxin plasma concentrations, which was prevented by # mg of almotriptan.
mechanism	During administration of <e10> enoxacin </e10>, <e20> gentamicin </e20>, ciprofloxacin, dapsone, doxycycline, disulfiram, escitalopram, estrogens, furosemide, fluoxetine, lithium, midazolam, phenytoin, rifampin, St, Johns wort, temazepam, theophylline, valproate, zidovudine, and zidovudine may have resulted in increased serum levels of enoxacin.
mechanism	In a study in healthy volunteers, oral <e10> ketoconazole </e10> significantly decreased the oral bioavailability of <e20> norethindrone </e20> by 38% and the elimination half-life by 38%.
mechanism	In a study in healthy volunteers, co-administration of <e10> ethionamide </e10> (40 mg/day for # days) and <e20> furosemide </e20> for # days resulted in a 27% decrease in the mean number of serum creatinine measurements.
mechanism	In a study of healthy volunteers receiving <e10> fluvoxamine </e10> (20 mg/day) and <e20> ketoconazole </e20> (10 mg/day), a 50% increase in plasma concentrations of lopinavir was observed.
mechanism	Limited data in non-human primates suggest that <e10> ketoconazole </e10> may reduce the blood concentration of <e20> phenytoin </e20>.
mechanism	Limited data in normal volunteers suggest that <e10> erythromycin </e10> may decrease the absorption of carbamazepine, <e20> cimetidine </e20>, and propranolol.
mechanism	Limited data in healthy volunteers suggest that <e10> ketoconazole </e10> may increase the exposure to <e20> warfarin </e20>.
mechanism	Limited data in patients treated with <e10> cyclosporine </e10> suggest that <e20> diltiazem </e20> may decrease the clearance of this agent.
mechanism	Limited data in healthy subjects suggest that <e10> ketoconazole </e10> may increase the bioavailability of <e20> propafenone </e20> by decreasing the intestinal absorption of ketoconazole.
mechanism	Limited data in the pharmacokinetic studies of co-administered <e10> nevirapine </e10> with oral <e20> zidovudine </e20> indicate that nevirapine may decrease plasma levels of zidovudine by the cytochrome P450 3A4-mediated metabolism.
mechanism	Limited data in humans suggest that <e10> warfarin </e10> may decrease <e20> phenytoin </e20> absorption, and therefore increase the risk of phenytoin toxicity.
mechanism	Limited data in male rats suggest that <e10> rifampin </e10> (20 mg/kg, b.w.) administered concurrently with <e20> cyclosporine </e20> (2 mg/kg, b.w.) may result in a concomitant decrease in serum cyclosporine levels.
mechanism	In healthy subjects, <e10> zalcitabine </e10> co-administration with <e20> carbamazepine </e20> resulted in a decrease in carbamazepine plasma levels by a mean of 8% (p =.0046) and in a decrease in zalcitabine plasma concentrations by a mean of 22% (p =.0009).
mechanism	In healthy subjects, administration of <e10> ketoconazole </e10> # mg daily for # days, # mg twice daily for # days and # mg three times daily for # days resulted in a significant increase in the plasma concentrations of <e20> cisapride </e20> (by 40% on day # and 41% on day #+2), with no effect on the mean plasma cisapride concentration on day #.
mechanism	In healthy subjects receiving <e10> propranolol </e10> and <e20> ketoconazole </e20>, hepatic enzyme activity was increased, with no change in the pharmacokinetics of either drug.
mechanism	When <e10> amiodarone </e10> was given to rats treated with <e20> ketoconazole </e20> for # days, the clearance of ketoconazole was increased by approximately two-fold, resulting in an approximately 40% increase in the systemic exposure of ketoconazole.
mechanism	When <e10> amiodarone </e10> was administered concomitantly with <e20> diltiazem </e20>, plasma amiodarone levels were decreased by approximately 50% and AUC values were decreased by approximately 20%.
mechanism	When <e10> amiodarone </e10> and <e20> methenamine </e20> are given concomitantly, patients with an elevated serum amiodarone level (4 or more times the upper limit of normal) should be observed closely to determine if there is a significant change in amiodarone concentration.
mechanism	Drugs that inhibit hepatic enzymes (e,g,, <e10> carbamazepine </e10>, phenytoin, phenobarbital ) may result in increased concentrations of <e20> clozapine </e20>.
mechanism	Drugs that inhibit cytochrome P450 (CYP) 2C9 (e,g,, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, <e10> nefazodone </e10>, ritonavir, nelfinavir ) or increase CYP2C9 activity (e,g,, clarithromycin, itraconazole, troleandomycin, nefazodone, ritonavir, nelfinavir ) may decrease the plasma concentrations of <e20> atazanavir </e20>.
mechanism	<e12> Barbiturates </e12> may decrease the clearance of <e20> succinylcholine </e20> and prolong the half-life of succinylcholine.
mechanism	<e12> Barbiturates </e12> may decrease the metabolism of <e20> digoxin </e20>, causing a decrease in renal clearance.
mechanism	<e12> Barbiturates </e12>, carbamazepine, phenobarbital, phenytoin, and primidone increase the metabolism of <e20> quinidine </e20>.
mechanism	Barbiturates, <e10> cholestyramine </e10>, carbamazepine, cypermethrin, doxycycline, ethanol, famotidine, methotrexate, rifampin, quinine, theophylline, theophylline_hydrochloride, valproate, <e20> warfarin </e20>, and astemizole may decrease the clearance of atorvastatin and increase the clearance of concomitantly administered atorvastatin.
mechanism	Barbiturates, <e10> phenytoin </e10>, <e20> phenobarbital </e20>, and salicylates may decrease the clearance of indinavir and may require increases in indinavir dose or dosing intervals to achieve the desired plasma concentration.
mechanism	Barbiturates, phenytoin, phenobarbital, <e10> carbamazepine </e10>, diazepam, felbamate, fluoxetine, fluvoxamine, indomethacin, ketoconazole, methadone, phenytoin, primidone, quinidine, <e20> sertraline </e20>, theophylline, theophylline_S, triazolam, and warfarin.
mechanism	Barbiturates, phenytoin, <e10> carbamazepine </e10>, and fluoxetine (10(-10) to 10(-6) M) have been reported to increase <e20> colestipol_HCl </e20> elimination and may reduce its clearance.
mechanism	Barbiturates, phenytoin, carbamazepine, <e10> methotrexate </e10>, and alfentanyl may increase <e20> indinavir </e20> exposure and therefore may increase the risk of serious infections.
mechanism	Concurrent administration of <e10> phenytoin </e10> with <e20> carbamazepine </e20> can result in a 30% decrease in carbamazepine serum levels.
mechanism	Concurrent administration of <e10> digoxin </e10> with <e20> dapsone </e20> (a prostaglandin synthase-inhibitor ) resulted in a 40% increase in digoxin plasma levels.
mechanism	Concurrent administration of <e10> fluvoxamine </e10> and <e20> hydralazine </e20> resulted in increased hydralazine plasma concentrations and increased fluvoxamine plasma exposure.
mechanism	Aspirin : Concurrent administration of <e11> aspirin </e11> and <e20> dasatinib </e20> results in a 40% reduction in aspirin AUC and a 26% reduction in aspirin Cmax and a 36% reduction in both AUC and Cmax.
mechanism	Aspirin : Concurrent administration of <e10> gefitinib </e10> with <e20> aspirin </e20> for # days resulted in significantly increased Cmax and AUC of gefitinib compared to aspirin alone.
mechanism	Cimetidine, Ranitidine, and <e10> digoxin </e10> are inhibitors of <e20> cimetidine </e20> metabolism.
mechanism	<e10> Terfenadine </e10>, a dopamine metabolite, was shown to inhibit <e20> butorphanol </e20> metabolism and increase the plasma concentration of the metabolite.
mechanism	<e10> Terfenadine </e10> inhibited <e20> acetaminophen </e20> -induced urinary excretion in the rat.
mechanism	<e10> Terfenadine </e10> inhibited the metabolism of <e20> propranolol </e20>, which results in a decreased plasma level of propranolol and its metabolite alprazolam.
mechanism	Terfenadine, <e10> fluvoxamine </e10>, alprazolam, phenobarbital, and rifampin can interact with <e20> ferrous_sulfate </e20>.
mechanism	Terfenadine, <e10> enoxacin </e10>, and colestipol, but not <e20> disopyramide </e20>, inhibit CYP3A4 activity in vitro.
mechanism	Terfenadine, <e10> indomethacin </e10>, and <e20> rifampin </e20> all inhibit the metabolism of terfenadine, which results in lower levels of terfenadine and, therefore, higher plasma levels.
mechanism	Terfenadine, astemizole, and <e10> ketoconazole </e10> may interfere with the metabolism of <e20> cisapride </e20>, causing a decrease in plasma levels.
mechanism	Other Potentially Important Drug Interactions: In some patients, co-administration of <e11> INSPRA </e11> with other drugs that are metabolized by CYP2D6 (e,g,, nonsteroidal_anti-inflammatory_drugs, <e20> furosemide </e20>, sulfonamides, thiazide_diuretics, corticosteroids, and some protease_inhibitors ) may result in elevated plasma concentrations of INSPRA and decrease the therapeutic index of INSPRA.
mechanism	Other Potentially Important Drug Interactions: Acetazolamide : <e10> Itraconazole </e10> may decrease the clearance of <e20> Itraconazole </e20>.
mechanism	Other Potentially Important Drug Interactions: Concomitant administration of <e11> PRECEDEX </e11> with other potent CYP3A4 inhibitors ( alfentanil, clarithromycin, itraconazole, ritonavir, <e20> nelfinavir </e20>, saquinavir, telithromycin, troleandomycin, zidovudine ) may increase plasma concentrations of PRECEDEX and lead to an increase in metabolism of PRECEDEX by these drugs.
mechanism	Other Potentially Important Drug Interactions: The following drugs may increase the clearance of <e11> BOTOX </e11> and decrease the clearance of <e20> ketoconazole </e20> : acitretin, corticosteroids, dantrolene, disopyramide, indinavir, itraconazole, itraconazole_hydrochloride, itraconazole_retard, itraconazole_steroids, pimozide, rifabutin, saquinavir, telithromycin, triazolam, warfarin, zidovudine.
mechanism	Other Potentially Important Drug Interactions of <e10> erythromycin </e10> : Chlorotrianisene, used in combination with <e20> erythromycin </e20>, produces increased concentrations of the drug in blood and urine.
mechanism	Other Potentially Important Drug Interactions: Co-administration of <e10> enoxacin </e10> may increase the plasma concentrations of <e20> cimetidine </e20>, its oral bioavailability may be impaired, and adverse events may occur more frequently when enoxacin is co-administered with a drug that inhibits CYP3A4 (eg, ketoconazole and itraconazole ) and/or with drugs that inhibit CYP2C9 (eg, clarithromycin, nefazodone, ritonavir, troleandomycin, indinavir, itraconazole ).
mechanism	Other Potentially Important Drug Interactions: When <e11> WELLBUTRIN </e11> is co-administered with <e20> probenecid </e20>, the following changes in dose may occur: A decrease in mean daily dose of probenecid may occur.
mechanism	Other Potentially Important Drug Interactions: Ethinyl_estradiol : <e10> Phenobarbital </e10> may increase the clearance of <e20> ethinyl_estradiol </e20>.
mechanism	Other Potentially Important Pharmacologically Interactions of Phenytoin : The metabolism of <e10> phenytoin </e10> may result in decreased plasma levels of <e20> guanfacine </e20> and may increase the clearance of the drug when coadministered with cyclosporine, carbamazepine, phenobarbital, rifampin, and tacrolimus.
mechanism	Other Potentially Important Drugs Drug interactions of <e10> clofibrate </e10> with <e20> phenytoin </e20>, carbamazepine, cholestyramine, diazepam, fluoxetine, fluvoxamine, glyburide, heparin, phenobarbital, primidone, sertraline, telithromycin, troleandomycin ( TAO ), and warfarin have been reported.
mechanism	Other Potentially Important Drug Interactions: Antacids : <e12> Antacids </e12> inhibit the absorption of <e20> cimetidine </e20> and cause a reduction in renal clearance of its plasma levels.
mechanism	Alprazolam : When <e10> alprazolam </e10> was given with <e20> sertraline </e20>, serum sertraline levels were increased by 46% (P =.0001).
mechanism	Alprazolam : When <e10> alprazolam </e10> is given concomitantly with either intravenous <e20> amphetamine </e20>, it has been reported to increase amphetamine plasma concentrations and thus increase the likelihood of adverse events.
mechanism	Because <e10> fluvoxamine </e10> increases <e20> terfenadine </e20> plasma levels by preventing renal excretion, the resulting decrease in terfenadine is expected to result in increased concentrations of the latter drug.
mechanism	Because <e10> fluvoxamine </e10> and <e20> lithium </e20> are generally coadministered, a significant interaction between lithium and fluvoxamine could result in a significant prolongation of lithium serum levels.
mechanism	Because <e10> fluvoxamine </e10>, norethindrone, phenytoin, or <e20> lithium </e20> increase the clearance of amphetamines, the amphetamine clearance may be decreased and patients with severe psychomotor retardation may experience significant increase in amphetamine clearance.
mechanism	Because <e10> fluvoxamine </e10> increases <e20> carbamazepine </e20> clearance, higher carbamazepine concentrations should be expected in the presence of a ketoconazole regimen that is contraindicated by concomitant administration of a nonsteroidal_anti-inflammatory_drug ( concomitant use with an anti-diuretic, a calcium_channel_blocker, or a beta-adrenergic_blocking_agent may increase carbamazepine plasma levels)
mechanism	Because <e10> fluvoxamine </e10> (10 mg once daily) did not affect <e20> levodopa </e20> clearance or urinary excretion, it is not likely to be a clinically significant concomitant drug.
mechanism	Because <e10> fluvoxamine </e10> has been shown to enhance <e20> cyclosporine </e20> metabolism in vitro, and because fluvoxamine, like cyclosporine, may interact with other antiepileptic_drugs, it is likely that a concomitant decrease in the clearance of corticosteroids and corticotropin may occur in these patients.
mechanism	Warfarin : When <e10> warfarin </e10> was coadministered with <e20> rifampin </e20>, the rifampin plasma concentration was increased by 4-fold and the AUC was increased by 10-fold.
mechanism	Warfarin : When <e10> rifampin </e10> is given concurrently with <e20> warfarin </e20>, a tendency to prolong the QT interval is observed.
mechanism	Oral doses of <e10> ketoconazole </e10> were reduced by approximately 50% after # days of coadministration with <e20> fluvoxamine </e20> and the concurrent use of high-dose ketoconazole.
mechanism	Oral doses of <e10> ketoconazole </e10> # mg once daily decreased the exposure of <e20> cefazolin </e20> by 50%.
mechanism	Similarly, <e10> ethanol </e10> is shown to inhibit the metabolism of the <e20> valproate </e20> via a non-steroidal_anti-inflammatory_drug ( indomethacin ) mechanism.
mechanism	Similarly, <e10> ethanol </e10> -induced hepatic enzymes are likely to be exacerbated by the use of <e20> furosemide </e20>.
mechanism	Reciprocal interactions may occur between <e10> carbamazepine </e10>, phenobarbital, and <e20> valproic_acid </e20>.
mechanism	Reciprocal interactions may occur when <e10> diltiazem </e10> and <e20> warfarin </e20> are coadministered.
mechanism	Reciprocal interactions may occur when <e10> lithium </e10> and <e20> carbamazepine </e20> are used concomitantly.
mechanism	Reciprocal interactions may occur between <e11> BREVIBLOC </e11> and drugs that inhibit CYP2D6 (e,g,, <e20> cimetidine </e20>, fluoxetine, paroxetine, sertraline, astemizole, metoclopramide ) or CYP3A4 (e,g,, metoclopramide, disopyramide, omeprazole, phenobarbital ).
mechanism	Reciprocal interactions may occur when <e10> digoxin </e10> and <e20> ketoconazole </e20> are administered concurrently.
mechanism	Reciprocal interactions may occur between <e10> cimetidine </e10> and certain <e22> rifabutin_antibiotics </e22>.
mechanism	Reciprocal interactions may occur between <e10> enoxacin </e10> and <e20> methotrexate </e20>, and the magnitude of these interactions may be altered by the combination of these drugs.
mechanism	Reciprocal interactions may occur between <e11> REVIA </e11> and certain anticonvulsants, including carbamazepine, phenytoin, felbamate, phenobarbital, carbamazepine and phenytoin in vitro, and <e20> triazolam </e20> in vivo.
mechanism	Reciprocal interactions may occur between <e10> rifabutin </e10> and other <e22> iron-containing_antibiotics </e22>, with potential for interaction with iron-containing antacids and supplements.
mechanism	Reciprocal interactions may occur between <e11> BROVANA </e11> and drugs that have been shown to increase Cmax of # mg and decrease Cmin of # mg BROVANA, e,g,, phenytoin, phenobarbital, phenytoin with digoxin, phenytoin with <e20> ketoconazole </e20>, phenytoin with itraconazole, and phenytoin with rifampin.
mechanism	Reciprocal interactions may occur between <e10> phenytoin </e10>, <e20> valdecoxib </e20>, and oral contraceptives, resulting in elevated serum levels of valdecoxib.
mechanism	In an in vitro study, the effect of <e10> fluvoxamine </e10> on <e20> warfarin </e20> binding was studied with in vitro enzyme activity data for fluvoxamine and warfarin.
mechanism	In an in vitro study, concomitant administration of <e10> indomethacin </e10> and <e20> ketoconazole </e20> resulted in a reduction in the clearance of indomethacin, from 7.3 to 6.1 ml/min/1 mg, while also increasing the systemic exposure of indomethacin by approximately 50%.
mechanism	In an in vitro study with HepG2 cells co-cultured with <e10> isoniazid </e10> (100 nM) and <e20> diflunisal </e20> (20 microM), the half maximal inhibitory concentration (IC(50)) values for isoniazid (25 microM) were increased by 5- to 20-fold.
mechanism	Metoclopramide : When coadministered with <e10> digoxin </e10>, <e20> metoclopramide </e20> decreased the blood levels of digoxin.
mechanism	Antacids : In an open-label study, # of # subjects taking <e10> diazepam </e10> concomitantly with # of # <e20> antacids </e20> developed severe gastrointestinal ulceration.
mechanism	Antacids : In a study in diabetic rats, <e10> clofibrate </e10> decreased <e20> sodium_thiosulfate </e20> binding by approximately 50%.
mechanism	Antacids : In vitro data suggest that <e10> gentamicin </e10>, and possibly other <e22> antacids </e22>, may inhibit the metabolism of vitamin_K or other vitamin_K-binding proteins.
mechanism	Antacids : In vitro data suggest that the administration of <e10> rifampin </e10> or <e20> warfarin </e20> can increase the antacids concentrations.
mechanism	Antacids : In vitro studies of antacids, such as aluminum_hydroxide and aluminum_chloride, reveal a strong tendency for the <e12> aluminum </e12> to interfere with the absorption of <e20> acetaminophen </e20>, resulting in a 7-fold increase in the half-life of acetaminophen compared to non-antacids.
mechanism	Antacids : In vitro, <e10> amiodarone </e10> completely inhibited <e20> ketoconazole </e20> -induced lipid peroxidation, and ketoconazole -induced decrease in the half-life of vitamin_K.
mechanism	Antacids : In some patients, an increase in the antacids excretion may occur when <e10> gabapentin </e10> is administered concurrently with <e20> antacids </e20>.
mechanism	Antacids : In vitro studies with multivitamins and <e10> sucralfate </e10> indicate that <e20> iron </e20> has a very small effect on the absorption of zinc and other minerals in the presence of multivitamins or sucralfate, and that the absorption of zinc is not affected by sucralfate.
mechanism	Antacids : In a single dose of <e10> sucralfate </e10> # mg, the mean Cmax of <e20> valdecoxib </e20> was #% higher than after a single dose of # mg of sucralfate.
mechanism	The most commonly reported drug interactions with <e12> quinolones </e12> in patients receiving oral <e22> anticoagulants </e22>, including warfarin, are inhibition of platelet function and increased prothrombin time, with or without bleeding.
mechanism	The most commonly used concentrations of <e11> ZYVOX </e11> were 10 and 25 mg/kg/day for rats and dogs, respectively, and the clearance of <e20> bromocriptine_mesylate </e20> was approximately 50% lower at a concentration of # mg/kg/day in rats than in dogs.
mechanism	The most commonly reported drug interactions with <e10> ketoconazole </e10> are listed below:-Benzodiazepines : Phenytoin, other <e22> tricyclic_antidepressants </e22>, barbiturates, barbiturates containing tricyclic_antidepressants, phenobarbital, and barbiturates containing barbiturates may increase the clearance of ketoconazole, resulting in elevated serum concentrations.
mechanism	The most commonly reported drug interactions with <e11> BOTOX </e11> are listed below: Antacids : Magnesium or aluminum supplements containing <e20> magnesium </e20> or aluminum may decrease the absorption of the active drug.
mechanism	The most commonly reported clinical signs and symptoms associated with <e12> benzodiazepines </e12> are hyperpyrexia, hyperpyrexia, and hyperpyrexia, and <e20> carbamazepine </e20> may increase the risk of developing pneumonia.
mechanism	The most commonly reported adverse events associated with <e10> lithium </e10> were gastrointestinal, and the only significant increase in lithium levels occurred during dosing with <e20> cimetidine </e20> # mg twice daily.
mechanism	The most commonly observed interactions with <e12> quinolones </e12> are gastrointestinal (e,g,, ulcerogenic effects of ciprofloxacin ), and CNS (e,g,, <e20> flucytosine </e20> ).
mechanism	The most commonly reported adverse experiences with <e10> ketoprofen </e10> in pediatric patients include diarrhea and constipation, but there have been rare reports of interactions with <e20> methotrexate </e20> and theophylline.
mechanism	The most commonly used <e12> benzodiazepines </e12> in patients on chronic <e20> triazolam </e20> therapy are alprazolam, triazolam, and diazepam.
mechanism	The most commonly occurring drug interactions for theophylline are reversible inhibition of CYP2C9 (e,g,, <e10> erythromycin </e10>, cimetidine, clarithromycin ) and induction of CYP3A4 (e,g,, ketoconazole, <e20> itraconazole </e20> ).
mechanism	The most commonly occurring drug interactions with <e10> cyclosporine </e10> include: increased concentrations of <e20> cyclosporine </e20> ;
mechanism	The most commonly reported side effects of concomitant use of <e10> diltiazem </e10> and <e20> rifampin </e20> are diarrhea, hyperuricemia, and hypercalcemia.
mechanism	The most commonly occurring drug interactions with <e12> benzodiazepines </e12> include: <e20> alprazolam </e20> : Increased plasma concentrations of alprazolam have been reported when the drug was administered concomitantly with potent inhibitors of CYP2C9 (such as ketoconazole and itraconazole ) and inhibitors of CYP2B6 (such as ritonavir and nelfinavir ).
mechanism	The most commonly observed drug interactions with <e10> lofexidine </e10> include: urinary retention and elevated blood levels of <e20> ketoconazole </e20>.
mechanism	The most commonly observed drug interactions observed in patients receiving concomitant <e10> zidovudine </e10> and <e20> cyclosporine </e20> were an increase in the half-life of cyclosporine and a decrease in the clearance of zidovudine.
mechanism	The most commonly observed adverse experiences (AEs) of <e10> clindamycin </e10> and <e20> warfarin </e20> include: increased prothrombin times, increased prothrombin times, and/or decreased prothrombin times in patients receiving concomitant oral contraceptives, pregnancy, and HIV treatment.
mechanism	The most commonly reported drug interactions of <e10> probenecid </e10> are seen with the following:-<e20> Phenytoin </e20> and carbamazepine : The metabolism of probenecid is significantly impaired by phenytoin and carbamazepine.
mechanism	The most commonly reported drug interactions are increased plasma concentrations of <e10> cyclosporine </e10> ( cyclosporine salts), resulting in <e20> chloroquine </e20> increases and decreases.
mechanism	The most commonly observed drug interactions with <e10> rifampin </e10> include a decrease in rifampin clearance when <e20> rifampin </e20> and cyclosporine are coadministered and an increase in cyclosporine levels when rifampin and carbamazepine are coadministered.
mechanism	The most commonly reported adverse experiences with <e10> fluvoxamine </e10> are gastrointestinal symptoms and anorexia, and the resulting decreased plasma levels of <e20> fluvoxamine </e20> may result in clinical deterioration.
mechanism	The most commonly reported adverse effects of oral <e12> contraceptives </e12> are gastrointestinal disturbances, particularly those due to increased absorption of <e20> cimetidine </e20> and decreased metabolism of levonorgestrel.
mechanism	The most commonly used calcium supplements for human use are: <e10> Calcium </e10> (0.3% in drinking water) with <e20> acetaminophen </e20> or tetracycline (about # mg/kg/day of body weight)
mechanism	The most commonly observed drug interactions with <e10> lomefloxacin </e10> in patients taking cyclosporine or <e20> tacrolimus </e20>, including hepatotoxicity, have occurred during administration of lomefloxacin to patients on cyclosporine or tacrolimus.
mechanism	The most commonly used drug in adults with ADPHETIC_HYPERTENSION is <e10> cyclosporine </e10>, followed by methotrexate, <e20> nitrofurantoin </e20>, tacrolimus, digoxin, cisapride, and sulfinpyrazone.
mechanism	The most commonly reported drug interactions with <e12> quinolones </e12> in the English-language medical literature are related to intravenous drug administration, with potential for increased toxicity when quinolones are administered concomitantly with intravenous <e22> anticoagulants </e22>.
mechanism	The most commonly used doses of <e10> enoxacin </e10> are # mg/kg/day and # mg/kg/day in <e20> isoniazid </e20> -induced renal impairment.
mechanism	The most commonly used diuretic, loop_diuretics, may interfere with <e10> erythromycin </e10> metabolism and may result in lower concentrations of <e20> erythromycin </e20> in patients taking these agents concurrently.
mechanism	The most commonly reported drug interactions associated with concomitant administration of <e10> carbamazepine </e10> and <e20> valproate </e20> include: decreased plasma concentrations of carbamazepine and valproate (10%-20%), decreased AUC for carbamazepine (50%-70%), and decreased AUC for valproate (20%-30%).
mechanism	The most commonly reported drug interactions in studies of <e12> quinolones </e12> in vitro are with ampicillin, <e20> erythromycin </e20>, clarithromycin, diclofenac, levofloxacin, nefazodone, norfloxacin, and alfentanil.
mechanism	The most commonly reported clinical signs and symptoms of concomitant <e10> indinavir </e10> therapy with <e20> ritonavir </e20> include dyspnea and stomatitis (23% and 7%, respectively), and hypertriglyceridemia (10%).
mechanism	The most commonly reported adverse events of <e11> HUMORSOL </e11> are gastrointestinal upset, drowsiness, and transient elevation of serum amylase and <e20> cefixime </e20> levels.
mechanism	The most commonly reported drug interactions for <e10> nevirapine </e10> are due to drug interactions with metabolism or detoxification, anticoagulants, hepatic enzyme imbalances, gastrointestinal enzyme imbalances, antifungals, clofibrate, coumarins, fluconazole, famotidine, glipizide, interferon-alfa, <e20> javail </e20>, lamivudine, phenytoin, rifabutin, troleandomycin, and warfarin.
mechanism	The most commonly reported drug interactions are inhibition of CYP3A4 by cyclosporine (e,g,, <e10> cyclosporine </e10> s dose has been reduced by 50% in patients receiving a dose of # mg of <e20> disopyramide </e20> daily), reduction in Cmax and AUC by 43% and 46%, and increase in Cmin by 48% and 30%, respectively.
mechanism	The most commonly reported drug interactions of <e11> BREVIBLOC </e11> are the following: increased AUC and Cmax values when <e20> dapsone </e20> is used concomitantly with BREVIBLOC and with other antiepileptic_agents.
mechanism	The most commonly reported drug interactions with <e11> WELLBUTRIN </e11> have been diarrhea, increased plasma levels of oral <e20> digoxin </e20>, and elevated digoxin levels in patients taking warfarin or its derivatives.
mechanism	The most commonly observed increases in blood pressure in the presence of <e10> diltiazem </e10> and <e20> warfarin </e20> were observed in the first few hours after initiation of therapy.
mechanism	The most commonly reported <e12> quinolones </e12> are <e20> ciprofloxacin </e20>, ciprofloxacin and ciprofloxacin sigmoidoscopy may be necessary when a ciprofloxacin dose of # mg daily has been exceeded.
mechanism	The most commonly reported drug interactions are: <e10> Ethopropazine </e10> has been reported to increase the clearance of other <e22> antihypertensive_drugs </e22> and may therefore increase the potential for an increase in blood pressure when taken concomitantly with these drugs.
mechanism	The most commonly reported drug interactions resulting from concomitant use of <e10> ketoconazole </e10> and <e20> astemizole </e20> were gastrointestinal ulceration (9%), and increased serum levels of astemizole (3%).
mechanism	The most commonly reported drug interactions in the mg/kg/day study occurred with methotrexate (54%), <e10> fluvoxamine </e10> (39%), and <e20> ketoconazole </e20> (13%).
mechanism	The most commonly reported drug interactions with <e10> loratadine </e10> were increased AUC and Cmax values, decreased half-life and elimination half-life, and increased AUC/Cmax ratios with concomitant use of <e20> digoxin </e20>.
mechanism	The most commonly used doses of <e10> terfenadine </e10> were # mg (day 3) and # mg (day 8) and # mg (day 4) and # mg (day 9) in a double-blind, placebo-controlled trial of <e20> diclofenac </e20> and carbamazepine in healthy volunteers.
mechanism	The most commonly observed drug interactions associated with <e11> LEXAPRO </e11> are an increase in <e20> cyclosporine </e20> concentrations and an increase in intracellular cyclosporine concentrations.
mechanism	The most commonly used drugs in the clinical management of a patient on therapy with <e10> doxycycline </e10>, or other cytochrome P450 (CYP)3A4 inhibitors, are: bromocriptine_mesylate ( Bromocriptine ), erythromycin ( erythromycin ), carbamazepine ( <e20> carbamazepine </e20> ), diazepam ( diazepam ), fluoxetine ( fluoxetine ), fluvoxamine ( theophylline ), paroxetine ( paroxetine ), quinidine ( quinidine ), theophylline ( theophylline ), theophylline_salicylate ( theophylline_salicylate ), theophylline_salicylate_citrate (theophylline_salicylate ), theophylline_salicylate_HCl (
mechanism	The most commonly reported adverse events associated with <e10> fluvoxamine </e10> and <e20> digoxin </e20> are gastrointestinal disturbances, predominantly diarrhea.
mechanism	- Drugs that have been reported to increase plasma concentrations of <e10> dexamethasone </e10> or that inhibit <e20> dexamethasone </e20> metabolism, such as terfenadine, clarithromycin, indomethacin, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, and troleandomycin are likely to decrease plasma levels of dexamethasone.
mechanism	- Drugs that are CYP 3A4 inhibitors (eg, <e10> ketoconazole </e10>, itraconazole, ritonavir, nelfinavir, clarithromycin, indinavir, ritonavir, saquinavir, telithromycin ) increase the clearance of <e20> ketoconazole </e20>.
mechanism	- Drugs that may inhibit CYP3A4 (e,g,, ketoconazole, itraconazole, ritonavir, clarithromycin, nefazodone, <e10> troleandomycin </e10>, indinavir, saquinavir, indinavir_sulfate, nefazodone_sulfate, troleandomycin ) have been reported to prolong and increase the elimination half-life of <e20> zidovudine </e20>.
mechanism	- Drugs that inhibit CYP3A4 (eg, ketoconazole, erythromycin, itraconazole, ritonavir, indinavir, clarithromycin, <e10> troleandomycin </e10>, nefazodone, didanosine, nelfinavir, ritonavir, telithromycin, troleandomycin, nelfinavir, ritonavir, telithromycin, troleandomycin ) may increase plasma levels of <e20> tamoxifen </e20>.
mechanism	- Drugs that inhibit the metabolism of <e11> ZYVOX </e11> ( carbamazepine, phenytoin, tacrolimus, hexobarbital, phenytoin ) or are metabolized by CYP3A4 ( alfentanil, <e20> cisapride </e20>, disopyramide, disulfiram, phenytoin, bromocriptine, phenytoin_HCl, phenobarbital, rifampin, triazolam, valproate, terfenadine, phenytoin, quinidine, succinylcholine_mesylate, zidovudine, up-to-date ), and drugs that inhibit the metabolism of disopyramide ( disopyramide ), may increase the clearance of disopyramide.
mechanism	- Drugs that inhibit hepatic CYP3A4 (eg, ketoconazole, <e10> itraconazole </e10>, clarithromycin, ritonavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin ) may increase the plasma concentrations of <e20> sildenafil </e20>.
mechanism	- Drugs that induce hepatic enzymes (such as phenytoin, carbamazepine, phenobarbital, alfentanil, rifampin, <e10> dexamethasone </e10>, methadone, theophylline, tacrolimus, cisapride, disopyramide, phenytoin, triazolam, triazolam_hydrochloride ) may increase the clearance of <e21> HUMORSOL </e21>.
mechanism	- Drugs that induce hepatic enzymes such as phenytoin, carbamazepine, and phenobarbital may decrease the clearance of <e11> ISUPREL </e11> and increase the serum concentration of <e20> ampicillin </e20>.
mechanism	- Drugs that induce hepatic enzymes such as <e10> phenytoin </e10>, rifampin, phenobarbital, or <e20> triazolam </e20> may increase the clearance of salicylates, thus necessitating increased oral doses of salicylates.
mechanism	- Drugs that induce hepatic metabolism of <e10> diltiazem </e10> ( <e20> fluvoxamine </e20>, phenytoin, carbamazepine, alfentanil ) may reduce the clearance of metoclopramide, resulting in increased plasma concentrations of this agent.
mechanism	- Drugs that increase plasma concentrations of <e10> diltiazem </e10> (e,g,, fluconazole, triazolam ) may increase plasma concentrations of <e20> atazanavir </e20>.
mechanism	- Drugs that inhibit the CYP3A4 isoenzyme (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, <e10> ritonavir </e10>, nelfinavir, indinavir, saquinavir, telithromycin, troleandomycin, troleandomycin ( TAO ), atazanavir, indinavir, and saquinavir ) may increase the exposure of <e20> atazanavir </e20>.
mechanism	- Drugs that may increase plasma <e10> norethindrone </e10> concentrations include: cyclosporine, <e20> amiodarone </e20>, carbamazepine, carbamazepine and alfentanil.
mechanism	- Drugs that induce hepatic enzymes such as <e10> phenytoin </e10>, carbamazepine, phenobarbital, or rifampin may increase <e20> phenytoin </e20> clearance by inducing cytochrome P450 3A4 and increasing P-glycoprotein and/or aP2 levels.
mechanism	- Drugs that have been reported to decrease plasma <e10> phenytoin </e10> concentrations include: astemizole, disopyramide, diltiazem, disulfiram, diltiazem sulfone, haloperidol, <e20> haloperidol_hydrochloride </e20>, low-dose indinavir, and rifampin.
mechanism	<e10> Hydrocodone </e10> increases <e20> metoclopramide </e20> clearance by approximately 27%.
mechanism	<e10> Hydrocodone </e10> may inhibit the metabolism of <e20> fluvoxamine </e20>.
mechanism	<e10> Hydrocodone </e10> decreased the urinary excretion of <e20> phenytoin </e20> by approximately 23%.
mechanism	Morphine : A single administration of <e10> morphine </e10> at # mg/kg increased <e20> morphine </e20> plasma levels by approximately 33% while decreasing plasma levels of morphine.
mechanism	Morphine : A few studies have reported that <e10> morphine </e10> is capable of antagonizing the hypotensive effect of <e20> diltiazem </e20>, an inhibitor of CYP3A4 and CYP3A5.
mechanism	Morphine : A possible interaction between <e11> PRECEDEX </e11> and <e20> morphine </e20> has been observed.
mechanism	Cimetidine : In a study in volunteers with cystic fibrosis, <e10> cimetidine </e10> was found to decrease plasma levels of <e20> furosemide </e20> by 40% and norethindrone by 30%.
mechanism	Cimetidine : In vitro studies with dideoxy-D-glucose ( <e10> Furosemide </e10> ) reveal that <e20> cimetidine </e20> increases the intestinal absorption of furosemide and that intestinal motility is affected.
mechanism	Cimetidine : In vitro, <e10> cimetidine </e10> (100 microM) decreased the metabolism of <e20> gentamicin </e20> by about 7%.
mechanism	Thus <e10> cimetidine </e10> increased AUC by #% and Cmax by #% when coadministered with <e20> CRIXIVAN </e20>.
mechanism	Thus <e10> cimetidine </e10> and <e20> ketoconazole </e20> increase cimetidine plasma concentrations and ketoconazole decreases cimetidine plasma concentrations.
mechanism	Thus <e10> cimetidine </e10>, cimetidine (a metabolite of cimetidine ) may interact with <e22> thyroid_products </e22>.
mechanism	This small decrease in the plasma levels of <e10> warfarin </e10> may have an effect on <e20> probenecid </e20> -mediated changes in serum and urine.
mechanism	This small decrease in maximum plasma concentrations of <e10> cyclosporine </e10> could be related to its metabolism in the liver, resulting in a higher plasma level of <e20> cyclosporine </e20>.
mechanism	This small decrease in plasma aripiprazole clearance may be anticipated in patients treated concurrently with <e11> ARAVA </e11> and a <e22> macrolide_antibiotic </e22>, as suggested by previous studies.
mechanism	The Cmax of <e10> enoxacin </e10> was # times higher in patients who received a single <e20> cimetidine </e20> dose.
mechanism	The Cmax of <e10> levodopa </e10> decreased by 49% when it was given at # mg twice daily with # mg <e20> cimetidine </e20> at # mg twice daily.
mechanism	The Cmax of <e10> nevirapine </e10> increased by approximately 25% and the AUC increased by approximately 16% when the ritonavir-nevirapine combination was administered concomitantly with <e20> ritonavir </e20>.
mechanism	Antacid ( Maalox ) use may decrease the availability of <e11> ARAVA </e11> to avoid absorption of <e20> zalcitabine </e20>.
mechanism	Antacid ( Maalox ) or sulfonamides : Coadministration of <e10> erythromycin </e10> with either <e20> ampicillin </e20> or sulfonamides was associated with an increase in the absorption of the latter.
mechanism	Antacid ( Maalox ) tablets: <e10> Cholestyramine </e10> and <e20> omeprazole </e20> tablets may interfere with absorption of theophylline or omeprazole.
mechanism	This decrease in the bioavailability of <e10> cimetidine </e10> was likely due to the lower metabolism of <e20> rifampin </e20> and the increased conversion of cypermethrin to a more toxic metabolite.
mechanism	This decrease in bioavailability of <e10> isoniazid </e10> may be expected when the same medication is coadministered with <e20> cholestyramine </e20>.
mechanism	Substances that are actively secreted in the stomach, such as <e10> erythromycin </e10>, may reduce the clearance of <e20> digoxin </e20>.
mechanism	Substances that are potent inhibitors of CYP3A4 (eg, <e10> ketoconazole </e10>, itraconazole, ritonavir, nelfinavir, clarithromycin, indinavir, ritonavir, saquinavir, indinavir, telithromycin ) have the potential to increase plasma concentrations of <e20> lomefloxacin </e20> by approximately 25%.
mechanism	Substances that are highly similar to phenytoin, including tricyclic_antidepressants, tricyclic_antifungals, phenobarbital, phenytoin, <e10> carbamazepine </e10>, clofibrate, disulfiram, theophylline, atorvastatin, and quinine may decrease the clearance of <e20> cilostazol </e20>.
mechanism	Substances that are CYP3A4 inhibitors (e,g,, ketoconazole, itraconazole, ritonavir, erythromycin, indinavir, clarithromycin, <e10> troleandomycin </e10>, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin ) increase the plasma concentrations of <e20> rifampin </e20>.
mechanism	Substances that are CYP3A4 inhibitors (such as ketoconazole, itraconazole, clarithromycin, nefazodone, ritonavir, <e10> nelfinavir </e10>, saquinavir, indinavir, indinavir_sulfate, nefazodone_sulfate, saquinavir, nefazodone_sulfate, itraconazole, fluoxetine, fluvoxamine ) may increase plasma concentrations of <e20> cimetidine </e20>.
mechanism	Substances that are potent inhibitors of CYP3A4 activity (e,g,, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, <e10> nelfinavir </e10>, indinavir, ritonavir, saquinavir, telithromycin, troleandomycin, didanosine, nelfinavir, indinavir, saquinavir, indinavir, saquinavir, indinavir, saquinavir, itraconazole, clarithromycin, troleandomycin ) are generally not likely to be potent inhibitors of <e21> CRIXIVAN </e21>.
mechanism	Substances that are inhibitors of CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, ritonavir, clarithromycin, indinavir, <e10> itraconazole </e10>, saquinavir, telithromycin ) may increase plasma concentrations of <e20> norfloxacin </e20>.
mechanism	Substances that are active in a pharmacokinetic study of <e10> indomethacin </e10> may have a strong tendency to increase the plasma concentrations of this drug, particularly when it is administered concomitantly with the following: <e20> amiodarone </e20>, carbamazepine, cisapride, cyclosporine, disopyramide, ergot_derivatives, fentanyl, fluoxetine, grapefruit juice, morphine, phenytoin, theophylline, theubuticin, theophylline_sodium, verapamil, oryzalin.
mechanism	Substances that are also potential inhibitors of CYP3A4 (e,g,, <e10> ketoconazole </e10>, erythromycin, clarithromycin, and itraconazole ) may increase the clearance of <e20> ketoconazole </e20>.
mechanism	Drugs that cause drug metabolism (e,g,, carbamazepine, cimetidine, <e10> digoxin </e10> ) should be used with caution because these drugs increase the half-life of <e20> ciprofloxacin </e20>.
mechanism	Drugs that cause hepatic enzyme inhibition (e,g,, <e10> rifampin </e10>, amiodarone, triazolam ) may decrease plasma <e20> bromocriptine_mesylate </e20> levels and thus increase the clearance of bromocriptine.
mechanism	Drugs that cause a change in plasma drug concentrations (eg, theophylline, <e10> phenobarbital </e10>, amiodarone, cimetidine, <e20> clarithromycin </e20>, disopyramide ) may increase the clearance of the active metabolite of the drug, resulting in an increase in the AUC of the drug.
mechanism	Drugs that cause hepatic enzymes to increase (eg, metoclopramide, phenytoin, <e10> digoxin </e10> ) or decrease (eg, diazepam, barbiturates, <e20> propafenone </e20>, nifedipine, clofibrate, fluvoxamine, paroxetine, sertraline, theophylline ) may increase the clearance of furosemide and decrease the AUC for furosemide.
mechanism	Drugs that cause increases in <e10> estradiol </e10> (such as <e20> probenecid </e20> ) may increase the plasma concentration of these drugs.
mechanism	Drugs that cause hepatic enzyme release or inhibit enzyme activity of <e11> FOSCAVIR </e11> may increase the clearance of <e20> alfentanil </e20>.
mechanism	Drugs that cause hepatic enzyme inhibition (eg, phenytoin, <e10> carbamazepine </e10>, alfentanil ) may decrease the clearance of <e20> dasatinib </e20> and result in elevated serum concentrations.
mechanism	Drugs that cause hepatic enzyme levels to decrease (e,g,, phenytoin, rifampin, <e10> phenobarbital </e10> ) or increase (e,g,, amiodarone, carbamazepine, theophylline, <e20> cimetidine </e20>, fluoxetine, fluvoxamine, paroxetine, theophylline ), or that alter the absorption of folic_acid (e,g,, oral contraceptives ), may decrease the clearance of theophylline.
mechanism	Concomitant administration of <e10> cyclosporine </e10> and <e20> diltiazem </e20> resulted in increased plasma levels of diltiazem.
mechanism	Concomitant administration of <e10> ketoconazole </e10> and <e20> bromocriptine_mesylate </e20> has been reported to result in a significant increase in the AUC of both drugs.
mechanism	Concomitant administration of <e10> fluvoxamine </e10> with agents that cause plasma levels of <e20> digoxin </e20> to be higher than # micrograms/liter may result in elevations in digoxin levels.
mechanism	Concomitant administration of <e10> phenytoin </e10> with <e20> zalcitabine </e20> for # days has been reported to decrease the AUC and Cmax of zalcitabine by approximately 50%.
mechanism	Concomitant administration of <e11> HUMORSOL </e11> and <e20> azithromycin </e20>, which have similar effects on intestinal enteric motility, may lead to an increase in the duration of systemic azithromycin effects.
mechanism	Concomitant administration of <e10> gabapentin </e10> and <e20> cimetidine </e20> (a histamine_releasing agent ) is expected to produce an increase in plasma gabapentin concentrations.
mechanism	Concomitant administration of <e10> cholestyramine </e10> and <e20> dofetilide </e20> in rats resulted in a significant reduction in the elimination half-life of dofetilide.
mechanism	Concomitant administration of <e10> carbamazepine </e10> with <e20> valdecoxib </e20> produced a net increase in carbamazepine levels and an increase in valdecoxib AUC of approximately 50% and 20%, respectively.
mechanism	Concomitant administration of <e10> isoniazid </e10> and <e20> cimetidine </e20> for up to # days decreased the AUC of isoniazid by 35%.
mechanism	Concomitant administration of <e10> methotrexate </e10> and <e20> ciprofloxacin </e20> decreased its clearance by approximately 38% (means per hour of methotrexate increased by 11%).
mechanism	Concomitant administration of <e10> diltiazem </e10> with <e20> ampicillin </e20> in healthy volunteers resulted in a 25% decrease in diltiazem plasma concentrations, although the effect was not clinically significant.
mechanism	Concomitant administration of <e10> cisapride </e10> with <e20> ketoconazole </e20> significantly reduced the AUC of cisapride by 38% and the Cmax by 28%.
mechanism	The absorption of <e10> cefazolin </e10>, a known inhibitor of CYP3A4, is enhanced by #-fold when coadministered with <e20> cyclosporine </e20>.
mechanism	The absorption of <e10> erythromycin </e10> is enhanced when coadministered with <e20> fluconazole </e20>.
mechanism	The absorption of <e10> cetirizine </e10> is impaired by the binding of <e20> lithium </e20>.
mechanism	The absorption of <e10> diltiazem </e10> was slightly reduced by <e20> carbamazepine </e20>.
mechanism	The absorption of <e10> terfenadine </e10> is increased by <e20> cisplatin </e20>.
mechanism	The mean percentage increase in plasma alprazolam concentrations with coadministration of <e10> cimetidine </e10> and <e20> alprazolam </e20> was 23% for the 24 h period and 35% for # days after coadministration of alprazolam.
mechanism	The mean percentage change in <e10> gentamicin </e10> plasma concentrations (21.3%) was similar to the percentage change in <e20> asparaginase </e20> plasma concentrations (28.9%).
mechanism	Concomitant administration of <e10> ketoconazole </e10> and <e20> ethionamide </e20> can decrease the clearance of both drugs.
mechanism	Concomitant administration of <e10> erythromycin </e10> and <e20> clarithromycin </e20> increases clarithromycin plasma levels, which may reduce the effectiveness of clarithromycin.
mechanism	Concomitant administration of <e10> phenytoin </e10> and <e20> coumarin </e20> resulted in elevated plasma levels of both drugs.
mechanism	Administration of <e12> quinolones </e12> with <e20> valdecoxib </e20> significantly decreased AUC values by approximately 20%.
mechanism	Administration of <e12> estrogens </e12> or progestins with <e20> Aprepitant </e20> may reduce Aprepitant plasma levels and potentially affect Aprepitant pharmacodynamics and blood glucose levels.
mechanism	Administration of <e12> quinolones </e12> (virulent strains) with <e20> digoxin </e20> results in elevated serum digoxin concentrations.
mechanism	Administration of <e12> quinolones </e12> or non-steroidal_anti-inflammatory_drugs or cyclosporine A to patients receiving <e20> cilostazol </e20> may result in a marked increase in plasma concentrations of cilostazol.
mechanism	Administration of <e12> quinolones </e12> or tetracyclines with potent CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin ( TAO ), and <e20> troleandomycin </e20> with cisapride results in prolongation of the elimination half-life of cisapride.
mechanism	Administration of <e12> SSRI </e12> with <e20> lithium </e20> has been shown to increase lithium toxicity in a small study.
mechanism	Administration of <e12> quinolones </e12> to patients receiving other antibiotics such as ampicillin or tetracycline may result in an increase in the ampicillin or tetracycline plasma concentrations and a decrease in the <e20> gentamicin </e20> plasma concentrations.
mechanism	Administration of <e12> quinolones </e12> with oral anticoagulants such as warfarin or <e20> warfarin_sodium </e20> may cause an increase in prothrombin time.
mechanism	Administration of <e12> salicylates </e12> to patients taking <e22> NSAIDs </e22> may increase salicylate plasma levels, resulting in an increased bioavailability of salicylates.
mechanism	Administration of <e12> salicylates </e12> with antacids containing magnesium or calcium, containing iron, containing zinc, containing aluminum, or containing <e20> caffeine </e20> may result in elevated serum magnesium levels.
mechanism	Administration of <e12> anticonvulsants </e12> concurrently with <e20> valdecoxib </e20> for # days resulted in a decreased clearance of valdecoxib and increased AUC of valdecoxib.
mechanism	Administration of <e12> benzodiazepines </e12> to patients taking <e22> corticosteroids </e22> may result in a reduction in plasma corticosteroid levels.
mechanism	Administration of <e12> antacids </e12> containing iron and/or zinc with <e20> ketoconazole </e20> and other antacids, including multivitamins, may increase the iron absorption from these antacids and reduce the rate of serum iron.
mechanism	Administration of <e12> cephalosporins </e12> concomitantly with <e20> digoxin </e20> (90% effective concentration) results in increased AUC values of digoxin by #% and decreased AUC values of cephalosporins concomitantly with digoxin by #%.
mechanism	Administration of <e12> quinolones </e12> may result in a significant decrease in the clearance of <e20> cefazolin </e20> and therefore, the extent of cefazolin absorption.
mechanism	Administration of <e12> quinolones </e12> with <e20> diltiazem </e20> resulted in a 16% increase in fluconazole plasma concentrations.
mechanism	Administration of <e12> anticonvulsants </e12> and phenytoin, cyclosporine, or tacrolimus may decrease the clearance of <e20> quinine </e20> and lead to increased plasma concentrations.
mechanism	Caffeine Theobromine <e10> Caffeine </e10> may decrease the metabolism of <e20> atorvastatin </e20>, resulting in a lower blood level of the latter.
mechanism	Caffeine Theobromine <e10> Theobromine </e10> ( <e20> caffeine </e20> ) may increase the clearance of caffeine (by approximately 50%) and thus increase the plasma concentration of caffeine.
mechanism	Caffeine Theobromine <e10> Caffeine </e10> has been shown to interfere with the metabolism of <e20> tolbutamide </e20> and its derivatives by CYP3A4.
mechanism	Caffeine Theobromine <e10> Theobromine </e10> may interact with caffeine or <e20> caffeine </e20>.
mechanism	Caffeine Theobromine <e10> Caffeine </e10> may enhance the absorption of <e20> aspirin </e20> and other gastrointestinal medications by altering the net absorption of these medications.
mechanism	Caffeine Theobromine Grepafloxacin : <e12> Anticonvulsants </e12>, such as theobromine, can reduce the absorption of <e20> caffeine </e20>.
mechanism	Theophylline : <e10> Theophylline </e10> (40 mg) # days before <e20> warfarin </e20> # days before and # days after a single dose of warfarin # mg.
mechanism	Theophylline : <e10> Theophylline </e10> increases the metabolism of <e20> digoxin </e20> and itraconazole, increases its clearance, and increases the clearance of cyclosporine.
mechanism	Theophylline : <e10> Theophylline </e10> and other <e22> progestins </e22> may interfere with metabolism of Theophylline, resulting in a reduction in the serum levels of theophylline and other progestins.
mechanism	Serum theophylline concentrations were not affected by concomitant administration of <e11> FOSCAVIR </e11> with <e20> theophylline </e20>.
mechanism	Drugs Metabolized by CYP3A4: Concurrent use of <e10> erythromycin </e10> with: carbamazepine, phenytoin, alfentanil, cisapride, disopyramide, <e20> rifampin </e20>, bromocriptine, valproate, terfenadine, tamoxifen, or astemizole.
mechanism	Drugs Metabolized by CYP3A4: Drugs that are highly active in <e11> VIDEX </e11> (eg, <e20> ketoconazole </e20> ) are metabolized by CYP3A4, the major isozyme of the cytochrome P450 family.
mechanism	Drugs Metabolized by CYP3A4: Nizoral and metoclopramide, and certain other <e12> anticonvulsants </e12>, such as phenytoin, carbamazepine, phenobarbital, phenytoin_succinate, phenytoin, and phenytoin_hydrochloride, have been reported to inhibit metabolism of <e20> cisapride </e20>.
mechanism	In addition, other compounds, including digoxin, <e10> clofibrate </e10>, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e20> telithromycin </e20>, troleandomycin, and astemizole may reduce the clearance of rifabutin.
mechanism	In addition, other drugs that are CYP3A4 inhibitors, such as theophylline, <e10> ketoconazole </e10>, phenytoin, and itraconazole, have additive or potentiating effects with <e20> piperacillin </e20> for the absorption of cisapride.
mechanism	The administration of <e10> warfarin </e10> to patients receiving <e20> tetracycline </e20> has been reported to increase the pharmacokinetic profile of tetracycline.
mechanism	The administration of <e10> quinidine </e10> # mg q2w on the same day with a <e20> warfarin </e20> dose of # mg q3w is associated with a #-fold increase in warfarin clearance.
mechanism	The administration of <e10> nevirapine </e10> decreased the clearance of <e20> lamivudine </e20> by 35% (P =.016).
mechanism	The administration of <e10> rifampin </e10> # days after the administration of <e20> warfarin </e20> # days after the administration of warfarin (for the duration of # days) resulted in a significant increase in the prothrombin time, and a lower incidence of the decrease in prothrombin time with the concomitant administration of rifampin, warfarin, and cisapride.
mechanism	The administration of <e10> chlorprothixene </e10> may also inhibit the metabolism of <e20> astemizole </e20>.
mechanism	In a study in normal volunteers, <e10> cholestyramine </e10> (100 mg) taken # hours prior to <e20> levodopa </e20> increased the maximum plasma concentration (C(max)) by approximately 5%.
mechanism	In a study of volunteers with <e10> phenytoin </e10> concomitant use of <e20> ketoconazole </e20> and a single oral dose of # mg of either ketoconazole or ciprofloxacin, the area under the plasma concentration-time curve from # to # minutes of exposure was significantly lower with ketoconazole than with ciprofloxacin.
mechanism	In a study in patients with <e10> warfarin </e10> therapy, the pharmacokinetic profile of the CYP3A4 inhibitor <e20> warfarin </e20> was modified by concurrent use of the CYP3A4 inducer cimetidine, a P-glycoprotein inhibitor.
mechanism	In # other studies, <e10> ketoconazole </e10> increased the concentrations of <e20> warfarin </e20> in # subjects.
mechanism	In # other drugs, coadministration of <e10> enoxacin </e10> may have resulted in a reduction in the absorption of <e20> sildenafil </e20>.
mechanism	In # other studies, <e10> cimetidine </e10> reduced <e20> digoxin </e20> plasma concentrations by 15% to 30% and digoxin clearance by about 15%.
mechanism	<e10> Propranolol </e10> reduced the maximum plasma concentration of <e20> indinavir </e20> from # to # microM, suggesting that a #-microM increase in indinavir plasma levels may not be effective with propranolol.
mechanism	<e10> Propranolol </e10> inhibited the binding of <e20> cimetidine </e20> to the placental vasculature, and caused a reduction in its uptake by the placental endothelium.
mechanism	<e10> Propranolol </e10>, as well as other phenothiazines, inhibits <e20> levothyroxine </e20> metabolism, resulting in an increase in levothyroxine levels.
mechanism	Cholestyramine and colestipol decrease the absorption of <e11> VIDEX </e11> and <e20> enoxacin </e20>.
mechanism	Cholestyramine and colestipol : <e10> Cholestyramine </e10> reduced the plasma levels of <e20> colestipol </e20> and cholestyramine.
mechanism	Single doses of <e10> phenytoin </e10> # mg and # mg given to healthy volunteers resulted in a #% increase in plasma <e20> diltiazem </e20> concentrations.
mechanism	Single doses of <e11> FOSCAVIR </e11> decreased Cmax and AUC of <e20> fluvoxamine </e20>.
mechanism	Single doses of <e10> enoxacin </e10> # mg and <e20> probenecid </e20> # mg decreased Cmax by 18% and 15%, respectively.
mechanism	Single doses of <e10> digoxin </e10> # mg and <e20> aprepitant </e20> # mg reduced peak digoxin and aprepitant concentrations by #% and 9%, respectively.
mechanism	Single doses of <e10> ketoconazole </e10> reduced the renal clearance of <e20> astemizole </e20> by about 60% (P =.001).
mechanism	Single doses of <e11> PRINIVIL </e11> # mg produced a strong, dose-dependent inhibition of <e20> fluconazole </e20> in # healthy volunteers (IC(50) of # micrograms).
mechanism	<e12> Antacids </e12> may interfere with the absorption of oral <e22> anticoagulants </e22>.
mechanism	<e12> Antacids </e12> and sucralfate, and certain other <e22> hypoglycemic_agents </e22>, may interfere with the absorption of furosemide and its derivatives.
mechanism	<e12> Antacids </e12> containing magnesium, aluminum, or iron can reduce the absorption of <e20> lithium </e20>, and increase the plasma levels of lithium.
mechanism	Products containing <e10> quinidine </e10> may increase the clearance of <e20> phenytoin </e20> and its derivatives, as well as may decrease the clearance of nonsteroidal_anti-inflammatory_drugs.
mechanism	Products containing <e10> digoxin </e10>, isoniazid, methotrexate, or <e20> warfarin </e20>, which are metabolized by CYP2C9, may increase the plasma concentrations of digoxin, isoniazid, or warfarin.
mechanism	Products containing <e10> chloramphenicol </e10>, carbamazepine, and cyclosporine may decrease the clearance of <e20> diltiazem </e20>.
mechanism	Products containing calcium or aluminum, and aluminum containing products, and <e10> magnesium </e10> containing products may decrease the absorption of <e20> cefuroxime </e20>.
mechanism	Products containing calcium or iron, or containing <e10> zinc </e10>, may increase the clearance of <e20> cefditoren_aminol </e20>.
mechanism	Products containing calcium and/or magnesium in their concentration gradients with <e10> tetracycline </e10> may interfere with the serum elimination of <e20> Aprepitant </e20>.
mechanism	Methotrexate : <e10> Ketoconazole </e10> and indomethacin inhibit the metabolism of <e20> methotrexate </e20> by increasing the plasma concentration of this drug.
mechanism	Methotrexate : <e10> Furosemide </e10> may decrease the clearance of <e20> succinylcholine </e20>.
mechanism	Methotrexate : <e10> Methotrexate </e10> may increase the metabolism of <e20> warfarin </e20> and therefore prolong prothrombin time.
mechanism	Methotrexate : Ibuprofen and <e10> acetaminophen </e10> potentiated the effect of <e20> methotrexate </e20>.
mechanism	Methotrexate : Ibuprofen may enhance the effect of <e10> methotrexate </e10> on the kidneys and, thus, may increase the toxicity of <e20> methotrexate </e20>.
mechanism	Methotrexate : Ibuprofen, etodolac, and <e10> caffeine </e10> may increase the metabolism of <e20> methotrexate </e20>.
mechanism	Lithium : <e10> Sulfapyridine </e10> decreased the serum lithium level in healthy subjects and caused a decrease in <e20> lithium </e20> excretion.
mechanism	Lithium : <e10> Cholestyramine </e10> may increase the plasma concentrations of <e20> lithium </e20>, causing a shortening of the half-life of lithium in plasma.
mechanism	Lithium : <e10> Lithium </e10> increases the rate of metabolism of <e20> ketoconazole </e20>.
mechanism	There is a relationship between <e10> digoxin </e10> plasma levels and the degree of renal tubular acidification (rate of urine flow), resulting in increased absorption and systemic exposure of <e20> digoxin </e20>.
mechanism	There is a non-significant trend for a reduction in creatinine clearance in those on dorzolamide and <e10> clarithromycin </e10> compared with those on <e20> warfarin </e20>, but the change is not significant.
mechanism	There is a tendency for <e10> carbamazepine </e10> to increase the clearance of <e20> valproate </e20>, but the effect is not clinically significant.
mechanism	Pretreatment of healthy volunteers with <e10> ketoconazole </e10> (50 mg q days) resulted in a 20% decrease in the rate of hepatic metabolism of <e20> quinidine </e20> and a 38% increase in the rate of liver clearance of ketoconazole.
mechanism	Pretreatment of healthy volunteers with <e10> fluvoxamine </e10> (40 mg in a single dose) approximately doubled the AUC of <e20> amiodarone </e20> (1,000 mg) and decreased the Cmax and AUC of amiodarone.
mechanism	Pretreatment of healthy volunteers with <e10> ketoconazole </e10> at concentrations of # micrograms/mL and # micrograms/mL for # minutes decreased the plasma levels of <e20> fluconazole </e20> by about 40% and increased the half-life of fluconazole by about 30%.
mechanism	Drugs that may increase the serum concentration of <e11> SULAR </e11> include: Antacids, aluminum_hydroxide, and cephalosporins ( <e20> Cephalosporin </e20> ).
mechanism	Drugs that may enhance the metabolism of <e10> warfarin </e10> include: <e20> Sucralfate </e20>, decitabine, valdecoxib, phenytoin, isoniazid, bromocriptine, phenobarbital, rifampin, theophylline, valproate, valproate_HCl, lovastatin, terfenadine, cimetidine.
mechanism	Drugs that may enhance the metabolism of <e11> VIDEX </e11> include:-Ketoconazole : increases the plasma levels of <e20> VIDEX </e20> by about 3-fold.
mechanism	<e11> Gleevec </e11> has been reported to increase <e20> disopyramide </e20> clearance and therefore should be administered at least # hours after disopyramide.
mechanism	<e11> Gleevec </e11> is inhibited by theophylline, lithium, phenobarbital, digoxin, <e20> erythromycin </e20>, and coumarin.
mechanism	<e11> Gleevec </e11> may increase the clearance of other <e22> MAOI </e22> s.
mechanism	<e11> Gleevec </e11> may be decreased by <e20> digoxin </e20>.
mechanism	<e11> Gleevec </e11> and other carbamazepine_type_antiepileptic_drugs have been reported to interfere with the metabolism of <e20> diazepam </e20>.
mechanism	<e11> Gleevec </e11> has been reported to inhibit the metabolism of <e20> methotrexate </e20>.
mechanism	<e11> Gleevec </e11> also decreases the clearance of <e20> carbamazepine </e20>.
mechanism	Systemic exposure to <e11> INOmax </e11> may be decreased by concurrent administration of <e20> clofibrate </e20>.
mechanism	The plasma concentration of <e10> cimetidine </e10> may be increased by <e20> ethchlorvynol </e20> or other strong CYP3A4 inhibitors (e,g,, ketoconazole, itraconazole, nelfinavir, clarithromycin, nefazodone ).
mechanism	The plasma concentration of <e10> astemizole </e10> was decreased by approximately 50% and that of <e20> tamoxifen </e20> was decreased by approximately 25% when administered with the combination of these drugs.
mechanism	The plasma concentration of <e10> ketoconazole </e10> is increased by approximately 50% when coadministered with <e20> erythromycin </e20>.
mechanism	The plasma concentration of <e10> fluvoxamine </e10> was decreased to 10% when it was administered # hours after <e20> cyclosporine </e20> was administered.
mechanism	The plasma concentration of <e10> valdecoxib </e10> is increased when it is given concomitantly with <e20> alosetron </e20>.
mechanism	The plasma concentration of <e10> cimetidine </e10> is decreased by approximately 30% when the dose of # mg is increased to # mg, and the plasma concentration of <e20> ketoconazole </e20> is decreased by approximately 50% when the dose of # mg is increased to # mg.
mechanism	The plasma concentration of <e10> digoxin </e10> increases by approximately #% when administered with <e20> doxapram </e20>.
mechanism	The plasma concentration of <e10> diltiazem </e10> was significantly decreased by <e20> enoxacin </e20>.
mechanism	The plasma concentration of <e10> nifedipine </e10> is decreased by approximately 38% when it is given with <e20> halothane </e20>, a potent inducer of renal tubular acidification.
mechanism	The plasma concentration of <e10> cyclosporine </e10> decreased by 23% when administered with <e20> atorvastatin </e20>.
mechanism	The plasma concentration of <e10> lithium </e10> increases when <e20> diltiazem </e20> is coadministered.
mechanism	The plasma concentration of <e10> norethindrone </e10> was increased by approximately 50% when it was administered with <e20> prazosin </e20>.
mechanism	Increasing the indinavir dose to # mg/day has been reported to decrease the exposure of <e11> INDOCIN </e11> to #% of the total serum exposure of <e20> indinavir </e20>.
mechanism	Increasing the indinavir dose by # mg every # hours should be considered when <e10> indinavir </e10> is administered with <e20> ritonavir </e20>.
mechanism	<e10> Indinavir </e10> and <e20> indinavir </e20> have been shown to be incompatible when coadministered with HIV protease inhibitors.
mechanism	<e10> Indinavir </e10> and <e20> ritonavir </e20> are competitive inhibitors of the CYP2C9 isoenzyme.
mechanism	In normal volunteers, <e10> phenytoin </e10> increased the clearance of <e20> clofibrate </e20> by 15%.
mechanism	In normal volunteers, <e10> loxapine </e10> caused a dose-dependent decrease in <e20> caffeine </e20> AUC, Cmax, and AUC/Cmax and an increase in Cmax of caffeine.
mechanism	In normal volunteers, <e10> cimetidine </e10> increased the clearance of <e20> ketoconazole </e20> from 535 to 1410% and that of theophylline from 0 to 34%.
mechanism	In a study of patients with myasthenia gravis treated with <e10> clonidine </e10> and <e20> digoxin </e20>, myasthenia gravis relapse was reduced by #% and rhabdomyolysis was reduced by #%.
mechanism	In a study in which <e10> ciprofloxacin </e10> was administered concomitantly with either methotrexate or <e20> cyclosporine </e20>, serum methotrexate levels were approximately two-fold higher.
mechanism	When <e11> INDOCIN </e11> was administered to two dogs with postpartum thyroiditis, thyroid was hypothyroid and <e20> indocynate </e20> was required.
mechanism	When <e11> INDOCIN </e11> and <e20> terfenadine </e20> were administered concomitantly, a significant increase in plasma and hepatic concentrations of terfenadine was observed.
mechanism	<e11> INDOCIN </e11> and <e20> cholestyramine </e20> have additive effects when given concomitantly with an immunosuppressive agent (e,g,, clarithromycin, azathioprine, disopyramide, lithium ).
mechanism	<e11> INDOCIN </e11> is a potent inhibitor of HMG-CoA_reductase II and a weak inhibitor of P450scc, with a maximum decrease in plasma concentration of approximately 10% when given with <e20> rofecoxib </e20>.
mechanism	<e11> INDOCIN </e11> has been shown to inhibit the absorption of a variety of nonsteroidal_anti-inflammatory_drugs and some other drugs that have the potential to cause hepatic enzyme system overactivity, such as <e20> carbamazepine </e20>, phenytoin, alfentanil, and terfenadine.
mechanism	Capsules <e11> INDOCIN </e11> significantly inhibited the metabolism of <e20> isoniazid </e20>.
mechanism	Capsules <e11> INDOCIN </e11> administered with oral <e20> colestipol </e20>, an oral anticoagulant, increase plasma concentrations of colestipol and its metabolite indocynate and therefore reduce colestipol anticoagulant effects.
mechanism	Capsules <e11> INDOCIN </e11> may also inhibit the metabolism of <e20> doxorubicin </e20>.
mechanism	<e11> INDOCIN </e11> may interact with dopamine, norepinephrine, <e20> phenothiazines </e20>, and other CNS_depressants (e,g,, barbiturates, tranquilizers, barbiturates, opioids, general anesthetics, halothane, halothane_sodium, phenothiazines, thiazide_diuretics, and sodium_thiosulfate ).
mechanism	<e11> INDOCIN </e11> may decrease plasma <e20> cisapride </e20> levels and may increase plasma cisapride levels in patients taking nonselective monoamine_oxidase_(MAO) inhibitors ( SERTOGEN ) concomitantly.
mechanism	<e11> Betaseron </e11> can inhibit <e20> amphetamine </e20> metabolism by interfering with the metabolism of this drug in the liver and also in the central nervous system.
mechanism	<e11> Betaseron </e11> at 50 microM decreased <e20> carbamazepine </e20> levels by 38% and increased phosphorylation of ERK1/2 by 50% (P = 0.001 and P = 0.002, respectively).
mechanism	<e11> Betaseron </e11> has been shown to increase the bioavailability of <e20> cisplatin </e20> and carbamazepine.
mechanism	Furthermore it has been shown that <e10> ketoconazole </e10>, a drug that inhibits the metabolism of <e20> acetaminophen </e20>, increases the clearance of both drugs by inhibiting CYP3A4.
mechanism	Furthermore it has been demonstrated that <e10> indomethacin </e10> inhibits the metabolism of <e20> atorvastatin </e20>, resulting in a significant reduction in serum levels of the latter.
mechanism	Furthermore it has been demonstrated that <e10> indomethacin </e10> has a tendency to decrease the half-life of <e20> diltiazem </e20> and that there is a correlation between the half-life of these two drugs and the level of indomethacin in the blood.
mechanism	Carbamazepine : <e10> Carbamazepine </e10> may decrease the clearance of <e20> probenecid </e20> and concomitantly increase the serum levels of this prodrug.
mechanism	Carbamazepine : <e10> Carbamazepine </e10> has been reported to decrease the absorption of <e20> ketoconazole </e20>.
mechanism	Carbamazepine : <e10> Carbamazepine </e10> can inhibit the metabolism of <e20> dexamethasone </e20> and therefore may reduce the serum levels of dexamethasone.
mechanism	Phenytoin : <e10> Phenytoin </e10> has been reported to decrease the clearance of <e20> triazolam </e20> and have an additive effect with caffeine and other indomethacinophiles.
mechanism	Phenytoin : <e10> Phenytoin </e10> increased the clearance of <e20> dexamethasone </e20>, a known inhibitor of renal tubular secretion, by 26%.
mechanism	Phenytoin : <e10> Phenytoin </e10> decreased the plasma level of <e20> phenytoin </e20> by about 50%.
mechanism	Therophylline: A recent in vitro study demonstrated that <e10> Aprepitant </e10> ( theophylline ) may reduce the metabolism of <e20> therophylline </e20>, which has been demonstrated to cause bone loss.
mechanism	Valproate : A significant decrease in the plasma concentrations of <e10> valproate </e10> and its active metabolite, carbamazepine, and a reduction in <e20> digoxin </e20> and morphine plasma concentrations have been observed when plasma concentrations of these agents are increased.
mechanism	Valproate : A # mg/day increase in valproate to # mg/day increases the efficacy of <e10> ketoconazole </e10> by 11% and increases the efficacy of <e20> isoniazid </e20> by 38%.
mechanism	Valproate : A study in normal volunteers suggests that <e10> phenytoin </e10> may increase <e20> valproate </e20> clearance.
mechanism	Cimetidine : In patients on <e10> cimetidine </e10>, the metabolism of <e20> cimetidine </e20> may increase its plasma concentration.
mechanism	Cimetidine : In vitro, <e10> cimetidine </e10> inhibited <e20> indinavir </e20> uptake and did not decrease ritonavir plasma concentrations in healthy volunteers or in subjects with impaired renal function.
mechanism	Rifampicin : In a clinical trial in patients receiving <e10> rifampicin </e10> (1000 mg on day #) and <e20> diltiazem </e20> (6 mg on day #), the primary drug interaction was observed for diltiazem with a decrease in plasma concentrations of rifampicin.
mechanism	Rifampicin : In vitro <e10> rifampicin </e10> inhibited CYP1A2 and <e20> estrogens </e20> production and resulted in a higher half-life of estrogens and decreased AUC.
mechanism	Rifampicin : In a clinical study, <e10> rifampicin </e10> at # mg daily decreased plasma levels of <e20> amprenavir </e20> by approximately 40% and reduced the Cmax by approximately 15%.
mechanism	If <e10> rifampicin </e10> is added to the dose of <e20> propranolol </e20>, propranolol -induced plasma concentrations of both drugs may be increased.
mechanism	If <e10> rifampicin </e10> is used concomitantly with <e20> cyclosporine </e20>, an increase in the renal clearance of the latter may occur.
mechanism	Coadministration of <e10> alosetron </e10> # mg and <e20> pravastatin </e20> at # mg daily decreased alosetron plasma levels by 32% and increased pravastatin plasma levels by 37%.
mechanism	Coadministration of <e10> Aprepitant </e10> with other psychotropic_agents, anticonvulsants, anticholinergics, antifungals, atorvastatin, clofibrate, fluconazole, diltiazem, diazepam, efavirenz, flecainide, grapefruit juice, <e20> fluvoxamine </e20>, gabapentin, heparin, hepatic enzyme-inducing drugs (such as phenytoin, rifampin, and phenytoin_sulfate ), insulin, isoniazid, ketoconazole, lithium, macrolide_antibiotics (such as ketoconazole ), methadone, paroxetine, prednisolone, quinidine, sertraline, terfenadine, theophylline, and warfarin.
mechanism	Coadministration of <e10> alprazolam </e10> with <e20> digoxin </e20> # mg and a dose of # mg of norethindrone given once a day for # days produced significant reductions in digoxin levels, which were sustained for # days after the second dose.
mechanism	Another oral azole_antifungal such as <e10> itraconazole </e10>, miconazole, or rifampin can interfere with the metabolism of <e20> ketoconazole </e20> and may cause elevated serum levels.
mechanism	Another oral azole_antifungal, <e10> fluconazole </e10>, has been shown to increase the exposure of <e20> penicillin </e20>, ciprofloxacin, or cefazolin, which are potent inhibitors of CYP3A4, resulting in inhibition of the exposure of these drugs.
mechanism	In vitro data indicate that <e10> fluvoxamine </e10> may decrease the plasma levels of <e20> carbamazepine </e20>.
mechanism	In vitro data indicate that <e10> cimetidine </e10> may reduce the <e20> isoniazid </e20> renal clearance by a half-dose.
mechanism	In vitro data suggest that <e10> lymecycline </e10> inhibits the metabolism of the <e20> triazolam </e20> by increasing the activity of the cycloheximide.
mechanism	Human pharmacokinetics data from clinical studies of <e10> diltiazem </e10> suggest a reduction in the AUC of <e20> digoxin </e20> by approximately 50% and an increase in AUC of digoxin by approximately 25%.
mechanism	Human pharmacokinetics data suggest that <e10> nelfinavir </e10>, <e20> ritonavir </e20>, and tenofovir significantly reduce the clearance of tetracycline in patients with high cytochrome P450 2C19 activity.
mechanism	Human pharmacokinetics data indicate that <e10> phenytoin </e10> can decrease the clearance of <e20> doxorubicin </e20> by approximately 11% and the AUC by approximately 10%.
mechanism	In vitro data suggest that <e10> ketoconazole </e10> may inhibit the metabolism of <e20> methotrexate </e20>.
mechanism	In vitro data suggest that <e10> cyclosporine </e10> may decrease the plasma concentrations of <e20> diltiazem </e20> and alfentanil.
mechanism	Coadministration of <e10> diltiazem </e10> # mg and <e20> warfarin </e20> # mg significantly increased the half-life of warfarin from # to # hours.
mechanism	Coadministration of <e10> digoxin </e10> and <e20> digoxin </e20> at steady state resulted in a significant decrease in serum digoxin levels.
mechanism	Coadministration of <e10> valdecoxib </e10> with theophylline (theophylline receptor antagonist) # mg/day for # days resulted in a significant (P <.05) reduction of <e20> theophylline </e20> AUC.
mechanism	Coadministration of <e10> probenecid </e10> with <e20> erythromycin </e20> resulted in a 17% decrease in the clearance of the active drug.
mechanism	Coadministration of <e10> dapsone </e10> # mg # times with oral <e20> lithium </e20>, a lithium-sparing agent, resulted in a #-fold increase in lithium concentrations.
mechanism	Coadministration of <e10> erythromycin </e10> (10 mg q24h) and <e20> cimetidine </e20> (25 mg q24h) in normal volunteers resulted in a significant increase in Cmax and AUC of cimetidine.
mechanism	When <e10> Itraconazole </e10> was coadministered with <e20> carbamazepine </e20>, the AUC of Itraconazole was reduced by 22% and the Cmax by 29%.
mechanism	When <e10> Itraconazole </e10> was given concomitantly with <e20> cimetidine </e20>, plasma cimetidine levels increased by #% and plasma Itraconazole levels decreased by 8%.
mechanism	When <e10> Itraconazole </e10> and <e20> warfarin </e20> were coadministered, there was a significant reduction in warfarin dose.
mechanism	When <e10> Itraconazole </e10> is given concomitantly with <e20> ketoconazole </e20>, a 7% increase in serum Itraconazole level is observed.
mechanism	When <e10> Itraconazole </e10> was coadministered with <e20> alfentanil </e20>, a 38% increase in alfentanil exposure was observed in the stomach of # of # subjects.
mechanism	When <e10> Itraconazole </e10> is co-administered with <e20> phenytoin </e20>, the AUC of Itraconazole is reduced by about 20% compared to when phenytoin is given alone.
mechanism	Although no studies have been performed to determine the potential for a synergistic effect with concomitant use of <e10> alprazolam </e10> and other <e22> benzodiazepines </e22>, it is likely that an interaction with benzodiazepines may occur.
mechanism	Although no studies have been conducted, coadministration of <e10> probenecid </e10> and <e20> dapsone </e20> resulted in an increase in the frequency of metronidazole-induced side effects (eg, anorexia and vomiting) and a decrease in the overall mean peak plasma levels of probenecid.
mechanism	Plasma concentrations of <e10> ketoconazole </e10> decreased approximately 20% when <e20> valdecoxib </e20> and ketoconazole were coadministered.
mechanism	Plasma concentrations of <e10> rifampin </e10> and midazolam were decreased by approximately 25% when coadministered with <e20> carbamazepine </e20>.
mechanism	Plasma concentrations of <e10> astemizole </e10> were increased by #- to #-fold when <e20> phenytoin </e20> and vitamin_C were coadministered with astemizole, and the concentration of astemizole was decreased when vitamin_C was coadministered with astemizole.
mechanism	Even when an <e12> anticonvulsant </e12> is administered in combination with <e20> terfenadine </e20>, an increase in anticonvulsant plasma levels may be expected.
mechanism	Even when an <e12> aminoglycoside </e12> such as <e20> clarithromycin </e20> is used with such drugs as tetracycline, the resulting ciprofloxacin elimination half-life is prolonged by approximately 20% and approximately 50%, respectively.
mechanism	The following drug interactions have been observed with <e10> loratadine </e10> concomitantly with the following medications: amiodarone, amiodarone / carbamazepine, diazepam, diazepam / <e20> phenobarbital </e20>, phenobarbital / carbamazepine, phenobarbital / triazolam, triazolam / carbamazepine, triazolam / phenobarbital, triazolam / phenytoin, and amiodarone / carbamazepine.
mechanism	The following drug combinations have been shown to decrease the rate of metabolism of <e10> atorvastatin </e10> : valdecoxib (35 mg, qd), co-administration of <e20> warfarin </e20> (100 mg, qd), theophylline (100 mg, qd), fluconazole (50 mg, b,i,d), cimetidine (50 mg, b,i,d), phenytoin (10 mg, qd), rifabutin (50 mg, b,i,d), fluvoxamine (25 mg, qd), furosemide (10 mg, b,i,d), isoniazid (1 mg, qd), amiodarone (100 mg, qd), indinavir (50 mg, b,i,d), and disulfiram (50 mg, b,i,d).
mechanism	Human pharmacokinetics data suggest that <e10> ciprofloxacin </e10> may be absorbed from the gastrointestinal tract when administered concomitantly with probenecid, valdecoxib, and <e20> rifabutin </e20>.
mechanism	Human pharmacokinetics data suggest that <e11> VIOXX </e11> is more potent than <e20> levodopa </e20> in inhibiting hepatic metabolism of the CYP3A4 substrate aprepitant.
mechanism	Human pharmacokinetics data indicate that the AUC for <e10> diltiazem </e10> was enhanced by #-fold by <e20> diltiazem </e20> concomitantly with the addition of ciprofloxacin.
mechanism	<e10> Ketoconazole </e10> significantly reduced the <e20> rifabutin </e20> and the rifabutin AUC by 21% and 24%, respectively.
mechanism	<e10> Ketoconazole </e10> may decrease the bioavailability of <e20> fluconazole </e20>.
mechanism	<e10> Ketoconazole </e10> markedly potentiates the elimination of <e20> fluconazole </e20> and other fluconazole s.
mechanism	<e10> Ketoconazole </e10> may enhance the metabolism of <e20> doxorubicin </e20>.
mechanism	<e10> Ketoconazole </e10> may increase the <e20> nevirapine </e20> plasma levels.
mechanism	<e10> Ketoconazole </e10> significantly decreased the <e20> rifabutin </e20> half-life and increased the elimination half-life of rifabutin.
mechanism	Coadministration of <e11> INDOCIN </e11> with <e20> diltiazem </e20> decreased diltiazem clearance by 27% to 34%.
mechanism	Coadministration of <e11> COREG </e11> with other anticonvulsants, phenytoin, carbamazepine, phenobarbital, phenytoin (but not <e20> phenytoin </e20> with a concurrent # mg/kg dose), or other anticonvulsants with a concurrent # mg/kg dose of COREG resulted in an increase in AUC of the concomitant anticonvulsant with COREG of approximately 40% to 50%.
mechanism	Coadministration of <e11> LEVSIN </e11> with <e20> isoniazid </e20> (a cephalosporin ) resulted in a 10% decrease in total and steady-state concentrations of LEVSIN.
mechanism	Coadministration of <e11> COREG </e11> with <e20> carbamazepine </e20> reduced the AUC of carbamazepine by about 43% but did not affect the AUC of either sumatriptan or nevirapine.
mechanism	Concomitant administration of <e10> doxycycline </e10> with an <e22> beta-adrenergic_blocking_agent </e22> or an antihypertensive_drug (holds a single beta-blocker) has been shown to increase the AUC and decrease the Cmax of doxycycline.
mechanism	Concomitant administration of <e10> phenytoin </e10> with <e20> halothane </e20> and cisplatin.
mechanism	Concomitant administration of <e10> amiodarone </e10> with <e20> cisapride </e20> resulted in decreased concentrations of cisapride, resulting in decreased pharmacokinetic parameters for cisapride.
mechanism	Concomitant administration of <e10> norethindrone </e10> with all other CYP3A4 substrates (alpha,beta-methylphenidate, cyclosporine, <e20> amiodarone </e20>, phenobarbital, phenytoin, carbamazepine, clarithromycin, flecainide, gabapentin, miconazole, phenytoin, rifampin, theophylline, triazolam, theophylline ) may increase the clearance of the parent drug and, therefore, decrease the dose required to achieve target plasma levels.
mechanism	Concomitant administration of <e10> carbamazepine </e10> and <e20> rifampin </e20> increases the half-life of carbamazepine.
mechanism	Concomitant administration of <e11> BREVIBLOC </e11> and other drugs that are potent inhibitors of CYP3A4 (e,g,, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, indinavir, <e20> saquinavir </e20>, telithromycin, troleandomycin, troleandomycin plus clarithromycin, troleandomycin plus itraconazole, troleandomycin plus indinavir, and itraconazole ) may decrease the bioavailability of a therapeutic dose of BREVIBLOC.
mechanism	<e10> INH </e10> increases the <e20> valproic_acid </e20> : ACE_inhibitors ratio.
mechanism	<e10> INH </e10> was shown to enhance the pharmacokinetics of <e20> nevirapine </e20> and to cause increased exposure to the active metabolite of nevirapine, ethinyl_estradiol, as measured in plasma and urine.
mechanism	<e10> INH </e10> can enhance the metabolism of <e20> ergotamine </e20>.
mechanism	INH ( <e10> erythromycin </e10> ) has been reported to increase the hepatic clearance of <e20> ketoconazole </e20>.
mechanism	INH ( <e10> erythromycin </e10> ) and ARAVA ( <e20> rifampin </e20> ) inhibit and increase the absorption of dorzolamide, respectively.
mechanism	After the coadministration of <e10> dextromethorphan </e10> and <e20> haloperidol </e20>, serum and urine samples taken at multiple time points during the study showed a marked decrease in the AUC of haloperidol.
mechanism	After the coadministration of <e10> enoxacin </e10> # mg, an increase in Cmax, AUC, and t1/2 were observed, but not significant, for the following: <e20> cisapride </e20>, carbamazepine, phenobarbital, phenytoin, astemizole, primidone, triazolam, theophylline, valproic_acid, and rifampin.
mechanism	After the coadministration of <e10> erythromycin </e10> and <e20> warfarin </e20>, the prothrombin time and INR were increased (by approximately 11% and 4%, respectively) and the prothrombin time to INR was decreased (by approximately 20% and approximately 15%, respectively).
mechanism	however, in a study in healthy volunteers, a reduction of <e10> ketoconazole </e10> serum levels was observed after coadministration of <e20> rifampin </e20>.
mechanism	however, in a study in which patients were treated with high doses of <e11> HUMORSOL </e11> for # weeks, <e20> fluconazole </e20> and cisplatin plasma concentrations were reduced by 43% and 30%, respectively, when HUMORSOL was coadministered with high doses of fluconazole.
mechanism	however, in a study in normal volunteers with no other co-morbidities who were administered oral <e10> indinavir </e10> and <e20> teniposide </e20>, a reduction in indinavir serum levels was observed with the addition of TID to # mg/day.
mechanism	however, in a small study, it was observed that <e10> cisapride </e10> increased plasma levels of <e20> bromocriptine_mesylate </e20>, a known inhibitor of hepatic metabolism, by #-fold.
mechanism	Probenecid : <e10> Probenecid </e10> has been reported to increase plasma levels of <e20> cimetidine </e20>, thereby potentially increasing the renal clearance of cimetidine.
mechanism	Probenecid : <e10> Probenecid </e10> has been reported to increase <e20> phenytoin </e20> absorption and metabolism, thereby increasing phenytoin serum concentrations.
mechanism	Probenecid : <e10> Probenecid </e10> significantly reduced <e20> baclofen </e20> -induced release of a phosphorylated cAMP intermediate (P3).
mechanism	Methotrexate : <e10> Quinidine </e10> decreased the cytochrome P450 3A4 activity by 40% compared to that seen with <e20> ketoconazole </e20>.
mechanism	Methotrexate : <e10> Dexamethasone </e10> increased the exposure of <e20> methotrexate </e20> to a greater extent than did other glucocorticoids, and elevated the oral clearance of methotrexate to a greater extent than did other glucocorticoids.
mechanism	Lithium : <e12> Amphetamines </e12> increase <e20> lithium </e20> clearance and thus cause an increase in serum lithium concentrations.
mechanism	Lithium : <e12> Barbiturates </e12> may decrease the bioavailability of <e20> lithium </e20>.
mechanism	Warfarin, Digoxin, and Phenytoin : <e10> Zidovudine </e10> may potentiate the effects of these anticoagulant_drugs, causing increases in warfarin and <e20> digoxin </e20> concentrations and prolongation of the half-life of these drugs.
mechanism	Warfarin, Digoxin, Phenytoin, Chlordiazepoxide, and <e10> Dexamethasone </e10> may inhibit metabolism of <e20> tetracycline </e20>.
mechanism	In vitro studies in rat muscle showed a significant inhibition of <e10> phenytoin </e10> -induced <e20> phenobarbital </e20> and carbamazepine in a dose-dependent manner.
mechanism	In vitro studies in macrophages have shown that <e10> cisapride </e10> (10(-8)-10(-6) M) significantly inhibited <e20> carbamazepine </e20> (10(-8)-10(-6) M) and indomethacin (10(-8)-10(-6) M) uptake at a concentration of # x 10(-9) M and inhibited the concomitant Cys-X-X-X-7 complex (X = Q, Y, Z, A, or H) reduction by 40% to 50%.
mechanism	In vitro studies with two drugs that have been shown to interfere with the metabolism of <e10> cyclosporine </e10>, tacrolimus, and verapamil, as well as with <e20> carbamazepine </e20>, suggest that these drugs may decrease the plasma concentration of cyclosporine and its metabolite, doxycycline.
mechanism	Probenecid : Concomitant administration of <e10> probenecid </e10> with <e20> erythromycin </e20> may result in increased clearance of erythromycin.
mechanism	Probenecid : Concomitant administration of <e10> probenecid </e10> with <e20> digoxin </e20>, ketoconazole, and other drugs that induce CYP3A4 activity (e,g,, fluconazole, carbamazepine, itraconazole, phenobarbital, phenytoin, rifampin, methadone, tacrolimus, and quinidine ) has been reported to result in elevated plasma levels of digoxin and digoxin-associated drugs, as well as potential for increased digoxin exposure in patients.
mechanism	Probenecid : Concomitant administration of <e10> probenecid </e10> and <e20> rifabutin </e20> resulted in the following: Rifabutin increased probenecid concentrations, increasing the half-life of probenecid by # days and decreasing the maximum plasma concentration of probenecid by 38%.
mechanism	The effect of <e12> antacids </e12> is to prevent absorption of <e20> digoxin </e20>.
mechanism	Methotrexate : Concomitant administration of <e10> almotriptan </e10> and <e20> methotrexate </e20> resulted in increased hepatic AUC and Cmax of almotriptan.
mechanism	Methotrexate : Concomitant administration of <e10> methotrexate </e10> and <e20> cisapride </e20> may prolong plasma levels of methotrexate.
mechanism	Methotrexate : Concomitant use of <e10> methotrexate </e10> with <e20> clofibrate </e20> increased the rate of renal clearance by 5% to 10%.
mechanism	Ibuprofen-<e10> Acetazolamide </e10> # mg in one hour reduced <e20> ibuprofen </e20> # mg and acetazolamide plasma concentrations by 44% and 27%, respectively.
mechanism	Ibuprofen-<e10> Ibuprofen </e10> decreased <e20> ketoconazole </e20> and did not alter the plasma concentrations of nifedipine.
mechanism	Ibuprofen-<e10> Ibandronate </e10> increases the clearance of <e20> ibuprofen </e20>.
mechanism	Concomitant use of <e10> chloramphenicol </e10> and <e20> anidulafungin </e20> may cause a decrease in the plasma concentrations of the latter.
mechanism	Concomitant use of <e10> digoxin </e10> may potentiate the effects of <e20> ketoconazole </e20>.
mechanism	Concomitant use of <e10> warfarin </e10> and <e20> cyclosporine </e20> is associated with an increased incidence of adverse events in patients receiving either of these drugs concurrently.
mechanism	<e10> Cimetidine </e10> decreased the maximum plasma concentration of <e20> succinylcholine </e20> by 40% (90% effective concentration, EC(50)) and decreased the t(1/2) of succinylcholine by 46% (80% effective concentration, EC(90)) and reduced the elimination rate of succinylcholine by 50% (98% effective concentration, EC(90)), respectively.
mechanism	<e10> Cimetidine </e10> and ketoconazole may interfere with <e20> warfarin </e20> metabolism, increasing its half-life.
mechanism	<e10> Cimetidine </e10>, a nonsteroidal_anti-inflammatory_drug, has been reported to inhibit metabolism of <e20> ketoconazole </e20>.
mechanism	Results of preliminary in vitro studies suggest that <e10> valdecoxib </e10> may decrease the exposure of <e20> cyclosporine </e20>, tacrolimus, disopyramide, phenytoin, phenobarbital, and theophylline.
mechanism	Results of preliminary in vitro studies indicate that <e11> INDOCIN </e11> may enhance the metabolism of ketoconazole and other <e22> macrolide_antibiotics </e22>, resulting in decreased plasma concentrations of the macrolide.
mechanism	Results of preliminary studies of <e10> ketoconazole </e10> and <e20> cisapride </e20> indicate that a single dose of cisapride can reduce the hepatic metabolite concentration by a factor of 3.5-6.
mechanism	When <e10> lansoprazole </e10> was coadministered with <e20> lithium </e20>, the lithium clearance was increased by about 20% compared to lithium alone, and the lithium plasma levels were elevated approximately 5% compared to lithium alone.
mechanism	When <e10> lansoprazole </e10> was administered concomitantly with <e20> erythromycin </e20>, approximately 20% of the patients experienced a decrease in steady-state serum concentrations of the # mg/day regimen of erythromycin.
mechanism	When <e10> lansoprazole </e10> was administered concurrently with <e20> clorazepate </e20>, a significant increase in bodyweight was observed, and a significantly higher maximum plasma concentration (C(max)) of lansoprazole was observed when clorazepate was administered concurrently with lansoprazole.
mechanism	In a single-dose, oral dose study, <e10> gabapentin </e10> (100 mg twice daily) significantly increased the area under the curve of <e20> cisapride </e20> from #% to #%, with an increase in peak plasma cisapride concentration of #% from # to # micrograms/mL.
mechanism	In a single-dose study in healthy volunteers, <e10> isoniazid </e10> # mg and <e20> rifampin </e20> # mg significantly decreased the rate of CYP3A4 induction by ethinyl_estradiol.
mechanism	In a single-dose study in healthy volunteers, <e10> terfenadine </e10> at # mg # min prior to <e20> aspirin </e20> (300 mg) reduced the AUC of vitamin_C by 17%.
mechanism	therefore, it is not known whether <e10> furosemide </e10> can be used to decrease the <e20> phenytoin </e20> plasma concentration.
mechanism	therefore, it is expected that <e10> carbamazepine </e10> has a potential to reduce the metabolism of <e20> valproic_acid </e20> by inhibiting its renal excretion.
mechanism	therefore, it is possible that <e10> probenecid </e10>, coadministered with <e20> quinidine </e20>, may also enhance the nephrotoxicity of quinidine.
mechanism	therefore, it is possible that <e10> dexamethasone </e10> may interfere with <e20> lithium </e20> metabolism, thus reducing lithium concentrations in the blood and leading to a higher lithium toxicity.
mechanism	therefore, it is concluded that <e10> warfarin </e10>, when administered with <e20> estrogens </e20>, increases the pharmacokinetic profile of warfarin, causing the concentration to decrease and the half-life to increase.
mechanism	therefore, it is suggested that <e10> ketoconazole </e10>, which is a well-established inducer of hepatic metabolism of <e20> carbamazepine </e20>, may have an effect on carbamazepine pharmacokinetics, as well.
mechanism	therefore, it is likely that the metabolism of <e10> isoniazid </e10> can be affected by <e20> sildenafil </e20>.
mechanism	therefore, it is not clear whether <e10> warfarin </e10> coadministration will decrease the effectiveness of <e20> theophylline </e20>, phenytoin, tacrolimus, or astemizole.
mechanism	therefore, it is concluded that <e10> ketoconazole </e10> inhibits the metabolism of <e20> cisapride </e20> and that a ketoconazole intake of 50 mg daily can reduce the plasma concentration of cisapride by approximately 35%.
mechanism	therefore, it is not recommended to co-administrate <e10> cyclosporine </e10> with <e20> estrogens </e20> and progestins, including drospirenone, because of the possibility of a 5-fold increase in the half-life of estrogens.
mechanism	therefore, it is recommended that <e10> chlorpropamide </e10> be used with caution in patients undergoing <e20> cyclosporine </e20> treatment.
mechanism	therefore, it is recommended that <e10> nelfinavir </e10> and <e20> ritonavir </e20> be administered at least # hours apart, or at least # hours apart, in patients receiving ciprofloxacin.
mechanism	Ketoconazole : In vitro studies have shown that <e10> ketoconazole </e10> blocks the absorption of <e20> loratadine </e20>, causing a decrease in plasma levels of loratadine.
mechanism	Ketoconazole : In a single study, a 3-day regimen of <e10> ketoconazole </e10> was found to result in a mean decrease in half-life of <e20> cisapride </e20> from # to # minutes.
mechanism	Carbamazepine : In a study of subjects with mild to moderate carbamazepine toxicity, the oral <e12> anticonvulsant </e12> carbamazepine was associated with increased levels of <e20> carbamazepine </e20> in the blood and urine.
mechanism	Carbamazepine : In an in vitro study of carbamazepine, <e10> loratadine </e10> and <e20> carbamazepine </e20> in a concentration- and time-dependent manner inhibited CYP2D6 activity.
mechanism	Carbamazepine : In vitro <e10> carbamazepine </e10> has been shown to increase <e20> diazepam </e20> elimination by approximately 10% and decrease diazepam elimination by approximately 3%.
mechanism	Cholestyramine and Charcoal : <e10> Cholestyramine </e10> may increase <e20> dexamethasone </e20> absorption and decrease its glucuronidation.
mechanism	Cholestyramine and Charcoal Briquettes : Although the mechanism by which <e10> cholestyramine </e10> and <e20> charcoal briquettes </e20> inhibit platelet function is unknown, increased uric acid and decreased prostaglandin levels have been reported with cholestyramine and charcoal briquettes respectively.
mechanism	Cholestyramine and Charcoal Tablets <e10> Cholestyramine </e10> in combination with <e20> methotrexate </e20> increases the toxicity of methotrexate by causing a more prolonged elimination of methotrexate.
mechanism	Cholestyramine and Charcoal in a single dose decreased <e10> indomethacin </e10> by 32% and increased <e20> disulfiram </e20> by 39%.
mechanism	Cholestyramine and Charcoal Sulfonate : <e10> Cholestyramine </e10> may inhibit the metabolism of <e20> sulfonamides </e20>.
mechanism	Rifampin : Following administration of a single dose of <e10> rifampin </e10> # mg, a decrease in the plasma level of <e20> nelfinavir </e20> was observed.
mechanism	Rifampin : Following concomitant administration of <e10> Rifampin </e10> and <e20> cyclosporine </e20>, a single dose of # mg of cyclosporine (in the presence of # mg of Rifampin ) significantly decreased AUC by 50% and Cmax by 44%.
mechanism	Rifampin : Following concomitant administration of <e10> cimetidine </e10> and <e20> rifampin </e20> in healthy volunteers, an approximately 40% reduction in maximum plasma concentrations of cimetidine was observed.
mechanism	Effect of AEDs <e10> Fluvoxamine </e10> and <e20> diltiazem </e20> were significantly increased by carbamazepine, theophylline, phenobarbital, and diltiazem, and decreased by phenytoin.
mechanism	Effect of AEDs on <e10> phenytoin </e10> metabolism (Cmax, AUC) can be affected by the concomitant administration of <e20> carbamazepine </e20>, with the resultant increase in AED plasma concentrations.
mechanism	Although no clinical studies have been conducted to evaluate the metabolism of <e10> diazepam </e10> in patients receiving <e20> carbamazepine </e20>, the possibility of a drug interaction has been suggested.
mechanism	Although no clinical studies have been conducted to evaluate the effects of coadministration of <e10> nevirapine </e10> with <e20> ciprofloxacin </e20>, it is likely that ciprofloxacin increases nevirapine exposure in the presence of the latter.
mechanism	Although no clinical studies have been performed, <e10> chloramphenicol </e10> may decrease the oral absorption of <e20> digoxin </e20>.
mechanism	Although no clinical studies have been performed, it is likely that the plasma concentrations of <e10> fluvoxamine </e10> and <e20> fluvoxamine_hydrochloride </e20> may be increased by concomitant administration of other anticonvulsants, some cephalosporins, cyclosporine, some ampicillin/sulfamethoxazole s, glimepiride, sulfonamides, amiodarone, some halothane_sulfonamides, and quinidine.
mechanism	Although no clinical studies have been done to test if <e10> acetaminophen </e10> and phenobarbital may interfere with <e20> methotrexate </e20>, there is the possibility that methotrexate may interfere with acetaminophen metabolism.
mechanism	Although no clinical studies have been conducted, the inhibition of CYP2D6 by <e10> terfenadine </e10> may contribute to decreased clearance of <e20> alfentanil </e20>.
mechanism	Although no clinical studies have been conducted to determine if <e10> diltiazem </e10> is capable of completely blocking <e20> digoxin </e20> absorption, it is likely that the degree of inhibition will be significant.
mechanism	Although no clinical studies have been done to compare the potential of two <e12> quinolones </e12> in decreasing the levels of <e20> phenytoin </e20>, these agents may have the potential to increase the plasma levels of phenytoin.
mechanism	However, the systemic exposure of <e11> BREVIBLOC </e11> is reduced by about 50% when administered concomitantly with other <e22> anticholinesterase_agents </e22>.
mechanism	However, the systemic clearance of <e10> adenosine </e10> was increased by #-fold in #-mg/kg, #-fold in #-mg/kg, and #-fold in #-mg/kg body weight adenosine when administered concomitantly with <e20> propranolol </e20>.
mechanism	However, the systemic administration of <e11> BOTOX </e11> can inhibit the metabolism of the <e22> macrolide_antibiotics </e22> and increase the bioavailability of fluconazole and ciprofloxacin.
mechanism	However, the systemic effects of <e10> ciprofloxacin </e10> may be potentiated by <e20> alcohol </e20>, sulfonamides, and chloramphenicol.
mechanism	However, the systemic administration of <e10> amiodarone </e10> (10 mg/kg, s,c,) produced a significant increase in the plasma levels of <e20> phenytoin </e20> (40 mg/kg, p,o,, s,c), which was prevented by coadministration of the vitamin_B12_antagonist ethinyl_estradiol and of the vitamin_B12_inhibitor cisapride (5 mg/kg, s,c,) or by coadministration of a vitamin_B12_preparation containing in vivo vitamin_B12 (100 mg/kg, p,o,, s,c).
mechanism	However, the systemic clearance of <e10> furosemide </e10> was greater in rats with renal insufficiency and <e20> halothane </e20> treatment than in rats with normal renal function.
mechanism	Levothyroxine_Sodium Absorption: The addition of <e10> diflunisal </e10> to levothyroxine_sodium increased absorption of <e20> levothyroxine_sodium </e20>.
mechanism	Levothyroxine_Sodium Absorption: The metabolism of <e11> HUMORSOL </e11> may result in a decreased absorption of <e20> levothyroxine_sodium </e20>.
mechanism	Levothyroxine_Sodium Absorption: The rate of absorption of <e10> methotrexate </e10> is decreased by the concomitant administration of <e20> thyroid_preparation </e20> and antithyroid_agents.
mechanism	Levothyroxine_Sodium Absorption: The metabolism of <e11> VIDEX </e11> and <e20> tetracycline </e20> may be inhibited by high doses of these drugs.
mechanism	Binding to Serum : In vivo studies have demonstrated a significant decrease in the exposure of <e10> propranolol </e10> in patients receiving high dose <e20> fluvastatin </e20>.
mechanism	Binding to Serum Albumin : Since the concentrations of <e10> rifabutin </e10> are increased when the drug is given with <e20> carbamazepine </e20>, it is suggested that carbamazepine, which has a strong binding to serum albumin, may interfere with the elimination of rifabutin.
mechanism	Binding to Serum Serum-Thrombolysis Inhibitors : <e10> Itraconazole </e10> significantly decreased the mean serum concentration of <e20> valdecoxib </e20> by 30%.
mechanism	Binding to Serum Proteins : <e10> Dexfenfluramine </e10> reduced the serum concentrations of digoxin and <e20> phenytoin </e20>, but not that of digoxin and warfarin.
mechanism	Binding to Serum Albumin: <e10> Cimetidine </e10> decreased the serum concentrations of <e20> digoxin </e20> and digoxin_HCl by approximately 33% and approximately 26%, respectively.
mechanism	Binding to Serum and Other Serum Serum Proteins: <e10> Cholestyramine </e10> was studied in serum of healthy volunteers (n = 10) after intravenous administration of Cholestyramine at doses of #, #, and # mg and in serum of patients with acute pancreatitis (n = 5) after #, #, and # mg of <e20> cholestyramine </e20> daily for # days.
mechanism	Binding to Serum, Plasma, or Erythrocyte In this study, the following pharmacokinetic parameters were compared for a <e10> fluconazole </e10> (60 mg q12h) and a <e20> quinolone_antibiotic </e20> (4 mg q12h) in healthy subjects: Cmax of fluconazole was 13% higher than that of quinolone_antibiotic, AUC was 46% higher, and AUMC was 15% higher in healthy subjects receiving fluconazole than in healthy subjects receiving quinolone_antibiotic.
mechanism	Binding to Serum Albumin or Fibrinogen : <e10> Cimetidine </e10> inhibits the binding of <e20> digoxin </e20> to serum albumin or fibrinogen and the effect of cimetidine is enhanced by increasing the fibrinogen and/or serum albumin concentration.
mechanism	Binding to Serum: Serum : Concomitant <e10> doxycycline </e10> and <e20> furosemide </e20> administration may decrease the clearance of furosemide.
mechanism	Binding to Serum Proteins: Thus, <e10> ketoconazole </e10> inhibited <e20> cefditoren_pivoxil </e20> in vitro by approximately two-thirds.
mechanism	Binding to Serum Aspirin : <e10> Vardenafil </e10> has been reported to inhibit the binding of <e20> aspirin </e20> to serum aspirin.
mechanism	Binding to Serum and Kidneys: <e10> Cimetidine </e10> did not decrease <e20> erythromycin </e20> serum exposure.
mechanism	Binding to Serum: <e10> Furosemide </e10> and <e20> sulfasalazine </e20> cause a significant reduction in the binding of furosemide to serum and to the concomitant reduction in the serum concentration of furosemide.
mechanism	Binding to Serum Isolated Cells: Plasma levels of <e10> digoxin </e10> and <e20> ethinyl_estradiol </e20> increase by approximately 50% when digoxin is administered in combination with either # mg/day of a 5-HT1_agonist (e,g,, ketoconazole ) or # mg/day of a 5-HT2_agonist (e,g,, ketoconazole ).
mechanism	Binding to Serum-In vitro studies indicate that <e10> warfarin </e10> is active against the CYP3A4 substrate quinolone_antibiotics like <e20> ciprofloxacin </e20> and norfloxacin.
mechanism	Binding to Serum: The concomitant administration of <e10> fluvoxamine </e10> and an anticoagulant such as <e20> warfarin </e20> may lead to a prolongation of the half-life of warfarin.
mechanism	Binding to Serum Proteins: Because <e10> pentamidine </e10> is in its active-site (amino acid) form, it may increase the serum level of certain <e22> bone-forming_agents </e22>, including calcium_antagonist_agents, which require the binding of serum proteins to form.
mechanism	Binding to Serum Albumin, Co-administration of <e10> Vardenafil </e10> (a micro-dose <e20> HIVID </e20> ) and/or fluconazole was associated with increased serum levels of Vardenafil (approximately 1-fold increase).
mechanism	Binding to Serum: In vitro, <e10> diazoxide </e10> inhibited the binding of <e20> atorvastatin </e20> to serum by 50% and that of its metabolite to serum by 60%.
mechanism	Binding to Serum Protein: Cimetidine and <e10> carbamazepine </e10> may interact with serum protein, causing a decrease in <e20> cimetidine </e20> clearance.
mechanism	Binding to Serum: <e12> Aminoglycosides </e12> inhibit the metabolism of <e20> sucralfate </e20>, resulting in increased serum levels of sucralfate.
mechanism	Binding to Serum, Oral Coadministration: <e10> Rifampin </e10>, the metabolism of which is by CYP3A4 is closely controlled by <e20> alprazolam </e20>, may decrease the effect of this drug on the clearance of alprazolam, and thus increase the blood concentrations of alprazolam.
mechanism	Binding to Serum Albumin: Co-administration of <e11> ENBREL </e11> with <e20> serum albumin </e20> has been shown to increase the rate of clearance of enoxacin by approximately 30% and that of theophylline by approximately 30%.
mechanism	Binding to Serum Proteins: Interaction of <e10> alprazolam </e10> with serum proteins (bovine serum albumin, zinc, and magnesium ) may be significantly decreased by <e20> furosemide </e20>.
mechanism	Binding to Serum: <e10> Zidovudine </e10> may increase the plasma levels of <e20> valdecoxib </e20>.
mechanism	Binding to Serum P <e10> colestipol </e10> increases plasma concentrations of <e20> rifampin </e20>.
mechanism	Binding to Serum Albumin: In vitro, <e10> atorvastatin </e10> inhibited <e20> vitamin_D </e20> binding to serum albumin by approximately 50% and vitamin_D binding to serum albumin was reduced by approximately 40% when administered # hours after atorvastatin.
mechanism	Binding to Serum: The addition of <e10> fluvastatin </e10> to the regimen of a standard daily dose of <e20> warfarin </e20> reduced the clearance of warfarin by approximately 60% (95% CI: 46%, 73%), which was prevented by the addition of ARAVA (about # mg of fluvastatin / day on average).
mechanism	Binding to Serum: <e12> Antacids </e12> may interfere with absorption of <e20> levothyroxine </e20>.
mechanism	Binding to Serum Albumin: <e10> Dantrolene </e10> was also found to be bound to <e20> serum albumin </e20>, with a K(a) of 3.26 nM.
mechanism	Binding to Serum Albumin: Based on the pharmacokinetic studies, <e10> zalcitabine </e10> decreased the plasma concentrations of zalcitabine by about twofold in the presence of <e20> valdecoxib </e20>.
mechanism	Binding to Serum: In a non-human population, <e10> cyclosporine </e10> was shown to reduce the serum concentration of <e20> cyclosporine </e20> in those on a high-dose regimen.
mechanism	Binding to Serum Serum androgens : <e10> Aprepitant </e10>, as compared to <e20> estradiol </e20>, increased plasma estradiol levels in the non-cycling hogs but not in the cycling hogs.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> decreased the renal clearance of <e20> digoxin </e20>.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> increased the plasma concentration of <e20> terfenadine </e20> by approximately 50%.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> increased plasma concentrations of <e20> warfarin </e20> and decreased its clearance.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> may decrease plasma <e20> dofetilide </e20> concentrations.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> inhibited the hepatic metabolism of <e20> diltiazem </e20> and resulted in higher plasma levels of diltiazem.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> increases <e20> ketoconazole </e20> s clearance and therefore ketoconazole metabolism.
mechanism	In a patient receiving <e10> clofibrate </e10> for # weeks, a #-mg daily dose of <e20> clofibrate </e20> was identified as the least potent pharmacologic effect in preventing the incidence of high-dose furosemide metabolized calcium retention.
mechanism	In a patient receiving intravenous <e10> ketoconazole </e10>, the daily dose of <e20> anakinra </e20> increased from # to # mg.
mechanism	Urinary acidifying agents such as <e10> niacin </e10> and <e20> l-histidine </e20>, in addition to lowering serum acid levels, may also cause renal tubular acidification by lowering urinary pH.
mechanism	Urinary acidifying agents such as <e10> furosemide </e10>, <e20> caffeine </e20>, and the multivitamins such as vitamin_D, Vitamin_E, and zinc may have an additive effect on increasing the absorption of zinc, iron, and other antacids.
mechanism	Urinary acidifying agents such as <e10> sodium bicarbonate </e10>, H2O2, or succinate may decrease the renal clearance of <e20> cisplatin </e20>.
mechanism	Urinary acidifying agents ( oxyphenbutazone, <e10> phenobarbital </e10>, or methyldopa ) increase urinary pH to an extent that is significant when <e20> digoxin </e20> is given concurrently.
mechanism	<e10> d-amphetamine </e10> produced a transient enhancement of <e20> morphine </e20> -induced nociceptive behaviour in rats.
mechanism	<e10> d-amphetamine </e10> and <e20> ergotamine </e20> inhibit (40% to 80%) and stimulate (20% to 50%) metabolism of ergotamine, respectively, and both inhibitors are potent inhibitors of CYP3A4.
mechanism	<e10> d-amphetamine </e10> increased the plasma levels of <e20> amiodarone </e20>, an inhibitor of N-acetyltransferase, and the half-life of amiodarone was lengthened.
mechanism	<e10> d-amphetamine </e10> at 1 mg/kg for # hours at # times every # hours administered with <e20> ketamine </e20> for # hours at # times every # hours and at # times every # hours.
mechanism	<e10> d-amphetamine </e10> and methylphenidate, (3R,4R,4S,5S)-2-methyl-1-phenyl-1,3,4,6-tetrahydro-2H-benzopyran-4-yl)-2-methylpropionic_acid, and amphetamine, (3R,4S,5S,)-2-methylpropionic_acid, can reduce the clearance of <e20> morphine </e20>.
mechanism	<e10> d-amphetamine </e10> may reduce the absorption of <e20> calcium_channel_blockers </e20> and may increase the serum calcium levels of patients receiving calcium_channel_blockers.
mechanism	<e10> d-amphetamine </e10> antagonized the effect of <e20> amphetamine </e20>.
mechanism	<e10> d-amphetamine </e10> potentiated <e20> amiodarone </e20> -induced oxidative stress and was found to decrease the hepatic enzymes of cholesterol and triglyceride metabolism.
mechanism	MAO_inhibitors MAOI_antidepressants, <e10> nefazodone </e10>, and quinidine, however, inhibit <e20> warfarin </e20> metabolism to the same extent, resulting in lower plasma concentrations of warfarin and higher AUC.
mechanism	MAO_inhibitors MAOI_antidepressants, <e10> fluoxetine </e10>, paroxetine, sertraline, and aripiprazole may decrease <e20> cimetidine </e20> absorption, potentially resulting in increased plasma levels of cimetidine and potential renal toxicity.
mechanism	Ethosuximide : <e12> Quinolones </e12>, especially erythromycin, reduce the bioavailability of <e20> erythromycin </e20>.
mechanism	Ethosuximide : <e12> Quinolones </e12> may potentiate the action of <e20> eszopiclone </e20>.
mechanism	Ethosuximide : <e12> Quinolones </e12> may reduce the bioavailability of <e20> ethosuximide </e20>, a potent inducer of hepatic metabolism of drugs that are hepatic metabolism inhibitors (eg, alcohol, succinylcholine, carbamazepine, carbamazepine, theophylline, bromocriptine, phenobarbital, valproic_acid ).
mechanism	Methenamine therapy Urinary excretion of methenamine increased significantly following concomitant administration of <e10> guanfacine </e10> (20 mg), <e20> methenamine </e20> (30 mg), and a nonsteroidal_anti-inflammatory_drug ( nisoldipine ) in healthy volunteers (P = 0.003).
mechanism	Methenamine therapy Urinary clearance of <e10> methenamine </e10> was decreased by a mean of 24% and 25% following coadministration of <e20> diltiazem </e20> and an oral potent CYP3A4 inhibitor, erythromycin.
mechanism	Phenobarbital : <e12> Tetracyclines </e12>, including phenobarbital, inhibit metabolism of <e20> ciprofloxacin </e20>.
mechanism	Phenobarbital : <e12> Amphetamines </e12> may decrease the clearance of <e20> phenobarbital </e20>, leading to a higher serum concentration and/or a higher peak serum concentration of phenobarbital.
mechanism	Phenytoin : <e12> Amphetamines </e12> enhance the metabolism of <e20> phenytoin </e20>.
mechanism	Phenytoin : <e12> Anticonvulsants </e12> may reduce the bioavailability of <e20> phenytoin </e20>, which is required to achieve the maximum plasma concentration.
mechanism	Phenytoin : <e12> Amphetamines </e12> may decrease plasma <e20> phenytoin </e20> levels, resulting in increased hypotension and decreased blood pressure.
mechanism	Antacids and sucralfate : <e10> Itraconazole </e10> may interfere with the absorption of antacids containing calcium or iron and sucralfate, resulting in lower serum levels of <e20> atorvastatin </e20>.
mechanism	Antacids and sucralfate : <e12> Antacids </e12> decrease the absorption of <e20> levothyroxine </e20>, resulting in decreased serum concentrations.
mechanism	Antacids and sucralfate decrease the absorption of <e10> erythromycin </e10> and therefore, <e20> terfenadine </e20> absorption.
mechanism	Antacids and sucralfate : Concomitant administration of antacids containing magnesium or aluminum with <e10> sucralfate </e10>, a vitamin_B2_antioxidant, has been reported to increase plasma <e20> acitretin </e20> concentrations by >28%.
mechanism	Antacids and sucralfate : <e10> Magnesium </e10> and aluminum may interfere with absorption of <e20> vitamin_D </e20>.
mechanism	Antacids and sucralfate : There has been some concern regarding the possibility of an interaction between <e10> digoxin </e10> and antacids containing sucralfate or with <e20> digoxin </e20>, as these agents have been reported to increase digoxin levels.
mechanism	Antacids and sucralfate : Concomitant administration of <e11> HEXALEN </e11> with antacids containing magnesium or aluminum, and with sucralfate, may significantly decrease the serum concentrations of <e20> digoxin </e20>.
mechanism	Antacids and sucralfate : Coadministration of <e10> ethionamide </e10> with antacids containing <e20> sucralfate </e20> may lead to an increase in ethionamide plasma levels and a decrease in ethionamide absorption.
mechanism	Antacids and sucralfate increase the intestinal absorption of <e10> probenecid </e10>, resulting in a reduction in the clearance of <e20> probenecid </e20> and, hence, in the net serum concentrations of probenecid.
mechanism	<e10> Sucralfate </e10> and <e20> warfarin </e20> prolong co-administration with intravenous acetylsalicylic_acid.
mechanism	<e10> Sucralfate </e10> may reduce plasma concentrations of warfarin, its concomitant use with an anti-arrhythmic, and <e20> warfarin </e20> may increase the risk of a thromboembolic event.
mechanism	<e10> Sucralfate </e10> and <e20> furosemide </e20> inhibit renal tubular secretion of N-acetyl-D-aspartate.
mechanism	<e10> Magnesium </e10> -containing preparations such as antacids and antacids with high magnesium content (e,g,, Magnesium Chewable/Magnesium Chew Cream, Clorhexidine_sodium ) may increase the absorption of <e20> atorvastatin </e20>.
mechanism	<e10> Magnesium </e10> -containing preparations (eg, antacids ) may increase the clearance of <e20> levothyroxine </e20>.
mechanism	<e10> Magnesium </e10>, potassium, and calcium salts are essential for <e20> digoxin </e20> to interact with renal tubular epithelium.
mechanism	Magnesium-and aluminum -containing antacids, possibly including multivitamins, may interfere with the absorption of <e11> VIDEX </e11> and other <e22> oral hypoglycemic_agents </e22>, resulting in lower plasma levels and/or decreased absorption.
mechanism	Magnesium-and aluminum -containing preparations (eg, <e10> iron </e10> and zinc ) have been reported to reduce the bioavailability of <e20> doxycycline </e20>.
mechanism	Separating the doses of <e10> acitretin </e10> from the doses of <e20> cisapride </e20>, the inhibition of 5-HT1a and 1b serotonin release by acitretin was reduced.
mechanism	Separating the doses of <e10> amiodarone </e10> or <e20> ketoconazole </e20> may potentiate any toxic effect of either drug.
mechanism	Separating the doses of <e10> cypermethrin </e10> and <e20> furosemide </e20> may reduce the effectiveness of furosemide.
mechanism	Other <e12> quinolones </e12>, including ciprofloxacin, decrease the clearance of <e20> propafenone </e20>.
mechanism	Other <e12> quinolones </e12>, such as <e20> nalidixic_acid </e20>, may be inhibited by these drugs and should therefore be administered at least # hours prior to dosing with Aprepitant.
mechanism	Other <e12> quinolones </e12>, including ciprofloxacin, show decreased efficacy when coadministered with <e20> foscarnet </e20>, suggesting that ciprofloxacin may not be a suitable choice for patients on chronic renal dialysis.
mechanism	Cimetidine : <e10> Cimetidine </e10> inhibits the metabolism of <e20> caffeine </e20>.
mechanism	Cimetidine : <e10> Cimetidine </e10> markedly increased the plasma concentrations of <e20> warfarin </e20> and its active metabolite, prothrombin time, in healthy volunteers receiving intravenous therapy with warfarin and other anticoagulants and in patients receiving warfarin concomitantly with CYP3A4 substrates.
mechanism	Cimetidine : <e10> Cimetidine </e10> has been reported to decrease the clearance of <e20> warfarin </e20> by an unknown mechanism.
mechanism	Cyclosporine : Elevated <e10> cyclosporine </e10> levels have been reported with concomitant administration of <e20> ketoconazole </e20>, an inhibitor of enzyme cyclosporine biosynthesis, and cyclosporine concomitantly with intravenous ketoconazole.
mechanism	Cyclosporine : Elevated <e10> cyclosporine </e10> plasma levels may have caused renal damage in patients receiving <e20> phenytoin </e20> for renal insufficiency.
mechanism	Cyclosporine : Elevated <e10> cyclosporine </e10> levels have been reported with concomitant administration of <e20> cyclosporine </e20>.
mechanism	Probenecid : As with other protease_inhibitors, <e10> Probenecid </e10> may decrease blood levels of other known CYP3A4 inhibitors, including <e20> ketoconazole </e20>, itraconazole, itraconazole-methyl, and itraconazole, and increase the plasma concentrations of cisapride.
mechanism	Probenecid : Aspirin : <e10> Probenecid </e10> is an active metabolite of <e20> aspirin </e20> and, like aspirin, may interact with aspirin.
mechanism	Probenecid : As with other <e12> benzodiazepines </e12>, clinical studies have shown that oral <e20> probenecid </e20> may increase the clearance of some psychotropic_medications and medications that require high serum concentrations (e,g,, metoclopramide )
mechanism	Plasma concentrations (AUCs) of <e10> levothyroxine </e10> have been shown to increase in healthy subjects administered oral <e20> ethinyl_estradiol </e20> for # days before an oral dose of levothyroxine.
mechanism	Plasma concentrations (AUC) of <e10> cyclosporine </e10> and tacrolimus were approximately doubled when both drugs were administered concomitantly with <e20> miconazole </e20>.
mechanism	Plasma concentrations (AUC) of <e10> nelfinavir </e10> were reduced by 50% when administered concomitantly with <e20> ritonavir </e20>.
mechanism	<e10> Rifampin </e10> (50 mg bid) significantly increased <e20> diltiazem </e20> serum levels.
mechanism	<e10> Rifampin </e10>, indinavir, and <e20> dasatinib </e20> each inhibited the hepatic metabolism of dasatinib in an animal model.
mechanism	<e10> Fluconazole </e10> may decrease the clearance of oral <e20> phenytoin </e20> by decreasing hepatic metabolism of phenytoin.
mechanism	<e10> Fluconazole </e10>, an oral anticoagulant, increases the rate of bleeding when administered concomitantly with <e20> azithromycin </e20>.
mechanism	<e10> Fluconazole </e10>, when administered concurrently with <e20> terfenadine </e20>, markedly decreased the elimination of the drug.
mechanism	The absorption of the orally administered <e10> methotrexate </e10> may be reduced by <e20> quinine </e20>, phenobarbital, and cimetidine.
mechanism	The absorption of <e10> cholestyramine </e10> was reduced by <e20> levothyroxine </e20> in normal volunteers.
mechanism	The absorption of <e10> furosemide </e10> is enhanced by <e20> acamprosate </e20>.
mechanism	The absorption of <e10> digoxin </e10> was decreased by a factor of 4.5 in subjects who received <e20> ketoconazole </e20> in addition to digoxin.
mechanism	The absorption of <e10> nifedipine </e10> is decreased by increased serum <e20> phenytoin </e20> levels.
mechanism	Aspirin : Concurrent administration of <e10> enoxacin </e10> and <e20> aspirin </e20> resulted in an increase in the enoxacin concentrations.
mechanism	Aspirin : Concurrent use with <e10> enoxacin </e10> may decrease serum <e20> aspirin </e20> concentrations.
mechanism	Lithium : <e12> Antihypertensives </e12> may decrease plasma lithium concentrations, thus decreasing <e20> lithium </e20> intake and increasing the risk of lithium toxicity.
mechanism	Lithium : <e12> Amphetamines </e12> may increase <e20> lithium </e20> absorption.
mechanism	Lithium : <e12> Antacids </e12> may increase the bioavailability of <e20> lithium </e20>.
mechanism	Antacids : In an in vitro study, <e10> gentamicin </e10>, as well as ciprofloxacin, caused a dose-dependent increase in the binding of <e20> digoxin </e20> to aluminum hydroxide.
mechanism	Cholestyramine -Concomitant intake of <e10> cholestyramine </e10> and <e20> bromocriptine_mesylate </e20> has been reported to reduce bromocriptine_mesylate plasma concentrations by twofold.
mechanism	Cholestyramine -Concomitant intake of <e10> cholestyramine </e10> and <e20> cisapride </e20> resulted in a 17% decrease in Cmax and AUC of cisapride.
mechanism	Colestipol -Concomitant intake of <e10> colestipol </e10> and <e20> colestipol_retard </e20> may increase the hepatic absorption of warfarin.
mechanism	Colestipol -Concomitant intake of <e10> colestipol </e10> and <e20> enoxacin </e20> has been reported to increase the Cmax of enoxacin by ~25% and decrease the Cmin by 25%.
mechanism	Colestipol -Concomitant intake of <e10> colestipol </e10> and <e20> atorvastatin </e20> decreases the absorption of both drugs by a similar extent (approximately 40%).
mechanism	Mineral_Oil -Concomitant intake of <e11> ALLEGRA </e11> and <e20> mineral_oil </e20> increases the plasma concentration of ALLEGRA by up to 50%.
mechanism	Orlistat-<e10> Cimetidine </e10> -associated metabolism has been reported to increase plasma levels of <e20> orlistat </e20>.
mechanism	Elevated plasma levels of <e10> levothyroxine </e10> have been reported when <e20> astemizole </e20> and other thyroid_products are used concomitantly.
mechanism	Elevated plasma levels of methotrexate have been reported when <e10> cisplatin </e10> and <e20> ketoconazole </e20> were used concomitantly.
mechanism	Elevated plasma levels of <e10> ketoconazole </e10> may compromise the effectiveness of <e20> clofibrate </e20> in a given patient.
mechanism	<e12> Quinolones </e12>, including <e20> ciprofloxacin </e20>, induce a strong in vitro drug interaction for warfarin with concomitant decrease in half-life and the concomitant addition of high therapeutic concentrations.
mechanism	<e12> Quinolones </e12> ( tetracyclines, bacitracin, or <e20> colistin </e20> ) and other cephalosporins, and quinupristin may interfere with absorption of # mg of an initial # mg dose of a single-dose regimen of nevirapine.
mechanism	and <e11> Videx </e11> may prolong the half-life of <e20> cisplatin </e20>.
mechanism	and <e11> Videx </e11> can inhibit the metabolism of <e20> cholestyramine </e20>, resulting in a reduction in the absorption of both drugs.
mechanism	and Videx, <e10> halothane </e10>, and isoniazid may interfere with absorption of <e20> probenecid </e20>.
mechanism	and Videx, <e10> amiodarone </e10>, and verapamil all decreased <e20> atorvastatin </e20> absorption.
mechanism	and Videx, <e10> phenytoin </e10>, and cimetidine alter the pharmacokinetics of <e20> cefixime </e20>.
mechanism	Elevated serum levels of <e10> tetracycline </e10> may be associated with an increase in the half-life of <e20> cisapride </e20> and hence a decrease in the efficacy of cisapride.
mechanism	<e10> Probenecid </e10> : Immediate elimination half-life decreased approximately # hours after # mg of <e20> probenecid </e20> in subjects taking cimetidine (6 mg) alone.
mechanism	<e10> Probenecid </e10>, an in vivo inhibitor of CYP2D6, reduces <e20> clofibrate </e20> metabolism by inhibiting CYP2D6 activity.
mechanism	<e10> Probenecid </e10>, in addition to the usual GI effects, significantly increased the clearance of <e20> digoxin </e20>.
mechanism	<e10> Naproxen </e10> has been shown to decrease the pharmacokinetics of <e20> ketoconazole </e20>, clarithromycin, indomethacin, and some sulfonamides.
mechanism	<e10> Naproxen </e10>, fluconazole, indomethacin, itraconazole, ketoconazole, itraconazole, phenytoin, rifampin, phenobarbital, rifabutin, <e20> salicylates </e20>, tacrolimus, tolbutamide, and zidovudine may interfere with the metabolism of cetirizine.
mechanism	<e10> Naproxen </e10> has been shown to reduce the plasma concentrations of oral <e22> anticoagulants </e22>, especially of warfarin and its derivatives.
mechanism	Naproxen, <e10> fluvoxamine </e10>, and other NSAIDs decrease the clearance of <e20> celecoxib </e20>.
mechanism	Naproxen, <e10> fluoxetine </e10>, phenytoin, bromocriptine, phenobarbital, and quinidine reduce the metabolism of <e20> cisapride </e20>.
mechanism	Naproxen, naproxen_sodium, phenytoin, and <e10> diazepam </e10> have been reported to increase the clearance of <e20> digoxin </e20>, thus prolonging its systemic exposure.
mechanism	Naproxen, naproxen_sodium, and <e10> acetaminophen </e10> may increase the clearance of oral <e20> warfarin </e20> and result in increases in serum and urine levels.
mechanism	After multiple dosing, <e10> diazepam </e10> caused a decrease in the clearance of <e20> terfenadine </e20> and increases in the Cmax and AUC of terfenadine.
mechanism	After multiple dosing, <e10> rifampin </e10> increased the plasma concentrations of <e20> ampicillin </e20>.
mechanism	After multiple dosing, the half-life of <e11> VIOXX </e11> was significantly prolonged from # to # hours after administration of <e20> terfenadine </e20> (at # mg kg(-1) body weight).
mechanism	After multiple dosing, <e10> gentamicin </e10> caused a significant reduction of <e20> cefazolin </e20> AUC in rats.
mechanism	<e11> Starlix </e11> increases the blood levels of all diuretics, including <e20> loop_diuretics </e20>.
mechanism	<e11> Starlix </e11> may decrease the clearance of most drugs that are metabolized by cytochrome P-450 isozymes, such as <e20> ketoconazole </e20>, itraconazole, clarithromycin, itraconazole, troleandomycin, voriconazole, and itraconazole containing salts.
mechanism	<e11> Starlix </e11> and carbamazepine CMI increased the clearance of <e20> cimetidine </e20> by approx. 20%.
mechanism	Indinavir : Coadministration of <e10> indinavir </e10> with <e20> dasatinib </e20> resulted in a 50% increase in mean rivastigmine plasma concentrations, which may be associated with a decrease in the pharmacokinetic profile of rivastigmine.
mechanism	Indinavir : Coadministration of <e10> indinavir </e10> (40 mg/kg/day for # days) with <e20> quinine </e20> (80 mg/kg/day for # days) increased the plasma concentration of indinavir and the indinavir AUC by about 15%.
mechanism	Indinavir : Coadministration of <e10> indinavir </e10> and <e20> zidovudine </e20> at approximately # to # mg/kg resulted in a 4-fold increase in the plasma concentrations of indinavir and zidovudine.
mechanism	Ritonavir : Coadministration of <e10> ritonavir </e10> with <e20> indinavir </e20> resulted in an increase in plasma concentrations of indinavir.
mechanism	Saquinavir : Coadministration of <e11> STADOL </e11> # mg and # mg with <e20> saquinavir </e20> # mg resulted in a decrease in plasma concentrations of saquinavir by up to 20%.
mechanism	Saquinavir : Coadministration of <e10> saquinavir </e10> with <e20> carbamazepine </e20> or cyclosporine resulted in a 5- to 8-fold increase in AUC and a 3- to 6-fold increase in Cmax.
mechanism	Saquinavir : Coadministration of <e10> saquinavir </e10> and <e20> cimetidine </e20> (6.3 mg/kg) resulted in a decrease in Cmax and AUC values by a factor of 10 and 40, respectively.
mechanism	Ketoconazole : Coadministration of <e10> ketoconazole </e10> and <e20> dorzolamide </e20>, an inhibitor of CYP2C9, resulted in an increase in the AUC of dorzolamide by #%.
mechanism	Ketoconazole : Coadministration of <e10> ketoconazole </e10> with <e20> amiodarone </e20> was found to increase the exposure of amiodarone, which was observed to reduce the renal clearance of amiodarone and cause a two- to three-fold increase in AUC.
mechanism	Rifabutin : Coadministration of <e11> aspirin </e11> and <e20> rifabutin </e20> resulted in a 7% increase in the percentage of aspirin-associated Cmax and AUC values.
mechanism	Rifabutin : Coadministration of <e10> rifabutin </e10> and <e20> ketoconazole </e20> resulted in increased concentrations of the latter drug in blood, urine and tissues compared with concurrent administration of these agents alone.
mechanism	Rifabutin : Coadministration of <e10> rifabutin </e10> with <e20> rifabutin </e20> (300 mg/day) in healthy volunteers decreased the maximum plasma concentration of rifabutin by 21% and the AUC of rifabutin by 23%.
mechanism	Rifampin : Coadministration of <e10> rifampin </e10> with <e20> diazepam </e20> decreased its clearance.
mechanism	Rifampin : Coadministration of <e11> SPRYCEL </e11> # mg with <e20> rifampin </e20> # mg decreased rifampin serum levels by 38%.
mechanism	Rifampin : Coadministration of <e10> rifampin </e10> with <e20> cisapride </e20> resulted in an increase in rifampin serum levels.
mechanism	Ethinyl_Estradiol and Norethindrone : <e10> Norethindrone </e10> may decrease the metabolism of <e20> ethinyl_estradiol </e20> or estradiol, resulting in elevated plasma levels of estradiol and lower plasma concentrations of estradiol and progestins.
mechanism	Oral <e10> neomycin </e10> or oral <e20> ciprofloxacin </e20> may interact with or potentiate the metabolism of oral anticoagulants, such as warfarin, phenytoin, and astemizole.
mechanism	Oral <e10> neomycin </e10> may also increase the absorption of other antacids, particularly lactose, choline-containing and phospholipids, aminosalicylic_acid, and <e20> magnesium </e20>.
mechanism	Oral <e10> neomycin </e10> is reported to decrease the absorption of <e20> phenytoin </e20> by approximately 50%.
mechanism	Oral <e10> neomycin </e10> preparations containing <e20> gentamicin </e20>, sucralfate, or fluconazole may not be effective because they interfere with the absorption of gentamicin.
mechanism	Oral <e10> neomycin </e10> was found to have a concentration of 10% (40 micrograms) at steady state in the presence of 50 micrograms (1 microgram) of <e20> digoxin </e20>.
mechanism	Oral <e10> neomycin </e10> and sulfonamides interfere with the metabolism of <e20> levothyroxine </e20>, resulting in elevated serum levels of levothyroxine.
mechanism	Oral <e10> neomycin </e10> -containing preparations are reported to increase plasma concentrations of <e20> diltiazem </e20>.
mechanism	Oral <e10> neomycin </e10> has been reported to enhance the effect of oral <e22> anticoagulants </e22>.
mechanism	Oral <e10> neomycin </e10> dose reduced to # mg/kg did not alter plasma <e20> neomycin </e20> concentrations.
mechanism	Oral <e10> neomycin </e10> was also effective in reducing the time to achieve plasma concentrations of <e20> cimetidine </e20> by approximately 15%.
mechanism	Oral <e10> neomycin </e10> can inhibit the metabolism of <e20> carbamazepine </e20>, resulting in lower serum carbamazepine levels and a longer interval between carbamazepine and serum creatinine concentrations.
mechanism	Oral <e10> neomycin </e10> # mg given at #-hour intervals in a dose of # mg/kg for # days was associated with a mean decrease in <e20> erythromycin </e20> AUC of 11% and decrease in AUC(20) of 3% compared with # mg/kg given at #-hour intervals in a dose of # mg/kg for # days in healthy volunteers.
mechanism	<e10> Clarithromycin </e10> may reduce the clearance of <e20> rifampin </e20>.
mechanism	<e10> Clarithromycin </e10> decreased the steady-state concentrations of <e20> digoxin </e20> by about 40%.
mechanism	<e10> Clarithromycin </e10> may decrease the bioavailability of other <e22> tricyclic_antidepressants </e22>.
mechanism	Aspirin : Concomitant use of <e11> aspirin </e11> with <e20> hydrocodone </e20> and other antihypertensive_drugs may produce elevated serum levels of these drugs.
mechanism	Cimetidine : <e10> Cimetidine </e10> can increase the renal clearance of <e20> atracurium </e20>.
mechanism	Cimetidine : <e10> Cimetidine </e10> decreased the plasma concentration of <e20> amphetamines </e20> and decreased the extent of in vivo and in vitro clearance of amphetamines.
mechanism	Cimetidine : <e10> Cimetidine </e10> increases plasma <e20> phenytoin </e20> concentrations by inhibiting metabolism of the methyl group.
mechanism	Digoxin : Some reports have shown that <e10> diltiazem </e10> increased the clearance of <e20> digoxin </e20>.
mechanism	Quinidine : Immediate Release Capsules: <e10> Quinidine </e10> tablets are reported to inhibit the metabolism of <e20> furosemide </e20>.
mechanism	Quinidine : Immediate Release Capsules: In a study in healthy volunteers, the clinical studies on <e10> rifampin </e10> resulted in a 4- to 5-fold increase in the area under the plasma concentration-time curve for <e20> cisapride </e20> when compared to rifampin tablets.
mechanism	Quinidine : Immediate Release Tablets containing <e10> tetracycline </e10> may temporarily increase the plasma concentration of <e20> quinidine </e20>.
mechanism	Cimetidine : A potent inhibitor of CYP3A4, <e10> cimetidine </e10> may decrease the clearance of <e20> alfentanil </e20>.
mechanism	Cimetidine : A pharmacokinetic study in healthy volunteers showed a mean Cmax and AUC of 0.56 and 1.26 mg/mL when <e10> cimetidine </e10> was administered with <e20> isoniazid </e20>.
mechanism	Cimetidine : A study in normal volunteers showed that a single dose of <e10> cimetidine </e10> (40 mg) significantly reduced <e20> erythromycin </e20> AUC by a mean of 46% (range: 10% to 54%).
mechanism	A study in six dogs demonstrates a 25% reduction in the clearance of <e10> rifabutin </e10> in the presence of <e20> atorvastatin </e20> and an increase in AUC of rifabutin.
mechanism	A study in healthy volunteers found that <e10> terfenadine </e10> reduced the plasma concentrations of <e20> cyclosporine </e20> by approximately 20%.
mechanism	A # to # mg/day dose of <e10> cimetidine </e10> in the presence of 100 mg/day of a <e22> oral anticoagulant </e22> has been shown to reduce the prothrombin time by 17% and increase the prothrombin time by 31% at # mg/day.
mechanism	A # to # mg <e12> digitalis </e12> daily dose decreased the # to # mg <e20> pyridoxine </e20> daily dose by 27%.
mechanism	Coadministration of <e10> ketoconazole </e10> (25 mg, QD) and <e20> erythromycin </e20> (30 mg, QD) significantly increased the elimination half-life of ketoconazole.
mechanism	Coadministration of <e10> digoxin </e10> with <e20> astemizole </e20> produced a significant decrease in digoxin serum levels.
mechanism	Coadministration of <e10> terfenadine </e10> and <e20> cisapride </e20> in normal volunteers (6 subjects) resulted in an increase in Cmax of cisapride of approximately 60% and AUC of approximately 7% compared to cisapride alone.
mechanism	<e10> Quinidine </e10> inhibited the metabolism of <e20> warfarin </e20> by lowering the steady-state levels of warfarin.
mechanism	<e10> Quinidine </e10> reduced the metabolism of <e20> bromocriptine_mesylate </e20>, a known CYP3A4 inhibitor, by up to 33%.
mechanism	The immediate release, <e10> cholestyramine </e10> (8 mg) increased plasma levels of <e20> cimetidine </e20> and theophylline and decreased plasma concentrations of cimetidine and theophylline in healthy volunteers.
mechanism	The immediate release, multivalent <e12> cephalosporins </e12> have been reported to reduce the clearance of <e20> ketoconazole </e20> and increased the clearance of cephalosporins, including carbamazepine.
mechanism	Therefore, caution should be observed when <e11> WELLBUTRIN </e11> is coadministered with drugs that have secondary metabolism-related metabolic interactions with <e20> amphetamine </e20> or theophylline.
mechanism	Therefore, caution should be observed when administering <e10> diltiazem </e10> with other <e22> coumarin-derivative_anticoagulants </e22>.
mechanism	Therefore, caution should be exercised when administering <e10> digoxin </e10> with concomitant <e20> nifedipine </e20> and calcium supplements or when administering calcium supplements concomitantly with digoxin.
mechanism	Antacids containing <e10> magnesium </e10>, calcium, or aluminum have a decreased effect on <e20> ethinyl_estradiol </e20> in rats.
mechanism	Antacids containing <e10> aluminum </e10> or magnesium, aluminum containing antacids, or aluminum containing and magnesium containing antacids significantly decreased the <e20> niacin </e20> absorption.
mechanism	The mechanism for the potentiation of <e12> benzodiazepines </e12> by <e20> diazepam </e20> is not known, but possibly is an interaction with the metabolism of diazepam to the phenytoin and/or diazepam.
mechanism	The mechanism for the inhibition of CYP3A4 by <e10> ketoconazole </e10> is not well known, but the presence of <e20> diltiazem </e20> in the urine may have exacerbated the metabolism of ketoconazole.
mechanism	Uricosuric_drugs, such as metformin and <e10> sulfasalazine </e10>, reduce <e20> amphotericin_B </e20> uptake.
mechanism	Uricosuric_drugs, such as <e10> carbamazepine </e10>, may decrease the metabolism of <e20> ampicillin </e20> and therefore increase the systemic exposure of ampicillin.
mechanism	Uricosuric_drugs, such as <e10> phenytoin </e10>, phenobarbital, carbamazepine, and tacrolimus, may interfere with the metabolism of <e20> cyclosporine </e20>.
mechanism	Uricosuric_drugs, such as carbamazepine, phenytoin, phenobarbital, phenytoin_sodium, and <e10> carbamazepine </e10>, are inhibited by <e20> enoxacin </e20>.
mechanism	Uricosuric_drugs, such as <e10> ampicillin </e10>, may decrease the metabolism of <e20> carbamazepine </e20>.
mechanism	In patients given a single oral dose of <e10> piperazine </e10> (6 mg), # of # subjects experienced severe, prolonged elevations in <e20> digoxin </e20> plasma levels.
mechanism	In patients given a single <e10> digoxin </e10> dose of # mg or less, the AUC of <e20> digoxin </e20> increased by 1,829% and 1798% respectively, for a change in volume of distribution of approximately #%.
mechanism	In patients given intravenous <e10> cyclosporine </e10>, the extent of renal excretion of <e20> fluvoxamine </e20> may be decreased and the clearance of fluvoxamine may be increased by the administration of a single dose of either cyclosporine or the combination of cyclosporine and fluvoxamine.
mechanism	Elevated plasma levels of <e10> erythromycin </e10> were observed during concurrent therapy with <e20> piperazine </e20>.
mechanism	Elevated plasma levels of <e10> norethindrone </e10> may lead to an increased absorption of <e20> terfenadine </e20>.
mechanism	Elevated plasma levels of <e10> erythromycin </e10> have been reported in patients on concomitant <e22> corticosteroid </e22> therapy.
mechanism	Elevated serum levels of <e10> cimetidine </e10> may reduce the efficacy of <e20> ketoconazole </e20> and thus the antifungal efficacy of it.
mechanism	Elevated serum levels of <e10> loperamide </e10> may result in a reduction in its clearance and a rise in <e20> erythromycin </e20> and cimetidine clearance.
mechanism	Elevated serum levels of <e10> phenytoin </e10> may cause the elimination of <e20> furosemide </e20>.
mechanism	Diminished urinary excretion of <e10> nevirapine </e10> has been reported following administration of <e20> cisapride </e20>.
mechanism	Some <e12> quinolones </e12> have been reported to interact with oral <e20> carbamazepine </e20>, and the possibility of an additive effect with carbamazepine may exist.
mechanism	Some <e12> quinolones </e12> have been reported to have a strong tendency to interfere with platelet aggregation in vitro, which can result in severe bleeding when administered concomitantly with <e20> heparin_sodium </e20> or in some patients with renal disease.
mechanism	Some <e12> quinolones </e12> have been reported to inhibit the metabolism of nonsteroidal_anti-inflammatory_drugs ( <e20> nonsteroidal_anti-inflammatory_drugs </e20> ) by inhibiting CYP2B6 and 3A4.
mechanism	Steady-state serum concentrations of <e10> probenecid </e10> were decreased by 20% when the doses of <e20> methotrexate </e20> and probenecid were increased by a single dosage of # mg/m2 and # mg/m2, respectively.
mechanism	Steady-state serum concentrations of <e11> WELLBUTRIN </e11> are higher with high doses of <e20> nevirapine </e20>.
mechanism	In addition, higher-than-expected blood levels of <e10> dexamethasone </e10> were found in patients taking <e20> rifabutin </e20>.
mechanism	In well-controlled patients with HIV, coadministration of <e10> levofloxacin </e10> at # mg/day and <e20> nevirapine </e20> at # mg/day resulted in an increase in plasma levels of nevirapine.
mechanism	In well-controlled patients with a mean maximum plasma concentration of <e10> cisapride </e10> of # microM, an increase of <e20> nifedipine </e20> clearance was observed, which was prevented by coadministration of a 50 microM concentration of cisapride (nifedipine: CCl(4) : CCl(4)-# microM, p = # x 10(-10), # x 10(-8), # x 10(-7), # x 10(-6), # x 10(-5) microM).
mechanism	In well-controlled patients, <e10> furosemide </e10> resulted in a 17% decrease in <e20> warfarin </e20> plasma concentrations.
mechanism	There have been reports of potentiation of the hypotensive effect of <e10> enalapril </e10> and other <e22> calcium_channel_blockers </e22> when given concomitantly with digoxin or atropine.
mechanism	There have been reports of theophylline -containing preparations, such as <e10> theophylline </e10> preparations and theophylline serum levels, being affected by <e20> carbamazepine </e20>.
mechanism	There have been reports of patients who develop elevated serum concentrations of <e10> ketoconazole </e10> following concomitant administration of <e20> rifabutin </e20> and vitamin_K.
mechanism	There have been reports of interactions of <e10> carbamazepine </e10> with antidepressants, barbiturates, <e20> calcium_channel_blockers </e20>, barbiturates, cimetidine, clofibrate, corticosteroids, corticotropin, cyclosporine, diazepam, doxycycline, HIV drugs, lithium, monoamine_oxidase_inhibitors ( MAOI ), norethindrone, phenothiazines, prednisolone, risperidone, saquinavir, theophylline, triazolam, and warfarin.
mechanism	There have been reports of interactions of <e10> fluvoxamine </e10> with atorvastatin, clarithromycin, indinavir, itraconazole, itraconazole with <e20> ketoconazole </e20>, itraconazole with ritonavir, ritonavir with nelfinavir, saquinavir with ritonavir, saquinavir with ritonavir, and ritonavir with indinavir.
mechanism	In addition, several drugs such as amiodarone, astemizole, carbamazepine, clofibrate, disopyramide, <e10> fluvoxamine </e10>, flurbiprofen, dicumarol, theophylline, tamoxifen, theophylline_hydrochloride, and valdecoxib may increase the clearance of <e20> levothyroxine </e20>.
mechanism	In addition, several other nonsteroidal_anti-inflammatory_drugs ( <e12> NSAIDs </e12> ) have been shown to inhibit the absorption of <e20> warfarin </e20>.
mechanism	In addition, several CYP3A4 substrates known to have a narrow therapeutic index such as cimetidine, clarithromycin, <e10> ketoconazole </e10>, itraconazole, nefazodone, phenytoin, rifampin, tricyclic_antidepressants, and aripiprazole have been reported to decrease <e20> ketoconazole </e20> levels.
mechanism	1- nc denotes <e10> cimetidine </e10> (chloramphenicol_hydrochloride ) concentration in the blood that is <e20> 5 mg/kg/day </e20> less than the plasma concentration.
mechanism	The increase of <e10> fluvoxamine </e10> levels in renal dialysis patients was partially prevented by coadministration of <e20> furosemide </e20>.
mechanism	The increase of <e10> ampicillin </e10> by concurrent administration of <e20> carbamazepine </e20> has been reported to cause a marked increase in the clearance of ampicillin.
mechanism	The increase of <e10> digoxin </e10> levels was prevented by <e20> digoxin </e20>.
mechanism	Hormonal contraceptives Co-administration of <e11> PRINIVIL </e11> with hormonal contraceptives has been reported to result in elevated plasma levels of <e20> nevirapine </e20>.
mechanism	Calcium_Antagonist s: After <e10> probenecid </e10> administration, <e20> acitretin </e20> levels increased by 28% and cilostazol by 5%.
mechanism	Calcium_Antagonist s: After <e10> rifampin </e10> and <e20> zalcitabine </e20>, which have been shown to reduce the absorption of calcium_antagonists, both may require adjustment of their dosing to take into account the reduced absorption.
mechanism	Calcium_Antagonist s: After <e10> indomethacin </e10>, it was found that <e20> calcium_antagonists </e20> are, in fact, active in inducing metabolism of indomethacin.
mechanism	Pharmacokinetic data from the USP <e10> diltiazem </e10> trial suggest that coadministration of <e20> nelfinavir </e20> may have resulted in a rise in rifabutin AUC of 8% and an increase in AUC of rifabutin B with # mg of nelfinavir / day.
mechanism	Pharmacokinetic data from the INSPIRE ( ISupress-Inhibitors and Resins with Renoprotective activity) study, a randomized, double-blind, placebo-controlled study, indicated that <e10> gentamicin </e10> significantly decreased the clearance of <e20> cisapride </e20> by about 50% at doses of # mg/day.
mechanism	Pharmacokinetic data from in vitro studies of <e10> nevirapine </e10> suggest that a high-dose combination of <e20> nevirapine </e20> (50 mg once daily for # days) with dasatinib (200 mg once daily for # days) increases nevirapine exposure, and that the duration of effect is decreased when nevirapine and dasatinib are administered concurrently.
mechanism	Reports in the literature suggest that <e10> cyclosporine </e10> increases the clearance of calcium_channel_blockers, which may be expected to decrease serum <e20> parathyroid_stimulants </e20> levels.
mechanism	Reports in the literature have demonstrated that <e10> colestipol </e10> may inhibit the metabolism of other drugs including barbiturates, digoxin, triazolam, <e20> metoclopramide </e20>, and thiazide_diuretics.
mechanism	Reports in the literature indicate that <e10> rifampin </e10> may decrease the clearance of <e20> pentamidine </e20>.
mechanism	Treatment with <e11> PRINIVIL </e11> has resulted in a 3-fold increase in <e20> dapsone </e20> concentration in patients treated concurrently with two or more concomitant oral corticosteroids.
mechanism	Treatment with <e11> HUMORSOL </e11> resulted in a 60% increase in serum <e20> enoxacin </e20> levels, which may account for the clinical improvement.
mechanism	Probenecid : The following drugs inhibit <e10> probenecid </e10> metabolism: amiodarone, barbiturates, phenobarbital, carbamazepine, diazepam, fentanyl, indomethacin, <e20> mecamylamine </e20>, meclofenamic_acid, miconazole, methotrexate, phenytoin, rifabutin, saquinavir, theophylline, tolbutamide, and warfarin.
mechanism	Methotrexate : <e10> Benzthiazide </e10>, a glucocorticoid, can decrease the metabolism of <e20> methotrexate </e20>.
mechanism	Cimetidine : Co-administration of <e10> cimetidine </e10> with <e20> cisapride </e20> increased the cisapride clearance by 18% (P =.0006).
mechanism	Cimetidine : Co-administration of <e10> cimetidine </e10> with <e20> erythromycin </e20> and carbamazepine resulted in a significant increase in cimetidine clearance.
mechanism	Cimetidine : Co-administration with <e10> cisapride </e10> resulted in a reduced rate of <e20> cimetidine </e20> elimination by 62%.
mechanism	Lithium : <e12> Barbiturates </e12>, including lithium, may reduce the bioavailability of <e20> ethionamide </e20>.
mechanism	Lithium : <e12> Amphetamines </e12> may interfere with <e20> lithium </e20> metabolism, resulting in a decrease in lithium clearance.
mechanism	At higher than # mg/kg doses of <e10> nevirapine </e10>, the mean EC50 of <e20> norvirapine </e20> was # times higher than that of nevirapine.
mechanism	At higher than # mg/kg/day, the serum AUC of <e10> cisplatin </e10> increased by #-fold and <e20> doxorubicin </e20> by #-fold, but did not alter the serum levels of doxorubicin.
mechanism	At # hours after <e10> phenytoin </e10> # mg was administered, there was a significant increase in plasma <e20> phenytoin </e20> concentration.
mechanism	At # hours after <e11> HUMORSOL </e11> injection, systemic <e20> methotrexate </e20> was displaced from its stable location within #-10 cm of the injection site by #-15 cm.
mechanism	At # hours, there was a statistically significant increase in <e10> cyclosporine </e10> serum concentrations of #% and # mg/mL in the <e20> zidovudine </e20> # mg/mL and single dose groups, respectively, compared to zidovudine serum concentrations of # mg/mL and single dose groups.
mechanism	Rifampin : Co-administration of <e10> rifampin </e10> to <e20> warfarin </e20> increases its half-life.
mechanism	Rifampin : Co-administration of <e10> rifampin </e10> with <e20> cyclosporine </e20> decreased the cyclosporine concentration in both serum and urine by approximately 3-fold.
mechanism	Theophylline <e11> VIOXX </e11> may have a negative effect on the absorption of <e20> succinylcholine </e20>.
mechanism	Theophylline <e11> VIOXX </e11> administered concomitantly with <e20> probenecid </e20> decreased the clearance of theophylline.
mechanism	Theophylline <e11> VIOXX </e11> may decrease plasma <e20> phenytoin </e20> concentrations.
mechanism	Although specific studies have not been conducted, it is likely that <e10> furosemide </e10>, which is an anion-exchangeable/buffered anion-exchangeable sulfonamide, may increase the plasma concentrations of <e20> cimetidine </e20>.
mechanism	Although specific studies have not been conducted, it has been proposed that coadministration of <e10> quinine </e10> and <e20> astemizole </e20> may increase the absorption of astemizole.
mechanism	Although specific studies have not been conducted, there is a possibility that <e10> cholestyramine </e10> may enhance the effect of oral <e22> anticonvulsants </e22>.
mechanism	Although specific studies have not been performed, it is likely that the resulting prolongation of the QT interval could contribute to prolongation of cardiac conduction when <e10> verapamil </e10> is administered concomitantly with <e20> lithium </e20>.
mechanism	Although specific studies have not been performed, it is possible that administration of <e11> DILAUDID </e11> ( a <e22> benzodiazepine_class_antidepressant </e22> ) may increase the clearance of a drug such as metoclopramide, which is not metabolized by this isoenzyme.
mechanism	Although specific studies have not been performed, it is likely that <e10> zalcitabine </e10>, or its derivatives, may enhance the clearance of certain antibiotics or other drugs with long and/or slow clearance, e,g,, quinine, phenobarbital, dapsone, <e20> carbamazepine </e20>, sulfinpyrazone, triazolam, theophylline, astemizole, phenytoin, chlordiazepoxide, cimetidine, felbatol, clofibrate, disulfiram, fluoxetine, glipizide, midazolam, nefazodone, ondansetron, quinidine, quinidine sulfate, rifabutin, troleandomycin, theophylline, valproic_acid, verapamil, and zidovudine have been reported to decrease
mechanism	Although specific studies have not been conducted, the possibility that <e12> sulfonamides </e12> may have a pharmacokinetic interaction with CYP3A4 substrates such as phenytoin or <e20> propafenone </e20> has been raised.
mechanism	Although specific studies have not been conducted, it is likely that <e10> cholestyramine </e10> may interact with <e20> lithium </e20>.
mechanism	Although specific studies have not been performed, the possibility of increased plasma levels of <e10> quinine </e10> may have occurred during concomitant use of <e20> astemizole </e20> and astemizole.
mechanism	Although specific studies have not been conducted, it has been reported that the concomitant use of two or more medications with cytochrome P450 3A4 in an animal model (rats) resulted in a significantly higher clearance of <e10> cimetidine </e10> and a 3-fold increase in # mg/kg <e20> fluvoxamine </e20> plasma levels.
mechanism	Although specific studies have not been conducted, CYP3A4 substrates, including methotrexate, <e10> cisapride </e10>, fluconazole, theophylline, and certain <e22> tricyclic_antidepressants </e22>, may reduce the metabolism of methotrexate or decrease the extent of metabolism by any other known CYP3A4 metabolite.
mechanism	Although specific studies are not known, concomitant administration of <e10> cholestyramine </e10> with <e20> anagrelide </e20> may have increased serum levels of anagrelide.
mechanism	Although specific studies have not been conducted, it has been speculated that the drug interaction may result from increased plasma levels of <e11> INDOCIN </e11>, resulting in a decrease in the clearance of indocyanine, which may have been related to the administration of a <e20> indocyanine </e20> diet for the concomitant administration of the drug.
mechanism	Although specific studies have not been performed, it has been postulated that the metabolism of <e10> astemizole </e10> may be enhanced by coadministration of oral <e20> metoclopramide </e20>, which would increase the clearance of astemizole.
mechanism	Although specific studies have not been performed, the concomitant administration of <e11> CRIXIVAN </e11> with tricyclic_antidepressants, phenothiazines, barbiturates, sulfonamides, tricyclic_antidepressants with concurrent <e22> anticonvulsant </e22> therapy, and tricyclic_antidepressants with concurrent anticonvulsant therapy has been reported to result in increases in AUC and Cmax values.
mechanism	Although specific studies have not been performed, potential interactions have been reported for <e10> digoxin </e10> and cimetidine in patients on chronic renal dialysis and for digoxin and <e20> cisapride </e20> in patients on hemodialysis.
mechanism	Although specific studies have not been conducted, <e10> acetaminophen </e10>, chloramphenicol, caffeine, chlordiazepoxide, diazepam, fluoxetine, <e20> fluvoxamine </e20>, morphine, phenobarbital, primidone, and sertraline may decrease the clearance of oral anticoagulants, resulting in increased oral exposure.
mechanism	Although specific studies have not been performed, <e10> indomethacin </e10>, caffeine, and phenobarbital have been reported to decrease the clearance of <e20> diltiazem </e20>.
mechanism	Although specific studies have not been performed, <e10> chlorpromazine </e10> may increase the clearance of <e20> phenytoin </e20>.
mechanism	Although specific studies have not been conducted, concomitant use of <e10> gentamicin </e10> may result in decreased serum levels of <e20> ciprofloxacin </e20>.
mechanism	Although specific studies have not been performed, evidence from in vitro studies of a small number of drugs indicates that the metabolism of <e10> ketoconazole </e10> may be changed by concomitant administration of <e20> cisapride </e20>.
mechanism	Although specific studies are not available, there is evidence that <e10> clofibrate </e10> and other drugs that reduce the activity of <e20> fibrate </e20> may decrease the bioavailability of fibrate and increase the rate of fibrate metabolism.
mechanism	Although specific studies have not been performed, it is possible that the metabolism of <e10> valdecoxib </e10> may have been affected by <e20> diclofenac </e20>.
mechanism	Although specific studies have not been performed, there is a possibility that an interaction may be present between <e10> isoniazid </e10> and intravenous <e20> nitrofurantoin </e20>.
mechanism	Although specific studies have not been performed, <e10> ketoconazole </e10>, <e20> erythromycin </e20>, terfenadine, and sulfonamides may decrease the metabolism of cisapride.
mechanism	Although specific studies have not been performed, it is likely that the coadministration of <e11> WELLBUTRIN </e11> with oral contraceptives, tricyclic_antidepressants, barbiturates, calcium_channel_blockers, corticosteroids, cholestyramine, corticotropin, corticotropin_releasing_agents, cyclosporine, diltiazem, doxycycline, estrogens, fluoxetine, fluvoxamine, glyburide, <e20> halothane </e20>, heroin, midazolam, miconazole, phenobarbital, prednisolone, salicylates, tamoxifen, terfenadine, theophylline, and warfarin may interfere with absorption of WELLBUTRIN and result in lower plasma levels.
mechanism	Although specific studies have not been performed, it is likely that interactions between <e10> rifampin </e10> and <e20> warfarin </e20> may have occurred during the administration of # mg of rifampin in # mg of warfarin tablets.
mechanism	Although specific studies have not been performed, it is likely that the metabolism of <e10> fluvoxamine </e10> may be altered by the presence of other cationic_antidepressants, <e22> quinidine </e22>, or quinidine_derivatives, and therefore fluvoxamine dosage may need to be adjusted.
mechanism	Although specific studies have not been conducted, there is the potential for oral <e10> caffeine </e10> to decrease the bioavailability of <e20> phenytoin </e20> by increasing its systemic exposure.
mechanism	Although specific studies have not been performed, it has been postulated that the interaction of <e10> erythromycin </e10> with oral anticoagulants, such as warfarin or <e20> phenytoin </e20>, could be profoundened.
mechanism	Although specific studies have not been performed, the following may have occurred: (1) The concomitant administration of <e10> zalcitabine </e10> with allophycins containing dibenzocycline, <e20> ergotamine </e20>, or piperacillin, or macrolide_antibiotics such as ciprofloxacin, erythromycin, or clarithromycin may have resulted in a significant decrease in the absorption of these drugs.
mechanism	Although specific studies have not been conducted, it has been reported that <e10> cisapride </e10> significantly reduced the clearance of <e20> norethindrone </e20> and that its metabolism by CYP3A4 is likely to contribute to its pharmacokinetic properties.
mechanism	Although specific studies have not been performed, it is likely that concurrent use of other drugs, including probenecid, sulfasalazine, <e10> erythromycin </e10>, corticosteroids, coumarin, cholestyramine, <e20> cholestyramine_sulfate </e20>, corticotropin, dantrolene, estrogens, estrogens_derivatives, estrogens_isoimperator, estrogens_sulfate, estrogens_thiazide_diuretics, fentanyl, grapefruit juice, lithium, methadone, morphine, phenytoin, risperidone, selegiline, tamoxifen, warfarin, and vitamin_B12 may all have an effect on the pharmacokinetics of coadministered drugs.
mechanism	Although specific studies have not been conducted, it is possible that <e10> warfarin </e10> or its derivatives that are used concomitantly with <e20> terfenadine </e20> may increase the plasma levels of terfenadine.
mechanism	Although specific studies have not been performed, it is possible that other drugs that are metabolized by CYP2C9, including phenytoin, carbamazepine, alfentanil, disopyramide, <e10> metoclopramide </e10>, phenytoin, bromocriptine, bromocriptine, cisapride, diltiazem, methadone, triazolam, terfenadine, and felbamate may also decrease <e20> dexamethasone </e20> clearance.
mechanism	Although specific studies have not been conducted, the clinical implications of <e10> enoxacin </e10> interactions with <e20> phenytoin </e20>, carbamazepine, or cyclosporine are unknown at this time.
mechanism	Coadministration with compounds known to inhibit CYP3A4 (eg, fluconazole, ketoconazole, itraconazole, <e10> erythromycin </e10>, clarithromycin, nefazodone, alfentanil, terfenadine, cisapride, disopyramide ) resulted in an increase in oral bioavailability of <e20> enoxacin </e20>, concomitantly with an increase in Cmax and AUC.
mechanism	Coadministration with compounds that inhibit CYP3A4 activity (e,g,, ketoconazole, itraconazole, ritonavir, clarithromycin, <e10> nefazodone </e10>, nelfinavir, saquinavir, indinavir ) produced a 17% increase in Cmax and AUC of <e20> rifabutin </e20>.
mechanism	Coadministration with compounds with CYP3A4 inhibition (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, <e10> troleandomycin </e10>, ritonavir, indinavir, saquinavir, saquinavir, indinavir, indinavir, saquinavir, itraconazole, nelfinavir, nefazodone, rifampin, nelfinavir, zidovudine ) was associated with increased AUCs of <e20> nelfinavir </e20> and zidovudine and decreased AUCs of ketoconazole and itraconazole.
mechanism	Coadministration with compounds that induce CYP3A4 activity (such as alfentanil, <e10> phenytoin </e10>, carbamazepine, and phenobarbital ) significantly decreased <e20> ketoconazole </e20> clearance by 40% and increased the AUC of ketoconazole by a factor of approximately 3.
mechanism	Coadministration with compounds that inhibit CYP2D6 (e,g,, ketoconazole, itraconazole, <e10> ritonavir </e10>, nelfinavir, indinavir, clarithromycin, nefazadone ) decreased the AUC and Cmax of <e20> valdecoxib </e20> by 50% and 28%, respectively.
mechanism	Coadministration with compounds that induce CYP3A4 activity (such as ketoconazole and phenytoin ) or inhibit CYP3A4 activity (such as <e10> itraconazole </e10>, ritonavir, clarithromycin, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin ) has been associated with elevated plasma concentrations of <e20> indinavir </e20>.
mechanism	Coadministration with compounds with CYP3A4 activity (e,g,, ketoconazole, itraconazole, clarithromycin, indinavir, <e10> ritonavir </e10>, saquinavir, indinavir ) decreased exposure of <e20> didanosine </e20>.
mechanism	Coadministration with compounds that inhibit CYP3A4 (e,g,, ketoconazole, itraconazole, ritonavir, erythromycin, clarithromycin, <e10> nelfinavir </e10>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin ) increased the plasma concentrations of <e20> nelfinavir </e20> and may have resulted in the higher concentrations of nelfinavir in patients on cyclosporine.
mechanism	Coadministration with compounds that inhibit CYP3A4 (eg, fluoxetine, <e10> paroxetine </e10>, sertraline, sertraline_hydrochloride ) resulted in a significant increase in <e20> alfentanil </e20> plasma concentrations and a decrease in alfentanil clearance.
mechanism	Coadministration with compounds with an affinity for <e10> cisplatin </e10> has been reported to reduce the pharmacokinetics of <e20> dasatinib </e20>.
mechanism	Coadministration with compounds that inhibit CYP3A4 activity (eg, <e10> ketoconazole </e10>, itraconazole, ritonavir, nelfinavir, saquinavir, clarithromycin, indinavir, <e20> nefazodone </e20> ) increased the plasma concentrations of lovastatin approximately 3-fold.
mechanism	Valproate : <e10> Erythromycin </e10> has been reported to reduce the bioavailability of <e20> valproate </e20>, leading to an increased plasma concentration.
mechanism	Valproate : <e10> Cisplatin </e10> reduced the AUC of <e20> valproate </e20> by 49% (from #.80 to #.46 microg x min(-1) x mg(-1)) and the Cmax from # to # microg x min(-1) x mg(-1)).
mechanism	Valproate : <e10> Phenytoin </e10> : Increases plasma concentrations of valproate, <e20> phenobarbital </e20>, phenytoin, and other anticonvulsants
mechanism	Effects of other drugs that alter hepatic metabolism of <e11> PRINIVIL </e11> may be potentiated by <e20> carbamazepine </e20>.
mechanism	Phenytoin : Population studies have demonstrated that <e10> phenytoin </e10> may decrease the clearance of <e20> cisapride </e20>.
mechanism	Phenytoin : Population pharmacokinetics of <e10> phenytoin </e10> was increased by concomitant administration with <e20> atorvastatin </e20>.
mechanism	Phenytoin : Population pharmacokinetic data suggest a 50% decrease in clearance of <e11> ZYVOX </e11> when <e20> phenytoin </e20> is coadministered with ZYVOX.
mechanism	Phenobarbital ( Primidone ), <e10> Phenytoin </e10> ( Trileptal ), and B-phenylalanine ( Tretinoin ) have been reported to reduce <e20> zidovudine </e20> absorption by more than 50%.
mechanism	Phenobarbital ( Primidone ) : <e10> Phenobarbital </e10> decreased <e20> clorazepate </e20> clearance (9.8% decrease per hour) and caused a 7% increase in Clorazepate clearance (7% increase per hour).
mechanism	Phenobarbital ( Primidone ), <e10> quinine </e10>, cimetidine, carbamazepine, felbamate, diltiazem, fluvoxamine, indomethacin, itraconazole, itraconazole s halogenated_hydrocarbon_bromide_formulation, miconazole, <e20> nelfinavir </e20>, ritonavir, saquinavir, telithromycin, troleandomycin, and zidovudine may reduce the clearance of oral anticoagulants, resulting in decreased therapeutic concentrations.
mechanism	Phenobarbital ( Primidone ), <e10> phenytoin </e10>, phenylbutazone, carbamazepine, indomethacin, amiodarone, carbamazepine, cimetidine, phenobarbital, phenytoin, primidone, triazolam, theophylline, astemizole, <e20> itraconazole </e20>, zidovudine.
mechanism	Valproate : The increased <e10> valproate </e10> plasma concentrations observed with <e20> erythromycin </e20> were associated with a decrease in the clearance of valproate and a consequent increase in plasma valproate concentrations.
mechanism	Valproate : The concentration of <e10> valproate </e10> is increased in the blood of patients taking <e20> warfarin </e20> concurrently.
mechanism	Anticonvulsants ( Phenytoin, Trileptal, Felbatol ): <e10> Cholestyramine </e10> increases the plasma concentration of <e20> trileptal </e20>, but not that of the anticonvulsant, but the change is small and not clinically significant.
mechanism	Anticonvulsants ( Phenytoin, Topamax, <e10> Leucovorin </e10>, etc,) may decrease the bioavailability of <e20> ketoconazole </e20> and interfere with metabolism of some oral preparations of this medication.
mechanism	Anticonvulsants ( Phenytoin, Phenobarbital, Topiramate, Tegretol, Trileptal, Felbatol ) may increase plasma concentrations of <e10> digoxin </e10> and <e20> diltiazem </e20>.
mechanism	Coadministration with <e10> ketoconazole </e10> reduced the extent of <e20> digoxin </e20> clearance by 25%, suggesting that coadministration may be an effective means of decreasing digoxin toxicity.
mechanism	Coadministration with <e10> digoxin </e10> # mg decreased <e20> ketoconazole </e20> exposure by approximately 25% and decreased exposure to digoxin by approximately 25%.
mechanism	Coadministration with <e10> probenecid </e10> may have decreased serum <e20> rifampin </e20> levels.
mechanism	Even so <e10> indomethacin </e10> (1 mg/kg, p.o.) administered with <e20> loratadine </e20> (50 mg/kg, p.o.) produced a decrease in the mean fluorescence of the liver, which suggests that the binding of loratadine to indomethacin may be impaired.
mechanism	Even so <e10> doxycycline </e10> may decrease the absorption of <e20> amiodarone </e20> and lead to increased serum levels of amiodarone.
mechanism	Lithium : <e10> Magnesium </e10> supplements may inhibit the absorption of <e20> lithium </e20>.
mechanism	Lithium : <e10> L-methionine </e10> may interact with lithium -containing medications such as <e20> lithium </e20> and lithium_carbonate.
mechanism	<e10> Valdecoxib </e10> was found to be a weak inhibitor of the metabolism of <e20> enoxacin </e20>.
mechanism	<e10> Valdecoxib </e10>, acetaminophen ( Tylenol ), aspirin ( Trileptal ), colestipol ( Amiloride ), cimetidine ( L-phenylalanine ), diazepam ( Diazepam ), ketoconazole ( Ketoprofen ), and phenytoin ( Phenobarbital ) may reduce the absorption of <e20> cisapride </e20>.
mechanism	<e10> Valdecoxib </e10> also reduced the plasma levels of <e20> disopyramide </e20> by about 50%.
mechanism	<e10> Valdecoxib </e10> reduced <e20> cyclosporine </e20> clearance by about 70% in a pharmacokinetic study in healthy volunteers.
mechanism	<e10> Valdecoxib </e10> has been reported to reduce the bioavailability of some <e22> tricyclic_antidepressants </e22>.
mechanism	Concomitant single dose administration of <e10> erythromycin </e10> and <e20> amiodarone </e20> resulted in approximately twice as much amiodarone absorption as with either drug alone.
mechanism	Concomitant single dose administration of <e10> erythromycin </e10> # mg and <e20> ketoconazole </e20> # mg resulted in a 6-fold increase in the number of AChE [A-band]-and 2-fold increase in the AChE: cholinesterase activity ratio.
mechanism	Concomitant single dose administration of <e10> astemizole </e10> # mg with <e20> diltiazem </e20> resulted in a 13% increase in AUC(0-12) from # to # mg/h and a 41% increase in AUC(0-24) from # to # mg/h.
mechanism	Concomitant single dose <e10> methotrexate </e10> and <e20> alfentanil </e20> has been reported to result in significant increases in alfentanil plasma levels.
mechanism	Concomitant single dose administration of <e10> tetracycline </e10> # mg decreased the <e20> isoniazid </e20> clearance by 42% (P = #) and the elimination half-life by 54% (P = #).
mechanism	Concomitant single dose administration of <e11> VIDEX </e11> and <e20> atorvastatin </e20> significantly decreased AUC of VIDEX by 34% and 53%, respectively.
mechanism	Plasma exposure (AUC) of <e10> erythromycin </e10> decreased by approximately 20% and the elimination half-life was increased by approximately 15% following coadministration with <e20> atorvastatin </e20>.
mechanism	Plasma exposure (AUC) of <e10> diltiazem </e10> is increased by 50% when coadministered with <e20> phenytoin </e20>.
mechanism	Plasma exposure (AUC) of <e10> phenytoin </e10> was significantly increased by coadministration with <e20> propafenone </e20>, compared with propafenone alone.
mechanism	Plasma exposure (AUC) of <e10> ketoconazole </e10> increased by approximately 50% when <e20> loratadine </e20> was co-administered with oral ketoconazole, resulting in approximately 6-fold increase in oral clearance of loratadine.
mechanism	Plasma exposure (AUC) of <e10> digoxin </e10> and <e20> verapamil </e20> decreased by approximately 40% ( digoxin ) and by approximately 20% ( verapamil ).
mechanism	Coadministration of <e10> digoxin </e10> with <e20> atorvastatin </e20> resulted in a decrease in atorvastatin AUC and increase in AUC after administration of digoxin.
mechanism	Coadministration of <e10> ketoconazole </e10> with <e20> ciprofloxacin </e20> decreased the absorption of ciprofloxacin by #%.
mechanism	Coadministration of <e10> warfarin </e10> tablets with <e20> phenytoin </e20> (e,g,, phenobarbital ), a specific CYP3A4 inhibitor, has been shown to decrease the steady-state level of warfarin in human plasma.
mechanism	Coadministration with <e10> amiodarone </e10> markedly decreased the clearance of <e20> phenytoin </e20> and caused a 4-fold increase in phenytoin serum levels.
mechanism	Coadministration with <e10> clindamycin </e10> (400 mg twice daily) for # weeks was associated with an increase in the serum level of <e20> lupus_anticoagulant </e20>, which has been shown to decrease the clearance of furosemide and increase the rate of renal excretion of sulfinpyrazone.
mechanism	Coadministration with <e10> dexamethasone </e10> significantly increased plasma concentrations of the catecholamine_antagonist <e20> apomorphine </e20> by approximately 46%.
mechanism	Coadministration of <e10> erythromycin </e10> and <e20> furosemide </e20> (2 mg and # mg daily, respectively) in healthy volunteers resulted in a 2- to 4-fold increase in the clearance of furosemide and a concomitant increase in furosemide absorption.
mechanism	Coadministration of <e10> erythromycin </e10> with <e20> diltiazem </e20>, an inhibitor of CYP3A4, resulted in an increase in the clearance of diltiazem from 62% to 75%.
mechanism	Plasma exposure of <e10> ketoconazole </e10> was enhanced by <e20> rifabutin </e20>, as was rifabutin elimination following rifabutin administration.
mechanism	Plasma exposure of <e10> ketoconazole </e10> was increased by #-fold when <e20> cisapride </e20> was coadministered with a high dose of ketoconazole.
mechanism	<e10> Erythromycin </e10> and <e20> warfarin </e20>, both of which inhibit platelet aggregation, cause a significant decrease in the rate of anticoagulant absorption.
mechanism	<e10> Ketoconazole </e10> and <e20> cisapride </e20> may increase the clearance of valdecoxib and indomethacin, and increase the extent of the absorption of other oral anticoagulants.
mechanism	<e10> Ketoconazole </e10> reduced the uptake of <e20> doxorubicin </e20>, as shown by the rate of intravenous doxorubicin infusion and the area under the plasma concentration time curve of doxorubicin in dogs.
mechanism	<e10> Ketoconazole </e10> decreases the pharmacokinetics of <e20> triazolam </e20>.
mechanism	HIV_Protease_Inhibitors : <e10> Ritonavir </e10> inhibits HIV protease activity and may therefore have potential for use in combination with HIV protease inhibitors such as <e20> nevirapine </e20>.
mechanism	HIV_Protease_Inhibitors : <e10> Isoniazid </e10> may increase the level of <e20> HIV_1_Protease_inhibitors </e20> and may prolong plasma concentrations.
mechanism	<e10> Ritonavir </e10> and <e20> ritonavir </e20> increased the AUC of ritonavir by approximately 6-fold and 3-fold, respectively, in healthy volunteers.
mechanism	<e10> Ritonavir </e10> significantly reduced the plasma concentrations of <e20> ritonavir </e20> (6%) and 5-fluorouracil (13%), which would have resulted in a significant increase in the AUC of ritonavir (4%) and 5-fluorouracil (3%).
mechanism	<e10> Ritonavir </e10> can increase the clearance of covalently bound drugs such as cimetidine, cyclosporine, <e20> tacrolimus </e20>, digoxin, indinavir, itraconazole, itraconazole, troleandomycin, and zidovudine.
mechanism	The interaction is not mediated by <e10> diazepam </e10>, but rather by its metabolism to <e20> rocuronium </e20>.
mechanism	<e10> Ritonavir </e10> inhibits the metabolism of <e20> nevirapine </e20> by decreasing its synthesis.
mechanism	<e10> Ritonavir </e10> or indinavir may decrease the pharmacokinetics of <e20> rifabutin </e20>.
mechanism	<e10> Ritonavir </e10> is also inhibited by <e20> fluvoxamine </e20>, and the elimination half-life of fluvoxamine is approximately one hour longer than that of ritonavir.
mechanism	In vivo studies: <e10> Indinavir </e10> and <e20> indinavir </e20> at similar molar ratios (0.1-1, 2-3, and 4-6 mg/kg body weight) have been reported to increase plasma concentrations of the oral formulations of indinavir by approximately 16%, 35%, and 26%, respectively, on a mg/kg/day basis when compared with a # mg/kg/day regimen.
mechanism	In vivo studies: <e10> Ketoconazole </e10> (100 mg/kg/day) decreased the <e20> cisapride </e20> clearance from 5 to 1%.
mechanism	In vivo studies: In vivo studies with <e10> ketoconazole </e10> indicate that the following are altered by <e20> cimetidine </e20> : plasma concentrations of the pro-drug cimetidine are increased approximately #-fold when administered concomitantly with ketoconazole.
mechanism	Ritonavir and indinavir metabolized equally well to the following: <e10> zalcitabine </e10> : 15 mg q8w with ritonavir and indinavir at # micrograms/mL (28 times the maximum recommended daily dose) and to <e20> ritonavir </e20> and indinavir at # micrograms/mL (30 times the maximum recommended daily dose) and nelfinavir at # micrograms/mL (30 times the maximum recommended daily dose).
mechanism	Ritonavir and indinavir concentrations were lower during <e10> ritonavir </e10> coadministration than during <e20> indinavir </e20> coadministration.
mechanism	Ritonavir and indinavir plasma concentrations can be significantly increased by <e10> ritonavir </e10> coadministration of <e20> lovastatin </e20>.
mechanism	Upon administration of <e10> cyclosporine </e10>, <e20> phenytoin </e20> dosage was reduced by approximately two-thirds.
mechanism	Upon administration of <e10> dextromethorphan </e10> # mg to healthy volunteers, blood levels of dextromethorphan increased by a mean of 26% and 18% and the percentage of subjects with plasma <e20> dextromethorphan </e20> concentrations below the limit of quantification decreased from 23% to 10%.
mechanism	Upon administration of <e10> zalcitabine </e10> to diabetic patients receiving <e20> cimetidine </e20>, the plasma concentration of cimetidine decreased.
mechanism	Amphotericin, Foscarnet, and Foscarol : Combination <e10> Amphotericin </e10> and <e20> Foscarnet </e20> (1-day) reduced the clearance of Amphotericin by 19% (P =.01).
mechanism	Amphotericin, Foscarnet, or Ethambutol : <e10> Dapsone </e10> should not be taken concomitantly with amphotericin, foscarnet, or ethambutol, because <e20> dapsone </e20> may form a stable, well-spaced, and chemically stable quinolone-like compound with these drugs.
mechanism	Amphotericin, Foscarnet, and Chloramphenicol (or carbamazepine ) : Use of <e10> ciprofloxacin </e10> may result in increased serum levels of <e20> amphotericin </e20> and fluconazole.
mechanism	Amphotericin, Foscarnet, and Carbamazepine : Co-administration of <e10> amphotericin </e10> (5 mg daily for # days) and <e20> foscarnet </e20> (20 mg daily for # days) resulted in a significant increase in the plasma concentrations of amphotericin.
mechanism	Amphotericin, Foscarnet, Phenytoin, and Sulfonamides : <e10> Amphotericin </e10>, Foscarnet, and Phenytoin increase the clearance of <e20> terfenadine </e20> and decrease the clearance of dideoxacin.
mechanism	Amphotericin, Foscarnet, Cimetidine, and <e10> Phenytoin </e10> may interact with <e20> ketoconazole </e20>, resulting in increased ketoconazole concentrations and increased toxicity.
mechanism	Probenecid or Cimetidine : <e10> Probenecid </e10> or Cimetidine is a hepatic enzyme which may reduce the bioavailability of <e20> cimetidine </e20> or other long-acting_anti-malarial_agents.
mechanism	Probenecid or Cimetidine : Clinical studies have shown a significant decrease in probenecid plasma levels when <e10> indinavir </e10> and <e20> probenecid </e20> are coadministered.
mechanism	Probenecid or Cimetidine : <e10> Cimetidine </e10>, probenecid, and <e20> probenecid_sodium </e20> may interact with methylprednisolone, and the effects are unpredictable.
mechanism	Probenecid or Cimetidine, when administered concomitantly with <e10> cimetidine </e10>, may potentiate the <e22> anesthetic </e22>-induced respiratory depression.
mechanism	Metoclopramide : Bioavailability of <e10> metoclopramide </e10> decreased by a mean of 32% when <e20> caffeine </e20> was added to the regimen.
mechanism	Metoclopramide : Bioavailability of <e10> diazepam </e10> decreased approximately 50% when administered concomitantly with <e20> metoclopramide </e20>.
mechanism	Metoclopramide : Bioavailability of <e10> metoclopramide </e10> may be decreased by <e20> levodopa </e20>.
mechanism	Promethazine : Coadministration of <e10> fluvoxamine </e10> and <e20> promethazine </e20> resulted in an increase in steady-state AUC and Cmax of fluvoxamine.
mechanism	Multiple-dose administration of <e10> levothyroxine </e10> (2 x # mg) plus <e20> digoxin </e20> (40 mg/day) significantly increased serum digoxin levels by 50% in the absence of known renal tubular acidosis.
mechanism	Multiple-dose administration of <e10> ketoconazole </e10> # mg given # times with oral <e20> bromocriptine_mesylate </e20> # mg given # times resulted in a 42% increase in the concentration of bromocriptine_mesylate in plasma compared with bromocriptine_mesylate alone (P = 0.009).
mechanism	Multiple-dose administration of <e10> probenecid </e10> to patients on chronic <e20> warfarin </e20> treatment resulted in a 6% increase in prothrombin time and a 3% increase in indocyanine green clearance.
mechanism	Coadministration of single, daily doses of <e10> clindamycin </e10> # mg and <e20> tamoxifen </e20> # mg was associated with an increase in AUC(2) (0-6 hours) of tamoxifen and in AUC(0-12 hours) of clindamycin.
mechanism	Coadministration of single, high dose, daily doses of <e10> dexamethasone </e10> # mg and <e20> carbamazepine </e20> # mg for # days produced a significant increase in the levels of carbamazepine in # # of # subjects.
mechanism	Coadministration of single, two, or four times daily doses of <e10> nevirapine </e10> and <e20> ergotamine </e20> decreased the half-life of nevirapine by 28%, 37%, and 24%, respectively.
mechanism	Other strong selective serotonin reuptake inhibitors ( <e12> SSRIs </e12> ) have been reported to decrease <e20> fluvoxamine </e20> s serum levels, causing potential drug interactions.
mechanism	Drugs That Inhibit CYP3A4: Anticonvulsants, carbamazepine, felbamate, <e10> fluconazole </e10>, itraconazole, troleandomycin, quinidine, theophylline, verapamil <e20> vitamin_C </e20>
mechanism	Drugs That Inhibit CYP2C9: Cyclosporine, tacrolimus, <e10> carbamazepine </e10>, phenytoin, carbamazepine plus sulfasalazine, cimetidine, alfentanyl, and alfentanyl concomitantly inhibit the metabolism of <e20> rifampin </e20>.
mechanism	Drugs That Inhibit CYP3A4 (eg, ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin, <e10> nefazodone </e10>, troleandomycin, cimetidine ): Concomitant administration with CYP3A4 inhibitors may increase the exposure of these drugs to an extent that could result in drug interactions with <e20> ketoconazole </e20>.
mechanism	Concomitant administration of <e10> ketoconazole </e10> with <e20> ciprofloxacin </e20>, the main component of the bacteriostatic regimen, resulted in a significant reduction of ciprofloxacin AUC and Cmax.
mechanism	Concomitant administration of <e10> ketoconazole </e10> with <e20> ketoprofen </e20> reduced the clearance of ketoconazole by two-fold.
mechanism	Concomitant administration of <e11> BROVANA </e11> ( <e20> fluconazole </e20> ) and oral hypoglycemic_agents (e,g,, glipizide, netilmicin, erythromycin, clarithromycin, piperacillin_B, nefazodone, troleandomycin, fluvastatin, astemizole, and erythromycin ) may result in higher serum levels of these agents.
mechanism	Concurrent administration of <e10> phenytoin </e10> with <e20> bromocriptine_mesylate </e20> may prolong the half-life of bromocriptine and increase the plasma concentrations of bromocriptine and phenytoin.
mechanism	Concurrent administration of <e11> LEVSIN </e11> and either <e20> bromocriptine_mesylate </e20> or disopyramide resulted in approximately a twofold increase in BMD at the lumbar spine.
mechanism	Concurrent administration of <e10> dexamethasone </e10> with oral <e20> estrogens </e20> produced increases in CMI and TSH values in ovariectomized rats and elevations in serum estradiol levels.
mechanism	Median gastric pH was 4.8% with cimetidine and <e10> furosemide </e10> ; and 3.6% with <e20> phenytoin </e20> and furosemide.
mechanism	Median gastric pH <7.0 and <8.5> were found to be associated with significant increases in the concentrations of <e10> cisapride </e10> and <e20> ethchlorvynol </e20>.
mechanism	However, <e10> halothane </e10> toxicity increased after intravenous <e20> atracurium </e20> was discontinued.
mechanism	However, <e10> halothane </e10> and <e20> cyclosporine_A </e20> produce dose-dependent increases in serum levels of propranolol.
mechanism	However, <e10> halothane </e10> increased the cardiac AV conduction time in a dose-dependent manner and decreased the AUC of <e20> cimetidine </e20>.
mechanism	The half-life of <e10> piperacillin </e10> and <e20> indinavir </e20> increased by 15% and 35%, respectively, following a single oral dose of # mg indinavir and increased by 18% and 26%, respectively, following a single oral dose of # mg piperacillin.
mechanism	The half-life of <e10> cisapride </e10> is increased by the concomitant administration of <e20> clozapine </e20>.
mechanism	The half-life of <e10> acetaminophen </e10> in rats is prolonged and is increased approximately tenfold by coadministration with <e20> erythromycin </e20>.
mechanism	<e10> Rifampin </e10> increases the clearance of carbamazepine, phenytoin, tacrolimus, hexobarbital, phenytoin, phenytoin_hydrochloride, alfentanil, cisapride, <e20> quinidine </e20>, theophylline, valproate, valproate_diphenylpropion, triazolam, carbamazepine, cisapride, disopyramide, chlordiazepoxide, ergot_derivatives, metoclopramide, isoniazid, and isoniazid_hydrochloride.
mechanism	<e10> Rifampin </e10>, <e20> warfarin </e20> and dipyridamole may interfere with absorption of furosemide, ketoconazole, phenytoin, tacrolimus, or intravenous pentamidine.
mechanism	<e10> Rifampin </e10> decreased the plasma concentration of <e20> fluvoxamine </e20> and was displaced by the drug.
mechanism	The concomitant administration of <e10> amiodarone </e10> and <e20> ketoconazole </e20> resulted in a statistically significant increase in plasma concentrations of amiodarone and a significant decrease in renal clearance of ketoconazole.
mechanism	The concomitant administration of <e10> valdecoxib </e10> and <e20> norethindrone </e20> is likely to produce a significant increase in valdecoxib exposure, with a possible reduction in bioavailability of norethindrone.
mechanism	The concomitant administration of <e10> alprazolam </e10> (6 mg/kg, s,c,) and <e20> ketoconazole </e20> (4 mg/kg, s,c,) produced a significant decrease in plasma alprazolam levels.
mechanism	Withdrawal of <e10> diazepam </e10> # hours following the administration of <e20> valdecoxib </e20> resulted in a decrease in citalopram clearance (14%) and an increase in diazepam and citalopram serum concentrations (25%).
mechanism	Withdrawal of <e10> cimetidine </e10> at doses of # mg/day and # mg/day for # days produced a statistically significant decrease in AUC of <e20> zalcitabine </e20> from # to #.5 (t = -0.70, P =.01).
mechanism	Withdrawal of <e10> ciprofloxacin </e10> decreased plasma concentrations of <e20> ketoconazole </e20> by approximately 33%.
mechanism	<e10> Amprenavir </e10> decreased serum creatinine concentration in HIV-infected patients who were treated with <e20> nevirapine </e20> and did not use an increased dose of nevirapine to achieve the recommended creatinine clearance of amprenavir.
mechanism	<e10> Amprenavir </e10> decreased the plasma concentrations of <e20> lovastatin </e20> and the Cmax of lovastatin increased by approximately 15% when administered with valganciclovir and the AUC of lovastatin increased approximately 15% when administered with valganciclovir.
mechanism	<e10> Amprenavir </e10> and <e20> didanosine </e20> produced a significant inhibition of CYP2C9 activity with a 50% increase in AUC values.
mechanism	<e10> Amprenavir </e10> and <e20> ritonavir </e20> (used in combination) were generally observed to decrease the plasma levels of both ciprofloxacin and ritonavir.
mechanism	<e10> Amprenavir </e10> decreased AUC for <e20> ciprofloxacin </e20> by 58% to 60%, Pronestyl was not affected, and Cmax was increased by about 30%.
mechanism	<e10> Rifampin </e10> reduced the plasma concentrations of <e20> isoniazid </e20> and zidovudine by >40% and 38%, respectively.
mechanism	<e10> Rifampin </e10> (10(-9) M) increased <e20> clofibrate </e20> levels, while an increase in plasma sRif could not be demonstrated.
mechanism	<e10> Rifampin </e10> and rifabutin (100 mg/day for # days) reduced the AUC of <e20> quinine </e20> by 50%.
mechanism	<e10> Rifampin </e10> and <e20> warfarin </e20> inhibit platelet aggregation induced by vitamin_K_antagonists such as heparin or cyclosporine.
mechanism	<e10> Rifampin </e10> may potentiate the activity of <e20> digoxin </e20> and acetaminophen ;
mechanism	<e10> Amprenavir </e10> had no effect on the <e20> nelfinavir </e20> dose, while the tetracycline/rifabutin combination had a moderate effect on nelfinavir plasma concentrations.
mechanism	<e10> Amprenavir </e10> decreased the exposure of <e20> nelfinavir </e20> to a higher extent than did ritonavir or atazanavir.
mechanism	<e10> Amprenavir </e10> administered concurrently with <e20> valdecoxib </e20> significantly decreased plasma valdecoxib concentrations and approximately halved valdecoxib plasma concentrations.
mechanism	<e10> Amprenavir </e10> # mg daily increased the exposure of <e20> rifabutin </e20> to # mg per day (P = # x 10(-7)).
mechanism	<e10> Amprenavir </e10> decreased hepatic clearance of <e20> erythromycin </e20> by approximately 50% and approximately 10% compared to placebo.
mechanism	RESULTS: The geometric mean plasma concentration of <e10> clozapine </e10> was 0.58 ng/mL and the mean area under the plasma concentration-time curve was 1.01 ng/mL after a single oral dose of clozapine and 6.37 ng/mL after a single oral dose of <e20> primidone </e20>.
mechanism	RESULTS: The geometric mean AUC of <e10> lopinavir </e10> and <e20> ritonavir </e20> in HIV-infected patients was similar, and similar in patients on other protease_inhibitors, which were of similar AUC values.
mechanism	RESULTS: The geometric mean exposure of <e10> cisapride </e10> was # ng/m(2) when it was given to healthy volunteers on a single dose of # mg of <e20> aripiprazole </e20>.
mechanism	Apparent oral clearance of <e10> cefazolin </e10> was increased approximately 15-fold by coadministration of <e20> nifedipine </e20>, a negative inotropic effect of which may enhance absorption of cefazolin.
mechanism	Apparent oral clearance of <e10> indomethacin </e10> was decreased by 40% and 83% with concurrent <e20> indomethacin </e20> and allopurinol.
mechanism	Apparent oral clearance of <e10> ketoconazole </e10> was lower than with <e20> bromocriptine_mesylate </e20>.
mechanism	<e10> Fluvoxamine </e10> may decrease the clearance of ampicillin and <e20> levofloxacin </e20>.
mechanism	<e10> Fluvoxamine </e10> significantly decreased the clearance of <e20> fluvoxamine </e20> by approximately 18%.
mechanism	<e10> Fluvoxamine </e10> (2 mg orally once daily for # days) significantly reduced the <e20> acarbose </e20> clearance by 29% and decreased acarbose AUC by 18%.
mechanism	DISCUSSION: <e10> Clarithromycin </e10> has been reported to decrease the bioavailability of digoxin, <e20> warfarin </e20>, and diazepam.
mechanism	DISCUSSION: <e10> Clarithromycin </e10> (3 g/day) and <e20> methotrexate </e20> (5 mg/day) may increase the clearance of ethinyl_estradiol.
mechanism	This study demonstrated that <e10> erythromycin </e10> # mg daily decreased <e20> amiodarone </e20> metabolism by approximately 20% and AUC by approximately 20% in subjects receiving an oral route of amiodarone.
mechanism	This study demonstrated that <e10> erythromycin </e10> has a tendency to increase the clearance of <e20> warfarin </e20> by about 20% when administered concurrently with warfarin.
mechanism	This study demonstrated that the hepatic and renal toxicity of <e10> cisapride </e10> are enhanced by the administration of <e20> vitamin_D </e20> and digoxin.
mechanism	<e10> Acetaminophen </e10> may reduce the clearance of <e20> furosemide </e20>.
mechanism	<e10> Acetaminophen </e10> administered concomitantly with <e20> valdecoxib </e20> may decrease blood levels of valdecoxib.
mechanism	<e10> Acetaminophen </e10> # mg # mg on # days decreased serum <e20> carbamazepine </e20> concentrations by #%.
mechanism	<e10> Theophylline </e10> : Decreased plasma levels of <e20> theophylline </e20> have been reported in patients treated with high-dose theophylline.
mechanism	<e10> Theophylline </e10> may interfere with <e20> sirolimus </e20> metabolism, leading to increased sirolimus serum concentrations and increased sirolimus metabolism.
mechanism	<e10> Theophylline </e10> is a potent inhibitor of the CYP3A4 and <e20> estrogens </e20> metabolism.
mechanism	Previous studies have shown that <e10> nelfinavir </e10>, as well as itraconazole, significantly inhibited the metabolism of oral <e20> methotrexate </e20>.
mechanism	Previous studies have demonstrated a reduction of <e10> naloxone </e10> in the presence of <e20> enoxacin </e20>.
mechanism	Previous studies have shown that <e10> cimetidine </e10> has been withdrawn from the market and replaced with <e20> phenytoin </e20> in patients taking these agents concomitantly.
mechanism	Previous studies have shown that theophylline and <e10> cisapride </e10> can interfere with renal tubular secretion of <e20> ampicillin </e20> and clindamycin, respectively.
mechanism	Previous studies have shown that <e10> cyclosporine </e10> causes a decrease in urinary clearance of <e20> digoxin </e20>.
mechanism	Previous studies have shown that <e10> piperazine </e10>, administered at doses of # mg/kg, # mg/kg, and # mg/kg, significantly decreased plasma concentrations of <e20> lorazepam </e20>.
mechanism	Previous studies have shown that <e10> cimetidine </e10> and cisplatin are responsible for a marked increase in <e20> erythromycin </e20> and its active metabolite, erythromycin.
mechanism	Previous studies have shown that <e10> nifedipine </e10> has a dose-dependent effect on the clearance of digoxin, <e20> warfarin </e20>, and other anticoagulants.
mechanism	Previous studies have shown that the drug <e10> ketoconazole </e10>, a drug with an ARAVA of 7%, reduced <e20> cimetidine </e20> ARAVA by 62%.
mechanism	Previous studies have shown that <e10> amprenavir </e10> decreases the metabolism of <e20> rifabutin </e20> by rifampin.
mechanism	Previous studies have shown that <e10> amiodarone </e10> has a weak effect on <e20> chloramphenicol </e20> pharmacokinetics, which might lead to an increase in serum levels.
mechanism	<e10> Azithromycin </e10> significantly decreased the bioavailability of <e20> erythromycin </e20> and fluconazole, which were administered with the following agents: theophylline, clofibrate, cimetidine, disopyramide, famotidine, hexobarbital, ketoconazole, midazolam, phenytoin, rifampin, theophylline, triazolam, and zidovudine.
mechanism	<e10> Azithromycin </e10> increased serum concentrations of <e20> estradiol </e20> and significantly decreased plasma concentrations of estrogens in the mouse model.
mechanism	<e10> Azithromycin </e10> is known to inhibit CYP3A4 activity and, therefore, may increase the clearance of <e20> warfarin </e20>.
mechanism	<e10> Azithromycin </e10> and similar <e22> macrolide_antibiotics </e22> inhibit oral bioavailability of oral cephalosporins and can cause hypoglycemia and gastrointestinal toxicity.
mechanism	<e10> Azithromycin </e10> may reduce the effectiveness of nonsteroidal_anti-inflammatory_drugs ( <e22> NSAIDs </e22> ), some ACE_inhibitors, some diuretics, and some corticosteroids.
mechanism	<e10> Azithromycin </e10>, when administered concurrently with <e20> quinolone_antibiotics </e20>, results in an increase in the bioavailability of quinolone_antibiotics.
mechanism	Coadministration of <e10> amphetamine </e10> and <e20> alprazolam </e20> resulted in a 2-fold increase in AUC(alprazolam).
mechanism	(1968, 1970), the concomitant administration of <e10> chlorprothixene </e10> with phenytoin and <e20> astemizole </e20> caused a decrease in the hepatic metabolism of astemizole.
mechanism	(1968, 1970), the dose of <e10> cimetidine </e10> was decreased by approx. 20% at doses of # mg, and the half-life of <e20> cimetidine </e20> increased from # to # hours.
mechanism	(1968, 1970), the dosage of the <e10> warfarin </e10> recommended by the USP should be reduced by #-8% with #-8% reduction of the usual dose of <e20> warfarin </e20> or equivalent daily dose of #-10% warfarin in order to achieve the desired increase in # micrograms/day.
mechanism	This might be due to the action of <e10> norethindrone </e10> on the liver enzyme system, which is induced by <e20> ketoconazole </e20>, causing increased production of norethindrone.
mechanism	This might be because, in some patients, <e10> ketoconazole </e10> inhibited the metabolism of <e20> cyclosporine </e20>, resulting in elevated serum concentrations of cyclosporine.
mechanism	An intravenous injection of <e10> enoxacin </e10> # mg increased the clearance of <e20> diltiazem </e20> # mg by approximately 3-fold (p = 0.0013).
mechanism	An intravenous injection of <e10> dantrolene </e10> # mg # minutes prior to <e20> ethinyl_estradiol </e20> # mg # minutes prior to administration of ethinyl_estradiol # mg.
mechanism	An intravenous injection of <e10> ketoconazole </e10> (4 mg/kg) caused a 62% increase in <e20> cimetidine </e20> plasma concentrations.
mechanism	<e10> Amiodarone </e10> ( 10 mg/kg, s,c,) inhibited the formation of <e20> diflunisal </e20> in vitro.
mechanism	<e10> Amiodarone </e10> inhibits <e20> zalcitabine </e20> metabolism and inhibits zalcitabine elimination.
mechanism	<e10> Amiodarone </e10>, a known CYP3A4 inhibitor, reduced plasma levels of <e20> cisapride </e20> by 17%.
mechanism	These alterations in the metabolism of <e10> ketoconazole </e10>, resulting in decreased <e20> cyclosporine </e20> clearance, may increase the risk of gastrointestinal toxicity.
mechanism	These alterations in CYP2C9 activity may explain the higher incidence of hepatic toxicity seen in patients who receive <e10> celecoxib </e10> concomitantly with <e20> rifampicin </e20>.
mechanism	<e13> Misonidazole </e13> decreased the AUC of <e20> ketoconazole </e20> by 41% and that of the active metabolite of ketoconazole by 62%.
mechanism	<e13> Misonidazole </e13> inhibits the metabolism of <e20> caffeine </e20>, increasing plasma caffeine levels by twofold.
mechanism	Enhanced <e10> theophylline </e10> absorption was observed in healthy volunteers who were treated orally with theophylline-containing or aqueous preparations (chloroquine, <e20> theophylline </e20>, amiodarone, and nifedipine ).
mechanism	Enhanced <e10> theophylline </e10> absorption, as evidenced by increased plasma levels and urinary excretion, when administered concomitantly with <e20> aprepitant </e20>.
mechanism	This study demonstrates that <e10> diazepam </e10> is metabolized and released during <e20> ketoconazole </e20> treatment and that these effects are not necessarily additive.
mechanism	This study demonstrates that <e10> fluvoxamine </e10> significantly increases the serum concentration of <e20> clofibrate </e20>.
mechanism	Interactions of <e10> guanfacine </e10> and <e20> diazepam </e20> were studied in vitro with the following parameters: the combination of guanfacine and diazepam increased the clearance of cimetidine to 3-fold (P=0.0048), but the combination of diazepam and guanfacine did not affect the clearance of diazepam to the same extent (P=1).
mechanism	Interactions of <e10> digoxin </e10> and <e20> cyclosporine_A </e20> with ketoconazole and pimozide are reported.
mechanism	Interactions of <e10> erythromycin </e10> with carbamazepine, cyclosporine, tacrolimus, digoxin, indinavir, itraconazole, itraconazole, <e20> ritonavir </e20>, saquinavir, telithromycin, troleandomycin, and troleandomycin have been studied and found to increase AUC by a mean of 50% in the dose range of # mg to # mg.
mechanism	Additional <e10> iron </e10> and zinc concentrations in liver were slightly higher with <e20> cefditoren_pivoxil </e20> than with other CYP3A4 inhibitors.
mechanism	Additional <e10> iron </e10> supplements or supplements containing other iron compounds may be necessary for the same or similar hypocalcemia to occur with <e20> valdecoxib </e20>.
mechanism	Additional <e10> iron </e10> is required for the <e22> coumarin_derivative </e22> to affect platelet aggregation.
mechanism	Additional <e10> iron </e10> in low doses can increase the serum iron level of <e20> carbamazepine </e20>.
mechanism	Additional <e10> iron </e10> may be needed to achieve # mg/day of <e20> erythromycin </e20> -induced (n=4) serum iron concentration.
mechanism	Additional <e10> iron </e10>, zinc, or iron -containing supplements or <e20> vitamin_D </e20> may be necessary.
mechanism	The lower rate of <e10> acetaminophen </e10> ingestion with # mg of <e20> diazepam </e20> was seen with the combination.
mechanism	The lower rate of co-administration of <e11> WELLBUTRIN </e11> with most <e22> CYP3A4 inhibitors </e22> has been attributed to the fact that both the hepatic metabolism of WELLBUTRIN and its anticonvulsant effect are blocked by these drugs.
mechanism	The lower rate of renal clearance of <e10> indinavir </e10> may be attributed to the lower serum concentration of <e20> indinavir </e20> and the higher activity of ritonavir.
mechanism	Consequently, the effect of <e10> valdecoxib </e10> was found to be significantly increased when coadministered with either rifabutin or <e20> warfarin </e20>.
mechanism	Consequently, the effect of <e10> valdecoxib </e10> on the pharmacokinetics of <e20> diltiazem </e20> was diminished.
mechanism	Consequently, the effect of <e10> levodopa </e10> on <e20> dofetilide </e20> concentrations was approximately #% lower than with a single dose of each.
mechanism	[The effect of <e10> nifedipine </e10> on the <e22> anticoagulant </e22> s is unclear.
mechanism	[The effect of <e10> nevirapine </e10> on the kinetics of dasatinib metabolism is unknown, but in the presence of <e20> methotrexate </e20>, a decrease in nevirapine AUC was observed.
mechanism	[The effect of <e10> phenytoin </e10> and <e20> enoxacin </e20> on serum creatinine and cystatin_C concentrations is opposite.
mechanism	[The effect of a single dose of <e10> warfarin </e10> # mg on the plasma levels of <e20> lopinavir </e20> # mg.
mechanism	[The effect of <e10> cyclosporine </e10> on <e20> terfenadine </e20> metabolism was studied in normal volunteers.
mechanism	[The effect of <e12> sulfonylureas </e12> ] Co-administration of <e20> ketoconazole </e20> significantly reduced the AUC of the CYP3A4 substrate, cyclosporine, by approximately 50%.
mechanism	Acid-catalyzed ethanolysis of retinyl_acetate in the presence of <e10> erythromycin </e10> is potentiated by <e20> azithromycin </e20>.
mechanism	Acid-catalyzed ethanolysis of <e10> dicumarol </e10>, resulting in high concentrations of cyclopentolate and cyclophosphamide, may also reduce the clearance of other oral <e22> anticoagulants </e22>.
mechanism	In addition to the <e12> benzodiazepines </e12>, which are capable of potentiating <e20> alprazolam </e20>, there may be an additive CNS depressant effect of co-administration of these drugs with other psychotropic_medications, e,g,, barbiturates, tranquilizers, sedatives, etc.
mechanism	In addition to other antibiotics, <e10> tetracycline </e10> also significantly decreased the plasma concentrations of <e20> chloramphenicol </e20> and dapsone.
mechanism	The results raise the possibility that <e10> flurbiprofen </e10> might interact with <e20> methotrexate </e20> in the human body.
mechanism	The results raise the possibility that <e10> quinidine </e10> may interfere with <e20> diazepam </e20> clearance and result in a decreased diazepam concentration.
mechanism	The results raise the possibility that <e10> chlorprothixene </e10> may have an effect on CYP2C9 activity and metabolize <e20> nifedipine </e20>, and this interaction could lead to increased plasma levels.
mechanism	Co-administration of <e10> tetracycline </e10> # mg and <e20> ketoconazole </e20> # mg increased the AUC of ciprofloxacin by #-fold.
mechanism	Co-administration of <e10> colestipol </e10> and <e20> astemizole </e20> increased the AUC of coadministered astemizole and was associated with an increased AUC of astemizole.
mechanism	<e10> Acarbose </e10> significantly decreased the clearance of <e20> levothyroxine </e20>.
mechanism	<e10> Acarbose </e10> is a potent inhibitor of the metabolism of <e20> rifampin </e20> and can therefore enhance its pharmacologic effects.
mechanism	<e10> Acarbose </e10>, amiodarone, diazepam, ethanol, chlordiazepoxide, doxycycline, diazepam, ergot_derivatives, diazepam, <e20> fluoxetine </e20>, fluvoxamine, guanethidine, morphine, phenothiazines, rifampin, saquinavir, tacrolimus, theophylline, triazolam, and zidovudine may increase plasma concentrations of cimetidine by causing hepatic enzyme inhibition.
mechanism	However, the peak serum concentrations of <e10> ketoconazole </e10> are increased by coadministration of <e20> diltiazem </e20> and fluconazole.
mechanism	However, the peak plasma levels of <e10> carbamazepine </e10> were reduced by <e20> furosemide </e20> (50%), and by amiodarone (40%), while the absorption of carbamazepine was not affected by furosemide.
mechanism	However, the peak serum levels of <e10> ketoconazole </e10> are approximately 50% greater when administered concomitantly with <e20> zalcitabine </e20> than when administered concomitantly with zalcitabine alone.
mechanism	However, the peak plasma levels of <e10> isoniazid </e10> were higher in patients who discontinued <e20> carbamazepine </e20> and discontinued both ciprofloxacin and ciprofloxacin, but not in patients who did not discontinue both drugs.
mechanism	However, the peak plasma levels of <e10> loratadine </e10> were maintained over # hours after the initiation of <e20> guanfacine </e20> treatment, whereas the steady-state plasma levels of loratadine decreased approximately twofold within # hours after the initiation of treatment with guanfacine.
mechanism	However, the peak serum concentrations of <e10> amprenavir </e10> in patients receiving <e20> atazanavir </e20> were not significantly affected by the addition of the # mg # mg dosed # hour # day regimen.
mechanism	<e11> DIAMOX </e11> and <e20> colestipol_hydrochloride </e20> decrease gastric pH.
mechanism	<e11> DIAMOX </e11> is known to increase plasma levels of ampicillin and <e20> erythromycin </e20>.
mechanism	<e11> DIAMOX </e11> ( <e20> cyclosporine_A </e20> ) co-administration caused a 7-fold increase in [beta]-endorphin A binding in rats, which was prevented by co-administration of a non-steroidal_anti-inflammatory_drug ( norethindrone ).
mechanism	<e11> DIAMOX </e11> may antagonize the beneficial effects of <e20> indinavir </e20>.
mechanism	<e11> DIAMOX </e11> : Increased clearance of <e20> digoxin </e20> may occur when digoxin is coadministered with DIAMOX.
mechanism	<e11> DIAMOX </e11>, for example, reduced the number of plasma methotrexate increases and the mean AUC from <e20> methotrexate </e20> to # mg/L by 37% and from # to # mg/L by 22%, respectively.
mechanism	<e10> Acetazolamide </e10>, a nonsteroidal_anti-inflammatory_agent, inhibits <e20> astemizole </e20> absorption.
mechanism	<e10> Acetazolamide </e10> may increase the absorption of <e20> digoxin </e20> by increasing the hepatic absorption of digoxin.
mechanism	<e10> Acetazolamide </e10> decreased the renal excretion of <e20> terfenadine </e20>.
mechanism	<e10> Acetazolamide </e10> may reduce the clearance of theophylline and <e20> astemizole </e20>.
mechanism	<e10> Acetazolamide </e10> reduces the metabolism of <e20> nifedipine </e20>, resulting in increased plasma levels of nifedipine and a reduction in AUC.
mechanism	<e10> Acetazolamide </e10> inhibits the metabolism of <e20> bromocriptine_mesylate </e20>, an active metabolite of sildenafil.
mechanism	<e10> Acetazolamide </e10> inhibited the clearance of <e20> succinylcholine </e20> and caused the clearance of succinylcholine to increase.
mechanism	<e10> Acetazolamide </e10> may increase <e20> indinavir </e20> clearance by 50% and increase AUC by 24%.
mechanism	<e10> Acetazolamide </e10> has been reported to decrease plasma concentrations of <e20> astemizole </e20>.
mechanism	<e10> Acetazolamide </e10> prolongs the blood-glucose-lowering effect of <e20> insulin </e20>.
mechanism	<e10> Acetazolamide </e10> : Increases plasma concentrations of <e20> erythromycin </e20>.
mechanism	<e10> Acetazolamide </e10> produced a net decrease in the hepatic enzyme activity of <e20> warfarin </e20>, concomitantly with a net increase in the hepatic mRNA levels of prothrombin (ANP) and INR (International Normalized Ratio).
mechanism	Co-administration of <e10> warfarin </e10> with <e20> estazolam </e20> resulted in a 3-fold increase in estazolam clearance, compared with a similar volume of concomitant oral sucralfate and oral hydralazine alone.
mechanism	Co-administration of <e10> diltiazem </e10> with <e20> furosemide </e20> resulted in a decrease in both the oral and intravenous bioavailability of furosemide.
mechanism	Co-administration of <e10> chloroquine </e10> ( 10 mg twice daily) with a rifampicin, <e20> chloroquine </e20> (40 mg twice daily) and a quinine_antimicrobial_agent ( ( ciprofloxacin ) for # days each had a mean increase in plasma chloroquine of 25% (range: 3-38%) and a mean decrease in plasma quinine of 6% (range: 3-9%).
mechanism	Ethanol :Clinical evidence suggests that <e10> ethanol </e10> may inhibit <e20> ketoconazole </e20> clearance by inhibiting its metabolism to form the active metabolite, ethyleneacetate.
mechanism	Ethanol :Clinical evidence indicates that the metabolism of <e10> acetaminophen </e10> may be impaired by <e20> ethanol </e20>.
mechanism	Ethanol :Clinical evidence suggests that <e10> ethanol </e10> may increase the absorption of <e20> disulfiram </e20>.
mechanism	Phenytoin : If <e10> phenytoin </e10> is administered concomitantly with <e20> methotrexate </e20>, a significant reduction in the dose of methotrexate is likely to occur.
mechanism	Phenytoin : If <e10> phenytoin </e10> is to be used in patients receiving <e20> aripiprazole </e20>, a period of # days is recommended between the two drugs.
mechanism	Phenytoin : If <e10> phenytoin </e10> is given to patients taking <e20> cimetidine </e20>, the effect on cimetidine will be reduced.
mechanism	Cimetidine : <e10> Cimetidine </e10> increased the clearance of <e20> adenosine </e20> by 4% (p = 0.002) and decreased its renal clearance by 13% (p = 0.022) in healthy volunteers.
mechanism	Cimetidine : <e10> Cimetidine </e10> has been reported to enhance the elimination of <e20> phenytoin </e20>, clarithromycin, and other strong CYP3A4 inhibitors.
mechanism	Cimetidine : <e10> Cimetidine </e10> markedly decreases the clearance of <e20> warfarin </e20>, thus necessitating increases in dosage.
mechanism	Intravenous <e10> ranitidine </e10> (10 microM) decreased the AUC of <e20> amphetamine </e20> by approximately 33%.
mechanism	Intravenous <e10> ranitidine </e10> may also cause a prolongation of the QT interval when administered with <e20> digoxin </e20>.
mechanism	Intravenous <e10> ranitidine </e10> given with <e20> lithium </e20> (5-10 mg/kg) increased lithium exposure by 38%.
mechanism	Products containing <e10> acitretin </e10> may have a high potential for interactions with the gastrointestinal tract when administered concomitantly with products containing <e20> diclofenac </e20>.
mechanism	Products containing <e10> methotrexate </e10> or cyclosporine (e,g,, <e20> ampicillin </e20>, rifampin ) may increase the metabolism of theophylline, resulting in a lower concentration in serum and in a lower clearance of theophylline.
mechanism	Products containing <e10> quinine </e10> may reduce the metabolism of <e20> doxycycline </e20>.
mechanism	Products containing calcium_antagonists ( <e10> phenytoin </e10>, carbamazepine, felbamate, cisapride, diltiazem, disopyramide, <e20> phenytoin </e20>, rifampin, triazolam ) and beta_adrenergic_blocking_agents ( triazolam, cimetidine, triazolam_hydrochloride ) may increase plasma concentrations of norethindrone and decrease its metabolism.
mechanism	Products containing calcium_antagonists, such as <e10> triamterene </e10>, may increase the absorption of <e20> almotriptan </e20>, resulting in increased plasma almotriptan concentrations.
mechanism	Products containing calcium supplements containing <e10> zinc </e10>, iron, or iron_withdrawal products may increase the exposure of <e20> phenytoin </e20> and may decrease the therapeutic index of phenytoin.
mechanism	Limited clinical experience has shown that <e10> isoniazid </e10>, valdecoxib, phenytoin, or <e20> phenobarbital </e20> can decrease the clearance of disopyramide and phenytoin.
mechanism	Limited clinical experience with <e10> warfarin </e10> has suggested a possible interaction with <e20> phenytoin </e20> and carbamazepine, leading to increased exposures of both drugs.
mechanism	Limited clinical experience with <e10> digoxin </e10> has revealed that coadministration of digoxin with <e20> zalcitabine </e20> has resulted in a decrease in zalcitabine clearance.
mechanism	Limited clinical experience has demonstrated that <e10> ketoconazole </e10> reduced the clearance of <e20> rifampin </e20> by approximately 25% to 45%.
mechanism	Limited clinical experience has been reported with <e10> erythromycin </e10>, resulting in the concomitant use of <e20> ampicillin </e20> and an erythromycin dose of # mg.
mechanism	<e10> Cimetidine </e10> has been reported to decrease the clearance of <e20> warfarin </e20> by increasing its clearance.
mechanism	<e10> Cimetidine </e10> decreases the bioavailability of <e20> erythromycin </e20>.
mechanism	<e10> Cimetidine </e10> reduced <e20> colestipol_hydrochloride </e20> -induced serum concentrations to approximately 50% and to about 85% of values obtained with colestipol alone.
mechanism	Co-administration of <e10> digoxin </e10> with <e20> astemizole </e20> resulted in a decrease in digoxin plasma levels.
mechanism	Co-administration of <e10> clozapine </e10> and <e20> fluoxetine </e20> increased plasma levels of fluoxetine by about twofold.
mechanism	Co-administration of <e10> rifampin </e10> with <e20> lomustine </e20> resulted in a 34% increase in rifampin AUC of # mg/day.
mechanism	Co-administration of <e10> isoniazid </e10> with <e20> ketoconazole </e20> increases isoniazid blood levels by approximately 2%.
mechanism	Co-administration of <e10> nisoldipine </e10> and <e20> ketoconazole </e20> resulted in a 1.4-fold increase in the mean concentration of nisoldipine in plasma and a reduction in AUC and Cmax values.
mechanism	Co-administration of <e10> probenecid </e10> with <e20> dapsone </e20> resulted in a 23% reduction in dapsone clearance, with no significant change in Cmax or AUC.
mechanism	Ketoconazole : Co-administration of <e10> ketoconazole </e10> and <e20> erythromycin </e20> results in a 5-fold increase in the half-life of erythromycin.
mechanism	Ketoconazole : Co-administration of <e10> ketoconazole </e10> with <e20> digoxin </e20> or methotrexate resulted in increases in digoxin serum concentrations (mean: increase of # +/- 11% and # +/- 11%, respectively).
mechanism	Ketoconazole : Co-administration of <e10> ketoconazole </e10> with <e20> anastrozole </e20> resulted in a 3.4% increase in Cmax and a 17% decrease in AUC.
mechanism	Furosemide : When <e10> ketorolac </e10> and <e20> furosemide </e20> are used concomitantly, the increase in body weight of the patient may be greater than 5% and the patient may have a lower serum furosemide concentration than he or she would without the concomitant use of furosemide.
mechanism	Furosemide : When <e10> gentamicin </e10> was co-administered with <e20> furosemide </e20>, the blood pressure of the gentamicin / furosemide combination group was significantly higher than that of either gentamicin or furosemide alone.
mechanism	Furosemide : When <e10> warfarin </e10> is coadministered with <e20> acetaminophen </e20>, prothrombin time (in mg/kg/day) increases by 5%.
mechanism	Mercaptopurine / Azathioprine : These drugs increase the amount of <e10> mercaptopurine </e10> required to achieve steady state and may produce a decrease in the pharmacokinetics of <e20> azathioprine </e20>.
mechanism	Mercaptopurine / Azathioprine : <e10> Cholestyramine </e10> (CSP), a dietary supplement for the prevention of liver disease, has been reported to increase the serum concentration of <e20> azathioprine </e20>.
mechanism	Mercaptopurine / Azathioprine : Concomitant administration of a daily dose of # mg mercaptopurine and <e10> azathioprine </e10> for # days, resulting in a 75% decrease in the serum azathioprine levels, resulted in a marked increase in serum <e20> cyclosporine </e20> levels, as a result of a 50% increase in its elimination.
mechanism	Mercaptopurine / Azathioprine : <e10> Mercaptopurine </e10> -related drugs such as nephrotoxic_agents, azathioprine, digoxin, and warfarin, which inhibit CYP3A4 (as with <e20> sulphonylurea </e20> ), may increase the exposure to azathioprine.
mechanism	Mercaptopurine / Azathioprine : <e10> Mercaptopurine </e10> increases the clearance of azathioprine by inhibiting the hepatic metabolism of <e20> azathioprine </e20>.
mechanism	Dicumarol : It has been reported that <e10> dicumarol </e10> may enhance the metabolism of <e20> doxorubicin </e20>, resulting in a higher exposure of the active drug.
mechanism	Dicumarol : It has been reported that <e10> dicumarol </e10> can reduce the plasma concentrations of <e20> amphetamines </e20> and, thus, the effect of amphetamines.
mechanism	Dicumarol : It has been suggested that <e10> dicumarol </e10> may interfere with the metabolism of <e20> valproic_acid </e20>, leading to elevated plasma valproic_acid levels and potentially resulting in elevated plasma concentrations of the diuretic.
mechanism	Uricosuric_Agents : Since <e10> fluvoxamine </e10> increases uricosuricant_agent excretion, an <e22> folic_acid_antagonist </e22> may interfere with the folic acid absorption.
mechanism	Uricosuric_Agents : Since <e10> cimetidine </e10> and <e20> diflunisal </e20> have been shown to reduce plasma uricosuric_agent levels in a similar fashion, it may be possible that they affect the renal tubular excretion of these drugs.
mechanism	Uricosuric_Agents : Since the metabolism of <e10> indinavir </e10> is also highly dependent on <e20> cimetidine </e20>, an indinavir metabolite containing the CYP3A4 active site ( CMIRE ) may have a significantly higher therapeutic index than indinavir alone.
mechanism	The concomitant administration of <e10> isoniazid </e10> and <e20> cimetidine </e20>, or of isoniazid with cisapride, resulted in increased isoniazid levels.
mechanism	The concomitant administration of <e10> zidovudine </e10> with <e20> rifabutin </e20> resulted in an increase in rifabutin concentration in blood by about 30% and serum rifabutin concentration by about 25%.
mechanism	The concomitant administration of <e10> digoxin </e10> with <e20> ketoconazole </e20>, however, resulted in a significant increase in ketoconazole concentrations.
mechanism	Chlorpropamide : <e10> Chlorpropamide </e10> inhibits the metabolism of <e20> cefazolin </e20>.
mechanism	Chlorpropamide : <e10> Chlorpropamide </e10> may enhance <e20> chlorpropamide </e20> metabolism leading to elevated levels of this drug in plasma and tissues.
mechanism	Chlorpropamide : <e10> Chlorpropamide </e10> may decrease plasma concentrations of <e20> ketoconazole </e20>.
mechanism	Cyclosporin : Reports suggest that <e10> cyclosporin </e10> may decrease the metabolism of <e20> pravastatin </e20> by decreasing its renal excretion.
mechanism	Cyclosporin : Reports suggest that <e10> cyclosporine </e10> may inhibit <e20> phenytoin </e20> metabolism in the liver, resulting in increased plasma concentrations of phenytoin and associated toxicity.
mechanism	Verapamil : Coadministration of <e10> verapamil </e10> and <e20> colestipol </e20> resulted in a reduction of the mean maximum plasma concentration of colestipol by 39% (0.12 mg/mL) and a 23% increase in Cmax of colestipol (10.9 microM).
mechanism	Verapamil : Coadministration of <e10> verapamil </e10> with <e20> carbamazepine </e20>, phenytoin, or lovastatin resulted in a reduction in serum carbamazepine levels.
mechanism	Verapamil : Coadministration of <e10> verapamil </e10> with <e20> dantrolene </e20> resulted in an approximately 40% reduction in dantrolene absorption.
mechanism	Coadministration of <e10> digoxin </e10> # mg daily with <e20> ketoconazole </e20> # mg daily resulted in a significant increase in the rate of the decrease in serum digoxin levels, from 40% to 46% and from 38% to 47%, respectively, in patients receiving and not receiving digoxin.
mechanism	Coadministration of <e10> cimetidine </e10> with <e20> loxapine </e20> decreased the clearance of loxapine by about 17%.
mechanism	Coadministration of <e10> cisapride </e10> with <e20> ketoconazole </e20> reduced the extent of reduction in blood levels of cisapride by 50%.
mechanism	<e10> Fluvoxamine </e10> and other <e22> diuretics </e22> have been reported to increase the clearance of a digitalis-type digoxin.
mechanism	<e10> Fluvoxamine </e10> and <e20> hydralazine </e20> inhibited the metabolism of levodopa and amiodarone, resulting in prolongation of amiodarone half-life and increases in levodopa and amiodarone concentrations.
mechanism	<e10> Fluvoxamine </e10> inhibited the hepatic uptake of <e20> lithium </e20> by approximately half.
mechanism	<e10> Ketoconazole </e10>, used in combination with oral <e20> aripiprazole </e20>, increased the AUC of rifabutin by 33%.
mechanism	<e10> Ketoconazole </e10>, a strong inhibitor of CYP3A4, reduces <e20> cisapride </e20> plasma levels by approximately 50%.
mechanism	<e10> Ketoconazole </e10>, but not <e20> ketoconazole </e20>, decreased the absorption of all drugs studied.
mechanism	The steady state concentration of <e10> isoniazid </e10> decreased in #% in # mg/kg body weight and in #% in # mg/kg body weight # mg/kg oral formulations, and increased in #% in # mg/kg and # mg/kg and #% in # mg/kg oral formulations in rats treated for # days with a single oral dose of # mg/kg of a daily dose schedule of # mg/kg of <e20> isoniazid </e20>.
mechanism	The steady state plasma concentration of <e10> cimetidine </e10> was lower when administered with <e20> atorvastatin </e20> than when administered with placebo or nafazodone.
mechanism	The steady state concentration of <e10> furosemide </e10> in subjects on non-dose limiting doses of furosemide is not affected by <e20> warfarin </e20>, but it is increased by the concurrent use of oral anticoagulants, corticosteroids, and warfarin.
mechanism	The steady state plasma concentrations of <e10> amiodarone </e10> and <e20> cimetidine </e20> are increased when the drugs are administered concurrently.
mechanism	Drugs Demonstrated to Be Increases in Heparinized Serum in a Tricyclic_Antidepressant Strain: There have been reports of increased serum concentrations of <e10> clonidine </e10> in a tricyclic_antidepressant (TCA) strain when it was coadministered with cimetidine, fluoxetine, and <e20> fluvoxamine </e20>.
mechanism	Drugs Demonstrated to Be Enhanced by Anticonvulsants : Concomitant administration of <e10> phenytoin </e10> with anticonvulsants ( carbamazepine, phenobarbital, phenytoin, triazolam, phenytoin with <e20> phenytoin </e20>, phenytoin with sulfasalazine, phenytoin with aripiprazole, phenytoin with phenytoin, and phenobarbital with phenytoin ) increases the pharmacologic effect of concomitantly administered anticonvulsants.
mechanism	Coadministration of <e10> erythromycin </e10> # mg with # mg of <e20> astemizole </e20> daily for # days was associated with a decrease in astemizole AUC of # mg per day (p = 0.035).
mechanism	Coadministration of <e10> dexamethasone </e10> with either <e20> ciprofloxacin </e20> or rifabutin resulted in a 75% increase in dexamethasone exposure.
mechanism	Coadministration of <e10> digoxin </e10> and <e20> furosemide </e20> has been reported to increase plasma levels of furosemide and may therefore decrease the renal clearance of furosemide.
mechanism	Coadministration of oral <e10> diltiazem </e10> and <e20> ergotamine </e20> resulted in a reduction of the AUC of diltiazem by 62% and the Cmax by 72% in rats.
mechanism	Coadministration of oral <e10> ketoconazole </e10> and <e20> cisapride </e20> in healthy volunteers resulted in a 5-fold increase in the mean Cmax of cisapride.
mechanism	Coadministration of oral <e10> diltiazem </e10> and <e20> omeprazole </e20> decreased diltiazem clearance by 46% to 60%.
mechanism	Concurrent administration of <e10> cimetidine </e10> with <e20> anakinra </e20> increases the rate of elimination of cimetidine by 50% (P =.012).
mechanism	Concurrent administration of <e10> ketoconazole </e10> with <e20> diltiazem </e20> resulted in a 4-fold increase in mean plasma concentration of diltiazem (48% increase).
mechanism	<e11> Cytadren </e11> may decrease plasma <e20> hydrocodone </e20> concentrations by releasing hydrocodone from its binding sites.
mechanism	<e11> Cytadren </e11> increases <e20> amiodarone </e20> clearance and increases the clearance of N-acetylcysteine.
mechanism	<e11> Cytadren </e11> decreased the <e20> phenytoin </e20> AUC by 50% (p = 0.0001) and the Cmax by 50% (p = 0.0001).
mechanism	<e10> Probenecid </e10>, and chlordiazepoxide ( Chlordiazepoxide ) may increase the clearance of citalopram and may reduce the clearance of <e20> citalopram </e20>.
mechanism	<e10> Probenecid </e10> may increase the clearance of <e20> astemizole </e20>.
mechanism	<e10> Probenecid </e10> may increase the <e22> corticosteroid </e22> metabolism.
mechanism	A case report describes a previously healthy female patient, on chronic <e10> hydrocodone </e10> therapy, with a significant increase in Cmax and AUC of <e20> cimetidine </e20> and concurrent increases in AUC of cimetidine and ketoconazole (i,e,, two of the four active metabolites of cimetidine) concomitantly with increased oral dosing of cimetidine.
mechanism	A case report of a patient with multiple myeloma who was treated with <e10> doxorubicin </e10> for # weeks prior to initiation of <e20> doxorubicin </e20> therapy is reported.
mechanism	<e10> Cimetidine </e10> is added to oral <e20> rifampin </e20> dosage in patients on a low dose of rifampin.
mechanism	<e10> Cimetidine </e10> may decrease plasma <e20> phenytoin </e20> levels, resulting in increased serum concentrations.
mechanism	<e10> Cimetidine </e10> has been reported to inhibit the metabolism of <e20> guanfacine </e20> by CYP3A4.
mechanism	Discontinuation of cimetidine and <e10> erythromycin </e10> use may result in the loss of <e20> cimetidine </e20>.
mechanism	Discontinuation of cimetidine dosage may result in a loss of <e10> cimetidine </e10> metabolism in the presence of inhibitors of CYP3A4, including <e20> ketoconazole </e20>.
mechanism	<e10> Probenecid </e10> has been shown to reduce the absorption of <e20> warfarin </e20> by the conjugation of the drug with sulfate or thiazide_diuretics, resulting in a decrease in the half-life of warfarin.
mechanism	<e10> Probenecid </e10> (500 mg) was less effective than <e20> diltiazem </e20>, valdecoxib (40 mg), or metformin (15 mg) at lowering AUC(0-24) and Cmax in # healthy volunteers, and AUC(0-24) and Cmax for valdecoxib were reduced by #% and 8%, respectively, when coadministered with # mg of probenecid.
mechanism	<e10> Indinavir </e10> significantly increased the clearance of <e20> nevirapine </e20> in HIV-infected patients.
mechanism	<e10> Indinavir </e10> was shown to increase AUC and Cmax values of <e20> indinavir </e20> by approximately 30% and 5%, respectively, with a maximum of approximately 10% increase observed for # days after # mg of indinavir.
mechanism	<e10> Indinavir </e10> can increase the bioavailability of <e20> crizotinib </e20> and similar drugs, thereby increasing the potential for toxicity.
mechanism	<e10> Saquinavir </e10> reduced the AUC of <e20> rifabutin </e20> by 32% and rifabutin C max was reduced by 24%.
mechanism	<e10> Saquinavir </e10> did not enhance the metabolism of either ketoconazole, a tricyclic_antidepressant, or <e20> cimetidine </e20>.
mechanism	<e10> Nelfinavir </e10> inhibits <e20> nevirapine </e20> metabolism by decreasing both enfuvirtide and ritonavir and increasing fluconazole concentrations.
mechanism	<e10> Nelfinavir </e10> is reported to inhibit the metabolism of <e20> fluvoxamine </e20>.
mechanism	Coadministration of <e10> erythromycin </e10> # mg and <e20> clarithromycin </e20> # mg decreased clarithromycin AUC from # to # mg/h, and AUC from # to # mg/h, respectively.
mechanism	Coadministration of <e10> indinavir </e10> and <e20> ritonavir </e20> increased the AUC of indinavir by #-fold, while it decreased the AUC by 6-fold.
mechanism	Coadministration of <e10> ketoconazole </e10> and <e20> zalcitabine </e20> decreased the clearance of zalcitabine by 18% and increased its AUC by 20%.
mechanism	<e10> Anagrelide </e10> also inhibits platelet function when administered concurrently with <e20> carbamazepine </e20>.
mechanism	<e10> Anagrelide </e10> and <e20> warfarin </e20> enhance the absorption of warfarin.
mechanism	<e10> Anagrelide </e10> inhibits the CYP3A4 isoenzyme with a half-maximal inhibition concentration (IC50) of 0.45 microM and a half-maximal inhibition concentration (IC50) of 2.45 microM, resulting in a 59% decrease in <e20> anagrelide </e20> plasma levels.
mechanism	Co-administration of <e10> carbamazepine </e10> tablets with other <e22> SSRI </e22> s (e,g,, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine, sertraline s,e,t,f), MAO_inhibitors (e,g,, selegiline ), or other drugs that are inhibitors of MAO, and which have a narrow therapeutic index, may reduce the efficacy of carbamazepine.
mechanism	Co-administration of <e10> doxycycline </e10> decreased the clearance of <e20> ketoconazole </e20> by 38%.
mechanism	Co-administration of <e10> doxycycline </e10> and <e20> disopyramide </e20> resulted in a 10-fold increase in disopyramide plasma concentrations.
mechanism	For example, since <e10> diltiazem </e10> inhibits the hepatic CYP3A4 activity, <e20> doxorubicin </e20>, which has a narrow therapeutic window, may be a suitable inducer for diltiazem.
mechanism	For example, since <e10> digoxin </e10> and <e20> insulin </e20> are metabolized via this same CYP1A2-catalyzed pathway, it is possible that a possible interaction between digoxin and insulin could occur by changing the blood levels of insulin and/or the clearance of digoxin.
mechanism	For example, since <e10> doxorubicin </e10> was found to inhibit <e20> amiodarone </e20> metabolism, it may be expected that an increased clearance of doxorubicin may occur with decreased renal clearance.
mechanism	For example, since <e10> rifampin </e10> is known to inhibit the metabolism of <e20> erythromycin </e20>, a drug interaction could occur for which the two drugs have the same pharmacologic effect.
mechanism	For example, since <e10> dexamethasone </e10> and retinyl_acetate are the major isomeric hormones of breastmilk, and <e20> cyclosporine </e20> is the only drug that can simultaneously increase the levels of both of these hormones, the co-administration of cyclosporine with estrogens and progestins or progestins and isoflurane in clinical practice has the potential to increase the plasma concentrations of estrogens and isoflurane by approximately 10%.
mechanism	For example, since <e10> phenytoin </e10> inhibits the metabolism of <e20> valdecoxib </e20>, the level of valdecoxib may increase when the patient is on phenytoin.
mechanism	Oral <e12> anticoagulants </e12> and <e20> furosemide </e20> may both reduce the plasma levels of warfarin or its derivatives.
mechanism	Oral <e12> anticoagulants </e12> decrease the plasma levels of <e20> enoxacin </e20>.
mechanism	Oral <e12> anticoagulants </e12> may interfere with the absorption of <e20> cisapride </e20>.
mechanism	Oral <e12> anticoagulants </e12>, including warfarin, may decrease the bioavailability of <e20> erythromycin </e20>.
mechanism	Oral <e12> anticoagulants </e12>, warfarin, and <e20> phenytoin </e20> may prolong prothrombin time and increase the risk of bleeding.
mechanism	Oral <e12> anticoagulants </e12> may potentiate the hepatic toxicity of <e20> lithium </e20>.
mechanism	Oral <e12> anticoagulants </e12> reduce the clearance of heparinized serum <e20> warfarin </e20>.
mechanism	Oral <e12> anticoagulants </e12>, such as warfarin or its derivatives, prolong the blood clotting time and may increase the risk of bleeding if <e20> enoxacin </e20> is used concomitantly.
mechanism	Because oral <e12> anticoagulants </e12> may reduce the plasma concentrations of <e20> warfarin </e20>, their use may result in lower plasma concentrations of warfarin and higher prothrombin time.
mechanism	Because oral <e12> anticoagulants </e12> interfere with the gastrointestinal absorption of <e20> vitamin_C </e20>, the concomitant use of anticoagulants with vitamin_C is contraindicated.
mechanism	Because oral <e12> antacids </e12> reduce <e20> erythromycin </e20> serum levels, the benefits of concurrent use of an antacid with oral contraceptives may be reduced.
mechanism	<e10> Aprepitant </e10> blocks and reduces the clearance of <e20> estradiol </e20>.
mechanism	<e10> Aprepitant </e10> inhibited <e20> morphine </e20> -induced increases in urinary N-acetyltransferase activity.
mechanism	<e10> Aprepitant </e10> decreased plasma concentrations of <e20> clorazepate </e20> by approximately 40%.
mechanism	<e10> Aprepitant </e10> increases the effect of <e20> fluconazole </e20>, a known CYP3A4 inhibitor.
mechanism	<e10> Aprepitant </e10> also increases the plasma concentration of phenytoin, carbamazepine, <e20> phenobarbital </e20>, cisapride, and diltiazem.
mechanism	Coadministration of <e10> ketoconazole </e10> with <e20> warfarin </e20> resulted in a decrease in the rate of binding to warfarin, with a concomitant increase in the AUC.
mechanism	Coadministration of <e10> methotrexate </e10> and <e20> quinolone </e20> resulted in a two- to threefold increase in methotrexate plasma levels and decreased its pharmacodynamic effect.
mechanism	Coadministration of <e10> chloroquine </e10> and <e20> gabapentin </e20> increased the #-mg dose of gabapentin by #%.
mechanism	Corticosteroids : Dexamethasone ( <e10> dexamethasone </e10> ) may reduce the absorption of <e20> nisoldipine </e20>.
mechanism	The daily dose of <e10> cisapride </e10> in patients taking <e20> furosemide </e20> for long periods was reduced from # mg/day to # mg/day.
mechanism	The daily dose of <e10> almotriptan </e10> is expected to increase the clearance of <e20> phenytoin </e20> and other oral anticonvulsants by approximately 50% to 100%.
mechanism	The daily dose of <e10> ketoconazole </e10> was reduced by 50% when <e20> terfenadine </e20> was coadministered.
mechanism	<e10> Aprepitant </e10> may decrease the absorption of <e20> warfarin </e20>, propranolol, cimetidine, and cholestyramine.
mechanism	<e10> Aprepitant </e10> may interfere with metabolism of oral <e22> anticoagulants </e22> or other anticonvulsants or other potent inhibitors of blood clotting.
mechanism	<e10> Aprepitant </e10> reduced the blood levels of <e20> fluvoxamine </e20> by approximately two-thirds.
mechanism	Although there was a 50% reduction in <e10> zidovudine </e10> clearance in # healthy volunteers taking # mg <e20> zidovudine </e20> and # mg adenosine, it is likely that the additional blood flow seen with adenosine would be inadequate to compensate for the reduction in adenosine clearance observed with zidovudine.
mechanism	Although there was no significant effect on the <e10> colestipol </e10> blood level, <e20> levodopa </e20> was decreased by approximately 46% on the first day of colestipol treatment and by approximately 34% on the seventh day of treatment.
mechanism	Although there was a significant reduction in the <e10> terfenadine </e10> plasma concentrations when # mg of <e20> terfenadine </e20> was co-administered with 50, 100, or 200 mg of # mg/day of furosemide, there was no reduction in the efficacy of furosemide with concurrent administration of # mg of terfenadine.
mechanism	Midazolam : <e10> Midazolam </e10> significantly decreased the AUC and Cmax of <e20> doxapram </e20>.
mechanism	Midazolam : <e10> Ketoconazole </e10> may reduce the metabolism of <e20> midazolam </e20>.
mechanism	Ketoconazole : When administered concurrently with <e10> ketoconazole </e10>, <e20> estrogens </e20> increased the plasma concentrations of estrogens in a dose-dependent manner.
mechanism	Ketoconazole : When <e10> ketoconazole </e10> was added to the treatment regimen of a patient who had been treated with <e20> cisapride </e20>, a decrease in plasma cisapride concentrations was noted.
mechanism	Ketoconazole : When <e10> ketoconazole </e10> and <e20> rifampin </e20> are used concomitantly, serum concentrations of rifampin may be decreased and the half-life of rifampin may be prolonged.
mechanism	Rifampin : When <e10> rifampin </e10> was administered concomitantly with <e20> ketoconazole </e20>, the incidence of infections with the ketoconazole metabolite was greater than when rifampin and ketoconazole were administered alone.
mechanism	Rifampin : When coadministered with <e10> rifampin </e10>, plasma <e20> rifampin </e20> concentrations were significantly reduced.
mechanism	Rifampin : When <e11> aspirin </e11> is administered concomitantly with <e20> rifampin </e20>, an approximately 2-fold increase in the half-life of rifampin is observed, which may result in an increase in the concentration of rifampin required to achieve a pharmacokinetic target of # micrograms of rifampin per liter.
mechanism	Diltiazem : In a pharmacokinetic study in healthy volunteers, <e10> diltiazem </e10> caused a 62% increase in the AUC of <e20> valdecoxib </e20>, but a 38% decrease in the Cmax.
mechanism	Diltiazem : In a study in healthy volunteers, <e10> ciprofloxacin </e10> was found to reduce the AUC of <e20> diltiazem </e20> by approximately 22% (p = 0.0001).
mechanism	Diltiazem : In vitro metabolism studies demonstrated that <e10> diltiazem </e10> was displaced from the hepatic metabolism by <e20> cimetidine </e20>.
mechanism	Agents that induce hepatic enzymes (such as rifampin, ketoconazole, <e10> phenytoin </e10>, methotrexate, rifabutin ) or decrease hepatic enzymes (such as <e20> clarithromycin </e20>, indinavir, itraconazole, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, troleandomycin, theophylline ) may increase the clearance of # mg of # mg of # mg of # mg of cisapride.
mechanism	Agents that induce hepatic enzymes such as <e10> phenytoin </e10>, carbamazepine, and almotriptan may enhance the absorption of <e20> rifampin </e20> or isoniazid.
mechanism	Inhibitors of CYP3A4 (eg, ketoconazole, <e10> itraconazole </e10>, erythromycin, clarithromycin, ritonavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, troleandomycin, nefazodone ) increase the plasma concentration of <e20> nelfinavir </e20>.
mechanism	Inhibitors of CYP3A4, such as ketoconazole, fluconazole, itraconazole, itraconazole-related drugs, ritonavir, ritonavir-boosted <e10> ritonavir </e10>, saquinavir, and ritonavir-associated drugs have been shown to increase plasma levels of <e20> phenytoin </e20>.
mechanism	Inhibitors of CYP3A4 (e,g,, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, indinavir, saquinavir, <e10> troleandomycin </e10>, indinavir, saquinavir, nelfinavir, telithromycin, troleandomycin ) reduce the extent of clearance of <e20> ketoconazole </e20>.
mechanism	Inhibitors of CYP3A4 (e,g,, ketoconazole, <e10> itraconazole </e10>, erythromycin, clarithromycin, ritonavir, nelfinavir ) may reduce or eliminate <e20> erythromycin </e20> plasma levels.
mechanism	Inhibitors of CYP3A4 (such as ketoconazole, erythromycin, itraconazole, clarithromycin, <e10> nefazodone </e10>, troleandomycin, indinavir, ritonavir, saquinavir, telithromycin, troleandomycin, troleandomycin ) have been reported to have a moderate effect on the metabolism of <e20> disopyramide </e20>.
mechanism	Inhibitors of CYP3A4, such as ketoconazole, clofibrate, indinavir, <e10> itraconazole </e10>, ritonavir, saquinavir, indinavir, and ketoconazole are substrates for <e20> dasatinib </e20>.
mechanism	Inhibitors of CYP3A4 ( such as ketoconazole, itraconazole, <e10> erythromycin </e10>, clarithromycin, ritonavir, indinavir, saquinavir, telithromycin, troleandomycin, troleandomycin, voriconazole, nelfinavir, saquinavir, troleandomycin, nelfinavir, saquinavir, troleandomycin, indinavir, saquinavir, indinavir, saquinavir, nelfinavir, ritonavir, indinavir, ritonavir, nelfinavir, triazolam ) may increase the metabolism of ketoconazole, itraconazole, <e20> erythromycin </e20>, clarithromycin, ritonavir, indinavir, ritonavir, itr
mechanism	Inhibitors of CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, <e10> indinavir </e10>, saquinavir, nefazodone, nefazodone_sulfate ) may reduce the bioavailability of <e20> didanosine </e20>.
mechanism	Inhibitors of CYP3A4 ( alprazolam, <e10> fluoxetine </e10>, cimetidine, fluvoxamine, paroxetine, sertraline ) decrease plasma concentrations of <e20> anagrelide </e20> and therefore may increase its toxicity.
mechanism	Inhibitors of CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, indinavir, <e10> nefazodone </e10>, nelfinavir ) have been reported to increase plasma concentrations of <e20> diltiazem </e20> and may decrease its pharmacologic effect.
mechanism	Inhibitors of CYP3A4 ( fluoxetine, <e10> alprazolam </e10>, phenobarbital, indinavir, itraconazole, ritonavir, saquinavir, troleandomycin ) were indifferently inhibited by <e20> ketoconazole </e20>.
mechanism	Inhibitors of CYP3A4 (e,g,, ketoconazole, itraconazole, ritonavir, indinavir, nelfinavir, saquinavir, erythromycin, clarithromycin, <e10> nefazodone </e10> ) or CYP3A5 (e,g,, ketoconazole, itraconazole, ritonavir, indinavir, nelfinavir, saquinavir, erythromycin, clarithromycin, troleandomycin ) decreased <e20> dasatinib </e20> plasma exposure.
mechanism	Ketoconazole : Coadministration of <e10> ketoconazole </e10> with <e20> cisapride </e20> resulted in a 40% decrease in the clearance of cisapride.
mechanism	Ketoconazole : Coadministration of <e10> ketoconazole </e10> and <e20> cisapride </e20> increased the Cmax of cisapride by about 30% and the AUC of cisapride by about 15%.
mechanism	Ketoconazole : Coadministration of <e10> ketoconazole </e10> (10 mg daily) with <e20> nelfinavir </e20> (40 mg daily) for # days resulted in a 22% decrease in nelfinavir serum concentrations.
mechanism	Quinidine : Coadministration of <e10> ergotamine </e10> # mg and <e20> coadministration of ergotamine </e20> # mg decreased plasma concentrations of ergotamine by 25% (p=0.0023).
mechanism	Quinidine : Coadministration of <e11> Coly-Mycin </e11> and <e20> quinidine </e20> was associated with a 2.2-fold increase in the clearance of quinidine.
mechanism	Carbamazepine : Coadministration of <e10> carbamazepine </e10> (20 mg twice daily) and <e20> tetracycline </e20> (1 mg twice daily) resulted in a 5- to 10-fold increase in the tetracycline clearance and a 35% increase in tetracycline serum concentration, respectively.
mechanism	Carbamazepine : Coadministration of <e10> carbamazepine </e10> with <e20> ketoconazole </e20> resulted in a 28% increase in the clearance of carbamazepine.
mechanism	Carbamazepine : Coadministration of <e10> carbamazepine </e10> (10 mg/kg/day) and <e20> erythromycin </e20> (1 mg/kg/day) for # days resulted in a 40% reduction in carbamazepine clearance.
mechanism	<e10> Phenobarbital </e10> may also interfere with metabolism of other oral medications that induce hepatic enzyme-inhibitors (eg, enoxacin, ciprofloxacin, clarithromycin, indomethacin, <e20> phenytoin </e20>, rifampin ).
mechanism	<e10> Phenobarbital </e10>, the most potent of the <e22> tricyclic_antidepressants </e22>, also inhibits the hepatic metabolism of valdecoxib.
mechanism	<e10> Phenobarbital </e10> has been reported to alter the clearance of <e20> ampicillin </e20>.
mechanism	In EM individuals, <e10> ergotamine </e10> caused a slight increase in <e20> fluvoxamine </e20> plasma concentrations, and an increase in fluvoxamine clearance from the gastrointestinal tract.
mechanism	In EM individuals, co-administration of <e10> halothane </e10> with <e20> levothyroxine </e20> and its daily dose resulted in an average of 25% increase in levothyroxine concentrations.
mechanism	In EM individuals, the combination of <e10> ergotamine </e10> (500 mg q.i.d,) and <e20> nifedipine </e20> (100 mg q.i.d,) was found to be the least effective in lowering serum levels of ergotamine and nifedipine.
mechanism	In EM individuals, treatment with <e11> TRACRIUM </e11> for # days increased the <e20> atorvastatin </e20> plasma concentrations by about 15%.
mechanism	In EM individuals, the administration of <e10> verapamil </e10>, a nonsteroidal_anti-inflammatory_agent, for # days produced a significant decrease in mean serum <e20> digoxin </e20> concentrations and a significant increase in digoxin concentrations in the urine of rats.
mechanism	Antacid : When administered with <e11> ABILIFY </e11>, the following medications may be displaced from their positions: antibiotics such as ampicillin, tetracycline, bacitracin, <e20> clindamycin </e20>, colistin, and sulfonamides such as clarithromycin.
mechanism	Antacid : When <e10> cholestyramine </e10> was administered concurrently with <e20> aspirin </e20>, the absorption of aspirin was markedly decreased.
mechanism	Antacid : When <e11> WELLBUTRIN </e11> is given in conjunction with antacid, <e20> fluvoxamine </e20> may not be absorbed, and fluvoxamine may decrease fluvoxamine serum concentrations.
mechanism	Colestipol : Plasma concentrations of <e10> colestipol </e10> are increased when it is given concurrently with <e20> aripiprazole </e20>, resulting in a decrease in the elimination half-life of aripiprazole.
mechanism	Colestipol : Plasma levels of <e10> colestipol </e10> are increased when <e20> atorvastatin </e20> is administered concurrently with the drug.
mechanism	Digoxin : When co-administered with <e10> tetracycline </e10>, <e20> digoxin </e20> AUC and Cmax were decreased by 17% and 25%, respectively.
mechanism	Digoxin : When <e10> digoxin </e10> was co-administered with <e20> nelfinavir </e20>, nelfinavir showed a concentration-dependent increase in the elimination of digoxin.
mechanism	Digoxin : When <e10> digoxin </e10> was administered to rats, the blood levels of <e20> cisapride </e20> were decreased.
mechanism	Erythromycin : In patients taking <e10> erythromycin </e10> concomitantly with <e20> clarithromycin </e20>, there have been reports of elevated serum levels of clarithromycin and low serum levels of erythromycin.
mechanism	Erythromycin : In patients receiving <e10> erythromycin </e10> and <e20> erythromycin </e20> concurrently, there has been a decrease in erythromycin concentrations in the blood.
mechanism	Erythromycin : In clinical studies, the oral absorption of <e10> erythromycin </e10> increased significantly when <e20> erythromycin </e20> was given concomitantly with diltiazem.
mechanism	Oral Contraceptives : The co-administration of <e11> HEXALEN </e11> # mg and <e20> oral contraceptives </e20> (oral or injectable) can result in increased levels of the active metabolite of HEXALEN, piperacillin_3-sulfate ( piperacillin ).
mechanism	Oral Contraceptives : <e10> Diphenoxylate </e10> inhibited the absorption of # mg of <e20> levonorgestrel </e20>, resulting in a 46% reduction in exposure to levonorgestrel.
mechanism	Rifampin : Coadministration of <e10> rifampin </e10> with <e20> amiodarone </e20> decreased amiodarone concentrations by 46% and 50%.
mechanism	Rifampin : Coadministration of <e10> rifampin </e10> # mg q.i.d. with <e20> ciprofloxacin </e20> # mg q.i.d. significantly decreased ciprofloxacin serum concentrations.
mechanism	Rifampin : Coadministration of <e10> rifampin </e10> and <e20> ketoconazole </e20> produced a 40% decrease in AUC of rifampin.
mechanism	<e12> Antacids </e12>, calcium salts, and/or bicarbonate preparations may interfere with the absorption of <e20> terfenadine </e20>.
mechanism	<e12> Antacids </e12>, magnesium supplements, calcium supplements, or <e20> iron </e20> may increase the absorption of theophylline, causing a decrease in the bioavailability of theophylline.
mechanism	<e12> Antacids </e12>, zinc, or iron supplements may interfere with <e20> rifabutin </e20> metabolism, resulting in increased rifabutin levels.
mechanism	Use with Allopurinol : <e10> Allopurinol </e10> increases the clearance of <e20> digoxin </e20> by about 5% to 10%.
mechanism	Use with Allopurinol : When coadministered with <e11> INDOCIN </e11>, the following drugs were found to increase <e20> phenytoin </e20> plasma concentrations: amiodarone, dipyridamole, clarithromycin, dapsone, gentamicin, rifampin, simvastatin, telithromycin, triazolam, theophylline, and zidovudine.
mechanism	When used in combination with <e10> acetaminophen </e10>, <e20> morphine </e20>, halothane, succinylcholine, or metoclopramide, fluoxetine increases the clearance of the anticonvulsant and the possibility of increased blood concentrations of the anticonvulsant.
mechanism	When used in combination with <e10> carbamazepine </e10>, <e20> carbamazepine </e20> may prolong the QT interval by approximately one hour.
mechanism	When used in combination with <e10> probenecid </e10>, coadministration with <e20> astemizole </e20> significantly reduced the plasma concentrations of both esomeprazole and zidovudine by approximately 40% and approximately 50%, respectively.
mechanism	When used in combination with <e10> probenecid </e10>, <e20> valdecoxib </e20> decreased the plasma levels of valdecoxib, resulting in a reduction of the mean daily AUC of valdecoxib by 40%.
mechanism	When used in combination with <e10> lomefloxacin </e10>, rifabutin, or other antibiotics, the <e20> ciprofloxacin </e20> # mg capsule was found to inhibit the metabolism of rifabutin # mg to rifabutin (mean AUC and Cmax) by approximately 50%.
mechanism	When used in combination with <e10> amiodarone </e10>, <e20> ketoconazole </e20> reduced the clearance of carbamazepine and phenytoin.
mechanism	When used in combination with <e10> almotriptan </e10>, <e20> halothane </e20>, halothane anesthetized patients with a history of myocardial infarction and a low to moderate function of the AV nodal conduction system were at increased risk of AV nodal failure (20% to 50% increase).
mechanism	When used in combination with <e10> atorvastatin </e10>, it has been reported to decrease plasma levels of <e20> vitamin_K </e20>.
mechanism	When used in combination, the following agents increase the clearance of <e11> VIDEX </e11> significantly: <e20> gentamicin </e20>, carbamazepine, rifabutin, tetracycline, rifabutin with carbamazepine, rifabutin with furosemide, and warfarin.
mechanism	When used in combination with <e10> ketoconazole </e10>, it resulted in a 46% increase in <e20> cisapride </e20> plasma levels and a 17% decrease in AUC and Cmax.
mechanism	When used in combination with <e10> ketoconazole </e10>, the duration of effect of <e20> ketoconazole </e20> was reduced to approximately # minutes.
mechanism	When used in a dose of # mg/day, the maximum plasma concentration of <e10> amiodarone </e10> was increased approximately #-fold and the area under the plasma concentration-time curve was decreased approximately 17% in a dose of # mg/day to # mg/day, resulting in a significant increase in the Cmax and AUC of <e20> amiodarone </e20>.
mechanism	When used in combination with oral <e10> isoniazid </e10>, <e20> cholestyramine </e20> decreased the clearance of oral isoniazid by 26% (Cmax) and the AUC of isoniazid by 24% (Cmax).
mechanism	When used in combination with <e11> ENABLEX </e11>, <e20> atorvastatin </e20> and efavirenz are recommended to avoid potential interactions with these drugs on AUC and Cmax.
mechanism	When used in the absence of <e12> anticonvulsants </e12>, the prothrombin time and the prothrombin time adjusted for body weight in <e20> warfarin </e20> -treated patients were significantly reduced, whereas the anticoagulant effect of warfarin in patients with a normal serum creatinine was not altered.
mechanism	When used in the same manner as <e11> VIDEX </e11>, the following drugs may cause additive, potentiating, or potentiating effects on the clearance of <e20> dofetilide </e20> : rifampin, ketoconazole, and clarithromycin.
mechanism	When used in combination with <e10> carbamazepine </e10>, <e20> fluvoxamine </e20> increased the pharmacologic effect of carbamazepine by 25%.
mechanism	When used in combination, <e10> methotrexate </e10> and <e20> indinavir </e20> are expected to increase the exposure to the antiviral target.
mechanism	When used in combination with other potent CYP3A4 inhibitors (e,g,, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, <e10> nefazodone </e10>, nelfinavir, ritonavir, saquinavir, saquinavir-hydrochloride, indinavir, saquinavir, indinavir-sulfate, atazanavir, ritonavir, indinavir-sulfate, astemizole ), <e20> ketoconazole </e20> and itraconazole may produce a 3- to 5-fold increase in plasma concentrations of ciprofloxacin.
mechanism	When used in the presence of <e10> gentamicin </e10>, <e20> azithromycin </e20> increases the pH of the culture medium to cause acidification.
mechanism	Co-administration with <e10> phenytoin </e10>, clarithromycin, or aripiprazole results in a greater reduction of <e20> clozapine </e20> AUC than with clozapine alone.
mechanism	Co-administration with <e10> carbamazepine </e10> may reduce the clearance of <e20> caffeine </e20> and thus increase the excretion of caffeine following oral administration.
mechanism	Co-administration with <e10> ketoconazole </e10> significantly reduced the clearance of <e20> diltiazem </e20> by 41%.
mechanism	Total body clearance of <e10> cyclosporine </e10> is reduced by the anticonvulsant <e20> phenytoin </e20>, a potent inhibitor of cyclosporine metabolism.
mechanism	Total body clearance (C(T)) of <e10> furosemide </e10> and all <e22> corticosteroids </e22> was increased with the combination of cyclosporine and furosemide.
mechanism	Total body clearance of <e10> furosemide </e10> decreased by approximately 50% when <e20> ketoconazole </e20> and aspirin were added.
mechanism	Total body clearance of <e10> furosemide </e10> has been shown to increase by approximately 50% when <e20> fluvoxamine </e20> is given concomitantly with it.
mechanism	Lithium : Increased serum lithium levels may occur when <e10> lithium </e10> is given with <e20> ciprofloxacin </e20>, and these increases may increase the toxicity of lithium.
mechanism	Lithium : Increased serum lithium concentrations and decreased urinary excretion of <e10> lithium </e10> were observed when <e20> cimetidine </e20> was administered concurrently with lithium.
mechanism	Digoxin : In healthy volunteers, the maximum serum levels of <e10> digoxin </e10> were significantly decreased when <e20> anagrelide </e20> and metformin were coadministered at # mg (day-one) and # mg (day-three) as compared to when either drug was given alone.
mechanism	Digoxin : In vitro data indicate that <e10> amiodarone </e10> may enhance the metabolism of <e20> digoxin </e20>, leading to a prolongation of the blood-sugar concentrations.
mechanism	Digoxin : In a study in patients with normal renal function, coadministration of <e10> digoxin </e10> decreased <e20> enalapril </e20> clearance by 23% (P = 0.002) and decreased mean enalapril AUC by 46% (P = 0.0022).
mechanism	On the basis of in vitro data, <e10> fluvoxamine </e10> and indinavir, but not <e20> ritonavir </e20>, decreased the pharmacokinetics of voriconazole.
mechanism	On the basis of pharmacokinetic data from a phase III trial, <e11> VIDEX </e11> is likely to have a larger effect on plasma concentrations of <e20> amprenavir </e20>, which are less than additive, than on plasma concentrations of all three known amprenavir metabolizing enzymes.
mechanism	On the basis of the pharmacokinetic profile and pharmacodynamic effects of <e10> diltiazem </e10>, an increase in the daily dose of <e20> gabapentin </e20> ( # mg) by approximately # mg was required in subjects treated with the # mg daily dose for # days.
mechanism	On the basis of reports of increased anticoagulant effects when <e10> warfarin </e10> and <e20> disulfiram </e20> were coadministered, a study was conducted to determine whether concomitant administration of warfarin and disulfiram would increase the risk of thromboembolic complications.
mechanism	On the basis of the results of a pharmacokinetic study in healthy subjects, it is possible that <e10> ketoconazole </e10> interferes with the metabolism of some <e22> corticosteroids </e22>.
mechanism	On the basis of evidence that <e10> flurbiprofen </e10> is a competitive inhibitor of <e20> sodium_thiosulfate </e20> -dependent renal tubular secretion, it is possible that flurbiprofen may reduce the renal tubular secretion of either diclofenac, ampicillin, or bacitracin.
mechanism	On the basis of in vitro and in vivo data, <e12> diuretics </e12> may have the potential to interfere with the renal excretion of <e20> furosemide </e20>.
mechanism	On the basis of these results, it is likely that other <e12> benzodiazepines </e12> that are metabolized by CYP3A4 may have an additive or potentiating effect on <e20> quinidine </e20> pharmacokinetics.
mechanism	On the basis of pharmacokinetic data, <e10> erythromycin </e10> was expected to increase the AUC of <e20> cimetidine </e20>.
mechanism	Furthermore, <e10> rifampin </e10> reduced <e20> ketoconazole </e20> concentrations by about 40%.
mechanism	Furthermore, <e10> rifampin </e10> may potentiate the adverse effects of <e20> carbamazepine </e20>.
mechanism	Furthermore, <e10> rifampin </e10> can enhance the effects of oral <e20> warfarin </e20>, phenytoin, and other known CYP3A4 inhibitors by decreasing their renal clearance.
mechanism	Furthermore, rifampin, phenytoin, and <e10> rifabutin </e10> may interfere with the metabolism of <e20> ciprofloxacin </e20>.
mechanism	Furthermore, rifampin, phenytoin, and <e10> carbamazepine </e10> markedly decreased <e20> gabapentin </e20> plasma concentrations, and resulted in a 50% increase in the gabapentin AUC.
mechanism	Furthermore, rifampin, phenytoin, <e10> carbamazepine </e10>, valproate, carbamazepine, phenobarbital, phenytoin, and disopyramide may increase the metabolism of <e20> cisapride </e20> and decrease the plasma concentration of cisapride.
mechanism	Furthermore, rifampin, phenytoin, and <e10> cimetidine </e10> have been reported to inhibit the metabolism of <e20> warfarin </e20>.
mechanism	Concomitant administration of <e11> Levo-Dromoran </e11> and <e20> phenytoin </e20> resulted in a significant increase in the half-life of Levo-Dromoran from approximately # to # minutes.
mechanism	Concomitant administration of <e10> ketoconazole </e10> tablets and <e20> triazolam </e20> has been reported to increase triazolam blood levels to approximately 3-fold higher than when triazolam is administered alone.
mechanism	Concomitant administration of <e10> ketoconazole </e10> and <e20> cimetidine </e20> produced a significant increase in the levels of both cimetidine and ketoconazole in the urine and feces.
mechanism	In vitro studies indicate that <e10> estradiol </e10> (4 microM) reduced the plasma concentrations of <e20> estradiol </e20> by 50% and that a similar reduction in AUC and Cmax of estradiol would occur in plasma given concurrently with a non-steroidal_anti-inflammatory_drug.
mechanism	In vitro studies, as well as in vivo studies, have demonstrated that <e10> diltiazem </e10> can inhibit the metabolism of <e20> tetracycline </e20>, a major metabolite of diltiazem.
mechanism	In vitro studies in normal rat brain microsomal fraction showed that <e10> ketoconazole </e10> and <e20> digoxin </e20> increased the clearance of both theophylline and ketoconazole.
mechanism	In vitro studies suggest that <e10> ketoconazole </e10> may inhibit the metabolism of <e20> ethinyl_estradiol </e20> and estrogens and may increase the rate of metabolism of these and other progestins.
mechanism	In vitro studies with <e10> cimetidine </e10> indicate a two- to three-fold enhancement of <e20> valdecoxib </e20> exposure with concurrent high-dose administration of either a proton_pump_inhibitor ( indinavir, ritonavir ) or a fluoroquinolone ( ciprofloxacin ) when compared to the same agents in a dose-response manner.
mechanism	Concurrent use of <e10> cholestyramine </e10> may reduce the bioavailability of <e20> carbamazepine </e20>, a potent CYP3A4 inhibitor.
mechanism	Concurrent use of <e10> diltiazem </e10> and <e20> isoniazid </e20> is associated with a high risk of isoniazid metabolism and of drug interactions, resulting in increases in plasma levels of isoniazid and decreased renal excretion.
mechanism	Concurrent use of <e10> cyclosporine </e10> may decrease the clearance of <e20> phenytoin </e20>.
mechanism	Steady-state <e10> bosentan </e10> concentrations were #% higher in # healthy volunteers taking <e20> cisapride </e20> or #% higher in # healthy volunteers taking # mg/day of bosentan.
mechanism	Steady-state <e10> bosentan </e10> concentrations were higher when the <e20> ketoconazole </e20> was added to the diet.
mechanism	Steady-state <e10> bosentan </e10> plasma concentrations of <e20> warfarin </e20> were approximately 2-fold higher following coadministration with the potent CYP3A4 inhibitor bromocriptine_mesylate than following coadministration with an oral anticoagulant such as warfarin or warfarin_sodium.
mechanism	Co-administration of <e10> warfarin </e10> with <e20> astemizole </e20> resulted in an increase in warfarin clearance and a decrease in the Cmax of warfarin.
mechanism	Co-administration of <e10> amiodarone </e10> with <e20> hydralazine </e20> or with amiodarone s plasma concentrations was abolished.
mechanism	Co-administration of <e10> ethambutol </e10> with carbamazepine, phenytoin, or other <e22> anticonvulsants </e22> (particularly phenytoin ) increases the clearance of carbamazepine, phenytoin, or other anticonvulsants by approximately 10%.
mechanism	Co-administration of <e10> alosetron </e10> (100 mg q12h) with <e20> lithium </e20> # mg/day for # days and lithium concomitantly with alosetron # mg q12h decreased lithium toxicity, indicating the importance of lithium in the metabolism of alosetron.
mechanism	Co-administration of <e10> cisplatin </e10> and <e20> rifampin </e20> was associated with increased rifampin exposure, suggesting a potential drug interaction.
mechanism	Co-administration of <e10> carbamazepine </e10> and <e20> phenytoin </e20> resulted in a 23% increase in carbamazepine AUC in patients taking both drugs concurrently.
mechanism	Co-administration of <e10> chlorpropamide </e10> and other agents known to alter platelet function (such as disopyramide, magnesium salts, certain aminoglycosides, certain antibiotics, and <e20> clofibrate </e20> ) has been shown to result in an increase in the inhibition of heparinized plasma samples of heparinized plasma from humans.
mechanism	Co-administration of <e10> ketoconazole </e10> and <e20> cisapride </e20> has been shown to decrease cisapride plasma concentrations by approximately 10% to 50%.
mechanism	Co-administration of <e10> rifampin </e10> with <e20> nalidixic_acid </e20>, a potent inhibitor of hepatic metabolism of catecholamines, resulted in elevated levels of catecholamine metabolites.
mechanism	<e10> Bosentan </e10> may increase plasma levels of <e20> lithium </e20> and the metabolite lithium carbonate.
mechanism	<e10> Bosentan </e10> was capable of decreasing the blood level of <e20> warfarin </e20> by approximately 30% and approximately 50%, respectively.
mechanism	<e10> Bosentan </e10> : Increases the bioavailability of <e20> ethinyl_estradiol </e20> and cetirizine.
mechanism	Ketoconazole : Co-administration of <e10> ketoconazole </e10> with <e20> ketoconazole </e20> resulted in a decrease in total ARAVA (13%) compared to the placebo and concomitant ARAVA (22%).
mechanism	Ketoconazole : Co-administration of <e10> Ketoconazole </e10> with <e20> fluconazole </e20> and clarithromycin resulted in an increase in fluconazole and clarithromycin concentrations.
mechanism	Ketoconazole : Co-administration of <e10> ketoconazole </e10> tablets (400 mg) with <e20> loratadine </e20> (3 mg) caused a 5% increase in loratadine exposure (mean +/- SD) and a mean increase in # mg loratadine clearance (3.0 +/- 0.9 mg/day).
mechanism	Simvastatin and Other Carbamazepine_Anticonvulsants ( <e10> carbamazepine </e10> ) have been reported to enhance the clearance of <e20> lovastatin </e20>, thus increasing its systemic exposure.
mechanism	<e10> Bosentan </e10> and <e20> diflunisal </e20> both inhibit CYP2D6.
mechanism	<e10> Bosentan </e10>, administered concurrently with or following a single dose of <e20> cyclosporine </e20>, causes a decrease in the elimination rate of cyclosporine (CSA) and its active metabolite, cyclosporine sulfate (CST), resulting in an increase in the CSA/CST ratio.
mechanism	<e10> Bosentan </e10> has been shown to have potentiating effects on the gastrointestinal absorption of <e20> digoxin </e20>, ampicillin, and tetracycline.
mechanism	<e10> Bosentan </e10> ( # mg/day) for # days was associated with a 6% increase in mean plasma levels of ketoconazole ( # mg/day), a 50% increase in mean plasma levels of <e20> ketoconazole </e20> ( # mg/day), a 17% increase in the mean area under the plasma concentration-time curve for ketoconazole ( # mg/day), and a 30% decrease in mean steady-state plasma levels of ketoconazole ( # mg/day).
mechanism	<e10> Bosentan </e10> increased plasma concentrations of <e20> ketoconazole </e20> and hexobarbital, decreased plasma concentrations of norethindrone, and slightly increased the clearance of norethindrone, nifedipine, and metoclopramide.
mechanism	<e10> Bosentan </e10> is associated with a transient increase in the concentration of <e20> acetaminophen </e20>, chloramphenicol, chloroquine, dicumarol, furosemide, levodopa, methadone, phenytoin, salicylates, thiazide_diuretics, and vitamin_C.
mechanism	Warfarin : Co-administration of <e10> rifampin </e10> decreased the exposure of <e20> warfarin </e20> to the liver and the renal tubules, resulting in a tendency for a lower plasma volume for warfarin than usual.
mechanism	Warfarin : Co-administration of <e10> rifampin </e10> with <e20> warfarin </e20> increased its exposure to warfarin.
mechanism	Warfarin : Co-administration of <e11> HUMORSOL </e11> with warfarin resulted in a reduction of the AUC of <e20> warfarin </e20> by approximately 75%.
mechanism	Warfarin : Co-administration of <e10> valdecoxib </e10> with <e20> warfarin </e20> produced a decrease in the Cmax and AUC of warfarin and a decrease in its half-life.
mechanism	Warfarin : Co-administration of <e10> amprenavir </e10> with <e20> warfarin </e20> has been shown to increase warfarin serum levels.
mechanism	Warfarin : Co-administration of <e10> warfarin </e10> with <e20> dexamethasone </e20> increased the half-life of warfarin by a factor of # on the liver and # on the bone, resulting in approximately # additional AUCs of warfarin for each mg of dexamethasone taken.
mechanism	Concomitant oral administration of <e10> anagrelide </e10> and <e20> warfarin </e20> may result in elevated plasma levels of warfarin, thus decreasing therapeutic efficacy of oral anticoagulants.
mechanism	Concomitant oral administration of <e11> VIOXX </e11> with certain other <e22> anticonvulsants </e22> ( phenytoin, carbamazepine, phenobarbital, phenytoin-methyl ) may lead to elevated plasma concentrations of these anticonvulsants.
mechanism	This antagonistic effect on the metabolism of <e10> gentamicin </e10> may occur when the drug is administered concomitantly with drugs that affect hepatic enzymes, e,g,, carbamazepine, <e20> phenobarbital </e20>, phenytoin, phenytoin sulfate, and ketoconazole.
mechanism	This antagonistic effect may be because <e10> lithium </e10> directly antagonizes the antihypertensive effects of <e20> guanethidine </e20>, phenytoin and theophylline.
mechanism	- Indomethacin : When <e11> INDOCIN </e11> and <e20> indomethacin </e20> are given concomitantly, the effect of indomethacin on the levels of cyclosporine, tacrolimus, and lithium may be significant.
mechanism	- Indomethacin : <e10> Indomethacin </e10> may inhibit the metabolism of <e20> digoxin </e20>, resulting in decreased serum concentrations and toxicity.
mechanism	- Indomethacin : Coadministration of <e10> indomethacin </e10> with <e20> nelfinavir </e20> reduced the AUC of nelfinavir by #%.
mechanism	In a study in volunteers, the AUC for <e10> aripiprazole </e10> was increased by approximately 7% and that for <e20> digoxin </e20> was decreased by approximately 15% when digoxin was coadministered with ARAVA.
mechanism	In a study in normal volunteers, <e10> digoxin </e10> (5 mg daily) decreased <e20> ketoconazole </e20> by 43%.
mechanism	In a study in normal volunteers, the oral <e10> gentamicin </e10> clearance was reduced by 50% when administered with <e20> methotrexate </e20> (12 micrograms daily).
mechanism	In a study in patients with moderate to severe symptomatic drug interactions between <e10> cimetidine </e10> and <e20> phenytoin </e20>, a single dose of cimetidine # mg significantly decreased the AUC of phenytoin by 40% and the Cmax of cimetidine by 37%.
mechanism	In a study of patients with high serum concentrations of <e10> cisapride </e10>, the <e20> cimetidine </e20> dose was increased to # mg and the cisapride /cimetidine AUC and Cmax were increased from # and # to # and 20%, respectively.
mechanism	In vitro, <e10> rifampin </e10> inhibited <e20> doxorubicin </e20> metabolism by blocking enzyme activity of CYP2D6.
mechanism	In vitro, <e10> ketoconazole </e10> inhibited the metabolism of <e20> lithium </e20>.
mechanism	In vitro, <e10> clozapine </e10> and clozapine / <e20> risperidone </e20> markedly inhibited the metabolism of risperidone.
mechanism	<e10> Itraconazole </e10>, an inducer of CYP3A4 activity, inhibits the metabolism of <e20> ketoconazole </e20>, increasing the half-life of itraconazole by 23%.
mechanism	<e10> Itraconazole </e10>, fluconazole, indinavir, <e20> ritonavir </e20>, and nelfinavir decrease the elimination half-life of rifampin by approx. 5% ( Itraconazole ), 2% ( fluconazole ), and 2% ( indinavir ).
mechanism	<e10> Phenytoin </e10> may decrease the absorption of <e20> isoniazid </e20> and cisplatin, leading to increased toxicities and increased pharmacokinetics.
mechanism	<e10> Phenytoin </e10> may increase plasma concentrations of <e20> amantadine </e20>.
mechanism	<e10> Phenytoin </e10> and other <e22> TCA </e22> inhibitors may enhance the effect of estrogens or progestins.
mechanism	Because busulfan is a methyltransferase, the plasma levels of <e10> busulfan </e10> may be decreased by the concurrent use of other agents that inhibit methylation (eg, <e20> terfenadine </e20>, furosemide, phenytoin ).
mechanism	Because busulfan is a multivalent_antigen, <e10> busulfan </e10> may interact with a number of other agents, including <e20> warfarin </e20>, corticosteroids, thiazide_diuretics, and some aminoglycosides.
mechanism	However, in another study, the addition of <e10> nifedipine </e10> to <e20> diclofenac </e20> # mg produced a 25% decrease in fluconazole serum levels, while the Cmax and AUC of fluconazole were increased by #- to #-fold.
mechanism	However, in another study, co-administration of <e10> diazoxide </e10> and <e20> cisapride </e20> (40 mg/day for # days) resulted in an increase in serum cisapride levels.
mechanism	Phenytoin / Phenobarbital : <e10> Phenobarbital </e10> is an antihypertensive_agent, which in addition to lowering blood pressure, may increase the metabolism of <e20> phenytoin </e20>.
mechanism	Phenytoin / Phenobarbital : <e10> Phenobarbital </e10> increases the clearance of <e20> ciprofloxacin </e20>, resulting in lower serum levels and a longer half-life of ciprofloxacin.
mechanism	Phenytoin / Phenobarbital : <e10> Diclofenac </e10> reduced the plasma levels of <e20> phenytoin </e20> and its active metabolite (methylphenytoin ).
mechanism	Phenytoin / Phenobarbital : <e10> Phenytoin </e10> decreases the metabolism of <e20> phenobarbital </e20>.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> may decrease the bioavailability of <e20> furosemide </e20> and may increase the clearance of norethindrone and warfarin.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> and other <e22> quinolones </e22> reduce the hepatic metabolism of drugs which have a narrow therapeutic index such as ketoconazole, erythromycin, rifampin, and furosemide, resulting in reduced clearance and decreased systemic exposure.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> (20 mg/kg) decreased <e20> erythromycin </e20> AUC by 20%.
mechanism	Phenytoin / Phenobarbital : <e10> Phenobarbital </e10>, like other <e22> corticosteroids </e22>, increases plasma concentrations of the corticosteroids phenytoin and methotrexate.
mechanism	Phenytoin / Phenobarbital : <e10> Cimetidine </e10> ( A similar drug profile was observed with the use of <e20> phenobarbital </e20>, suggesting the involvement of cytochrome P-450 3A4 in metabolism of cimetidine.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> can inhibit the metabolism of <e20> rifampin </e20>.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> (100 mg) and <e20> Cimetidine </e20> (50 mg) decreased the effect of Cimetidine (30 mg).
mechanism	Ketoconazole : <e10> Ketoconazole </e10> inhibits the metabolism of <e20> lisinopril </e20> by increasing its clearance and the metabolism of its active metabolite.
mechanism	Corticosteroids : A potential drug interaction between <e10> cilostazol </e10> and <e20> corticosteroids </e20> has been reported.
mechanism	Corticosteroids : A dose of <e10> cisapride </e10> # mg once daily decreased the plasma concentration of <e20> furosemide </e20> by 46% (47% in the first and 26% in the second month).
mechanism	Lithium Reversible increases in plasma lithium levels have been reported when <e10> lithium </e10> is given concomitantly with <e20> lithium_chloride </e20>.
mechanism	Lithium Reversible increases in plasma lithium concentrations have been observed when <e10> lithium </e10> is given concomitantly with <e20> ethinyl_estradiol </e20> and with other thyroid_products.
mechanism	Lithium Reversible increases in lithium plasma concentrations have been reported when <e10> lithium </e10> is administered concomitantly with other <e22> lithium </e22> s, especially with potassium-containing salts.
mechanism	Leucovorin : The coadministration of <e10> warfarin </e10> and <e20> nelfinavir </e20> resulted in a significant increase in the steady-state level of warfarin.
mechanism	Leucovorin : The concomitant administration of <e10> nevirapine </e10> with <e20> levothyroxine </e20> decreased the renal clearance of levothyroxine.
mechanism	Leucovorin : The oral clearance of <e10> zalcitabine </e10> increased significantly following administration of <e20> leucovorin </e20> at # mg/kg/day.
mechanism	Agents that are CYP3A4 substrates (eg, <e10> fluconazole </e10>, itraconazole, ketoconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir, <e20> saquinavir </e20> ) have a lower clearance and increase the need for high-dose metronidazole and clarithromycin therapy.
mechanism	Agents that are potent inhibitors of CYP3A4 (eg, ketoconazole, itraconazole, nefazodone, ritonavir, <e10> nelfinavir </e10>, clarithromycin, saquinavir, indinavir, saquinavir, saquinavir, nefazodone ) may result in increased plasma concentrations of <e20> atazanavir </e20>.
mechanism	Agents that are potent inhibitors of CYP2C9 (eg, ketoconazole, <e10> itraconazole </e10>, nefazodone, troleandomycin, clarithromycin, nefazodone, ritonavir, indinavir, saquinavir, saquinavir_topiramate ) may increase plasma levels of <e20> ketoconazole </e20>.
mechanism	Agents with Increased Potassium Injection: An intravenous infusion of <e10> carbamazepine </e10> # mg increased <e20> nevirapine </e20> plasma potassium concentration from # to # mg/L and decreased nevirapine plasma potassium concentration from # to # mg/L.
mechanism	Agents with Increased Potassium: <e10> Cholestyramine </e10> and <e20> apomorphine </e20> have been shown to increase the absorption of calcium and phosphate in a dose-dependent fashion.
mechanism	Agents with Increased Aminotransferase Activity Quinidine and <e10> fluconazole </e10> decrease <e20> acetaminophen </e20> renal clearance.
mechanism	Agents with Increased Hepatic Release: <e10> Acetazolamide </e10> was the only medication studied in which a significant increase in systemic exposure was observed during # weeks of therapy with <e20> cimetidine </e20>, a known CYP3A4 inhibitor.
mechanism	Agents with Increased Interaction With Cholestyramine : (i) Enalapril : <e10> Enalapril </e10> decreased the elimination of <e20> cholestyramine </e20>.
mechanism	<e11> Geocillin </e11> ( nafazodone ) -induced gastric ulceration was reduced by >50% when <e20> guanfacine </e20> was administered concurrently.
mechanism	<e11> Geocillin </e11> may interfere with the metabolism of certain <e22> tricyclic_antidepressants </e22>, causing increase in their plasma levels.
mechanism	<e11> Geocillin </e11> may be more potent if given with <e20> ciprofloxacin </e20> and not with ciprofloxacin.
mechanism	Geocillin ( <e10> levofloxacin </e10> ) and Carbamazepine decrease the metabolism of <e20> phenytoin </e20> by approximately 50%.
mechanism	Geocillin ( <e10> ciprofloxacin </e10> ) tablets, as well as similar preparations, may inhibit the metabolism of <e20> ampicillin </e20> and some other antibiotics by interfering with the binding of drugs to the intracellular enzyme system.
mechanism	Geocillin ( <e10> gentamicin </e10> ) at 10(-9) M, but not at 1 M, inhibited <e20> foscarnet </e20> at a dose of # mg/kg/day, as did carbamazepine at a dose of # mg/kg/day.
mechanism	<e10> Iron </e10> decreased the <e20> dofetilide </e20> clearance, and iron chelation by oral or intravenous administration decreased the dofetilide absorption rate in dogs.
mechanism	<e10> Iron </e10>, magnesium, calcium, and zinc may inhibit <e20> diltiazem </e20> s metabolism.
mechanism	<e10> Iron </e10>, and/or vitamin_B12 may interfere with the absorption of <e20> quinine </e20>, thus resulting in lower plasma levels.
mechanism	<e10> Iron </e10> has been reported to decrease the absorption of <e20> cimetidine </e20>.
mechanism	<e10> Iron </e10> -induced iron deficiency in rats causes a significant decrease in the <e20> erythromycin </e20> absorption, resulting in decreased absorption of both drugs.
mechanism	Serum concentration of the <e12> anticoagulants </e12> is increased in the presence of <e20> guanfacine </e20>.
mechanism	Serum concentration of <e10> valdecoxib </e10> was reduced by 25% when <e20> diazepam </e20> was coadministered.
mechanism	Serum concentration of <e10> phenytoin </e10> may increase if a phenobarbital or <e20> lithium </e20> is given concurrently.
mechanism	Inducers and Inhibitors of CYP2C9 (e,g,, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, indinavir, <e10> nefazodone </e10>, nelfinavir, saquinavir, telithromycin, troleandomycin, troleandomycin at a dose of # mg/day and a single dose of # mg/day) have been reported to cause a significant reduction in oral bioavailability of <e20> metoclopramide </e20>.
mechanism	Inducers and Inhibitors of CYP3A4 (eg, <e10> erythromycin </e10>, clarithromycin, itraconazole, nefazodone, troleandomycin, alfentanil ): In vitro metabolism of <e20> quinine </e20> was inhibited by all these drugs, resulting in increased levels of quinine and decreased quinine absorption.
mechanism	<e11> CANCIDAS </e11> : In vitro analysis of a patient with chronic renal insufficiency has shown that <e20> nevirapine </e20> decreased the rate of Cmax of the l-methyldopa preparation by more than 50%.
mechanism	<e11> CANCIDAS </e11> and <e20> tacrolimus </e20> inhibit the synthesis of platelet_aggregation_inhibitors, which are also inhibitors of platelet-aggregation.
mechanism	<e11> CANCIDAS </e11> may increase the clearance of drugs that are highly CYP3A4 substrates (e,g,, phenobarbital, <e20> carbamazepine </e20>, phenytoin, rifampin, quinine, theophylline, triazolam ) or decrease the clearance of these drugs (e,g,, indinavir, ritonavir, saquinavir, didanosine ).
mechanism	In two clinical studies, co-administration of <e10> cyclosporine </e10> and <e20> warfarin </e20> resulted in a 5% decrease in Cmax and a 5% decrease in AUC of cyclosporine.
mechanism	In two clinical studies, it was shown that coadministration of <e10> rifampin </e10> with <e20> gentamicin </e20> for up to # weeks caused a 3-fold increase in rifampin exposure.
mechanism	In two clinical studies, <e10> warfarin </e10> with <e20> rifampin </e20> was displaced from its binding sites in the serum of healthy volunteers by approximately 18%, concomitant with an increase in rifampin clearance.
mechanism	A drug-drug interaction study of <e11> FORADIL </e11> revealed a decreased clearance of cisapride following coadministration with <e20> disopyramide </e20>.
mechanism	A drug-drug interaction study of <e11> PRECEDEX </e11> ( cimetidine ) demonstrated that a single dose of # mg/kg of <e20> cimetidine </e20> produced a 3- to 4-fold increase in blood levels of methotrexate, resulting in a mean increase of approximately 2% in methotrexate clearance.
mechanism	A drug-drug interaction study with <e10> fluconazole </e10> in combination with <e20> ergotamine </e20> revealed that ergotamine decreased fluconazole plasma concentrations by approximately twofold.
mechanism	In addition, results of in vitro studies of <e10> clofibrate </e10>, fibrate, and simvastatin in combination with <e20> warfarin </e20> suggest that warfarin may inhibit the metabolism of some drugs (e,g,, fibrate ) by increasing the clearance of fibrate and that the metabolism of clofibrate may increase when it is co-administered with warfarin.
mechanism	In addition, results from in vitro studies of <e10> phenytoin </e10> indicated a potential drug interaction with the following: An increase in <e20> phenytoin </e20> plasma levels was observed when the two drugs were coadministered;
mechanism	In addition, results from in vitro studies of <e10> phenytoin </e10> ( <e20> terfenadine </e20> ) indicate that phenytoin may decrease the metabolism of the diuretic, furosemide, and renal tubular secretion.
mechanism	<e10> Probenecid </e10> and <e20> cimetidine </e20>, respectively, may inhibit the metabolism of levodopa.
mechanism	<e10> Probenecid </e10> inhibited <e20> cholestyramine </e20> absorption and increased cholestyramine levels in healthy volunteers.
mechanism	Iron_Supplements and Foods (Fermented Meat, Dairy, and Eggs) increase the plasma levels of <e10> rifampin </e10> and <e20> ketoconazole </e20>.
mechanism	Iron_Supplements and Foods: The intake of <e10> iron </e10> supplements or foods containing iron ( iron containing ) should be reduced by at least 50% when administered concomitantly with <e20> phenytoin </e20>.
mechanism	H2-Receptor_Antagonists : Co-administration of <e11> RAPTIVA </e11> and a certain <e22> H2-receptor_antagonist </e22> (e,g,, ketoconazole, clarithromycin, nelfinavir, indinavir, itraconazole, nefazodone, troleandomycin ) with RAPTIVA resulted in an increase in AUC for RAPTIVA and a decrease in Cmax and AUC for RAPTIVA.
mechanism	H2-Receptor_Antagonists : Co-administration of <e11> Anafranil </e11> # mg (e,g,, <e20> ethinyl_estradiol </e20> ) resulted in an approximately #-fold increase in the AUC of ethinyl_estradiol and an approximately #-fold increase in the AUC of a single dose of Anafranil # mg (e,g,, ethinyl_estradiol ).
mechanism	H2-Receptor_Antagonists : Co-administration of <e11> PRECEDEX </e11> and H2-receptor_antagonists, such as phenothiazines, haloperidol, <e20> butyrophenones </e20>, halothane, phenothiazines, and methadone increases plasma concentrations of PRECEDEX and increases the clearance of PRECEDEX, potentially resulting in prolongation of its duration of action.
mechanism	Carbamazepine : Elevated plasma concentrations of <e10> carbamazepine </e10> may increase the clearance of <e20> lorazepam </e20>, resulting in a decrease in the AUC and Cmax values.
mechanism	Carbamazepine : Elevated plasma concentrations of <e10> carbamazepine </e10> have been reported when <e20> amiodarone </e20> and carbamazepine are used concomitantly.
mechanism	Carbamazepine : Elevated plasma concentrations of <e10> carbamazepine </e10> have been reported with concomitant administration of <e20> ketoconazole </e20>.
mechanism	Concomitant administration of <e10> levothyroxine </e10> and other thyroid_products with <e20> cyclosporine </e20>, tacrolimus, digoxin, and cyclosporine_HCl may increase serum levels of these drugs.
mechanism	Concomitant administration of <e10> indinavir </e10> with <e20> zalcitabine </e20> at a dosage of # mg in a single oral dose resulted in a #-fold increase in exposure to zalcitabine.
mechanism	Concomitant administration of <e10> astemizole </e10> and <e20> quinidine </e20> may result in elevated plasma concentrations of quinidine and thus decrease the therapeutic effect of quinidine.
mechanism	however, # mg <e10> nevirapine </e10> decreased the maximum plasma concentrations of # mg <e20> amiodarone </e20> by 40%.
mechanism	however, # mg <e10> halothane </e10> caused a 6-fold increase in the <e20> methotrexate </e20> area under the curve (AUC).
mechanism	however, # mg/kg/day of <e10> cisplatin </e10> produced a 62% reduction in <e20> quinine </e20> plasma levels.
mechanism	however, # mg # mg and # mg # mg # mg # mg formulations resulted in #% and #% inhibition of <e10> cisapride </e10> formation, respectively, compared to # mg # mg and # mg # mg (CISPR) administered concomitantly with # mg # mg # mg, whereas # mg # mg # mg did not inhibit <e20> cisapride </e20> formation.
mechanism	however, # mg of <e10> gabapentin </e10> /day for # days has been shown to significantly reduce the <e20> aripiprazole </e20> plasma AUC and Cmax values.
mechanism	however, # mg/kg oral <e10> clorazepate </e10> significantly inhibited the hepatic metabolism of <e20> ciprofloxacin </e20> in rats.
mechanism	Fluconazole : Concomitant administration of <e10> fluconazole </e10> and <e20> erythromycin </e20> (a potent inhibitor of CYP2D6) produced a mean increase in fluconazole exposure of 17%, compared to a decrease of 10% in fluconazole exposure with either drug alone.
mechanism	Fluconazole : Concomitant administration of <e11> INOmax </e11> and <e20> fluconazole </e20> significantly decreased the clearance of fluconazole.
mechanism	Lithium : In rats, <e10> lofexidine </e10> and <e20> lithium </e20> co-administered significantly decreased the AUC of lithium.
mechanism	Lithium : In rats, <e10> lithium </e10> -containing preparations (eg, tablets, oatmeal, etc,) have been reported to decrease the serum levels of <e20> rifampicin </e20>.
mechanism	Lithium : In vitro studies of lithium <e12> quinolones </e12> suggest that they may inhibit <e20> lithium </e20> absorption by competitive inhibition of absorption through hepatic enzymes such as cytochrome P450 3A4 (CYP3A4) and CYP3A5 (CYP3A4, 3A5).
mechanism	Metformin : In vitro and in vivo studies have shown that <e10> metformin </e10> can decrease the metabolism of <e20> quinidine </e20>.
mechanism	Metformin : In vitro data indicate that <e10> metformin </e10> increases the bioavailability of <e20> digoxin </e20>.
mechanism	Although not observed, the concomitant use of <e10> cyclosporine </e10> with <e20> tacrolimus </e20> may increase tacrolimus plasma concentrations by an unknown mechanism.
mechanism	Although not observed, <e10> warfarin </e10> may interact with the following <e22> TCA </e22> s: Cisapride : warfarin s lower serum cisapride concentrations may increase the exposure of cisapride to the renal tubular cells.
mechanism	Probenecid : As with other tricyclic_antidepressants, <e10> Probenecid </e10> has been shown to increase <e20> fluoxetine </e20> plasma levels and to decrease probenecid plasma levels when given concomitantly.
mechanism	In the first study, a significant increase in <e10> acetaminophen </e10> plasma levels was observed when <e20> cimetidine </e20> was administered at a dose of # mg/kg of body weight # times a day for # days.
mechanism	In the first study, <e10> diflunisal </e10> reduced the <e20> halothane </e20> plasma levels by 50% at a dose of # mg/kg, a dose that was twofold greater than the therapeutic plasma levels of halothane.
mechanism	ERYTHROMYCIN : In vitro data suggest a possible antagonistic effect of <e10> estradiol </e10> and <e20> erythromycin </e20> on the metabolism of estradiol.
mechanism	ERYTHROMYCIN : In a single-dose, randomized study, <e10> ergotamine </e10> at a dose of # mg decreased plasma levels of <e20> ethinyl_estradiol </e20> by 22%.
mechanism	In a multiple-dose study of <e10> atorvastatin </e10> in patients on fluconazole, <e20> cimetidine </e20> increased AUC from 1,903 to 3,926 mcg/mL (p =.001).
mechanism	In a multiple-dose study in healthy volunteers, # mg of <e10> diltiazem </e10> # hours after an oral dose of <e20> warfarin </e20> # mg resulted in a significant increase in warfarin levels (P =.016) in a significant number of subjects.
mechanism	In a multiple-dose study, a <e12> quinolone </e12> with antifungal activity was shown to reduce the plasma levels of <e20> gabapentin </e20> by approximately 25%.
mechanism	There was a decrease in the mean area under the curve for <e10> cisapride </e10> following administration of <e20> alprazolam </e20>.
mechanism	There was a significant decrease in the area under the concentration-time curve of <e10> diltiazem </e10> following coadministration of <e20> clarithromycin </e20> # mg once daily.
mechanism	Cimetidine : <e10> Cimetidine </e10> decreased the number of <e20> rifabutin </e20> required to reach steady state by 38% compared to rifabutin # mg.
mechanism	Cimetidine : <e10> Cimetidine </e10> may increase the renal clearance of <e20> methotrexate </e20>, resulting in lower plasma concentrations of the latter.
mechanism	Cimetidine : <e10> Cimetidine </e10> may enhance the metabolism of <e20> estrogens </e20>, causing estrogen levels to increase.
mechanism	Ampicillin : In a randomized, double-blind, placebo-controlled trial of healthy subjects receiving a dose of # mg <e10> ampicillin </e10> once daily for # days, daily doses of # mg for # days produced a decrease in <e20> phenytoin </e20> AUC and Cmax values by about #% and AUC and Cmax values by about 6%.
mechanism	Ampicillin : In a clinical study, <e10> ampicillin </e10> significantly decreased the clearance of <e20> zalcitabine </e20> from 0.83% # min to 0.52% # min, and the elimination half-life from 17.6 hours to 13.2 hours.
mechanism	Ampicillin : In the in vitro study, <e10> ampicillin </e10> was significantly less effective than <e20> rifampin </e20> at inhibiting the AUC for Cmax, AUC for Cmin, AUC for Cmin/AUC, and AUC for Cmin/Cmax.
mechanism	Cyclosporin : After administration of <e10> cyclosporin </e10> to a rat model, there was a decrease in serum <e20> methotrexate </e20> levels.
mechanism	Cyclosporin : After administration of <e10> cyclosporin </e10> to normal volunteers, serum concentrations of <e20> dofetilide </e20> were approximately two-fold higher than with any other previously reported oral contraceptive (approximately # to # times higher).
mechanism	Cyclosporin : After # days of <e10> cyclosporin </e10> treatment, <e20> carbamazepine </e20> serum levels decreased by 39%.
mechanism	- Cholestyramine and <e10> cetirizine </e10> enhance the clearance of <e20> methotrexate </e20>.
mechanism	- Cholestyramine and <e10> ketoconazole </e10>, alone and in combination, inhibit <e20> probenecid </e20> binding to the high affinity binding site on the T cell receptor.
mechanism	- Cholestyramine and <e10> fluvastatin </e10> may increase plasma concentrations of <e20> warfarin </e20> and decrease clearance of warfarin.
mechanism	<e10> Chlorprothixene </e10> in moderate doses (5 mg/day) inhibits the metabolism of <e20> fluvoxamine </e20> and increases the clearance of amiodarone and cimetidine.
mechanism	<e10> Chlorprothixene </e10> may increase the clearance of a number of drugs, including corticosteroids, corticotropin, amphotericin_B, disopyramide, digoxin, <e20> fluconazole </e20>, grapefruit juice, isoniazid, itraconazole, morphine, phenobarbital, quinidine, rifampin, saquinavir, theophylline, tamoxifen, and zidovudine.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> increases the clearance of <e20> clofibrate </e20>, resulting in a decrease in plasma clofibrate levels and a significant increase in urinary clofibrate excretion.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> prolongs the duration of the <e20> ketoconazole </e20> -induced gastrointestinal transit time (16.2% increase in AUC).
mechanism	Ketoconazole : <e10> Ketoconazole </e10> may reduce the bioavailability of oral <e20> probenecid </e20>.
mechanism	<e10> Cholestyramine </e10> and cimetidine may increase the serum concentration of <e20> triazolam </e20>, cimetidine, and its active metabolite.
mechanism	<e10> Cholestyramine </e10> and <e20> zidovudine </e20> decrease catecholamine levels by a concentration-dependent reduction.
mechanism	<e10> Cholestyramine </e10> also has been shown to have the capacity to inhibit platelet-aggregation induced by <e20> prothrombin_III </e20> and anti-thrombin_III.
mechanism	<e10> Cholestyramine </e10> : Since <e20> cholestyramine </e20> has been reported to reduce the absorption of many drugs, it is not likely that the elimination of these drugs will be altered by the addition of cholestyramine.
mechanism	<e10> Cholestyramine </e10> may potentiate the effects of other <e22> corticosteroids </e22>.
mechanism	<e10> Cholestyramine </e10> (a nonsteroidal_anti-inflammatory_agent ) has been shown to reduce <e20> bromocriptine_mesylate </e20> -induced dopamine release in the nucleus accumbens.
mechanism	<e10> Cholestyramine </e10>, sodium bicarbonate and NaCl may reduce the absorption of <e20> astemizole </e20>, causing an increase in the area under the plasma concentration-time curve (AUC) of the drug.
mechanism	<e10> Cholestyramine </e10>, a drug used to inhibit the hepatic metabolism of <e20> phenytoin </e20>, may reduce the effect of cimetidine, which has been reported to increase the metabolism of other CYP3A4 inhibitors.
mechanism	In another drug-drug interaction study in volunteers, <e10> Isoniazid </e10> given concomitantly with <e20> ciprofloxacin </e20> # mg increased the AUC of ciprofloxacin by 5-fold and the Cmax by 23%.
mechanism	In another drug interaction study, coadministration of <e10> diclofenac </e10> with other anticonvulsants, phenytoin, carbamazepine, cyclosporine, tacrolimus, <e20> hexobarbital </e20>, phenytoin, phenylbutazone, primidone, risperidone, alfentanyl, and cimetidine resulted in an increase in Cmax of diclofenac, and AUC of diclofenac.
mechanism	Probenecid : <e10> Probenecid </e10> decreased the Cmax and AUC of <e20> doxapram </e20> by 40% and 17%, respectively, and the AUC of metoclopramide by 22%.
mechanism	Probenecid : <e10> Probenecid </e10> reduced the hepatic concentrations of <e20> ketoconazole </e20> by 44% and the hepatic concentrations of piperacillin by 39%.
mechanism	Probenecid : <e10> Probenecid </e10> has been reported to increase the clearance of <e20> indinavir </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> can reduce the metabolism of <e20> ketoconazole </e20> and increase the clearance of cisapride.
mechanism	Probenecid : <e10> Probenecid </e10> significantly reduced the plasma concentrations of <e20> digoxin </e20> and dexamethasone.
mechanism	Probenecid : <e10> Probenecid </e10> has been reported to decrease the clearance of <e20> dexamethasone </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> inhibits <e20> ketoconazole </e20> metabolism and, therefore, results in increased hepatic concentrations of ketoconazole and inhibits hepatic absorption of other ketoconazole s.
mechanism	Probenecid : <e10> Probenecid </e10> blocks concomitant binding of <e20> phenytoin </e20>, carbamazepine, and valproic_acid.
mechanism	Probenecid : <e10> Probenecid </e10> is known to inhibit the metabolism of certain <e22> steroids </e22>.
mechanism	Probenecid : <e10> Probenecid </e10> may inhibit <e20> cyclosporine </e20> clearance by decreasing the renal excretion of cyclosporine, which may result in an increase in prothrombin time and other adverse effects.
mechanism	Probenecid : <e10> Probenecid </e10> significantly reduced the metabolism of <e20> indomethacin </e20>, a potent inhibitor of CYP3A, by approximately 70%.
mechanism	Probenecid : <e10> Probenecid </e10> reduced the plasma level of <e20> enoxacin </e20> and the enoxacin-induced urinary pH change by approximately 20% and decreased the enoxacin effect on plasma ascorbic acid by approximately 20%.
mechanism	Probenecid : <e10> Probenecid </e10> may interfere with the metabolism of <e20> chlorpropamide </e20>, resulting in decreased clearance of cephalosporins, sulfonamides, sulfonamides with hepatic metabolism, and quinine, resulting in lower half-life and increased half-life.
mechanism	Probenecid : <e10> Probenecid </e10> has been reported to inhibit <e20> acetaminophen </e20> metabolism, and thus its metabolism may have occurred prior to or during the administration of acetaminophen.
mechanism	Probenecid : <e10> Probenecid </e10> decreases the metabolism of <e20> astemizole </e20>, resulting in a higher AUC and Cmax.
mechanism	Probenecid : <e10> Probenecid </e10> increases the absorption of <e20> ciprofloxacin </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> significantly decreased the norethindrone AUC and Cmax of <e20> norethindrone </e20>, but increased the AUC and Cmax of disulfiram.
mechanism	Probenecid : <e10> Probenecid </e10> increased the plasma levels of <e20> amphetamine </e20> (10 microg/mL) by approximately 25%.
mechanism	Probenecid : <e10> Probenecid </e10> increases the metabolism of <e20> phenytoin </e20> by causing increased elimination and decreased absorption resulting in a decrease in the total phenytoin dose.
mechanism	Probenecid : <e10> Probenecid </e10> may be an inhibitor of <e20> digoxin </e20> metabolism and increased the plasma concentration of digoxin.
mechanism	Probenecid : <e10> Probenecid </e10> reduced the plasma concentrations of <e20> rifampin </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> is a potent inhibitor of CYP3A4 and is likely to inhibit the metabolism of <e20> alprazolam </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> inhibited the metabolism of <e20> amiodarone </e20> and increased the exposure to amiodarone.
mechanism	Probenecid : <e10> Probenecid </e10> reduced the number of <e20> furosemide </e20> -induced acidotic reactions by 28%.
mechanism	Probenecid : <e10> Probenecid </e10> may inhibit hepatic enzymes that are responsible for the metabolism of <e20> norethindrone </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> may interfere with the metabolism of <e20> aripiprazole </e20> and may increase the clearance of the drug.
mechanism	Probenecid : <e10> Probenecid </e10> may inhibit the metabolism of <e20> ketoconazole </e20> and may prolong the half-life of ketoconazole.
mechanism	Probenecid : <e10> Probenecid </e10>, in addition to its reported toxic effects on heart and kidneys, has been reported to reduce blood levels of a range of adrenergic_agonists, including <e20> enflurane </e20>, procainamide, and astemizole.
mechanism	Probenecid : <e10> Probenecid </e10> decreased the binding of <e20> phenytoin </e20> by 26%.
mechanism	Probenecid : <e10> Probenecid </e10> is a potent inhibitor of CYP3A4, and therefore, it may decrease the efficacy of oral <e20> atazanavir </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> has been reported to cause a reduction in <e20> caffeine </e20> plasma levels, but not to cause any observed side effects when given concomitantly with caffeine.
mechanism	Probenecid : <e10> Probenecid </e10> may increase the serum levels of <e20> cisapride </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> can decrease the clearance of <e20> fentanyl </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> may inhibit the metabolism of <e20> cyclosporine </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> has been shown to decrease plasma levels of <e20> fluvoxamine </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> may enhance the absorption of oral <e22> anticoagulants </e22> by decreasing the blood levels of the anticoagulants.
mechanism	Probenecid : <e10> Probenecid </e10> inhibited the metabolism of <e20> clofibrate </e20>.
mechanism	Pharmacokinetic studies have demonstrated that <e10> rifabutin </e10> significantly increases plasma concentrations of <e20> digoxin </e20> and isoniazid and significantly decreases plasma concentrations of digoxin and nicotinamide.
mechanism	Pharmacokinetic studies have shown that coadministration of <e10> cimetidine </e10> with a <e22> macrolide_antibiotic </e22>, a phenytoin_anticonvulsant, or an anticonvulsant, may significantly reduce the oral bioavailability of cimetidine.
mechanism	Pharmacokinetic studies have shown that <e10> lomefloxacin </e10> significantly increases the AUC of <e20> atorvastatin </e20> by 2-fold and the Cmax by 3-fold.
mechanism	Population pharmacokinetic studies have shown that oral <e10> methotrexate </e10> plasma levels increase with increases in <e20> alfentanil </e20> dose.
mechanism	Population pharmacokinetic studies in healthy volunteers, which did not take <e10> rifampin </e10>, did not demonstrate any significant interaction between rifampin and <e20> ketoconazole </e20>.
mechanism	Population pharmacokinetic studies of <e10> fluvoxamine </e10> have shown that the AUC and Cmax of <e20> norethindrone </e20> increased by approximately 17% and 3% with coadministration of fluvoxamine, respectively.
mechanism	<e11> Tagamet </e11> significantly inhibited the <e20> phenytoin </e20> metabolism by approximately 95% and completely inhibited the hepatic metabolism of the phenytoin A.
mechanism	<e11> Tagamet </e11>, although less potent than other antihypertensive_drugs, showed strong hypotensive effect with decreased <e20> alprazolam </e20> plasma levels, suggesting that Tagamet may be a potent antihypertensive_agent in some clinical situations.
mechanism	<e11> Tagamet </e11> may decrease the plasma concentrations of some <e22> antipsychotic_agents </e22>, e,g,, haloperidol, risperidone, thioridazine, thioridazine, thiazide_diuretics, corticosteroids, and beta_adrenergic_blocking_agents.
mechanism	<e11> Tagamet </e11>, and <e20> enoxacin </e20>, and the effect of other antibiotics in combination with Tagamet or enoxacin were studied in rats.
mechanism	<e11> Tagamet </e11>, as with other nonsteroidal_anti-inflammatory_drugs, may interfere with the metabolism of oral <e20> salicylates </e20> and, hence, increase the clearance of salicylates, potentially leading to increases in serum salicylate levels.
mechanism	<e11> Tagamet </e11>, a protease_inhibitor, inhibits CYP3A4 and has been reported to decrease the clearance of several <e22> potent, but rarely used, anticoagulants </e22>, such as warfarin or its derivatives or its derivatives and its salts.
mechanism	<e11> Tagamet </e11>, which is highly concentrated in the stomach, may inhibit gastric acid secretion and may increase the levels of <e20> acetaminophen </e20> in the blood.
mechanism	<e11> Tagamet </e11>, when administered concomitantly with, or following the administration of, <e20> alfentanil </e20>, has the potential to affect the pharmacokinetics of alfentanil and its absorption.
mechanism	<e11> Tagamet </e11>, if given concomitantly, significantly increases the plasma concentrations of <e20> fluvoxamine </e20>.
mechanism	<e11> Tagamet </e11>, which inhibits TCA metabolism, markedly increases the metabolism of <e20> acetaminophen </e20>, which in turn increases the elimination of acetaminophen.
mechanism	<e11> Tagamet </e11>, therefore, may enhance the clearance of cimetidine, a therapeutic metabolite of <e20> cimetidine </e20>, which is the most toxic and extensively metabolized metabolite of cimetidine.
mechanism	<e11> Tagamet </e11>, as with other methotrexate_drugs, has been reported to interfere with the metabolism of <e20> alfentanil </e20>, a potent inducer of hepatic metabolism.
mechanism	<e11> Tagamet </e11>, has been shown to increase the clearance of <e20> valdecoxib </e20> and other nonsteroidal_anti-inflammatory_drugs and may increase the clearance of certain cephalosporins, ampicillin, ampicillin/sulbactam, ciprofloxacin, colistin, dapsone, fluconazole, indinavir, itraconazole, nelfinavir, ritonavir, saquinavir, theophylline, theophylline_HCl, theophylline_HCl_acid_supplemented, triazolam, and zidovudine.
mechanism	<e11> Tagamet </e11>, when administered at the recommended daily dose of # mg for # days to # healthy volunteers, has been shown to cause a rapid ( # minutes) and sustained increase in serum <e20> cyclosporine </e20> levels (5-10% increase).
mechanism	<e11> Tagamet </e11>, an oral <e22> anticoagulant </e22>, may increase the bleeding tendency of prothrombin time.
mechanism	<e11> Tagamet </e11>, in contrast, reduced the activity of <e20> rifampin </e20> and the half-life of aripiprazole, with no effect on Cmax or AUC.
mechanism	<e11> Tagamet </e11> decreased the clearance of <e20> ketoconazole </e20>.
mechanism	<e11> Tagamet </e11> is a potent inhibitor of <e20> indinavir </e20> metabolism.
mechanism	<e11> Tagamet </e11> has been shown to reduce the release of metoclopramide and <e20> indomethacin </e20>.
mechanism	<e11> Tagamet </e11> tablets have been reported to cause hypotension and may increase blood pressure when administered concomitantly with certain ACE_inhibitors ( <e20> angiotensin_II_converting_enzyme_inhibitors </e20>, dipyridamole, amiodarone, cilostazol, disopyramide, dofetilide, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin ).
mechanism	<e11> Tagamet </e11> may also enhance the absorption of <e20> terfenadine </e20>, which is a terfenadine metabolite, by stimulating hepatic enzymes.
mechanism	<e11> Tagamet </e11> has been reported to decrease the metabolism of the anticonvulsant carbamazepine, phenobarbital, phenytoin, alfentanil, phenytoin, valproate, terfenadine, cisapride, disopyramide, carbamazepine, felbamate, phenobarbital, phenytoin, phenytoin_HCl, <e20> carbamazepine_HCl </e20>, phenytoin_HCl_D, cisapride, disopyramide, felbamate, phenytoin_HCl, phenytoin_HCl_D, cisapride_HCl, disopyramide, phenytoin_HCl_D, disopyramide_HCl, phenytoin_HCl_D, disopyramide_HCl_D, disopyramide_HCl_
mechanism	<e11> Tagamet </e11> may interfere with the absorption of <e20> loratadine </e20>.
mechanism	<e11> Tagamet </e11> may increase the clearance of tricyclic_antidepressants, <e20> phenothiazines </e20>, barbiturates, certain sulfonamides, thiazide_diuretics, and certain anticonvulsants.
mechanism	However, a crossover study in healthy volunteers demonstrated a significantly increased bioavailability of <e10> diltiazem </e10>, but not of <e20> methotrexate </e20>, when co-administered with an oral # mg regimen of diltiazem and two # mg tablets of methotrexate.
mechanism	However, a crossover study of <e10> phenytoin </e10> and <e20> ergotamine </e20> in healthy subjects demonstrated that, in addition to ergotamine, the metabolism of phenytoin was significantly inhibited by ergotamine.
mechanism	However, a crossover study in healthy volunteers indicated that <e10> ergotamine </e10> increased the <e20> cimetidine </e20> dose by approximately 3%.
mechanism	However, a crossover study with <e11> INDOCIN </e11> and <e20> cimetidine </e20> (10 mg/day for # days, # days with rifampin, # days with clarithromycin, # days with didanosine, # days with clarithromycin, # days with gefitinib ) found a 7% decrease in the half-life of cimetidine when INDOCIN was given with rifampin and clarithromycin.
mechanism	However, a crossover study in healthy subjects demonstrated a decrease in AUC of <e10> dexamethasone </e10> and <e20> erythromycin </e20> following coadministration with concomitant administration of a single dose of both drugs in patients with Type 2 diabetes.
mechanism	Co-administration of <e10> ketoconazole </e10> and <e20> levothyroxine </e20> results in a decrease in serum levothyroxine levels.
mechanism	Co-administration of <e10> almotriptan </e10> with either diazepam, <e20> ketoconazole </e20>, or indomethacin (if taking diazepam or ketoconazole concurrently) was associated with a higher level of almotriptan in plasma than when almotriptan was not co-administered.
mechanism	Co-administration of <e10> halothane </e10> with <e20> halothane </e20> increased the HALO-binding half-life from # to # minutes.
mechanism	<e12> Quinolones </e12>, including nalidixic_acid, which are used to treat liver disease and may increase plasma concentrations of the <e20> digoxin </e20>, have been reported to cause hepatic toxicity when given concomitantly with other drug classes.
mechanism	<e12> Quinolones </e12>, such as <e20> ciprofloxacin </e20>, inhibit the metabolism of oral anticoagulants (such as warfarin, corticosteroids, etc,) leading to lower levels of the active compound.
mechanism	<e12> Quinolones </e12>, including ciprofloxacin, may inhibit the metabolism of oral anticoagulants, including <e20> warfarin </e20>, phenytoin, corticosteroids, and theophylline.
mechanism	<e12> Antacids </e12>, theophylline, and iron may interfere with the absorption of <e20> methotrexate </e20>.
mechanism	<e12> Antacids </e12> containing calcium, magnesium, or iron salts may increase <e20> digoxin </e20> absorption.
mechanism	Antacids or <e10> digoxin </e10> tablets may decrease the absorption of <e20> digoxin </e20>.
mechanism	Antacids or <e10> magnesium </e10> containing <e20> digoxin </e20> may reduce serum digoxin levels and may decrease the renal excretion of digoxin.
mechanism	Antacids or <e10> sucralfate </e10> containing magnesium or aluminum, probenecid, or a vitamin_B-containing preparations (including multivitamins ) may interfere with absorption of <e20> zidovudine </e20>.
mechanism	Also, concomitant administration of <e11> INDOCIN </e11> and <e20> cimetidine </e20> resulted in increased serum concentrations of cimetidine.
mechanism	Also, concomitant administration of <e10> lopinavir </e10> with <e20> ritonavir </e20> may increase the plasma concentration of ritonavir.
mechanism	Also, concomitant administration of <e10> carbamazepine </e10> and <e20> gabapentin </e20> in rats significantly decreased the absorption of gabapentin.
mechanism	Also, concomitant administration of <e10> digoxin </e10> with <e20> warfarin </e20> is likely to decrease the plasma concentration of warfarin.
mechanism	Also, concomitant administration of <e10> diltiazem </e10> with <e20> warfarin </e20> increases the AUC of warfarin by 44% and decreases its AUC by 17%.
mechanism	Also, concomitant administration of <e10> zalcitabine </e10> with <e20> diltiazem </e20> is likely to reduce zalcitabine exposure.
mechanism	Also, concomitant administration of <e10> ketoconazole </e10> with <e20> erythromycin </e20> resulted in an approximately tenfold increase in erythromycin plasma concentrations.
mechanism	Also, concomitant administration of <e10> diltiazem </e10> with <e20> ketoconazole </e20> resulted in a significant increase in the clearance of diltiazem.
mechanism	Also, concomitant administration of <e10> probenecid </e10> with <e20> carbamazepine </e20>, which causes hypercalcemia, caused an increase in plasma carbamazepine levels.
mechanism	Also, concomitant administration of <e10> probenecid </e10> (40 mg/kg) with <e20> cisapride </e20> (10 mg/kg) significantly decreased cisapride plasma concentrations.
mechanism	Also, concomitant administration of <e10> cholestyramine </e10> with <e20> cimetidine </e20> (Citretin ) may result in the release of citrate, which may have an effect on plasma levels of CPT.
mechanism	Also, concomitant administration of <e10> warfarin </e10> and <e20> zidovudine </e20> increases the AUC of zidovudine by 32%.
mechanism	Some <e12> quinolones </e12> have been reported to inhibit CYP3A4 and may increase the half-life of intravenous <e20> dasatinib </e20>.
mechanism	Some <e12> quinolones </e12> are known to reduce the absorption of <e20> furosemide </e20>.
mechanism	Methotrexate Renal tubular secretion of <e10> ketoconazole </e10> increased the level of <e20> ketoconazole </e20>.
mechanism	Methotrexate Renal tubular secretion of <e10> methotrexate </e10> may be decreased by <e20> phenytoin </e20> and some CYP3A4 inhibitors.
mechanism	Multivalent Cation-Containing Products: The rate of absorption of <e10> diltiazem </e10> decreased approximately one-third as a result of simultaneous administration of <e20> zalcitabine </e20> and multivalent cation-containing products (e,g,, sucralfate ).
mechanism	Multivalent Cation-Containing Products: Cation-Containing Products (e,g,, lithium-containing products and lithium-containing preparations, <e10> lithium </e10> preparations, etc,) that are taken in combination with <e20> valdecoxib </e20> may raise the plasma levels of valdecoxib.
mechanism	Multivalent Cation-Containing Products: Use of <e11> WELLBUTRIN </e11> Tablets for <e20> acyclovir </e20>, valacyclovir, or astemizole in combination with these multivalent cation-containing products may increase the risk of gastrointestinal toxicity.
mechanism	Multivalent Cation-Containing Products: Cation-Containing Product: <e10> Phenytoin </e10> and <e20> disulfiram </e20> are the most potent inhibitors of CYP3A4.
mechanism	Multivalent Cation-Containing Products: Cimetidine : In vitro binding studies of <e10> cimetidine </e10> with carbamazepine, <e20> cimetidine </e20>, felbamate, and phenytoin indicate a weak affinity of cimetidine for these 3 agents.
mechanism	Multivalent Cation-Containing Products: Clinical studies with multivalent cation-containing products (eg, <e10> tetracycline </e10> ) have shown that concurrent use with <e20> doxycycline </e20> may result in increased doxycycline serum concentrations and toxicity.
mechanism	Multivalent Cation-Containing Products: Combination of <e10> guanfacine </e10> and other multivalent cation-containing products such as <e20> boric_acid </e20>, citric_acid, sulfate-reducing boric_acid, and polysulfate with the perchlorate salt of guanfacine (preparation #) may decrease the absorption of guanfacine by approximately 30%.
mechanism	Multivalent Cation-Containing Products: The potential for significant interactions with multivalent cation-containing products including aspirin, other nonsteroidal_anti-inflammatory_drugs ( <e12> NSAIDs </e12> ), salicylates, some ketoconazole and other sulfonamides, and sulfonamides including ketoconazole and some <e20> sulfonamides </e20> may be enhanced by these agents.
mechanism	Multivalent Cation-Containing Products: Concomitant administration of <e10> warfarin </e10> and multivalent cation-containing products such as lithium, <e20> magnesium </e20>, or iron may reduce the bioavailability of warfarin.
mechanism	Multivalent Cation-Containing Products: Although multivalent cation-containing products may inhibit the metabolism of <e10> digoxin </e10>, the <e22> anticoagulant_agents </e22> may be displaced to another site of metabolism.
mechanism	Multivalent Cation-Containing Products: <e10> Cimetidine </e10> may decrease the bioavailability of multivalent cation-containing products such as <e20> ethionamide </e20>, diltiazem, diltiazem hydrochloride, phenytoin, phenobarbital, and triazolam.
mechanism	Multivalent Cation-Containing Products: Multivalent cation-containing products (such as decongestant_agents and anticholinergics ) may reduce the absorption of <e11> BREVIBLOC </e11> and may therefore require a higher dose of oral <e20> cisapride </e20> to achieve the desired plasma concentrations.
mechanism	Multivalent Cation-Containing Products: A significant increase in serum <e10> allopurinol </e10> concentrations may occur with the concomitant use of multivalent cation-containing products containing <e20> magnesium </e20>, aluminum, and calcium.
mechanism	Multivalent Cation-Containing Products: Cation-containing drugs such as <e11> PROLEUKIN </e11> may reduce the absorption of other <e22> tricyclic_antidepressants </e22>.
mechanism	Multivalent Cation-Containing Products: <e10> Cholestyramine </e10> has been reported to decrease the bioavailability of cation-containing products such as magnesium salts, <e20> calcium_preparations </e20>, some multivalent cation-containing products (e,g,, magnesium salts, calcium supplements, Boric_acid, Acetazolamide, boric_acid ), magnesium salts and boric_acid.
mechanism	Multivalent Cation-Containing Products: Cation-containing products (eg, <e10> niacin </e10> ) that have been reported to cause hypercalcemia when given concomitantly with <e20> digoxin </e20> have been reported to have similar effects when given concomitantly with the multivalent cation-binding catalyst digoxin.
mechanism	Multivalent Cation-Containing Products: Phenytoin, carbamazepine, <e10> clarithromycin </e10>, and bromocriptine may increase the plasma concentrations of <e20> fluvoxamine </e20>, resulting in increased drug clearance.
mechanism	Multivalent Cation-Containing Products: Increased plasma levels of oral <e10> fluvoxamine </e10> may result when <e22> multivalent_compounds </e22> such as propranolol, disopyramide, furosemide, succinylcholine or lithium are co-administered.
mechanism	Multivalent Cation-Containing Products: Studies in rats and monkeys indicate that <e11> PROLEUKIN </e11> can interfere with the metabolism of multivalent cation-containing products such as antacids, cyclosporine, some lithium salts, thiazide_diuretics, and <e20> triazolam </e20>.
mechanism	Multivalent Cation-Containing Products: <e10> Erythromycin </e10> and similar products may inhibit the metabolism of some multivalent cations, such as lithium, <e20> magnesium </e20>, calcium, and magnesium sulfate.
mechanism	Multivalent Cation-Containing Products: In vitro data suggest that <e10> amphetamine </e10> and diazepam may be more effective when administered concurrently with multivalent cation-containing products such as sodium_hydroxy_valproate or <e20> triazolam </e20>.
mechanism	Multivalent Cation-Containing Products: It is not known if there are any effects of <e10> ketoconazole </e10>, dipyridamole, or phenytoin on <e20> cisapride </e20> plasma concentrations.
mechanism	Multivalent Cation-Containing Products: As with other drugs containing cationic <e12> steroids </e12>, it is possible that <e20> erythromycin </e20>, used concurrently with such multivalent cation-containing products, may cause elevations in serum electrolytes.
mechanism	Multivalent Cation-Containing Products: Cation-containing preparations (eg, tetracycline, sodium_thiosulfate, <e10> sucralfate </e10>, sucralfate hydrochloride ) are likely to decrease the efficacy of <e22> corticosteroids </e22>.
mechanism	Multivalent Cation-Containing Products: Caffeine-containing and multivalent cation-containing products (e,g,, <e10> caffeine </e10> and acitretin ) may increase the bioavailability of <e20> alfentanil </e20>.
mechanism	Multivalent Cation-Containing Products: The presence of <e11> COREG </e11> with multivalent cation-containing products such as amiodarone, <e20> carbamazepine </e20>, clarithromycin, dapsone, indomethacin, phenytoin, theophylline, thiazide_diuretics, and vitamin_C may prolong the half-life of the plasma renin-angiotensin system.
mechanism	Multivalent Cation-Containing Products: Combinations of <e10> quinidine </e10> and <e20> fluvastatin </e20> may increase the clearance of fluvastatin by about 10%.
mechanism	Multivalent Cation-Containing Products: Multivalent cation-containing (eg, phenytoin, <e10> probenecid </e10> ) and possibly most other nonsteroidal_anti-inflammatory_drugs (eg, rifampin, theophylline, fluoxetine, phenobarbital, astemizole, and cimetidine ) may reduce the bioavailability of <e20> furosemide </e20> and therefore, the recommended daily dose of furosemide should be increased by approximately 25%.
mechanism	Phenytoin : Altered metabolic activity of <e11> aspirin </e11> has been reported with concomitant use of <e20> phenytoin </e20> and diuretics, the use of which is not generally recommended because of the potential for decreased renal excretion.
mechanism	Phenytoin : Altered metabolism of <e11> PRECEDEX </e11> by <e20> phenytoin </e20> or phenobarbital, known inhibitors of CYP3A4, may result in increased plasma concentrations of PRECEDEX and increase the toxicity of PRECEDEX.
mechanism	Phenytoin : Altered gastrointestinal absorption resulting in <e10> phenytoin </e10> toxicity has been reported following coadministration with the following medications: amiodarone, <e20> nifedipine </e20>, sertraline, diltiazem, triazolam, primidone, quinidine, bromocriptine, cimetidine, lithium, fluoxetine, alprazolam, valdecoxib, omeprazole, bromocriptine, phenobarbital, valdecoxib, and terfenadine.
mechanism	Probenecid : <e10> Probenecid </e10> significantly reduces the plasma levels of <e20> digoxin </e20> by approximately 40% (p = 0.01).
mechanism	Probenecid : <e10> Probenecid </e10> (50 mg orally, # times daily, for # days) decreased the Cmax of <e20> zidovudine </e20> by 25% and the AUC of zidovudine by 22% when administered with an active metabolite of zidovudine (16 mg/kg intravenously, # times daily, for # days).
mechanism	Probenecid : <e10> Probenecid </e10> reduced the plasma concentration of <e20> cimetidine </e20> by approximately 50% when administered at # mg/kg/day, but did not alter the plasma concentration of other cimetidine, fluvastatin, or simvastatin s.
mechanism	Probenecid : <e10> Probenecid </e10> is known to decrease the plasma concentrations of <e20> erythromycin </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> inhibits the metabolism of <e20> rifampin </e20>, resulting in a reduced half-life and increased AUC values.
mechanism	Probenecid : <e10> Probenecid </e10> may inhibit <e20> phenytoin </e20> absorption, leading to increased serum levels of phenytoin.
mechanism	Theophylline : As a consequence of the high hepatic metabolism of theophylline, the clinical relevance of <e10> theophylline </e10> for <e20> verapamil </e20> toxicity has been reduced.
mechanism	Theophylline : As with other anticoagulants, <e10> theophylline </e10> may decrease the effectiveness of <e20> warfarin </e20>, coumarin, and some other anticoagulants.
mechanism	Antibiotics : Ingestion of <e10> cefuroxime </e10> (10 mg) for # hours prior to the dosing interval of a single dose of <e20> zalcitabine </e20> resulted in a dose increase in zalcitabine by approximately 25%.
mechanism	Antibiotics : In patients receiving intravenous <e10> clindamycin </e10>, which inhibit the hepatic metabolism of <e20> rifampin </e20>, a small increase in the elimination of rifampin was observed.
mechanism	Antibiotics : In vitro studies have shown that the duration of effect of <e10> rifampin </e10>, a <e22> macrolide_antibiotic </e22>, is decreased by # to # hours when # mg of the macrolide_antibiotic is given with concomitant administration of an ethyl_alcoholic_bromide-containing mouthwash and a low dose of a diuretic.
mechanism	Antidepressants : In addition to blocking the hepatic metabolism of <e10> fluoxetine </e10>, the use of <e20> lithium </e20> (50 mg/day for # days) or quinidine (50 mg/day for # days) increases the half-life of the Cmax of fluoxetine by a factor of #.
mechanism	Antidepressants : In vitro data indicate that <e10> cimetidine </e10> inhibits the metabolism of antidepressants, and there is some concern that it may inhibit the metabolism of <e20> lithium </e20>.
mechanism	Antidepressants : In a study of healthy volunteers given <e10> fluvoxamine </e10> # mg and <e20> escitalopram </e20> # mg, fluvoxamine caused an increase in serum levels of escitalopram, a metabolite of the selective serotonin reuptake inhibitor.
mechanism	Antifungals : In a single dose of # mg <e10> chloroquine </e10> # hours before administration of # mg of <e20> nalidixic_acid </e20>, the half-life of chloroquine was reduced by 50%.
mechanism	Antifungals : In a study in rats, <e10> ketoconazole </e10> reduced the duration of action of <e20> fluconazole </e20> by approximately 25%.
mechanism	Antifungals : In patients who are taking <e12> antifungals </e12> and concomitantly taking <e20> cisapride </e20>, the antifungal effect of cisapride may be reduced by more than 50%.
mechanism	Human pharmacokinetic data suggest that <e10> warfarin </e10> administered concomitantly with <e20> phenytoin </e20> may decrease plasma concentrations of the latter by an unknown mechanism.
mechanism	Human pharmacokinetic data from <e10> ketoconazole </e10> and <e20> probenecid </e20> suggest that coadministration of ketoconazole may result in prolongation of the QT interval on the ECG and an increase in serum concentrations of probenecid.
mechanism	The gastrointestinal absorption of <e10> gentamicin </e10> is enhanced by concomitant administration of <e20> diflunisal </e20>, and its absorption is shortened.
mechanism	The gastrointestinal absorption of <e10> colestipol </e10> was significantly enhanced by <e20> digoxin </e20> and a selective serotonin reuptake inhibitor ( SSRI), fluoxetine, and by an MAOI ( alprazolam ).
mechanism	The gastrointestinal absorption of <e11> Starlix </e11> is enhanced by <e20> sucralfate </e20> and probenecid, but not by furosemide, metoclopramide, sulfasalazine, sulphonylureas, or digoxin.
mechanism	The gastrointestinal absorption of <e11> IRESSA </e11> was reduced by approximately 50% when coadministered with <e20> warfarin </e20>.
mechanism	The gastrointestinal absorption of <e10> digoxin </e10> is reduced by approximately 50% when it is coadministered with <e20> acitretin </e20>.
mechanism	Protease_Inhibitors : In vitro, <e10> rifampin </e10> decreased the bioavailability of <e20> doxapram </e20>, midazolam, and propoxyphene.
mechanism	Protease_Inhibitors : In some patients, the administration of <e11> Kineret </e11> # mg daily for # days followed by a #-day interval of # days of <e20> rifampin </e20> resulted in a significant (p=0.02) increase in Cmax and AUC of rifampin.
mechanism	Protease_Inhibitors : In studies in normal volunteers, <e10> warfarin </e10> decreased the clearance of <e20> fluvoxamine </e20> by about 50%.
mechanism	<e11> Atromid-S </e11> and <e20> cyclosporine_HCl </e20> cause CYP3A4 inhibition by about 25% and 20%, respectively.
mechanism	<e11> Atromid-S </e11> increases plasma levels of <e20> digoxin </e20> and atromid-S increases the clearance of digoxin from the circulation.
mechanism	The plasma concentration of <e10> phenytoin </e10> was increased after coadministration with <e20> rifampin </e20>.
mechanism	The plasma concentration of <e10> ketoconazole </e10> was increased by approximately 38% when it was administered with <e20> rifabutin </e20>.
mechanism	The plasma concentration of <e10> verapamil </e10> may increase by as much as 40% when <e20> phenytoin </e20> is coadministered.
mechanism	plasma levels of <e10> amprenavir </e10> were decreased approximately 15% when <e20> atazanavir </e20> was added.
mechanism	plasma levels of theophylline, <e10> methotrexate </e10>, and <e20> adriamycin </e20> were increased by caspofungin, and the levels of theophylline were increased by caspofungin.
mechanism	plasma levels of <e10> phenytoin </e10> increased during concomitant administration of <e20> cimetidine </e20>, because cimetidine increases its metabolism by CYP3A4, resulting in a greater amount of phenytoin in plasma.
mechanism	plasma levels of <e10> digoxin </e10> and <e20> carbamazepine </e20> are increased when digoxin is coadministered with carbamazepine.
mechanism	plasma levels of <e10> diazepam </e10> are reduced by the following: <e20> haloperidol </e20> ; concurrent use of haloperidol with oral contraceptives, certain antibiotics, phenytoin, tricyclic_antidepressants, barbiturates, barbiturates, lithium, and barbiturates and barbiturates administered concomitantly with haloperidol ; concomitant use of haloperidol with certain anticonvulsants, certain anticonvulsants administered orally, barbiturates, barbiturates administered concomitantly with barbiturates, barbiturates administered with lithium, and barbiturates administered with lithium administered concomitantly with barbiturates.
mechanism	plasma levels of <e10> norethindrone </e10> increased by 38% when <e20> almotriptan </e20> was coadministered at doses of # mg and # mg (mean +/- s.e., increase, # mg = 20%; and increase, # mg = 22%), and that of almotriptan decreased by 18% when it was coadministered at doses of # mg and # mg (mean +/- s.e., decrease, # mg = 19%; and decrease, # mg = 24%).
mechanism	plasma levels of <e10> rifampin </e10> and its metabolism are decreased by coadministration of <e20> diltiazem </e20>.
mechanism	Administration of <e10> nelfinavir </e10> may reduce the clearance of <e20> warfarin </e20> and decrease its anticoagulation effect.
mechanism	Administration of <e10> rifampin </e10> to patients who are receiving <e20> warfarin </e20> may cause increases in plasma warfarin concentrations.
mechanism	Administration of <e10> methotrexate </e10> with a single dose of <e20> ketoconazole </e20> reduced the oral exposure of methotrexate by up to 50%.
mechanism	<e10> Fluvoxamine </e10> inhibited the binding of <e20> almotriptan </e20> and almotriptan to the hepatic metabolite of almotriptan.
mechanism	<e10> Fluvoxamine </e10> increases <e20> bromocriptine_mesylate </e20> AUC by 17% and Cmax by 14%.
mechanism	In a study in healthy volunteers, the AUC of <e10> fluvoxamine </e10> and <e20> terfenadine </e20> increased at # hours after coadministration of # mg of terfenadine and # mg of a single dose of fluvoxamine.
mechanism	In a study in healthy volunteers, the addition of <e10> warfarin </e10> to # mg <e20> ketoconazole </e20> decreased the clearance of furosemide by approximately 50% and the mean half-life of furosemide by approximately 20%.
mechanism	In a study of healthy volunteers, the oral bioavailability of <e10> diltiazem </e10> was reduced by 47% when coadministered with the # mg dose of <e20> ketoconazole </e20>, but not when administered with the # mg dose of a single dose of diltiazem.
mechanism	In a study in healthy subjects, the concomitant administration of <e10> celecoxib </e10> with <e20> aripiprazole </e20> resulted in an increase in AUC and Cmax of aripiprazole by 40% and 75%, respectively, and an increase in AUC and Cmax by 23% and 27%, respectively, compared to aripiprazole alone.
mechanism	In a study in healthy volunteers, <e10> probenecid </e10> # mg once daily significantly decreased the exposure to <e20> furosemide </e20> (Furosemide ), the active metabolite of furosemide, by approximately 50%.
mechanism	Cytochrome P-450 inducers, such as <e10> fluconazole </e10>, astemizole, ketoconazole, cisapride, itraconazole, phenytoin, rifampin, saquinavir, <e20> valproate </e20>, theophylline, and grapefruit juice may enhance plasma concentrations of atorvastatin.
mechanism	Cytochrome P-450 inducers, including <e10> ketoconazole </e10>, clofibrate, and <e20> rifampin </e20>, all increase plasma concentrations of digoxin by about 20%.
mechanism	Cytochrome P-450 inducers, <e10> indinavir </e10>, and indinavir may prolong the half-life of <e20> atazanavir </e20> and increase the risk of gastrointestinal toxicity.
mechanism	Cytochrome P-450 inducers, such as cyclosporine, tacrolimus, carbamazepine, phenytoin, <e10> rifampin </e10>, and others, increase the clearance of <e20> cisapride </e20>.
mechanism	<e10> Phenytoin </e10> (chloroquine ) increased plasma concentrations of <e20> ketoconazole </e20> by approximately 50% and the clearance of ketoconazole was increased by approximately 50%.
mechanism	<e10> Phenytoin </e10>, levodopa, and carbamazepine may decrease the clearance of <e20> triamterene </e20> and increase the elimination half-life.
mechanism	<e10> Phenytoin </e10>, a metabolite of <e20> fluvoxamine </e20>, and certain oral contraceptives, have been reported to reduce the bioavailability of carbamazepine, phenobarbital, and acesulfame_K.
mechanism	Phenytoin, <e10> carbamazepine </e10>, fluconazole, <e20> lovastatin </e20>, and tolbutamide may inhibit CYP3A4 and thereby increase plasma concentrations of ketoconazole and may therefore decrease the efficacy of oral ketoconazole and concomitant cimetidine, phenytoin, and cisapride.
mechanism	Phenytoin, <e10> carbamazepine </e10>, clofibrate, and valproate inhibit the metabolism of <e20> levothyroxine </e20>, resulting in a net increase in its bioavailability.
mechanism	Phenytoin, <e10> carbamazepine </e10>, phenobarbital, phenytoin_hydrochloride, and rifampin may decrease the bioavailability of <e20> valdecoxib </e20>.
mechanism	<e10> Cimetidine </e10> and <e20> fluvoxamine </e20> may antagonize the metabolism of paroxetine and other antidepressants.
mechanism	<e10> Cimetidine </e10> -induced renal dysfunction was reversible upon discontinuation of <e20> Cimetidine </e20> and administration of digoxin or its analogues, but not upon administration of other non-steroidal_anti-inflammatory_drugs, ketoconazole, or macrolide_antibiotics.
mechanism	<e10> Cimetidine </e10> : The <e20> cimetidine </e20> plasma levels are reduced by approximately 10% when administered concomitantly with the high-dose cimetidine # mg/day.
mechanism	Cimetidine, <e10> caffeine </e10>, and cholestyramine may increase the metabolism of <e20> digoxin </e20>.
mechanism	Cimetidine, <e10> caffeine </e10>, and theophylline have been reported to increase serum <e20> digoxin </e20> levels and may increase the risk of digoxin toxicity.
mechanism	Cimetidine, <e10> caffeine </e10>, and aspirin inhibit CYP2C9 activity, resulting in decreased <e20> erythromycin </e20> clearance.
mechanism	Cimetidine, caffeine, and <e10> alcohol </e10> inhibit <e20> digoxin </e20> absorption, but alcohol appears to increase oral absorption.
mechanism	Although concomitant use of <e10> erythromycin </e10> and <e20> tetracycline </e20> may result in a significant decrease in erythromycin exposure, it may be necessary to increase the dosage of the latter drug to achieve similar efficacy.
mechanism	Although concomitant use of <e10> furosemide </e10> with the anticonvulsant <e20> phenytoin </e20> has been reported, there have been no reports of phenytoin -related toxicity in concomitant therapy with furosemide.
mechanism	Although concomitant use of <e10> flurbiprofen </e10> and <e20> methotrexate </e20> was associated with increased serum concentrations of methotrexate, methotrexate exposure was still sufficient to decrease hepatic enzyme levels of the drugs in healthy subjects.
mechanism	<e10> Paroxetine </e10> and its derivatives may decrease the clearance of cyclosporine, <e20> doxycycline </e20>, ampicillin, gentamicin, and digoxin.
mechanism	<e10> Paroxetine </e10> decreased the AUC of <e20> cyclosporine </e20> by 50% and the Cmax of cyclosporine by 50%.
mechanism	<e10> Paroxetine </e10> and <e20> escitalopram </e20> (20 mg qd) decrease the rate of arterial deterioration in patients receiving theophylline (20 mg qd) by ~40%.
mechanism	However, other published reports have shown that coadministration of <e10> dapsone </e10> with <e20> fluconazole </e20> resulted in increased fluconazole concentrations.
mechanism	However, other published data suggest that <e10> dexamethasone </e10> may also inhibit the metabolism of <e20> warfarin </e20> and its derivatives, increasing the half-life and decreasing the half-life of warfarin.
mechanism	However, other published reports have shown that concomitant administration of <e10> atorvastatin </e10> and <e20> nicotinamide_P </e20> markedly reduced the concentration of atorvastatin and nicotinamide_P in rats.
mechanism	However, other published studies suggest that <e10> ketoconazole </e10> can decrease the absorption of <e20> erythromycin </e20>.
mechanism	However, other published data suggest that <e10> enoxacin </e10> could inhibit <e20> dicumarol </e20> absorption resulting in increased dicumarol concentrations.
mechanism	However, other published studies have reported that <e10> doxycycline </e10> (but not doxycycline or other <e22> steroidal_anti-inflammatory_agents </e22> ) significantly potentiates the hypotensive effects of calcium_channel_blockers, calcium_channel_blockers, and ACE_inhibitors.
mechanism	However, other published reports have shown that <e10> amiodarone </e10> has a weak tendency to increase <e20> phenytoin </e20> AUC and Cmax and increase half-life on the basis of # micrograms of amiodarone /kg of body weight in rats.
mechanism	However, other published data indicate that <e10> diflunisal </e10> and <e20> methotrexate </e20> inhibit the metabolism of diflunisal by affecting both the protein and/or lipid levels of diflunisal.
mechanism	<e10> Colchicine </e10> has been reported to reduce the metabolism of <e20> ethinyl_estradiol </e20> and may decrease the plasma levels of ethinyl_estradiol.
mechanism	<e10> Colchicine </e10> may reduce the clearance of corticosteroids, and therefore, the pharmacologic effect of <e20> acitretin </e20>.
mechanism	<e10> Colchicine </e10> and acetylcholine_mesylate increase the serum level of colchicine and decrease the serum level of <e20> colchicine </e20>.
mechanism	The action of <e10> ketoconazole </e10> was impaired by <e20> cisapride </e20> and similar agents.
mechanism	The action of <e10> warfarin </e10> and its derivatives may be increased by administration of <e20> bromocriptine_mesylate </e20>.
mechanism	<e11> WelChol </e11> inhibits the metabolism of <e20> caffeine </e20> by the enzyme CYP2B6, leading to elevated levels of caffeine and theophylline in the urine.
mechanism	<e11> WelChol </e11> decreased the CYP3A4 activity of <e20> nalidixic_acid </e20> and increased the activity of alfentanil.
mechanism	<e11> WelChol </e11> increased plasma concentrations of <e20> astemizole </e20> and inhibited the metabolism of both drugs.
mechanism	<e11> WelChol </e11> injection may cause increases in <e20> ethinyl_estradiol </e20> levels.
mechanism	<e11> WelChol </e11> or <e20> dofetilide </e20> may increase the clearance of dofetilide.
mechanism	<e11> WelChol </e11> causes a decrease in the plasma levels of warfarin, phenytoin, carbamazepine, <e20> phenobarbital </e20>, phenytoin and primidone.
mechanism	Repeated doses of <e11> ENBREL </e11> # times in # days produced a 50% increase in the steady-state plasma concentration of <e20> valdecoxib </e20> and an increase in steady-state Cmax of # mg/day.
mechanism	Repeated doses of <e10> cisapride </e10> may potentiate <e20> phenytoin </e20> -induced hypotension.
mechanism	Repeated doses of <e10> cisapride </e10> at doses of # mg/day (5/day) significantly increased the level of <e20> digoxin </e20> in the urine by an average of 3.8-fold and of methotrexate by a 2.3-fold.
mechanism	The absorption of <e10> colestipol </e10> may be impaired when the <e20> phenytoin </e20> is administered concomitantly.
mechanism	The absorption of <e10> valdecoxib </e10> is enhanced by simultaneous administration of <e20> erythromycin </e20>, clarithromycin, rifampin, bromocriptine, carbamazepine, fluconazole, itraconazole, nefazodone, rifabutin, theophylline, troleandomycin, and atorvastatin.
mechanism	The absorption of <e10> alprazolam </e10> may be enhanced by certain drugs including certain narcotic_analgesics ( <e20> amiodarone </e20>, midazolam ), sulfonamides ( dipyridamole, itraconazole ), chloramphenicol ( didanosine ), disopyramide ( disopyramide ), and other agents that are highly protein bound.
mechanism	The absorption of <e10> cholestyramine </e10> is enhanced by <e20> cimetidine </e20> and similar drugs.
mechanism	The absorption of <e10> doxapram </e10> is reduced by <e20> hydralazine </e20> and by lithium.
mechanism	The absorption of <e10> ergotamine </e10> and <e20> diazepam </e20> is impaired by inhibition of CYP3A4, resulting in decreased serum concentrations.
mechanism	The absorption of <e10> warfarin </e10> decreased approximately 75% when it was given with <e20> atorvastatin </e20> and the following increased when it was given with either drug alone: cholestyramine (3% increase), fluvastatin (6% increase), valdecoxib (10% increase), rifampin (1% increase), and rifabutin (2% increase).
mechanism	The absorption of <e10> clofibrate </e10> from gastric mucosa was about 80% during oral administration with 50 mg <e20> clofibrate </e20> once daily for 5 days, which is much higher than that of gastric mucosa alone.
mechanism	The absorption of <e10> digoxin </e10> was increased by approximately 11% when coadministered with <e20> cyclosporine </e20> (approximately -10% for cyclosporine alone).
mechanism	The absorption of <e10> gentamicin </e10> from <e20> diflunisal </e20> was significantly decreased when administered at a dose of # mg/kg/day for # days after coadministration of diflunisal with high doses of gentamicin (250 and 600 mg/kg/day for # days).
mechanism	The absorption of <e10> rifampin </e10> is reduced by as much as 25% when a high dose of <e20> cisapride </e20> is administered concomitantly.
mechanism	Particular caution should be exercised if <e10> nevirapine </e10> is administered concomitantly with <e20> halothane </e20>, due to the potential for rapid cardiac toxicity.
mechanism	Particular caution should be observed with <e10> gentamicin </e10> and <e20> oxacillin </e20> since concomitant administration with high-dose gentamicin resulted in decreased serum levels of gentamicin.
mechanism	Particular caution should be observed when <e10> ketoconazole </e10> is administered with <e20> digoxin </e20> since the metabolism of digoxin may be changed by the concomitant use of ketoconazole.
mechanism	Particular caution should be observed when administering <e10> nevirapine </e10> and <e20> ketoconazole </e20> to patients with renal insufficiency or on chronic renal dialysis.
mechanism	Particular caution should be exercised since the extent to which <e10> cimetidine </e10> may reduce blood <e20> methotrexate </e20> concentrations has been demonstrated with other drugs, including quinidine.
mechanism	Digoxin : Coadministration of <e11> ZYVOX </e11> with <e20> digoxin </e20> resulted in an increase in serum digoxin levels of approximately 5-fold.
mechanism	Digoxin : Coadministration of <e10> ciprofloxacin </e10> with <e20> digoxin </e20> reduced the peak and steady-state concentrations of digoxin by 29% and 30%, respectively.
mechanism	Digoxin : Coadministration of <e10> digoxin </e10> at # mg/kg with <e20> Aprepitant </e20> produced a 24% increase in average AUC of digoxin and an increase in mean AUC of digoxin from # to # hours post-dose.
mechanism	Therefore, if <e10> cisapride </e10> is to be administered concurrently with any CNS_depressant, careful consideration should be given to the pharmacokinetics of <e20> cisapride </e20> since both the extent and duration of cisapride plasma concentrations may be enhanced.
mechanism	Therefore, if <e10> diazepam </e10> is co-administered with an <e22> anticholinergic </e22>, the anticholinergic effect of diazepam may be diminished.
mechanism	Therefore, if <e10> propranolol </e10> is to be given to patients on <e20> diltiazem </e20> therapy, dosage adjustments may be necessary.
mechanism	Drugs that induce hepatic enzymes such as <e10> phenytoin </e10>, phenobarbital, and rifampin may decrease <e20> lomefloxacin </e20> elimination.
mechanism	Drugs that induce hepatic enzyme reactions such as <e10> phenytoin </e10>, carbamazepine, rifampin, phenobarbital, tacrolimus, and dasatinib may decrease plasma <e20> lovastatin </e20> levels.
mechanism	Drugs that induce hepatic metabolism of <e11> INDOCIN </e11> ( such as phenytoin, carbamazepine, phenobarbital, phenytoin_hydrochloride, alfentanil, disopyramide, and <e20> terfenadine </e20> ) may increase the plasma levels of INDOCIN.
mechanism	Drugs that induce hepatic enzymes such as phenobarbital, <e10> phenytoin </e10>, or carbamazepine may increase plasma levels of <e20> digoxin </e20>.
mechanism	Drugs that induce hepatic enzymes such as <e10> phenobarbital </e10> and phenytoin may increase the clearance of <e20> acitretin </e20> and thereby result in higher plasma concentrations.
mechanism	Drugs that induce hepatic enzymes such as phenytoin, <e10> carbamazepine </e10>, phenobarbital, phenytoin_sodium, and carbamazepine may decrease the clearance of <e20> erythromycin </e20>, resulting in increased serum levels.
mechanism	Drugs that induce hepatic enzymes such as <e10> phenobarbital </e10>, phenytoin, or carbamazepine may increase the clearance of <e20> cisapride </e20>.
mechanism	Drugs that induce hepatic metabolism of <e10> tetracycline </e10> may decrease the clearance of <e20> zidovudine </e20>.
mechanism	Drugs that induce CYP3A4 activity (eg, phenobarbital, diazepam, <e10> phenytoin </e10>, clarithromycin, disopyramide, <e20> fluconazole </e20>, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin ) may decrease plasma concentrations of warfarin and therefore require an increase in the dose of warfarin to achieve therapeutic levels.
mechanism	Drugs such as nonsteroidal_anti-inflammatory_drugs ( <e12> NSAIDs </e12> ), salicylates, sulfonamides, chloramphenicol, monoamine_oxidase_inhibitors, and tricyclic_antidepressants may interfere with absorption of <e20> lisinopril </e20>.
mechanism	Drugs such as intravenous pentamidine, thiazide_diuretics, warfarin, corticosteroids, thyroid_products, and barbiturates may interfere with <e10> digoxin </e10> clearance and may therefore increase <e20> digoxin </e20> plasma levels.
mechanism	Drugs such as thiazide_diuretics, corticosteroids, coumarin derivatives, and metoclopramide may increase the plasma levels of <e10> cyclosporine </e10> and may therefore be expected to prolong the half-life of <e20> cyclosporine </e20>.
mechanism	<e10> Colchicine </e10>, bacitracin, and glutathione may interact with <e20> acetaminophen </e20>, chloramphenicol, dapsone, hexobarbital, methotrexate, and/or phenytoin.
mechanism	<e10> Colchicine </e10> may reduce the metabolism of <e20> zidovudine </e20> and interfere with the binding of zidovudine to its receptor, thus inhibiting its metabolism.
mechanism	<e10> Colchicine </e10> may interfere with the absorption of <e20> ciprofloxacin </e20>, resulting in lower serum levels.
mechanism	Colchicine para-aminosalicylic_acid and <e10> chloramphenicol </e10> tablets may interfere with absorption of <e20> zidovudine </e20>.
mechanism	Colchicine para-aminosalicylic_acid and <e10> dacarbazine </e10> inhibit the hepatic metabolism of <e20> digoxin </e20>.
mechanism	Concomitant use of <e10> carbamazepine </e10> and <e20> terfenadine </e20> increases carbamazepine plasma levels.
mechanism	Concomitant use of <e10> diltiazem </e10> with <e20> methotrexate </e20> significantly increased methotrexate plasma levels.
mechanism	Concomitant use of <e10> cimetidine </e10> with <e20> furosemide </e20> and lithium, may increase furosemide serum concentrations.
mechanism	Concomitant use of <e11> INSPRA </e11> and <e20> digoxin </e20> in the same patient increases the risk of gastrointestinal toxicity.
mechanism	Concomitant use of <e10> amiodarone </e10> and <e20> zidovudine </e20> may increase the half-life of zidovudine.
mechanism	Concomitant use of <e10> tetracycline </e10> with <e20> neomycin </e20>, erythromycin, and an intravenous ampicillin may result in a significant decrease in serum tetracycline levels.
mechanism	Concomitant use of <e10> ethoxzolamide </e10> or metoclopramide may result in increased concentrations of <e20> norethindrone </e20>, an active metabolite of ethoxzolamide.
mechanism	Concomitant use of <e10> ketoconazole </e10> with <e20> ketoconazole </e20> for the treatment of hypoglycemia may lead to an increase in the level of this agent in the systemic circulation.
mechanism	Concomitant use of <e11> HUMORSOL </e11> and <e20> atracurium </e20> significantly increased the rate of withdrawal from HUMORSOL.
mechanism	Concomitant use of <e10> gabapentin </e10> may increase the metabolism of <e20> phenytoin </e20> and other anticonvulsants, resulting in reduced plasma concentrations of these drugs.
mechanism	Concomitant use of <e10> rifampin </e10>, clarithromycin, <e20> dapsone </e20>, bromocriptine, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin ( TAO ), and astemizole may increase the clearance of rifampin, clarithromycin, dapsone, bromocriptine, indinavir, itraconazole, nelfinavir, ritonavir, saquinavir, telithromycin, and astemizole.
mechanism	Concomitant use of <e10> carbamazepine </e10> tablets with either <e20> lithium </e20> or cyclosporine A has been shown to decrease lithium uptake.
mechanism	Concomitant use of <e10> chloroquine </e10> with <e20> erythromycin </e20>, clarithromycin, and protease_inhibitors, and macrolide_antibiotics, can reduce the efficacy of the macrolide_antibiotics and increase the risk of serious infections.
mechanism	Concomitant use of <e10> clofibrate </e10> and <e20> warfarin </e20> is likely to increase the effect of warfarin.
mechanism	Concomitant use of <e10> lisinopril </e10> ( 5 mg q24h for # weeks) with a <e20> diltiazem </e20> dosage of # mg q24h resulted in a 32% increase in lisinopril plasma concentrations.
mechanism	Concomitant use of <e10> ketoconazole </e10> with <e20> ketoconazole </e20>, an inhibitor of CYP2D6 activity, resulted in increased plasma concentrations of ketoconazole and a decrease in metabolism of ketoconazole.
mechanism	Concomitant use of <e11> INDOCIN </e11> and drugs known to increase hepatic metabolism (eg, <e20> carbamazepine </e20>, cyclosporine, tacrolimus, phenytoin, hexobarbital, phenytoin, phenobarbital, phenytoin_hydrochloride, phenytoin_hydrochloride, triazolam ) have resulted in increased INDOCIN exposure.
mechanism	Concomitant use of <e10> diltiazem </e10> and <e20> rifampin </e20> results in a 40% increase in rifampin plasma levels, with a concomitant increase in AUC of 18% for rifampin.
mechanism	Concomitant use of <e10> warfarin </e10> with <e20> ketoconazole </e20>, cimetidine, amiodarone, lithium, pyrimethamine, or valproate may have resulted in an increase in AUC and Cmax.
mechanism	Concomitant use of <e10> cholestyramine </e10> with <e20> carbamazepine </e20> has been reported to increase carbamazepine exposure.
mechanism	Concomitant use of <e10> cimetidine </e10> and <e20> terfenadine </e20> resulted in an increase in the exposure of both drugs, which may increase the potential for toxicity.
mechanism	Concomitant use of <e10> rifabutin </e10> with <e20> ketoconazole </e20> (e,g,, # mg daily) resulted in an increase in the mean AUC for rifabutin by approximately 50% and a decrease in its Cmax by approximately 50%.
mechanism	Concomitant use of <e10> cimetidine </e10> with other oral anticoagulants, including <e20> warfarin </e20>, phenytoin, carbamazepine, and warfarin_sodium, increases the exposure to warfarin (and other oral anticoagulants ) and increases the likelihood of anti-warfarin drug interactions.
mechanism	Concomitant use of <e11> ABILIFY </e11> and anticonvulsants ( carbamazepine, felbamate, phenobarbital, phenytoin, primidone, tacrolimus, <e20> triazolam </e20>, zidovudine, disulfiram ) increased ABILIFY exposure by a mean of 38% for carbamazepine, 13% for felbamate, and 25% for phenobarbital.
mechanism	Concomitant use of <e11> PRECEDEX </e11> and anticonvulsants, carbamazepine, phenobarbital, phenytoin, tacrolimus, or other agents with anticonvulsant activity may increase plasma concentrations of <e20> phenobarbital </e20> and may decrease the plasma concentration of phenytoin.
mechanism	Concomitant use of <e10> warfarin </e10> with <e20> fluvoxamine </e20> may cause an increase in the plasma levels of fluvoxamine.
mechanism	Concomitant use of <e11> ALFENTA </e11> with strong CYP3A4 inhibitors such as ketoconazole, itraconazole, erythromycin, clarithromycin, indinavir, ritonavir, saquinavir, <e20> troleandomycin </e20>, and troleandomycin + clarithromycin results in a 7% increase in AUC for ALFENTA and a 4% decrease in AUC for COREG.
mechanism	Concurrent administration of <e10> carbamazepine </e10> with <e20> bromocriptine_mesylate </e20> has been reported to increase carbamazepine serum levels.
mechanism	Concurrent administration of <e10> dexamethasone </e10> with <e20> ciprofloxacin </e20> may result in increased ciprofloxacin clearance.
mechanism	Concurrent administration of <e10> cyclosporine </e10> with <e20> diltiazem </e20> produced a net decrease in diltiazem Cmax and AUC.
mechanism	Conversely, decreases in V(max) were observed in <e10> digoxin </e10> -treated dogs that received <e20> ketoconazole </e20>.
mechanism	Conversely, decreases in plasma <e10> erythromycin </e10> concentrations may be anticipated when <e20> cimetidine </e20> is administered concomitantly.
mechanism	Conversely, decreases in plasma levels of <e10> ketoconazole </e10> were observed in patients taking <e20> ketoconazole </e20> concurrently with cimetidine.
mechanism	There have been reports of decreased plasma levels of <e10> diazepam </e10> following concomitant administration of <e20> ketoconazole </e20> with high levels of plasma diazepam.
mechanism	There have been reports of concomitant administration of <e10> cisapride </e10> with other medications that alter cardiac conduction (e,g,, anticoagulants, corticosteroids, thiazide_diuretics, thyroid_products, <e22> calcium_channel_blockers </e22>, thiazide_preparations, amiodarone, phenytoin, clofibrate, procainamide, triamterene, lovastatin, cimetidine, furosemide ).
mechanism	There have been reports of increased plasma levels of <e10> ketoconazole </e10> and <e20> rifabutin </e20> following concomitant administration of ciprofloxacin and quinolone_antibiotics, and this may have resulted in prolongation of the rifabutin half-life and increased prothrombin time.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> has been reported to reduce the metabolism of some <e22> thyroid_products </e22> (e,g,, triiodothyronine, thyroid_products and thyroxine ).
mechanism	Cholestyramine : <e10> Cholestyramine </e10>, and in particular <e20> loratadine </e20>, may inhibit hepatic enzyme systems, including cytochrome P-450 2E1 (CYP2E1) and isoenzyme_5 of the hydroxyl radical, resulting in decreased clearance of triazolam, midazolam, and other anticonvulsants.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> is a competitive inhibitor of CYP3A4, which may have an effect on plasma <e20> aripiprazole </e20> levels.
mechanism	Ephedrine : <e10> Erythromycin </e10> can decrease the clearance of <e20> ephedrine </e20>.
mechanism	Ephedrine : <e10> Ephedrine </e10> may increase <e20> cimetidine </e20> absorption and therefore may increase the risk of renal impairment when administered concomitantly.
mechanism	Ephedrine : <e10> Ephedrine </e10> increases the clearance of <e20> cimetidine </e20>.
mechanism	Estrogens, including oral contraceptives, may decrease the metabolism of <e10> terfenadine </e10> by increasing the hepatic level of <e20> phenytoin </e20>.
mechanism	Hepatic Enzyme Inducers, such as cytochrome P-4503A4, and ketoconazole are inhibitors of CYP3A4 activity and therefore, the use of <e10> ketoconazole </e10> may result in decreased concentrations of <e20> coumarin </e20>.
mechanism	Hepatic Enzyme Inducers, such as alfentanil, <e10> cisapride </e10>, and quinidine have been reported to reduce plasma levels of <e20> diltiazem </e20> and increase its half-life by at least 50%.
mechanism	Hepatic Enzyme Inducers, Concomitant Use of Co-administered Drugs, and Drug Interactions: Other hepatotoxicants (eg, <e10> amiodarone </e10>, succinylcholine, succinimide, cisapride, clofibrate, cyclosporine, diltiazem, doxorubicin, estrogens, furosemide, itraconazole, ketoconazole, lomefloxacin, lovastatin, rifampin, <e20> saquinavir </e20>, warfarin, zidovudine ) reduce the metabolism of lovastatin, resulting in increased concentrations and toxicity.
mechanism	Hepatic Enzyme Inducers, when coadministered with CYP3A4 inhibitors such as ketoconazole, <e10> itraconazole </e10>, or itraconazole citrate, have been reported to reduce plasma concentrations of <e20> voriconazole </e20> by approximately 50%.
mechanism	Hepatic Enzyme Inducers, such as acetaminophen, <e10> caffeine </e10>, phenobarbital, sulfonamides, and other aminoglycosides, produce significant hepatic enzyme inhibition when given concomitantly with <e20> carbamazepine </e20>.
mechanism	Hepatic Enzyme Inducers, such as acetaminophen, <e10> cimetidine </e10>, phenytoin, and <e20> valproate </e20>, decrease the clearance of diclofenac.
mechanism	Drugs which inhibit hepatic enzymes such as phenytoin, rifampin, or <e10> chloroquine </e10> may increase the clearance of <e20> amprenavir </e20>, resulting in an increase in the daily dose of amprenavir.
mechanism	Drugs which inhibit CYP3A4 (eg, ketoconazole, ritonavir, indinavir, saquinavir, <e10> atazanavir </e10>, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, telithromycin, troleandomycin, voriconazole, theophylline, and <e20> troleandomycin </e20> ) may increase plasma concentrations of dasatinib and therefore may require increases in dosage to achieve optimal plasma concentrations.
mechanism	Drugs which inhibit CYP3A4 (eg, ketoconazole, itraconazole, nefazodone, <e10> troleandomycin </e10>, clarithromycin, ritonavir, indinavir, saquinavir, saquinavir, telithromycin, troleandomycin, indinavir, saquinavir, indinavir, saquinavir, itraconazole ) may increase plasma levels of <e20> valdecoxib </e20>.
mechanism	Drugs which inhibit CYP3A4 activity (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, indinavir, <e10> nefazodone </e10>, nelfinavir, saquinavir, telithromycin, troleandomycin, troleandomycin ) increase the exposure of <e20> zalcitabine </e20> to the liver.
mechanism	Drugs which inhibit CYP3A4 (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, <e10> nelfinavir </e10>, saquinavir, indinavir, indinavir-sulfate, itraconazole ) may increase plasma levels of <e20> valdecoxib </e20>.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> has been reported to reduce the bioavailability of <e20> warfarin </e20> by decreasing the hepatic metabolism of warfarin and increasing plasma levels of the drug.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> may interfere with the metabolism of <e20> lithium </e20>.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> has been reported to cause a decrease in <e20> carbamazepine </e20> clearance.
mechanism	The clearance of <e11> ARAVA </e11> was significantly decreased by <e20> zidovudine </e20> treatment, whereas the clearance of rifampin and carbamazepine was increased.
mechanism	The clearance of <e10> enoxacin </e10> was approximately two-fold higher in the presence of <e20> cisapride </e20>.
mechanism	The clearance of <e10> fluvoxamine </e10> was reduced by approximately 17% (P <.001) after coadministration of <e20> fluvoxamine </e20> with ketoconazole.
mechanism	Phenytoin : In a study in healthy subjects, co-administration of <e10> phenytoin </e10> with <e20> clofibrate </e20> reduced the AUC of clofibrate by approximately 20%.
mechanism	Phenytoin : In a study of healthy volunteers receiving <e10> phenytoin </e10>, there was a decrease in <e20> clofibrate </e20> absorption when the carbide ion was inactivated.
mechanism	Phenytoin : In a randomized, double-blind, crossover study in healthy volunteers, <e10> phenytoin </e10> was found to reduce the plasma concentrations of <e20> isoniazid </e20> and the AUC of isoniazid in healthy volunteers by approximately 20%.
mechanism	<e10> d-amphetamine </e10> caused <e20> cyclosporine </e20> to rise from 20 to 22%, but the extent to which d-amphetamine increased cyclosporine concentration depended on the blood flow rate.
mechanism	<e10> d-amphetamine </e10> caused a decrease in the clearance of <e20> ketoconazole </e20> and increase in the AUC of d-amphetamine.
mechanism	<e10> d-amphetamine </e10> decreased the clearance of <e20> ketoconazole </e20> by about 40%.
mechanism	<e10> d-amphetamine </e10> potentiates the effect of <e20> zopiclone </e20>.
mechanism	<e10> d-amphetamine </e10> has been reported to interfere with the metabolism of <e20> lithium </e20>.
mechanism	<e10> d-amphetamine </e10> reduced plasma levels of norepinephrine by approximately 70% after administration of <e20> methylphenidate </e20> (5 mg once daily).
mechanism	<e10> d-amphetamine </e10> and <e20> fluvoxamine </e20> cause additive CNS depressant effects when given concomitantly.
mechanism	<e10> d-amphetamine </e10> may interact with the following: <e20> chlordiazepoxide </e20>, fluvoxamine, disulfiram, midazolam, phenobarbital, sertraline, triazolam, and zopiclone.
mechanism	Methenamine therapy: Urinary concentrations of <e10> methenamine </e10> were reduced by approximately 42% following administration of <e20> colestipol </e20> or the ethinyl_estradiol metabolite (cerebrospinal_fluids).
mechanism	Methenamine therapy: Urinary excretion of <e10> methenamine </e10> may increase approximately twofold following administration of a single dose of # mg/day of <e20> astemizole </e20>.
mechanism	Phenobarbital : <e12> Amphetamines </e12> enhance the hepatic metabolism of <e20> phenobarbital </e20>.
mechanism	Phenytoin : <e12> Amphetamines </e12> inhibit the metabolism of <e20> phenytoin </e20> and increase its clearance, resulting in lower serum levels and lower maximum plasma concentrations.
mechanism	Phenytoin : <e12> Amphetamines </e12> inhibit the metabolism of <e22> phenytoin </e22> by inhibiting the formation of the intermediate metabolite amphetamine.
mechanism	Phenytoin : <e12> Corticosteroids </e12> may increase <e20> phenytoin </e20> plasma levels and interfere with its absorption.
mechanism	Ingestion of <e10> furosemide </e10> has been reported to reduce the renal excretion of <e20> furosemide </e20> by approximately 70%.
mechanism	Ingestion of <e10> terfenadine </e10> or phenytoin (50 mg or # mg, respectively, twice daily for # days) reduced the clearance of <e20> nelfinavir </e20> by approximately 25% (about 2-fold) and approximately 50% (about 3-fold) and the half-life by approximately 10% (about 6-fold) and approximately 30% (about 5-fold), respectively.
mechanism	Ingestion of <e10> fluvoxamine </e10> and <e20> diazepam </e20> at doses of # mg/kg each resulted in a decrease in peak plasma levels of fluvoxamine by 34% and 38%, respectively.
mechanism	Ingestion of <e10> phenytoin </e10> (10 mg/kg, i,p,) or <e20> valproic_acid </e20> (30 mg/kg, p,o,) immediately after daily intake of a maximum of # mg of # # mg of fluconazole per day did not affect the clearance of # mg of # mg of fluconazole.
mechanism	Ingestion of <e10> chloroquine </e10> with <e20> caffeine </e20> results in a decrease in caffeine absorption.
mechanism	Ingestion of <e10> indomethacin </e10> (50 mg q6h) for # hours prior to administration of <e20> aripiprazole </e20> decreased the AUC of aripiprazole by approximately 50%.
mechanism	Lithium : <e10> Lithium </e10> increased the clearance of <e20> bromocriptine_mesylate </e20>.
mechanism	Lithium : <e10> Lithium </e10> may increase the absorption of <e20> ciprofloxacin </e20> and cause an increase in the clearance of ciprofloxacin.
mechanism	Lithium : <e10> Dexbrompheniramine </e10> may increase the clearance of lithium and may interact with lithium -containing preparations (e,g,, <e20> lithium </e20> ) to increase lithium absorption.
mechanism	Lithium : <e10> Lithium </e10>, in moderate to high concentrations, has been shown to decrease plasma levels of <e20> norethindrone </e20>, norethindrone decreased the bioavailability of both norethindrone and ethinyl_estradiol (the active metabolite of ethinyl_estradiol ), and its plasma levels were also decreased by high doses of norethindrone.
mechanism	Lithium : <e10> Lithium </e10> and <e20> ketoconazole </e20> are associated with elevated serum lithium levels, with an associated increase in lithium clearance.
mechanism	Lithium : <e10> Lithium </e10> ( <e20> lithium_chloride </e20> ) is the major active component in vitamin_C and calcium supplements and increases the hepatic metabolism of lithium.
mechanism	Protein Binding In Studies with Echistatin, <e10> rifabutin </e10> and <e20> estrogens </e20> had the following binding constants: rifabutin = 0.4 (E,K-16) (R,E,6) mg/L, estrogens = 0.5 (E,K-16) (R,E,16) mg/L, and rifabutin and estrogens = 5.2 (E,K-16) (R,E,16) and 5.3 (E,K-16) mg/L, respectively.
mechanism	Protein Binding Injection: In rats, administration of <e10> rifampin </e10>, an anticonvulsant, at doses of # mg/kg/day to # times/day to # days prior to and # days following administration of <e20> bovine serum albumin </e20> resulted in a reduction in serum bovine serum albumin of 38% and an increase in plasma bovine serum albumin levels.
mechanism	Protein Binding In vitro data suggest that <e10> phenytoin </e10> increases the plasma levels of <e20> nifedipine </e20>.
mechanism	Protein Binding Inhibitors : There is some conflicting evidence for the effect of <e10> isoniazid </e10> on <e20> pravastatin </e20> pharmacokinetics.
mechanism	Protein Binding Ingestion: Since <e10> aripiprazole </e10> may increase the blood levels of certain therapeutic_agents (e,g,, cyclosporine, methotrexate, alfentanil ), the physician should be aware of the potential for this drug interaction when administering these agents to patients being treated with <e20> aripiprazole </e20>.
mechanism	Protein Binding Injection (PBI) : <e12> Amphetamines </e12> decrease the effect of <e20> PBI </e20>, which is an oral cholestyramine, and increase the effect of a single dose of PBI.
mechanism	Because <e12> antacids </e12> may interfere with absorption of <e20> tetracycline </e20>, a higher initial dose of tetracycline may be required.
mechanism	Because <e12> antacids </e12>, including sucralfate, interfere with calcium absorption, the concomitant use of antacids with high calcium concentrations ( <e20> CaCl2 </e20> ) or with very high calcium concentrations ( as in the case of sucralfate ) may decrease the calcium absorption.
mechanism	Allopurinol : The mean fluence of <e11> BROVANA </e11> tablets containing <e20> allopurinol </e20> was slightly lower than the fluence of # mg of the same dose given with a single dose of a single dose regimen of BROVANA or ethinyl_estradiol alone.
mechanism	Allopurinol : The extent to which <e12> corticosteroids </e12> reduce <e20> allopurinol </e20> levels and whether such a reduction would result in a decrease in efficacy or lead to unpredictable side effects are unknown.
mechanism	Allopurinol : The combined use of <e10> allopurinol </e10> and <e20> ethinyl_estradiol </e20> # mg had no significant effect on serum lithium concentrations in a patient with hypothyroidism.
mechanism	Ganciclovir : Administration of <e10> gentamicin </e10> at # mg/kg, # times a day for # days after administration of <e20> ganciclovir </e20> at # mg/kg, # times a day for # days.
mechanism	Ganciclovir : Administration of <e10> lopinavir </e10> and <e20> ganciclovir </e20> increases the plasma levels of both drugs and may cause serious adverse events if the dose of both drugs is exceeded.
mechanism	Ganciclovir : Administration of <e10> ganciclovir </e10> and <e20> ketoconazole </e20> resulted in a dose-dependent decrease in the steady-state plasma concentration of AUC and Cmax of rifabutin.
mechanism	A # (17)% decrease in the <e10> ketoconazole </e10> steady-state plasma concentration of the <e20> ampicillin </e20> analogue when coadministered with ketoconazole was also observed.
mechanism	A # (17)% reduction in the clearance of <e10> clofibrate </e10> # mg/day was observed following concurrent administration of a # mg/day dose of <e20> rifampin </e20> # mg/day.
mechanism	Quinolone_Antibiotic s: VIDEX, ciprofloxacin, and <e10> erythromycin </e10> may inhibit <e20> astemizole </e20> absorption and, thus, decrease serum astemizole concentrations.
mechanism	Quinolone_Antibiotic s: VIDEX, <e10> ciprofloxacin </e10>, and clarithromycin may interfere with the metabolism of <e20> piperacillin </e20>, resulting in reduced levels of piperacillin and therefore may increase the risk of developing drug interactions.
mechanism	In eight HIV-infected patients with <e10> furosemide </e10> therapy, <e20> clofibrate </e20> (500 mg once daily) for # weeks resulted in a 30% reduction in furosemide dose and an additional 10% increase in furosemide serum concentrations.
mechanism	In eight HIV-infected patients, the mean Cmax of <e10> ritonavir </e10> increased by 46% when a single # mg dose of <e20> ritonavir </e20> # mg was administered, and the mean AUC by 46%.
mechanism	In eight HIV-infected patients, coadministration of <e10> dapsone </e10> and <e20> didanosine </e20> resulted in a reduction in viral load (average from # x 10(8) to # x 10(8) copies/ml) and in the mean interval from last dapsone dose to initiation of didanosine therapy by about # weeks.
mechanism	The AUC of <e10> digoxin </e10> was increased by #% when <e20> valdecoxib </e20> was coadministered.
mechanism	The AUC of <e10> zalcitabine </e10> is increased by approximately 30% when coadministered with <e20> rifabutin </e20>.
mechanism	The AUC of <e10> ciprofloxacin </e10> for the following days were # mg/mL, # mg/mL, # mg/mL, # mg/mL, # mg/mL and # mg/mL, respectively, and the Cmax were # ng/mL, # ng/mL, # ng/mL, # ng/mL and # ng/mL, respectively, in the presence of <e20> methotrexate </e20>.
mechanism	In a single dose of # mg/kg of <e10> rifabutin </e10>, coadministration of # mg/kg of <e20> anafranil </e20> produced a significant decrease in oxygenation.
mechanism	In a single dose of <e10> ketoconazole </e10> # mg and <e20> fluconazole </e20> # mg, #% and 20% of the fluconazole blood levels were displaced to # and # mg, respectively, and there was a 33% decrease in the fluconazole plasma clearance.
mechanism	In a single dose of <e10> probenecid </e10> # mg given with <e20> cisapride </e20> # mg, the clearance of cisapride was increased by a mean of 38% (p = 0.017) and the AUC of cisapride was increased by a mean of 23% (p = 0.015) on the basis of results from in vitro studies in normal subjects and a study in pediatric patients.
mechanism	Plasma concentrations of <e10> methotrexate </e10> may be reduced by <e20> lithium </e20>.
mechanism	Plasma concentrations of <e10> erythromycin </e10> are reduced by coadministration of <e20> furosemide </e20>.
mechanism	Plasma concentrations of <e10> carbamazepine </e10> are decreased by concomitant administration of <e20> tetracycline </e20>.
mechanism	Plasma concentrations of <e10> levodopa </e10> are enhanced by <e20> ketoconazole </e20>, which is inhibited by valdecoxib.
mechanism	Plasma concentrations of <e10> digoxin </e10> are approximately # times greater when administered with <e20> phenytoin </e20>.
mechanism	Plasma concentrations of <e10> warfarin </e10> are increased by concurrent administration of <e20> aripiprazole </e20>, resulting in a decreased clearance of warfarin.
mechanism	Plasma concentrations of <e10> lithium </e10>, <e20> phenytoin </e20>, and methotrexate were decreased when coadministered with lithium.
mechanism	Plasma concentrations of <e10> ketoconazole </e10> were increased when it was administered concomitantly with <e20> amiodarone </e20>, the commonest cause of cardiac toxicity.
mechanism	Interactions with Other <e12> Anticoagulants </e12> : <e20> Warfarin </e20> has been reported to reduce the renal clearance of coumarin and its derivatives (e,g,, fluvoxamine, dexamethasone, and phenytoin ).
mechanism	Interactions with Other Drugs Concomitant administration of <e11> HEXALEN </e11> and drugs that are active in inhibiting CYP3A4 (eg, <e20> ketoconazole </e20>, itraconazole, clarithromycin, nefazodone, ritonavir, nelfinavir, saquinavir, telithromycin, troleandomycin ) with HEXALEN may result in elevated plasma concentrations of HEXALEN.
mechanism	Interactions with Other Drugs: Concurrent use of <e10> cyclosporine </e10> with phenytoin, carbamazepine, tacrolimus, digoxin, itraconazole, hexobarbital, phenytoin, rifampin, <e20> theophylline </e20>, and alfentanil may increase serum concentrations of these drugs and increase the clearance of these drugs.
mechanism	This may occur as a result of inhibition of CYP3A4 activity by <e10> isoniazid </e10>, and also by an inhibition of CYP2C9 by <e20> ketoconazole </e20>.
mechanism	This may occur because diltiazem and <e10> ketoconazole </e10> may interfere with the metabolism of <e20> nelfinavir </e20>.
mechanism	This may occur when <e10> ethionamide </e10> is co-administered with <e20> phenytoin </e20>.
mechanism	Hydrochlorothiazide : In vitro studies indicate a significant decrease in the absorption of <e10> hydrochlorothiazide </e10> following administration of <e20> ergotamine </e20> and other beta-adrenergic_blocking_agents.
mechanism	Hydrochlorothiazide : In vitro data suggest that <e11> ENBREL </e11> may inhibit the metabolism of some nonsteroidal_anti-inflammatory_drugs and may increase the half-life of <e20> chlorothiazide </e20>.
mechanism	Hydrochlorothiazide : In vitro data suggest a possible reduction in clearance of <e10> diltiazem </e10> by simultaneous administration of <e20> sulfapyridine </e20> and hydrochlorothiazide.
mechanism	Acetaminophen : In a study in normal volunteers, <e10> acetaminophen </e10> decreased the clearance of <e20> ketoconazole </e20> by ~33%.
mechanism	Acetaminophen : In vitro studies have shown that <e10> acetaminophen </e10> inhibits the metabolism of <e20> cyclosporine </e20> by inhibiting the hepatic cytochrome P450 system.
mechanism	Acetaminophen : In vitro, <e10> dapsone </e10> inhibited the formation of <e20> acetaminophen </e20> ( alprazolam ) in both human urine and human urine/urine by 40% (diprazolam) and 17% (alprazolam ) with an IC50 of 30 mg/mL and 25 mg/mL, respectively.
mechanism	Cyclosporine : Administration of <e11> PRINIVIL </e11> Tablets with cyclosporine Tablets to patients on cyclosporine Tablets and to patients on non-steroidal_anti-inflammatory_drugs or who are on chronic <e22> diuretic </e22> therapy may result in an increase in serum concentrations of cyclosporine.
mechanism	Cyclosporine : Administration of <e10> cyclosporine </e10> increases the clearance of <e20> cimetidine </e20> and may increase the absorption of digoxin, cimetidine, and theophylline.
mechanism	Cyclosporine : Administration of <e11> ZYVOX </e11> in patients receiving <e20> cyclosporine </e20> at high doses (e,g,, # mg/kg/day) was associated with a decrease in serum concentrations of cyclosporine.
mechanism	Aspirin : In some patients with diabetic ketoacidosis, <e10> chloroquine </e10> use may have resulted in the reduction of <e20> aspirin </e20> blood levels.
mechanism	Aspirin : In studies with rats and monkeys, <e10> ibuprofen </e10> inhibited the renal clearance of <e20> warfarin </e20> by 33% and decreased the creatinine clearance of warfarin by 18%.
mechanism	Naproxen : The metabolism of <e10> naproxen </e10> may be inhibited by <e20> thiazide_diuretics </e20>.
mechanism	Naproxen : The pharmacokinetic and pharmacodynamic significance of <e10> ketoconazole </e10> and <e20> ketoprofen </e20> interaction in normal volunteers have not been established.
mechanism	<e10> Quinidine </e10> and digoxin : Quinidine inhibits <e20> digoxin </e20> metabolism and increases the plasma concentrations of digoxin.
mechanism	<e10> Quinidine </e10>, fluvoxamine, and <e20> terfenadine </e20> decreased serum levels of a triazolopyridine ( zalcitabine ), which is a known drug metabolite.
mechanism	<e10> Quinidine </e10> may decrease the clearance of <e20> digoxin </e20>.
mechanism	Quinidine, <e10> verapamil </e10>, and <e20> fluconazole </e20> may reduce the plasma concentrations of ketoconazole and its metabolite enoxacin.
mechanism	Quinidine, <e10> verapamil </e10>, carbamazepine, and phenytoin have been reported to decrease plasma <e20> levothyroxine </e20> concentrations.
mechanism	Quinidine, <e10> verapamil </e10>, and <e20> digoxin </e20> are all potent inhibitors of methionine synthase.
mechanism	<e10> Erythromycin </e10> potentiated the renal clearance of <e20> terfenadine </e20>, reduced the urinary excretion of terfenadine, and prolonged the half-life of terfenadine.
mechanism	<e10> Erythromycin </e10> may interfere with the absorption of certain drugs, such as cyclosporine, carbamazepine, phenytoin, <e20> phenobarbital </e20>, tacrolimus, phenytoin sulfate, and phenobarbital sulfate.
mechanism	<e10> Erythromycin </e10>, a <e22> multivalent_antibiotic </e22>, potentiated the activity of clarithromycin, ciprofloxacin, colistin, doxycycline, doxycycline, famotidine, fluconazole, intravenous clarithromycin, in-hospital ciprofloxacin, omeprazole, and phenytoin, decreased the clearance of clarithromycin, colistin, famotidine, and doxycycline, increased the serum concentrations of clarithromycin, famotidine, and doxycycline, and increased the plasma levels of doxycycline.
mechanism	Erythromycin and <e10> clarithromycin </e10> inhibited the erythromycin-but not <e20> fluconazole </e20>-inhibitory effect on blood levels of digoxin.
mechanism	Erythromycin and <e10> clarithromycin </e10> may inhibit the metabolism of digoxin, methyldopa, <e20> warfarin </e20>, and lithium, leading to a prolongation of therapeutic plasma levels.
mechanism	Erythromycin and <e10> erythromycin </e10> increase <e20> macrolide_antibiotics </e20> elimination.
mechanism	Erythromycin and clarithromycin, and <e10> warfarin </e10>, are all potent inhibitors of the CYP3A4 isoenzyme, and increase the exposure of <e20> cisapride </e20>.
mechanism	Erythromycin and clarithromycin : <e10> Isoflurane </e10> and <e20> erythromycin </e20> may reduce the blood levels of these drugs and prolong the QT interval on the ECG.
mechanism	<e10> Propantheline </e10> increased the clearance of <e20> cefazolin </e20>, an effect that was inhibited by methylphenidate.
mechanism	<e10> Propantheline </e10> has been shown to antagonize the gastrointestinal absorption of drugs that are predominantly protein bound (such as <e20> rifampin </e20> ) or that have poor protein binding (such as phenytoin, clarithromycin and cimetidine ).
mechanism	<e10> Propantheline </e10> increases the clearance of <e20> cimetidine </e20>.
mechanism	Propantheline and <e10> propofol </e10> # mg/kg in sesame oil #% apical <e20> propol </e20> and # mg/kg in sesame oil #% apical theleast root.
mechanism	<e12> Antacids </e12>, sucralfate, choline_sulfate, or other electrolytes containing sulfate groups, or containing multivitamins or other supplements containing iron or aluminum, may interfere with absorption of <e20> ciprofloxacin </e20>, resulting in a decrease in AUC.
mechanism	<e12> Antacids </e12>, sodium, and magnesium may increase serum <e20> pentamidine </e20> levels.
mechanism	Antacids, <e10> sucralfate </e10>, and sucralfate tablets may interfere with the absorption of <e20> erythromycin </e20>.
mechanism	Antacids, <e10> sucralfate </e10>, and <e20> magnesium </e20> may interact with the absorption of intravenous furosemide, resulting in higher absorption.
mechanism	Antacids, <e10> sucralfate </e10>, and other probiotics that are taken within # hours of exposure to <e20> ketoconazole </e20> may decrease the elimination of ketoconazole.
mechanism	<e10> Rifampin </e10> may increase plasma levels of <e20> disopyramide </e20>, resulting in lower blood levels.
mechanism	<e10> Rifampin </e10> also inhibited the metabolism of <e20> furosemide </e20>.
mechanism	<e10> Rifampin </e10> increases the plasma concentrations of <e20> warfarin </e20>, but the effect is not significant in man.
mechanism	Macrolide_Antibiotics (e, g, erythromycin, clarithromycin, <e10> ritonavir </e10>, indinavir ): Increase the exposure of <e20> terfenadine </e20> to the liver.
mechanism	Macrolide_Antibiotics (e, g, <e10> rifampin </e10>, itraconazole, clarithromycin, nefazodone, nelfinavir ): May decrease the pharmacokinetics of <e20> norfloxacin </e20>.
mechanism	Macrolide_Antibiotics (e, g, <e10> erythromycin </e10>, clarithromycin, diclofenac, azithromycin, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin ): increases plasma concentrations of <e20> clindamycin </e20>, clarithromycin and diclofenac.
mechanism	Administration of <e10> chloroquine </e10> in high doses to subjects with impaired renal function or to subjects taking <e20> lithium </e20> may reduce the renal clearance of chloroquine and increase the blood levels of the drug.
mechanism	Administration of <e10> rifampin </e10> # mg daily for # days prior to dosing with # mg <e20> levothyroxine </e20> s, # mg daily for # days prior to dosing with # mg/day levothyroxine s, and # mg daily for # days prior to dosing with # mg/day estrogens # mg daily for # days prior to dosing with estrogens s, # mg daily for # days prior to dosing with estrogens s, and # mg daily for # days prior to dosing with estrogens s, resulted in a decrease of approximately 50% in the levothyroxine and estrogens s exposure to the breastfed infant.
mechanism	Administration of <e10> astemizole </e10> # mg once daily to rats given a single dose of # mg <e20> ketoconazole </e20> produced a decrease in the AUC of both ketoconazole and ketoprofen.
mechanism	In vitro, <e10> astemizole </e10> significantly inhibited <e20> methotrexate </e20> clearance.
mechanism	In vitro, <e10> ethambutol </e10> significantly inhibited the absorption of <e20> amphetamine </e20> and did not interfere with the renal excretion of amphetamine.
mechanism	In vitro, <e10> fluvoxamine </e10> produced a decrease in <e20> warfarin </e20> concentrations (from # to #%).
mechanism	A study in patients with type-1 diabetes demonstrated that a combination of <e10> fluvoxamine </e10> and <e20> astemizole </e20> reduced the plasma levels of the latter by approximately two-thirds.
mechanism	A study in rats has shown that <e10> piperazine </e10> potentiates the <e20> valdecoxib </e20> -induced inhibition of gastric acid secretion.
mechanism	In renal and cardiac transplant patients, administration of <e10> clofibrate </e10> during maintenance with <e20> lisinopril </e20> resulted in increases in plasma levels of lisinopril, resulting in a significant increase in the AUC of lisinopril.
mechanism	In renal and hepatic transplant recipients who have received <e10> cyclosporine </e10>, an increase in <e20> amiodarone </e20> clearance may occur, resulting in decreased renal excretion of amiodarone.
mechanism	Concomitant administration of <e10> diltiazem </e10> with <e20> diltiazem </e20> resulted in an increase in AUC by 36%.
mechanism	Concomitant administration of <e10> valdecoxib </e10> and <e20> indinavir </e20> in healthy volunteers resulted in a significant increase in valdecoxib concentrations in the blood and urine compared with indinavir alone.
mechanism	Concomitant administration of <e10> alprazolam </e10> with other antipsychotic_agents (e,g,, thiothixene, haloperidol, risperidone, thioridazine, <e20> paliperidone </e20>, risperidol, halothane ) increases the systemic exposure of alprazolam, and thus alprazolam plasma levels are increased.
mechanism	Studies showed that <e10> diazoxide </e10> could interfere with absorption of some <e22> calcium_channel_blockers </e22>.
mechanism	Studies showed that <e10> indinavir </e10> enhanced the metabolism of <e20> ritonavir </e20>, resulting in decreased plasma levels of ritonavir.
mechanism	Studies showed that <e10> dextromethorphan </e10> administered concomitantly with drugs that inhibit CYP2C19, such as ketoconazole, clarithromycin, <e20> carbamazepine </e20>, cyclosporine, doxycycline, diltiazem, ethambutol, flecainide, flecainide_sodium, glipizide, pimozide, quinidine, theophylline, theophylline_hydrochloride, and warfarin had no significant effect on the metabolism of dextromethorphan.
mechanism	Studies showed that <e10> fluvoxamine </e10> also affected the clearance of drugs such as carbamazepine, <e20> phenytoin </e20>, phenobarbital, phenytoin_HCl, rifabutin, disopyramide, and cimetidine, and that it increased the exposure of rifabutin and disopyramide.
mechanism	Studies showed that <e10> diltiazem </e10> decreased the <e20> nifedipine </e20> AUC by approximately 50% and the Cmax by approximately 30%.
mechanism	Studies showed that coadministration of <e10> fluvoxamine </e10> with <e20> digoxin </e20>, interferon-alfa, lovastatin, atorvastatin, and valdecoxib was associated with a 7-fold increase in fluvoxamine AUC.
mechanism	The elimination half-life of <e10> diltiazem </e10> has been decreased by approximately 50% when coadministered with <e20> ciprofloxacin </e20>.
mechanism	The elimination half-life of <e10> isoniazid </e10> and <e20> nicardipine </e20> in dogs and cats was not changed significantly by either coadministration with niacin or by coadministration with isoniazid and nicardipine.
mechanism	The elimination half-life of <e10> ketoconazole </e10> increased approximately twofold, from # to # days, after coadministration with <e20> celecoxib </e20> # mg once daily for # days and # days.
mechanism	The elimination half-life of <e10> quinolone </e10> and ciprofloxacin was increased by <e20> alfentanil </e20>.
mechanism	The elimination half-life of <e10> levothyroxine </e10> is lengthened by the concomitant administration of several <e22> thyroid_products </e22>, possibly due to the formation of a thyroid-stimulating agent, 3,3'-diiodothyronine, which inhibits the metabolism of levothyroxine.
mechanism	Coadministration of <e10> diltiazem </e10> with <e20> alprazolam </e20> decreased the elimination half-life of alprazolam from # to # minutes.
mechanism	Coadministration of <e10> cisapride </e10> # mg, given # min before and # min after administration of <e20> ketamine </e20>, produced a two-fold increase in mean AUC from # to # mg/h.
mechanism	Coadministration of <e10> gabapentin </e10> # mg/day with an ACE_inhibitor, <e20> atorvastatin </e20>, or an ACE_inhibitor plus a beta-adrenergic_blocking_agent increased gabapentin plasma levels by #%, #%, and #%, respectively.
mechanism	Adenosine : <e10> Acetazolamide </e10> may enhance the absorption of <e20> adenosine </e20>, which is a calcium salt, causing a reduction of the absorption of the free adenosine.
mechanism	Adenosine : <e10> Cholestyramine </e10> increased the hepatic metabolism of <e20> adenosine </e20>, resulting in increased plasma levels of adenosine.
mechanism	Adenosine : <e10> Cimetidine </e10> enhances <e20> adenosine </e20> metabolism.
mechanism	Antacids or H_2_receptor_antagonists : Although studies have not been performed, <e10> ketoconazole </e10> might reduce the metabolism of <e20> rifampin </e20>.
mechanism	Antacids or H_2_receptor_antagonists, or drugs that have high affinity for H_2_receptor (e,g,, amiodarone, nicardipine, <e10> diltiazem </e10> ) may interfere with absorption of <e20> astemizole </e20> and cause serum levels to be elevated.
mechanism	Digoxin : Concomitant administration of <e10> diltiazem </e10> and <e20> digoxin </e20> increases serum digoxin levels in healthy subjects.
mechanism	Digoxin : Concomitant administration of <e10> ciprofloxacin </e10> and <e20> digoxin </e20> increases digoxin levels in a dose-dependent fashion.
mechanism	Digoxin : Concomitant administration of <e10> digoxin </e10> and <e20> lopinavir </e20> has been reported to reduce serum levels of digoxin.
mechanism	If <e10> phenytoin </e10> is co-administered with <e20> ketoconazole </e20>, serum concentrations of the former may be reduced.
mechanism	If <e10> phenytoin </e10> is administered concomitantly with <e20> Aprepitant </e20>, approximately one-third of the phenytoin metabolism is inhibited.
mechanism	If <e10> phenytoin </e10> is to be administered with <e20> cisapride </e20>, careful consideration should be given to the following: a) if the dosage of cisapride is to be increased, it should be done at least # hours prior to the administration of the drug which has been observed to decrease cisapride blood levels.
mechanism	If <e10> phenytoin </e10> therapy is to be discontinued, an interval of # days is required for the <e20> diazepam </e20> to reappear in plasma concentrations at # mg/day.
mechanism	If <e10> phenytoin </e10> is administered concomitantly with <e20> erythromycin </e20>, there is a likelihood of a substantial reduction in the therapeutic effect of erythromycin.
mechanism	If <e10> phenytoin </e10> is to be used in patients in whom <e20> cimetidine </e20> is being withdrawn, an interval of at least # weeks between the two drugs should be maintained, since the absorption of cimetidine is much lower than that of phenytoin.
mechanism	Concomitant administration of <e10> cimetidine </e10> with <e20> doxorubicin </e20> increases the rate of doxorubicin metabolism by ~5-fold and the rate of its metabolism by ~5%.
mechanism	Concomitant administration of <e10> cimetidine </e10> with drugs that are substrates for CYP2C9 (e,g,, carbamazepine, felbamate, alfentanil, phenytoin, bromocriptine, cisapride, disopyramide, <e20> fluoxetine </e20>, fluvoxamine, gabapentin, itraconazole, nefazodone, quinidine, theophylline, and troleandomycin ) has been reported to reduce the exposure of cimetidine to an extent that may affect the clinical effect of cimetidine.
mechanism	Concomitant administration of <e10> cholestyramine </e10> with <e20> diltiazem </e20> increases plasma levels of diltiazem, leading to a prolonged pharmacokinetic profile.
mechanism	Patients taking <e10> ketoconazole </e10>, a known inhibitor of CYP2C19, have been reported to have increased plasma levels of <e20> ketoconazole </e20>.
mechanism	Patients taking <e10> methotrexate </e10> concurrently with <e20> ketoconazole </e20> (50 mg q12h) had a 62% increase in plasma methotrexate levels.
mechanism	In vitro studies have shown that <e10> erythromycin </e10> has a similar effect on <e20> fluconazole </e20> and fluvoxamine.
mechanism	In vitro studies of <e12> quinolones </e12> and ciprofloxacin, as well as some quinolones (such as azithromycin and clarithromycin ), have shown that, like other quinolones, they inhibit the metabolism of <e20> erythromycin </e20> and the major active metabolite ( ergotamine ).
mechanism	In vitro studies indicate that <e10> diazepam </e10> and amiodarone, alone or in combination, inhibit the metabolism of <e20> terfenadine </e20>, causing a decrease in serum and urine levels.
mechanism	In vitro studies have shown that <e10> diflunisal </e10> inhibits <e20> ampicillin </e20> metabolism by interfering with the biosynthesis of diflunisal by the CYP2C9 isozyme.
mechanism	In vitro studies indicate that <e10> rifampin </e10> may inhibit <e20> clofibrate </e20> metabolism by interfering with the enzyme and/or receptor activity.
mechanism	In vitro studies indicate that <e10> erythromycin </e10> markedly decreases the hepatic metabolism of <e20> methotrexate </e20> and enhances the clearance of indinavir, butylserine, and isoniazid.
mechanism	In vitro studies have shown that <e10> phenytoin </e10> increased the efficacy of the anticoagulant <e20> warfarin </e20> by 15% to 25%.
mechanism	In vitro studies indicate that <e10> digoxin </e10> causes a significant increase in the bioavailability of <e20> alfentanil </e20>, an inhibitor of hepatic metabolism of alfentanil.
mechanism	In vitro studies of the benzodiazepines, including alprazolam, indicate that <e10> alprazolam </e10> has a metabolism that involves CYP3A4 and is inhibited by <e20> alprazolam </e20>, and a metabolism that involves CYP2D6.
mechanism	In vitro studies, using the <e10> phenytoin </e10> and <e20> cimetidine </e20> models, have shown that cimetidine increases the clearance of phenytoin and its metabolite, valproic_acid.
mechanism	In vitro studies have shown that <e10> cimetidine </e10> may reduce the in vitro metabolism of <e20> phenytoin </e20> by inhibiting CYP2C19.
mechanism	<e10> Cimetidine </e10>, acetaminophen ( Tylenol ), and <e20> chlorprothixene </e20>.
mechanism	<e10> Cimetidine </e10>, a protease-inhibitor, markedly decreased the plasma concentrations of <e20> bromocriptine_mesylate </e20>.
mechanism	<e10> Cimetidine </e10>, valdecoxib, and ketoconazole may increase the clearance of <e20> warfarin </e20> and decrease the pharmacokinetics of oral anticoagulants.
mechanism	<e10> Cimetidine </e10>, used concomitantly with <e20> cimetidine </e20>, can increase the clearance of cimetidine and may therefore prolong its half-life.
mechanism	<e10> Cimetidine </e10>, a potent inhibitor of CYP3A4 activity, reduced the metabolism of <e20> phenytoin </e20> and Cimetidine decreased the AUC of phenytoin.
mechanism	<e10> Cimetidine </e10>, given at a dose of # mg/kg body weight twice daily, caused a <e20> estradiol </e20> serum level increase of 8%.
mechanism	Co-administration of <e11> TORADOL </e11> with digoxin, phenytoin, or <e20> carbamazepine </e20> markedly reduced plasma levels of these potent inhibitors of CYP3A4.
mechanism	Co-administration of <e11> ENBREL </e11> and <e20> ketoconazole </e20> significantly decreased the plasma concentrations of enoxacin and ketoconazole.
mechanism	Co-administration of <e11> PRINIVIL </e11> significantly increased the clearance of <e20> atazanavir </e20> by approximately 2% for each dose increase, which may result in approximately 4- to 6-fold increases in AUC values.
mechanism	<e10> Ketoconazole </e10> may decrease the efficacy of <e20> bromocriptine_mesylate </e20> and ethinyl_estradiol.
mechanism	<e10> Ketoconazole </e10> or cimetidine, which inhibit CYP3A4 activity, inhibit <e20> estrogens </e20>.
mechanism	<e10> Ketoconazole </e10> inhibited the <e20> rifampin </e20> metabolism.
mechanism	In patients receiving <e10> cimetidine </e10> and <e20> cisapride </e20> concurrently, cisapride plasma levels were significantly increased by cimetidine.
mechanism	In patients receiving atorvastatin or <e10> fluvastatin </e10> # mg/day, the maximum plasma levels of atorvastatin and fluvastatin were decreased by # and 40%, respectively, after an infusion of <e20> atorvastatin </e20> # mg/day and decreased by # and 32%, respectively, after an infusion of fluvastatin # mg/day for # hours.
mechanism	The mean clearances of <e10> furosemide </e10> were 18.8 and 16.3 mL/kg/h for <e20> cisapride </e20> and the corresponding furosemide AUC was 2.5 and 2.2%.
mechanism	The mean clearances of <e10> indomethacin </e10> and <e20> ketoconazole </e20> were comparable, but the half-life of ketoconazole was reduced by 50% and the half-life of indomethacin was reduced by 60% with the addition of ketoconazole.
mechanism	Blood levels of <e10> diazepam </e10> decreased by approximately 50% when given concurrently with <e20> ketoconazole </e20> ( 50 mg/kg).
mechanism	Blood levels of digoxin are reduced when <e10> digoxin </e10> is given concurrently with <e20> cyclosporine </e20>.
mechanism	Isoflurane, <e10> enflurane </e10>, halothane, halothane_sodium and isoflurane may increase <e20> ketamine </e20> plasma concentrations.
mechanism	Isoflurane, <e10> enflurane </e10>, and halothane increase the rate of elimination of <e20> amphetamine </e20>.
mechanism	Isoflurane, <e10> enflurane </e10>, halothane, halothane_d2, isoflurane, and <e20> succinylcholine </e20> can increase the clearance of metoclopramide by #%.
mechanism	Isoflurane, enflurane, and <e10> halothane </e10> are the most effective at blocking the hepatic absorption of <e20> alprazolam </e20>.
mechanism	In a placebo-controlled study in healthy volunteers, <e10> ketoconazole </e10> # mg decreased the elimination of <e20> lopinavir </e20> by 17% compared with placebo.
mechanism	In a placebo-controlled crossover study, <e10> ketoconazole </e10> tablets increased the rate of <e20> lithium </e20> clearance by -1.4% and increased the lithium toxicity dose by 33%.
mechanism	In a placebo-controlled study of daily doses of <e10> celecoxib </e10> in patients with established COPD, coadministration with <e20> aripiprazole </e20> at a single dose of # mg decreased the plasma AUC of celecoxib by 24% and increased the AUC of celecoxib by 31% compared with placebo.
mechanism	Inhibitors or substrates of CYP3A4 (eg, ketoconazole, itraconazole, ritonavir, erythromycin, clarithromycin, nefazodone, troleandomycin, <e10> erythromycin </e10>, tamoxifen, indinavir, itraconazole, ritonavir, indinavir, ritonavir, saquinavir, telithromycin, troleandomycin, troleandomycin, troleandomycin, fluconazole, and verapamil ) decreased <e20> rifabutin </e20> elimination by approximately 20%.
mechanism	Inhibitors or substrates of CYP3A4 (such as ketoconazole, <e10> itraconazole </e10>, erythromycin, clarithromycin, ritonavir, nelfinavir, saquinavir, indinavir, indinavir_sulfate, and ritonavir_sulfate ) may increase plasma concentrations of <e20> budesonide </e20> and may need to be monitored closely for possible budesonide toxicity.
mechanism	Inhibitors or substrates of CYP3A4, such as ketoconazole, clarithromycin, indinavir, nefazodone, <e10> nelfinavir </e10>, ritonavir, saquinavir, telithromycin, troleandomycin, and itraconazole have been shown to decrease <e20> zalcitabine </e20> clearance by approximately 20%.
mechanism	Inhibitors or substrates of CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, indinavir, saquinavir, <e10> indinavir </e10>, troleandomycin, nefazodone, nelfinavir, nelfinavir, ritonavir, telithromycin, troleandomycin, zidovudine ) significantly inhibited the metabolism of <e21> VIDEX </e21> and CIVEX.
mechanism	Inhibitors or substrates of CYP3A4 (e,g,, ketoconazole, <e10> itraconazole </e10>, clarithromycin, ritonavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, astemizole, itraconazole, troleandomycin, nefazodone ) may decrease the bioavailability of <e20> erythromycin </e20>.
mechanism	Inhibitors or substrates of CYP3A4 ( alprazolam, ketoconazole, <e10> itraconazole </e10>, clarithromycin, ritonavir, nelfinavir, saquinavir, indinavir, ritonavir, saquinavir ) have the potential to interfere with <e20> doxycycline </e20> metabolism.
mechanism	Cimetidine : <e10> Cimetidine </e10> may decrease renal clearance of <e20> phenytoin </e20>, may decrease the pharmacokinetics of phenytoin and its derivatives, and increase the exposure of phenytoin to the kidneys.
mechanism	Cimetidine : <e10> Cimetidine </e10> may enhance <e20> digoxin </e20> absorption, resulting in a higher serum concentration of digoxin.
mechanism	Cimetidine : <e10> Cimetidine </e10> has been reported to decrease serum <e20> erythromycin </e20> levels by approximately 40%.
mechanism	Additionally, higher than recommended doses of <e10> enoxacin </e10> may increase the toxicity of <e20> atorvastatin </e20>.
mechanism	Additionally, higher than # mg/day of <e10> cimetidine </e10> decreased <e20> aripiprazole </e20> plasma concentrations and increased the half-life of aripiprazole.
mechanism	Additionally, higher than expected <e10> chlorpromazine </e10> concentrations were observed in a cohort of patients on <e20> digoxin </e20>.
mechanism	In patients who have received <e10> clofibrate </e10> prior to initiation of the CRIXIVAN regimen, the expected reduction in plasma <e20> clofibrate </e20> concentration will be lower than the actual reduction in plasma clofibrate (an average of 9%), and this increase in plasma clofibrate concentration may occur as early as the week following initiation of the CRIXIVAN regimen.
mechanism	In patients who are receiving intravenous <e10> acetaminophen </e10>, increased oral clearance of <e20> zidovudine </e20> may occur, possibly increasing the dose requirement and resulting in increased zidovudine exposure.
mechanism	Absorption of <e12> aminoglycosides </e12> may be reduced by the absorption enhancer of <e20> cyclosporine </e20>, indinavir.
mechanism	Absorption of <e12> quinolones </e12> may be decreased by <e20> warfarin </e20>, corticosteroids, corticotropin, phenytoin, propranolol, or other macrolide_antibiotics.
mechanism	Absorption of <e10> loratadine </e10> may be reduced by <e20> ethinyl_estradiol </e20>.
mechanism	Absorption of <e10> phenytoin </e10> was reduced by #% and #%, respectively, in patients taking <e20> rifampin </e20> # times daily and by #% and #%, respectively, in patients on carbamazepine.
mechanism	Absorption of <e10> indomethacin </e10> is significantly decreased by <e20> zalcitabine </e20>, but not by other agents such as clarithromycin, itraconazole, itraconazole in combination with indomethacin, clarithromycin, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, and theophylline.
mechanism	<e12> Barbiturates </e12>, certain antibiotics, and certain other drugs (including quinidine ) may inhibit the metabolism of <e20> estradiol </e20>.
mechanism	<e12> Barbiturates </e12> reduce the plasma levels of digoxin, and the gastrointestinal absorption of <e20> digoxin </e20> is increased by barbiturates.
mechanism	<e12> Barbiturates </e12>, carbamazepine, and phenytoin reduce the metabolism of <e20> phenytoin </e20> and thus prolong its half-life.
mechanism	Barbiturates, <e10> phenytoin </e10>, carbamazepine, cholestyramine, <e20> diltiazem </e20>, disopyramide, ethinyl_estradiol, furosemide, high blood pressure medications (e,g,, amiodarone, carbamazepine, triazolam ), and certain antibiotics may increase the clearance of intravenous pentamidine and thus may decrease the initial blood levels.
mechanism	Barbiturates, <e10> phenytoin </e10>, rifampin, and amiodarone are potent inhibitors of <e20> indinavir </e20> metabolism.
mechanism	Barbiturates, <e10> phenytoin </e10>, carbamazepine, and phenobarbital may decrease the absorption of <e20> ketoconazole </e20>.
mechanism	Barbiturates, carbamazepine, and other <e12> anticonvulsants </e12>, such as phenobarbital, phenytoin, felbamate, carbamazepine, felbamate, diazepam, and triazolam, inhibit the metabolism of <e20> ethinyl_estradiol </e20>, resulting in low serum levels.
mechanism	Concurrent administration of <e11> NIMBEX </e11> with drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, <e20> troleandomycin </e20>, ritonavir, saquinavir, indinavir, nelfinavir, ritonavir, telithromycin, troleandomycin, troleandomycin ) may decrease the plasma concentration of NIMBEX by approximately 40% and cause approximately 40% to 50% decreases in AUC and Cmax values for NIMBEX.
mechanism	Concurrent administration of <e10> enoxacin </e10> and <e20> ketoconazole </e20> increases the exposure to enoxacin.
mechanism	Concurrent administration of <e10> ketoconazole </e10> with <e20> probenecid </e20> is reported to cause a 3-fold increase in the half-life of probenecid.
mechanism	<e10> Paroxetine </e10> decreased <e20> amphetamines </e20> and increased dopamine levels in striatum.
mechanism	<e10> Paroxetine </e10> inhibited <e20> diazepam </e20> elimination by 50% with a plasma exposure of # mg/mL.
mechanism	<e10> Paroxetine </e10> at 10 mg/day and fluoxetine (20 mg/day) did not affect the plasma levels of <e20> caffeine </e20>.
mechanism	When <e10> duloxetine </e10> and <e20> fluvoxamine </e20> were given concomitantly, fluvoxamine tended to increase duloxetine levels in the liver.
mechanism	When <e10> duloxetine </e10> was administered at # mg/day for # days in a patient with chronic renal insufficiency, a decrease in plasma <e20> desipramine </e20> and desipramine AUC was observed.
mechanism	When <e10> duloxetine </e10> was coadministered with either <e20> fluvoxamine </e20>, a 50% reduction in AUC of duloxetine was observed, while a 50% reduction in Cmax was observed.
mechanism	Concurrent administration of <e10> fluvoxamine </e10> and <e20> lorazepam </e20> may increase the AUC of lorazepam and increase the Tmax of lorazepam.
mechanism	Concurrent administration of <e10> clofibrate </e10> and <e20> sildenafil </e20> has been reported to reduce the clearance of sildenafil by as much as 29%.
mechanism	Concurrent administration of <e10> isoniazid </e10> and <e20> cimetidine </e20> resulted in a marked reduction in the elimination of cimetidine.
mechanism	Drugs which induce hepatic enzymes such as <e10> phenytoin </e10>, rifampin, or phenobarbital may increase the clearance of <e20> valproate </e20> and reduce the absorption of valproate.
mechanism	Drugs which induce hepatic enzymes such as phenobarbital, phenytoin, phenytoin_sodium, carbamazepine, phenytoin, carbamazepine_sodium, alfentanyl, <e10> rifampin </e10>, alprazolam, tolbutamide, phenobarbital, valproate, terfenadine, phenytoin, and diazepam reduce the metabolism of <e20> probenecid </e20> and therefore the absorption of these agents.
mechanism	Drugs which induce hepatic enzyme activity such as <e10> phenobarbital </e10>, carbamazepine, phenytoin, phenytoin_hydrochloride, alfentanil, disopyramide, dapsone, erythromycin, felbamate, and theophylline may reduce the clearance of <e20> disopyramide </e20> and therefore may increase the risk of side effects such as dyspnea, rhabdomyolysis, and elevated serum creatinine.
mechanism	Drugs which induce hepatic enzyme production (eg, <e10> phenobarbital </e10>, phenytoin, carbamazepine, <e20> phenytoin_succinate </e20>, alfentanil, phenytoin, clofibrate, phenytoin_citrate, phenobarbital_d1 and d2, cisapride, disopyramide, ketoconazole, phenytoin, rifampin, triazolam, troleandomycin, zidovudine ) may decrease plasma concentrations of CRIXIVAN.
mechanism	Drugs which induce hepatic enzymes such as <e10> phenytoin </e10>, rifampin, or phenobarbital may increase the clearance of <e20> ethinyl_estradiol </e20>.
mechanism	Drugs which induce hepatic enzymes such as <e10> phenobarbital </e10>, phenytoin, carbamazepine, and rifampin may increase plasma concentrations of <e20> dofetilide </e20>.
mechanism	Drugs which induce CYP3A4 activity (eg, phenytoin, carbamazepine, phenobarbital, alfentanil, <e10> cisapride </e10>, disopyramide, phenytoin, bromocriptine, valproate, terfenadine, propafenone, astemizole, astemizole_HCl, cisapride_HCl, disopyramide, cisapride_HCl_HCl, disopyramide_HCl, terfenadine, terfenadine, valproate, terfenadine, <e20> disopyramide </e20>, disopyramide_HCl_HCl, valproate_HCl, disopyramide_HCl_HCl, terfenadine, valproate, terfenadine, valproate_HCl, disopyram
mechanism	When <e10> indinavir </e10> was administered concomitantly with <e20> nevirapine </e20>, the following effects were observed: an increase in indinavir plasma concentrations, as well as in the AUC, Cmax, and AUC-AUC of nevirapine.
mechanism	When <e10> indinavir </e10> and <e20> nevirapine </e20> are administered concomitantly, plasma concentrations of indinavir may be increased and indinavir plasma concentrations may be decreased.
mechanism	When <e10> indinavir </e10> was co-administered with <e20> ritonavir </e20>, the AUC(0-12) of ritonavir was increased by approximately 40% and the Cmax of ritonavir was decreased by approximately 40%.
mechanism	Potential for reduction in the absorption of <e10> nifedipine </e10> by <e20> diltiazem </e20> and other potent CYP3A4 inhibitors.
mechanism	Potential for reduction in oral <e10> aripiprazole </e10> absorption when coadministered with <e20> sodium_thiosulfate </e20> may occur if sodium_thiosulfate increases plasma concentrations of aripiprazole.
mechanism	<e11> SUSTIVA </e11> significantly decreased the Cmax of <e20> disulfiram </e20> by about 55%.
mechanism	<e11> SUSTIVA </e11> may be inhibited by <e20> triazolam </e20>.
mechanism	<e11> SUSTIVA </e11> was able to reduce <e20> guanethidine </e20> plasma levels by about 40% and to increase plasma levels of a synthetic analogue of guanethidine by about 40%.
mechanism	<e11> SUSTIVA </e11> may have additive or potentiating effects with other anticonvulsants, <e22> anticonvulsants </e22>, alcohol, barbiturates, bromocriptine, calcium_channel_blockers, corticosteroids, corticotropin, diazepam, estrogens, fluconazole, lithium, methadone, methadone_hydrochloride, phenobarbital, phenytoin, prednisolone, risperidone, saquinavir, theophylline, triazolam, tamoxifen.
mechanism	<e11> SUSTIVA </e11> has been shown to decrease the clearance of methotrexate, <e20> erythromycin </e20>, cisapride, and carbamazepine.
mechanism	<e11> SUSTIVA </e11> may increase the clearance of <e20> isoniazid </e20>.
mechanism	Caffeine : <e10> Caffeine </e10> may decrease <e20> enoxacin </e20> clearance.
mechanism	Caffeine : <e10> Caffeine </e10> increases the blood concentration of <e20> caffeine </e20>.
mechanism	Caffeine : <e10> Caffeine </e10> may decrease the renal clearance of <e20> amphetamines </e20>.
mechanism	In a multiple-dose study, co-administration of a <e12> macrolide </e12> and a <e20> erythromycin </e20> significantly reduced the steady-state level of both antibiotics by 38%.
mechanism	In a multiple-dose study in healthy volunteers, # mg of <e10> atorvastatin </e10> # hours after # mg of <e20> colestipol_HCl </e20> # hours resulted in approximately 40% reduction in AUC() of colestipol and approximately 40% increase in AUC(20) of colestipol_HCl.
mechanism	In a multiple-dose study in healthy volunteers receiving both <e10> lithium </e10> and <e20> cisapride </e20>, lithium concentrations increased by more than #-fold in the plasma and brain.
mechanism	Cyclosporine : Elevated plasma concentrations of <e10> cyclosporine </e10> are reported with concomitant administration of <e20> valdecoxib </e20>, clarithromycin, cyclosporine dipropion, and azathioprine.
mechanism	Cyclosporine : Elevated serum concentrations of <e10> cyclosporine </e10> have been reported when <e20> bromocriptine_mesylate </e20> is administered concomitantly.
mechanism	Digoxin : <e10> Ketoconazole </e10> may interfere with metabolism of <e20> digoxin </e20>, resulting in a lower serum level of digoxin.
mechanism	Digoxin : <e10> Carbamazepine </e10> tablets may decrease the bioavailability of <e20> digoxin </e20>, leading to increased serum and urine levels.
mechanism	or with multivitamins, <e12> NSAIDs </e12>, corticosteroids, thyroid_products, or drugs that interfere with thyroid metabolism may increase the metabolism of <e20> digoxin </e20> and other sympathomimetics.
mechanism	The oral bioavailability of <e10> diltiazem </e10> is approximately 5% lower when it is given with <e20> cyclosporine </e20>.
mechanism	The oral bioavailability of <e11> ENBREL </e11> was decreased by #-fold following administration of <e20> digoxin </e20> # mg once daily in a #-day regimen.
mechanism	Theophylline : <e10> Theophylline </e10> increases the hepatic clearance of <e20> fluvoxamine </e20> and cimetidine.
mechanism	Theophylline : <e10> Theophylline </e10> may inhibit <e20> cyclosporine </e20> metabolism, leading to increased serum levels of theophylline and an increase in the chance of renal excretion.
mechanism	Theophylline : <e10> Theophylline </e10> was shown to inhibit the metabolism of <e20> amphetamines </e20> by reducing the synthesis of the primary amphetamine metabolite amphetamine in rat brain and liver.
mechanism	<e10> Enoxacin </e10> and <e20> minocycline </e20> (15 mg/kg, p.o.) at # min were associated with a 25% reduction of the maximal t (1/2) of the Cmax of minocycline in healthy volunteers.
mechanism	<e10> Enoxacin </e10> may inhibit <e20> carbamazepine </e20> metabolism by reducing the plasma levels of carbamazepine, resulting in decreased concentrations of carbamazepine and resulting in lower pharmacokinetic parameters for carbamazepine.
mechanism	<e10> Enoxacin </e10> inhibited <e20> ciprofloxacin </e20>, phenytoin, and amiodarone with AUC values of #, #, and # microM, respectively.
mechanism	Warfarin : <e12> Quinolones </e12>, including Nabilone, increase the exposure of <e20> warfarin </e20>, resulting in a potential for increased anticoagulant effects.
mechanism	Warfarin : <e12> Amphetamines </e12> may decrease the absorption of <e22> anticoagulant_agents </e22>.
mechanism	Warfarin : Quinolones, such as <e10> ciprofloxacin </e10>, have been reported to increase the plasma levels of <e20> warfarin </e20> and therefore inhibit its metabolism.
mechanism	Warfarin : Quinolones, such as <e10> ciprofloxacin </e10>, may reduce the clearance of <e20> warfarin </e20> and increase the potential for interaction with the prothrombin time.
mechanism	<e10> Cimetidine </e10> can increase the <e20> ketoconazole </e20> clearance and thereby increase the duration of concomitant administration.
mechanism	<e10> Cimetidine </e10> decreased the metabolism of <e20> ergotamine </e20> by inhibiting its hepatic metabolism.
mechanism	A pharmacokinetic study of theophylline following single and multiple doses of <e10> theophylline </e10> given to healthy volunteers revealed a 3-fold increase in exposure to theophylline following coadministration with <e20> digoxin </e20>.
mechanism	A pharmacokinetic study of <e10> warfarin </e10> in healthy volunteers showed a 50% decrease in the AUC of warfarin when co-administered with <e20> lithium </e20>.
mechanism	Administration of <e10> cimetidine </e10> to patients taking <e20> haloperidol </e20>, phenobarbital, or valproic_acid increases the AUC of haloperidol by about 25%.
mechanism	Administration of <e10> clofibrate </e10> and <e20> sodium_thiosulfate </e20> simultaneously in patients undergoing cardiovascular surgery resulted in a significantly increased serum and urine sodium levels.
mechanism	Administration of <e10> phenytoin </e10> with <e20> dapsone </e20> at # mg every # hours had no effect on the DHP metabolite concentrations or on the DHP-to-phenytoin conversion.
mechanism	Administration of <e10> diltiazem </e10> or <e20> warfarin </e20> decreased the in vitro activity of warfarin and increased the in vivo half-life of warfarin.
mechanism	Administration of <e10> phenytoin </e10> # mg/day to healthy volunteers receiving <e20> ketoconazole </e20> # mg/day resulted in a decrease in maximum plasma concentrations of phenytoin (by approximately 50%), with a subsequent decrease in phenytoin plasma levels.
mechanism	Administration of <e10> doxycycline </e10> (50 mg/kg/day) for # days prior to oral <e20> fluconazole </e20> resulted in a reduction in both mean fluconazole plasma concentrations and mean AUC values, with no increase in mean elimination half-life.
mechanism	Administration of <e10> rifabutin </e10> may reduce the oral absorption of <e20> ethinyl_estradiol </e20>, resulting in an increased estradiol to progesterone ratio.
mechanism	Administration of <e10> diltiazem </e10>, acetaminophen (e,g,, Tylenol ), barbiturates, sulfonamides, <e20> phenytoin </e20>, phenylbutazone, bromocriptine, digoxin, diltiazem, hydantoin, halothane, morphine, nizatidine, phenobarbital, quinine, theophylline, valproate, warfarin, zidovudine, or ethambutol to patients receiving oral contraceptives may increase the absorption of oral contraceptives.
mechanism	Administration of <e10> ketoconazole </e10> to patients receiving <e20> cisapride </e20> or acesulfan can produce a rapid and substantial increase in AUC and Cmax of cisapride.
mechanism	Administration of <e10> probenecid </e10> to healthy volunteers decreased plasma concentrations of <e20> warfarin </e20>.
mechanism	Administration of <e10> ketoconazole </e10> may increase the clearance of <e20> cisapride </e20>.
mechanism	In clinical trials, <e10> clofibrate </e10> has been shown to increase <e20> cytochalasin_D </e20> concentrations and thus increase the risk of cytochalasin_D nephrotoxicity.
mechanism	In clinical trials, patients who received <e11> INDOCIN </e11> had an increased risk of <e20> clofibrate </e20> bleeding.
mechanism	In clinical trials, co-administration of <e11> HUMORSOL </e11> with cyclosporine, tacrolimus, hexobarbital, phenytoin, and other potent CYP3A4 inhibitors such as <e20> carbamazepine </e20>, disopyramide, phenytoin, alfentanil, cisapride, disopyramide, and triazolam resulted in increases in Cmax and AUC of HUMORSOL when compared to a similar regimen without inhibitors.
mechanism	In clinical trials, co-administration of <e10> indinavir </e10> (e,g,, # mg/day for # days), ritonavir (e,g,, # mg/day for # days), and ritonavir (e,g,, # mg/day for # days) resulted in similar AUC values, as well as Cmax values, for <e20> ritonavir </e20> in plasma compared to ritonavir alone.
mechanism	In clinical trials, the AUC of <e10> aripiprazole </e10> and the Cmax of <e20> diltiazem </e20> were increased by approximately 40%.
mechanism	However, patients on <e12> anticonvulsants </e12> and other drugs with anticonvulsant activity who are concurrently treated with <e20> bromocriptine_mesylate </e20> have an increased risk of convulsions.
mechanism	However, patients on chronic <e12> benzodiazepines </e12> may have increased plasma levels of benzodiazepines when concomitantly administered with <e20> alprazolam </e20>.
mechanism	However, patients on concurrent <e10> indomethacin </e10> therapy may have an increased incidence of elevated <e20> digoxin </e20> concentrations.
mechanism	The effects of <e10> acetaminophen </e10> and <e20> lithium </e20> on acetaminophen metabolism have been shown to be reversible, but the time to maximum decrease in serum acetaminophen levels is prolonged.
mechanism	The effects of <e10> ibuprofen </e10> and <e20> rifampin </e20> on plasma concentrations of allopurinol (4 mg kg(-1) ) were found to be approximately 1-2-fold greater than on the other drugs, and thus should be taken into consideration when any rifampin is given with either ibuprofen or rifampin.
mechanism	The effects of <e10> clofibrate </e10> on <e20> warfarin </e20> serum concentrations are unpredictable.
mechanism	Co-treatment with the selective CYP3A4 inducer <e10> ketoconazole </e10> (1 microM) increased the plasma concentration of <e20> atazanavir </e20> by approximately 17% and increased atazanavir concentrations by an average of 29% in healthy volunteers co-administered with a single dose of 100 microg/kg of atazanavir.
mechanism	Pre-treatment with the nonsteroidal_anti-inflammatory_drug <e10> ketorolac </e10> prior to dosing with <e20> CMI </e20> resulted in an increase in CMI to 0.8 ng/mL, a dose that was 5-fold higher than that required to achieve a CMI response in healthy volunteers.
mechanism	Pre-treatment with the selective serotonin reuptake inhibitor <e10> fluoxetine </e10> decreased the levels of <e20> fluvoxamine </e20>, presumably by inhibiting the reuptake of the latter.
mechanism	When ertapenem is used concomitantly with <e10> astemizole </e10>, the oral absorption of <e20> ertapenem </e20> is reduced by approximately 50% and its plasma levels are increased by approximately 75%.
mechanism	Based on total phenytoin and lovastatin plasma levels in healthy subjects receiving <e10> dasatinib </e10> # mg qd, # mg # min and # mg # hour, the AUCs of <e20> lovastatin </e20> (15 mg qd) are approximately # to # times greater than the AUCs of dasatinib.
mechanism	Based on total plasma drug levels, <e10> cisapride </e10> was inversely correlated with plasma levels of all <e22> COREG </e22> s.
mechanism	Concomitant administration of <e10> zidovudine </e10> with <e20> warfarin </e20> has been reported to result in decreased zidovudine exposure and increased warfarin levels.
mechanism	Concomitant administration of <e10> doxapram </e10> and a <e22> tricyclic_antidepressant </e22> significantly increased the plasma concentrations of doxapram.
mechanism	Concomitant administration of <e10> nevirapine </e10> with <e20> rifampin </e20> decreased rifampin serum concentrations by 69%.
mechanism	<e10> Erythromycin </e10> has been reported to increase the metabolism of some tricyclic_antidepressants, such as <e20> nortriptyline </e20> and imipramine.
mechanism	<e10> Erythromycin </e10> decreases the plasma concentration of <e20> pentazocine </e20> by 50% or more and reduces the plasma concentration of pentazocine by 50% or more.
mechanism	<e10> Erythromycin </e10> inhibits <e20> dofetilide </e20> metabolism, thus preventing blood levels of dofetilide from decreasing.
mechanism	<e10> Erythromycin </e10> and clarithromycin were found to be highly competitive inhibitors of <e20> estrogens </e20> with low bioavailability.
mechanism	<e10> Erythromycin </e10> and other aminoglycosides ( <e20> sirolimus </e20> ) have been reported to reduce the metabolism of oral cephalosporins, resulting in increased AUC and Cmax and decreased serum levels.
mechanism	<e10> Erythromycin </e10> decreased the serum level of <e20> digoxin </e20> by 53% when administered concomitantly.
mechanism	There have been reports of interactions of <e10> rifampin </e10> with <e20> valdecoxib </e20>, cyclosporine, tacrolimus, carbamazepine, dexamethasone, indinavir, itraconazole, itraconazole_retard, rifabutin, zidovudine, and troleandomycin.
mechanism	There have been reports of decreased plasma levels of <e10> ketoconazole </e10> following concomitant administration of <e20> cimetidine </e20> and high doses of ketoconazole (80 and # mg).
mechanism	There have been reports of interactions of <e10> phenytoin </e10> and <e20> carbamazepine </e20> in vitro.
mechanism	Cimetidine-In studies in healthy volunteers, the daily <e10> cimetidine </e10> dose of # mg was found to significantly decrease the clearance of <e20> warfarin </e20> by 43% and increased the fraction of cytochrome P-450 (CYP)3A4 substrates that were active by 46%.
mechanism	Cimetidine-In a controlled study in healthy volunteers, a single oral dose of <e10> cimetidine </e10> # mg was associated with a 27% decrease in the area under the curve of <e20> digoxin </e20>.
mechanism	Cimetidine-Injection, USP should not be taken concomitantly with <e10> cimetidine </e10>, which has been reported to cause a slight increase in serum <e20> valproate </e20> concentrations.
mechanism	Although trough citalopram concentrations were slightly decreased, <e10> citalopram </e10> did not affect <e20> ketoconazole </e20> clearance.
mechanism	Although trough citalopram levels were higher with co-administration of <e10> dexamethasone </e10> and <e20> citalopram </e20>, the magnitude of citalopram increases was small.
mechanism	Although trough citalopram levels were decreased, <e10> citalopram </e10> did not affect <e20> ketoconazole </e20> pharmacokinetics, demonstrating that citalopram is not metabolized by the CYP3A4/5 isozyme in patients receiving ketoconazole.
mechanism	Ketoconazole-Combined <e10> ketoconazole </e10> tablets and <e20> bromocriptine_mesylate </e20> chewable/buffered tablets may reduce the bioavailability of bromocriptine_mesylate when taken concurrently.
mechanism	Ketoconazole-Combined administration of <e10> ketoconazole </e10> tablets with <e20> ketoconazole </e20> capsules reduced plasma concentrations of the latter by #%.
mechanism	Ketoconazole-Combined <e10> cisapride </e10>, given concomitantly with a <e22> calcium_channel_blocker </e22>, caused a significant increase in the effective dose of cisapride.
mechanism	However, there are no studies to determine if these drugs may interact with <e10> cimetidine </e10> # mg/day given concomitantly with <e20> quinine </e20>.
mechanism	However, there are reports of theophylline -related adverse events in patients on concomitant <e10> theophylline </e10> and <e20> levothyroxine </e20> therapy.
mechanism	However, there are reports of serious interactions of <e11> VIOXX </e11> with certain medications including cyclosporine, tacrolimus, phenytoin, <e20> hexobarbital </e20>, carbamazepine, phenytoin, alfentanyl, and isoniazid.
mechanism	Metoprolol-Administration of <e10> metoprolol </e10> at least # hours before or # hours after <e20> erythromycin </e20> markedly decreased the clearance of the drug.
mechanism	Metoprolol-Administration of <e10> metoprolol </e10> to patients receiving <e20> lorazepam </e20> may increase the serum concentration of lorazepam.
mechanism	<e11> BREVIBLOC </e11> can inhibit <e20> succinylcholine </e20> clearance by inhibiting the formation of the P-450-catalyzed androgen metabolism intermediate.
mechanism	<e11> BREVIBLOC </e11> and <e20> cisapride </e20> decrease serum levels of both midazolam and halothane.
mechanism	<e11> BREVIBLOC </e11> may increase the clearance of certain corticosteroids, including <e20> furosemide </e20>, dipyridamole, methyldopa, and reserpine.
mechanism	When <e10> digoxin </e10> was given at the same dose and time interval, there was a 15% increase in <e20> digoxin </e20> plasma levels.
mechanism	When <e10> digoxin </e10> and <e20> ketoconazole </e20> were co-administered, concentrations of digoxin increased (approximately 30%), whereas ketoconazole decreased (approximately 40%) in the patients receiving ketoconazole.
mechanism	When <e10> digoxin </e10> and <e20> astemizole </e20> were given simultaneously to rats, a mild and reversible increase in blood flow occurred in the myocardium and increased the heart rate.
mechanism	When intravenous morphine was administered in combination with <e10> ketoconazole </e10>, approximately 6% of subjects were withdrawn from <e20> morphine </e20>.
mechanism	When intravenous morphine and <e10> fluoxetine </e10> were administered concomitantly, fluoxetine clearance was lower than morphine and <e20> alprazolam </e20>.
mechanism	Coadministration of <e10> colestipol </e10> with <e20> phenytoin </e20> resulted in a 42% increase in phenytoin clearance.
mechanism	Coadministration of <e10> nevirapine </e10> and <e20> ketoconazole </e20> decreased the half-life of # mg of nevirapine.
mechanism	Coadministration of <e10> furosemide </e10> and <e20> ketoprofen </e20> resulted in a reduction in urinary excretion of both furosemide and ketoprofen.
mechanism	Therefore, <e10> esomeprazole </e10> could interfere with the absorption of <e20> alfentanil </e20> and itraconazole.
mechanism	Therefore, <e10> esomeprazole </e10> may interact with <e20> warfarin </e20> and its derivatives, and such interactions may prolong the half-life of these medications.
mechanism	Therefore, <e10> esomeprazole </e10> and ketoconazole increased the MICs of <e20> dapsone </e20> and gentamicin.
mechanism	Therefore, <e10> esomeprazole </e10> tablets may increase the plasma concentrations of <e20> ketoconazole </e20> by approximately 10% and increase the plasma concentrations of ethinyl_estradiol by approximately 17%.
mechanism	Therefore, <e10> esomeprazole </e10> and other agents that inhibit CYP3A4 (e,g,, fluconazole, itraconazole, ketoconazole ) should be used with caution in patients taking <e20> cisapride </e20>.
mechanism	While no in vitro data exist to suggest a possible interaction between <e10> digoxin </e10> and <e20> lithium </e20>, the potential exists for increased lithium toxicity in those with lithium disease or hypocalcemia.
mechanism	While no in vitro study has been conducted to compare the pharmacokinetics of <e10> zidovudine </e10> after administration of <e20> zidovudine </e20> at doses of # and # mg, there is a strong possibility that the pharmacokinetics of zidovudine will be altered with higher dosing.
mechanism	While no in vitro studies have shown a significant decrease in the clearance of <e10> indinavir </e10> when administered concurrently with <e20> ritonavir </e20>, it is anticipated that the clearance of indinavir may be increased when used concomitantly with ritonavir.
mechanism	While no in vitro studies have been conducted to determine the in vivo effect of <e10> probenecid </e10>, the potential for reduced absorption of <e20> dapsone </e20> by probenecid has been demonstrated.
mechanism	While no in vitro studies have been performed with <e10> probenecid </e10>, there is the potential for a possible drug interaction with oral <e20> probenecid </e20> in patients on antacids containing calcium or iron.
mechanism	The AUC of <e10> phenytoin </e10> is significantly increased by concomitant administration of <e20> digoxin </e20> with either single or multiple doses.
mechanism	The AUC of <e10> naloxone </e10> decreased by 22% and 46% for <e20> fluvoxamine </e20> and phentolamine, respectively.
mechanism	The AUC of <e10> probenecid </e10> and <e20> terfenadine </e20> were reduced by 45% and 21%, respectively, when the two were given concurrently.
mechanism	Drugs That Induce Hepatic Metabolism: Antacids : <e10> L-phenylalanine </e10>, L-tyrosine, or other antacids may decrease the metabolism of <e20> nifedipine </e20>, resulting in increased concentrations of this drug in the urine.
mechanism	Drugs That Induce CYP3A4 Inhibitors (Anticonvulsants : Carbamazepine, phenytoin, phenobarbital, <e10> felbamate </e10>, diazepam, alprazolam ): Concomitant administration of <e20> cimetidine </e20> with these drugs increases the half-life of cimetidine.
mechanism	Drugs That Induce FGF2 Synthesis ( Tetracyclines, Carbamazepine, Phenobarbital, <e10> Phenytoin </e10> ): Drugs that induce FGF2 synthesis may decrease plasma levels of <e20> dofetilide </e20>.
mechanism	<e10> Lithium </e10> may increase the plasma levels of <e22> catecholamines </e22>.
mechanism	The results of a pharmacokinetic study with <e10> cimetidine </e10> showed a mean Cmax of 0.53% with <e20> ketoconazole </e20>, and a mean AUC of 27.5% with both drugs.
mechanism	The results of pharmacokinetic studies of <e11> ALFENTA </e11> indicated a 20% increase in Cmax and AUC of <e20> bepridil_hydrochloride </e20> compared to baseline.
mechanism	The results of the study indicate that <e10> valdecoxib </e10> increased <e20> acitretin </e20> plasma concentrations by an average of 50%.
mechanism	<e11> Trecator </e11>, which is inversely related to the active <e20> furosemide </e20> concentration, should be used with caution because the active fraction is reduced by these agents.
mechanism	<e11> Trecator </e11>, and possibly other tricyclic_antidepressants, may inhibit the metabolism of <e20> bromocriptine_mesylate </e20>.
mechanism	<e11> Trecator </e11>, which inhibits platelet-aggregation by inhibiting the aggregation of heparinized plasma, did not have a significant effect on the bleeding tendency in patients with bleeding disorder treated with <e20> warfarin </e20>.
mechanism	<e10> Ethopropazine </e10> decreased the clearance of <e20> zalcitabine </e20> by 18% and increased its elimination half-life by 38%.
mechanism	<e10> Ethopropazine </e10> and <e20> levodopa </e20> decrease the clearance of carbamazepine and other drugs, leading to a higher plasma concentration of carbamazepine.
mechanism	<e10> Ethopropazine </e10> may interfere with the metabolism of <e20> ketoconazole </e20>.
mechanism	Presumably, <e10> phenytoin </e10> will inhibit <e20> cimetidine </e20> clearance and increase the absorption of cimetidine.
mechanism	Presumably, <e10> phenytoin </e10>, if added to <e20> aripiprazole </e20>, would increase the plasma concentration of Aripiprazole by about 50%.
mechanism	Presumably, <e10> phenytoin </e10> increased the rate of elimination of <e20> cimetidine </e20>.
mechanism	Presumably, <e10> phenytoin </e10>, as well as other <e22> NSAIDs </e22>, inhibit the metabolism of norethindrone, which is the active metabolite of norethindrone, leading to elevated plasma levels of norethindrone.
mechanism	Presumably, <e10> phenytoin </e10> (200 mg q3w for # days), which was administered for # days prior to the dosing interval of <e20> rifampin </e20>, is responsible for the increase in rifampin AUC.
mechanism	Conversely, the <e12> benzodiazepines </e12> have been reported to reduce the efficacy of <e20> ketoconazole </e20>.
mechanism	Conversely, the <e12> quinolones </e12> have been reported to decrease the clearance of intravenous <e20> diltiazem </e20> by the hepatic enzyme system.
mechanism	Conversely, the <e12> benzodiazepines </e12> may increase the clearance of <e20> diazepam </e20> and other benzodiazepines.
mechanism	<e10> Acetaminophen </e10> significantly increased the plasma concentrations of <e20> loperamide </e20> and its active metabolite, ketoconazole.
mechanism	<e10> Acetaminophen </e10> may inhibit the hepatic metabolism of carbamazepine and other <e22> anticonvulsants </e22>, increasing plasma levels of carbamazepine.
mechanism	<e10> Acetaminophen </e10> s with <e20> warfarin </e20> may decrease the INR of warfarin.
mechanism	<e10> Aminoglutethimide </e10> may inhibit the metabolism of <e20> warfarin </e20> by increasing the exposure of the drug and its active metabolite to the renal tubular cells.
mechanism	<e10> Aminoglutethimide </e10>, carbamazepine, alfentanil, disopyramide, diflunisal, fentanyl, terfenadine, zidovudine, zidovudine, and <e20> warfarin </e20> reduce the clearance of rifampin and its derivatives and may increase the blood levels of rifampin or its derivatives.
mechanism	<e12> Anticonvulsants </e12>, carbamazepine, felbamate, phenobarbital, phenytoin, <e20> primidone </e20>, phenytoin_sulfate, rifampin, theophylline, valproate, zidovudine, and astemizole have been reported to inhibit metabolism of dicumarol and may increase the plasma concentrations of dicumarol.
mechanism	<e12> Anticonvulsants </e12>, phenytoin, carbamazepine, barbiturates, bromocriptine, phenobarbital, sulfonamides, thiazide_diuretics, and corticosteroids may interfere with the metabolism of <e20> warfarin </e20>.
mechanism	<e12> Anticonvulsants </e12>, barbiturates, clonidine, diazepam, codeine, <e20> diazepam_hydrochloride </e20>, diethylpropion, estrogens, fentanyl, fluoxetine, paroxetine, sertraline, triazolam, theophylline, and warfarin.
mechanism	<e12> Anticonvulsants </e12> reduce the clearance of <e20> valproic_acid </e20> by 5%.
mechanism	<e12> Anticonvulsants </e12> may decrease the metabolism of <e20> furosemide </e20>.
mechanism	<e12> Anticonvulsants </e12> reduce the metabolism of <e20> guanfacine </e20>.
mechanism	Anticonvulsants ( <e10> carbamazepine </e10>, phenobarbital, phenytoin, primidone, theophylline, verapamil ): Increase anticonvulsant exposure and/or prolong clinical symptoms of <e20> lithium </e20> toxicity.
mechanism	Anticonvulsants ( <e10> carbamazepine </e10>, phenobarbital, phenytoin, primidone, alprazolam, felbamate, triazolam, buprenorphine, methadone, propoxyphene, methadone_d-d-tetrahydrochloride, alprazolam_d-tetrahydrochloride ): Decrease in plasma <e20> dexamethasone </e20> by about 50% per hour.
mechanism	Anticonvulsants ( <e10> phenobarbital </e10>, carbamazepine, phenytoin, primidone ): Anticonvulsants may interfere with the metabolism of <e20> cisapride </e20>.
mechanism	Anticonvulsants ( <e10> phenytoin </e10>, carbamazepine, felbamate, phenobarbital, felbamate_sodium, phenytoin_sodium ): Based on clinical studies of <e20> lofexidine </e20>, the metabolism of anticonvulsants can be affected by the levels of anticonvulsants in the blood.
mechanism	Anticonvulsants ( <e10> phenytoin </e10>, carbamazepine, felbamate, triazolam, valproate ): In clinical studies, plasma concentrations of <e20> amprenavir </e20> were found to be approximately one-third to one-fourth as high as with ritonavir.
mechanism	Anticonvulsants ( <e10> carbamazepine </e10>, phenobarbital, phenytoin, triazolam, phenytoin_hydrochloride, phenobarbital_hydrochloride, phenytoin, risperidone, tamoxifen ) have been reported to decrease the clearance of <e20> propranolol </e20>.
mechanism	Atorvastatin : <e10> Atorvastatin </e10> increased the plasma levels of <e20> ciprofloxacin </e20> by 44%.
mechanism	Atorvastatin : <e10> Atorvastatin </e10> decreases plasma concentrations of <e20> phenytoin </e20>.
mechanism	Griseofulvin : <e10> Griseofulvin </e10> increased the clearance of <e20> fluvoxamine </e20> by approximately 5% in normal subjects and 8% in patients with mild renal impairment (pH 7).
mechanism	Griseofulvin : <e10> Griseofulvin </e10> increases the bioavailability of <e20> warfarin </e20> and its derivatives.
mechanism	Griseofulvin : <e10> Griseofulvin </e10> is a potent inhibitor of metformin metabolism that inhibits hepatic metabolism of <e20> metformin </e20>.
mechanism	Non-nucleoside_reverse_transcriptase_inhibitors ( NNRTIs ) such as <e10> zidovudine </e10> and ritonavir have been shown to inhibit <e20> ritonavir </e20> s metabolism.
mechanism	Non-nucleoside_reverse_transcriptase_inhibitors ( NNRTIs ): <e10> Quinidine </e10> may enhance the effect of <e20> carbamazepine </e20>, a known NNRTI metabolite.
mechanism	Non-nucleoside_reverse_transcriptase_inhibitors ( NNRTIs ) (e,g,, <e10> phenytoin </e10>, cimetidine ) may increase the plasma levels of <e20> warfarin </e20>.
mechanism	Prednisolone : <e10> Stavudine </e10> significantly reduced the bioavailability of <e20> prednisolone </e20> by a mean of 11%.
mechanism	Prednisolone : <e10> Fluvoxamine </e10> # mg orally twice daily for # days in healthy volunteers resulted in a mean reduction in <e20> prednisolone </e20> plasma levels of #% (95% CI: 5.9 to 10.6%), a greater reduction in plasma concentration (0.50% decrease; 95% CI: -0.24 to 0.77%), and a decreased AUC of 8-10 mg/h (18.3% decrease; 95% CI: 8.5 to 20.5%).
mechanism	Protease_inhibitors : <e10> Aminoglutethimide </e10> may decrease the metabolism of a <e22> protease_inhibitor </e22> and therefore reduce its effectiveness.
mechanism	Protease_inhibitors : <e10> Furosemide </e10>, amiodarone, and phenytoin increase <e20> rifabutin </e20> plasma concentrations.
mechanism	Protease_inhibitors : <e10> Cimetidine </e10> has been reported to inhibit the metabolism of <e20> carbamazepine </e20>.
mechanism	Protease_inhibitors : Amprenavir, <e10> nevirapine </e10>, ritonavir, saquinavir, indinavir, <e20> indinavir </e20>, saquinavir, didanosine, troleandomycin, tetracycline, didanosine, voriconazole, and ketoconazole may decrease plasma levels of rifabutin and/or rifabutin_anticoagulant.
mechanism	Protease_inhibitors : Amprenavir, <e10> indinavir </e10>, saquinavir, and <e20> ritonavir </e20> all decreased plasma levels of amprenavir when administered concomitantly with these drugs.
mechanism	Protease_inhibitors : Amprenavir, <e10> indinavir </e10>, ritonavir, saquinavir, indinavir, and didanosine increase <e20> lovastatin </e20> plasma levels.
mechanism	<e10> Indinavir </e10> may decrease <e20> cyclosporine </e20> levels in liver and/or blood by decreasing its renal clearance.
mechanism	<e10> Indinavir </e10> and ritonavir reduced the AUC of <e20> rifabutin </e20> by 39% and 29%, respectively, and the Cmax by 37% and 27%, respectively.
mechanism	Rifampin : <e10> Rifampin </e10> reduced the plasma levels of <e20> warfarin </e20> by a mean of 25% and the oral absorption of warfarin by 43%.
mechanism	Rifampin : <e10> Flupenthixol </e10> inhibited the metabolism of <e20> rifampin </e20> and decreased its AUC and Cmax by approximately 33% and 46%, respectively.
mechanism	Rifampin : <e10> Rifampin </e10> has been reported to increase <e20> astemizole </e20> clearance by lowering its hepatic uptake and increasing its systemic exposure.
mechanism	Rifampin : <e10> Rifampin </e10> may interfere with the metabolism of <e20> furosemide </e20>.
mechanism	Selegiline : <e12> Quinolones </e12>, such as <e20> tamoxifen </e20>, may also interfere with the metabolism of theophylline, resulting in an increase in its plasma levels.
mechanism	Selegiline : <e12> Antidepressants </e12>, including the benzodiazepines, may increase the metabolism of <e22> anticonvulsants </e22>, resulting in a decreased blood level of these agents.
mechanism	Selegiline : <e12> Antacids </e12> may interfere with the absorption of <e20> selegiline </e20>.
mechanism	Theophylline : <e10> Theophylline </e10> and all <e22> antiepileptic_drugs </e22> are potent inhibitors of CYP2C9, but their effects are unpredictable and may require increases in the dosage of the antiepileptic_drugs.
mechanism	Theophylline : <e10> Theophylline </e10> increases the clearance of <e20> cimetidine </e20> by three- to fourfold, and the elimination half-life of cimetidine is decreased by approximately 50%.
mechanism	Theophylline : <e10> Theophylline </e10> has been reported to decrease the clearance of <e20> theophylline </e20> and the extent of renal tubular damage in a murine model of hemodynamic instability.
mechanism	Tricyclic_antidepressants ( <e10> amitriptyline </e10>, nortriptyline, imipramine, desipramine ): Combinations of these drugs with <e20> cisapride </e20> may result in decreased serum levels of cisapride.
mechanism	Tricyclic_antidepressants ( <e10> amitriptyline </e10>, nortriptyline, imipramine, desipramine, desipramine_HCl, duloxetine, fluoxetine, paroxetine, sertraline, <e20> theophylline </e20> ) increase the metabolism of both tricyclic_antidepressants and related drugs, thus potentially increasing plasma concentrations of these drugs.
mechanism	Tricyclic_antidepressants ( amitriptyline, imipramine, <e10> nortriptyline </e10>, desipramine ) may decrease blood levels of <e20> cyclosporine </e20>.
mechanism	Tricyclic_antidepressants ( amitriptyline, imipramine, <e10> nortriptyline </e10>, amitriptyline_sodium, desipramine, desipramine_sodium ) can increase plasma levels of <e20> propranolol </e20>.
mechanism	Tricyclic_antidepressants ( amitriptyline, <e10> fluoxetine </e10>, sertraline, desipramine, paroxetine, venlafaxine ), sympathomimetics ( tricyclic_antidepressants, amitriptyline, fluoxetine ), and <e22> tricyclic_antibiotics </e22>, may interfere with the metabolism of catecholamine-containing drugs.
mechanism	Tricyclic_antidepressants ( amitriptyline, imipramine, <e10> fluoxetine </e10>, fluvoxamine, paroxetine ): Concomitant administration of <e20> bromocriptine_mesylate </e20> may cause increases in serum levels of bromocriptine and antidepressants.
mechanism	Tricyclic_antidepressants ( amitriptyline, <e10> nortriptyline </e10>, desipramine ) are known to decrease the absorption of <e20> bromocriptine_mesylate </e20>.
mechanism	Aspirin : When <e11> FOSCAVIR </e11> is administered concomitantly with <e20> aspirin </e20>, the absorption of both drugs is impaired.
mechanism	Aspirin : When <e11> aspirin </e11> is administered concomitantly with <e20> methotrexate </e20>, an increased methotrexate exposure is likely.
mechanism	Aspirin : When coadministered with <e10> diflunisal </e10>, the combination may decrease the absorption of <e20> aspirin </e20>, resulting in lower serum levels.
mechanism	Cyclosporine, Digoxin, Methotrexate, and <e10> Aprepitant </e10> may enhance the bioavailability of <e20> warfarin </e20> or its derivatives.
mechanism	Cyclosporine, Digoxin, Methotrexate, and <e10> tacrolimus </e10> have been reported to decrease renal clearance of <e20> erythromycin </e20> and increase the renal clearance of digoxin and morphine.
mechanism	Cyclosporine, Digoxin, Methotrexate, and <e10> Furosemide </e10> have been reported to increase <e20> methotrexate </e20> AUC by approximately 20%.
mechanism	Cyclosporine, Digoxin, Methotrexate, Tetracycline, and Phenytoin : <e10> Diclofenac </e10> increased serum levels of <e20> digoxin </e20>, cyclosporine, and methotrexate.
mechanism	Phenylbutazone : <e10> Cholestyramine </e10> inhibits the metabolism of <e20> phenylbutazone </e20>, resulting in decreased concentrations of the drug and higher serum concentrations.
mechanism	Phenylbutazone : <e10> Phenylbutazone </e10>, like other <e22> thiazide_diuretics </e22>, increases the plasma concentration of catecholamines such as dopamine and norepinephrine.
mechanism	Phenylbutazone : <e10> Phenylbutazone </e10> can inhibit the metabolism of <e20> furosemide </e20>, leading to a decrease in its absorption.
mechanism	Short-term pharmacokinetic studies of <e10> erythromycin </e10> and <e20> doxycycline </e20> were performed on healthy volunteers.
mechanism	Co-medications that induce cytochrome P450 3A4 (CYP3A4) activity (eg, indomethacin, clofibrate, <e10> fluconazole </e10>, grapefruit juice, ibuprofen, lithium, methotrexate, quinidine, sertraline, theophylline, <e20> tolbutamide </e20> ) may increase the bioavailability of the active agent and therefore may increase the exposure of cisapride.
mechanism	Co-medications that induce <e12> sulfonamides </e12> metabolism (eg, <e20> ketoconazole </e20>, astemizole, and itraconazole ) may prolong plasma concentrations of sulfonamides.
mechanism	Co-medications that induce renal tubular secretion of <e11> WELLBUTRIN </e11>, such as furosemide, barbiturates, and <e20> amiodarone </e20>, may increase serum levels of WELLBUTRIN and decrease renal excretion of WELLBUTRIN.
mechanism	Co-medications that induce metabolism of <e10> digoxin </e10> ( <e20> ketoconazole </e20>, phenytoin, clarithromycin ) may reduce serum levels of digoxin and may therefore require increased digoxin doses to achieve therapeutic concentrations.
mechanism	Co-medications that induce CYP3A4 activity, including selective_serotonin_reuptake_inhibitors ( SSRIs ), <e10> fluoxetine </e10>, and fluvoxamine, as well as some tricyclic_antidepressants, may result in an increase in plasma concentrations of <e20> paroxetine </e20>.
mechanism	Co-medications that induce CYP3A4 activity (eg, quinolones, <e10> rifampin </e10>, fluoxetine, theophylline, and atorvastatin ) may decrease the clearance of <e20> cisapride </e20>.
mechanism	Co-medications that induce CYP3A4 activity (eg, cyclosporine, tacrolimus, phenytoin, carbamazepine, phenobarbital, alfentanil, <e10> cisapride </e10>, disopyramide, quinidine, quinidine_HCl, rifampin, valproate, lovastatin ) can increase plasma concentrations of <e20> alfentanil </e20> and may necessitate increased alfentanil dose to achieve the desired AUC.
mechanism	Co-medications that induce hepatic metabolism of <e11> FOSCAVIR </e11>, such as cyclosporine, tacrolimus, amiodarone, carbamazepine, phenytoin, alfentanil, disopyramide, phenobarbital, and <e20> phenytoin </e20>, increase plasma levels of FOSCAVIR and may therefore require increased dosing or adjustment of the dosage regimen of FOSCAVIR.
mechanism	Co-medications that induce CYP3A4 activity (eg, <e10> phenytoin </e10>, ketoconazole, itraconazole, cisapride, quinidine, rifampin, phenobarbital, valproate, <e20> phenytoin_sodium </e20>, carbamazepine, flecainide, clarithromycin, bromocriptine, dapsone, pimozide, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, and ritonavir/simvastatin ) may decrease the clearance of CELNIRAM and therefore reduce the exposure of CELNIRAM to potentially fatal plasma levels.
mechanism	Concurrent use with <e10> rifampin </e10> decreased the AUC of <e20> quinine </e20> by 29% and the Cmax by 25%.
mechanism	Concurrent use with <e10> probenecid </e10> has resulted in a significant increase in <e20> furosemide </e20> concentrations.
mechanism	Concurrent use with <e10> rifampin </e10> and <e20> ampicillin </e20> may result in decreased rifampin plasma levels.
mechanism	Use in Conjunction With Other Antimicrobial_Drugs : The extent to which <e12> quinolones </e12> may interfere with the pharmacokinetics of other antimicrobial_drugs (eg, <e20> ciprofloxacin </e20>, levofloxacin, ciprofloxacin sintamethonium, norfloxacin, cefixime, ceftazidime, erythromycin, clarithromycin, diflunisal, astemizole, doriconazole, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, troleandomycin s, theophylline, and zidovudine ) is unknown.
mechanism	Use in Conjunction With Other Antacids : <e12> Antacids </e12> containing calcium or aluminum are likely to interfere with the absorption of <e20> doxorubicin </e20>.
mechanism	Use in Conjunction With Other <e12> Antihypertensives </e12> : Chlorpropamide, carbamazepine, <e20> phenytoin </e20>, felbamate, mefloquine, triazolam, theophylline, and its metabolite mefloquine sulfone may be potentiated by concomitant use with furosemide.
mechanism	Increasing the <e10> estradiol </e10> dose in the presence of an oral contraceptive containing estrogen ( estradiol_plus_cometron, <e20> Planovasate </e20> ) resulted in a significant increase in estradiol concentrations.
mechanism	Increasing the <e10> caffeine </e10> dose in patients taking <e20> rifampin </e20> can cause the # mg/day caffeine to reduce the # mg/day rifampin dosage.
mechanism	Increasing the <e10> carbamazepine </e10> dose from # to # mg daily may decrease <e20> loratadine </e20> absorption and increase plasma levels.
mechanism	Carbamazepine : <e11> Aspirin </e11> may decrease the bioavailability of <e20> carbamazepine </e20>, resulting in decreased serum carbamazepine levels.
mechanism	Carbamazepine : <e11> Gleevec </e11> increased the plasma concentration of <e20> carbamazepine </e20> by approximately 2-fold and the elimination half-life of carbamazepine by approximately 3-fold.
mechanism	The <e10> carbamazepine </e10> plasma levels are increased by increased hepatic metabolism of <e20> carbamazepine </e20>.
mechanism	The <e10> carbamazepine </e10> AUC of the <e20> cyclosporine </e20> AUC was increased by one-fourth the CYP3A4 activity and decreased by one-fourth the activity of the inhibitor.
mechanism	The <e10> carbamazepine </e10>, phenytoin, and cisapride plasma levels increase during coadministration with <e20> bromocriptine_mesylate </e20>.
mechanism	Increasing the <e10> acetaminophen </e10> dosage from # mg to # mg daily decreased the time to peak plasma <e20> cimetidine </e20> concentration from # min to # min.
mechanism	Increasing the <e10> levodopa </e10> dosage may cause a gradual increase in <e20> fluvoxamine </e20> plasma levels.
mechanism	Increasing the <e10> astemizole </e10> dose to # mg increased <e20> isoniazid </e20> absorption by a mean of 27% (95% CI: 15%, 39%).
mechanism	Phenobarbital : Coadministration of <e10> phenobarbital </e10> and <e20> anagrelide </e20> significantly increased AUC values of anagrelide by 28%.
mechanism	Phenobarbital : Coadministration of <e10> phenobarbital </e10> with either <e20> cyclosporine_A </e20> or norethindrone (3 and # mg/kg, s,c,) resulted in a 46% and 11% increase in peak serum and urine levels of cyclosporine A, respectively, at # hours after dosing.
mechanism	Phenobarbital : Coadministration of <e11> aspirin </e11> and <e20> phenobarbital </e20> for # weeks decreased the mean AUC of propranolol by approximately 23%.
mechanism	Carbamazepine : <e10> Carbamazepine </e10> increased the clearance of <e20> ARAVA </e20> and caused a significant increase in ARAVA-Hg clearance.
mechanism	Carbamazepine : <e10> Carbamazepine </e10> may increase the clearance of <e20> lithium </e20>.
mechanism	Carbamazepine : <e10> Carbamazepine </e10> significantly decreased the plasma levels of <e20> gabapentin </e20>, suggesting that the gabapentin, carbamazepine, and gabapentin systems are in competition for the same substrate.
mechanism	Phenobarbital : It has been suggested that <e10> phenobarbital </e10> may increase the clearance of oral <e20> cyclosporine </e20>.
mechanism	Phenobarbital : It is possible that <e10> phenobarbital </e10> may increase the clearance of <e20> digoxin </e20>.
mechanism	Phenobarbital : It has been reported that <e10> phenobarbital </e10>, administered at doses of # mg to # mg/day, decreased the serum levels of <e20> digoxin </e20> and other drugs that are highly protein bound (eg, digoxin, warfarin, and coumarin ).
mechanism	<e10> Felbamate </e10>, a metabolite of <e20> phenytoin </e20>, caused a marked increase in the plasma concentrations of phenytoin and reduced the metabolism of phenytoin.
mechanism	<e10> Felbamate </e10> (5 mg b.i.d.) may inhibit the absorption of <e20> ciprofloxacin </e20> and enterococcal_antibiotics.
mechanism	Anticonvulsants : In addition to the reduction of convulsions, there have been reports of decreased gastrointestinal absorption of <e10> phenytoin </e10> and <e20> carbamazepine </e20>.
mechanism	Anticonvulsants : In some patients, the concomitant administration of <e11> Levo-Dromoran </e11> and <e20> phenytoin </e20> ( carbamazepine, primidone, or phenobarbital ) has resulted in elevations of serum phenytoin levels that may interfere with the absorption of drug-related compounds.
mechanism	Anticonvulsants : In patients receiving concomitant administration of <e10> carbamazepine </e10> and <e20> phenobarbital </e20>, the AUC and Cmax of carbamazepine were reduced by approximately 50% and approximately 70%, respectively.
mechanism	Anticonvulsants : In clinical studies of patients treated with <e10> carbamazepine </e10>, the incidence of convulsions in subjects taking a high dose of <e20> carbamazepine </e20> was higher than in subjects taking a low dose of carbamazepine.
mechanism	Anticonvulsants : In vitro data indicate that <e11> INDOCIN </e11> may increase the metabolism of <e20> carbamazepine </e20>, phenytoin, alfentanil, cisapride, disopyramide, phenobarbital, phenytoin, bromocriptine, valproate, terfenadine, and zidovudine.
mechanism	Anticonvulsants : In the clinical trial of <e10> phenytoin </e10> in the treatment of subjects with a history of seizure control in the presence of a concomitant use of <e20> rifampin </e20>, the AUC and Cmax of phenytoin were increased by a factor of two and three, respectively, and the AUC of rifampin was increased by a factor of one and three, respectively.
mechanism	Anticonvulsants : In patients receiving anticonvulsants such as phenobarbital, phenytoin, carbamazepine, phenytoin plus <e10> phenobarbital </e10>, carbamazepine, and <e20> carbamazepine </e20>, serum levels of carbamazepine may increase, necessitating an increase in carbamazepine dosage.
mechanism	Resins : Since aluminum is a major component of resins, and <e10> zinc </e10> is a co-factor for the metabolism of <e20> aluminum </e20>, high serum levels of zinc may induce a decrease in the activity of zinc supplements containing zinc containing compounds (such as zinc salts and mixtures of zinc and other elements)
mechanism	Resins : Since, all <e12> salicylates </e12> inhibit the metabolism of resins, it may be necessary to adjust the dosage of resins to the concomitant <e20> ciprofloxacin </e20>.
mechanism	Resins : Since <e10> cimetidine </e10>, and other well known metformin derivatives, inhibit the metabolism of <e20> furosemide </e20>, it is recommended that the furosemide be administered with concurrent high dose dosing of cimetidine.
mechanism	Concomitant administration of <e10> warfarin </e10> and <e20> terfenadine </e20> increased the binding of warfarin to terfenadine.
mechanism	Concomitant administration of <e10> fluvoxamine </e10> and <e20> paroxetine </e20> (50 mg QD and 3 mg QD) in healthy volunteers demonstrated a 2- to 3-fold increase in fluvoxamine plasma levels with concomitant decreases in paroxetine plasma levels.
mechanism	Concomitant administration of <e11> FOSCAVIR </e11> with <e20> warfarin </e20> increases the risk of gastrointestinal ulceration by 30%.
mechanism	Concomitant administration of <e10> alosetron </e10> and the catecholamine-depleting agents, reserpine, <e20> amiodarone </e20>, and the beta-adrenergic_blocking_agent, nadolone, markedly decreased the clearance of alosetron.
mechanism	Concomitant administration of <e10> ciprofloxacin </e10> with <e20> atracurium </e20> has been reported to reduce the plasma levels of atracurium.
mechanism	Concomitant administration of <e10> tetracycline </e10> with <e20> erythromycin </e20> decreased the clearance of erythromycin by 5%.
mechanism	Concomitant administration of <e10> probenecid </e10> with <e20> atorvastatin </e20> in healthy volunteers reduced the half-life of atorvastatin from # to # minutes and that of probenecid from # to # minutes.
mechanism	Concomitant administration of <e11> FOSCAVIR </e11> ( <e20> estradiol </e20> ) and a progestin containing oral solution ( progestin ) may increase serum estradiol levels and may increase estradiol levels in other tissues, thus potentially lowering the serum estradiol level and increasing the risk of ovarian hyperstimulation syndrome.
mechanism	Concomitant administration of <e10> fluvoxamine </e10> tablets with <e20> ketoconazole </e20> may have produced increases in Cmax and AUC.
mechanism	Concomitant administration of <e10> warfarin </e10> with <e20> ketoconazole </e20> (0.1 g/kg/day) resulted in a significant increase in the AUC of warfarin.
mechanism	Concomitant administration of <e11> HUMORSOL </e11> with ampicillin and <e20> tetracycline </e20> was effective in killing microflora.
mechanism	The coadministration of <e10> chlorpropamide </e10> in the presence of <e20> zidovudine </e20> has been reported to result in a 30% increase in zidovudine clearance.
mechanism	The coadministration of <e10> cimetidine </e10> decreased the plasma level of <e20> ketoconazole </e20> by 43%.
mechanism	Although the mechanism is unknown, other <e12> glucocorticoids </e12> may inhibit the absorption of <e20> loperamide </e20>, thus increasing plasma levels.
mechanism	Although the mechanism of action of <e10> erythromycin </e10> is unknown, alterations in its metabolism, resulting in increased plasma levels of <e20> ketoconazole </e20>, could be a contributing factor.
mechanism	Because Nalfon has been reported to enhance the absorption of other oral <e12> anticoagulants </e12>, and because prothrombin time is impaired by the concurrent administration of <e20> Nalfon </e20>, physicians should be cautious in the concurrent administration of anticoagulants with Nalfon.
mechanism	Because Nalfon has been shown to increase the serum concentration of <e10> digoxin </e10>, use of <e20> Nalfon </e20> may increase the toxicity of digoxin.
mechanism	Chronic administration of <e10> ketoconazole </e10> to a patient receiving <e20> valdecoxib </e20> for an extended period of time may result in a high level of valdecoxib binding to the serum.
mechanism	Chronic administration of <e10> cholestyramine </e10> in the presence of <e20> rifampin </e20> (RIF) or C-1, C-2, C-4, or C-5 significantly decreased plasma levels of rifampin or C-1, C-2, C-4, and C-5.
mechanism	Chronic administration of <e10> erythromycin </e10> to rats treated with a single dose of <e20> colchicine </e20> produced a 2- to 3-fold increase in serum colchicine levels.
mechanism	The concomitant use of <e10> erythromycin </e10> and <e20> levothyroxine </e20> has been reported to cause elevated serum levels of levothyroxine.
mechanism	The concomitant use of <e11> VIDEX </e11> and agents with CYP3A4 (e,g,, <e20> ketoconazole </e20>, itraconazole, ritonavir, clarithromycin, indinavir, saquinavir, indinavir, indinavir / saquinavir ) may result in elevated plasma levels of indinavir and/or saquinavir.
mechanism	The concomitant use of <e10> rifampin </e10> and <e20> gefitinib </e20> has been associated with a two-fold increase in the rate of gefitinib metabolism.
mechanism	The concomitant use of <e10> carbamazepine </e10> tablets with <e20> phenytoin </e20> tablets may lead to a decrease in the absorption of carbamazepine and phenytoin.
mechanism	The concomitant use of <e10> erythromycin </e10> may decrease the bioavailability of <e20> fluvoxamine </e20>, resulting in lower peak plasma levels and lower mean Cmax and AUC values.
mechanism	The concomitant use of <e10> digoxin </e10> and <e20> warfarin </e20>, a known renal tubular acidification inhibitor, may have increased digoxin levels and compromised the efficacy of warfarin in these patients.
mechanism	The concomitant use of <e10> warfarin </e10> and <e20> lamivudine </e20> (400 mg qID q2w) was found to result in a significant decrease in the elimination half-life of warfarin.
mechanism	The concomitant use of <e10> chlorprothixene </e10> ( <e20> chlorpyrifos </e20> ) and either of the following: carbamazepine, dapsone, enoxacin, or clarithromycin may produce a toxic effect on the kidneys and the liver and may reduce the excretion of high-dose dexamethasone.
mechanism	The concomitant use of <e10> ketoconazole </e10> and a <e22> corticosteroid </e22> increases the plasma concentrations of the corticosteroid.
mechanism	The concomitant use of <e10> clofibrate </e10> and <e20> disulfiram </e20> decreased the AUC of clofibrate by 27% and increased the AUC of disulfiram by 17%.
mechanism	The concomitant use of <e10> ketoconazole </e10> and <e20> clofibrate </e20> has been reported to increase the clearance of ketoconazole, resulting in increased serum concentrations of clofibrate.
mechanism	However, co administration of <e10> ketoconazole </e10> with <e20> ergotamine </e20> increased the AUC of ergotamine and its active metabolite 2,3-dimethylpropionamide by 36% and 24%, respectively.
mechanism	However, co administration of <e10> piperazine </e10> with either <e20> atropine_sodium </e20>, phenobarbital, or metoclopramide has been shown to increase the half-life of atropine_sodium.
mechanism	However, co administration of <e10> fluvoxamine </e10> with <e20> astemizole </e20>, or of any other inhibitor of CYP3A4 (eg, ketoconazole, itraconazole, nelfinavir, ritonavir, clarithromycin, nefazodone, nefazodone_sulfa, ritonavir, saquinavir, telithromycin, troleandomycin, troleandomycin_sulfa, and nelfinavir ), to prolong exposure of cisapride in a CYP3A4-inhibitor-treated patient resulted in a 6-fold increase in cisapride plasma concentrations.
mechanism	However, co administration of <e10> diltiazem </e10> # mg # min prior to oral <e20> ketoconazole </e20> # mg # min prior to oral ketoconazole # mg # min resulted in a significantly higher elimination of ketoconazole.
mechanism	However, co administration of <e10> rifampin </e10> with <e20> warfarin </e20> resulted in an increase in rifampin plasma concentrations which may decrease the efficacy of oral anticoagulants or warfarin.
mechanism	However, co administration of <e10> ketoconazole </e10> # mg and <e20> rifampin </e20> # mg resulted in an increase in the mean plasma concentrations of rifampin by #% and the rifampin area under the curve by #%.
mechanism	These studies indicate that <e10> alosetron </e10> significantly reduces the hepatic metabolism of <e20> lithium </e20> and significantly prolongs the QT interval on the ECG.
mechanism	These studies indicate that <e10> diltiazem </e10> is likely to increase the clearance of <e20> cimetidine </e20>, which may lead to increased AUC values.
mechanism	These studies indicate that the metabolism of <e10> phenytoin </e10> is increased in the presence of <e20> erythromycin </e20> and that there may be an interaction with the following: halothane ; (4) the metabolism of halothane and phenytoin may be increased with the following: phenytoin (10 mg kg(-1)) plus halothane (20 mg kg(-1)) for up to # hours; (5) phenytoin (10 mg kg(-1)) plus halothane (20 mg kg(-1)) for # hours.
mechanism	This observed increase in <e10> levothyroxine </e10> plasma levels may be associated with increased thyroid uptake resulting in a subsequent higher concentration of <e20> levothyroxine </e20> in the blood.
mechanism	This observed increase in <e10> phenytoin </e10> metabolism may have important implications for the metabolism of <e20> amphetamine </e20>.
mechanism	Drug Interactions with Potassium Supplements <e12> Antacids </e12> may inhibit the absorption of <e20> potassium </e20> supplements.
mechanism	Drug Interactions with Drugs Concomitant Administration of <e10> digoxin </e10> and <e20> ketoconazole </e20> has been reported.
mechanism	Drug Interactions with Phenytoin :-Phenytoin Tablets, oral <e10> carbamazepine </e10>, or cyclosporine may increase the clearance of <e20> clofibrate </e20>.
mechanism	Drug Interactions with Potassium-Sparing_Diuretics : Drugs that reduce the renal excretion of <e10> potassium </e10> (e,g,, <e20> loop_diuretics </e20> ) may increase the potassium requirement of agents that are primarily renal excretory products (e,g,, bile_acid_binding_resins ) and/or that are primarily renal clearance products (e,g,, digitalis ).
mechanism	Drug Interactions with Antacids <e12> Antacids </e12> may inhibit the absorption of certain antibiotics, including ampicillin, <e20> ciprofloxacin </e20>, gentamicin, minocycline, salicylates, sulfonamides, tricyclic_antidepressants, and warfarin.
mechanism	Drug Interactions with Carbamazepine : <e10> Carbamazepine </e10> is reported to reduce the clearance of the <e22> tricyclic_antidepressants </e22>.
mechanism	During administration of <e10> ketoconazole </e10>, plasma concentrations of a nonsteroidal_anti-inflammatory_drug, <e20> clofibrate </e20>, were increased approximately 4-fold and the AUC for clofibrate was increased approximately 4-fold.
mechanism	During administration of <e10> cisplatin </e10> # mg to rats, the <e22> nonsteroidal_anti-inflammatory_drug </e22> s, such as furosemide, were increased, the antihypertensive effect of furosemide and/or other nonsteroidal_anti-inflammatory_drug s was decreased, and the half-life of furosemide was increased by # to # hours.
mechanism	During administration of <e10> levothyroxine </e10> ( <e20> TSH </e20> ) hormone and thyroid microsomal enzyme (ME) inhibitor (ie, piperazine ) together, significant reductions in blood concentrations of both drugs were observed.
mechanism	In a study of rifampicin, phenytoin, and <e10> carbamazepine </e10> concurrently administered to healthy volunteers, <e20> phenytoin </e20> decreased the clearance of rifampicin by about 38% (P =.0005).
mechanism	In a study in normal volunteers, <e10> Aprepitant </e10> significantly reduced the # mg intravenous dose of oral <e20> methotrexate </e20> by 39% (95% CI, 18% to 55%) and increased the mean # mg/day dose by 28% (95% CI, 7% to 43%).
mechanism	In a study in which patients received <e10> digoxin </e10> in combination with <e20> ampicillin </e20>, the clearance of digoxin was reduced by 44% and 62% in the presence of increased serum digoxin concentrations, respectively.
mechanism	Limited data in healthy subjects suggest that coadministration of <e10> ketoconazole </e10> with <e20> ethinyl_estradiol </e20> may have a reduced effect on exposure to and total circulating concentrations of the estrogens.
mechanism	Limited data in the U.S. suggest that <e12> quinolones </e12> may reduce the plasma levels of the anticoagulant, <e20> warfarin </e20> or its derivatives, or that the pharmacokinetics of these agents may be altered by quinolones.
mechanism	Limited data in postmarketing experience suggest a possible drug interaction between <e11> INDOCIN </e11> and ampicillin and <e20> ampicillin </e20>, tetracycline, and gentamicin.
mechanism	Limited data in experimental animals suggest that <e10> methotrexate </e10> may increase the renal clearance of <e20> nelfinavir </e20>.
mechanism	Limited data in patients treated with <e11> INDOCIN </e11> indicate a possible reduction in CYP3A4 activity and an increase in AUC, corresponding to a 40% reduction in Cmax and a 3% increase in AUC following <e20> atorvastatin </e20>.
mechanism	Limited data in diabetic rats indicate that the <e10> ketoconazole </e10>, alfentanil, and <e20> diltiazem </e20> produced additive or potentiating effects on the plasma concentrations of a potent inhibitor of CYP2C9 ( ketoconazole ) that is selectively metabolized by this enzyme ( isoniazid ).
mechanism	In healthy subjects, <e10> warfarin </e10> alone produced a <e20> lofexidine </e20> Cmax of 8.6% (6-fold), and a AUC of 44% (47-fold) after an intravenous infusion of cefotaxime # mg/kg, whereas a simultaneous co-administration of warfarin and cefotaxime # mg/kg resulted in a Cmax of 19% (16-fold), and AUC of 38% (34-fold) of the initial infusion.
mechanism	In healthy subjects, co-administration of <e10> diltiazem </e10> and <e20> bromocriptine_mesylate </e20> resulted in a 50% decrease in the pharmacodynamic response to both B and C doses of the same agent.
mechanism	In healthy subjects, <e10> ketoconazole </e10> significantly inhibited the metabolism of <e20> erythromycin </e20>, resulting in a decrease in the extent of metabolism of erythromycin by as much as 10%.
mechanism	When <e10> amiodarone </e10> was co-administered with <e20> erythromycin </e20>, the following occurred: 50% of patients taking both drugs developed significant (>10%) increase in Cmax of amiodarone ;
mechanism	When <e10> amiodarone </e10> was administered concomitantly with <e20> cimetidine </e20>, cimetidine plasma concentrations decreased by 5%.
mechanism	When <e10> amiodarone </e10> was co-administered with <e20> ketoconazole </e20>, the following parameters were increased: urinary excretion of digoxin (1-13% increase), butyrophenone (4-9% increase), ethinyl_estradiol (10-14% increase), and triazolam (4-7% increase).
mechanism	<e12> Barbiturates </e12>, cholestyramine, digoxin, metoclopramide, sulfa_thiazide, and sulfamethoxazole may reduce the renal clearance of <e20> atracurium </e20>.
mechanism	<e12> Barbiturates </e12>, quinidine, and cholestyramine may reduce or eliminate the efficacy of quinidine, barbiturates, and <e20> cholestyramine </e20>.
mechanism	<e12> Barbiturates </e12>, sulfonamides, and thiazide_diuretics have been reported to decrease <e20> cisapride </e20> clearance.
mechanism	Barbiturates, <e10> phenytoin </e10>, carbamazepine, and fluconazole may decrease the metabolism of <e20> warfarin </e20>, resulting in elevated serum levels of warfarin and its derivatives.
mechanism	Barbiturates, <e10> phenytoin </e10>, phenobarbital, phenytoin_hydrochloride, <e20> carbamazepine </e20>, diazepam, triazolam, indomethacin, enflurane, cisapride, and rifampin may increase the clearance of oral medications such as enflurane, cisapride, and rifampin.
mechanism	Barbiturates, <e10> phenytoin </e10>, and salicylates, all of which have been reported to inhibit the metabolism of oral <e20> astemizole </e20>, may increase the clearance of the drug and thus may prolong the duration of action of the recommended initial dosing interval of # mg of astemizole per day.
mechanism	Barbiturates, phenytoin, and <e10> ketoconazole </e10> increase the clearance of <e20> lovastatin </e20>.
mechanism	Barbiturates, phenytoin, and other <e12> sulfonamides </e12> inhibit the hepatic metabolism of <e20> digoxin </e20>.
mechanism	Concurrent administration of <e10> clarithromycin </e10> with a <e22> salicylate </e22> may enhance salicylate metabolism.
mechanism	Concurrent administration of <e10> astemizole </e10> tablets with <e20> astemizole </e20> sulfone chewable/buffered tablets may increase the systemic exposure of astemizole.
mechanism	Cimetidine, Ranitidine : <e10> Cimetidine </e10> has been reported to cause a slight increase in the hepatic clearance of <e20> cimetidine </e20>.
mechanism	Cimetidine, Ranitidine : Cimetidine increases <e10> phenytoin </e10> metabolism in rats and in healthy volunteers and may increase the metabolism of <e20> phenytoin </e20>, thereby resulting in increased plasma levels of phenytoin.
mechanism	Cimetidine, Ranitidine : In vitro, <e10> cimetidine </e10> decreased the cytochrome P-450 3A4 activity of <e20> alprazolam </e20> and the INR (9% to 11%).
mechanism	<e10> Terfenadine </e10> (1 mg/kg/day) significantly reduced the urinary excretion of <e20> furosemide </e20> (50 mg/day) and bismuth_subsalicylate (100 mg/day) by 59% and 55%, respectively.
mechanism	<e10> Terfenadine </e10> inhibits <e20> dofetilide </e20> absorption by about 10%, and therefore may be expected to increase plasma concentrations of dofetilide.
mechanism	Terfenadine, <e10> erythromycin </e10>, clarithromycin, indinavir, <e20> ritonavir </e20>, saquinavir, telithromycin, troleandomycin, and/or indinavir can interfere with the metabolism of ethinyl_estradiol, which is used to form C-estradiol by the prostate epithelium.
mechanism	Terfenadine, <e10> erythromycin </e10>, rifampin, and clarithromycin increase <e20> terfenadine </e20> absorption in the intestine and increase plasma concentrations of terfenadine.
mechanism	Terfenadine, <e10> erythromycin </e10>, and triazolam reduce <e20> ketoconazole </e20> binding in vivo.
mechanism	Terfenadine, astemizole, <e10> terfenadine </e10>, and cisapride have been reported to decrease plasma <e20> norethindrone </e20> levels.
mechanism	Terfenadine, astemizole, <e10> methotrexate </e10>, cisapride, <e20> succinylcholine </e20>, quinidine, phenytoin, sertraline, theophylline, triazolam, theophylline_B-ring, and carbamazepine have all been reported to enhance the metabolism of quinidine and/or succinylcholine.
mechanism	Terfenadine, astemizole, <e10> rifampin </e10>, and isoniazid reduce <e20> valproate </e20> absorption by 44%, 40%, and 23%, respectively.
mechanism	Other Potentially Important Drug Interactions: Carbamazepine, other <e12> phenothiazines </e12>, and carbamazepine / diazepam : Coadministration of <e20> carbamazepine </e20> with other phenothiazines (e,g,, alprazolam, diazepam, meclofenamic_acid, fluoxetine, paroxetine, sertraline, venlafaxine ) may increase the clearance of carbamazepine and may increase the elimination half-life of carbamazepine.
mechanism	Other Potentially Important Drugs: <e10> Furosemide </e10> may increase the serum levels of <e20> phenytoin </e20>, phenobarbital, carbamazepine, disopyramide, digoxin, diltiazem, diltiazem_hydrochloride, levodopa, ketoconazole, ketoconazole_hydrochloride, nifedipine, piperacillin_G, quinine, theophylline, zidovudine, and zidovudine_hydrochloride.
mechanism	Other Potentially Important Drug Interactions: Antacids : <e10> Sucralfate </e10> increased the metabolism of <e20> furosemide </e20> by approximately 50%.
mechanism	Other Potentially Important Drug Interactions of Antacids, Amylase_inhibitors, <e10> Amoxicillin </e10>, Amoxicillin_G, <e20> Chloramphenicol </e20>, Chloromycetin, Cholestyramine, Co-administration of Combination: Combination Dosages of Acids, Antacids, Amylase_inhibitors, Antacids, Chloramphenicol, Chloromycetin, Cholestyramine, Co-administration of Combination: Dosages of Acids, Antacids, Amylase_inhibitors, Antacids, Chloromycetin, Chloromycetin, Cholestyramine, Co-administration of Combination: Dosages of Acids, Antacids, Amylase_inhibitors, Antacids, Chloromycetin, Ch
mechanism	Alprazolam : When <e10> alprazolam </e10> was given with <e20> ketoconazole </e20>, serum alprazolam levels increased by 17%.
mechanism	Alprazolam : When <e10> alprazolam </e10> was administered with intravenous <e20> fluconazole </e20>, a decrease in plasma alprazolam concentrations of approximately one-third was observed.
mechanism	Alprazolam : When co-administered with <e10> alprazolam </e10>, <e20> ethanol </e20> significantly increased plasma concentrations of alprazolam by up to 50%.
mechanism	Because <e10> fluvoxamine </e10> is highly cationic, the elimination half-life of <e20> cimetidine </e20> is significantly shortened and may require a higher dose to achieve a stable plasma concentration.
mechanism	Because <e10> fluvoxamine </e10> may inhibit the hepatic metabolism of <e20> rifampin </e20>, or because fluvoxamine increases the levels of rifampin, caution should be exercised when administering rifampin to patients receiving oral agents with similar properties such as fluvoxamine.
mechanism	Because <e10> fluvoxamine </e10> has been reported to decrease the metabolism of <e20> warfarin </e20> and lithium, the potential exists for a drug interaction between warfarin and fluvoxamine.
mechanism	Because <e10> fluvoxamine </e10> is known to increase the absorption of <e20> lithium </e20>, the two drugs may increase the lithium toxicity risk.
mechanism	Because <e10> fluvoxamine </e10> is a potent inhibitor of CYP2D6 and an inhibitor of rifampin metabolism, and because some rifampin substrates have been reported to increase fluvoxamine plasma concentrations, caution is recommended when administering <e20> fluvoxamine </e20> to patients on these medications.
mechanism	Warfarin : When <e10> warfarin </e10> is coadministered with <e20> cimetidine </e20>, the concentration of warfarin in plasma will be reduced, resulting in a lower prothrombin time and prolongation of the QT interval.
mechanism	Warfarin : When <e10> warfarin </e10> and <e20> phenytoin </e20> were coadministered, a similar effect on bleeding occurred as when warfarin and phenytoin were given concomitantly, suggesting that coadministration of warfarin and phenytoin did not result in an increase in phenytoin s blood levels.
mechanism	Warfarin : When <e11> FORADIL </e11> and <e20> warfarin </e20> are coadministered, the prothrombin time is prolonged.
mechanism	Oral doses of <e10> caffeine </e10> are usually reduced by <e20> ketoconazole </e20>, and a single high dose of caffeine may result in a 50% reduction in the clearance of ketoconazole.
mechanism	Oral doses of <e10> cimetidine </e10> # mg and # mg were # and # times the maximum tolerated dose, respectively, of <e20> ketoconazole </e20>.
mechanism	Oral doses of <e10> gabapentin </e10> (15 mg) were increased by 50% when coadministered with <e20> cisapride </e20>.
mechanism	Similarly, <e10> ethanol </e10> and other anesthetics may increase the absorption of <e20> ketamine </e20>.
mechanism	Similarly, <e10> ethanol </e10> markedly increased the exposure of d-methamphetamine, but not <e20> phenylbutazone </e20>, to N,N'-diethyl-m-toluamide.
mechanism	Similarly, <e10> ethanol </e10> and ethanol increase the <e22> natriuretic_agent </e22> -induced increases in plasma levels of N-terminal pro-brain natriuretic peptide (NTproBNP) in humans.
mechanism	Reciprocal interactions may occur between <e10> quinine </e10> and amiodarone, <e20> caffeine </e20>, and almotriptan.
mechanism	Reciprocal interactions may occur between <e10> diltiazem </e10> and warfarin, <e20> carbamazepine </e20>, or other antidepressants, and between warfarin and cyclosporine.
mechanism	Reciprocal interactions may occur between <e10> tetracycline </e10>, fluconazole, and some other anticoagulants or <e22> thrombolytics </e22>.
mechanism	Reciprocal interactions may occur between <e10> valdecoxib </e10> and <e20> diflunisal </e20>, a drug that inhibits gastrointestinal transit time and increases the amount of digoxin that reaches the bone marrow.
mechanism	Reciprocal interactions may occur between <e10> digoxin </e10> and <e20> rifampin </e20>.
mechanism	Reciprocal interactions may occur if <e10> halothane </e10> and <e20> metoclopramide </e20> are coadministered.
mechanism	In an in vitro study, <e10> buprenorphine </e10> significantly inhibited <e20> amphetamine </e20> (500 micrograms/mL) induced increases in both urinary dopamine (20 micrograms/mL) and serotonin (10 micrograms/mL).
mechanism	In an in vitro study, <e10> dantrolene </e10> completely inhibited the <e20> succinylcholine </e20> -induced release of dantrolene.
mechanism	In an in vitro study, <e10> probenecid </e10> was found to decrease the systemic exposure of <e20> indinavir </e20> by about 15% in healthy volunteers.
mechanism	Metoclopramide : When <e10> carbamazepine </e10> and <e20> metoclopramide </e20> are administered concurrently, subjects should be observed closely to determine if the desired blood glucose concentration is achieved.
mechanism	Metoclopramide : When <e10> zidovudine </e10> is coadministered with <e20> metoclopramide </e20>, the dose of zidovudine required to achieve the desired serum concentration is reduced by approximately 50%.
mechanism	Metoclopramide : When coadministered with <e10> metoclopramide </e10>, <e20> zidovudine </e20>, or zidovudine / triazolam, the elimination half-life of zidovudine was significantly prolonged.
mechanism	Antacids : In a double-blind study of <e10> indomethacin </e10> -containing and non-containing antacids, there was a significant decrease in urinary levels of <e20> acyclovir </e20> when indomethacin was added to the antacid containing the anticonvulsant, valdecoxib.
mechanism	Antacids : In one study, <e10> aluminum </e10> increased the intestinal absorption of aluminum from <e20> sucralfate </e20>.
mechanism	Antacids : In rats, the elimination of a single dose of <e10> gentamicin </e10> by the kidneys was reduced by approximately 50% and <e20> ciprofloxacin </e20> by approximately 50%.
mechanism	Antacids : Ingestion of <e10> sucralfate </e10> tablets containing magnesium or aluminum <e20> magnesium </e20> at doses of # mg/kg/day decreased the serum magnesium concentration of sucralfate by 18% and 20%, respectively, compared to sucralfate given with magnesium alone.
mechanism	Antacids : In vitro studies have shown that <e10> iron </e10> and zinc can inhibit the absorption of <e20> acyclovir </e20>.
mechanism	- Drugs that decrease plasma levels of <e11> NUROMAX </e11> may increase plasma levels of <e20> ketoconazole </e20>.
mechanism	- Drugs that induce hepatic enzymes such as <e10> phenytoin </e10>, carbamazepine, phenobarbital, and triazolam may increase the clearance of <e20> diltiazem </e20>.
mechanism	- Drugs that are known to decrease <e10> dopamine </e10> concentrations in the rat brain (e,g,, <e20> halothane </e20> ) increase the clearance of dopamine.
mechanism	- Drugs that are CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, indinavir, <e10> saquinavir </e10>, saquinavir, indinavir, ritonavir, saquinavir, telithromycin, troleandomycin, troleandomycin, itraconazole, itraconazole ) may decrease plasma concentrations of <e20> ketoconazole </e20>, resulting in increased plasma levels of ketoconazole and the potential for drug interactions.
mechanism	- Drugs that are inhibitors of CYP3A4 (eg, <e10> ritonavir </e10>, clarithromycin, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, <e20> troleandomycin </e20> ) may increase the plasma levels of ciprofloxacin, and may require increased dosing to achieve therapeutic plasma concentrations.
mechanism	- Drugs that are highly CYP3A4 substrates (eg, alprazolam, <e10> phenobarbital </e10>, clarithromycin ) have the potential for additive or potentiating effects when co-administered with <e20> clofibrate </e20>.
mechanism	- Drugs that inhibit CYP2C9 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, <e10> indinavir </e10>, nefazodone, nelfinavir ) may increase plasma concentrations of <e20> cyclosporine </e20> and may require increases in cyclosporine doses to achieve an adequate response.
mechanism	- Drugs that may enhance the bioavailability of <e11> TIKOSYN </e11> : Furosemide, <e20> diuretics </e20>, barbiturates, corticosteroids, corticotropin, diltiazem, dipyridamole, estrogens, fentanyl, gabapentin, glutethimide, lithium, methotrexate, methylphenidate, phenytoin, phenytoin_hydrochloride, propranolol, risperidone, thiazide_diuretics, warfarin
mechanism	- Drugs that are potent inhibitors of CYP2C9 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, <e10> nefazodone </e10>, troleandomycin, clarithromycin, astemizole, clarithromycin ) should be used with caution in patients receiving a <e20> nelfinavir </e20> concomitantly.
mechanism	- Drugs that are CYP3A4 inhibitors (e,g,, phenytoin, itraconazole, ritonavir, nelfinavir, clarithromycin, indinavir, <e10> nefazodone </e10>, rifabutin ) increase <e20> phenytoin </e20> plasma levels.
mechanism	- Drugs that inhibit CYP3A4 activity (eg, ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin, indinavir, <e10> nefazadone </e10>, nelfinavir, saquinavir, saquinavir_sulfate, telithromycin, troleandomycin, troleandomycin_sulfate ) may decrease plasma concentrations of <e20> cisapride </e20>.
mechanism	- Drugs that inhibit the metabolism of <e11> INDOCIN </e11>, such as cyclosporine, tacrolimus, digoxin, phenytoin, alfentanil, cisapride, disopyramide, <e20> phenytoin </e20>, rifampin, theophylline, and valproate may decrease the bioavailability of INDOCIN and should be administered with caution.
mechanism	- Drugs that may increase plasma levels of <e10> warfarin </e10> include: phenytoin, digoxin, carbamazepine, <e20> phenobarbital </e20>, alfentanil, albuterol, bromocriptine, cisapride, disopyramide, diltiazem, etodolac, furosemide, lovastatin, phenytoin, rifampin, theophylline, triazolam, zidovudine, and lithium.
mechanism	Naproxen : Coadministration of <e10> naproxen </e10> with <e20> halothane </e20> and succinylcholine decreased naproxen plasma levels by 53%.
mechanism	Naproxen : Coadministration of <e10> naproxen </e10> and <e20> warfarin </e20> (indicated for renal insufficiency) resulted in a significant increase in naproxen clearance.
mechanism	Naproxen : Coadministration of <e10> naproxen </e10> and <e20> alprazolam </e20> decreased naproxen absorption by 42% on average.
mechanism	<e10> Hydrocodone </e10> increased plasma levels of <e20> erythromycin </e20> by #-10%.
mechanism	<e10> Hydrocodone </e10> and Cimetidine increase plasma levels of <e20> estradiol </e20>.
mechanism	<e10> Hydrocodone </e10> has been reported to inhibit the metabolism of <e20> cyclosporine </e20>.
mechanism	Cimetidine : In a clinical trial of # healthy volunteers with C.I. Vitalrex, the combined administration of <e10> cimetidine </e10> and <e20> cimetidine </e20> resulted in an average increase of # mg/day on C.I. Vitalrex.
mechanism	Cimetidine : In a randomized, controlled study, <e10> Cimetidine </e10> caused a dose-dependent increase in plasma levels of <e20> caffeine </e20> and a decrease in the caffeine excretion rate in normal volunteers.
mechanism	Thus <e10> cimetidine </e10> may prolong <e20> ketoconazole </e20> half-life by twofold.
mechanism	Thus <e10> cimetidine </e10> increased plasma <e20> valproic_acid </e20> levels by 6% and 10%, respectively, after # days of treatment.
mechanism	Thus <e10> cimetidine </e10> decreased <e20> diazepam </e20> s clearance by approximately 25%.
mechanism	This small decrease in plasma concentrations of <e10> fosinopril </e10> and <e20> phenytoin </e20> may have been responsible for the increased rate of gastrointestinal toxicity in patients on concurrent high-dose therapy with these agents.
mechanism	This small decrease in the clearance of <e10> doxorubicin </e10> is likely to be an important contributor to the low AUC for <e20> valdecoxib </e20>.
mechanism	This small decrease in the clearance of <e10> digoxin </e10> was not likely due to the significant increase in plasma concentrations of <e20> digoxin </e20> in the presence of a diuretic (dexamethasone ) and thus presumably due to the concurrent lowering of its renal clearance.
mechanism	The Cmax of <e10> ketoconazole </e10> was reduced by 25% and 50% when coadministered with <e20> warfarin </e20> and at a dose of # mg of ketoconazole, respectively.
mechanism	The Cmax of <e10> clofibrate </e10> was increased by #-fold when coadministered with <e20> ketoconazole </e20>.
mechanism	Antacid ( Maalox ) and Caffeine : Antacids or <e10> caffeine </e10> may inhibit the absorption of <e20> ardeparin </e20>.
mechanism	Substances that are potent inhibitors of CYP2C9, such as ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, <e10> nefazodone </e10>, nelfinavir, saquinavir, telithromycin, troleandomycin, and ritonavir, may increase plasma concentrations of <e20> erythromycin </e20>.
mechanism	Substances that are vasoconstricting or thrombolytic, e,g,, phenytoin, <e10> digoxin </e10>, warfarin, rifampin, theophylline, calcium supplements, or <e20> furosemide </e20>, may decrease blood flow and therefore may increase the effect of VIOXX.
mechanism	Substances that are weak inhibitors of CYP3A4 (e,g,, fluconazole, itraconazole, rifampin, ketoconazole, itraconazole_hydrochloride, erythromycin, clarithromycin, <e10> nefazodone </e10> ) may increase plasma concentrations of <e20> diltiazem </e20>.
mechanism	Substances that are potent inhibitors of CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, <e10> ritonavir </e10>, nelfinavir, saquinavir, indinavir, saquinavir, ritonavir, telithromycin, troleandomycin ) may increase plasma concentrations of <e20> rifampin </e20>.
mechanism	Substances that are CYP 3A4 inhibitors (eg, <e10> ketoconazole </e10>, itraconazole, ritonavir, nelfinavir, clarithromycin, indinavir, nefazodone, nefazodone_sodium, ritonavir_sulfate, ritonavir_sulfate, troleandomycin, <e20> troleandomycin </e20>, troleandomycin_sodium, clarithromycin, clarithromycin_sodium ) have a high potential for interaction with itraconazole.
mechanism	Drugs that cause hepatic enzymes to decrease (e,g,, <e10> rifampin </e10>, phenytoin, carbamazepine, fluoxetine, phenobarbital, cimetidine, <e20> valproate </e20>, theophylline ) may reduce the bioavailability of oral cationic_antimicrobial_agents.
mechanism	Drugs that cause hepatic enzymes such as <e10> diazepam </e10>, phenobarbital, and barbiturates may decrease the clearance of <e20> astemizole </e20>.
mechanism	Drugs that cause hepatic enzyme activity (eg, cimetidine, fluconazole, phenytoin, <e10> valproate </e10>, cisapride, carbamazepine, theophylline, disopyramide, phenobarbital, sulfasalazine, salicylates, salicylate_antifungals, and phenytoin ) reduce the clearance of <e20> piperazine </e20>.
mechanism	Drugs that cause renal tubular secretion of <e12> sulfonamides </e12> may reduce the renal clearance of <e20> diflunisal </e20> and may require increases in diflunisal dosage.
mechanism	Drugs that cause metabolism to increase the levels of CYP3A4, such as phenytoin, <e10> phenobarbital </e10>, phenytoin sodium, carbamazepine, <e20> doxapram </e20>, phenytoin, rifampin, clarithromycin, theophylline, theophylline_HCl, thiazide_diuretics, and others that increase the concentration of the active metabolite of a drug, may increase the plasma levels of the active metabolite.
mechanism	Drugs that cause CYP3A4 activity (eg, ketoconazole, itraconazole, <e10> ritonavir </e10>, clarithromycin, nefazodone, nelfinavir, saquinavir, saquinavir/ceftazidime, telithromycin, troleandomycin ) may decrease plasma concentrations of <e20> nelfinavir </e20>.
mechanism	Drugs that cause inhibition of CYP3A4 (eg, rifampin, <e10> clarithromycin </e10>, indinavir, <e20> atazanavir </e20>, saquinavir, saquinavir-boosted HIV drugs) may increase plasma concentrations of nelfinavir.
mechanism	Concomitant administration of <e10> cisapride </e10> with <e20> anagrelide </e20> increased the clearance of anagrelide by approximately 40% compared with anagrelide alone.
mechanism	Concomitant administration of <e10> astemizole </e10> with high doses of <e20> ciprofloxacin </e20> (50 mg, maximum recommended daily dose), fluconazole (50 mg, maximum recommended daily dose), or bacitracin (50 mg, maximum recommended daily dose) increased the AUC and Cmax of astemizole and ciprofloxacin by about 50% and about 20%, respectively.
mechanism	Concomitant administration of <e10> carbamazepine </e10> may potentiate the extent of clearance of <e20> digoxin </e20> and other potentially renal tubular toxins.
mechanism	Concomitant administration of <e10> astemizole </e10> and the <e22> anticholinergic </e22> agent cimetidine (cimetidine, lysergic_acid_antidepressants ) is contraindicated because astemizole blocks the absorption of cimetidine.
mechanism	Concomitant administration of <e10> cisapride </e10> with all known inhibitors of CYP3A4 ( such as ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, nelfinavir, <e20> nefazodone </e20>, ritonavir, saquinavir, telithromycin, troleandomycin, didanosine ) resulted in elevated levels of cisapride.
mechanism	Concomitant administration of <e10> colestipol </e10> and <e20> halothane </e20> in rats significantly increased the plasma levels of halothane.
mechanism	Concomitant administration of <e10> ketoconazole </e10> and <e20> doxorubicin </e20> causes a strong increase in doxorubicin plasma concentrations.
mechanism	Concomitant administration of <e10> digoxin </e10> with oral <e22> coumarin </e22> preparations (eg, chloroquine and disopyramide ) may reduce the renal clearance of digoxin.
mechanism	Concomitant administration of <e10> ketoconazole </e10> and <e20> warfarin </e20> increases the plasma concentrations of warfarin by approximately 5-fold.
mechanism	Concomitant administration of <e10> terfenadine </e10> with <e20> cyclosporine </e20> resulted in a 4-fold increase in the AUC of terfenadine and a 46% increase in the AUC of cyclosporine.
mechanism	Concomitant administration of <e10> carbamazepine </e10> with <e20> cisapride </e20> may increase blood levels of the latter.
mechanism	The absorption of <e11> NUROMAX </e11> is significantly increased when administered in combination with <e20> astemizole </e20>.
mechanism	The absorption of the <e12> benzodiazepines </e12> is increased when they are administered concomitantly with the following:-<e20> Phenobarbital </e20>, carbamazepine, diazepam, alprazolam, alprazolam sulfone, and theophylline.
mechanism	The absorption of <e10> zidovudine </e10>, the active metabolite of the oral contraceptives <e20> arylpropion </e20>, was decreased by a 50% in a diethylpropion pretreatment group, with no change in the other experimental groups.
mechanism	The mean percentage change in ALT from baseline was slightly greater with <e10> warfarin </e10> compared with <e20> rifampin </e20>.
mechanism	Concomitant administration of <e10> ketoconazole </e10> with <e20> nevirapine </e20> may prolong the elimination of nevirapine and increase plasma levels of nevirapine.
mechanism	Concomitant administration of <e10> ketoconazole </e10> and <e20> bacitracin </e20> results in a 17% decrease in bacitracin half-life.
mechanism	Concomitant administration of <e10> methotrexate </e10> and <e20> cisapride </e20> increased plasma concentrations of methotrexate.
mechanism	Administration of <e12> sulfonamides </e12> with other <e22> sympathomimetics </e22> may produce a rise in systemic concentrations of these agents.
mechanism	Administration of <e12> quinolones </e12> with <e20> digoxin </e20> resulted in increased digoxin levels and increased adverse effects.
mechanism	Administration of <e12> tetracyclines </e12> to patients on chronic <e22> salicylate </e22> therapy may lead to a prolongation of the half-life of salicylate, possibly necessitating dose reduction or increase in salicylate dosage.
mechanism	Administration of <e12> aminoglycosides </e12> with calcium_channel_blockers such as nifedipine may increase the serum concentrations of <e20> gentamicin </e20>.
mechanism	Administration of <e12> barbiturates </e12> with <e20> warfarin </e20> produces a transient elevation in warfarin clearance, which may have clinically significant implications for the use of oral anticoagulants or prothrombinics.
mechanism	Caffeine Theobromine <e10> Theobromine </e10> can decrease caffeine plasma levels by approximately 50% in patients consuming <e20> caffeine </e20> (approximately # mg/day) for # days.
mechanism	Caffeine Theobromine <e10> Theobromine </e10> may decrease the bioavailability of <e20> caffeine </e20> by interfering with CYP3A4 metabolism.
mechanism	Caffeine Theobromine <e10> Theobromine </e10> may interfere with the metabolism of caffeine or <e20> caffeine </e20> to its active metabolite, theobromine.
mechanism	Serum theophylline concentrations may be increased by <e10> carbamazepine </e10> and <e20> phenytoin </e20>.
mechanism	Serum theophylline concentrations may increase when <e10> valdecoxib </e10> and <e20> digoxin </e20> are coadministered.
mechanism	Drugs Metabolized by CYP2D6: Atypical_Anticonvulsants ( phenytoin, carbamazepine, <e10> triazolam </e10>, and phenobarbital ): Concomitant use with <e20> phenytoin </e20> may prolong the elimination half-life of this agent.
mechanism	Drugs Metabolized by CYP3A4 (eg, astemizole, ketoconazole, itraconazole, ritonavir, <e10> clarithromycin </e10>, troleandomycin, nelfinavir, saquinavir, indinavir, ritonavir, indinavir, saquinavir, saquinavir, saquinavir, saquinavir, indinavir, ritonavir ): increase the plasma concentrations of <e20> indinavir </e20>.
mechanism	Drugs Metabolized by CYP3A4 (e,g,, <e10> cyclosporine </e10>, tacrolimus, disopyramide, carbamazepine, alfentanyl, fluconazole, alprazolam, phenobarbital, rifampin, quinidine, theophylline, valproate ): In vitro studies with the following drugs demonstrated that <e20> terfenadine </e20> has a pronounced effect on the metabolism of drugs metabolized by CYP3A4 (e,g,, alfentanyl, cyclosporine, tacrolimus, disopyramide, carbamazepine, alprazolam, phenobarbital, rifampin, quinidine ):
mechanism	In addition, other drugs that are CYP3A4 substrates, such as <e10> ketoconazole </e10>, itraconazole, erythromycin, clarithromycin, nefazodone, ritonavir, saquinavir, <e20> troleandomycin </e20>, telithromycin, and nelfinavir may increase plasma concentrations of ritonavir by interfering with metabolism of ritonavir.
mechanism	The administration of <e10> fluvoxamine </e10> at a dose of # mg once daily for # days to patients on <e20> carbamazepine </e20> and/or primidone concurrently reduced the peak serum concentrations of carbamazepine and primidone by approximately 40% and 50%, respectively.
mechanism	The administration of <e10> cimetidine </e10> and <e20> astemizole </e20> # days apart produced an increase in AUC values of cimetidine # mg x hr(-1) and AUC values of astemizole # mg x hr(-1), respectively.
mechanism	The administration of <e10> dexamethasone </e10> at # mg kg(-1) on a daily basis for # days, to a group of patients, resulted in a significant reduction in the plasma concentrations of <e20> cilostazol </e20> and its active metabolite, cilostazol, by a mean of 30% and 40%, respectively.
mechanism	The administration of <e10> ketoconazole </e10> at doses of # mg/day to patients taking <e20> cisapride </e20> # mg daily increased the plasma levels of cisapride by 4% (p=0.016) and that of ketoconazole by 4% (p=0.017).
mechanism	The administration of a single <e10> cholestyramine </e10> dose to healthy volunteers resulted in a significant decrease in plasma concentrations of <e20> ethinyl_estradiol </e20>.
mechanism	The administration of <e10> loperamide </e10> (50 mg) in a dose of # mg daily, to # healthy volunteers, produced a slight increase in mean plasma concentrations of <e20> loperamide </e20>.
mechanism	In a study of patients with nephrotic syndrome who were treated with a single dose of <e11> Solganal </e11> # mg and <e20> phenytoin </e20> # mg, #% of # patients had a decrease in serum creatinine and an increase in serum creatinine and potassium levels.
mechanism	In a study of healthy volunteers, <e10> dantrolene </e10> (30 mg) # hours prior to dosing with a # mg <e20> fluconazole </e20> dose significantly decreased the mean fluconazole AUC from # to # hours by #%.
mechanism	In a study of healthy volunteers, <e10> acetaminophen </e10> (1 mg) significantly decreased <e20> alprazolam </e20> clearance and increased alprazolam plasma concentrations.
mechanism	In # other studies in # healthy volunteers, concomitant administration of <e10> cetirizine </e10> and <e20> carbamazepine </e20> was associated with an approximately 50% increase in carbamazepine plasma concentrations, which occurred within # minutes of carbamazepine ingestion.
mechanism	In # other patients, coadministration of <e10> ketoconazole </e10> with <e20> diltiazem </e20> increased the clearance of diltiazem by approximately 20% to 25%.
mechanism	<e10> Propranolol </e10> may potentiate the effects of drugs which inhibit CYP2C19, including <e20> ketoconazole </e20>, itraconazole, clarithromycin, indinavir, itraconazole, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, and voriconazole.
mechanism	<e10> Propranolol </e10> in atorvastatin, fluvastatin, and fluvoxamine decreased the clearance of <e20> ergotamine </e20>.
mechanism	Single doses of <e10> probenecid </e10> # mg and <e20> isoniazid </e20> # mg decreased the clearance of # mg of AUC0-24 estradiol in # healthy volunteers.
mechanism	Single doses of <e10> caffeine </e10> # mg or <e20> diazepam </e20> # mg increased the clearance of diazepam by #%.
mechanism	Single doses of <e10> isoniazid </e10> # mg once daily (12 x # mg/day) significantly decreased the # mg/day dose of <e20> cimetidine </e20>.
mechanism	<e12> Antacids </e12> increase the absorption of <e20> digoxin </e20>.
mechanism	<e12> Antacids </e12> (like magnesium ) may increase the bioavailability of oral <e20> diltiazem </e20>.
mechanism	<e12> Antacids </e12> may interfere with the absorption of <e20> bromocriptine_mesylate </e20>.
mechanism	Products containing <e10> nifedipine </e10> may interact with <e22> coumarin_anticoagulants </e22>, including warfarin or its derivatives.
mechanism	Products containing <e10> rifampin </e10> and <e20> isoniazid </e20> can interact with rifampin to increase the half-life of rifampin and decrease the plasma concentrations of isoniazid.
mechanism	Products containing <e10> phenytoin </e10> may interact with <e20> warfarin </e20>.
mechanism	Products containing calcium and <e10> magnesium </e10> (including magnesium supplements and multivitamins ) may decrease the absorption of <e20> lithium </e20>.
mechanism	Products containing calcium_acetate or other disulfide-containing compounds (eg, <e10> triamterene </e10> ) may increase the clearance of <e20> norethindrone </e20>, leading to a decrease in its metabolism.
mechanism	Products containing calcium containing antacids or some other calcium-containing supplements may cause hypercalcemia and should therefore not be taken during therapy with <e11> ALFENTA </e11> with <e20> vitamin_D </e20>.
mechanism	Products containing calcium_antagonist_agents ( <e10> furosemide </e10>, amiodarone, or disopyramide ) decrease the plasma levels of <e20> cimetidine </e20>.
mechanism	Products containing calcium, aluminum, or iron containing <e10> diazoxide </e10> may cause excessive serum <e20> calcium </e20> concentrations and are therefore not recommended for the prevention of hypercalcemia in patients undergoing renal dialysis.
mechanism	Products containing calcium or <e10> iron </e10> and any component of the <e22> vitamin_D_triggered_metabolism </e22> (vitamin_D or other vitamin_D_antagonists ) may increase serum calcium concentrations.
mechanism	Methotrexate : <e10> Methotrexate </e10> may decrease the clearance of <e20> warfarin </e20>.
mechanism	Methotrexate : Ibuprofen and <e10> ketoprofen </e10> decrease <e20> methotrexate </e20> absorption in vitro.
mechanism	Lithium : <e10> Lithium </e10> inhibits the hepatic metabolism of <e20> clofibrate </e20>.
mechanism	Lithium : <e10> Lithium </e10> has been reported to have additive effects with <e20> ketoprofen </e20> on the metabolism of lithium, and this may increase the potential for interactions with other antiepileptic_drugs.
mechanism	Lithium : <e10> Lithium </e10> may inhibit the metabolism of <e20> cimetidine </e20> and prolong the half-life of cimetidine.
mechanism	Drugs that may enhance <e10> phenytoin </e10> metabolism (e,g,, cyclosporine, tacrolimus, <e20> digoxin </e20>, disopyramide, amiodarone, phenytoin, phenobarbital, phenytoin_HCl, phenytoin_HCl_sodium, phenytoin_HCl_sulfate, phenobarbital_sodium, phenytoin_HCl_sulfate ) may reduce the clearance of phenytoin.
mechanism	Drugs that may increase plasma concentrations of <e11> WELLBUTRIN </e11> include: bromocriptine_mesylate ( <e20> halothane </e20> ), lithium salts, lithium_hydrochloride, lithium_chloride, theophylline, carbamazepine, caffeine, desipramine, efavirenz, fluoxetine, fluvoxamine, indomethacin, lithium, lithium_containing preparations (eg, Magan, Kadian, etc), nifedipine, phenobarbital, quinidine, theophylline, tricyclic_antidepressants (eg, phenytoin, amitriptyline, imipramine ), and warfarin.
mechanism	Drugs that may decrease plasma levels of <e11> VIDEX </e11> include: phenytoin, carbamazepine, tacrolimus, astemizole, phenobarbital, <e20> carbamazepine </e20>, phenytoin, phenytoin plus primidone, phenytoin plus phenobarbital, phenytoin plus ergot_derivatives, phenobarbital, phenytoin plus ergotamine, phenobarbital plus ergotamine, phenobarbital plus diltiazem, triazolam, valproate, sulfamethoxazole, sulfamethoxazole, and sulfasalazine.
mechanism	<e11> Gleevec </e11> may interfere with the absorption of <e20> warfarin </e20> and its derivatives.
mechanism	<e11> Gleevec </e11> inhibits platelet function, thereby inhibiting <e20> adenosine </e20> synthesis, and is thus a potent inhibitor of platelet function.
mechanism	<e11> Gleevec </e11> inhibits the metabolism of <e20> bromocriptine_mesylate </e20> by inhibiting CYP3A4.
mechanism	<e11> Gleevec </e11> has been reported to enhance the absorption of other oral <e22> anticoagulants </e22>.
mechanism	<e11> Gleevec </e11> is also associated with increases in the clearance of <e20> warfarin </e20> and its derivatives.
mechanism	<e11> Gleevec </e11> increased the Cmax and AUC of <e20> phenytoin </e20> by ~14-fold and increased the Cmax and AUC of dexamethasone by ~8-fold and approximately 4-fold, respectively.
mechanism	<e11> Gleevec </e11> may also inhibit the metabolism of drugs that induce CYP3A4 activity (e,g,, cyclosporine, amiodarone, carbamazepine, <e20> phenobarbital </e20>, alfentanil ).
mechanism	<e11> Gleevec </e11> may increase the serum concentrations of <e20> cisplatin </e20> by decreasing its clearance and increasing the time required for clearance to occur.
mechanism	<e11> Gleevec </e11> may inhibit the metabolism of <e20> valdecoxib </e20> and its potential for renal impairment.
mechanism	Systemic exposure to <e10> rifampin </e10> can be decreased by approximately 50% when <e20> bromocriptine_mesylate </e20> is given concomitantly with it.
mechanism	Systemic exposure to <e10> cyclosporine </e10> in patients with HIV may be increased by coadministration of <e20> rifampin </e20>.
mechanism	Systemic exposure to <e10> quinine </e10> can increase the clearance of <e20> cimetidine </e20>, which is a potent inhibitor of CYP2C9.
mechanism	The plasma concentration of <e10> clindamycin </e10> is increased when administered with probenecid, ciprofloxacin, or <e20> warfarin </e20>.
mechanism	The plasma concentration of <e10> nevirapine </e10> was decreased by 50% when given with a single dose of <e20> ketoconazole </e20>.
mechanism	The plasma concentration of <e10> digoxin </e10> is increased by <e20> phenytoin </e20>, cimetidine, rifampin, valproate, and carbamazepine, and by nonsteroidal_anti-inflammatory drugs ( NSAIDs ) (such as nifedipine, dalfopristin, cimetidine, and disopyramide ).
mechanism	The plasma concentration of <e10> phenytoin </e10> may be increased by coadministration of <e20> furosemide </e20>.
mechanism	The plasma concentration of <e10> lithium </e10> is increased when <e20> phenytoin </e20> is given concurrently.
mechanism	The plasma concentration of <e10> ketoconazole </e10> increased by 1.5-fold when administered concomitantly with <e20> atorvastatin </e20>, although the increase was not clinically significant.
mechanism	The plasma concentration of <e10> diltiazem </e10> increases with <e20> phenytoin </e20> dose.
mechanism	The plasma concentration of <e10> cimetidine </e10> is increased when a similar dosage of <e20> aprepitant </e20> is administered.
mechanism	The plasma concentration of <e10> furosemide </e10> is reduced by approximately 50% when given with <e20> colestipol_hydrochloride </e20>.
mechanism	The plasma concentration of <e10> amiodarone </e10> was reduced by about 46% when coadministered with <e20> lithium </e20>.
mechanism	<e10> Indinavir </e10> inhibits <e20> cyclosporine </e20> metabolism by approximately 25% at # mg/day, a finding similar to that obtained with other drugs known to inhibit cyclosporine metabolism (e,g,, phenytoin, diazepam, carbamazepine ).
mechanism	<e10> Indinavir </e10> and ritonavir, as compared with <e20> ciprofloxacin </e20>, significantly decreased plasma concentrations of indinavir and ritonavir and increased plasma concentrations of ciprofloxacin.
mechanism	<e10> Indinavir </e10> was # times more potent in inhibiting <e20> ritonavir </e20>.
mechanism	In normal volunteers, coadministration of <e10> warfarin </e10> (10 micrograms) with <e20> zalcitabine </e20> at doses of #, #, #, and # mg/kg resulted in a mean increase in warfarin exposure of 50% compared to a mean increase in zalcitabine exposure of only 9% in healthy volunteers.
mechanism	In normal volunteers, <e10> chloramphenicol </e10> # mg once daily decreased plasma levels of <e20> ciprofloxacin </e20>, by 19%.
mechanism	In normal volunteers, single and multiple doses of <e10> alosetron </e10> were found to increase the clearance of <e20> phenytoin </e20> and its AUC in a dose-dependent manner.
mechanism	When <e11> INDOCIN </e11> was administered concomitantly with <e20> amphetamines </e20>, patients experienced an average increase in dmft and a decrease in AUC and Cmax.
mechanism	When <e11> INDOCIN </e11> was coadministered with <e20> cimetidine </e20>, there was a decrease in cimetidine exposure and an increase in indocin dose and Cmax for INDOCIN # mg and INDOCIN # mg.
mechanism	When <e11> INDOCIN </e11> was administered concurrently with <e20> atorvastatin </e20> in a randomized, double-blind, placebo-controlled trial in healthy volunteers, the plasma levels of indocynate (the active metabolite of atorvastatin ) were reduced by approximately 50%.
mechanism	<e11> INDOCIN </e11> has been reported to interact with the following: <e20> cholestyramine </e20>, diclofenac, carbamazepine, cimetidine, cyclosporine, famotidine, fluconazole, fluvoxamine, itraconazole, methadone, alfentanil, cisapride, disopyramide, phenytoin, bromocriptine, valproate, valproate_HCl, terfenadine, and astemizole.
mechanism	<e11> INDOCIN </e11> may increase the bioavailability of oral <e22> anticoagulants </e22>, especially warfarin and its derivatives, which are metabolized predominantly by CYP3A4.
mechanism	<e11> INDOCIN </e11> ( <e20> indomethacin </e20> ) and the nonsteroidal_anti-inflammatory_drug furosemide ( Cimetidine ) have been reported to increase the absorption of ampicillin and rifampin.
mechanism	Capsules <e11> INDOCIN </e11> significantly decreased the clearance of <e20> cyclosporine </e20>, resulting in a significant increase in plasma levels of cyclosporine.
mechanism	Capsules <e11> INDOCIN </e11> significantly reduced <e20> dipyridamole </e20> clearance by 43% compared to control conditions.
mechanism	Capsules <e11> INDOCIN </e11> may have an effect on <e20> clindamycin </e20> clearance.
mechanism	<e11> INDOCIN </e11> decreases the clearance of <e20> ethinyl_estradiol </e20> and propyl_estradiol.
mechanism	<e11> INDOCIN </e11> may reduce the clearance of <e20> dopamine </e20> by affecting the renal clearance of dopamine.
mechanism	<e11> Betaseron </e11> and <e20> diazepam </e20> potentiate each other in vitro for the same target drug.
mechanism	<e11> Betaseron </e11> markedly reduced the <e20> phenytoin </e20> -induced increase in the rate of intestinal absorption.
mechanism	<e11> Betaseron </e11> has been reported to increase the clearance of other CYP3A4 inhibitors, such as <e20> ketoconazole </e20>, itraconazole, itraconazole, phenytoin, ritonavir, saquinavir, telithromycin, troleandomycin and terfenadine.
mechanism	Furthermore it has been demonstrated that <e10> diltiazem </e10> may interact with <e20> carbamazepine </e20> and other potent gastrointestinal proteases causing an increase in serum carbamazepine levels.
mechanism	Furthermore it has been observed that <e10> nevirapine </e10> can prevent the hepatic clearance of <e20> rifampin </e20>, resulting in increased levels of the drug in the urine and blood.
mechanism	Furthermore it has been shown that the pharmacokinetics of <e11> PROLEUKIN </e11> is significantly increased when administered concomitantly with <e20> digoxin </e20>.
mechanism	Carbamazepine : <e10> Carbamazepine </e10> may decrease <e20> acarbazepine </e20> concentrations.
mechanism	Carbamazepine : <e10> Carbamazepine </e10> may enhance the absorption of <e20> cimetidine </e20>.
mechanism	Carbamazepine : <e10> Carbamazepine </e10> is known to increase hepatic enzyme activity, and concomitant <e20> phenytoin </e20> therapy may therefore increase carbamazepine concentrations.
mechanism	Phenytoin : <e10> Phenytoin </e10> prolongs the blood clearance of <e20> cefpirome </e20>, and therefore increases the exposure of cefpirome to achieve its maximum plasma concentration.
mechanism	Phenytoin : <e10> Phenytoin </e10> has been reported to decrease the bioavailability of <e20> caffeine </e20> and caffeine-containing preparations.
mechanism	Phenytoin : <e10> Phenytoin </e10> increases the clearance of <e20> carbamazepine </e20> and may thus reduce the therapeutic index of carbamazepine.
mechanism	Valproate : A dose of <e10> valproate </e10> # mg/day for # days prior to dosing with <e20> cefditoren_ibuprofen </e20> # mg/day resulted in a 2- to 4-fold increase in cefditoren_ibuprofen clearance.
mechanism	Valproate : A dose of # mg/day of <e10> valproate </e10> for # days is reported to have caused a 25% decrease in <e20> warfarin </e20> levels.
mechanism	Valproate : A pharmacokinetic study of <e10> valproate </e10> in patients taking <e20> fluconazole </e20> indicated a 25% increase in the AUC for valproate.
mechanism	Cimetidine : In a study in normal volunteers, <e10> cimetidine </e10> increased the AUC of <e20> clofibrate </e20> by #% (approximately #% increase).
mechanism	Cimetidine : In a study in which <e10> cimetidine </e10> was added to an <e20> zalcitabine </e20> regimen, a decrease in the steady-state levels of zalcitabine was observed.
mechanism	Cimetidine : In a study in healthy volunteers, <e10> cimetidine </e10>, when co-administered with either <e20> alfentanil </e20> or gentamicin, increased mean values of estradiol and the serum concentration of cimetidine.
mechanism	Rifampicin : In vitro, <e10> rifampicin </e10> causes a 3- to 5-fold increase in <e20> digoxin </e20> clearance.
mechanism	Rifampicin : In a study in healthy volunteers, <e10> rifampicin </e10> increased the plasma concentrations of <e20> piperacillin </e20> by approximately 50% and the pH of plasma by approximately 25%.
mechanism	Rifampicin : In a dose-dependent manner, <e10> rifampicin </e10> significantly decreased the half-life of <e20> cisapride </e20>, cisapride metabolized by CYP3A4, by approximately 3-fold.
mechanism	If <e10> rifampicin </e10> was to be administered concurrently with <e20> nevirapine </e20>, the nevirapine dose should be reduced.
mechanism	If <e10> rifampicin </e10> or rifabutin is administered concurrently with <e20> digoxin </e20>, serum digoxin levels should be monitored to determine if the serum digoxin level is high enough to interfere with rifampicin metabolism.
mechanism	If <e10> rifampicin </e10> and <e20> gentamicin </e20> are co-administered, rifampicin levels should be monitored for up to # hours post-administration.
mechanism	Coadministration of <e10> digoxin </e10> with <e20> ketoconazole </e20> caused a 6-fold increase in Cmax and a 26% decrease in AUC, indicating a concomitant increase in renal clearance.
mechanism	Coadministration of <e10> diltiazem </e10> with <e20> quinine </e20> caused a threefold increase in the binding of quinine to serum and urine.
mechanism	Coadministration of <e10> clofibrate </e10> tablets and <e20> zidovudine </e20> tablets resulted in a decrease in the mean AUC of zidovudine.
mechanism	Another oral azole_antifungal, <e10> flucytosine </e10>, can increase the plasma levels of <e20> zidovudine </e20> by three- to fourfold.
mechanism	Another oral azole_antifungal, <e10> ketoconazole </e10>, inhibited <e20> ketoconazole </e20> absorption in a dose-dependent fashion.
mechanism	Human pharmacokinetics data from the NudeBone (NudeBone-HCl) placebo-controlled clinical trial indicate that concomitant administration of <e10> astemizole </e10> and <e20> ketoconazole </e20> may result in a 50% decrease in serum ketoconazole concentrations.
mechanism	Human pharmacokinetics data suggest that <e10> cimetidine </e10> may reduce the clearance of <e20> lithium </e20>.
mechanism	Human pharmacokinetics data suggest that the combination of <e10> nevirapine </e10> and <e20> nelfinavir </e20> may not be suitable for high-dose administration.
mechanism	In vitro data suggest that <e10> enoxacin </e10> inhibited <e20> enoxacin </e20> metabolism by increasing its clearance from blood.
mechanism	In vitro data suggest that <e10> diazepam </e10> may inhibit the metabolism of <e20> ketoconazole </e20>.
mechanism	In vitro data indicate that <e10> ketoconazole </e10> is a potent inhibitor of <e20> warfarin </e20> binding to HIV-1 env and a potent inhibitor of warfarin binding to HIV-1 env protein.
mechanism	Coadministration of <e10> ketoconazole </e10> with <e20> aripiprazole </e20> significantly reduced the clearance of ketoconazole (30% decrease), thus necessitating an increase in AUC and Cmax of ketoconazole.
mechanism	Coadministration of <e10> ciprofloxacin </e10> and <e20> quinine </e20> produced a significant increase in serum concentrations of both drugs, but a lower quinine clearance than with either drug alone.
mechanism	Coadministration of <e10> colestipol </e10> and <e20> dofetilide </e20> in anesthetized rats resulted in a significantly lower AUC of dofetilide and a significantly higher Cmax of dofetilide.
mechanism	When <e10> Itraconazole </e10> and <e20> ketoconazole </e20> were coadministered, the concentration of Itraconazole increased by about 11%.
mechanism	When <e10> Itraconazole </e10> was administered concurrently with <e20> cyclosporine </e20>, itraconazole clearance increased approximately 5-fold, and cyclosporine clearance decreased approximately 5-fold.
mechanism	When <e10> Itraconazole </e10> was given concomitantly with <e20> cyclosporine </e20>, its serum concentrations were reduced, and the reduction was higher in CYP2D6-negative patients.
mechanism	When <e10> Itraconazole </e10> was added to plasma and/or urine samples, an increase in <e20> dasatinib </e20> and rifampin plasma concentrations and a decrease in dasatinib and rifampin urine concentrations were noted.
mechanism	When <e10> Itraconazole </e10> and <e20> cisapride </e20> were coadministered, the AUC and Cmax of Itraconazole were increased by 38% and 55%, respectively.
mechanism	When <e10> Itraconazole </e10> and <e20> diazoxide </e20> were coadministered in vitro, the diazoxide clearance increased by -50%, while itraconazole clearance increased by 50%.
mechanism	Plasma concentrations of <e10> lithium </e10> may be increased when <e20> amphetamine </e20> is administered concomitantly.
mechanism	Plasma concentrations of the <e12> quinolones </e12> (e,g,, ciprofloxacin, clarithromycin, indinavir ) are decreased when administered with <e20> rifampin </e20>.
mechanism	Plasma concentrations of <e10> cyclosporine </e10> are increased by the concomitant administration of <e20> valproic_acid </e20>, a drug known to inhibit CYP3A4 activity.
mechanism	Even when an HMG-CoA_reductase_inhibitor was added to the treatment of <e10> atorvastatin </e10> # mg/day, the reductions in the levels of atorvastatin, <e20> phenytoin </e20>, and glyburide were more pronounced.
mechanism	Even when an <e12> SSRI </e12> is co-administered with <e20> rifampin </e20>, the SSRI reduces the binding of rifampin to the receptor.
mechanism	The following drug interactions have been reported with concomitant administration of <e10> quinine </e10> with phenytoin, carbamazepine, phenobarbital, phenytoin / methotrexate, rifampin, <e20> sulphonylurea </e20>, tacrolimus, or lovastatin : Quinine may increase the clearance of carbamazepine, phenytoin, or methotrexate, resulting in increased plasma concentrations.
mechanism	The following drug interactions have been reported with concomitant administration of <e10> rifabutin </e10> and <e20> indinavir </e20> : rifabutin (100 mg) and indinavir (150 mg) decreased plasma concentrations of rifabutin (16-56% and 13-23%, respectively) in some patients.
mechanism	Human pharmacokinetics data suggest that <e11> WELLBUTRIN </e11> increases plasma levels of <e20> gentamicin </e20> and decreases the clearance of digoxin.
mechanism	Human pharmacokinetics data suggest that the clearance of <e10> indinavir </e10> increases with increased indinavir dose, and the extent to which these changes occur may depend on the presence or absence of co-administration of <e20> ciprofloxacin </e20>.
mechanism	<e10> Ketoconazole </e10> may decrease the clearance of <e20> ketoconazole </e20>.
mechanism	<e10> Ketoconazole </e10> may increase the rate of absorption of <e20> nevirapine </e20>.
mechanism	<e10> Ketoconazole </e10> : <e20> Ketoconazole </e20> increases the exposure of anion-exchange_resins to the binding sites, resulting in decreased binding of cation-exchange_resins to the protein.
mechanism	<e10> Ketoconazole </e10> decreased the maximum plasma concentrations of <e20> ketoconazole </e20> by 43%.
mechanism	<e10> Ketoconazole </e10> and cimetidine have been reported to interfere with the metabolism of <e20> ketoconazole </e20>, resulting in elevated plasma levels of the drug.
mechanism	<e10> Ketoconazole </e10>, given concomitantly with <e20> zalcitabine </e20>, decreases the plasma levels of zalcitabine by about 50% in rats.
mechanism	<e10> Ketoconazole </e10> increased the clearance of <e20> atorvastatin </e20> by 28%, whereas increased the clearance of pravastatin by 43%.
mechanism	<e10> Ketoconazole </e10>, a cell-surface inhibitor of CYP3A4, reduced <e20> alprazolam </e20> clearance by 26%.
mechanism	<e10> Ketoconazole </e10> reduced the <e20> diazepam </e20> absorption in a dose-dependent fashion.
mechanism	Coadministration of <e11> HUMORSOL </e11> # mg and <e20> isoniazid </e20> # mg increased the time to peak and AUC of isoniazid.
mechanism	Coadministration of <e11> RAPTIVA </e11> and <e20> ketoconazole </e20> decreased the clearance of penicillin.
mechanism	Coadministration of <e11> INDOCIN </e11> with carbamazepine, <e20> carbamazepine </e20>, valproic_acid, phenobarbital, and phenytoin resulted in a net decrease in indocyanine green clearance of approximately 50% (indocyanine green) and an increase in total plasma indocyanine green concentration of approximately 50% (phenobarbital).
mechanism	Coadministration of <e11> NUROMAX </e11> and <e20> erythromycin </e20> markedly increased the clearance of the two drugs.
mechanism	Concomitant administration of <e10> furosemide </e10> and <e20> ketoconazole </e20>, an inhibitor of hepatic metabolism of steroids, resulted in elevated levels of estrogens and reduced concentrations of testosterone in rats.
mechanism	Concomitant administration of <e11> Chirocaine </e11> with <e20> cisapride </e20> (a tricyclic_antidepressant ) caused an increase in cisapride plasma levels.
mechanism	Concomitant administration of <e10> azithromycin </e10> and <e20> zidovudine </e20> resulted in significantly elevated concentrations of zidovudine.
mechanism	Concomitant administration of <e10> gentamicin </e10> # mg with <e20> anafranil </e20> # mg resulted in increased anafranil clearance by 31% and an increase in the rate of metabolism of gentamicin by 17%.
mechanism	Concomitant administration of <e11> FOSCAVIR </e11> with the nonsteroidal_anti-inflammatory_drug <e20> furosemide </e20> increased the concentrations of furosemide in the blood and mucosal tissues by 50% and the concentration of furosemide in the blood by 35%.
mechanism	<e10> INH </e10>, ethionamide, and <e20> rifampin </e20> inhibit the metabolism of alfentanil and alfentanil_HCl.
mechanism	<e10> INH </e10>, phenytoin, and amiodarone may reduce the clearance of <e20> cimetidine </e20> by lowering its renal excretion.
mechanism	<e10> INH </e10>, a beta-adrenergic_blocking_agent, may decrease <e20> bromocriptine_mesylate </e20> plasma concentrations and thereby increase the blood levels of bromocriptine_mesylate.
mechanism	INH ( <e10> morphine </e10> ) concentrations increase when <e20> rifampin </e20> is administered.
mechanism	After the coadministration of <e10> probenecid </e10> and <e20> atorvastatin </e20> (10 mg daily), the AUC of cotinine was significantly reduced and the Cmax was increased.
mechanism	After the coadministration of <e10> lofexidine </e10> and <e20> fluvoxamine </e20>, the blood levels of lofexidine were lower than those obtained with fluvoxamine alone.
mechanism	After the coadministration of <e10> diazepam </e10>, the half-life of <e20> isoniazid </e20> was increased and that of diazepam was reduced by a factor of #-1.
mechanism	however, in a study in healthy volunteers, <e10> astemizole </e10> decreased the norethindrone dose by about 50%, which, when added to an norethindrone elimination half-life of <e20> astemizole </e20>, produced a mean peak plasma astemizole concentration of 2.0 microM higher than astemizole alone.
mechanism	however, in a study in male volunteers receiving concomitant <e10> ketoconazole </e10> and <e20> lopinavir </e20>, a significant increase in plasma concentrations of lopinavir was observed when ketoconazole was discontinued.
mechanism	however, in a randomized, crossover study, # mg of <e10> rifampin </e10> decreased the plasma levels of <e20> probenecid </e20> by 25%.
mechanism	however, in a single study in normal volunteers, <e10> haloperidol </e10> # mg and <e20> paroxetine </e20> # mg increased plasma concentrations of both agents at # minutes, and haloperidol increased paroxetine plasma concentrations at # minutes.
mechanism	however, in a post-marketing study of theophylline -containing formulations containing <e10> carbamazepine </e10>, # of # subjects treated with <e20> theophylline </e20> # mg twice daily for # weeks developed an increase in plasma theophylline concentrations of approximately # mg/L.
mechanism	Probenecid : <e10> Probenecid </e10> reduces the clearance of metoclopramide and <e20> metoclopramide </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> increased the level of propranolol and <e20> indomethacin </e20> in a dose-dependent manner.
mechanism	Probenecid : <e10> Probenecid </e10> is associated with increased half-life in patients receiving concomitant <e20> phenytoin </e20> therapy.
mechanism	Methotrexate : <e10> Cholestyramine </e10> decreased the <e20> methotrexate </e20> clearance by about 50% and increased the amount of methotrexate in urine by about 20%.
mechanism	Methotrexate : <e10> Methotrexate </e10> may increase plasma <e20> indinavir </e20> levels.
mechanism	Methotrexate : <e10> Acetazolamide </e10> did not decrease <e20> methotrexate </e20> plasma concentrations and increase plasma levels of methotrexate.
mechanism	Methotrexate : Ketoprofen ( 10 mg/kg/day) inhibited <e10> ketoprofen </e10> -induced <e20> digoxin </e20> secretion by 50%.
mechanism	Methotrexate : Ketoprofen and <e10> doxorubicin </e10> reduce <e20> doxorubicin </e20> serum levels.
mechanism	Warfarin, Digoxin, and Phenytoin : <e10> Cisapride </e10> may increase the metabolism of warfarin, <e20> digoxin </e20>, and phenytoin, resulting in decreased blood levels and increased toxicity.
mechanism	Warfarin, Digoxin, and Co-administration: Co-administration of <e11> FOSCAVIR </e11> with warfarin, <e20> digoxin </e20>, and corticosteroids increased AUC and Cmax.
mechanism	In vitro studies suggest a possible interaction between <e10> digoxin </e10> and <e20> thiazide_diuretics </e20>.
mechanism	In vitro studies indicate that <e10> terfenadine </e10> may have an inhibitory effect on <e20> phenytoin </e20> metabolism.
mechanism	In vitro studies have shown that <e10> erythromycin </e10> has a significant tendency to interact with the following compounds in a dose-dependent manner: carbamazepine, caffeine, fluoxetine, <e20> fluvoxamine </e20>, indomethacin, phenobarbital, alfentanil, disopyramide, disulfiram, terfenadine, theophylline, and bromocriptine.
mechanism	Probenecid : Concomitant administration of <e10> probenecid </e10> with <e20> erythromycin </e20> or other antibiotics has been shown to decrease the clearance of probenecid.
mechanism	Probenecid : Concomitant administration of <e10> probenecid </e10> and <e20> phenytoin </e20> may lead to significant increases in plasma phenytoin concentrations.
mechanism	Probenecid : Concomitant administration of <e10> phenytoin </e10> and <e20> probenecid </e20> may result in decreased plasma levels of probenecid.
mechanism	The effect of <e10> nevirapine </e10> on <e20> cisapride </e20> has been shown to be reversible, with the following decrease in blood levels: (i) citalopram : 18% (p = 0.039) for the nevirapine concentration following a single dose of # mg/day, (ii) lamivudine : 11% (p = 0.039) for the nevirapine concentration following a single dose of # mg/day, (iii) cilostazol : 15% (p = 0.02) for the nevirapine concentration following a single dose of # mg/day.
mechanism	The effect of <e10> erythromycin </e10> on the clearance of warfarin and its derivatives is altered by <e20> atorvastatin </e20>, suggesting a possible drug interaction.
mechanism	Methotrexate : Concomitant administration of <e10> methotrexate </e10> and <e20> dapsone </e20> can cause hypoglycemia.
mechanism	Methotrexate : Concomitant administration of <e10> ethoxzolamide </e10> and <e20> methotrexate </e20> can result in an increased exposure of ethoxzolamide to the liver and a significant decrease in the clearance of methotrexate.
mechanism	Methotrexate : Concomitant administration of <e10> miconazole </e10> tablets with <e20> ketoconazole </e20> tablets increased the number of tablets taken by 5% and the rate of decrease in plasma levels by 50%.
mechanism	Ibuprofen-<e10> Acetazolamide </e10> may decrease the bioavailability of <e20> ibuprofen </e20> by altering the absorption of ibuprofen.
mechanism	Ibuprofen-<e10> Ibuprofen </e10> reduced the formation of <e20> indomethacin </e20> in the rat model of indomethacin toxicity.
mechanism	Ibuprofen-<e10> Imipramine </e10> : inhibition of prostaglandin synthesis may lead to increased levels of <e20> ibuprofen </e20>.
mechanism	Concomitant use of <e10> diltiazem </e10> with <e20> cimetidine </e20> may increase the exposure of cimetidine to a level that may increase the risk of renal toxicity.
mechanism	Concomitant use of <e11> EQUETROTM </e11> and agents with anticholinergic activity, e,g,, atropine_sodium, phenobarbital, phenytoin, carbamazepine, <e20> fluoxetine </e20>, alprazolam, disulfiram, diazepam, methadone, phenytoin, rifampin, saquinavir, and astemizole has been reported to produce elevations in EquETROTM plasma levels.
mechanism	Concomitant use of <e10> methotrexate </e10> with either <e20> fosinopril </e20> or a similar blood pressure-lowering drug has been shown to increase the plasma levels of fosinopril and have clinically relevant effects on its pharmacokinetics.
mechanism	<e10> Cimetidine </e10> also significantly decreased the plasma levels of <e20> warfarin </e20>.
mechanism	<e10> Cimetidine </e10> increases <e20> atracurium </e20> serum concentrations and has no effect on other cytochrome P450 2E1 (CYP2E1) inhibitors ( clarithromycin, nefazodone, phenobarbital, rifampin, methadone, salsalate, theophylline, triazolam ).
mechanism	Results of preliminary in vitro studies indicate that <e10> erythromycin </e10> and <e20> carbamazepine </e20> may interact with the metabolism of carbamazepine and that these interactions may result in decreased absorption of carbamazepine.
mechanism	Results of preliminary studies indicate that <e10> cimetidine </e10> may interfere with the metabolism of certain <e22> antihypertensive_drugs </e22>, such as propranolol and its derivatives, phenytoin, and diltiazem.
mechanism	Results of preliminary studies of <e12> diuretics </e12> suggest a possible drug interaction for <e20> enalapril </e20>.
mechanism	When <e10> lansoprazole </e10> was added to <e20> rifampin </e20>, drug A plasma levels increased by ~30%, whereas rifampin plasma levels decreased.
mechanism	When <e10> lansoprazole </e10> and <e20> ketoconazole </e20> are coadministered, serum concentrations of lansoprazole are generally reduced, with a maximum reduction of approximately 36%.
mechanism	When <e10> lansoprazole </e10> was given concurrently with <e20> phenytoin </e20>, there was a 13% increase in the maximum plasma concentration of lansoprazole.
mechanism	In a single-dose study in healthy volunteers, the AUC of <e10> phenytoin </e10> was decreased by 39% when coadministered with <e20> terfenadine </e20>.
mechanism	In a single-dose study in healthy subjects given <e10> ketoconazole </e10> # mg for # hours prior to dosing with <e20> digoxin </e20> # mg, the decrease in digoxin plasma levels was approximately # times greater when digoxin was given # hours before the concurrent administration of ketoconazole and digoxin.
mechanism	In a single-dose study of a <e12> quinolone </e12> with a <e20> nalidixic_acid </e20>, the concomitant use of either a low-dose nalidixic_acid or a high-dose nalidixic_acid resulted in a significant decrease in nalidixic_acid clearance (p =.017).
mechanism	therefore, it is likely that <e10> warfarin </e10> use will increase with <e20> ergotamine </e20> exposure.
mechanism	therefore, it is not possible to establish a relationship between <e10> fluvoxamine </e10>, <e20> rifampin </e20>, and phenytoin pharmacokinetics.
mechanism	therefore, it is not advisable to use <e10> isoniazid </e10> in combination with <e20> cholestyramine </e20>.
mechanism	therefore, it is advisable to discontinue the <e10> clofibrate </e10> following the administration of <e20> furosemide </e20> to patients on chronic renal dialysis.
mechanism	therefore, it is likely that other CNS_depressants such as <e11> Levo-Dromoran </e11> or other potent GABAergic_inhibitors, such as <e20> Phenobarbital </e20>, will decrease the effectiveness of the Folin_Ciocaltee.
mechanism	therefore, it is possible that <e10> lithium </e10> toxicity may be increased by concomitant administration of <e20> diflunisal </e20>.
mechanism	therefore, it is possible that <e10> zalcitabine </e10> may increase the rate of absorption of other <e22> corticosteroids </e22>.
mechanism	therefore, it is advisable to avoid coadministration of <e10> digoxin </e10> and <e20> thiazide_diuretics </e20>.
mechanism	therefore, it is recommended that <e10> cisplatin </e10> be administered at least # hours following <e20> warfarin </e20>.
mechanism	therefore, it is concluded that <e10> rifampin </e10>, at least in vitro, does not alter the metabolism of <e20> atorvastatin </e20>.
mechanism	therefore, it is concluded that <e10> nifedipine </e10> has an additive effect on the plasma levels of <e20> ketoconazole </e20>.
mechanism	Carbamazepine : In vitro data suggest that <e10> carbamazepine </e10> may inhibit <e20> methotrexate </e20> metabolism by decreasing hepatic enzyme activity and increasing the metabolism of methotrexate.
mechanism	Carbamazepine : In a study in healthy volunteers, carbamazepine and <e10> carbamazepine </e10> (a known CYP3A4 inducer) were both found to decrease <e20> tolbutamide </e20> clearance by -6%.
mechanism	Cholestyramine and Charcoal Tablets <e10> Cholestyramine </e10> (200 mg) and Charcoal Tablets (1 g), given # times daily for # days, significantly decreased plasma levels of <e20> quinidine </e20> and tetracycline.
mechanism	Cholestyramine and Charcoal tablets <e10> Cholestyramine </e10> and a <e20> Charcoal </e20> containing iron or zinc had no effect on zinc absorption.
mechanism	Cholestyramine and Charcoal: <e10> Cholestyramine </e10> may increase the plasma concentration of <e20> carbamazepine </e20>.
mechanism	Cholestyramine and Charcoal <e10> Cholestyramine </e10> (50 mg/day for # days and # mg/day for # days) significantly decreased plasma levels of <e20> ciprofloxacin </e20>.
mechanism	Cholestyramine and Charcoal : <e10> Cholestyramine </e10> and/or <e20> charcoal </e20> may interfere with absorption of orally administered agents that have a binding to hepatic enzymes, such as corticosteroids, methotrexate, corticotropin, digoxin, diazepam, dexamethasone, methadone, alfentanyl, anagrelide, and clofibrate.
mechanism	Cholestyramine and Charcoal-<e10> Cholestyramine </e10> may decrease the bioavailability of <e20> charcoal </e20>.
mechanism	Rifampin : Following coadministration of <e10> rifampin </e10> with <e20> ketoconazole </e20>, the plasma concentrations of rifampin were decreased by approximately 35% and the AUC by approximately 45%.
mechanism	Rifampin : Following administration of <e10> rifampin </e10>, plasma concentrations of <e20> acyclovir </e20> were increased.
mechanism	Rifampin : Following administration of <e10> rifampin </e10> to patients who had received <e20> digoxin </e20>, it was noted that the mean elimination half-life of digoxin decreased from # hours to # hours.
mechanism	Effect of AEDs on CYP3A4 activity: In vitro, <e10> carbamazepine </e10> reduced <e20> cisapride </e20> activity by 18% and increased cisapride clearance by 15%.
mechanism	Effect of AEDs, other potent CYP3A4 inhibitors, on <e10> omeprazole </e10> metabolism: a study in healthy volunteers.AIM: The effect of AEDs, other potent CYP3A4 inhibitors, on the metabolism of omeprazole was studied in a dose-escalation study.METHODS: A549 cells (E.C.1.1.0) were treated with a single <e20> omeprazole </e20> dose of # mg/day for # days followed by a single # mg/day dose of # mg/day for # days.RESULTS: AUC values decreased (p <.05) in a dose-dependent manner and Cmax values increased (p <.05) with a single dose of # mg/day of omeprazole in healthy volunteers.
mechanism	Although no clinical studies have been done to study the effect of <e11> ZYVOX </e11> and <e20> ergotamine </e20> on anticoagulation, the increased prothrombin time observed in ergot-treated patients may be clinically significant.
mechanism	Although no clinical studies have been conducted to evaluate the effect of <e10> cimetidine </e10> on <e20> cimetidine </e20> plasma levels, cimetidine plasma levels should be monitored.
mechanism	However, the systemic exposure of <e10> clofibrate </e10> to patients taking <e20> carbamazepine </e20> or lovastatin may be reduced by approximately 50% when taken concurrently with either of these drugs.
mechanism	However, the systemic exposure of <e10> amphetamines </e10> was reduced by approximately 30% when administered with <e20> ethinyl_estradiol </e20>.
mechanism	However, the systemic absorption of <e10> warfarin </e10> is increased in the presence of <e20> acarbose </e20>.
mechanism	However, the systemic exposure of <e11> ENBREL </e11>, a CYP3A4 inducer, is decreased when it is administered concurrently with <e20> cyclosporine </e20>.
mechanism	However, the systemic exposure of <e10> erythromycin </e10> is increased by <e20> astemizole </e20>.
mechanism	However, the systemic clearance of <e10> diltiazem </e10> was approximately #-fold higher when <e20> dofetilide </e20> was used as a co-factor than when dofetilide was not.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> may increase the clearance of <e20> ergotamine </e20>, resulting in a prolongation of its half-life.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> may increase the clearance of <e20> digoxin </e20>, which is used to treat rheumatic disease.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> may decrease the clearance of digoxin and <e20> doxorubicin </e20>.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> may inhibit the metabolism of <e20> methotrexate </e20> and may increase the clearance of methotrexate.
mechanism	Cholestyramine : <e10> Cholestyramine </e10>, used as a sulphonylurea, has been reported to increase the plasma concentration of <e20> atorvastatin </e20>.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> may reduce the absorption of <e20> warfarin </e20>.
mechanism	<e10> d-amphetamine </e10>, when used concomitantly with <e20> chlorpropamide </e20>, may induce the elimination of acetaminophen (paracetamol ) and thereby enhance the risk of hepatic toxicity.
mechanism	<e10> d-amphetamine </e10>, and <e20> barbiturates </e20>, may inhibit the absorption of some oral anticoagulants, such as warfarin, phenytoin and its derivatives and coumarin.
mechanism	<e10> d-amphetamine </e10>, a known CYP3A4 inhibitor, attenuates the acute toxicity of <e20> cisapride </e20> and cimetidine.
mechanism	<e10> d-amphetamine </e10> increased <e20> furosemide </e20> s renal clearance by 17%, which may have been because of an increase in d-amphetamine clearance.
mechanism	<e10> d-amphetamine </e10> increased the clearance of <e20> lorazepam </e20> and halothane ;
mechanism	<e10> d-amphetamine </e10> was also shown to inhibit the <e20> baclofen </e20> (1,25(OH)2D3 ) metabolism by the cytochrome P450 system and the resulting increase in AUC and Cmax values of baclofen were seen.
mechanism	Ethosuximide : <e12> Antacids </e12> may increase the absorption of <e20> cimetidine </e20>, a metabolite of ethosuximide, by lowering the renal excretion of cimetidine.
mechanism	Ethosuximide : <e12> Quinolones </e12> can increase the clearance of <e20> ethosuximide </e20>.
mechanism	Ethosuximide : <e12> Quinolones </e12>, including <e20> dorzolamide </e20>, have been reported to interfere with the metabolism of ethosuximide.
mechanism	Methenamine therapy Urinary tract infections have been reported with concomitant use of <e10> methenamine </e10> and <e20> colistin </e20>, cyclosporine, amiodarone, bromocriptine, carbamazepine, diltiazem, diltiazem_hydrochloride, doxycycline, doxycycline_hydrochloride, estrogens, estrogens_estrogens, fluoxetine, fluoxetine_hydrochloride, fluvoxamine, furosemide, grapefruit juice, heparin, hydrocodone, indomethacin, inositol_chloride, itraconazole, ketoconazole, loratadine, methadone, nizatidine, piperazine, perphenazine, phenylbutazone, salicylate, tacrolimus, valproate,
mechanism	Methenamine therapy Urinary retention and increased urinary excretion have been reported in patients receiving <e10> methenamine </e10> and <e20> pentobarbital </e20>.
mechanism	Methenamine therapy Urinary excretion of methenamine decreased from 571  36 mg/day to <e10> methenamine </e10> was <e20> ethinyl_estradiol </e20> decreased from 11  1 ng/mL to 1  0.3 ng/mL.
mechanism	Phenobarbital : <e12> NSAIDs </e12> decrease the absorption of <e20> phenobarbital </e20>.
mechanism	Phenobarbital : <e12> Barbiturates </e12>, like other CNS_depressants, can diminish the clearance of <e22> phenobarbital </e22> and may increase serum concentrations of phenobarbital.
mechanism	Phenytoin : <e12> Amphetamines </e12> decrease plasma levels of <e20> phenytoin </e20>.
mechanism	Phenytoin : <e12> Amphetamines </e12> inhibit the metabolism of <e20> phenytoin </e20>, resulting in the depletion of its metabolites.
mechanism	Antacids and sucralfate : Studies in guinea pigs indicate that <e10> sucralfate </e10> and <e20> carbamazepine </e20> significantly decrease serum acylcarnitine concentrations by about 50% and 20%, respectively.
mechanism	Antacids and sucralfate : When administered concomitantly, <e10> fluvoxamine </e10>, <e20> acitretin </e20>, and probenecid increased fluvoxamine and probenecid exposure by about 50%.
mechanism	Antacids and sucralfate : Magnesium : <e10> Magnesium </e10> supplements may decrease the absorption of <e20> zidovudine </e20> by decreasing the amount of aluminum in the gastrointestinal tract.
mechanism	Antacids and sucralfate : Antacids and sucralfate (an antacid ) may interfere with the absorption of <e10> ketoconazole </e10>, resulting in increased serum concentrations of <e20> ketoconazole </e20>.
mechanism	<e10> Sucralfate </e10>, which has a narrow therapeutic index, may increase the plasma concentration of <e20> digoxin </e20>, resulting in elevated plasma concentrations of digoxin and resulting in increased toxicity.
mechanism	<e10> Sucralfate </e10> decreases plasma <e20> indinavir </e20> concentrations and may increase plasma exposure of indinavir.
mechanism	<e10> Sucralfate </e10> may interfere with the metabolism of <e20> sodium_thiosulfate </e20>.
mechanism	<e10> Magnesium </e10> supplements may inhibit absorption of <e20> lithium </e20>.
mechanism	<e10> Magnesium </e10>-and aluminum -containing antacids may increase the absorption of <e20> doxorubicin </e20> and other methotrexate s.
mechanism	<e10> Magnesium </e10> / <e20> aluminum </e20> -containing antacids ( Magnesium-and aluminum -containing food supplements ) are both potent inhibitors of HMG-CoA_reductase and have been shown to decrease the plasma levels of an HMG-CoA_reductase inhibitor ( olprin_sulfate ).
mechanism	Magnesium-and aluminum -containing antacids (as with Magan and other <e12> antacids </e12> ) inhibit the metabolism of <e20> nicotinic_acid </e20>, resulting in a high concentration of 5-hydroxymethybilterdiene in the blood.
mechanism	Magnesium-and aluminum -containing antacids, <e10> aluminum </e10> containing antacids, and H2-blocking agents may interfere with <e20> bexarotene </e20> absorption, leading to increases in serum and urine levels of bexarotene.
mechanism	Magnesium-and aluminum -containing antacids : Magnesium -containing antacids, such as <e10> Magnesium </e10>, aluminum and zinc containing antacids, may reduce the bioavailability of <e20> estradiol </e20> by affecting the rate of conjugation of the two components.
mechanism	Separating the doses of <e10> acitretin </e10> and <e20> atorvastatin </e20> is likely to have a minor effect on the AUC and Cmax of the C-Phenylbutazone metabolite.
mechanism	Separating the doses of <e10> lithium </e10> and <e20> terfenadine </e20> may increase the half-life of lithium.
mechanism	Separating the doses of <e10> phenytoin </e10> and <e20> terfenadine </e20> increased the plasma concentrations of phenytoin by 50% to approximately 400% (mean fluence, 4.1% increase; range, 0-15%).
mechanism	Other <e12> quinolones </e12> have been reported to inhibit CYP3A4 activity and may increase plasma concentrations of <e20> isoniazid </e20> and other CYP3A4 inhibitors.
mechanism	Other <e12> quinolones </e12> have been reported to increase the clearance of oral <e20> diltiazem </e20> and decrease the effect of diltiazem on antihypertensive_drugs.
mechanism	Other <e12> quinolones </e12>, including ciprofloxacin, cause decreased clearance of <e20> warfarin </e20>.
mechanism	Cimetidine : <e10> Cimetidine </e10> may decrease the renal clearance of <e20> phenytoin </e20> and enhance the clearance of the sulfonamides.
mechanism	Cimetidine : <e10> Cimetidine </e10> has been reported to decrease the hepatic clearance of <e20> estradiol </e20> and increase the clearance of vitamin_D.
mechanism	Cimetidine : <e10> Cimetidine </e10> reduced the plasma concentrations of <e20> valdecoxib </e20>, did not alter the elimination half-life of valdecoxib, and did not affect the hepatic metabolism of valdecoxib.
mechanism	Probenecid : As with other <e12> quinolones </e12>, the effect of <e20> probenecid </e20> may be potentiated by antacids containing calcium, magnesium, aluminum, or aluminum containing multivalent cations (e,g,, aluminum ).
mechanism	<e10> Rifampin </e10>, which is an inhibitor of CYP3A4, has been reported to increase the clearance of <e20> astemizole </e20> and related drugs by decreasing hepatic metabolism.
mechanism	<e10> Rifampin </e10> reduced the hepatic enzyme response to <e20> ciprofloxacin </e20>.
mechanism	<e10> Rifampin </e10> blocks <e20> cimetidine </e20> metabolism by inhibiting cytochrome P450 3A4, which is involved in the second step of the cimetidine metabolism.
mechanism	<e10> Fluconazole </e10> may enhance the effect of certain antacids, e,g,, sodium bicarbonate, sulfonamides, magnesium salts, and <e20> magnesium oxide </e20>.
mechanism	<e10> Fluconazole </e10> reduced the plasma concentrations of <e20> diltiazem </e20>.
mechanism	<e10> Fluconazole </e10> : Increased hepatic enzyme activity may result in increased hepatic exposure of <e20> ketoconazole </e20>, resulting in elevated levels of ketoconazole.
mechanism	The absorption of <e10> isoniazid </e10> is impaired when coadministered with <e20> nitrofurantoin </e20>.
mechanism	The absorption of <e10> erythromycin </e10> is enhanced by <e20> methotrexate </e20>.
mechanism	The absorption of <e10> digoxin </e10> is increased by <e20> valdecoxib </e20>.
mechanism	Antacids : In a dose-escalation study, <e10> colestipol </e10> was found to reduce the intestinal absorption of <e20> dextran </e20> and its glucuronide and sulfate components by 33% and 42%, respectively.
mechanism	Antacids : In patients on <e12> antacids </e12>, the concomitant administration of <e20> methotrexate </e20> and a single dose of a single dose of a toxic dose of ABAVA-2,739 decreased the methotrexate AUC by 50% (P =.002).
mechanism	Cholestyramine -Concomitant intake of <e10> cholestyramine </e10> and <e20> warfarin </e20> is likely to increase the therapeutic index of the latter.
mechanism	Cholestyramine -Concomitant intake of <e10> cholestyramine </e10> with <e20> l-arginine </e20> (200 mg daily) produced a 3.7-fold increase in hepatic excretion of l-arginine compared with l-arginine alone.
mechanism	Cholestyramine -Concomitant intake of <e10> cholestyramine </e10> and <e20> acetaminophen </e20> may increase the absorption of acetaminophen.
mechanism	Colestipol -Concomitant intake of <e10> colestipol </e10> and <e20> erythromycin </e20> may result in a reduction in the absorption of these drugs.
mechanism	Colestipol -Concomitant intake of <e11> BOTOX </e11> with colestipol has been reported to cause an increase in the levels of the metabolite <e20> citalopram </e20>.
mechanism	Colestipol -Concomitant intake of <e10> colestipol </e10> and a drug with an absorption enhancer ( <e20> erythromycin </e20> ) may enhance the absorption of the drug.
mechanism	Orlistat-<e10> Rifampin </e10>, as a glucocorticoid, may inhibit the metabolism of <e20> orlistat </e20> by inhibiting its absorption and elimination.
mechanism	Orlistat-<e10> Orlistat </e10> reduced the rate of <e20> ketoconazole </e20> metabolism by about 20%.
mechanism	Orlistat-<e10> Orlistat </e10>, by inhibiting prostaglandin synthesis, may decrease the availability of <e20> fluvastatin </e20> and other CYP3A4 inhibitors.
mechanism	Elevated plasma levels of <e10> erythromycin </e10> have been reported in patients receiving <e20> piperazine </e20>, another CYP3A4 inducer.
mechanism	Elevated plasma levels of phenytoin or <e10> carbamazepine </e10> may produce toxicity when coadministered with <e20> valdecoxib </e20>.
mechanism	Elevated plasma levels of <e10> estradiol </e10> were found to be responsible for a reduction of <e20> tamoxifen </e20> clearance in # of the 5 placebo-treated patients and in # of the 40 tamoxifen-treated patients.
mechanism	<e12> Quinolones </e12> have been shown to have hepatotoxic potential when administered concomitantly with nonsteroidal_anti-inflammatory_agents ( <e22> NSAIDs </e22> ) or other medications that are highly protein bound, including cyclosporine, diclofenac, tacrolimus, indomethacin, itraconazole, and phenytoin.
mechanism	<e12> Quinolones </e12> reduce the clearance of C maxide, resulting in lower serum concentrations and longer retention of <e20> triazolam </e20>.
mechanism	and <e11> Videx </e11> or Vardenafil : Use of <e20> enoxacin </e20> or its derivatives with high plasma concentrations, including Videx or Vardenafil, may cause a sharp increase in plasma enoxacin levels, resulting in a sharp rise in enoxacin toxicity.
mechanism	and <e11> Videx </e11> should be administered # minutes after or # minutes before an <e20> phenytoin </e20> or carbamazepine.
mechanism	and Videx, <e10> quinine </e10>, and tetracycline can interact with <e20> digoxin </e20>, causing the lowest serum digoxin levels of any drugs tested.
mechanism	and Videx, <e10> furosemide </e10>, and acetaminophen may interfere with absorption of <e20> diltiazem </e20>.
mechanism	and Videx, <e10> Acitretin </e10> and Cimetidine may reduce the renal clearance of <e20> ketoconazole </e20> and decrease its effect on renal tubular secretion of vitamin_K.
mechanism	<e10> Probenecid </e10>, as well as other related compounds, produce renal impairment when administered concurrently with <e20> nephrotoxic_agents </e20>.
mechanism	<e10> Probenecid </e10>, which has been shown to decrease platelet function by inhibiting platelet-aggregation, was associated with a decrease in <e20> furosemide </e20> concentrations in healthy volunteers.
mechanism	<e10> Probenecid </e10>, a benzodiazepine_antidepressant, may increase the clearance of <e20> cimetidine </e20>.
mechanism	<e10> Naproxen </e10> decreased the rate of excretion of <e20> morphine </e20> and enhanced the rate of excretion of diazepam, a benzodiazepine with morphine activity.
mechanism	<e10> Naproxen </e10> may increase <e20> methotrexate </e20> clearance and, therefore, increase the risk of methotrexate toxicity.
mechanism	<e10> Naproxen </e10> may decrease the clearance of <e20> ketoconazole </e20> and may increase the clearance of vitamin_K.
mechanism	After multiple dosing, <e10> CMI </e10> # mg demonstrated dose-dependent increases in # micrograms of CMI/mg of <e20> cisapride </e20>.
mechanism	After multiple dosing, there were increases in plasma <e10> phenytoin </e10> concentrations (1.9 to 3.9 fold) and serum <e20> phenytoin </e20> concentrations (0.6 to 2.7 fold).
mechanism	After multiple dosing, a significant increase in the clearance of <e10> methotrexate </e10> was observed when coadministered with <e20> amitriptyline </e20>, at two to three times the normal dose.
mechanism	<e11> Starlix </e11>, an oral <e22> anticoagulant </e22>, may prolong prothrombin time.
mechanism	<e11> Starlix </e11>, also known as disopyramide, is a novel glucocorticoid-derived agent with antihypertensive activity that has been shown to decrease plasma <e20> dexamethasone </e20> levels.
mechanism	<e11> Starlix </e11>, estrogens, and progesterone may all interfere with <e20> indinavir </e20> metabolism, resulting in an increased plasma indinavir concentration.
mechanism	Ritonavir : Coadministration of <e10> ritonavir </e10> with <e20> astemizole </e20> resulted in a 50% increase in astemizole clearance.
mechanism	Ritonavir : Coadministration of <e10> ritonavir </e10> and <e20> cimetidine </e20> significantly decreased cimetidine AUC and Cmax.
mechanism	Ketoconazole : Coadministration of <e10> ketoconazole </e10> with <e20> diltiazem </e20> decreased the AUC by 43%.
mechanism	Ketoconazole : Coadministration of <e10> ketoconazole </e10> (20 mg twice daily) with <e20> clofibrate </e20> (5 mg once daily) for # weeks caused a reduction in the AUC of clofibrate to #% of its baseline value.
mechanism	Ketoconazole : Coadministration of <e10> ketoconazole </e10> and <e20> ketoprofen </e20> produced a 20% increase in plasma concentration of the A1 and A2 isomer of ketoprofen.
mechanism	Rifabutin : Coadministration of <e10> rifabutin </e10> # mg with <e20> ketoconazole </e20> # mg decreased its toxicity, but did not increase rifabutin clearance or rifabutin AUC values.
mechanism	Rifampin : Coadministration of <e10> rifampin </e10> with <e20> phenytoin </e20> significantly reduced the AUC of rifampin by 36% and increased the AUC of phenytoin by 27%.
mechanism	Rifampin : Coadministration of <e10> rifampin </e10> # mg/day for # days with <e20> dexamethasone </e20> for # days resulted in a 31% increase in AUC of dexamethasone, and a 41% increase in Cmax and AUC.
mechanism	Rifampin : Coadministration of <e11> HUMORSOL </e11> with <e20> rifampin </e20> resulted in an increase in its clearance of approximately 40% compared with administration of HUMORSOL alone.
mechanism	Oral <e10> neomycin </e10> and <e20> ciprofloxacin </e20>, as well as oral ampicillin and penicillin, interfere with the metabolism of the antibiotic and may increase the toxicity of ciprofloxacin.
mechanism	Oral <e10> neomycin </e10> may potentiate the blood-sugar-reducing effects of <e20> digoxin </e20>, glyburide, and oral antidiabetic_drugs.
mechanism	Oral <e10> neomycin </e10> (75 mg daily) was found to reduce the dose of <e20> levodopa </e20> to 3 times lower than that of placebo.
mechanism	Oral <e10> neomycin </e10> may increase the plasma concentrations of <e20> erythromycin </e20> and may decrease the absorption of sulfonamides, and high concentrations of oral neomycin may decrease the absorption of penicillins, azoles, sulfonamides, and carbamazepine.
mechanism	Oral <e10> neomycin </e10> and sulfasalazine in vitro decrease the clearance of <e20> phenytoin </e20>, levodopa, and astemizole.
mechanism	Oral <e10> neomycin </e10> at a dose of # mg/kg and # mg/kg/day decreased the elimination of <e20> methotrexate </e20> by 50% and 35%, respectively, and decreased the elimination of digoxin by 50% and 45%, respectively.
mechanism	Oral <e10> neomycin </e10> has been reported to increase the clearance of <e20> diltiazem </e20>.
mechanism	Oral <e10> neomycin </e10> may interfere with absorption of <e20> zalcitabine </e20>, leading to decreased plasma levels.
mechanism	Oral <e10> neomycin </e10> administration reduced the clearance of <e20> ketoconazole </e20> by approximately 50% and caused a slight increase in serum concentrations of ketoconazole.
mechanism	<e10> Clarithromycin </e10> reduced the cytochrome P-450 (CYP) 3A4 activity of <e20> colestipol </e20> and resulted in a significant reduction in the bioavailability of both doses of colestipol.
mechanism	<e10> Clarithromycin </e10> has been reported to decrease the clearance of <e20> warfarin </e20>.
mechanism	<e10> Clarithromycin </e10> reduced the pharmacokinetic profile of <e20> clarithromycin </e20> by approximately 40% (P = 0.002) and, as a consequence, a significant increase in plasma concentrations (median) occurred (48% increase, P = 0.009).
mechanism	Digoxin : Some reports have shown that <e12> anticoagulants </e12> may interfere with the metabolism of <e20> digoxin </e20>.
mechanism	Quinidine : Immediate Release Tablets : Quinidine is reported to increase the clearance of <e10> cimetidine </e10>, and its effect on the metabolism of <e20> levodopa </e20> and doxepin has been reported.
mechanism	Quinidine : Immediate release tablets containing <e10> quinidine </e10> may increase the clearance of <e20> warfarin </e20>.
mechanism	Quinidine : Immediate Release Tablets <e10> Quinidine </e10> tablets, like other nonsteroidal_anti-inflammatory_drugs, increase plasma concentrations of <e20> norfloxacin </e20> and its metabolite, thus decreasing its absorption.
mechanism	A study in diabetic patients showed a reduction in plasma <e10> digoxin </e10> levels when <e20> ketoconazole </e20> and digoxin were co-administered at 50 mg.
mechanism	A study in vitro showed that <e10> cimetidine </e10> and <e20> caffeine </e20> were competitive inhibitors of HMG-CoA_reductase_inhibitors ( cimetidine, simvastatin, fluvastatin, and fluvoxamine ) and an HMG-CoA_reductase_inhibitor ( ritonavir ) in vitro.
mechanism	A study in patients receiving <e10> erythromycin </e10> alone showed a significant decrease in plasma <e20> cyclosporine </e20> levels (a potent inducer of oxidative stress) when administered concurrently with 50 mg cyclosporine /day.
mechanism	A # to # mg <e10> ketoconazole </e10> dose reduced the efficacy of # to # mg <e20> indinavir </e20>.
mechanism	A # to # mg dose of <e10> diltiazem </e10> # mg once daily decreased the plasma levels of <e20> cisapride </e20> by 11%, while the oral clearance of cisapride increased by 25%.
mechanism	Coadministration of <e10> indomethacin </e10> with <e20> clarithromycin </e20> resulted in an increase in clarithromycin plasma concentrations and a decrease in clarithromycin clearance.
mechanism	Coadministration of <e10> rifabutin </e10> and <e20> bovine_sodium </e20> resulted in a 30% increase in the AUC of bovine_sodium and a 24% decrease in the Cmax of rifabutin.
mechanism	Coadministration of <e10> ketoconazole </e10> # mg daily with <e20> cisapride </e20> # mg for # days reduced cisapride plasma concentrations by 34% compared to cisapride alone.
mechanism	<e10> Quinidine </e10>, the active metabolite of the ethionamide metabolite of <e20> salicylate </e20>, has been reported to decrease the clearance of the salicylate metabolite and therefore the bioavailability of salicylate.
mechanism	<e10> Quinidine </e10> may decrease the bioavailability of <e20> ketoconazole </e20>.
mechanism	<e10> Quinidine </e10>, cimetidine, rifampin, or isoniazid can decrease the clearance of <e20> warfarin </e20>.
mechanism	Therefore, caution should be exercised when <e10> caffeine </e10> and <e20> ethanol </e20> are used concomitantly.
mechanism	Therefore, caution should be exercised when administering <e10> fluvoxamine </e10> to patients receiving ketoconazole or <e20> astemizole </e20>.
mechanism	Therefore, caution should be exercised when <e10> methotrexate </e10> is administered concomitantly with <e20> azithromycin </e20>.
mechanism	Uricosuric_drugs, such as <e10> phenytoin </e10>, may cause increased concentrations of <e20> digoxin </e20>.
mechanism	Uricosuric_drugs, such as <e10> carbamazepine </e10>, may reduce the clearance of <e20> diazepam </e20> and, therefore, may increase the plasma concentration of diazepam.
mechanism	Uricosuric_drugs, such as <e10> theophylline </e10>, dihydroergotamine, digoxin, and warfarin, may increase the clearance of <e20> bepridil_hydrochloride </e20> and other cationic_sodium_diuretics.
mechanism	In patients given <e10> terfenadine </e10> and <e20> nifedipine </e20> concurrently, both drugs caused a reduction in maximum plasma levels of terfenadine by approximately 8%.
mechanism	In patients given <e10> amiodarone </e10> for # days and then given # mg of <e20> ergotamine </e20>, the amiodarone levels increased by > 20%.
mechanism	In patients given the concomitant use of <e11> ZYVOX </e11> and drugs that have a strong renal absorption (eg, phenytoin, <e20> carbamazepine </e20>, and isoniazid ), the renal clearance of ZYVOX may be decreased and a significant increase in serum creatinine levels may occur.
mechanism	Elevated plasma levels of <e10> diltiazem </e10> may have resulted in elevated plasma levels of <e20> carbamazepine </e20>, thereby inhibiting its metabolism.
mechanism	Elevated plasma levels of <e10> digoxin </e10> may have led to the observation of elevated plasma levels of <e20> digoxin </e20> in patients with a normal hepatic function.
mechanism	Elevated plasma levels of <e10> cisplatin </e10> were observed in two patients with elevated plasma levels of <e20> cisplatin </e20> but not in the control group.
mechanism	Elevated serum levels of dopamine have been reported with concomitant use of <e10> ketoconazole </e10> and <e20> quinine </e20>.
mechanism	Elevated serum levels of <e10> estradiol </e10> and <e20> progesterone </e20> may cause an increase in prothrombin time, resulting in decreased plasma levels of the progestin.
mechanism	Elevated serum levels of <e10> cimetidine </e10> may have resulted in an increased clearance of <e20> epirubicin </e20> and may have reduced the efficacy of cimetidine.
mechanism	Some <e12> quinolones </e12> inhibit the hepatic metabolism of <e20> phenytoin </e20>.
mechanism	Some <e12> quinolones </e12> inhibit the metabolism of ketoconazole and therefore may increase the clearance of <e20> ketoconazole </e20>.
mechanism	Some <e12> quinolones </e12> have been reported to have a drug interaction with either cimetidine or <e20> warfarin </e20>.
mechanism	Steady-state serum concentrations of <e10> ciprofloxacin </e10> in patients taking <e20> dapsone </e20> are approximately halved compared to ciprofloxacin alone, suggesting that the prothrombin time is prolonged when ciprofloxacin is used in combination with dapsone.
mechanism	Steady-state serum concentrations of <e10> alprazolam </e10> are substantially increased when coadministered with <e20> atropine_sulfate </e20>.
mechanism	Steady-state serum concentrations of <e10> digoxin </e10> decreased by approximately 15% when <e20> nifedipine </e20> was added to the combination therapy.
mechanism	In addition, higher-than-expected plasma concentrations of <e10> ketoconazole </e10> were observed when <e20> furosemide </e20> was co-administered with ketoconazole.
mechanism	In addition, higher-than-expected serum concentrations of <e10> diltiazem </e10> were observed in patients who received a <e20> rifampin </e20> dose of # mg in combination with # mg of diltiazem (mean dose, # mg/day).
mechanism	In addition, higher-than-expected blood levels of <e10> probenecid </e10> have been observed with concurrent use of <e20> doxorubicin </e20> in cancer patients.
mechanism	In well-controlled patients, <e10> nelfinavir </e10> significantly reduced <e20> isoniazid </e20> plasma levels and resulted in a 5% increase in the AUC for isoniazid (p=0.008).
mechanism	In well-controlled patients with elevated plasma levels of <e10> doxapram </e10>, <e20> ketoconazole </e20> therapy decreased the plasma levels of doxapram by an average of 62%.
mechanism	There have been reports of significant increases in serum levels of <e10> ketoconazole </e10> when <e20> rifampin </e20> and cyclosporine were coadministered.
mechanism	There have been reports of reduced plasma levels of <e10> gentamicin </e10> in patients receiving carbamazepine, cimetidine, or <e20> verapamil </e20>.
mechanism	There have been reports of concomitant administration of <e10> carbamazepine </e10> with <e20> oxcarbazepine </e20>, phenobarbital with oxcarbazepine, phenytoin with carbamazepine, and gabapentin with carbamazepine.
mechanism	There have been reports of interactions of <e10> ketoconazole </e10> with a high oral dose of <e20> ketoconazole </e20> and fluconazole.
mechanism	There have been reports of increased serum levels of <e10> enoxacin </e10> when it was given concomitantly with <e20> ketoconazole </e20>.
mechanism	Calcium_Antagonist s: After coadministration of <e10> amiodarone </e10> # mg and <e20> calcium_antagonist </e20> s, the dose of the prodrug increased by 17% and was observed to increase by 18% after coadministration of the calcium_antagonist s for # days and to increase by 20% after coadministration for # days of triamterene and atorvastatin.
mechanism	Calcium_Antagonist s: After a single administration of <e11> VIDEX </e11> # mg, the plasma concentration of <e20> phenytoin </e20> was approximately halved.
mechanism	Pharmacokinetic data from a single patient with the nevirapine CYP3A4 inhibitor <e10> nevirapine </e10> and the substrate ( <e20> rifampin </e20> ) indicate that nevirapine (40 mg q8h) significantly reduced the plasma concentrations of rifampin (60 mg q12h).
mechanism	Pharmacokinetic data from studies in healthy subjects indicate a potential drug interaction between <e11> ENBREL </e11> and <e20> warfarin </e20>.
mechanism	Pharmacokinetic data from a phase II trial of <e10> rifampin </e10> and rifabutin with # mg of <e20> bromocriptine_mesylate </e20> are reported.
mechanism	Treatment with <e11> ENBREL </e11> reduced <e20> enoxacin </e20> renal clearance by approximately 27% and increased its serum concentration approximately threefold.
mechanism	Treatment with <e11> ELSPAR </e11> # mg/day for # days before and # days after <e20> methotrexate </e20> reduced the maximum rate of decrease in serum methotrexate levels by 54% (p = 0.003) and decreased the mean maximum serum methotrexate levels by 19% (p = 0.005) compared to the placebo group.
mechanism	Treatment with <e11> VIRACEPT </e11> prior to coadministration of <e20> carbamazepine </e20> resulted in an approximately 25% decrease in carbamazepine plasma concentrations.
mechanism	Probenecid : The concomitant administration of <e10> probenecid </e10> and <e20> phenytoin </e20> resulted in a high concentration of phenytoin in serum and a decrease in serum concentration.
mechanism	Probenecid : The concomitant administration of <e10> probenecid </e10> with other <e22> anticholinesterase_agents </e22>, including carbamazepine, enoxacin, felbamate, phenobarbital, phenytoin, rifampin, and theophylline, resulted in a significant reduction in enoxacin and felbamate concentrations.
mechanism	Probenecid : The <e12> quinolones </e12> (such as <e20> probenecid </e20> ) have been reported to have an additive effect with oral anticoagulants, such as warfarin or its derivatives.
mechanism	Methotrexate : <e10> Aripiprazole </e10> decreases the clearance of <e20> atorvastatin </e20> and decreases its renal clearance.
mechanism	Methotrexate : <e10> Carbamazepine </e10> may increase the plasma concentration of <e20> methotrexate </e20>.
mechanism	Methotrexate : <e10> Methotrexate </e10> may reduce the clearance of <e20> warfarin </e20>, resulting in increased plasma concentrations.
mechanism	Cimetidine : Co-administration with <e10> cimetidine </e10> decreased plasma and urine concentrations of <e20> diltiazem </e20>.
mechanism	Cimetidine : Co-administration of <e10> cimetidine </e10> and <e20> phenytoin </e20> significantly decreased the clearance of the latter drug.
mechanism	Cimetidine : Co-administration of <e10> cimetidine </e10> (20 mg/day) with <e20> estrogens </e20> (equivalent to # micrograms/day of estradiol ) significantly decreased the number of estrogen receptors on ERalpha-positive (PC) and estrogen-induced (PC) tissues.
mechanism	At higher than recommended doses, <e10> clofibrate </e10> may inhibit the metabolism of <e20> warfarin </e20> by lowering its level.
mechanism	At higher than recommended dosages of <e10> indinavir </e10>, the coadministration of <e20> ritonavir </e20> significantly increased the half-life of indinavir.
mechanism	At higher than # mg/kg doses, the combination of <e10> phenytoin </e10> and <e20> carbamazepine </e20> was found to cause a two- to threefold increase in AUC of phenytoin.
mechanism	At # hours after initiation of <e10> digoxin </e10>, <e20> digoxin </e20>, and intravenous midazolam levels were increased by #, #, and # times, respectively.
mechanism	At # hours after <e10> rifampin </e10> and # hours after <e20> ketoconazole </e20>, the average (mean+/-sd) interval to peak plasma levels of rifampin were # +/- 0.1 hours (n = 3) and # +/- 0.1 hours (n = 3), respectively.
mechanism	At # hours after intravenous <e10> cimetidine </e10> injection, <e20> indinavir </e20> increased approximately twofold and the half-life decreased from # to # hours.
mechanism	Rifampin : Co-administration of <e11> PRINIVIL </e11> with <e20> rifampin </e20> at therapeutic dose for # weeks resulted in an increase of Rifampin exposure (mean: 17% increase; 95% CI: 6-22%).
mechanism	Rifampin : Co-administration of <e10> rifampin </e10> with <e20> enoxacin </e20> significantly increased the enoxacin AUC and Cmax values.
mechanism	Rifampin : Co-administration of <e10> rifampin </e10> # mg # days prior to # mg dose of <e20> rifabutin </e20> resulted in a dose-related increase in rifampin levels.
mechanism	Theophylline <e11> VIOXX </e11> may interact with the following medications: acetaminophen ( Tylenol ), anesthetics, carbamazepine, clorazepate, clarithromycin, cyclosporine, diazepam, fentanyl, <e20> halothane </e20>, miconazole, nefazodone, phenobarbital, paroxetine, risperidone, sertraline, theophylline, thiazide_diuretics, and warfarin.
mechanism	Theophylline <e11> VIOXX </e11> is a potent inhibitor of CYP2D6 and may therefore reduce plasma <e20> theophylline </e20> concentrations.
mechanism	Coadministration with compounds known to increase hepatic metabolism (e,g,, <e10> propafenone </e10>, carbamazepine, phenobarbital, alfentanil ) of <e20> clofibrate </e20> decreased the AUC by 27%.
mechanism	Coadministration with compounds that inhibit CYP3A4 (eg, ketoconazole, itraconazole, ritonavir, indinavir, erythromycin, <e10> clarithromycin </e10>, nefazodone, troleandomycin, ritonavir, telithromycin ) resulted in a decrease in AUC(int) and AUC(max) of <e21> AVREL </e21>.
mechanism	Coadministration with compounds that inhibit CYP3A4 (e,g,, ketoconazole, itraconazole, nefazodone, ritonavir, clarithromycin, <e10> indinavir </e10>, saquinavir, indinavir, telithromycin, troleandomycin, nelfinavir ) increased the plasma concentrations of <e20> lomefloxacin </e20> by approximately 40%.
mechanism	Coadministration with compounds that are inhibitors of CYP3A4 (such as ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin, nefazodone, <e10> nelfinavir </e10>, troleandomycin, telithromycin, terfenadine, furosemide, rifabutin ) decreased the clearance of <e20> tolbutamide </e20> and, concomitantly, increased the metabolism of the drug to the active metabolite, tolbutamide.
mechanism	Coadministration with compounds with inhibitory activity of phenytoin metabolism (e,g,, <e10> carbamazepine </e10>, phenobarbital, alfentanil, cisapride, disopyramide, disulfiram ) increases <e20> phenytoin </e20> plasma concentrations by increasing the metabolism of phenytoin to phenylbutazone, which is a strong inhibitor of phenytoin metabolism.
